10-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20541

FORM 10-K

ý     ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2017

o     TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to              

Commission file number: 001-36007 (Physicians Realty Trust)

Commission file number: 333-205034-01 (Physicians Realty L.P.)

PHYSICIANS REALTY TRUST

PHYSICIANS REALTY L.P.

(Exact Name of Registrant as Specified in Its Charter)

Maryland (Physicians Realty Trust) Delaware (Physicians Realty L.P.)	46-2519850 80-0941870
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)
309 N. Water Street Suite 500 Milwaukee, Wisconsin	53202
(Address of Principal Executive Offices)	(Zip Code)

(414) 367-5600

(Registrant’s telephone number, including area code)

Securities registered under Section 12(b) of the Act:

Registrant	Title of Each Class	Name of Each Exchange On Which Registered
Physicians Realty Trust	Common Shares, $0.01 par value	New York Stock Exchange

Securities registered under Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. 

Physicians Realty Trust        Yes ý No o            Physicians Realty L.P.        Yes o No ý    

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. 

Physicians Realty Trust        Yes o No ý            Physicians Realty L.P.        Yes o No ý

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Physicians Realty Trust        Yes ý No o            Physicians Realty L.P.        Yes ý No o    

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). 

Physicians Realty Trust        Yes ý No o            Physicians Realty L.P.        Yes ý No o    

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Physicians Realty Trust Large accelerated filer ý     Accelerated filer o Non-accelerated filer o (Do not check if a smaller reporting company) Smaller reporting company o Emerging growth company o

Physicians Realty L.P. Large accelerated filer o     Accelerated filer o Non-accelerated filer ý (Do not check if a smaller reporting company) Smaller reporting company o Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Physicians Realty Trust      o     Physicians Realty L.P. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). 

Physicians Realty Trust        Yes o No ý            Physicians Realty L.P.        Yes o No ý

The aggregate market value of Physicians Realty Trust’s common shares held by non-affiliates as of June 30, 2017 was approximately $3,154,991,308 based upon the closing price reported for such date on the New York Stock Exchange. There is no established trading market for units of Physicians Realty L.P.

As of February 23, 2018, there were 181,758,250 shares of Physicians Realty Trust’s common shares outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

The information required by Part III of this Annual Report on Form 10-K, to the extent not set forth in this Form 10-K, is incorporated herein by reference from Physicians Realty Trust’s definitive proxy statement relating to the annual meeting of shareholders to be held on May 3, 2018, to be filed with the Securities and Exchange Commission within 120 days after the end of the Registrant’s fiscal year ended December 31, 2017.

EXPLANATORY NOTE

This Annual Report on Form 10-K combines the Annual Reports on Form 10-K for the year ended December 31, 2017 of Physicians Realty Trust (the “Trust”), a Maryland real estate investment trust, and Physicians Realty L.P. (the “Operating Partnership”), a Delaware limited partnership. Unless otherwise indicated or unless the context requires otherwise, all references in this report to “we,” “us,” “our,” “our company,” the “Company,” and “Physicians Realty” refer to the Trust, together with its consolidated subsidiaries, including the Operating Partnership, and the historical business and operations of four healthcare real estate private equity funds, organized as limited liability companies under the laws of Delaware, managed by B.C. Ziegler & Company, that we have classified for accounting purposes as our “Predecessor” and which we sometimes refer to as the “Ziegler Funds,” and references to the “Operating Partnership” mean collectively the Operating Partnership together with its consolidated subsidiaries. In this report, all references to “common shares” refer to the common shares of the Trust and references to “our shareholders” refer to shareholders of the common shares of the Trust, the term “OP Units” refers to partnership interests of the Operating Partnership and the term “Series A Preferred Units” refers to Series A Participating

Redeemable Preferred Units of the Operating Partnership. As of February 23, 2018, 104,172 Series A Preferred Units were outstanding.

The Trust is a self-managed real estate investment trust (“REIT”) formed primarily to acquire, selectively develop, own, and manage healthcare properties that are leased to physicians, hospitals, and healthcare delivery systems. The Trust operates in an umbrella partnership REIT structure (“UPREIT”) in which the Operating Partnership and its subsidiaries hold substantially all of the assets. The Trust’s operations are conducted through the Operating Partnership and wholly-owned and majority-owned subsidiaries of the Operating Partnership. The Trust, as the general partner of the Operating Partnership, controls the Operating Partnership and consolidates the assets, liabilities, and results of operations of the Operating Partnership.

The Trust conducts substantially all of its operations through the Operating Partnership. As of December 31, 2017, the Trust held a 97.1% interest in the Operating Partnership and owns no Series A Preferred Units. Apart from this ownership interest, the Trust has no independent operations.

Noncontrolling interests in the Operating Partnership, shareholders’ equity of the Trust and partners’ capital of the Operating Partnership are the primary areas of difference between the consolidated financial statements of the Trust and those of the Operating Partnership. OP Units not owned by the Trust are accounted for as limited partners’ capital in the Operating Partnership’s consolidated financial statements and as noncontrolling interests in the Trust’s consolidated financial statements. The differences between the Trust’s shareholders’ equity and the Operating Partnership’s partners’ capital are due to the differences in the equity issued by the Trust and the Operating Partnership, respectively.

The Company believes combining the Annual Reports of the Trust and the Operating Partnership, including the notes to the consolidated financial statements, into this single report results in the following benefits:

• a combined report enhances investors’ understanding of the Trust and the Operating Partnership by enabling investors to view the business as a whole in the same manner as management views and operates the business;

• a combined report eliminates duplicative disclosure and provides a more streamlined and readable presentation, as a substantial portion of the Company’s disclosure applies to both the Trust and the Operating Partnership; and

• a combined report creates time and cost efficiencies through the preparation of one combined report instead of two separate reports.

To help investors understand the significant differences between the Trust and the Operating Partnership, this report presents the following separate sections for each of the Trust and the Operating Partnership:

• the market for registrant’s common equity, related stockholder matters and issuer purchases of equity securities in Item 5 of this report;

• selected financial data in Item 6 of this report;

• the consolidated financial statements in Item 8 and Item 15 of this report;

• certain accompanying notes to the consolidated financial statements, including Note 3 (Acquisitions and Dispositions), Note 14 (Earnings Per Share and Earnings Per Unit) and Note 16 (Quarterly Data);

• controls and procedures in Item 9A of this report; and

• the certifications of the Chief Executive Officer and the Chief Financial Officer included as Exhibits 31 and 32 to this report.

PHYSICIANS REALTY TRUST AND PHYSICIANS REALTY L.P.

Annual Report on Form 10-K for the Year Ended December 31, 2017

 Table of Contents

	Page
PART I	4
Item 1. Business	4
Item 1A. Risk Factors	15
Item 1B. Unresolved Staff Comments	33
Item 2. Properties	34
Item 3. Legal Proceedings	36
Item 4. Mine Safety Disclosures	36
PART II	37
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	37
Item 6. Selected Financial Data	40
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations	43
Item 7A. Quantitative and Qualitative Disclosures About Market Risk	63
Item 8. Financial Statements and Supplementary Data	65
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	114
Item 9A. Controls and Procedures	114
Item 9B. Other Information	115
PART III	116
Item 10. Directors, Executive Officers and Corporate Governance	116
Item 11. Executive Compensation	116
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	116
Item 13. Certain Relationships and Related Transactions, and Director Independence	116
Item 14. Principal Accountant Fees and Services	116
PART IV	117
Item 15. Exhibits, Financial Statement Schedules	117
Item 16. Form 10-K Summary	118

Forward-Looking Statements

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K contains forward-looking statements made pursuant to safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts may be forward-looking statements within the meaning of the federal securities laws. In particular, statements pertaining to our capital resources, property performance and results of operations contain forward-looking statements. Likewise, all of our statements regarding anticipated growth in our funds from operations and anticipated market conditions, demographics and results of operations are forward-looking statements. You can identify forward-looking statements by the use of forward-looking terminology such as “believes,” “expects,” “may,” “will,” “should,” “seeks,” “approximately,” “intends,” “plans,” “pro forma,” “estimates” or “anticipates” or the negative of these words and phrases or similar words or phrases which are predictions of or indicate future events or trends and which do not relate solely to historical matters. You can also identify forward-looking statements by discussions of strategy, plans, expectations or intentions.

These forward-looking statements reflect the views of our management regarding current expectations and projections about future events and are based on currently available information. These forward-looking statements are not guarantees of future performance and involve numerous risks and uncertainties and you should not rely on them as predictions of future events. Forward-looking statements depend on assumptions, data or methods which may be incorrect or imprecise and we may not be able to realize them. We do not guarantee that the transactions and events described will happen as described (or that they will happen at all). The following factors, among others, could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements:

• general economic conditions;

• adverse economic or real estate developments, either nationally or in the markets where our properties are located;

• our failure to generate sufficient cash flows to service our outstanding indebtedness, or our ability to pay down or refinance our indebtedness;

• fluctuations in interest rates and increased operating costs;

• the availability, terms and deployment of debt and equity capital, including our unsecured revolving credit facility;

• our ability to make distributions on our common shares;

• general volatility of the market price of our common shares;

• our increased vulnerability economically due to the concentration of our investments in healthcare properties;

• our geographic concentration in Texas causes us to be particularly exposed to downturns in the Texas economy or other changes in Texas market conditions;

• changes in our business or strategy;

• our dependence upon key personnel whose continued service is not guaranteed;

• our ability to identify, hire and retain highly qualified personnel in the future;

• the degree and nature of our competition;

• changes in governmental regulations, tax rates and similar matters;

• defaults on or non-renewal of leases by tenants;

• decreased rental rates or increased vacancy rates;

• difficulties in identifying healthcare properties to acquire and completing acquisitions;

2

• competition for investment opportunities;

• any adverse effects to the business, financial position or results of operations of Catholic Health Initiatives (“CHI”), or one or more of the CHI-affiliated tenants, that impact the ability of CHI-affiliated tenants to pay us rent;

• the impact of our investment in joint ventures;

• the financial condition and liquidity of, or disputes with, any joint venture and development partners with whom we may make co-investments in the future;

• cybersecurity incidents could disrupt our business and result in the compromise of confidential information;

• our ability to operate as a public company;

• changes in accounting principles generally accepted in the United States (GAAP);

• lack of or insufficient amounts of insurance;

• other factors affecting the real estate industry generally;

• our failure to maintain our qualification as a real estate investment trust (or REIT) for U.S. federal income tax purposes;

• limitations imposed on our business and our ability to satisfy complex rules in order for us to qualify as a REIT for U.S. federal income tax purposes;

• changes in governmental regulations or interpretations thereof, such as real estate and zoning laws and increases in real property tax rates and taxation of REITs; and

• factors that may materially adversely affect us, or the per share market price of our common shares, including:

• higher market interest rates;

• the number of our common shares available for future issuance or sale;

• our issuance of equity securities or the perception that such issuance might occur;

• future debt;

• failure of securities analysts to publish research or reports about us or our industry; and

• securities analysts’ downgrade of our common shares or the healthcare-related real estate sector.

While forward-looking statements reflect our good faith beliefs, they are not guarantees of future performance. We disclaim any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this report, except as required by applicable law. You should not place undue reliance on any forward-looking statements that are based on information currently available to us or the third parties making the forward-looking statements. For a further discussion of these and other factors that could impact our future results, performance or transactions, see “Part I, Item 1A. Risk Factors” of this report.

3

PART I

ITEM 1. BUSINESS

Overview

Physicians Realty Trust (the “Trust”), a Maryland real estate investment trust, and Physicians Realty L.P. (the “Operating Partnership”), a Delaware limited partnership, were organized in April 2013 to acquire, selectively develop, own and manage healthcare properties that are leased to physicians, hospitals and healthcare delivery systems. Unless otherwise indicated or unless the context requires otherwise, all references in this report to “we,” “us,” “our,” “our company,” the “Company,” and “Physicians Realty” refer to the Trust, together with its consolidated subsidiaries, including the Operating Partnership, and the Ziegler Funds, and references to the “Operating Partnership” mean collectively the Operating Partnership together with its consolidated subsidiaries. We completed our initial public offering (“IPO”) in July 2013. The Trust’s common shares are listed on the NYSE and it is included in the MSCI US REIT Index.

We have grown our portfolio of gross real estate investments from approximately $124 million at the time of our IPO to approximately $4.3 billion as of December 31, 2017. As of December 31, 2017, our portfolio consisted of 280 healthcare properties located in 30 states with approximately 13,996,802 net leasable square feet, which were approximately 96.6% leased with a weighted average remaining lease term of approximately 8.3 years. As of December 31, 2017, approximately 85.1% of the net leasable square footage of our portfolio was either on campus with a hospital or other healthcare facility or strategically located and affiliated with a hospital or other healthcare facility.

We receive a cash rental stream from healthcare providers under our leases. Approximately 90.8% of the annualized base rent payments from our properties as of December 31, 2017 are from absolute and triple-net leases, pursuant to which the tenants are responsible for all operating expenses relating to the property, including but not limited to real estate taxes, utilities, property insurance, routine maintenance and repairs, and property management. This structure helps insulate us from increases in certain operating expenses and provides relatively predictable cash flow. We seek to structure our triple net leases to generate attractive returns on a long-term basis. Our leases typically have initial terms of five to 15 years and include annual rent escalators of approximately 1.5% to 3.0%. Our operating results depend significantly upon the ability of our tenants to make required rental payments. We believe that our portfolio of medical office buildings and other healthcare facilities will enable us to generate stable cash flows over time because of the diversity of our tenants, staggered lease expiration schedule, long-term leases, and low historical occurrence of tenants defaulting under their leases. As of December 31, 2017, leases representing a percentage of our portfolio on the basis of leasable square feet will expire as follows: 

Year	Portfolio Lease Expirations
MTM (1)	0.5%
2018	2.9%
2019	3.9%
2020	3.6%
2021	4.9%
2022	4.9%
2023	4.2%
2024	6.2%
2025	7.3%
2026	25.6%
2027	9.7%
Thereafter	22.9%
Total	96.6%

(1) “MTM” means month-to-month. This line also includes 4 leases which expired on December 31, 2017, representing 0.1% of portfolio leasable square feet.

We invest in real estate that is integral to providing high quality healthcare services. Our properties are typically located on a campus with a hospital or other healthcare facilities or strategically located and affiliated with a hospital or other healthcare system. We believe the impact of government programs and continuing trends in the healthcare industry create attractive opportunities for us to invest in healthcare-related real estate. Our management team has significant public healthcare REIT experience and has long established relationships with physicians, hospitals and healthcare delivery system decision makers that we believe will provide quality investment and growth opportunities. Our principal investments include medical

4

office buildings, outpatient treatment facilities, and other real estate integral to health care providers. We seek to invest in stabilized medical facility assets with initial cash yields of 5.0% to 9.0%, although we invested in certain medical facility assets in 2017 with anticipated initial cash yields below 5.0% and we may invest in other medical facility assets with initial cash yields outside of this range. We seek to generate attractive risk-adjusted returns for our shareholders through a combination of stable and increasing dividends and potential long-term appreciation in the value of our properties and our common shares.

We had no business operations prior to completion of the IPO and the related formation transactions on July 24, 2013. Our Predecessor, which is not a legal entity, is comprised of the four healthcare real estate private equity funds, organized as limited liability companies under the laws of Delaware, managed by B.C. Ziegler & Company, which we refer to as the Ziegler Funds, that owned directly or indirectly interests in entities that owned our initial properties we acquired on July 24, 2013 in connection with completion of our IPO and related formation transactions.

The Trust is a Maryland real estate investment trust and has elected to be taxed as a REIT for U.S. federal income tax purposes. We conduct our business through an umbrella partnership REIT structure in which our properties are owned by the Operating Partnership directly or through limited partnerships, limited liability companies, or other subsidiaries. The Trust is the sole general partner of the Operating Partnership and, as of February 23, 2018, owned approximately 97.1% of the partnership interests in the Operating Partnership (“OP Units”). 

Our Objectives and Growth Strategy

Overview

Our principal business objective is to provide attractive risk-adjusted returns to our shareholders through a combination of (i) sustainable and increasing rental revenue and cash flow that generate reliable, increasing dividends, and (ii) potential long-term appreciation in the value of our properties and common shares. Our primary strategies to achieve our business objective are to leverage our physician and hospital relationships nationwide to invest in off-market assets that maximize risk-adjusted returns to our shareholders, to invest in, own, and manage a diversified portfolio of high quality healthcare properties, and to pay careful attention to our tenants’ real estate strategies, which we believe will drive high retention, high occupancy and reliable, increasing rental revenue and cash flow.

We intend to grow our portfolio of high-quality healthcare properties leased to physicians, hospitals, healthcare delivery systems, and other healthcare providers primarily through acquisitions of existing healthcare facilities that provide stable revenue growth and predictable long-term cash flows. We may also selectively finance the development of new healthcare facilities through joint venture or fee arrangements with premier healthcare real estate developers. Generally, we only expect to make investments in new development properties when approximately 70% or more of the development property has been pre-leased before construction commences. We seek to invest in properties where we can develop strategic alliances with financially sound healthcare providers and healthcare delivery systems that offer need-based healthcare services in sustainable healthcare markets. We focus our investment activity on the following types of healthcare properties:

• medical office buildings;

• outpatient treatment and diagnostic facilities;

• physician group practice clinics;

• ambulatory surgery centers; and

• specialty hospitals and treatment centers.

We believe that shifting consumer preferences, limited space in hospitals, the desire of patients and healthcare providers to limit non-essential services provided in a hospital setting, and cost considerations, among other trends, continue to drive the industry trend of performing procedures in outpatient facilities that have traditionally been performed in hospitals, such as surgeries and other invasive medical procedures. As these trends continue, we believe that demand for medical office buildings and similar healthcare properties will continue to rise, and that our investment strategy accounts for these trends.

We may invest opportunistically in life science facilities, assisted living, and independent senior living facilities and in the longer term, senior housing properties, including skilled nursing. Consistent with the Trust’s qualification as a REIT, we may also opportunistically invest in companies that provide healthcare services, and in joint venture entities with operating partners structured to comply with the REIT Investment Diversification Act of 2007 (“RIDEA”).

5

In connection with our review and consideration of healthcare real estate investment opportunities, we generally take into account a variety of market considerations, including:

• whether the property is anchored by a financially-sound healthcare delivery system or whether tenants have strong affiliation to a healthcare delivery system;

• the performance of the local healthcare delivery system and its future prospects;

• property location, with a particular emphasis on proximity to healthcare delivery systems;

• demand for medical office buildings and healthcare related facilities, current and future supply of competing properties, and occupancy and rental rates in the market;

• population density and growth potential;

• ability to achieve economies of scale with our existing medical office buildings and healthcare related facilities or anticipated investment opportunities; and

• existing and potential competition from other healthcare real estate owners and operators.

In addition, our management team has maintained a conservative balance sheet while investing over $4.3 billion as of December 31, 2017 in real estate assets since our IPO in July 2013. For short-term purposes, we may borrow on our primary unsecured credit facility. From time to time, we replace these borrowings with long-term capital such as senior unsecured notes and equity. We selectively utilize capital market transactions in furtherance of our investment strategy, including, during 2017, the issuance by the Operating Partnership of $750.0 million of senior notes through two public debt offerings, and the raising of an additional $721.5 million of equity through two follow-on offerings and $122.5 million of equity through sales under our ATM Program (as hereinafter defined).

Business Strategy

We are focused on building and maintaining a portfolio of high-quality healthcare properties leased to physicians, hospitals, healthcare delivery systems, and other healthcare providers. Our investment strategy includes a focus on investments with the following key attributes:

• We seek to invest in properties serving healthcare systems with dominant market share, high credit quality and those who are investing capital into their campuses. In particular, we seek to own off-market or selectively marketed assets with attractive demographics, economic growth, and high barriers to entry. We seek to invest in and maintain well occupied properties that we believe are critical to the delivery of healthcare.

• We emphasize ensuring an appropriate and balanced mix of tenants to provide synergies within both individual buildings and the broader health system campus. Our primary tenants are healthcare systems, academic medical centers and leading physician groups. These groups typically have strong and stable financial performance. We believe this helps ensure stability in our rental income and tenant retention over time.

• We seek to maintain a core, critical portfolio of properties and to build our reputation as a dedicated leading MOB owner and operator.

• We seek to maintain or increase our average rental rates, and focus on actively leasing our vacant space and reducing leasing concessions.

In addition, we seek to invest in properties where we can develop strategic alliances with financially sound healthcare providers and healthcare delivery systems that offer need-based healthcare services in sustainable healthcare markets, and consider long-term relationship building when assessing acquisition potential.

Finally, we actively manage our balance sheet to maintain our investment grade credit rating, to maintain an appropriate level of leverage and to preserve financing flexibility for funding of future acquisitions. In particular, we:

• Continue to maintain a high level of liquidity, including borrowing availability under our unsecured revolving credit facility.

• Maintain access to multiple sources of capital, including private debt issuances, public bond offerings, public equity offerings, unsecured bank loans, and secured property level debt.

• Closely monitor our existing debt maturities and average interest rates.

6

2017 Highlights and Other Recent Developments

Investment Activity

• For the full year 2017, we completed acquisitions of 40 operating healthcare properties, 2 condominium units, and 1 parking deck, located in 15 states for an aggregate purchase price of approximately $1.37 billion. In addition, we funded $42.9 million of other investments, including the issuance of loans and buyouts of noncontrolling interests, resulting in total investments of $1.41 billion.

• During 2017, we completed acquisitions of 8 healthcare properties as a result of the exercise of certain rights of first refusal by the sellers. These properties comprising approximately 1,402,872 net leasable square feet in three states for an aggregate purchase price of $677.7 million.

• Since January 1, 2018, we have completed acquisitions of 2 healthcare properties for an aggregate purchase price of $98.7 million containing an aggregate of 220,140 net leasable square feet. One of these properties was partially funded by issuing an aggregate of 104,172 preferred operating partnership units valued at approximately $22.7 million on the date of issuance.

Assets Slated for Disposition

• We consider 10 properties in four states, representing an aggregate of approximately 391,014 square feet of gross leasable area, to be slated for disposition as of December 31, 2017. These assets consist of five assets leased to entities who have succeeded to the interests of certain Foundation Healthcare, Inc. affiliates (“Former Foundation Assets”) and five additional properties which we believe no longer meet our core business strategy from a size, age, geography, or line of business perspective.

Capital Markets and Dividends

• In August 2016, we entered into separate At Market Issuance Sales Agreements with each of KeyBanc Capital Markets Inc., Credit Agricole Securities (USA) Inc., JMP Securities LLC, Raymond James & Associates, Inc. and Stifel Nicolaus & Company, Incorporated (the “Agents”), pursuant to which we may issue and sell, from time to time, our common shares having an aggregate offering price of up to $300.0 million, through the Agents (the “ATM Program”). During the fiscal year-ended December 31, 2017, we issued and sold pursuant to the ATM Program 6,347,914 common shares at a weighted average price of $19.48 per share, resulting in net proceeds to us of approximately $122.5 million.

• In March 2017, the Operating Partnership issued and sold $400.0 million in aggregate principal amount of its 4.30% Senior Notes which will mature on March 15, 2027. Our net proceeds from the offering, after deducting underwriting discounts and expenses, were approximately $396.1 million. We used the net proceeds of the public debt offering to repay a portion of the outstanding indebtedness under our unsecured revolving credit facility and for general corporate purposes, including working capital and funding acquisitions.

• In March 2017, we completed a follow-on public offering of 17,250,000 common shares of beneficial interest, including 2,250,000 common shares issued upon exercise of the underwriters’ overallotment option, resulting in net proceeds to us of approximately $300.8 million. We contributed the net proceeds of this offering to the Operating Partnership in exchange for 17,250,000 OP Units, and the Operating Partnership used the net proceeds of the public offering to repay borrowings under its unsecured revolving credit facility and for general corporate purposes, including working capital and funding acquisitions.

• In July 2017, we completed a follow-on public offering of 21,500,000 common shares of beneficial interest, including 1,500,000 common shares issued upon partial exercise of the underwriters’ option to purchase additional shares, resulting in net proceeds to us of approximately $420.7 million. We contributed the net proceeds of this offering to the Operating Partnership in exchange for 21,500,000 OP Units, and the Operating Partnership used the net proceeds of the public offering to repay borrowings under its unsecured revolving credit facility and for general corporate purposes, including working capital and funding acquisitions.

7

• On December 1, 2017, the Operating Partnership issued and sold $350.0 million in aggregate principal amount of its 3.95% Senior Notes which will mature on January 15, 2028. Our net proceeds from the offering, after deducting underwriting discounts and expenses, were approximately $347.0 million. We used the net proceeds of the public debt offering to repay outstanding indebtedness under our unsecured revolving credit facility and for general corporate purposes, including working capital and funding acquisitions.

• The Board of Trustees authorized and the Trust declared a cash dividend of $0.225 per common share and OP Unit for the quarterly period ended March 31, 2017, which was paid on April 18, 2017 to common shareholders and OP Unit holders of record as of the close of business on April 5, 2017. The Board of Trustees authorized and the Trust declared a cash dividend of $0.23 per common share and OP Unit for the quarterly period ended June 30, 2017, which was paid on July 18, 2017 to common shareholders and OP Unit holders of record as of the close of business on July 3, 2017. The Board of Trustees authorized and the Trust declared a cash dividend of $0.23 per common share and OP Unit for the quarterly period ended September 30, 2017, which was paid on October 18, 2017 to common shareholders and OP Unit holders of record as of the close of business on October 3, 2017. The Board of Trustees authorized and the Trust declared a cash dividend of $0.23 per common share and OP Unit for the quarterly period ended December 31, 2017, which was paid on January 18, 2018 to common shareholders and OP Unit holders of record as of the close of business on January 3, 2018.

Our Industry and Market Opportunity

The nature of healthcare delivery continues to evolve due to the impact of government programs, regulatory changes and consumer preferences. We believe these changes have increased the need for capital among healthcare providers and increased pressure on these providers to integrate more efficient real estate solutions in order enhance the delivery of quality healthcare. In particular, we believe the following factors and trends are creating an attractive environment in which to invest in healthcare properties.

$3.3 Trillion Healthcare Industry Projected to Grow to $5.7 Trillion (and 19.7% of U.S. GDP) by 2026

According to the U.S. Department of Health and Human Services (“HHS”), healthcare spending accounted for 17.9% of U.S. gross domestic product (“GDP”) in 2016. The general aging of the population, driven by the Baby Boomer generation and advances in medical technology and services which increase life expectancy, are key drivers of the growth in healthcare expenditures. The anticipated continuing increase in demand for healthcare services, together with an evolving complex and costly regulatory environment, changes in medical technology and reductions in government reimbursements are expected to pressure capital-constrained healthcare providers to find cost effective solutions for their real estate needs.

We believe the demand by healthcare providers for healthcare real estate will increase as healthcare spending in the United States continues to increase. According to the Centers for Medicare & Medicaid Services’ National Health Expenditure Projections 2017-2026, national healthcare expenditures continue to rise and are projected to grow from an estimated $3.5 trillion in 2017 to $5.7 trillion by 2026, representing an average annual rate of growth of 5.5%, reaching a projected 19.7% of GDP in 2026.

Source: Centers for Medicare & Medicaid Services, Office of the Actuary

8

Aging Population

The aging of the U.S. population has a direct effect on the demand for healthcare as older persons generally utilize healthcare services at a rate well in excess of younger people. According to the U.S. Census Bureau, the U.S. population over 65 years of age is projected to more than double from 47.8 million to nearly 98.2 million and the 85 and older population is expected to more than triple, from 6.3 million to 19.7 million, between 2015 and 2060. Also according to the U.S. Census Bureau, the number of older Americans is growing as a percentage of the total U.S. population with the number of persons older than 65 estimated to comprise 14.9% of the total U.S. population in 2015 and projected to grow to 23.6% by 2060.

We believe that healthcare expenditures for the population over 65 years of age will continue to rise as a disproportionate share of healthcare dollars is spent on older Americans. To illustrate, in 2012 the elderly (65+ years old) represented only 14% of the population while accounting for 34% of all healthcare-related spending. We believe the older population group increasingly will require treatment and management of chronic and acute health ailments and that this increased demand for healthcare services will create a substantial need for additional medical office buildings and other facilities that serve the healthcare industry in many regions of the United States. Additionally, we believe there will likely be a focus on lowering the cost of outpatient care to support the aging U.S. population, which will continue to support medical office and outpatient facility property demand in the long term. We believe these trends will result in a substantial increase in the number of properties meeting our investment criteria.

We believe advances in medical technology will continue to enable healthcare providers to identify and treat once fatal illnesses and improve the survival rate of critically ill and injured patients who will require continuing medical care. Along with these technical innovations, the U.S. population is growing older and living longer.

Source: U.S. Census Bureau

Affordable Care Act

The Affordable Care Act (as hereinafter defined) constituted a significant overhaul of many aspects of healthcare regulations and health insurance, and created the framework for healthcare services over the near term. It required every American to have health insurance or be subjected to a tax. Those who cannot afford health insurance are offered insurance subsidies or Medicaid coverage. The U.S. Census Bureau estimated that approximately 50 million Americans did not have healthcare insurance in 2009, before the Affordable Care Act was enacted. The HHS reported that approximately 28.1 million Americans did not have health insurance in 2016. The Affordable Care Act and subsequent legislation, executive orders and events, as well as their potential impact on our business, are discussed more fully under Item I, “Business,” under the caption “Certain Government Regulations.”

We believe the increase in the number of Americans with access to health insurance will result in an increase in physician office visits and an overall rise in healthcare utilization which in turn will drive a need for expansion of medical, outpatient, and smaller specialty hospital facilities. We also believe the increased dissemination of health research through media outlets, marketing of healthcare products, and availability of advanced screening techniques and medical procedures have contributed to a more engaged population of healthcare users and has created increased demand for customized facilities providing specialized, preventive and integrative healthcare services.

9

We further believe the provisions of the Affordable Care Act that are designed to lower certain reimbursement amounts under Medicare and tie reimbursement levels to the quality of services provided will increase the pressure on healthcare providers to become more efficient in their business models, invest capital in their businesses, lower costs and improve the quality of care, which in turn will drive healthcare systems to monetize their real estate assets and create demand for new, modern and specialized facilities.

Clinical Care Continues to Shift to Outpatient Care

According to the American Hospital Association, procedures traditionally performed in hospitals, such as certain types of surgery, are increasingly moving to outpatient facilities driven by advances in clinical science, shifting consumer preferences, limited or inefficient space in existing hospitals, and lower costs in the outpatient environment. This continuing shift toward delivering healthcare services in an outpatient environment rather than a traditional hospital environment increases the need for additional outpatient facilities and smaller, more specialized and efficient hospitals. Studies by the Medicare Payment Advisory Commission and others have shown that healthcare is delivered more cost effectively and with higher patient satisfaction when it is provided on an outpatient basis. Increasingly, hospital admissions are reserved for the critically ill, and less critical patients are treated on an outpatient basis with recuperation in their own homes. We believe healthcare market trends toward outpatient care will continue to push healthcare services out of larger, older, inefficient hospitals and into newer, more efficient and conveniently located outpatient facilities and smaller specialized hospitals. We believe that increased specialization within the medical field is also driving demand for medical facilities designed specifically for particular specialties and that physicians want to locate their practices in medical office space that is in or adjacent to these facilities.

Impact of BBA on Outpatient Care    

Section 603 Assets: Section 603 of the Bipartisan Budget Act of 2015 (the “2015 BBA”) generally prohibits hospital outpatient departments (“HOPDs”) from charging preferential hospital outpatient department rates for Medicare patients treated in “off-campus” locations on or after January 1, 2017, potentially impacting their profitability. These preferential Medicare rates are only permitted if the hospital provides HOPD services in a building within 250 yards of the hospital’s main inpatient location, unless the hospital’s HOPD service location is grandfathered by the 2015 BBA. A hospital’s HOPD locations, and thus the legislative right to bill at the higher HOPD rates, are grandfathered in all locations in existence as of November 2, 2015, as long as the hospital was billing services in that location on a HOPD basis as of November 2, 2015 and continues to provide those services in that location. “Grandfathered” hospitals providing HOPD services in our portfolio are referred to as 603 assets in our SEC reports and other public disclosures.

We own a number of assets that will continue to be reimbursed at hospital inpatient rates, which we refer to as “603 assets” after the applicable section of the BBA. Rent derived from these 603 assets accounts for approximately 19.7% of our total portfolio annualized base rent as of December 31, 2017. Depending upon the implementation of the regulations, the BBA may enhance the value of these 603 assets because existing HOPDs may lose their higher reimbursements rates should they choose to change locations.

Portfolio Summary

Please see “Item 2. Properties” for a table that summarizes our portfolio as of December 31, 2017.

Geographic Concentration

For the year ended December 31, 2017, approximately 16.4% of our total annualized base rent was derived from properties located in Texas. 

As a result of this geographic concentration, we are particularly exposed to downturns in the Texas economy or other changes in local real estate market conditions. Any material change in the current payment programs or regulatory, economic, environmental, or competitive conditions in Texas could have a disproportionate effect on our overall business results. In the event of negative economic or other changes in the Texas market, our business, financial condition, and results of operations, our ability to make distributions to our shareholders and the market price of our common shares may be adversely affected. See the discussion under Item 1A, “Risk Factors,” under the caption, “Economic and other conditions that negatively affect geographic areas in which we conduct business, and in particular Texas, and other areas to which a greater percentage of our revenue is attributed could materially adversely affect our business, results of operations, and financial condition.”

10

Customer Concentration

We receive substantially all of our revenue as rent payments from tenants under leases of space in our healthcare properties, with our five largest tenants based upon rental revenue representing approximately $49.4 million, or 17.4%, of the annualized base rent from our properties as of December 31, 2017. No one tenant represents more than 5.6% of our total annualized base rent; however, 18.7% of our total annualized base rent as of December 31, 2017 is from tenants affiliated with CHI. We have no control over the success or failure of our tenants’ businesses and, at any time, any of our tenants may experience a downturn in its business that may weaken its financial condition. Our business, financial position, or results of operation could be materially adversely affected if CHI were to experience a material adverse effect on its business, financial position, or results of operations.

Competition

We compete with many other entities engaged in real estate investment activities for acquisitions of healthcare properties, including national, regional and local operators, acquirers, and developers of healthcare-related real estate properties and other investors such as private equity firms, some of whom may have greater financial resources and lower costs of capital than we do. The competition for healthcare-related real estate properties may significantly increase the price that we must pay for healthcare properties or other assets that we seek to acquire, and our competitors may succeed in acquiring those properties or assets themselves. In addition, our potential acquisition targets may find our competitors to be more attractive because they may have greater resources, may be willing to pay more for the properties or may have a more compatible operating philosophy. In particular, larger REITs that target healthcare properties may enjoy significant competitive advantages that result from, among other things, a lower cost of capital, enhanced operating efficiencies, more personnel, and market penetration and familiarity with markets. In addition, the number of entities and the amount of funds competing for suitable investment properties may increase. Increased competition would result in increased demand for the same assets and therefore increase prices paid for them. Those higher prices for healthcare properties or other assets may adversely affect our returns from our investments.

We also face competition in leasing available MOBs and other facilities that serve the healthcare industry to prospective tenants. As a result, we may have to provide rent concessions, incur charges for tenant improvements, offer other inducements, or we may be unable to timely lease vacant space in our properties, all of which may have a material adverse impact on our results of operations.

Seasonality

Our business has not been, and we do not expect it to become, subject to material seasonal fluctuations.

Employees

At December 31, 2017, we had 63 full-time employees, none of whom are subject to a collective bargaining agreement. We believe that relations with our employees are positive.

Environmental Matters

As an owner of real estate, we are subject to various federal, state, and local environmental laws, regulations, and ordinances and also could be liable to third parties as a result of environmental contamination or noncompliance at our properties even if we no longer own such properties. See the discussion under Item 1A, “Risk Factors,” under the caption “Environmental compliance costs and liabilities associated with owning, leasing, developing and operating our properties may affect our results of operations.”

11

Certain Government Regulations

Overview

Our tenants and operators are typically subject to extensive and complex federal, state, and local healthcare laws and regulations relating to fraud and abuse practices, government reimbursement, licensure, and certificate of need and similar laws governing the operation of healthcare facilities, and we expect that the healthcare industry, in general, will continue to face increased regulation and pressure in the areas of fraud, waste and abuse, cost control, healthcare management, and provision of services, among others. These regulations are wide-ranging and can subject our tenants and operators to civil, criminal and administrative sanctions. Affected tenants and operators may find it increasingly difficult to comply with this complex and evolving regulatory environment because of a relative lack of guidance in many areas as certain of our healthcare properties are subject to oversight from several government agencies and the laws may vary from one jurisdiction to another. Changes in laws and regulations, reimbursement enforcement activity and regulatory non-compliance by our tenants and operators can all have a significant effect on their operations and financial condition, which in turn may adversely impact us, as detailed below and set forth under Item 1A, “Risk Factors,” under the caption “The healthcare industry is heavily regulated, and new laws or regulations, changes to existing laws or regulations, loss of licensure, or failure to obtain licensure could adversely impact our company and result in the inability of our tenants to make rent payments to us.”

In 2017, Congress came within a single vote of repealing of the Affordable Care Act (the “ACA”) and substantially reducing funding to the Medicaid program. New legislation is likely to be introduced proposing similar changes, if not full repeal, in 2018. Beyond this, significant changes to commercial health insurance and government-sponsored insurance (i.e., Medicare and Medicaid) remain possible. Commercial and government payors are likely to continue imposing larger discounts and tighter cost controls upon operators, through changes in reimbursement rates and methodologies, discounted fee structures, the assumption by healthcare providers of all or a portion of the financial risk or otherwise. A shift toward less comprehensive health insurance coverage and increased consumer cost-sharing on health expenditures could have a material adverse effect on certain of our operators’ liquidity, financial condition, and results of operations and, in turn, their ability to satisfy their contractual obligations, including making rental payments under and otherwise complying with the terms of our leases.

The following is a discussion of certain laws and regulations generally applicable to our operators, and in certain cases, to us.

Healthcare Legislation

Health Reform Laws.  On March 23, 2010, President Obama signed into law the Patient Protection and Affordable Care Act of 2010 (the “Affordable Care Act”) and the Health Care and Education Reconciliation Act of 2010, which amends the Affordable Care Act (collectively with other subsequently enacted federal health care laws and regulations, the “Health Reform Laws”). The Health Reform Laws contain various provisions that may directly impact us or the operators and tenants of our properties. Some provisions of the Health Reform Laws may have a positive impact on our operators’ or tenants’ revenues, by, for example, increasing coverage of uninsured individuals, while others may have a negative impact on the reimbursement of our operators or tenants by, for example, altering the market basket adjustments for certain types of health care facilities. The Health Reform Laws also enhance certain fraud and abuse penalty provisions that could apply to our operators and tenants, in the event of one or more violations of the federal health care regulatory laws. In addition, there are provisions that impact the health coverage that we and our operators and tenants provide to our respective employees. The Health Reform Laws also provide additional Medicaid funding to allow states to carry out the expansion of Medicaid coverage to certain financially-eligible individuals beginning in 2014, and have also permitted states to expand their Medicaid coverage to these individuals since April 1, 2010, if certain conditions are met. On June 28, 2012, the United States Supreme Court upheld the individual mandate of the Health Reform Laws but partially invalidated the expansion of Medicaid. The ruling on Medicaid expansion allows states not to participate in the expansion-and to forego funding for the Medicaid expansion-without losing their existing Medicaid funding. As of December 31, 2017, 18 states have pursued this option. The participation by states in the Medicaid expansion could have the dual effect of increasing our tenants’ revenues, through new patients, but could also further strain state budgets. While the federal government paid for approximately 100% of those additional costs from 2014 to 2016, states now are expected to pay for part of those additional costs. 

Challenges to the Health Reform Laws and Potential Repeal and/or Further Reforms under Trump Administration.  Since the enactment of the Health Care Laws, there have been multiple attempts through legislative action and legal challenge to repeal or amend the Health Reform Laws, including the case that was before the U.S. Supreme Court, King v. Burwell.  Although the Supreme Court in Burwell upheld the use of subsidies to individuals in federally-facilitated health care exchanges on June 25, 2015, which ultimately did not disrupt significantly the implementation of the Health Reform Laws, we cannot predict whether other current or future efforts to repeal, amend or challenge the validity of all or part of the Health Reform

12

Laws will be successful, nor can we predict the impact that such a repeal, amendment or challenge would have on our operators or tenants and their ability to meet their obligations to us.

In 2017, President Trump and Congress unsuccessfully sought to repeal and replace the Affordable Care Act. On January 20, 2017, President Trump issued an Executive Order stating that it is the administration’s official policy to repeal the Affordable Care Act and instructing the Secretary of Health and Human Services and the heads of all other executive departments and agencies with authority and responsibility under the Affordable Care Act to, among other matters, delay implementation of or grant an exemption from any provision of the Affordable Care Act that would impose a fiscal burden on any state or a cost, fee, tax, penalty, or regulatory burden on individuals, families, healthcare providers, health insurers, patients, and others. On December 22, 2017, the Tax Cuts and Jobs Act (the “Tax Act”) was signed into law. The Tax Act, among other things, reduces the Affordable Care Act’s individual mandate penalty to zero beginning in 2019. The elimination of the penalties does not remove the requirement to obtain healthcare coverage; however, without penalties there effectively will be no enforcement. It is expected that Congress will continue to consider other legislation to repeal the Affordable Care Act or repeal and replace some or all elements of the Affordable Care Act.

We cannot predict the effect of either the Executive Order or the Tax Act’s 2019 repeal of the individual mandate penalty on the Affordable Care Act, or whether Congress’ attempt to repeal or repeal and replace the law will be successful. Further, we cannot predict how the Affordable Care Act might be amended or modified, either through the legislative or judicial process, and how any such modification might impact our tenants’ operations or the net effect of this law on us. If the operations, cash flows or financial condition of our operators and tenants are materially adversely impacted by any repeal or modification of the law, our revenue and operations may be materially adversely affected as well.

Fraud and Abuse Enforcement

There are various extremely complex federal and state laws and regulations governing healthcare providers’ relationships and arrangements and prohibiting fraudulent and abusive practices by such providers. These laws include (i) federal and state false claims acts, which, among other things, prohibit providers from filing false claims or making false statements to receive payment from Medicare, Medicaid or other federal or state healthcare programs, (ii) federal and state anti-kickback and fee-splitting statutes, including the Medicare and Medicaid anti-kickback statute, which prohibit the payment or receipt of remuneration to induce referrals or recommendations of healthcare items or services, (iii) federal and state physician self-referral laws (commonly referred to as the “Stark Law”), which generally prohibit referrals by physicians to entities with which the physician or an immediate family member has a financial relationship, (iv) the federal Civil Monetary Penalties Law, which prohibits, among other things, the knowing presentation of a false or fraudulent claim for certain healthcare services and (v) federal and state privacy laws, including the privacy and security rules contained in the Health Insurance Portability and Accountability Act of 1996, which provide for the privacy and security of personal health information. Violations of healthcare fraud and abuse laws carry civil, criminal and administrative sanctions, including punitive sanctions, monetary penalties, imprisonment, denial of Medicare and Medicaid reimbursement, and potential exclusion from Medicare, Medicaid or other federal or state healthcare programs. These laws are enforced by a variety of federal, state, and local agencies and can also be enforced by private litigants through, among other things, federal and state false claims acts, which allow private litigants to bring qui tam or “whistleblower” actions. Many of our operators and tenants are subject to these laws, and some of them may in the future become the subject of governmental enforcement actions if they fail to comply with applicable laws.

Reimbursement

Sources of revenue for many of our tenants and operators include, among other sources, governmental healthcare programs, such as the federal Medicare program and state and Medicaid program, and non-governmental payors, such as insurance carriers and HMOs. As federal and state governments focus on healthcare reform initiatives, and as the federal government and many states face significant budget deficits, efforts to reduce costs by these payors will likely continue, which may result in reduced or slower growth in reimbursement for certain services provided by some of our tenants and operators.

We cannot predict whether future Congressional proposals will seek to reduce physician reimbursements. Efforts by other payors to reduce healthcare costs are likely to continue, which may result in reductions or slower growth in reimbursement for certain services provided by some of our tenants. Further, revenue realizable under third-party payor agreements can change after examination and retroactive adjustment by payors during the claims settlement process or as a result of post-payment audits. For example, payors may disallow requests for reimbursement based on determinations that certain costs are not reimbursable or reasonable, because additional documentation is necessary or because certain services were not covered or were not medically necessary. The Healthcare Reform Laws and regulatory changes could impose further limitations on government and private payments to healthcare providers. In some cases, states have enacted or are considering enacting measures designed to reduce their Medicaid expenditures and to make changes to private healthcare insurance. In

13

addition, the failure of any of our tenants to comply with various laws and regulations could jeopardize their ability to continue participating in Medicare, Medicaid and other government sponsored payment programs. The financial impact on our tenants’ failure to comply with such laws and regulations could restrict their ability to make rent payments to us.

Healthcare Licensure and Certificate of Need

Certain healthcare facilities in our portfolio are subject to extensive federal, state and local licensure, certification and inspection laws, and regulations. In addition, various licenses and permits are required to dispense narcotics, operate pharmacies and laboratories, handle radioactive materials, and operate equipment. Many states require certain healthcare providers to obtain a certificate of need, which requires prior approval for the construction, expansion, and closure of certain healthcare facilities. The approval process related to state certificate of need laws may impact some of our tenants’ and operators’ abilities to expand or change their businesses.

Available Information

Our website address is www.docreit.com. We make available, free of charge through the Investor Relations portion of the website, annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (as amended, the “Exchange Act”) as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission (the “SEC” or the “Commission”). Reports of beneficial ownership filed pursuant to Section  16(a) of the Exchange Act are also available on our website. These reports and other information are also available, free of charge, at www.sec.gov. Alternatively, the public may read and copy any materials we file with the SEC at the SEC’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Information on the operation of the Public Reference Room may be obtained by calling the SEC at 1-800-SEC-0330.

In addition, the Trust’s board of trustees has established a Code of Business Conduct and Ethics that applies to our officers, including our Chief Executive Officer and President and Chief Financial Officer, trustees, and employees. The Code of Business Conduct and Ethics provides a statement of the Company’s policies and procedures for conducting business legally and ethically. A copy of the Code of Business Conduct and Ethics is available in the Investor Relations section of our website (www.docreit.com) under the tab “Governance Documents.” Any amendments to or waivers from the Code of Business Conduct and Ethics will be disclosed on our website. Information contained on our website is not part of this report.

14

ITEM 1A. RISK FACTORS

The following summarizes the material risks of purchasing or owning our securities. Additional unknown risks may also impair our financial performance and business operations. Our business, financial condition, and/or results of operation may be materially adversely affected by the nature and impact of these risks. In such case, the market value of our securities could be detrimentally affected, and investors may lose part or all of the value of their investment. You should carefully consider the risks and uncertainties described below.

 We have grouped these risk factors into the following general categories:

• Risks related to our business;

• Risks related to the healthcare industry; 

• Risks related to the real estate industry; 

• Risks related to financings;

• Risks related to our portfolio and structure; and 

• Risks related to our qualification and operation as a REIT.

Risks Related To Our Business

Our real estate investments are concentrated in healthcare properties, making us more vulnerable economically than if our investments were diversified in other segments of the economy.

We acquire, own, manage, operate and selectively develop properties for lease primarily to physicians, hospitals, and healthcare delivery systems. We are subject to risks inherent in concentrating investments in real estate, and further from the concentration of our investments in the healthcare sector. Any adverse effects that result from these risks could be more pronounced than if we diversified our investments outside of healthcare properties. Given our concentration in this sector, our tenant base is especially concentrated and dependent upon the healthcare industry generally, and any industry downturn could adversely affect the ability of our tenants to make lease payments and our ability to maintain current rental and occupancy rates. Our tenant mix could become even more concentrated if a significant portion of our tenants practice in a particular medical field or are reliant upon a particular healthcare delivery system. Accordingly, a downturn in the healthcare industry generally, or in the healthcare-related facility specifically, could adversely affect our business, financial condition, and results of operations, our ability to make distributions to our shareholders, and the market price of our common shares.

Economic and other conditions that negatively affect geographic areas in which we conduct business, and in particular Texas, and other areas to which a greater percentage of our revenue is attributed could materially adversely affect our business, results of operations, and financial condition.

Our operating results depend upon our ability to maintain and increase occupancy levels and rental rates at our properties. Adverse economic or other conditions in the geographic markets in which we operate, including periods of economic slowdown or recession, industry slowdowns, periods of deflation, relocation of businesses, changing demographics, earthquakes and other natural disasters, fires, terrorist acts, civil disturbances or acts of war, and other man-made disasters which may result in uninsured or underinsured losses, and changes in tax, real estate, zoning, and other laws and regulations, may lower our occupancy levels and limit our ability to increase rents or require us to offer rental concessions.

For the year ended December 31, 2017, approximately 1.9 million of our gross leasable area and $46.9 million of our total annualized base rent was derived from properties located in Texas (13.8% of our gross leasable area and 16.4% of our total annualized base rent). As a result of these geographic concentrations, we are particularly exposed to downturns in the Texas economy or other changes in local real estate market conditions. Any material change in the current payment programs or regulatory, economic, environmental, or competitive conditions in Texas could have a disproportionate effect on our overall business results. In the event of negative economic or other changes in any of the markets in which we conduct business, our business, financial condition, and results of operations, our ability to make distributions to our shareholders, and the market price of our common shares may be adversely affected.

15

Our healthcare properties and tenants face competition from nearby hospitals and other healthcare properties, and we may not realize the benefits that we anticipate from focusing on healthcare properties that are strategically aligned with a healthcare delivery system and from the relationships established through such strategic alignments. Further, we may not be able to maintain or expand our relationships with our existing and future hospital and healthcare delivery system clients.

As part of our business strategy, we focus on healthcare properties that are strategically aligned with a healthcare delivery system by (i) seeking to acquire, own, manage, and develop healthcare properties that are located on medical campuses where the underlying land is owned by a healthcare delivery system or by us, or (ii) seeking to acquire, own, manage, and develop healthcare properties located in close proximity to a healthcare delivery system or strategically aligned with a healthcare delivery system through leasing or other arrangements. We may not realize the benefits that we anticipate as a result of these strategic relationships, such as increased rents and reduced tenant turnover rates as compared to healthcare properties that are not strategically aligned. Moreover, building a portfolio of healthcare properties that are strategically aligned does not assure the success of any given property. The associated healthcare delivery system may not be successful and the strategic alignment that we seek for our healthcare properties could dissolve, and we may not succeed in replacing them. In addition, our healthcare properties, the associated healthcare delivery systems with which our healthcare properties are strategically aligned, and our tenants may be unable to compete successfully with nearby hospitals, medical practices, other healthcare properties that provide comparable services, pharmacies and other retailers that may initiate or expand healthcare clinic operations and services to compete with our tenants. Any of our properties may be materially and adversely affected if the healthcare delivery system with which it is strategically aligned is unable to compete successfully. If we do not realize the benefits that we anticipate from our business strategy and our strategic alignments dissolve and we are not successful in replacing them, our reputation, business, financial results, and prospects may be adversely affected.

The success of our business depends, to a large extent, on our current and future relationships with hospital and healthcare delivery system clients. We invest a significant amount of time to develop, maintain and be responsive to these relationships, and our relationships have helped us to secure acquisition and development opportunities, as well as other advisory, property management, and projects, with both new and existing clients. If our relationships with hospital or health system clients deteriorate, if a conflict of interest or non-compete arrangement prevents us from expanding these relationships, or if a hospital on or near whose campus one of our properties is located fails or becomes unable to meet its financial obligations, the business of our tenants could be adversely affected or our ability to secure new acquisition and development opportunities or other advisory, property management, and hospital project management projects could be adversely impacted and our professional reputation within the industry could be damaged.

Any failure, inability, or unwillingness by our tenants to pay rent or other amounts under leases could materially adversely affect our financial results; we may have difficulty finding suitable replacement tenants in the event of a tenant default or non-renewal of our leases, especially for our properties located in smaller markets.

Our portfolio of healthcare properties is leased to physicians, hospitals, healthcare delivery systems, and other healthcare providers. We cannot provide assurance that our tenants will have sufficient assets, income and access to financing to enable them to satisfy their respective obligations to us, and any failure, inability or unwillingness by our tenants to do so could adversely affect our financial results. We have had tenants pay us rent late or fail to pay rent, which has adversely affected our financial results.

We cannot predict whether our tenants will renew or extend existing leases beyond their current terms. Nearly all of our properties are subject to leases which have multi-year terms. As of December 31, 2017, leases representing 2.9% and 3.9% of leasable square feet at our properties will expire in 2018 and 2019, respectively, and leases representing 0.1% of leasable square feet had expired as of December 31, 2017. If any of our leases are not renewed or extended, or if a tenant defaults under the terms of its lease or becomes insolvent, we would attempt to relet those spaces or properties to other tenants or new tenants. In case of non-renewal, we generally have advance notice before expiration of the lease term to arrange for reletting or repositioning of the spaces or the properties and our tenants are required to continue to perform all of their obligations (including the payment of all rental amounts) under the non-renewed leases until such expiration. However, following expiration of a lease term or if we exercise our right to replace a tenant in default, rental payments on the related properties could decline or cease altogether while we relet or reposition the spaces or the properties with suitable replacement tenants. We also might not be successful in identifying suitable replacement tenants or entering into leases with new tenants on a timely basis or on terms as favorable to us as our current leases, or at all, and we may be required to fund certain expenses and obligations (e.g., real estate taxes, debt costs, and maintenance expenses) to preserve the value of, and avoid the imposition of liens on, our properties while they are being relet or repositioned. Our ability to relet or reposition our properties, or spaces within our properties, with suitable tenants could be significantly delayed or limited by state licensing, receivership, certificate of need or other laws, as well as by the Medicare and Medicaid change-of-ownership rules. We could also incur substantial additional expenses in connection with any licensing, receivership, or change-of-ownership proceedings. In addition, our ability

16

to locate suitable replacement tenants could be impaired by the specialized healthcare uses or contractual restrictions on use of the properties, and we may be required to spend substantial amounts to adapt the properties to other uses. Any such delays, limitations and expenses could adversely impact our ability to collect rent, obtain possession of leased properties, or otherwise exercise remedies for tenant default and could have a material adverse effect on us or cause us to take an impairment charge on a property.

All of these risks may be greater in smaller markets, where there may be fewer potential replacement tenants, making it more difficult to replace tenants, especially for specialized spaces, like hospital or outpatient treatment facilities located in our properties, and could have a material adverse effect on us.

If the business, financial position or results of operations of CHI or one or more of our CHI-affiliated tenants suffer or are adversely affected, it could have a material adverse effect on our business, financial position, or results of operations. 

As of December 31, 2017, approximately 18.7% of our total annualized base rent is from tenants affiliated with CHI.

Although CHI is not a party to nor a guarantor of the related lease agreements, it controls each of the subsidiaries and affiliates that are parties to the master lease agreement, which was entered into in connection with the closing of the transactions. Given this control, if CHI’s business, financial position or results of operations suffer or are adversely affected, it could adversely affect CHI’s ability to provide any financial or operational support for the subsidiaries and affiliates it controls, which could adversely affect one or more of the CHI-affiliated tenants’ ability to pay rent to us. Additionally, if CHI’s business, financial position or results of operations were to suffer or its credit ratings were to be downgraded, it could cause investors to lose confidence in our ability to collect rent from the CHI-affiliated tenants and could cause our stock price to decline. Moreover, there can be no assurance that CHI’s subsidiaries and affiliates will have sufficient assets, income, and access to financing to enable them to satisfy their payment obligations under their lease agreements. The inability of CHI’s subsidiaries and affiliates to meet their rent obligations could materially adversely affect our business, financial position, or results of operations including our ability to pay dividends to our stockholders as required to maintain our status as a REIT. The inability of CHI’s subsidiaries and affiliates to satisfy their other obligations under their lease agreements such as the payment of taxes, insurance, and utilities could have a material adverse effect on the condition of the leased properties as well as on our business, financial position, and results of operations. For these reasons, if CHI were to experience a material adverse effect on its business, financial position, or results of operations, our business, financial position, or results of operations could also be materially adversely affected.

Failure by CHI’s subsidiaries and affiliates to comply with the terms of their lease agreements or to comply with the healthcare regulations to which the leased properties and CHI’s operations are subject could require us to find other lessees for any affected leased properties and there could be a decrease or cessation of rental payments by CHI’s subsidiaries and affiliates. In such event, we may be unable to locate suitable replacement lessees willing to pay similar rental rates or at all, which would have the effect of reducing our rental revenues and could materially adversely affect our business, financial position, or results of operations.

We may not be successful in identifying and completing off-market acquisitions and other suitable acquisitions or investment opportunities, which may impede our growth and adversely affect our business, financial condition, and results of operations and our ability to make distributions to our shareholders.

An important component of our growth strategy is to acquire “off-market” properties before they are widely marketed by the owners. Facilities that are acquired off-market are typically more attractive to us as a purchaser because of the absence of a formal marketing process, which could lead to higher prices or other unattractive terms. If we cannot obtain off-market deal flow in the future, our ability to locate and acquire facilities at attractive prices could be adversely affected. We expect to compete with many other entities engaged in real estate investment activities for acquisitions of healthcare properties, including national, regional, and local operators, acquirers and developers of healthcare-related real estate properties, and other investors such as private equity firms, some of whom may have greater financial resources and lower costs of capital than we do. The competition for healthcare-related real estate properties may significantly increase the price that we must pay for healthcare properties or other assets that we seek to acquire, and our competitors may succeed in acquiring those properties or assets themselves. In addition, our potential acquisition targets may find our competitors to be more attractive because they may have greater resources, may be willing to pay more for the properties, or may have a more compatible operating philosophy. In particular, larger REITs that target healthcare properties may enjoy significant competitive advantages that result from, among other things, a lower cost of capital, enhanced operating efficiencies, more personnel and market penetration, and familiarity with markets. In addition, the number of entities and the amount of funds competing for suitable investment properties may increase. Increased competition would result in increased demand for these assets and therefore likely would increase prices

17

paid for them. Those higher prices for healthcare properties or other assets may adversely affect our returns from our investments.

 During 2017, we saw an increased level of competition for healthcare properties and, as a result, an increase in prices paid for them. In turn, this has had a negative impact on the initial cash yields on potential asset acquisitions. We seek to invest in stabilized medical facility assets with initial cash yields of 5.0% to 9.0%, although we invested in certain medical facility assets in 2017 with anticipated initial cash yields below 5.0% and we may invest in other medical facility assets with initial cash yields outside of this range.

Some of our existing properties and properties we acquire in the future are and may be subject to ground lease or other restrictions on the use of the space. If we are required to undertake significant capital expenditures to procure new tenants, then our business and results of operations may suffer.

Seventy-eight of our properties, representing approximately 39.1% of our total leasable square feet and 36.9% of our annualized revenue based on rental payments for the month ended December 31, 2017, are subject to ground leases that contain certain restrictions. These restrictions include limits on our ability to re-let our initial properties to tenants not affiliated with the healthcare delivery system that owns the underlying property, rights of purchase and rights of first offer and refusal with respect to sales of the property and limits on the types of medical procedures that may be performed. In addition, lower than expected rental rates upon re-letting could impede our growth. We may not be able to re-let space on terms that are favorable to us or at all. Further, we may be required to undertake significant capital expenditures to renovate or reconfigure space to attract new tenants. If we are unable to promptly re-let our initial properties, if the rates upon such re-letting are significantly lower than expected, or if we are required to undertake significant capital expenditures in connection with re-letting, our business, financial condition, and results of operations, our ability to make distributions to our shareholders, and the market price of our common shares may be adversely affected.

Uninsured losses or losses in excess of our insurance coverage could adversely affect our financial condition and our cash flows.

We maintain comprehensive liability, fire, flood, earthquake, wind (as deemed necessary or as required by our lenders), extended coverage, and rental loss insurance with respect to our properties. Certain types of losses, however, may be either uninsurable or not economically insurable, such as losses due to earthquakes, riots, acts of war, or terrorism. Should an uninsured loss occur, we could lose both our investment in and anticipated profits and cash flows from a healthcare-related facility. If any such loss is insured, we may be required to pay a significant deductible on any claim for recovery of such a loss prior to our insurer being obligated to reimburse us for the loss, or the amount of the loss may exceed our coverage for the loss. In addition, future lenders may require such insurance, and our failure to obtain such insurance could constitute a default under loan agreements. We may determine not to insure some or all of our properties at levels considered customary in our industry, which would expose us to an increased risk of loss. As a result, our business, financial condition, and results of operations, our ability to make distributions to our shareholders, and the market price of our common shares may be adversely affected.

Environmental compliance costs and liabilities associated with owning, leasing, developing, and operating our properties may affect our results of operations.

Under various U.S. federal, state, and local laws, ordinances, and regulations, current and prior owners and tenants of real estate may be jointly and severally liable for the costs of investigating, remediating, and monitoring certain hazardous substances or other regulated materials on or in such property. In addition to these costs, the past or present owner or tenant of a property from which a release emanates could be liable for any personal injury or property damage that results from such releases, including for the unauthorized release of asbestos-containing materials and other hazardous substances into the air, as well as any damages to natural resources or the environment that arise from such releases. These environmental laws often impose such liability without regard to whether the current or prior owner or tenant knew of, or was responsible for, the presence or release of such substances or materials. Moreover, the release of hazardous substances or materials, or the failure to properly remediate such substances or materials, may adversely affect the owner’s or tenant’s ability to lease, sell, develop, or rent such property or to borrow by using such property as collateral. Persons who transport or arrange for the disposal or treatment of hazardous substances or other regulated materials may be liable for the costs of removal or remediation of such substances at a disposal or treatment facility, regardless of whether or not such facility is owned or operated by such person.

Certain environmental laws impose compliance obligations on owners and tenants of real property with respect to the management of hazardous substances and other regulated materials. For example, environmental laws govern the management and removal of asbestos-containing materials and lead-based paint. Failure to comply with these laws can result in penalties or other sanctions. If we incur substantial costs to comply with these environmental laws or we are held liable under these laws,

18

our business, financial condition, and results of operations, our ability to make distributions to our shareholders, and the market price of our common shares may be adversely affected.

We may be unable to make distributions which could result in a decrease in the market price of our common shares.

Substantially all of our assets are held through the Operating Partnership, which holds substantially all of its properties and assets through subsidiaries. Our Operating Partnership’s cash flow is dependent upon cash distributions to it by its subsidiaries, and in turn, substantially all of the Trust’s cash flow is dependent upon cash distributions to it by the Operating Partnership. The creditors of each of our direct and indirect subsidiaries are entitled to payment of that subsidiary’s obligation to them, as and when due and payable, before distributions may be made by that subsidiary to its equity holders. Therefore, our Operating Partnership’s ability to make distributions to holders of OP Units depends on its subsidiaries’ ability first to satisfy their obligations to their creditors and then to make distributions to the Operating Partnership. Furthermore, holders of Series A Preferred Units are entitled to receive preferred distributions before payment of distributions to OP Unit holders, including the Trust. Finally, the Trust’s ability to pay dividends to holders of common shares depends upon our Operating Partnership’s ability to first satisfy its obligations to its creditors and then to make distributions to the Trust.

While we expect to make regular quarterly distributions to the holders of our common shares, if sufficient cash is not available for distribution from our operations, we may have to fund distributions from working capital, borrow to provide funds for such distributions, or reduce the amount of such distributions. To the extent we borrow to fund distributions, our future interest costs would increase, thereby reducing our earnings and cash available for distributions from what they otherwise would have been. If cash available for distribution generated by our assets is less than expected, or if such cash available for distribution decreases in future periods from expected levels, our inability to make distributions could result in a decrease in the market price of our common shares. All distributions are made at the discretion of our board of trustees. Any inability to make distributions, or to make distributions at expected levels in the future, could result in a decrease in the market price of our common shares.

Cybersecurity incidents could disrupt our business and result in the compromise of confidential information.

Our business is at risk from and may be impacted by cybersecurity attacks, including attempts to gain unauthorized access to our confidential data, and other electronic security breaches. Such cyber attacks can range from individual attempts to gain unauthorized access to our information technology systems to more sophisticated security threats. While we employ a number of measures to prevent, detect and mitigate these threats, there is no guarantee such efforts will be successful in preventing a cyber attack. Cybersecurity incidents could disrupt our business and compromise confidential information of ours and third parties, including our tenants.

We may not be able to sustain our growth rate level.

Since our inception in 2013 through December 31, 2017, our compounded annual growth rate was 120.0%. This growth rate has contributed significantly to our growth in revenue. While we expect to continue to grow through property acquisitions and investments as our asset base continues to increase, we expect our annual growth rate to decelerate in the future. Over time we may experience a decline in our growth rate as a result of various factors, including changes in the economic and other conditions in geographic markets in which we conduct business, changes in the real estate market, changes in healthcare regulations, and the competitiveness of the real estate market. Additionally, our significant growth has resulted in increased levels of responsibility for our management, who may experience additional demands related to managing our current properties portfolio.

Our ability to issue equity to expand our business will depend, in part, upon the market price of our common shares, and our failure to meet market expectations with respect to our business could negatively affect the market price of our common shares and thereby limit our ability to raise capital and our issuance of equity securities could decrease the per share market price of our common shares.

The availability of equity capital to us will depend, in part, upon the market price of our common shares which, in turn, will depend upon various market conditions and other factors that may change from time to time. Our failure to meet the market’s expectation with regard to future earnings and cash distributions would likely adversely affect the market price of our common shares and, as a result, the cost and availability of equity capital to us.

In addition, the vesting of any restricted shares granted to trustees, executive officers, and other employees under our 2013 Equity Incentive Plan, the issuance of our common shares or OP Units in connection with future property, portfolio or business acquisitions, and other issuances of our common shares may cause dilution to our shareholders and could have an

19

adverse effect on the per share market price of our common shares and may adversely affect the terms upon which we may be able to obtain additional capital through the sale of equity securities.

Increases in interest rates may increase our interest expense and adversely affect our cash flows, our ability to service our indebtedness and our ability to make distributions to our shareholders, and could cause our stock price to decline. Failure to hedge effectively against interest rate changes may adversely affect our results of operations.

One of the factors that influences the market price of our common shares is the dividend yield on common shares (as a percentage of the price of our common shares) relative to market interest rates. In response to the global financial crisis, the U.S. Federal Reserve took actions which resulted in low interest rates prevailing in the marketplace for a historically long period of time. Since December 2015, the U.S. Federal Reserve has raised its benchmark interest rate by a quarter of a percentage point five times to a range of 1.25% to 1.50% and is projected to raise its benchmark interest rate several times in 2018. Further increases in market interest rates may lead prospective purchasers of our common shares to expect a higher dividend yield (with a resulting decline in the market price of our common shares) and higher interest rates would likely increase our borrowing costs for both our existing and future indebtedness and potentially decrease funds available for distribution. Thus, higher market interest rates could cause the market price of our common shares to decrease.

Additionally, as of December 31, 2017, we had approximately $108.5 million of variable-rate indebtedness outstanding that has not been swapped for a fixed interest rate and we expect that more of our indebtedness in the future, including borrowings under our unsecured revolving credit facility since December 31, 2017 and thereafter, will be subject to variable interest rates. Increases in interest rates on any variable rate indebtedness will increase our interest expense, which could adversely affect our cash flow and our ability to pay distributions to our shareholders.

In certain cases, we may seek to manage our exposure to interest rate volatility by using interest rate hedging arrangements. Hedging involves risks, such as the risk that the counterparty may fail to honor its obligations under an arrangement, that the arrangements may not be effective in reducing our exposure to interest rate changes, and that a court could rule that such an agreement is not legally enforceable. In addition, we may be limited in the type and amount of hedging transactions that we may use in the future by our need to satisfy the REIT income tests under the Code. Failure to hedge effectively against interest rate changes may have an adverse effect on our business, financial condition, results of operations, our ability to make distributions to our shareholders, and the market price of our common shares.

The income from certain of our properties is dependent on the ability of our property managers to successfully manage those properties.

We depend upon the performance of our property managers to effectively manage certain of our properties and real estate assets. We do not control these third party property managers, and are accordingly subject to various risks generally associated with outsourcing of management of day-to-day activities. The income we recognize from any properties managed by third party property managers is dependent on the ability of the property manager of such property to successfully manage the property, which such property management is not within our control. Property managers generally compete with other companies in the management of properties, with respect to the quality of care provided, reputation, physical appearance of the property, and price and location, among other attributes. A property manager’s inability to successfully compete with other companies on one or more of the foregoing aspects could adversely impact our business and results of operations. Additionally, because we do not control third party property managers, any adverse events such as issues related to insufficient internal controls, cybersecurity incidents, or other adverse events may impact the income we recognize from properties managed by such third party property managers. We may be unable to anticipate such events or properly assess the magnitude of any such events because we do not control third party property managers who provide property management services to us.

20

Risks Related to the Healthcare Industry

The healthcare industry is heavily regulated, and new laws or regulations, changes to existing laws or regulations, loss of licensure, or failure to obtain licensure could adversely impact our company and result in the inability of our tenants to make rent payments to us.

The healthcare industry is heavily regulated by U.S. federal, state and local governmental authorities. Our tenants generally are subject to laws and regulations covering, among other things, licensure, certification for participation in government programs, billing for services, privacy and security of health information, and relationships with physicians and other referral sources. In addition, new laws and regulations, changes in existing laws and regulations or changes in the interpretation of such laws or regulations could negatively affect our financial condition and the financial condition of our tenants. These changes, in some cases, could apply retroactively. The enactment, timing, or effect of legislative or regulatory changes cannot be predicted.

The Affordable Care Act is changing how healthcare services are covered, delivered, and reimbursed through expanded coverage of uninsured individuals and reduced Medicare program spending. In addition, it reforms certain aspects of health insurance, expands existing efforts to tie Medicare and Medicaid payments to performance and quality, and contains provisions intended to strengthen fraud and abuse enforcement. The complexities and ramifications of the Affordable Care Act are significant and are being implemented in a phased approach which began in 2010. It remains difficult to predict the full effects of the Affordable Care Act and its impact on our business, our revenues, and financial condition and those of our tenants due to the law’s complexity, lack of implementing regulations or interpretive guidance, gradual implementation, partial repeal, and possible full repeal. Further, we are unable to foresee how individuals and businesses will respond to the choices afforded them by the Affordable Care Act, or the effect of any potential changes made to the Affordable Care Act or other healthcare laws and programs. The Affordable Care Act could adversely affect the reimbursement rates received by our tenants, the financial success of our tenants and strategic partners and consequently us.

In 2012, the United States Supreme Court upheld the individual mandate of the Affordable Care Act but partially invalidated the expansion of Medicaid. The ruling on Medicaid expansion allow states not to participate in the expansion (and to forego funding for the Medicaid expansion) without losing their existing Medicaid funding. While the U.S. federal government paid for approximately 100% of those additional costs from 2014 to 2016, states now are expected to pay a small percentage of those additional costs. Because the U.S. federal government substantially funds the Medicaid expansion, it is unclear how many states ultimately will elect this option. As of January 2018, 32 states and Washington, D.C. have elected to participate in the Medicaid expansion. The participation by states in the Medicaid expansion could have the effect of increasing some of our tenants’ revenues but also could be a strain on U.S. federal government and state budgets.

In 2017, President Trump and Congress unsuccessfully sought to repeal and replace the Affordable Care Act. On January 20, 2017, President Trump issued an Executive Order stating that it is the administration’s official policy to repeal the Affordable Care Act and instructing the Secretary of Health and Human Services and the heads of all other executive departments and agencies with authority and responsibility under the Affordable Care Act to, among other matters, delay implementation of or grant an exemption from any provision of the Affordable Care Act that would impose a fiscal burden on any state or a cost, fee, tax, penalty, or regulatory burden on individuals, families, healthcare providers, health insurers, patients, and others. On December 22, 2017, the Tax Cuts and Jobs Act (the “Tax Act”) was signed into law. The Tax Act, amongst other things, repeals the Affordable Care Act’s individual mandate penalty beginning in 2019. The elimination of the penalties does not remove the requirement to obtain healthcare coverage; however, without penalties there effectively will be no enforcement. It is expected that Congress will continue to consider other legislation to repeal the Affordable Care Act or repeal and replace some or all elements of the Affordable Care Act.

We cannot predict the effect of either the Executive Order or the Tax Act’s 2019 repeal of the individual mandate penalty on the Affordable Care Act, or whether Congress’ attempt to repeal or repeal and replace the law will be successful. Further, we cannot predict how the Affordable Care Act might be amended or modified, either through the legislative or judicial process, and how any such modification might impact our tenants’ operations or the net effect of this law on us. If the operations, cash flows, or financial condition of our operators and tenants are materially adversely impacted by any repeal or modification of the law, our revenue and operations may be materially adversely affected as well.

21

Recent changes to healthcare laws and regulations, including to government reimbursement programs such as Medicare and reimbursement rates applicable to our current and future tenants, could have a material adverse effect on the financial condition of our tenants and, consequently, their ability to meet obligations to us.

Statutory and regulatory policy changes and decisions may impact one or more specific unique providers that lease space in any of our facilities. In particular, the following recent changes to healthcare laws and regulations may apply to our tenants:

• Recent amendments to an existing statutory moratorium on the establishment of new long-term care hospitals (“LTCH”), the establishment of new LTCH satellite facilities, and bed increases within such existing facilities, which is in effect through December 31, 2017, could impact the Medicare participation of facilities that are not already participating in the Medicare program as LTCHs.

• The Medicare Access and CHIP Reauthorization Act of 2015 (“MACRA”) reforms Medicare payment policy for services paid under the Medicare physician fee schedule and adopts a series of policy changes affecting a wide range of providers and suppliers. MACRA repeals the sustainable growth rate (the “SGR”) formula effective January 1, 2015, and establishes a new payment framework which may impact payment rates for our tenants, including LTCHs.

• The Bipartisan Budget Act of 2013 establishes new payment limits for Medicare patients discharged from an LTCH who do not meet specified criteria. For any Medicare patient who does not meet the new criteria, the LTCH will be paid a lower “site-neutral” payment rate, which may impact the financial condition of tenants affected by the lower payment rate. Additionally, new rules may cause all discharges from LTCHs to be paid at the site-neutral rate if the number of discharges for which payment is made under the site-neutral payment rate is greater than 50% of the total number of discharges from the LTCH.

• The Bipartisan Budget Act of 2015 (H.R. 1314) (the “BBA”) provides changes to the requirements for providers who seek “hospital outpatient department” (“HOPD”) reimbursement under Medicare. The 2015 BBA generally requires providers who seek to qualify for HOPD to be located on the campus of the hospital that seeks such HOPD, which generally is higher than reimbursement for providers that do not qualify as HOPD providers. The BBA specifically grandfathers HOPD providers in existence as of November 2, 2015 and does not change such HOPD providers’ eligibility for HOPD reimbursement.

We have a number of existing tenants that may be reimbursed as HOPD providers and but for the grandfathering protection of the BBA, may not be eligible for HOPD reimbursement in the future. Any provider who establishes a new HOPD location after November 2, 2015 will be subject to the BBA requirements and if any such provider does not satisfy the new requirements, then such provider will be reimbursed for claims billed on or after January 1, 2017 at generally lower reimbursement levels. Failure to comply with the BBA requirements could adversely affect the ability of certain of our tenants to make rent payments to us, which may have an adverse effect on our business, financial condition, and results of operations, our ability to make distributions to our shareholders, and the market price of our common shares.

• The Affordable Care Act instituted a market basket payment adjustment to LTCHs. In fiscal years 2017 through 2019, the market basket update will be reduced by 0.75%. The Affordable Care Act specifically allows these market basket reductions to result in a less than 0% payment update and payment rates that are less than the prior year. MACRA sets the annual update for fiscal year 2018 at 1% after taking into account the market basket payment reduction of 0.75% mandated by the Affordable Care Act.

These regulatory changes may have an adverse financial impact on the net operating revenues and profitability of many LTCHs for cost reporting periods beginning on or after July 1, 2016, which could have an impact on their ability to pay rent due to us.

Many states also regulate the establishment and construction of healthcare facilities and services, and the expansion of existing healthcare facilities and services through certificate of need, or CON, laws, which may include regulation of certain types of beds, medical equipment, and capital expenditures. Under such laws, the applicable state regulatory body must determine a need exists for a project before the project can be undertaken. If any of our tenants seeks to undertake a CON-regulated project, but are not authorized by the applicable regulatory body to proceed with the project, these tenants could be prevented from operating in their intended manner and could be materially adversely affected.

The application of lower reimbursement rates to our tenants or failure to qualify for existing rates under certain exceptions, the failure to comply with these laws and regulations, or the failure to secure CON approval to undertake a desired project could adversely affect our tenants’ ability to make rent payments to us which may have an adverse effect on our business, financial condition, and results of operations, our ability to make distributions to our shareholders, and the market price of our common shares.

22

Adverse trends in healthcare provider operations may negatively affect our lease revenues and our ability to make distributions to our shareholders.

The healthcare industry is currently experiencing, among other things:

• changes in the demand for and methods of delivering healthcare services; 

• changes in third party reimbursement methods and policies;

• consolidation and pressure to integrate within the healthcare industry through acquisitions and joint ventures; and

• increased scrutiny of billing, referral and other practices by U.S. federal and state authorities.

These factors may adversely affect the economic performance of some or all of our tenants and, in turn, our lease revenues, which may have a material adverse effect on our business, financial condition, and results of operations, our ability to make distributions to our shareholders, and the market price of our common shares.

Reductions in reimbursement from third party payors, including Medicare and Medicaid, could adversely affect the profitability of our tenants and hinder their ability to make rent payments to us or renew their lease.

Sources of revenue for our tenants typically include the U.S. federal Medicare program, state Medicaid programs, private insurance payors and health maintenance organizations. Healthcare providers continue to face increased government and private payor pressure to control or reduce healthcare costs and significant reductions in healthcare reimbursement, including reduced reimbursements and changes to payment methodologies under the Affordable Care Act. In some cases, private insurers rely upon all or portions of the Medicare payment systems to determine payment rates which may result in decreased reimbursement from private insurers.

The slowdown in the United States economy has negatively affected state budgets, thereby putting pressure on states to decrease spending on state programs including Medicaid. The need to control Medicaid expenditures may be exacerbated by the potential for increased enrollment in state Medicaid programs due to unemployment and declines in family incomes. Historically, states have often attempted to reduce Medicaid spending by limiting benefits and tightening Medicaid eligibility requirements. Many states have adopted, or are considering the adoption of, legislation designed to enroll Medicaid recipients in managed care programs and/or impose additional taxes on hospitals to help finance or expand the states’ Medicaid systems. Potential reductions to Medicaid program spending in response to state budgetary pressures could negatively impact the ability of our tenants to successfully operate their businesses.

Efforts by payors to reduce healthcare costs will likely continue which may result in reductions or slower growth in reimbursement for certain services provided by some of our tenants. A reduction in reimbursements to our tenants from third party payors for any reason could adversely affect our tenants’ ability to make rent payments to us which may have a material adverse effect on our businesses, financial condition and results of operations, our ability to make distributions to our shareholders and the market price of our common shares. 

Our tenants and our company are subject to fraud and abuse laws, the violation of which by a tenant may jeopardize the tenant’s ability to make rent payments to us.

There are various federal and state laws prohibiting fraudulent and abusive business practices by healthcare providers who participate in, receive payments from, or are in a position to make referrals in connection with government-sponsored healthcare programs, including the Medicare and Medicaid programs. Our lease arrangements with certain tenants may also be subject to these fraud and abuse laws.

Violations of these laws may result in criminal and/or civil penalties that range from punitive sanctions, damage assessments, penalties, imprisonment, denial of Medicare and Medicaid payments, and/or exclusion from the Medicare and Medicaid programs. In addition, the Affordable Care Act clarifies that the submission of claims for items or services generated in violation of the Anti-Kickback Statute constitutes a false or fraudulent claim under the False Claims Act. The federal government has taken the position, and some courts have held, that violations of other laws, such as the Stark Law, can also be a violation of the False Claims Act. Additionally, certain laws, such as the False Claims Act, allow for individuals to bring whistleblower actions on behalf of the government for violations thereof. Imposition of any of these penalties upon one of our tenants or strategic partners could jeopardize that tenant’s ability to operate or to make rent payments or affect the level of occupancy in our healthcare properties, which may have a material adverse effect on our business, financial condition, and results of operations, our ability to make distributions to our shareholders, and the market price of our common shares. Further, we enter into leases and other financial relationships with healthcare delivery systems that are subject to or impacted by these

23

laws. We also have other investors who are healthcare providers in certain of our subsidiaries that own our healthcare properties. If any of our relationships, including those related to the other investors in our subsidiaries, are found not to comply with these laws, we and our healthcare provider investors may be subject to civil and/or criminal penalties.

Our healthcare-related tenants may be subject to significant legal actions that could subject them to increased operating costs and substantial uninsured liabilities, which may affect their ability to pay their rent payments to us, and we could be subject to healthcare industry violations.

As is typical in the healthcare industry, our tenants may become subject to claims that their services have resulted in patient injury or other adverse effects. Many of these tenants may have experienced an increasing trend in the frequency and severity of professional liability and general liability insurance claims and litigation asserted against them. The insurance coverage maintained by these tenants may not cover all claims made against them nor continue to be available at a reasonable cost, if at all. In some states, insurance coverage for the risk of punitive damages arising from professional liability and general liability claims and/or litigation may not, in certain cases, be available to these tenants due to state law prohibitions or limitations of availability. As a result, these types of tenants of our healthcare properties and healthcare-related facilities operating in these states may be liable for punitive damage awards that are either not covered or are in excess of their insurance policy limits.

We also believe that there has been, and will continue to be, an increase in governmental investigations of certain healthcare providers, particularly in the area of Medicare/Medicaid false claims, as well as an increase in enforcement actions resulting from these investigations. Insurance is not available to cover such losses. Any adverse determination in a legal proceeding or governmental investigation, any settlements of such proceedings, or investigations in excess of insurance coverage, whether currently asserted or arising in the future, could have a material adverse effect on a tenant’s financial condition. If a tenant is unable to obtain or maintain insurance coverage, if judgments are obtained or settlements reached in excess of the insurance coverage, if a tenant is required to pay uninsured punitive damages, or if a tenant is subject to an uninsurable government enforcement action or investigation, the tenant could be exposed to substantial additional liabilities, which may affect the tenant’s ability to pay rent, which in turn could have a material adverse effect on our business, financial condition, and results of operations, our ability to pay distributions to our shareholders, and the market price of our common shares. We could also be subject to costly government investigations or other enforcement actions which could have a material adverse effect on our business, financial condition, and results of operations, our ability to pay distributions to our shareholders, and the market price of our common shares.

Risks Related to the Real Estate Industry

Our operating performance is subject to risks associated with the real estate industry.

Real estate investments are subject to various risks and fluctuations and cycles in value and demand, many of which are beyond our control. Certain events may decrease cash available for distributions as well as the value of our properties. These events include, but are not limited to:

• vacancies or our inability to rent space on favorable terms, including possible market pressures to offer tenants rent abatements, tenant improvements, early termination rights, or tenant-favorable renewal options;

• inability to collect rent from tenants;

• competition from other real estate investors with significant capital, including other real estate operating companies, REITs, and institutional private equity or other investment funds;

• reductions in the level of demand for healthcare properties and changes in the demand for certain healthcare-related properties;

• increases in the supply of medical office space;

• increases in expenses associated with our real estate operations, including, but not limited to, insurance costs, third party management fees, energy prices, real estate assessments, and other taxes and costs of compliance with laws, regulations and governmental policies, and restrictions on our ability to pass such expenses on to our tenants; and

• changes in, and changes in interpretation or enforcement of, laws, regulations, and governmental policies associated with real estate, including, without limitation, health, safety, environmental, real estate and zoning and tax laws, increases in real property tax rates and taxation of REITs, governmental fiscal policies, and the ADA. 

24

In addition, periods of economic slowdown or recession, such as the recent U.S. economic downturn, rising interest rates or declining demand for real estate, or the public perception that any of these events may occur, could result in a general decline in rents or an increased incidence of defaults under existing leases. If we cannot operate our properties to meet our financial expectations, our business, financial condition, results of operations, cash flow, per share market price of our common shares, and ability to satisfy our debt service obligations and to make distributions to our shareholders could be adversely affected.

Illiquidity of real estate investments could significantly impede our ability to respond to adverse changes in the performance of any of our properties.

Because real estate investments are relatively illiquid, our ability to promptly sell one or more of our properties in response to changing economic, financial, and investment conditions is limited. The real estate market is affected by many factors, such as general economic conditions, availability of financing, interest rates, and other factors, including supply and demand, that are beyond our control. We cannot predict whether we will be able to sell any of our properties for the price or on the terms set by us or whether any price or other terms offered by a prospective purchaser would be acceptable to us. We also cannot predict the length of time needed to find a willing purchaser and to close the sale of any of our properties. We may be required to expend funds to correct defects or to make improvements before a property can be sold. We cannot assure that we will have funds available to correct those defects or to make those improvements.

In acquiring a property, we may agree to transfer restrictions that materially restrict us from selling that property for a period of time or impose other restrictions, such as a limitation on the amount of debt that can be placed on that property. These transfer restrictions would impede our ability to sell a property even if we deem it necessary or appropriate. These facts and any others that would impede our ability to respond to adverse changes in the performance of our properties may have an adverse effect on our business, financial condition, results of operations, or ability to make distributions to our shareholders and the market price of our common shares.

Uncertain market conditions could cause us to sell our healthcare properties at a loss in the future.

We intend to hold our various real estate investments until such time as we determine that a sale or other disposition appears to be advantageous to achieve our investment objectives. Our senior management team and the Trust’s board of trustees may exercise their discretion as to whether and when to sell a healthcare related facility, and we will have no obligation to sell our buildings at any particular time. We generally intend to hold our healthcare properties for an extended period of time, and we cannot predict with any certainty the various market conditions affecting real estate investments that will exist at any particular time in the future. Because of the uncertainty of market conditions that may affect the future disposition of our healthcare properties, we may not be able to sell our properties at a profit in the future or at all. In addition, if we are unable to access the capital markets for financing in the future, we may need to sell some of our properties to raise capital. We may incur prepayment penalties in the event that we sell a property subject to a mortgage earlier than we otherwise had planned. Additionally, we could be forced to sell healthcare properties at inopportune times which could result in us selling the affected property at a substantial loss. Accordingly, the extent to which we will pay cash distributions and realize potential appreciation on our real estate investments will, among other things, be dependent upon fluctuating market conditions. Any inability to sell a healthcare property could adversely impact our ability to make debt payments and distributions to our shareholders.

Our assets may be subject to impairment charges.

We will periodically evaluate our real estate investments and other assets for impairment indicators. The judgment regarding the existence of impairment indicators is based upon factors such as market conditions, tenant performance, and legal structure. For example, the termination of a lease by a major tenant may lead to an impairment charge. If we determine that an impairment has occurred, we would be required to make an adjustment to the net carrying value of the asset, which could have an adverse effect on our results of operations in the period in which the impairment charge is recorded. We recorded a $1.0 million impairment loss on a vacant medical office building in Port Charlotte, Florida during 2017.

Our investments in, or originations of, mezzanine and term loans will be subject to specific risks relating to the particular company, and our loan assets will involve greater risks of loss than senior loans secured by income-producing properties.

As of December 31, 2017, we have ten mezzanine loans and two term loans outstanding, and in the future, we may originate further loans. These investments involve special risks relating to the particular borrower, including its financial condition, liquidity, results of operations, business, and prospects. We may also originate other real estate-related investments which take the form of subordinated loans secured by second mortgages on the underlying property or loans secured by a pledge of the ownership interests of either the entity owning the property or a pledge of the ownership interests of the entity

25

that owns the interest in the entity owning the property or other properties. These types of assets involve a higher degree of risk than long-term senior mortgage lending secured by income producing real property, because the loan may become unsecured as a result of foreclosure by the senior lender and because it is in second position and there may not be adequate equity in the property. In the event of a bankruptcy of the entity providing the pledge of its ownership interests as security, we may not have full recourse to the assets of such entity, or the assets of the entity may not be sufficient to satisfy such loan. If a borrower defaults on a loan or debt senior to our loan, or in the event of a borrower bankruptcy, such loan will be satisfied only after the senior debt. We may be unable to enforce guaranties of payment and/or performance given as security for some loans. As a result, we may not recover some or all of our initial expenditure. Mezzanine and term loans may partially finance the construction of real estate projects and so involve additional risks inherent in the construction process, such as adherence to budgets and construction schedules. In addition, mezzanine and term loans may have higher loan-to-value ratios than conventional mortgage loans, resulting in less equity in the property and increasing the risk of loss of principal. Significant losses related to our mezzanine and term loans would result in operating losses for us and may limit our ability to make distributions to our shareholders.

Risks Related to Financings

Required payments of principal and interest on borrowings may leave us with insufficient cash to operate our properties or to pay the distributions currently contemplated or necessary to qualify as a REIT and may expose us to the risk of default under our debt obligations.

We historically borrow on our unsecured revolving credit facility to acquire properties. Then, as market conditions dictate, we have issued equity or long-term fixed rate debt to repay borrowings under our unsecured revolving credit facility. We are subject to risks associated with debt financing, including the risk that existing indebtedness may not be refinanced or that the terms of refinancing may not be as favorable as the terms of current indebtedness. The majority of our borrowings were completed under indentures or contractual agreements that limit the amount of indebtedness we may incur. Accordingly, in the event that we are unable to raise additional equity or borrow money because of these limitations, our ability to acquire additional properties may be limited. 

As of December 31, 2017, we had approximately $186.7 million of mortgage debt on individual properties and approximately $330.0 million of borrowings outstanding under our unsecured credit facility. In addition, in January 2016, August 2016, March 2017 and December 2017 we issued and sold $150.0 million, $75.0 million, $400.0 million, and $350.0 million, respectively, aggregate principal amount of senior notes. We expect to incur additional debt in the future. We do not anticipate that our internally generated cash flow will be adequate to repay our existing indebtedness upon maturity, and, therefore, we expect to repay our indebtedness through refinancings and future offerings of equity and debt securities, either of which we may be unable to secure on favorable terms or at all. Our level of debt and the limitations imposed upon us by our debt agreements could have adverse consequences, including the following:

• our cash flow may be insufficient to meet our required principal and interest payments;

• we may be unable to borrow additional funds as needed or on favorable terms, including to make acquisitions;

• we may be unable to refinance our indebtedness at maturity or the refinancing terms may be less favorable than the terms of our original indebtedness;

• because a portion of our debt bears, or is expected to bear, interest at variable rates, an increase in interest rates could materially increase our interest expense;

• we may fail to effectively hedge against interest rate volatility;

• we may be forced to dispose of one or more of our properties, possibly on disadvantageous terms if we are able to do so at all;

• our leverage could place us at a competitive disadvantage compared to our competitors who have less debt;

• we may experience increased vulnerability to economic and industry downturns, reducing our ability to respond to changing business and economic conditions;

• we may default on our obligations and the lenders or mortgagees may foreclose on our properties that secure their loans and receive an assignment of rents and leases;

• we may violate financial covenants contained in our various loan documents which would cause a default on our obligations, giving lenders various remedies, including increased interest rates, foreclosure, and liability for additional expenses;

26

• we may inadvertently violate non-financial restrictive covenants in our loan documents, such as covenants that require us to maintain the existence of entities, maintain insurance policies and provide financial statements, which would entitle the lenders to accelerate our debt obligations; and

• our default under any of our mortgage loans with cross-default or cross-collateralization provisions could result in default on other indebtedness and result in the foreclosures of other properties.

The realization of any or all of these risks may have an adverse effect on our business, financial condition, and results of operations, our ability to make distributions to our shareholders, and the market price of our common shares.

As of December 31, 2017, we had approximately $330.0 million of borrowings outstanding under our unsecured credit facility (including the term loan feature of our unsecured credit facility), during 2016 and 2017, we issued an aggregate of $975.0 million of debt, and in January 2018 we issued 104,172 Series A Preferred Units of the Operating Partnership (“Series A Preferred Units”), all of which is senior to our common shares upon liquidation, and we may in the future make offerings of debt or preferred equity securities which may be senior to our common shares for purposes of dividend distributions or upon liquidation, any of which may materially adversely affect the per share market price of our common shares.

As of December 31, 2017, there were approximately $330.0 million of borrowings outstanding under our unsecured credit facility (including the term loan feature of our unsecured credit facility), and during 2016 and 2017, we issued $975.0 million of aggregate principal amount of senior notes. In January 2018, we issued 104,172 Series A Preferred Units. In the future, we may attempt to increase our capital resources by making additional offerings of debt or equity securities (or causing the Operating Partnership to issue debt securities), including medium-term notes, senior or subordinated notes, and classes or series of preferred shares. Upon liquidation, holders of our debt securities and preferred shares and lenders with respect to other borrowings will be entitled to receive our available assets prior to distribution to the holders of our common shares. Additionally, any convertible or exchangeable securities that we issue in the future may have rights, preferences, and privileges more favorable than those of our common shares and may result in dilution to owners of our common shares. Holders of our common shares are not entitled to preemptive rights or other protections against dilution. Our preferred shares would have a preference on liquidating distributions or a preference on dividend payments that could limit our ability pay dividends or other distributions to the holders of our common shares. Because our decision to issue securities in any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing, or nature of our future offerings. Thus, our shareholders bear the risk that our future offerings could reduce the per share market price of our common shares and dilute their interest in us.

The derivative instruments that we may use to hedge against interest rate fluctuations may not be successful in mitigating our risks associated with interest rates and could reduce the overall returns on our shareholders’ investment.

We may use derivative instruments to hedge exposure to changes in interest rates on certain of our variable rate loans, but no hedging strategy can protect us completely. We cannot assure our shareholders that our hedging strategy and the derivatives that we use will adequately offset the risk of interest rate volatility or that our hedging of these transactions will not result in losses. Any settlement charges incurred to terminate unused derivative instruments may result in increased interest expense, which may reduce the overall return on our investments. These instruments may also generate income that may not be treated as qualifying REIT income for purposes of the 75% or 95% REIT income tests.

We rely upon external sources of capital to fund future capital needs, and, if we encounter difficulty in obtaining such capital, we may not be able to make future acquisitions necessary to grow our business or meet maturing obligations.

In order to qualify as a REIT under the Internal Revenue Code of 1986, as amended (the “Code”), we are required, among other things, to distribute each year to our shareholders at least 90% of our taxable income, without regard to the deduction for dividends paid and excluding net capital gain. Because of this distribution requirement, we may not be able to fund all of our future capital needs from cash retained from operations, including capital needed to make investments and to satisfy or refinance maturing obligations. As a result, we expect to rely upon external sources of capital, including debt and equity financing, to fund future capital needs. If we are unable to obtain needed capital on satisfactory terms or at all, we may not be able to make the investments needed to expand our business or to meet our obligations and commitments as they mature. Our access to capital will depend upon a number of factors over which we have little or no control, including general stock and bond market conditions and investor interest, the market’s perception of our current and potential future earnings, analyst reports about us and the REIT industry, cash distributions and the market price of our common shares, and other factors such as governmental regulatory action and changes in REIT tax laws. We may not be in a position to take advantage of attractive investment opportunities for growth if we are unable to access the capital markets on a timely basis on favorable terms. Moreover, additional equity offerings may result in substantial dilution of our shareholders’ interests, and additional debt

27

financing may substantially increase our leverage, either of which could cause the per share price of our common shares to decline.

If we become highly leveraged in the future, the resulting increase in outstanding debt could adversely affect our ability to make debt service payments, to pay our anticipated distributions, and to make the distributions required to qualify as a REIT.

As of December 31, 2017, our indebtedness represented approximately 35.8% of our total assets. If we become more highly leveraged, the resulting increase in outstanding debt could adversely affect our ability to make debt service payments, to pay our anticipated distributions, and to make the distributions required to qualify as a REIT. The occurrence of any of the foregoing risks could adversely affect our business, financial condition, and results of operations, our ability to make distributions to our shareholders, and the market price of our common shares.

We are subject to covenants in our debt agreements that may restrict or limit our operations and acquisitions and our failure to comply with the covenants in our debt agreements could have a material adverse impact on our business, results of operations, and financial condition.

The terms of the instruments governing our existing indebtedness require us to comply with a number of customary financial and other covenants, such as maintaining certain leverage and coverage ratios and minimum tangible net worth requirements. Our continued ability to incur additional debt and to conduct business in general is subject to our compliance with these covenants, which limit our operational flexibility. Breaches of these covenants could result in defaults under the instruments governing the applicable indebtedness, in addition to any other indebtedness cross-defaulted against such instruments. Any such default could have a material adverse impact on our business, results of operations, and financial condition or our ability to make distributions to our shareholders.

A downgrade in our credit ratings could materially adversely affect our business and financial condition.

Our credit rating and the credit ratings assigned to our debt securities could change based upon, among other things, our results of operations and financial condition. These ratings are subject to ongoing evaluation by credit rating agencies, and any rating could be changed or withdrawn by a rating agency in the future if, in its judgment, circumstances warrant such action.

If any of the credit rating agencies that have rated our securities downgrades or lowers its credit rating, or if any credit rating agency indicates that it has placed any such rating on a “watch list” for a possible downgrade or lowering, or otherwise indicates that its outlook for that rating is negative, such action could have a material adverse effect on our costs and availability of funding, which could in turn have a material adverse effect on our financial condition, results of operations, cash flows, the market price of our securities, and our ability to satisfy our debt service obligations, among other obligations.

If securities analysts do not publish research or reports about our industry or if they downgrade our common shares or the healthcare-related real estate sector, the market price of our common shares could decline.

The market for our common shares depends in part upon the research and reports that industry or financial analysts publish about us and our industry. We have no control over these analysts. Furthermore, if one or more of the analysts who do cover us downgrades our shares or our industry, or the stock of any of our competitors, the price of our common shares could decline. If one or more of these analysts ceases coverage of our company, we could lose attention in the market which in turn could cause the market price of our common shares to decline.

Risks Related to Our Portfolio and Structure

We have no direct operations and rely upon funds received from the Operating Partnership to meet our obligations.

The Trust conducts substantially all of its operations through the Operating Partnership. As of February 23, 2018, the Trust owned approximately 97.1% of the OP Units and apart from this ownership interest, the Trust does not have any independent operations. As a result, the Trust relies upon distributions from the Operating Partnership to pay any distributions that the Trust might declare on the Trust’s common shares. We also rely upon distributions from the Operating Partnership to the Trust to meet our obligations, including tax liability on taxable income allocated to the Trust from the Operating Partnership (which might make distributions to the Trust not equal to the tax on such allocated taxable income). Shareholders’ claims will consequently be structurally subordinated to all existing and future liabilities and obligations (whether or not for borrowed money) of the Operating Partnership and its subsidiaries. Therefore, in the event of bankruptcy, liquidation or reorganization of

28

the Trust, claims of the Trust’s shareholders will be satisfied only after all of the Trust’s and the Operating Partnership’s and its subsidiaries’ liabilities and obligations have been paid in full.

Our business could be harmed if key personnel terminate their employment with us or if we are unsuccessful in integrating new personnel into our operations.

Our success depends, to a significant extent, on the continued services of Mr. Thomas, our President and Chief Executive Officer; Mr. Theiler, our Executive Vice President and Chief Financial Officer; Mr. Taylor, our Executive Vice President – Investments; Mr. Lucey, our Senior Vice President – Chief Accounting and Administrative Officer; Mr. Theine, our Senior Vice President of Asset and Investment Management; Mr. Page, our Senior Vice President and General Counsel; and Mr. Klein, our Senior Vice President – Investments and Deputy Chief Investment Officer. We do not maintain key person life insurance on any of our officers. Our ability to continue to acquire and develop healthcare properties depends upon the significant relationships that our senior management team has developed over many years.

Although the Trust has entered into employment agreements with Messrs. Thomas, Theiler, Taylor, Lucey, Theine, Page, and Klein, we cannot provide any assurance that any of them will remain employed by the Trust. Our ability to retain our senior management team, or to attract suitable replacements should any member of the senior management team leave, is dependent on the competitive nature of the employment market. The loss of services of, or the failure to successfully integrate one or more new members of, our senior management team could adversely affect our business and our prospects.

The Trust’s declaration of trust restricts the ownership and transfer of our outstanding shares of beneficial interest which may have the effect of delaying, deferring, or preventing a transaction or change of control of our company.

In order for us to qualify as a REIT, no more than 50% of the value of the Trust’s outstanding shares of beneficial interest may be owned, beneficially or constructively, by five or fewer individuals at any time during the last half of each taxable year other than our initial REIT taxable year. Subject to certain exceptions, the Trust’s declaration of trust prohibits any shareholder from owning beneficially or constructively more than 9.8% in value or number of shares, whichever is more restrictive, of the outstanding shares of any class or series of our shares of beneficial interest, although the Trust has granted, and may in the future grant, a waiver from the ownership limitations. The constructive ownership rules under the Code are complex and may cause the outstanding shares owned by a group of related individuals or entities to be deemed to be constructively owned by one individual or entity. As a result, the acquisition of less than 9.8% of our outstanding shares of any class or series by an individual or entity could cause that individual or entity to own constructively in excess of 9.8% of the outstanding shares of any class or series of our shares of beneficial interest and to be subject to the Trust’s declaration of trust’s ownership limit. The Trust’s declaration of trust also prohibits, among other prohibitions, any person from owning our shares of beneficial interest that would result in our being “closely held” under Section 856(h) of the Code or otherwise cause us to fail to qualify as a REIT. Any attempt to own or transfer shares of our beneficial interest in violation of these restrictions may result in the shares being automatically transferred to a charitable trust or may be void. The share ownership restrictions of the Code for REITs and the 9.8% share ownership limit and other restrictions on ownership and transfer of our shares contained in the Trust’s declaration of trust may inhibit market activity in our shares of beneficial interest and restrict our business combination opportunities.

Certain provisions of Maryland law could inhibit changes of control, which may discourage third parties from conducting a tender offer or seeking other change of control transactions that could involve a premium price for our common shares or that our shareholders otherwise believe to be in their best interests.

Certain provisions of the Maryland General Corporation Law, or MGCL, applicable to Maryland real estate investment trusts may have the effect of inhibiting a third party from making a proposal to acquire the Trust (and, indirectly, the Operating Partnership) or of impeding a change of control under circumstances that otherwise could provide the Trust’s common shareholders with the opportunity to realize a premium over the then-prevailing market price of such shares, including:

• “business combination” provisions that, subject to limitations, prohibit certain business combinations between us and an “interested shareholder” (defined generally as any person who beneficially owns 10% or more of the voting power of our shares or an affiliate or associate of ours who was the beneficial owner, directly or indirectly, of 10% or more of the voting power of our shares at any time within the two-year period immediately prior to the date in question) or an affiliate thereof for five years after the most recent date on which the shareholder becomes an interested shareholder, and thereafter imposes certain minimum price and/or supermajority shareholder voting requirements on these combinations; and

29

• “control share” provisions that provide that holders of “control shares” of our Trust (defined as shares that, when aggregated with all other shares controlled by the shareholder, entitle the shareholder to exercise one of three increasing ranges of voting power in electing trustees) acquired in a “control share acquisition” (defined as the direct or indirect acquisition of ownership or control of issued and outstanding “control shares,” subject to certain exceptions) have no voting rights with respect to their control shares, except to the extent approved by our shareholders by the affirmative vote of at least two-thirds of all the votes entitled to be cast on the matter, excluding all interested shares.

Pursuant to the statute, the Trust’s board of trustees has by resolution exempted any business combination between us and any other person from the business combination provisions of the MGCL, provided that the business combination is first approved by the board of trustees (including a majority of trustees who are not affiliates or associates of such person). In addition, the Trust’s bylaws contain a provision exempting any and all acquisitions of our shares from the control share provisions of the MGCL. However, the board of trustees may at any time alter or repeal the resolution exempting certain businesses from the business combination provisions of the MGCL and we may at any time amend or eliminate the provision of our bylaws exempting acquisitions of our shares from the control share provisions of the MGCL.

Certain provisions of the MGCL permit the board of trustees, without shareholder approval and regardless of what is currently provided in the Trust’s declaration of trust or bylaws, to implement certain corporate governance provisions with respect to the Trust, some of which (for example, a classified board) are not currently applicable to us. If implemented, these provisions may have the effect of limiting or precluding a third party from making an unsolicited acquisition proposal for us or of delaying, deferring, or preventing a change in control of us under circumstances that otherwise could provide our common shareholders with the opportunity to realize a premium over the then current market price. Pursuant to our declaration of trust, we have elected to be subject to the provisions of Title 3, Subtitle 8 of the MGCL relating to the filling of vacancies on our board of trustees.

We could increase the number of authorized shares, classify and reclassify unissued shares, and issue shares without shareholder approval.

The Trust’s board of trustees, without shareholder approval, has the power under the Trust’s declaration of trust to amend our declaration of trust to increase or decrease the aggregate number of shares or the number of shares of any class or series of the Trust that we are authorized to issue, and to authorize us to issue authorized but unissued common shares or preferred shares. In addition, under the declaration of trust, the board of trustees has the power to classify or reclassify any unissued common or preferred shares into one or more classes or series of shares and set or change the preference, conversion or other rights, voting powers, restrictions, limitations as to dividends and other distributions, qualifications or terms or conditions of redemption for such newly classified or reclassified shares. As a result, we may issue series or classes of common shares or preferred shares with preferences, dividends, powers, and rights, voting or otherwise, that are senior to, or otherwise conflict with, the rights of holders of our common shares. Although the board of trustees has no such intention at the present time, it could establish a class or series of preferred shares that could, depending on the terms of such class or series, delay, defer, or prevent a transaction or a change of control that might involve a premium price for our common shares or that our shareholders otherwise believe to be in their best interests.

Certain provisions in the partnership agreement of the Operating Partnership may delay or prevent unsolicited acquisitions of us.

Provisions in the partnership agreement of the Operating Partnership may delay, or make more difficult, unsolicited acquisitions of us or changes of our control. These provisions could discourage third parties from making proposals involving an unsolicited acquisition of us or change of our control, although some shareholders might consider such proposals, if made, desirable. These provisions include, among others:

• redemption rights;

• a requirement that the Trust may not be removed as the general partner of the Operating Partnership without our consent;

• transfer restrictions on OP Units;

• the Trust’s ability, as general partner, in some cases, to amend the partnership agreement and to cause the Operating Partnership to issue units with terms that could delay, defer, or prevent a merger or other change of control of the Trust or the Operating Partnership without the consent of the limited partners; and

30

• the right of the limited partners to consent to direct or indirect transfers of the general partnership interest, including as a result of a merger or a sale of all or substantially all of our assets, in the event that such transfer requires approval by our common shareholders.

The Trust’s declaration of trust and bylaws, Maryland law, and the partnership agreement of the Operating Partnership also contain other provisions that may delay, defer, or prevent a transaction or a change of control that might involve a premium price for our common shares or that our shareholders otherwise believe to be in their best interest.

Risks Related to Our Qualification and Operation as a REIT

If we fail to qualify as a REIT in any taxable year, we will face serious tax consequences that would substantially reduce funds available for distributions to our shareholders.

Since our formation, the Trust has been organized and has operated in such a manner as to qualify for taxation as a REIT under the U.S. federal income tax laws, and we intend to continue to operate in such a manner, but no assurances can be given that we will operate in a manner so as to qualify or remain qualified as a REIT.

Failure to qualify as a REIT, or failure to remain qualified as a REIT, would cause us to be taxed as a regular corporation, which would substantially reduce funds available for distributions to our shareholders. If we fail to qualify as a REIT in any taxable year, we would face serious tax consequences that will substantially reduce the funds available for distributions to our shareholders because:

• we would not be allowed a deduction for dividends paid to shareholders in computing our taxable income and would be subject to U.S. federal income tax at regular corporate rates;

• we could possibly be subject to increased state and local taxes; and

• unless we are entitled to relief under certain U.S. federal income tax laws, we could not re-elect REIT status until the fifth calendar year after the year in which we failed to qualify as a REIT.

In addition, if the Trust fails to qualify as a REIT, we will no longer be required to make distributions. As a result of all these factors, the Trust’s failure to qualify as a REIT could impair our ability to expand our business and raise capital, and it would adversely affect the value of our shares of beneficial interest.

Failure to make required distributions would subject us to U.S. federal corporate income tax.

The Trust intends to operate in a manner so as to qualify as a REIT for U.S. federal income tax purposes. In order to qualify as a REIT, we generally are required to distribute at least 90% of our REIT taxable income, determined without regard to the dividends paid deduction and excluding any net capital gain, each year to our shareholders. To the extent that we satisfy this distribution requirement, but distribute less than 100% of our REIT taxable income, we will be subject to U.S. federal corporate income tax on our undistributed taxable income. In addition, we will be subject to a 4% nondeductible excise tax if the actual amount that we pay out to our shareholders in a calendar year is less than a minimum amount specified under the Code.

Complying with REIT requirements may cause us to forego otherwise attractive opportunities or liquidate otherwise attractive investments.

To qualify as a REIT for federal income tax purposes, we must continually satisfy tests concerning, among other things, the sources of our income, the nature and diversification of our assets, the amounts we distribute to our shareholders, and the ownership of our shares of beneficial interest. In order to meet these tests, we may be required to forego investments we might otherwise make. Thus, compliance with the REIT requirements may hinder our performance.

In particular, we must ensure that at the end of each calendar quarter, at least 75% of the value of our assets consists of cash, cash items, government securities, and qualified real estate assets. The remainder of our investment in securities (other than government securities, securities of TRSs, and qualified real estate assets) generally cannot include more than 10% of the outstanding voting securities of any one issuer or more than 10% of the total value of the outstanding securities of any one issuer. In addition, in general, no more than 5% of the value of our assets (other than government securities, securities of TRSs, and qualified real estate assets) can consist of the securities of any one issuer, and no more than 20% of the value of our total assets can be represented by the securities of one or more TRSs. Further, debt instruments that do not otherwise qualify as real estate assets issued to us by publicly offered REITs will be treated as qualified real estate assets for purposes of the asset test,

31

but no more than 25% of the value of our total assets may be represented by such debt instruments. If we fail to comply with these requirements at the end of any calendar quarter, we must correct the failure within 30 days after the end of the calendar quarter or qualify for certain statutory relief provisions to avoid losing our REIT qualification and suffering adverse tax consequences. As a result, we may be required to liquidate otherwise attractive investments. These actions could have the effect of reducing our income and amounts available for distribution to our shareholders.

The prohibited transactions tax may limit our ability to dispose of our properties.

A REIT’s net income from prohibited transactions is subject to a 100% tax. In general, prohibited transactions are sales or other dispositions of property other than “foreclosure property,” held primarily for sale to customers in the ordinary course of business. We may be subject to the prohibited transactions tax equal to 100% of net gain upon a disposition of real property. Although a safe harbor to the characterization of the sale of real property by a REIT as a prohibited transaction is available, we cannot assure you that we can comply with the safe harbor or that we will avoid owning property that may be characterized as held primarily for sale to customers in the ordinary course of business. Consequently, we may choose not to engage in certain sales of our properties or may conduct such sales through any TRS that we may form, which would be subject to federal and state income taxation.

Any ownership of a TRS we may form in the future will be subject to limitations and our transactions with a TRS will cause us to be subject to a 100% penalty tax on certain income or deductions if those transactions are not conducted on arm’s-length terms.

Overall, for taxable years beginning after December 31, 2017, no more than 20% of the value of a REIT’s assets may consist of stock or securities of one or more TRSs. In addition, the Code also imposes a 100% excise tax on certain transactions between a TRS and its parent REIT that are not conducted on an arm’s-length basis, including “redetermined TRS service income” relating to gross income of a TRS attributable to services provided to, or on behalf of, the REIT (less the deductions properly allocable thereto) to the extent the amount of such income (less such deductions) would be increased on distribution, apportionment, or allocation under Code Section 482. We will monitor the value of our respective investments in any TRS that we may form for the purpose of ensuring compliance with TRS ownership limitations and will structure our transactions with any TRS on terms that we believe are arm’s-length to avoid incurring a 100% excise tax on such transactions. There can be no assurance, however, that we will be able to comply with the 20% limitation or avoid application of the 100% excise tax.

If leases of our properties are not respected as true leases for federal income tax purposes, we would fail to qualify as a REIT and would be subject to higher taxes and have less cash available for distribution to our shareholders.

To qualify as a REIT, we must satisfy two gross income tests, under which specified percentages of our gross income must be derived from certain sources, such as “rents from real property.” Rents paid to the Operating Partnership by third party lessees and any TRS lessee that we may form in the future pursuant to the leases of our properties will constitute substantially all of our gross income. In order for such rent to qualify as “rents from real property” for purposes of the gross income tests, the leases must be respected as true leases for federal income tax purposes and not be treated as service contracts, joint ventures, or some other type of arrangement. If our leases are not respected as true leases for federal income tax purposes, we would fail to qualify as a REIT.

Dividends payable by REITs do not qualify for the reduced tax rates available for some dividends.

The maximum tax rate applicable to “qualified dividend income” payable to U.S. shareholders that are taxed at individual rates is 23.8%. Dividends payable by REITs, however, generally are not eligible for the reduced rates on qualified dividend income. The more favorable rates applicable to regular corporate qualified dividends could cause investors who are taxed at individual rates to perceive investments in REITs to be relatively less attractive than investments in the stocks of non-REIT corporations that pay dividends, which could adversely affect the value of the shares of REITs, including our common shares.

We may be subject to adverse legislative or regulatory tax changes that could reduce the market price of our common shares.

At any time, the U.S. federal income tax laws governing REITs or the administrative interpretations of those laws may be amended. We cannot predict when or if any new U.S. federal income tax law, regulation, or administrative interpretation, or any amendment to any existing U.S. federal income tax law, regulation, or administrative interpretation, will be adopted, promulgated or become effective and any such law, regulation, or interpretation may take effect retroactively. We and our

32

shareholders could be adversely affected by any such change in the U.S. federal income tax laws, regulations, or administrative interpretations.

On December 22, 2017 the Tax Cuts and Jobs Act was signed into law. The Tax Cuts and Jobs Act makes significant changes to the U.S. federal income tax rules for taxation of individuals and corporations, generally effective for taxable years beginning after December 31, 2017. In addition to reducing corporate and non-corporate tax rates, the Tax Cuts and Jobs Act eliminates or restricts various deductions. Most of the changes applicable to individuals are temporary and apply only to taxable years beginning after December 31, 2017 and before January 1, 2026. The Tax Cuts and Jobs Act makes numerous large and small changes to the tax rules that do not affect REITs directly but may affect our shareholders and may indirectly affect us.

While the changes in the Tax Cuts and Jobs Act generally appear to be favorable with respect to REITs, the extensive changes to non-REIT provisions in the Code may have unanticipated effects on us or our stockholders. Moreover, Congressional leaders have recognized that the process of adopting extensive tax legislation in a short amount of time without hearings and substantial time for review is likely to have led to drafting errors, issues needing clarification, and unintended consequences that will have to be reviewed in subsequent tax legislation. At this point, it is not clear when Congress will address these issues or when the Internal Revenue Service will be able to issue administrative guidance on the changes made in the Tax Cuts and Jobs Act.

ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

33

ITEM 2. PROPERTIES

Geographic Diversification/Concentration

The following table lists the states in which our properties are located and provides certain information regarding our portfolio’s geographic diversification/concentration as of December 31, 2017:

State	Number of Properties	GLA (1) (square feet)	Percent of GLA		Annualized Base Rent (2) (thousands)		Percent of Annualized Base Rent
Alabama	11	509,501	3.6	%	$	9,825	3.4	%
Arizona	13	733,791	5.2	%	15,751		5.5	%
Arkansas	8	283,440	2.0	%	4,401		1.5	%
Colorado	5	129,620	1.0	%	2,753		1.0	%
Connecticut	1	72,022	0.5	%	1,705		0.6	%
Florida	24	470,914	3.4	%	12,066		4.2	%
Georgia	23	1,289,838	9.2	%	27,457		9.6	%
Illinois	4	187,673	1.3	%	3,575		1.3	%
Indiana	22	1,039,767	7.4	%	18,283		6.4	%
Kentucky	12	976,620	7.0	%	16,028		5.6	%
Louisiana	3	150,777	1.1	%	5,680		2.0	%
Maine	1	44,677	0.3	%	1,298		0.5	%
Maryland	3	166,594	1.2	%	3,782		1.3	%
Michigan	8	447,794	3.2	%	9,713		3.4	%
Minnesota	18	662,416	4.7	%	13,143		4.6	%
Mississippi	2	97,294	0.7	%	2,466		0.9	%
Missouri	2	69,184	0.5	%	1,851		0.6	%
Montana	3	185,085	1.3	%	5,194		1.8	%
Nebraska	13	979,303	7.0	%	17,304		6.1	%
New Mexico	2	53,029	0.4	%	1,376		0.5	%
New York	13	613,496	4.4	%	14,242		5.0	%
North Carolina	1	29,422	0.2	%	634		0.2	%
North Dakota	8	434,215	3.1	%	7,612		2.7	%
Ohio	12	650,319	4.6	%	13,225		4.6	%
Oklahoma	1	52,000	0.4	%	480		0.2	%
Pennsylvania	11	407,911	3.0	%	5,518		1.9	%
Tennessee	11	534,725	3.8	%	10,149		3.6	%
Texas	29	1,930,348	13.8	%	46,850		16.4	%
Washington	10	589,141	4.2	%	7,994		2.8	%
Wisconsin (3)	6	205,886	1.5	%	5,315		1.8	%
Total	280	13,996,802	100.0	%	$	285,670	100.0	%

(1) “GLA” means gross leasable area.

(2) Annualized base rent is calculated by multiplying (a) base rental payments for the month ended December 31, 2017, by (b) 12.

(3) Excludes leases related to the Company’s 108,843 square foot corporate office building.

34

Scheduled Lease Expirations

The following table provides a summary of lease expirations for our properties owned as of December 31, 2017, for the periods indicated.

Expiration (1)	Number of Leases Expiring	GLA	Percent of GLA		Annualized Base Rent (2) (thousands)		Percent of Annualized Base Rent		Annualized Base Rent Leased per Square Foot (3)
2018	115	412,406	2.9	%	8,266		2.9	%	$	20.04
2019	105	539,574	3.9	%	11,939		4.2	%	22.13
2020	116	498,110	3.6	%	10,548		3.7	%	21.18
2021	160	688,399	4.9	%	14,709		5.1	%	21.37
2022	106	684,229	4.9	%	16,300		5.7	%	23.82
2023	87	594,185	4.2	%	13,023		4.6	%	21.92
2024	87	862,954	6.2	%	17,524		6.1	%	20.31
2025	132	1,027,311	7.3	%	24,384		8.5	%	23.74
2026	126	3,576,886	25.6	%	71,566		25.1	%	20.01
2027	78	1,362,904	9.7	%	27,181		9.5	%	19.94
Thereafter	104	3,199,457	22.9	%	69,153		24.2	%	21.61
Month to month (4)	44	73,781	0.5	%	1,077		0.4	%	14.60
Vacant	—	476,606	3.4	%	—		—		—
Total / Weighted average	1,260	13,996,802	100.0	%	$	285,670	100.0	%	$	21.13

(1) Excludes leases related to the Company’s 108,843 square foot corporate office building.

(2) Annualized base rent is calculated by multiplying (a) base rental payments for the month ended December 31, 2017, by (b) 12.

(3)  Annualized base rent per leased square foot is calculated by dividing (a) annualized base rent as of December 31, 2017, by (b) square footage under commenced leases as of December 31, 2017.

(4) Includes 4 leases which expired on December 31, 2017, representing 0.1% of portfolio leasable square feet.

Tenants

As of December 31, 2017, our properties were 96.6% leased. No single tenant accounted for more than 5.6% of our total annualized base rent or 4.3% of total base revenue as of December 31, 2017; however, 18.7% of our total annualized base rent as of December 31, 2017 is from tenants affiliated with CHI.

35

The following table sets forth certain information about the 10 largest tenants in our portfolio based on total annualized base rent as of December 31, 2017.

Tenant	# of Properties	Leased GLA	% GLA		Annualized Base Rent (1) (thousands)		% of Portfolio Annualized Rent
CHI - Nebraska	13	893,098	6.4	%	$	15,906	5.6	%
CHI - KentuckyOne Health	11	744,101	5.3	%	13,120		4.6	%
Baylor Scott and White Health	2	268,639	1.9	%	7,402		2.6	%
US Oncology	6	256,988	1.8	%	6,706		2.4	%
CHI - St. Alexius (ND)	7	362,284	2.6	%	6,239		2.2	%
Northside Hospital (GA)	4	329,249	2.4	%	6,018		2.1	%
HonorHealth (AZ)	6	243,482	1.7	%	5,768		2.0	%
CHI - Franciscan (Seattle - Tacoma)	8	329,754	2.4	%	5,594		2.0	%
Great Falls Hospital (MT)	3	185,085	1.3	%	5,194		1.8	%
LifeCare	3	310,352	2.2	%	5,021		1.8	%
Total	63	3,923,032	28.0	%	$	76,968	27.1	%

(1) Calculated for each tenant as the monthly contracted base rent per the terms of such tenant’s lease, as of December 31, 2017, multiplied by 12.

Before entering into a lease and during the lease term, we seek to manage our exposure to significant tenant credit issues. In most instances, we seek to obtain tenant financial information, including credit reports, financial statements, and tax returns. Where appropriate, we seek to obtain financial commitments in the form of letters of credit, security deposits, or personal guarantees from tenants. On an ongoing basis, we monitor accounts receivable and payment history for both tenants and properties and seek to identify any credit concerns as quickly as possible. In addition, we keep in close contact with our tenants in an effort to identify and address negative changes to their businesses prior to such adverse changes affecting their ability to pay rent to us.

Ground Leases

We lease the land upon which 78 of our properties are built, representing approximately 39.1% of our total leasable square feet and 36.9% of our annualized base revenue as of December 31, 2017. The ground leases subject these properties to certain restrictions. These restrictions may limit our ability to re-let such facilities to tenants not affiliated with the healthcare delivery system that owns the underlying land. Restrictions may also include rights of first offer and refusal with respect to sales of the properties and may limit the types of medical procedures that may be performed at the facilities.

ITEM 3. LEGAL PROCEEDINGS

From time to time, we are party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of our business. We are not currently a party, as plaintiff or defendant, to any legal proceedings which, individually or in the aggregate, would be expected to have a material effect on our business, financial condition or results of operations if determined adversely to us.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

36

PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Physicians Realty Trust

The Trust’s common shares are traded on the New York Stock Exchange (“NYSE”) under the symbol “DOC.” As of February 23, 2018, the Trust had 260 registered shareholders of record for the Trust’s common shares.

The following table sets forth, for the periods indicated, the high and low sale prices of the Trust’s common shares for the fiscal years ended December 31, 2016 and 2017, respectively, as reported on the NYSE, and the dividends declared by the Trust with respect to those periods.

2016	High		Low		Dividends (1)
First quarter	$	18.90	$	15.41	$	0.225	(2)
Second quarter	$	21.36	$	17.83	$	0.225	(3)
Third quarter	$	22.03	$	19.73	$	0.225	(4)
Fourth quarter	$	21.45	$	17.12	$	0.225	(5)

2017	High		Low		Dividends (1)
First quarter	$	20.19	$	18.18	$	0.225	(6)
Second quarter	$	21.85	$	18.75	$	0.230	(7)
Third quarter	$	20.41	$	17.38	$	0.230	(8)
Fourth quarter	$	19.03	$	17.25	$	0.230	(9)

(1) Dividend information is for dividends declared with respect to that quarter.

(2) On March 18, 2016, the Trust declared a cash dividend of $0.225 per share for the quarterly period ended March 31, 2016. The dividend was paid on April 18, 2016 to common shareholders and OP Unit holders of record on April 1, 2016.

(3) On June 23, 2016, the Trust declared a cash dividend of $0.225 per share for the quarterly period ended June 30, 2016. The dividend was paid on July 18, 2016 to common shareholders and OP Unit holders of record on July 5, 2016.

(4) On September 26, 2016, the Trust declared a cash dividend of $0.225 per common share for the quarterly period ended September 30, 2016. The dividend was paid on October 18, 2016 to common shareholders and OP Unit holders of record on October 6, 2016.

(5) On December 22, 2016, the Trust declared a cash dividend of $0.225 per share for the quarter ending December 31, 2016. The dividend was paid on January 18, 2017 to common shareholders and OP Unit holders of record on January 5, 2017.

(6) On March 17, 2017, the Trust declared a cash dividend of $0.225 per share for the quarterly period ended March 31, 2017. The dividend was paid on April 18, 2017 to common shareholders and OP Unit holders of record on April 5, 2017.

(7) On June 12, 2017, the Trust declared a cash dividend of $0.230 per share for the quarterly period ended June 30, 2017. The dividend was paid on July 18, 2017 to common shareholders and OP Unit holders of record on July 3, 2017.

(8) On September 21, 2017, the Trust declared a cash dividend of $0.230 per share for the quarterly period ended September 30, 2017. The dividend was paid on October 18, 2017 to common shareholders and OP Unit holders of record on October 3, 2017.

(9) On December 21, 2017, the Trust declared a cash dividend of $0.230 per share for the quarterly period ended December 31, 2017. The dividend was paid on January 18, 2018 to common shareholders and OP Unit holders of record on January 3, 2018.

It has been the Trust’s policy to declare quarterly dividends to its shareholders so as to comply with applicable provisions of the Code governing REITs. The declaration and payment of quarterly dividends remains subject to the review and approval of the Board of Trustees.

Physicians Realty L.P.

There is no established public market for the OP Units or Series A Preferred Units. As of February 23, 2018, there were no holders of record and 187,396,618 OP Units outstanding, 181,932,401 of which were held by the Trust. As of February 23, 2018, there were 104,172 Series A Preferred Units outstanding. The following table sets forth, for the periods

37

indicated, the distributions paid by the Operating Partnership to holders of its Series A Preferred Units and OP Units with respect to those periods.

2016	Distributions
First quarter	$	0.225
Second quarter	$	0.225
Third quarter	$	0.225
Fourth quarter	$	0.225

2017	Distributions
First quarter	$	0.225
Second quarter	$	0.230
Third quarter	$	0.230
Fourth quarter	$	0.230

All distributions paid by the Operating Partnership were declared and paid at the same time as dividends that were distributed by the Trust to common shareholders, except that holders of Series A Preferred Units received a 5% cumulative annual return.

It has been the Operating Partnership’s policy to declare quarterly distributions so as to allow the Trust to comply with applicable provisions of the Code governing REITs. The declaration and payment of quarterly distributions remains subject to the review and approval of the Trust’s Board of Trustees.

38

Stock Performance Graph

This performance graph shall not be deemed “soliciting material” or to be “filed” with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any filing of Physicians Realty Trust under the Securities Act or the Exchange Act.

The graph below compares the cumulative total return of our common shares, the Standard & Poor’s 500, and the MSCI US REIT Index (RMS), from July 19, 2013 (the date of our IPO) through December 31, 2017. The comparison assumes $100 was invested on July 19, 2013 in our common shares and in each of the foregoing indexes and assumes reinvestment of dividends, as applicable. The MSCI US REIT Index consists of equity REITs that are included in the MSCI US Investable Market 2500 Index, except for specialty equity REITS that do not generate a majority of their revenue and income from real estate rental and leasing operations. We have included the MSCI US REIT Index because we joined the MSCI US REIT Index in November 2014 and therefore we believe that it is representative of the industry in which we compete and is relevant to an assessment of our performance.

 

	Period Ending
Index	7/19/2013		12/31/2013		12/31/2014		12/31/2015		12/31/2016		12/31/2017
Physicians Realty Trust	$	100.00	$	112.34	$	156.36	$	167.80	$	197.82	$	196.89
Standard & Poor’s 500	$	100.00	$	110.29	$	125.39	$	127.13	$	142.33	$	173.40
MSCI US REIT (RMS)	$	100.00	$	91.70	$	119.56	$	122.57	$	133.11	$	139.86

Recent Sales of Unregistered Securities

From time to time, the Operating Partnership issues OP Units to the Trust, as required by the Partnership Agreement, to reflect additional issuances of common shares by the Trust and to preserve equitable ownership ratios.

39

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

The following table sets forth information relating to repurchases of our common shares of beneficial interest and OP Units during the three months ended December 31, 2017:

ISSUER PURCHASES OF EQUITY SECURITIES

Period	(a) Total Number of Shares (or Units) Purchased		(b) Average Price Paid per Share (or Unit)		(c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs	(d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs
October 1, 2017 - October 31, 2017	8,265	(1)	$	17.57	N/A	N/A
November 1, 2017 - November 30, 2017	—		—		N/A	N/A
December 1, 2017 - December 31, 2017	—		—		N/A	N/A
Total	8,265		$	17.57	—	—

(1) Represents OP Units redeemed by holders in exchange for common shares of the Trust.

ITEM 6. SELECTED FINANCIAL DATA

The following selected financial data should be read together with the discussion under the caption “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and the consolidated financial statements and related notes thereto included in this report.

We had no business operations prior to completion of the IPO and the formation transactions on July 24, 2013. The balance sheet data as of December 31, 2017, 2016, 2015, 2014, and 2013 reflects our financial condition. The notes to the consolidated financial statements refer, unless the context indicates otherwise, to the Company for the period July 24, 2013, the date of completion of the IPO and the related formation transactions, through December 31, 2017, and the Predecessor for all prior periods.

Our Predecessor is comprised of the four healthcare real estate private equity funds, organized as limited liability companies under the laws of Delaware, managed by B.C. Ziegler & Company, which we refer to as the Ziegler Funds, that owned directly or indirectly interests in entities that owned our initial properties we acquired on July 24, 2013 in connection with completion of our IPO and related formation transactions.

40

Physicians Realty Trust and Predecessor

	Year Ended December 31,
(in thousands, except per share data)	2017			2016			2015			2014			2013 (1)
Statement of Operations Data
Revenues:
Rental revenues	$	259,673		$	186,301		$	103,974		$	46,397		$	13,565
Expense recoveries	75,425			45,875			21,587			5,871			3,234
Interest income on real estate loans and other	8,486			8,858			3,880			1,066			246
Total revenues	343,584			241,034			129,441			53,334			17,045
Expenses:
Interest expense	47,008			23,864			10,636			6,907			4,295
General and administrative	22,957			18,397			14,908			11,440			3,214
Operating expenses	97,035			65,999			31,026			10,154			4,650
Depreciation and amortization	125,159			86,589			45,471			16,731			5,107
Acquisition expenses	16,744			14,778			14,893			10,897			1,938
Management fees	—			—			—			—			475
Impairment loss	965			—			—			1,750			—
Total expenses	309,868			209,627			116,934			57,879			19,679
Income (loss) before equity in income of unconsolidated entities and gain (loss) on sale of investment properties	33,716			31,407			12,507			(4,545		)	(2,634		)
Equity in income of unconsolidated entities	183			115			104			95			—
Gain (loss) on sale of investment properties	5,874			—			130			32			(2		)
Net income (loss)	39,773			31,522			12,741			(4,418		)	(2,636		)
Net (income) loss attributable to noncontrolling interests:
Predecessor	—			—			—			—			576
Operating Partnership	(1,136		)	(825		)	(576		)	695			470
Partially owned properties (2)	(491		)	(716		)	(377		)	(314		)	(71		)
Net income (loss) attributable to controlling interest	38,146			29,981			11,788			(4,037		)	(1,661		)
Preferred distributions	(731		)	(1,857		)	(1,189		)	—			—
Net income (loss) attributable to common shareholders	$	37,415		$	28,124		$	10,599		$	(4,037	)	$	(1,661	)
Net income (loss) per share:
Basic	$	0.23		$	0.22		$	0.15		$	(0.12	)	$	(0.13	)
Diluted	$	0.23		$	0.22		$	0.15		$	(0.12	)	$	(0.13	)
Dividends and distributions declared per common share and OP Unit	$	0.915		$	0.900		$	0.900		$	0.900		$	0.410
Balance Sheet Data (as of end of period):
Assets:
Net real estate investments	$	4,045,388		$	2,767,624		$	1,579,483		$	773,650		$	227,539
Cash and cash equivalents	2,727			15,491			3,143			15,923			56,478
Tenant receivables, net	9,966			9,790			2,977			1,324			837
Other assets	106,302			95,187			53,283			15,806			5,901
Total assets	$	4,164,383		$	2,888,092		$	1,638,886		$	806,703		$	290,755
Liabilities and Equity:
Credit facility	$	324,394		$	643,742		$	389,375		$	134,144		$	—
Notes payable	966,603			224,330			—			—			—
Mortgage debt	186,471			123,083			94,240			77,091			40,716
Accounts payable	11,023			4,423			644			700			836
Dividends and distributions payable	43,804			32,179			20,783			16,548			5,681
Accrued expenses and other liabilities	56,405			42,287			24,473			6,140			2,685
Acquired lease intangible, net	15,702			9,253			5,950			2,871			—
Total liabilities	1,604,402			1,079,297			535,465			237,494			49,918
Redeemable noncontrolling interest – Series A Preferred Units (2016 and 2015) and partially owned properties	12,347			26,477			26,960			—			—
Total shareholders’ equity	2,473,172			1,738,451			1,021,132			534,730			204,904
Total noncontrolling interests	74,462			43,867			55,329			34,479			35,933
Total liabilities and equity	$	4,164,383		$	2,888,092		$	1,638,886		$	806,703		$	290,755

(1) Because our IPO and the formation transactions were completed on July 24, 2013 and we had no operations prior to completion of our IPO, the results of operations, for the year ended December 31, 2013 reflect the results of operations of the Predecessor from January 1, 2013 through July 23, 2013 and of the Company from July 24, 2013 through December 31, 2013.

(2) An adjustment of $0.3 million and $0.1 million was required for net income attributable to redeemable noncontrolling interests for the year ended December 31, 2017 and December 31, 2016, respectively. No such adjustment was required for the year ended December 31, 2015.

41

Physicians Realty L.P. and Predecessor

	Year Ended December 31,
(in thousands, except per unit data)	2017			2016			2015			2014			2013 (1)
Statement of Operations Data
Revenues:
Rental revenues	$	259,673		$	186,301		$	103,974		$	46,397		$	13,565
Expense recoveries	75,425			45,875			21,587			5,871			3,234
Interest income on real estate loans and other	8,486			8,858			3,880			1,066			246
Total revenues	343,584			241,034			129,441			53,334			17,045
Expenses:
Interest expense	47,008			23,864			10,636			6,907			4,295
General and administrative	22,957			18,397			14,908			11,440			3,214
Operating expenses	97,035			65,999			31,026			10,154			4,650
Depreciation and amortization	125,159			86,589			45,471			16,731			5,107
Acquisition expenses	16,744			14,778			14,893			10,897			1,938
Management fees	—			—			—			—			475
Impairment loss	965			—			—			1,750			—
Total expenses	309,868			209,627			116,934			57,879			19,679
Income (loss) before equity in income of unconsolidated entities and gain (loss) on sale of investment properties	33,716			31,407			12,507			(4,545		)	(2,634		)
Equity in income of unconsolidated entities	183			115			104			95			—
Gain (loss) on sale of investment properties	5,874			—			130			32			(2		)
Net income (loss)	39,773			31,522			12,741			(4,418		)	(2,636		)
Net (income) loss attributable to noncontrolling interests:
Predecessor	—			—			—			—			576
Partially owned properties (2)	(491		)	(716		)	(377		)	(314		)	(71		)
Net income (loss) attributable to controlling interest	39,282			30,806			12,364			(4,732		)	(2,131		)
Preferred distributions	(731		)	(1,857		)	(1,189		)	—			—
Net income (loss) attributable to common unitholders	$	38,551		$	28,949		$	11,175		$	(4,732	)	$	(2,131	)
Net income (loss) per unit:
Basic	$	0.23		$	0.22		$	0.15		$	(0.12	)	$	(0.13	)
Diluted	$	0.23		$	0.22		$	0.15		$	(0.12	)	$	(0.13	)
Dividends and distributions declared per common unit	$	0.915		$	0.900		$	0.900		$	0.900		$	0.410
Balance Sheet Data (as of end of period):
Assets:
Net real estate investments	$	4,045,388		$	2,767,624		$	1,579,483		$	773,650		$	227,539
Cash and cash equivalents	2,727			15,491			3,143			15,923			56,478
Tenant receivables, net	9,966			9,790			2,977			1,324			837
Other assets	106,302			95,187			53,283			15,806			5,901
Total assets	$	4,164,383		$	2,888,092		$	1,638,886		$	806,703		$	290,755
Liabilities and Capital:
Credit facility	$	324,394		$	643,742		$	389,375		$	134,144		$	—
Notes payable	966,603			224,330			—			—			—
Mortgage debt	186,471			123,083			94,240			77,091			40,716
Accounts payable	11,023			4,423			644			700			836
Dividends and distributions payable	43,804			32,179			20,783			16,548			5,681
Accrued expenses and other liabilities	56,405			42,287			24,473			6,140			2,685
Acquired lease intangible, net	15,702			9,253			5,950			2,871			—
Total liabilities	1,604,402			1,079,297			535,465			237,494			49,918
Redeemable noncontrolling interest – Series A Preferred Units (2016 and 2015) and partially owned properties	12,347			26,477			26,960			—			—
Total partners’ capital	2,547,016			1,781,593			1,066,583			568,457			240,214
Noncontrolling interest - partially owned properties	618			725			9,878			752			623
Total liabilities and capital	$	4,164,383		$	2,888,092		$	1,638,886		$	806,703		$	290,755

(1) Because the formation transactions were completed on July 24, 2013 and we had no operations prior to completion of the Trust’s IPO, the results of operations, for the year ended December 31, 2013 reflect the results of operations of the Predecessor from January 1, 2013 through July 23, 2013 and of the Company from July 24, 2013 through December 31, 2013.

(2) An adjustment of $0.3 million and $0.1 million was required for net income attributable to redeemable noncontrolling interests for the year ended December 31, 2017 and December 31, 2016, respectively. No such adjustment was required for the year ended December 31, 2015.

42

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with our financial statements, including the notes to those statements, included in this report, and the Section entitled “Cautionary Statement Regarding Forward-Looking Statements” in this report. As discussed in more detail in the Section entitled “Cautionary Statement Regarding Forward-Looking Statements,” this discussion contains forward-looking statements which involve risks and uncertainties. Our actual results may differ materially from the results discussed in the forward-looking statements. Factors that might cause those differences include those discussed in “Part I, Item 1. Business” and “Part I, Item 1A. Risk Factors” and elsewhere in this report.

Overview

We are a self-managed healthcare real estate company organized in April 2013 to acquire, selectively develop, own, and manage healthcare properties that are leased to physicians, hospitals, and healthcare delivery systems. We invest in real estate that is integral to providing high quality healthcare services. Our properties are typically located on a campus with a hospital or other healthcare facilities or strategically located and affiliated with a hospital or other healthcare facilities. We believe the impact of government programs and continuing trends in the healthcare industry create attractive opportunities for us to invest in healthcare related real estate. In particular, we believe the demand for healthcare will continue to increase as a result of the aging population as older persons generally utilize healthcare services at a rate well in excess of younger people. Our management team has significant public healthcare REIT experience and has long-established relationships with physicians, hospitals, and healthcare delivery system decision makers that we believe will provide quality investment and growth opportunities. Our principal investments include medical office buildings, outpatient treatment facilities, acute and post-acute care hospitals, as well as other real estate integral to healthcare providers. During 2017, we saw an increased level of competition for healthcare properties and, as a result, an increase in prices paid for them. In turn, this has had a negative impact on the initial cash yields on potential asset acquisitions. We seek to invest in stabilized medical facility assets with initial cash yields of 5.0% to 9.0%, although we invested in certain medical facility assets in 2017 with anticipated initial cash yields below 5.0% and we may invest in other medical facility assets with initial cash yields outside of this range. We seek to generate attractive risk-adjusted returns for our shareholders through a combination of stable and increasing dividends and potential long-term appreciation in the value of our properties and our common shares. 

We have grown our portfolio of gross real estate investments from approximately $124 million at the time of our IPO in July 2013 to approximately $4.3 billion as of December 31, 2017. Since the date of our IPO through to December 31, 2017, our compounded annual growth rate was 120.0%. While we expect to continue to grow through property acquisitions and investments as our asset base continues to increase, our growth rate decelerated in 2017 and we expect our annual growth rate to decelerate in the future.

As of December 31, 2017, our portfolio consisted of 280 healthcare properties located in 30 states with approximately 13,996,802 net leasable square feet, which were approximately 96.6% leased with a weighted average remaining lease term of approximately 8.3 years. As of December 31, 2017, approximately 85.1% of the net leasable square footage of our portfolio was either on campus with a hospital or other healthcare facility or strategically located and affiliated with a hospital or other healthcare facility.

43

As of December 31, 2017, leases representing a percentage of our portfolio on the basis of leasable square feet will expire as follows:

Year (1)	Portfolio Lease Expirations
MTM (2)	0.5%
2018	2.9%
2019	3.9%
2020	3.6%
2021	4.9%
2022	4.9%
2023	4.2%
2024	6.2%
2025	7.3%
2026	25.6%
2027	9.7%
Thereafter	22.9%
Total	96.6%

(1) “MTM” means month-to-month.

(2) Includes 4 leases which expired on December 31, 2017, representing 0.1% of portfolio leasable square feet.

We receive a cash rental stream from these healthcare providers under our leases. Approximately 90.8% of the annualized base rent payments from our properties as of December 31, 2017 are from absolute and triple-net leases, pursuant to which the tenants are responsible for all operating expenses relating to the property, including but not limited to real estate taxes, utilities, property insurance, routine maintenance and repairs, and property management. This structure helps insulate us from increases in certain operating expenses and provides more predictable cash flow.

Approximately 7.0% of the annualized base rent payments from our properties as of December 31, 2017 are from modified gross base stop leases which allow us to pass through certain increases in future operating expenses (e.g., property tax and insurance) to tenants for reimbursement, thus protecting us from increases in such operating expenses. We seek to structure our triple-net leases to generate attractive returns on a long-term basis. Our leases typically have initial terms of 5 to 15 years and include annual rent escalators of approximately 1.5% to 3.0%. Our operating results depend significantly upon the ability of our tenants to make required rental payments. We believe that our portfolio of medical office buildings and other healthcare facilities will enable us to generate stable cash flows over time because of the diversity of our tenants, staggered lease expiration schedule, long-term leases, and low historical occurrence of tenants defaulting under their leases.

We intend to grow our portfolio of high-quality healthcare properties leased to physicians, hospitals, healthcare delivery systems and other healthcare providers primarily through acquisitions of existing healthcare facilities that provide stable revenue growth and predictable long-term cash flows. We may also selectively finance the development of new healthcare facilities through joint venture or fee arrangements with premier healthcare real estate developers. Generally, we only expect to make investments in new development properties when approximately 70% or more of the development property has been pre-leased before construction commences. We seek to invest in properties where we can develop strategic alliances with financially sound healthcare providers and healthcare delivery systems that offer need-based healthcare services in sustainable healthcare markets. We focus our investment activity on the following types of healthcare properties:

• medical office buildings;

• outpatient treatment and diagnostic facilities;

• physician group practice clinics;

• ambulatory surgery centers; and

• specialty hospitals and treatment centers.

We believe that shifting consumer preferences, limited space in hospitals, the desire of patients and healthcare providers to limit non-essential services provided in a hospital setting, and cost considerations, among other trends, continue to drive the industry trend of performing procedures in outpatient facilities that have traditionally been performed in hospitals, such as surgeries and other invasive medical procedures. As these trends continue, we believe that demand for medical office buildings and similar healthcare properties will continue to rise, and that our investment strategy accounts for these trends.

We may invest opportunistically in life science facilities, assisted living, and independent senior living facilities and in the longer term, senior housing properties, including skilled nursing. Consistent with our qualification as a REIT, we may also

44

opportunistically invest in companies that provide healthcare services, and in joint venture entities with operating partners, structured to comply with RIDEA.

The Trust is a Maryland real estate investment trust and elected to be taxed as a REIT for U.S. federal income tax purposes. We conduct our business through an UPREIT structure in which our properties are owned by our Operating Partnership directly or through limited partnerships, limited liability companies, or other subsidiaries. The Trust is the sole general partner of our Operating Partnership and, as of December 31, 2017, owned approximately 97.1% of the OP Units. As of February 23, 2018, we have 181,758,250 common shares outstanding.

2017 Investment Activity

During 2017, we completed acquisitions of 40 operating healthcare properties, 2 condominium units, and 1 parking deck, located in 15 states for an aggregate purchase price of approximately $1.37 billion. In addition, we funded $42.9 million of other investments, including the issuance of loans and buyouts of noncontrolling interests, resulting in total investments of $1.41 billion. Acquisitions are detailed in Note 3 to our consolidated financial statements included in Item 8 to this report.

Of the acquisitions completed during 2017, we acquired 8 healthcare properties as a result of the exercise of certain rights of first refusal, comprising approximately 1,402,872 net leasable square feet in three states for an aggregate purchase price of $677.7 million.

In addition, we completed several key financing transactions during fiscal year 2017, which are summarized under the heading “Liquidity and Capital Resources” below.

Recent Developments

On December 21, 2017, the Trust’s Board of Trustees authorized and we declared a cash distribution of $0.230 per common share and OP Unit for the quarterly period ended December 31, 2017. The distribution was paid on January 18, 2018 to common shareholders and OP Unit holders of record as of the close of business on January 3, 2018.

2018 Investment Activity

Since December 31, 2017, we have completed acquisitions of 2 healthcare properties for an aggregate purchase price of $98.7 million containing an aggregate of 220,140 net leasable square feet and disposed of one property for $1.4 million, resulting in no gain or loss. In addition, the Operating Partnership funded a $2.0 million loan through a separate transaction, resulting in aggregate investment activity of $100.7 million. Property acquisitions subsequent to January 1, 2018 are summarized below.

Property		Location	Acquisition Date	Investment  (in thousands)
Hazelwood Medical Commons	(1)	Maplewood, MN	January 9, 2018	$	70,702
Lee's Hill Medical Plaza		Fredericksburg, VA	January 23, 2018	28,000
Loan Investment		Pensacola, FL	February 16, 2018	2,000
				$	100,702

(1) The Company partially funded the purchase price of this acquisition by issuing a total of 104,172 Preferred OP Units valued at approximately $22.7 million in the aggregate on the date of issuance.

Assets Slated for Disposition

We consider 10 properties in four states, representing an aggregate of approximately 391,014 square feet of gross leasable area, to be slated for disposition as of December 31, 2017. These assets consist of five assets leased to entities who have succeeded to the interests of certain Foundation Healthcare, Inc. affiliates (“Former Foundation Assets”) and five additional properties which we believe no longer meet our core business strategy from a size, age, geography, or line of business perspective. No assurance can be made, however, that any or all of the properties will be sold, that the Company will receive the anticipated consideration for the sale of any or all of the properties, or as to the timing of any such sale or sales.

45

Components of Our Revenues, Expenses, and Cash Flow

Revenues

Revenues consist primarily of the rental revenues and property operating expense recoveries we collect from tenants pursuant to our leases. Additionally, we recognize certain cash and non-cash revenues. These cash and non-cash revenues are highlighted below.

Rental revenues. Rental revenues represent rent under existing leases that is paid by our tenants, straight-lining of contractual rents, and below-market lease amortization reduced by lease inducements and above-market lease amortization.

Expense recoveries. Certain of our leases require our tenants to make estimated payments to us to cover their proportional share of operating expenses, including but not limited to real estate taxes, property insurance, routine maintenance and repairs, utilities, and property management expenses. We collect these estimated expenses and are reimbursed by our tenants for any actual expenses in excess of our estimates or reimburse tenants if our collected estimates exceed our actual operating expenses. The net reimbursed operating expenses are included in revenues as expense recoveries.

We have certain tenants with absolute net leases. Under these lease agreements, the tenant is responsible for operating and building expenses. For absolute net leases, we do not recognize operating expense or expense recoveries.

Interest income on real estate loans and other. Represents interest income on mezzanine loans, term loans, notes receivable, income generated on tenant improvements, changes in the fair value of derivative liabilities, and other. Interest income on the loans are recorded as earned based on the terms of the loans subject to evaluation of collectability risks.

Expenses

Expenses consist primarily of interest expense, general and administrative costs associated with operating our properties, operating expenses of our properties, depreciation and amortization, and costs we incur to acquire properties.

Interest expense. We recognize the interest expense we incur on our borrowings as interest expense. Additionally, we incur amortization expense for charges such as legal fees, commitment fees, and arrangement fees that reflect costs incurred with arranging certain debt financings. We generally recognize these costs over the term of the respective debt instrument for which the costs were incurred as a component of interest expense.

General and administrative. General and administrative expenses include certain expenses such as compensation, accounting, legal, and other professional fees as well as certain other administrative and travel costs, and expenses related to bank charges, franchise taxes, corporate filing fees, exchange listing fees, officer and trustee insurance costs, and other costs associated with being a public company.

Operating Expenses. Operating expenses include property operating expenses such as real estate taxes, property insurance, routine maintenance and repairs, utilities, and third party property management expenses, some of which are reimbursed to us by tenants under the terms of triple net leases.

Depreciation and amortization. We incur depreciation and amortization expense on all of our long-lived assets. This non-cash expense is designed under generally accepted accounting principles, or GAAP, to reflect the economic useful lives of our assets.

Acquisition expenses. Acquisition costs are costs we incur in pursuing and closing property acquisitions accounted for as business combinations. These costs include legal, accounting, valuation, other professional or consulting fees, and the compensation of certain employees who dedicate substantially all of their time to acquisition related job functions. We account for acquisition-related costs as expenses in the period in which the costs are incurred and the services are received.

Equity in income of unconsolidated entities. We recognize our 40% share of earnings and losses from the entity that owns the land under Crescent City Surgical Centre. During 2017 we had a 43% voting interest in the entity Desert Cove MOB, of which we bought the remaining interest on December 18, 2017. The Company reports investments in unconsolidated entities over whose operating and financial policies it has the ability to exercise significant influence under the equity method of accounting.

46

Gain or loss on sale of investment properties. Upon the sale of investment properties, gains or losses are recorded based upon the difference between the disposal sale price and the net book value of the asset.

Cash Flow

Cash flows from operating activities. Cash flows from operating activities are derived largely from net income by adjusting our revenues for those amounts not collected in cash during the period in which the revenue is recognized and for cash collected that was billed in prior periods or will be billed in future periods. Net income is further adjusted by adding back expenses charged in the period that is not paid for in cash during the same period. We expect to make our distributions based largely from cash provided by operations.

Cash flows from investing activities. Cash flows from investing activities consist of cash that is used during a period for making new investments and capital expenditures, offset by cash provided from sales of real estate investments.

Cash flows from financing activities. Cash flows from financing activities consist of cash we receive from debt and equity financings. This cash provides the primary basis for investments in new properties and capital expenditures. While we may invest a portion of our cash from operations into new investments, as a result of the distribution requirements to maintain our REIT status, it is likely that additional debt or equity financings will finance the majority of our investment activity. Cash used in financing activities consists of repayment of debt and distributions paid to shareholders and OP Unit holders.

Results of Operations

Year Ended December 31, 2017 compared to the Year Ended December 31, 2016.

The following table summarizes our results of operations for the years ended December 31, 2017 and 2016 (in thousands):

	2017		2016		Change			%
Revenues:
Rental revenues	$	259,673	$	186,301	$	73,372		39.4
Expense recoveries	75,425		45,875		29,550			64.4
Interest income on real estate loans and other	8,486		8,858		(372		)	(4.2	)
Total revenues	343,584		241,034		102,550			42.5
Expenses:
Interest expense	47,008		23,864		23,144			97.0
General and administrative	22,957		18,397		4,560			24.8
Operating expenses	97,035		65,999		31,036			47.0
Depreciation and amortization	125,159		86,589		38,570			44.5
Acquisition expenses	16,744		14,778		1,966			13.3
Impairment loss	965		—		965			NM
Total expenses	309,868		209,627		100,241			47.8
Income before equity in income of unconsolidated entities and gain on sale of investment properties:	33,716		31,407		2,309			7.4
Equity in income of unconsolidated entities	183		115		68			59.1
Gain on sale of investment properties	5,874		—		5,874			NM
Net income	$	39,773	$	31,522	$	8,251		26.2

NM = Not Meaningful

Revenues

Total revenues increased $102.6 million, or 42.5%, for the year ended December 31, 2017 as compared to the year ended December 31, 2016. An analysis of selected revenues follows.

Rental revenues. Rental revenues increased $73.4 million, or 39.4%, from $186.3 million for the year ended December 31, 2016 to $259.7 million for the year ended December 31, 2017. The increase in rental revenues primarily resulted

47

from our 2017 and 2016 acquisitions which resulted in additional rental revenue of $35.4 million and $48.9 million, respectively. Revenues for the year ended December 31, 2017 were partially offset by declines in rental income recognized at the Kennewick medical office building located in Kennewick, Washington (the “Kennewick MOB”) of $7.4 million and at certain of our buildings formerly occupied by Foundation Healthcare of $2.7 million.

Expense recoveries. Expense recoveries increased $29.6 million, or 64.4%, for the year ended December 31, 2017 as compared to the year ended December 31, 2016. The increase in expense recoveries primarily resulted from our 2017 and 2016 acquisitions which resulted in additional expense recoveries of $12.1 million and $16.7 million, respectively.

Interest income on real estate loans and other. Interest income on real estate loans and other decreased $0.4 million for the year ended December 31, 2017 as compared to the year ended December 31, 2016. Loan transactions completed during the prior twelve months resulted in $2.0 million of increased interest revenue, while other income decreased $1.6 million relative to the prior year due to the payoff of a real estate loan, and interest income from note receivables decreased $0.8 million which relates to a note that was paid off during January 2017.

Expenses

Total expenses increased by $100.2 million, or 47.8%, for the year ended December 31, 2017 as compared to the year ended December 31, 2016. An analysis of selected expenses follows.

Interest expense. Interest expense for the year ended December 31, 2017 was $47.0 million compared to $23.9 million for the year ended December 31, 2016, representing an increase of $23.1 million, or 97.0%. An increase of $15.5 million resulted from the issuance of our March 2017 and December 2017 public debt offerings, an increase of $3.8 million resulted from borrowings under the term loan provision of our unsecured credit facility, an increase of $2.2 million was the result of an increase in interest due to new mortgage debt, and an increase of $2.0 million resulted from the issuance of our 2016 senior notes.

General and administrative. General and administrative expenses increased $4.6 million or 24.8%, from $18.4 million during the year ended December 31, 2016 to $23.0 million during the year ended December 31, 2017. The increase is attributable to increased salaries and benefits, including non-cash share compensation of $1.1 million, increased office expenditures of $1.1 million, increased professional fees of $1.1 million, and increased travel expenditures of $0.5 million.

Operating expenses. Operating expenses increased $31.0 million or 47.0%, from $66.0 million during the year ended December 31, 2016 to $97.0 million during the year ended December 31, 2017. The increase is primarily due to our 2017 and 2016 property acquisitions which resulted in additional operating expenses of $13.5 million and $21.4 million, respectively, partially offset by a reduction in operating expenses associated with the previously existing portfolio.

Depreciation and amortization. Depreciation and amortization increased $38.6 million, or 44.5%, from $86.6 million during the year ended December 31, 2016 to $125.2 million during the year ended December 31, 2017. The increase is due to our 2017 and 2016 property acquisitions which resulted in additional depreciation and amortization of $18.8 million and $22.0 million, respectively, partially offset by a reduction in depreciation and amortization associated with the previously existing portfolio.

Acquisition expenses. Acquisition expenses increased $2.0 million, or 13.3%, from $14.8 million during the year ended December 31, 2016 to $16.7 million during the year ended December 31, 2017. During the twelve month periods ending December 31, 2017 and 2016, we acquired $1.2 billion and $735.8 million, respectively, of real estate that were considered business combinations and as such, the related acquisition costs were expensed.

Impairment loss. The Company recorded a $1.0 million impairment loss on one medical office building for the year ended December 31, 2017. No such impairment loss was recorded for the year ended December 31, 2016.

Equity in income of unconsolidated entity. The change in equity income from unconsolidated entity for the year ended December 31, 2016 compared to the year ended December 31, 2017 is not significant.

Gain on sale of properties. On April 7, 2017, the Company sold four properties with 80,292 net leasable square feet located in Georgia for approximately $18.2 million, recording a gain of $5.2 million. On December 18, 2017, the Company sold one property with 20,939 net leasable square feet located in Nebraska for approximately $2.5 million, recording a gain of $0.7 million. We did not dispose of any properties during the year ended December 31, 2016.

48

Year Ended December 31, 2016 compared to the Year Ended December 31, 2015.

The following table summarizes our results of operations for the years ended December 31, 2016 and 2015 (in thousands):

	2016		2015		Change			%
Revenues:
Rental revenues	$	186,301	$	103,974	$	82,327		79.2
Expense recoveries	45,875		21,587		24,288			112.5
Interest income on real estate loans and other	8,858		3,880		4,978			128.3
Total revenues	241,034		129,441		111,593			86.2
Expenses:
Interest expense	23,864		10,636		13,228			124.4
General and administrative	18,397		14,908		3,489			23.4
Operating expenses	65,999		31,026		34,973			112.7
Depreciation and amortization	86,589		45,471		41,118			90.4
Acquisition expenses	14,778		14,893		(115		)	(0.8	)
Total expenses	209,627		116,934		92,693			79.3
Income before equity in income of unconsolidated entities and gain on sale of investment properties:	31,407		12,507		18,900			151.1
Equity in income of unconsolidated entities	115		104		11			10.6
Gain on sale of investment properties	—		130		(130		)	NM
Net income	$	31,522	$	12,741	$	18,781		147.4

NM = Not Meaningful

Revenues

Total revenues increased $111.6 million, or 86.2%, for the year ended December 31, 2016 as compared to the year ended December 31, 2015. An analysis of selected revenues follows. 

Rental revenues. Rental revenues increased $82.3 million, or 79.2%, from $104.0 million for the year ended December 31, 2015 to $186.3 million for the year ended December 31, 2016. The increase in rental revenues primarily resulted from our 2016 and 2015 acquisitions which resulted in additional rental revenue of $52.1 million and $31.3 million, respectively. 

Expense recoveries. Expense recoveries increased $24.3 million, or 112.5%, for the year ended December 31, 2016 as compared to the year ended December 31, 2015. The increase in expense recoveries primarily resulted from our 2016 and 2015 acquisitions which resulted in additional expense recoveries of $14.0 million and $10.2 million, respectively. 

Interest income on real estate loans and other. Interest income on real estate loans and other increased $5.0 million for the year ended December 31, 2016 as compared to the year ended December 31, 2015. Loan transactions completed during 2016 resulted in $1.9 million of increased interest revenue, while other income increased $2.9 million relative to 2015 due to the buyout of a purchase option ($2.1 million) and the write-off of an expired contingent liability ($0.8 million).

Expenses

Total expenses increased by $92.7 million, or 79.3%, for the year ended December 31, 2016 as compared to the year ended December 31, 2015. An analysis of selected expenses follows. 

Interest expense. Interest expense for the year ended December 31, 2016 was $23.9 million compared to $10.6 million for the year ended December 31, 2015, representing an increase of $13.2 million, or 124.4%. An increase of $7.9 million resulted from the issuance of our senior notes, an increase of $3.5 million resulted from borrowings under the term loan provision of our unsecured credit facility, an increase of $1.0 million resulted from the amortization deferred financing fees on our credit facility, and an increase of $0.9 million was the result of an increase in interest on new mortgage debt.

49

General and administrative. General and administrative expenses increased $3.5 million or 23.4%, from $14.9 million during the year ended December 31, 2015 to $18.4 million during the year ended December 31, 2016. The increase included salaries and benefits of $2.0 million (including non-cash share compensation of $0.8 million), increased office expenditures of $0.7 million, and increased travel expenditures of $0.3 million. 

Operating expenses. Operating expenses increased $35.0 million or 112.7%, from $31.0 million during the year ended December 31, 2015 to $66.0 million during the year ended December 31, 2016. The increase is primarily due to our 2016 and 2015 property acquisitions which resulted in additional operating expenses of $19.8 million and $11.8 million, respectively. 

Depreciation and amortization. Depreciation and amortization increased $41.1 million, or 90.4%, from $45.5 million during the year ended December 31, 2015 to $86.6 million during the year ended December 31, 2016. The increase is due to our 2016 and 2015 property acquisitions which resulted in additional depreciation and amortization of $24.5 million and $15.1 million, respectively. 

Acquisition expenses. Acquisition expenses decreased $0.1 million, or 0.8%, from $14.9 million during the year ended December 31, 2015 to $14.8 million during the year ended December 31, 2016. During the twelve month periods ending December 31, 2016 and 2015, we acquired $735.8 million and $779.2 million, respectively, of real estate that were considered business combinations and as such, the related acquisition costs were expensed.

Equity in income of unconsolidated entities. The change in equity income from unconsolidated entities for the year ended December 31, 2015 compared to the year ended December 31, 2016 is not significant. 

Gain on sale of properties. On March 26, 2015, the Company sold a 20,329 square foot medical office building located in Ohio for approximately $1.6 million, resulting in an insignificant loss. On July 31, 2015, the Company sold a 26,783 square foot medical office building located in Michigan for approximately $1.5 million, recording a gain of $0.1 million. We did not dispose of any properties during the year ended December 31, 2016.

Cash Flows

Year Ended December 31, 2017 compared to the Year Ended December 31, 2016 (in thousands).

	2017			2016
Cash provided by operating activities	$	180,471		$	127,197
Cash used in investing activities	(1,302,638		)	(1,262,816		)
Cash provided by financing activities	1,109,403			1,147,967
Increase (decrease) in cash and cash equivalents	$	(12,764	)	$	12,348

Cash flows from operating activities. Cash flows provided by operating activities was $180.5 million during the twelve months ended December 31, 2017 compared to $127.2 million during the twelve months ended December 31, 2016, representing an increase of $53.3 million. This change is primarily attributable to the increased operating cash flows resulting from our 2017 and 2016 acquisitions.

Cash flows from investing activities. Cash flows used in investing activities was $1.30 billion during the twelve months ended December 31, 2017 compared to cash flows used in investing activities of $1.26 billion during the twelve months ended December 31, 2016, representing a change of $39.8 million. The increase in cash flows used in investing activities was primarily attributable to our $31.8 million increase in acquisition activity over the prior year and cash used to fund real estate loans and notes totaling $28.9 million. These were partially offset by $20.4 million in proceeds on sale of investment property.

Cash flows from financing activities. Cash flows provided by financing activities was $1.11 billion during the twelve months ended December 31, 2017 compared to cash flows provided by financing activities of $1.15 billion during the twelve months ended December 31, 2016, representing a decrease of $38.6 million. The 2017 activity was primarily attributable to sales of our common shares, resulting in net proceeds of $844.7 million, $927.0 million of proceeds from the credit facility, and $743.1 million from our issuance of senior notes. These were partially offset by the $1.2 billion of payoffs on our credit facility and $143.1 million of dividends paid.

50

Year Ended December 31, 2016 compared to Year Ended December 31, 2015 (in thousands).

 

	2016			2015
Net cash provided by operating activities	$	127,197		$	59,352
Net cash used in investing activities	(1,262,816		)	(799,716		)
Net cash provided by financing activities	1,147,967			727,584
Increase (decrease) in cash and cash equivalents	$	12,348		$	(12,780	)

Cash flows from operating activities. Cash flows provided by operating activities was $127.2 million during the twelve months ended December 31, 2016 compared to $59.4 million during the twelve months ended December 31, 2015, representing an increase of $67.8 million. This change is primarily attributable to the increased operating cash flows resulting from our 2016 and 2015 acquisitions. 

Cash flows from investing activities. Cash flows used in investing activities was $1.26 billion during the twelve months ended December 31, 2016 compared to cash flows used in investing activities of $799.7 million during the twelve months ended December 31, 2015, representing a change of $463.1 million. The increase in cash flows used in investing activities was primarily attributable to our $492.3 million increase in acquisition activity over the prior year, partially offset by reductions in cash used to fund real estate loans and notes totaling $32.7 million.

Cash flows from financing activities. Cash flows provided by financing activities was $1.15 billion during the twelve months ended December 31, 2016 compared to cash flows provided by financing activities of $727.6 million during the twelve months ended December 31, 2015, representing an increase of $420.4 million. The 2016 activity was primarily attributable to sales of our common shares, resulting in net proceeds of $766.8 million, $1.18 billion of proceeds from the credit facility, and $225.0 million from our issuance of senior notes. These were partially offset by the $925.0 million of payoffs on our credit facility and $104.9 million of dividends paid.

Non-GAAP Financial Measures

This report includes Funds From Operations (FFO), Normalized FFO, Normalized Funds Available For Distribution (FAD), Net Operating Income (NOI), Cash NOI, Same-Store Cash NOI, Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) and Adjusted EBITDA, which are non-GAAP financial measures. For purposes of Item 10(e) of Regulation S-K promulgated under the Securities Act, a non-GAAP financial measure is a numerical measure of a company’s historical or future financial performance, financial position or cash flows that excludes amounts, or is subject to adjustments that have the effect of excluding amounts, that are included in the most directly comparable financial measure calculated and presented in accordance with GAAP in the statement of operations, balance sheet, or statement of cash flows (or equivalent statements) of the company, or includes amounts, or is subject to adjustments that have the effect of including amounts, that are excluded from the most directly comparable financial measure so calculated and presented. As used in this report, GAAP refers to generally accepted accounting principles in the United States of America. Pursuant to the requirements of Item 10(e) of Regulation S-K promulgated under the Securities Act, we have provided reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures.

51

Funds From Operations (FFO) and Normalized FFO

We believe that information regarding FFO is helpful to shareholders and potential investors because it facilitates an understanding of the operating performance of our properties without giving effect to real estate depreciation and amortization, which assumes that the value of real estate assets diminishes ratably over time. We calculate FFO in accordance with standards established by the National Association of Real Estate Investment Trusts (“NAREIT”). NAREIT defines FFO as net income or loss (computed in accordance with GAAP) before noncontrolling interests of holders of OP units, excluding preferred distributions, gains (or losses) on sales of depreciable operating property, impairment write-downs on depreciable assets, plus real estate related depreciation and amortization (excluding amortization of deferred financing costs). Our FFO computation may not be comparable to FFO reported by other REITs that do not compute FFO in accordance with the NAREIT definition or that interpret the NAREIT definition differently than we do. The GAAP measure that we believe to be most directly comparable to FFO, net income, includes depreciation and amortization expenses, gains or losses on property sales, impairments, and noncontrolling interests. In computing FFO, we eliminate these items because, in our view, they are not indicative of the results from the operations of our properties. To facilitate a clear understanding of our historical operating results, FFO should be examined in conjunction with net income (determined in accordance with GAAP) as presented in our financial statements. FFO does not represent cash generated from operating activities in accordance with GAAP, should not be considered to be an alternative to net income or loss (determined in accordance with GAAP) as a measure of our liquidity, and is not indicative of funds available for our cash needs, including our ability to make cash distributions to shareholders.

We use Normalized FFO, which excludes from FFO net change in fair value of derivative financial instruments, acquisition expenses, acceleration of deferred financing costs, and other normalizing items. However, our use of the term Normalized FFO may not be comparable to that of other real estate companies as they may have different methodologies for computing this amount. Normalized FFO should not be considered as an alternative to net income or loss (computed in accordance with GAAP), as an indicator of our financial performance or of cash flow from operating activities (computed in accordance with GAAP), or as an indicator of our liquidity, nor is it indicative of funds available to fund our cash needs, including its ability to make distributions. Normalized FFO should be reviewed in connection with other GAAP measurements.

The following is a reconciliation from the Trust’s net income, the most direct financial measure calculated and presented in accordance with GAAP, to FFO and Normalized FFO (in thousands, except per share data):

	Year Ended December 31,
	2017			2016
Net income	$	39,773		$	31,522
Earnings per share - diluted	$	0.23		$	0.22
Net income	$	39,773		$	31,522
Net income attributable to noncontrolling interests - partially owned properties	(491		)	(716		)
Preferred distributions	(731		)	(1,857		)
Depreciation and amortization expense	125,022			86,501
Depreciation and amortization expense - partially owned properties	(531		)	(683		)
Gain on the sale of investment properties	(5,874		)	—
Impairment loss	965			—
FFO applicable to common shares and OP Units	$	158,133		$	114,767
FFO per common share and OP Unit	$	0.94		$	0.88
Net change in fair value of derivative	150			(240		)
Acquisition expenses	16,744			14,778
Net change in fair value of contingent consideration	(472		)	(840		)
Normalized FFO applicable to common shares and OP Units	$	174,555		$	128,465
Normalized FFO per common share and OP Unit	$	1.04		$	0.98
Weighted average number of common shares and OP Units outstanding	168,231,299			130,446,893

52

Normalized Funds Available for Distribution (FAD)

We use Normalized FAD, a non-GAAP measure, which excludes from Normalized FFO non-cash compensation expense, straight-line rent adjustments, amortization of acquired above- or below-market leases and assumed debt, amortization of deferred financing costs, amortization of lease inducements, and recurring capital expenditures related to tenant improvements and leasing commissions, and includes cash payments from seller master leases and rent abatement payments. Other REITs or real estate companies may use different methodologies for calculating Normalized FAD, and accordingly, our computation may not be comparable to those reported by other REITs. Although our computation of Normalized FAD may not be comparable to that of other REITs, we believe Normalized FAD provides a meaningful supplemental measure of our performance due to its frequency of use by analysts, investors, and other interested parties in the evaluation of our performance as a REIT. Normalized FAD should not be considered as an alternative to net income or loss attributable to controlling interest (computed in accordance with GAAP) or as an indicator of our financial performance. Normalized FAD should be reviewed in connection with other GAAP measurements.

The following is a reconciliation from the Trust’s Normalized FFO to Normalized FAD (in thousands):

	Year Ended December 31,
	2017			2016
Net income	$	39,773		$	31,522
Normalized FFO applicable to common shares and OP Units	$	174,555		$	128,465
Normalized FFO applicable to common shares and OP Units	$	174,555		$	128,465
Non-cash share compensation expense	5,073			3,920
Straight-line rent adjustments	(16,202		)	(16,226		)
Amortization of acquired above/below-market leases/assumed debt	3,596			2,778
Amortization of lease inducements	1,309			892
Amortization of deferred financing costs	2,299			2,325
TI/LC and recurring capital expenditures	(15,319		)	(8,087		)
Seller master lease and rent abatement payments	973			1,032
Normalized FAD applicable to common shares and OP Units	$	156,284		$	115,099

Net Operating Income (NOI) and Cash NOI

NOI is a non-GAAP financial measure that is defined as net income or loss, computed in accordance with GAAP, generated from our total portfolio of properties before general and administrative expenses, acquisition expenses, depreciation and amortization expense, interest expense, net change in the fair value of derivative financial instruments, gain or loss on the sale of investment properties, and impairment losses. We believe that NOI provides an accurate measure of operating performance of our operating assets because NOI excludes certain items that are not associated with management of the properties. Our use of the term NOI may not be comparable to that of other real estate companies as they may have different methodologies for computing this amount.

Cash NOI is a non-GAAP financial measure which excludes from NOI straight-line rent adjustments, amortization of acquired above- and below-market leases, and other non-cash and normalizing items. Other non-cash and normalizing items include items such as the amortization of lease inducements, and payments received from seller master leases and rent abatements. We believe that Cash NOI provides an accurate measure of the operating performance of our operating assets because it excludes certain items that are not associated with management of the properties. Additionally, we believe that Cash NOI is a widely accepted measure of comparative operating performance in the real estate community. Our use of the term Cash NOI may not be comparable to that of other real estate companies, as such other companies may have different methodologies for computing this amount.

53

The following is a reconciliation from the Trust’s net income, the most direct financial measure calculated and presented in accordance with GAAP, to NOI, and Cash NOI (in thousands):

	Year Ended December 31,
	2017			2016
Net income	$	39,773		$	31,522
General and administrative	22,957			18,397
Acquisition expenses	16,744			14,778
Depreciation and amortization	125,159			86,589
Interest expense	47,008			23,864
Net change in the fair value of derivative	150			(240		)
Gain on the sale of investment properties	(5,874		)	—
Impairment loss	965			—
NOI	$	246,882		$	174,910
NOI	$	246,882		$	174,910
Straight-line rent adjustments	(16,202		)	(16,226		)
Amortization of acquired above/below-market leases/assumed debt	3,596			2,778
Amortization of lease inducements	1,309			892
Seller master lease and rent abatement payments	973			1,032
Change in fair value of contingent consideration	(472		)	(840		)
Cash NOI	$	236,086		$	162,546

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) and Adjusted EBITDA

We define EBITDA as net income or loss computed in accordance with GAAP plus depreciation and amortization, interest expense, and net change in the fair value of derivative financial instruments. We define Adjusted EBITDA as net income or loss computed in accordance with GAAP plus depreciation and amortization, interest expense, net change in the fair value of derivative financial instruments, acquisition expenses, non-cash share compensation, change in fair value of contingent consideration, and other normalizing items. We consider EBITDA and Adjusted EBITDA important measures because they provide additional information to allow management, investors, and our current and potential creditors to evaluate and compare our core operating results and our ability to service debt.

The following is a reconciliation from the Trust’s net income, the most direct financial measure calculated and presented in accordance with GAAP, to EBITDA and Adjusted EBITDA (in thousands):

	Year Ended December 31,
	2017			2016
Net income	$	39,773		$	31,522
Depreciation and amortization	125,159			86,589
Interest expense	47,008			23,864
Net change in fair value of derivatives	150			(240		)
EBITDA	$	212,090		$	141,735
Acquisition expenses	16,744			14,778
Non-cash share compensation expense	5,074			3,920
Change in fair value of contingent consideration	(472		)	(840		)
Impairment loss	965			—
Adjusted EBITDA	$	234,401		$	159,593

54

Liquidity and Capital Resources

Our short-term liquidity requirements consist primarily of operating and interest expenses and other expenditures directly associated with our properties, including:

• property expenses;

• interest expense and scheduled principal payments on outstanding indebtedness;

• general and administrative expenses; and

• capital expenditures for tenant improvements and leasing commissions.

In addition, we will require funds for future distributions expected to be paid to our common shareholders and OP Unit holders in our Operating Partnership.

As of December 31, 2017, we had a total of $2.7 million of cash and cash equivalents and $753.0 million of near-term availability on our unsecured revolving credit facility. Our primary sources of cash include rent we collect from our tenants, borrowings under our unsecured credit facility, and financings of debt and equity securities. We believe that our existing cash and cash equivalents, cash flow from operating activities, and borrowings available under our unsecured revolving credit facility will be adequate to fund any existing contractual obligations to purchase properties and other obligations through the next twelve months. However, because of the 90% distribution requirement under the REIT tax rules under the Code, we may not be able to fund all of our future capital needs from cash retained from operations, including capital needed to make investments and to satisfy or refinance maturing obligations. As a result, we expect to rely upon external sources of capital, including debt and equity financing, to fund future capital needs. If we are unable to obtain needed capital on satisfactory terms or at all, we may not be able to make the investments needed to expand our business or to meet our obligations and commitments as they mature. We will rely upon external sources of capital to fund future capital needs, and, if we encounter difficulty in obtaining such capital, we may not be able to make future acquisitions necessary to grow our business or meet maturing obligations.

Our long-term liquidity needs consist primarily of funds necessary to pay for acquisitions, recurring and non-recurring capital expenditures, and scheduled debt maturities. We expect to satisfy our long-term liquidity needs through cash flow from operations, unsecured borrowings, issuances of equity and debt securities, and, in connection with acquisitions of additional properties, the issuance of OP Units of our Operating Partnership, and proceeds from select property dispositions and joint venture transactions.

Our ability to access capital in a timely and cost-effective manner is essential to the success of our business strategy as it affects our ability to satisfy existing obligations, including repayment of maturing indebtedness, and to make future investments and acquisitions. Factors such as general market conditions, interest rates, credit ratings on our debt and equity securities, expectations of our potential future earnings and cash distributions, and the market price of our common shares, each of which are beyond our control and vary or fluctuate over time, all impact our access to and cost of capital. In particular, to the extent interest rates continue to rise, we may experience a decline in the market price of our common shares, which may impact our decision to conduct equity offerings for capital raising purposes. We will likely also experience higher borrowing costs as interest rates rise, which may also impact our decisions to incur additional indebtedness or to engage in transactions for which we may need to fund through borrowing.

We expect to continue to utilize equity and debt financings to support our future growth and investment activity. For the twelve months ended December 31, 2017, we raised $750.0 million in senior unsecured notes, and decreased the outstanding balance on our primary unsecured revolving credit facility to $80.0 million. A summary of our key financing activities during fiscal year 2017 is included below.

We also continuously evaluate opportunities to finance future investments. New investments are generally funded from temporary borrowings under our primary unsecured credit facility and the proceeds from financing transactions such as those discussed above. Our investments generate cash from net operating income and principal payments on loans receivable. Permanent financing for future investments, which generally replaces funds drawn under our primary unsecured credit facility, has historically been provided through a combination of the issuance of debt and equity securities and the incurrence or assumption of secured debt.

We intend to invest in additional properties as suitable opportunities arise and adequate sources of financing are available. We are currently evaluating additional potential investments consistent with the normal course of our business. There can be no assurance as to whether or when any portion of these investments will be completed. Our ability to complete investments is subject to a number of risks and variables, including our ability to negotiate mutually agreeable terms with

55

sellers and our ability to finance the investment. We may not be successful in identifying and consummating suitable acquisitions or investment opportunities, which may impede our growth and negatively affect our results of operations and may result in the use of a significant amount of management’s resources. We expect that future investments in properties will depend on and will be financed by, in whole or in part, our existing cash, borrowings, including under our unsecured revolving credit facility, or the proceeds from additional issuances of equity or debt securities.

While we intend to sell the 10 assets slated for disposition for other business reasons, we currently do not expect to sell any of our properties to meet our liquidity needs, although we may do so in the future.

We intend either to repay in full at maturity the mortgage notes payable that have maturity balloon payments or to refinance such notes if we are able to obtain favorable terms and conditions.

We currently are in compliance with all debt covenants on our outstanding indebtedness.

Credit Facility

On June 10, 2016, the Operating Partnership, as borrower, and the Trust entered into an amended and restated Credit Agreement with KeyBank National Association, as administrative agent, KeyBanc Capital Markets Inc., BMO Capital Markets, and Citizens Bank N.A., as joint lead arrangers and co-book runners, BMO Capital Markets and Citizens Bank N.A., as co-syndication agents, and the lenders party thereto (the “Credit Agreement”) which increased the maximum principal amount available under an unsecured revolving credit facility from $750 million to $850 million. The Credit Agreement contains a 7-year term loan feature allowing us to borrow in a single drawing up to $250 million, increasing the borrowing capacity to an aggregate $1.1 billion. The Credit Agreement also includes a swingline loan commitment for up to 10% of the maximum principal amount and provides an accordion feature allowing us to increase borrowing capacity by up to an additional $500 million, subject to customary terms and conditions, resulting in a maximum borrowing capacity of $1.6 billion.

On July 7, 2016, the Operating Partnership borrowed $250.0 million under the 7-year term loan feature of the Credit Agreement. Borrowings under the term loan feature of the Credit Agreement bear interest on the outstanding principal amount at a rate which is determined by the Trust’s credit rating, currently equal to LIBOR + 1.80%. The Trust simultaneously entered into a pay-fixed receive-variable rate swap for the full borrowing amount, fixing the LIBOR component of the borrowing rate to 1.07%, for an all-in fixed rate of 2.87%. Both the borrowing and pay-fixed receive-variable swap have a maturity date of June 10, 2023.

The Credit Agreement has a maturity date of September 18, 2020 and includes a one-year extension option. Borrowings under the Credit Agreement bear interest on the outstanding principal amount at an adjusted LIBOR rate, which is based on the Trust’s investment grade rating under the Credit Agreement. As of December 31, 2017, the Trust had an investment grade rating from Moody’s of Baa3 and from S&P of BBB- and as such, borrowings under the revolving credit facility of the Credit Agreement accrued interest on the outstanding principal at a rate of LIBOR plus 1.20%. The Credit Agreement includes a facility fee equal to 0.25% per annum, which is also determined by the Trust’s investment grade rating.

The Credit Agreement contains financial covenants that, among other things, require compliance with leverage and coverage ratios and maintenance of minimum tangible net worth, as well as covenants that may limit our ability to incur additional debt or make distributions. We may, at any time, voluntarily prepay any revolving or swingline loan under the Credit Agreement in whole or in part without premium or penalty. Prepayments of term borrowings require payment of premiums of up to 2.0% of the amount of prepayment, dependent on date of such prepayment. As of December 31, 2017, we were in compliance with all financial covenants.

The Credit Agreement includes customary representations and warranties by us and imposes customary covenants on us. The Credit Agreement also contains customary events of default, and if an event of default occurs and continues, the Operating Partnership is subject to certain actions by the administrative agent, including without limitation, the acceleration of repayment of all amounts outstanding under the Credit Agreement.

56

The Credit Agreement provides for revolving credit and term loans to the Operating Partnership. Base Rate Loans, Adjusted LIBOR Rate Loans, and Letters of Credit (each, as defined in the Credit Agreement) will be subject to interest rates, based upon the Trust’s investment grade rating as follows:

Credit Rating	Margin for Revolving Loans: Adjusted LIBOR Rate Loans and Letter of Credit Fee	Margin for Revolving Loans: Base Rate Loans		Margin for Term Loans: Adjusted LIBOR Rate Loans and Letter of Credit Fee	Margin for Term Loans: Base Rate Loans
At Least A- or A3	LIBOR + 0.85%	—	%	LIBOR + 1.40%	0.40	%
At Least BBB+ or Baa1	LIBOR + 0.90%	—	%	LIBOR + 1.45%	0.45	%
At Least BBB or Baa2	LIBOR + 1.00%	0.10	%	LIBOR + 1.55%	0.55	%
At Least BBB- or Baa3	LIBOR + 1.20%	0.20	%	LIBOR + 1.80%	0.80	%
Below BBB- or Baa3	LIBOR + 1.55%	0.60	%	LIBOR + 2.25%	1.25	%

As of December 31, 2017, there were $80.0 million of borrowings outstanding under our unsecured revolving credit facility and $250.0 million of borrowings outstanding under the term loan feature of the Credit Agreement. As of December 31, 2017, the Company has issued a letter of credit for $17.0 million with no outstanding balance. As defined by the Credit Agreement, as of December 31, 2017, the Trust had $753.0 million of near-term availability on our unsecured revolving credit facility without adding additional properties to the unencumbered borrowing base of assets.

Senior Notes

Senior Notes Issued in 2016

On January 7, 2016, the Operating Partnership issued and sold $150.0 million aggregate principal amount of senior notes, comprised of (i) $15.0 million aggregate principal amount of 4.03% Senior Notes, Series A, due January 7, 2023, (ii) $45.0 million aggregate principal amount of 4.43% Senior Notes, Series B, due January 7, 2026, (iii) $45.0 million aggregate principal amount of 4.57% Senior Notes, Series C, due January 7, 2028, and (iv) $45.0 million aggregate principal amount of 4.74% Senior Notes, Series D, due January 7, 2031. On August 11, 2016, the note agreement for these notes was amended to make certain changes to its terms, including certain changes to affirmative covenants, negative covenants and definitions contained therein. Interest on each respective series of the January 2016 Senior Notes is payable semi-annually. The proceeds of the Notes were used to repay borrowings under our unsecured revolving credit facility and for general corporate and working capital purposes and funding acquisitions.

On August 11, 2016, the Operating Partnership issued and sold $75.0 million aggregate principal amount of senior notes, comprised of (i) $25.0 million aggregate principal amount of 4.09% Senior Notes, Series A, due August 11, 2025, (ii) $25.0 million aggregate principal amount of 4.18% Senior Notes, Series B, due August 11, 2026, and (iii) $25.0 million aggregate principal amount of 4.24% Senior Notes, Series C, due August 11, 2027. Interest on each respective series of the August 2016 Senior Notes is payable semi-annually.

The note agreements covering the notes described above contain covenants that are substantially similar to those contained in the Credit Agreement, including financial covenants that require compliance with leverage and coverage ratios and maintenance of minimum tangible net worth, as well as other affirmative and negative covenants that may limit, among other things, our ability to incur additional debt, make distributions or investments, incur liens and sell, transfer or dispose of assets. The note agreements also include customary representations and warranties and customary events of default substantially similar to those contained in the Credit Agreement.

2027 Senior Notes

On March 7, 2017, the Operating Partnership issued $400.0 million in aggregate principal amount of 4.30% Senior Notes due March 15, 2027 (the “2027 Senior Notes”) in a public offering (the “March Debt Offering”) through underwriters for whom J.P. Morgan Securities LLC, Credit Agricole Securities (USA) Inc., and Jefferies LLC acted as representatives (the “Representatives”) pursuant to an underwriting agreement, dated March 2, 2017 (the “Underwriting Agreement”), among the Operating Partnership, the Trust, and the Representatives.

The 2027 Senior Notes were registered under the Securities Act on the Trust’s and the Operating Partnership’s automatic shelf registration statement on Form S-3ASR (File No. 333-216214), filed with the Commission on February 24, 2017.

57

The 2027 Senior Notes began accruing interest on March 7, 2017 and began paying interest semi-annually beginning September 15, 2017. The 2027 Senior Notes were sold at an issue price of 99.68% of their face value, before the underwriters’ discount. Our net proceeds from the offering, after deducting underwriting discounts and expenses, were approximately $396.1 million. We used the net proceeds of the March Debt Offering to repay a portion of the outstanding indebtedness under our unsecured revolving credit facility and for general corporate purposes, including working capital and funding acquisitions.

The 2027 Senior Notes are subject to customary events of default, which may result in the accelerated maturity of the 2027 Senior Notes.

2028 Senior Notes

On December 1, 2017, the Operating Partnership issued $350.0 million in aggregate principal amount of 3.95% Senior Notes due January 15, 2028 (the “2028 Senior Notes”) in a public offering (the “December Debt Offering”) through underwriters for whom J.P. Morgan Securities LLC, Credit Agricole Securities (USA) Inc., and Jefferies LLC acted as representatives (the “Representatives”) pursuant to an underwriting agreement, dated November 28, 2017 (the “Underwriting Agreement”), among the Operating Partnership, the Trust, and the Representatives.

The 2028 Senior Notes were registered under the Securities Act on the Trust’s and the Operating Partnership’s automatic shelf registration statement on Form S-3ASR (File No. 333-216214), filed with the Commission on February 24, 2017.

The 2028 Senior Notes began accruing interest on December 1, 2017 and will begin paying interest semi-annually on July 15, 2018. The 2028 Senior Notes were sold at an issue price of 99.78% of their face value, before the underwriters’ discount. The net proceeds of the Offering were approximately $347.0 million, after deducting the underwriting discount and estimated offering expenses of the Trust and the Operating Partnership. We used the net proceeds of the December Debt Offering (i) to repay outstanding indebtedness under its unsecured revolving credit facility and (ii) for general corporate purposes, including, without limitation, working capital and investment in real estate.

The 2028 Senior Notes are subject to customary events of default, which may result in the accelerated maturity of the 2028 Senior Notes.

Senior Notes Summary

As of December 31, 2017, we had $975.0 million aggregate principal amount of senior notes issued and outstanding by the Operating Partnership, as follows: (i) $15.0 million aggregate principal amount of 4.03% Senior Notes, Series A, due January 7, 2023, (ii) $45.0 million aggregate principal amount of 4.43% Senior Notes, Series B, due January 7, 2026, (iii) $45.0 million aggregate principal amount of 4.57% Senior Notes, Series C, due January 7, 2028, (iv) $45.0 million aggregate principal amount of 4.74% Senior Notes, Series D, due January 7, 2031, (v) $25.0 million aggregate principal amount of 4.09% Senior Notes, Series A, due August 11, 2025, (vi) $25.0 million aggregate principal amount of 4.18% Senior Notes, Series B, due August 11, 2026, (vii) $25.0 million aggregate principal amount of 4.24% Senior Notes, Series C, due August 11, 2027, (viii) $400.0 million aggregate principal amount of 4.30% Senior Notes, due March 15, 2027, and (ix) $350.0 million aggregate principal amount of 3.95% Senior Notes due January 15, 2028.

The Senior Notes are the senior unsecured indebtedness of the Operating Partnership and rank equally in right of payment with all of the Operating Partnership’s existing and future senior unsecured indebtedness. As a result, the Senior Notes effectively are subordinated in right of payment to all of the Operating Partnership’s existing and future secured indebtedness (to the extent of the value of the collateral securing such indebtedness), and all mortgages, preferred equity, and indebtedness and other liabilities, whether secured or unsecured, of the Operating Partnership’s subsidiaries. The Operating Partnership’s obligations under the Senior Notes are fully and unconditionally guaranteed by the Trust.

The note agreements covering the notes contain covenants that are substantially similar to those contained in the Credit Agreement, including financial covenants that require compliance with leverage and coverage ratios and maintenance of minimum tangible net worth, as well as other affirmative and negative covenants that may limit, among other things, our ability to incur additional debt, make distributions or investments, incur liens and sell, transfer, or dispose of assets. The note agreements also include customary representations and warranties and customary events of default substantially similar to those contained in the Credit Agreement.

58

Follow-on Equity Offerings

In March 2017, the Trust completed a follow-on public offering of 17,250,000 common shares of beneficial interest, including 2,250,000 common shares issued upon exercise of the underwriters’ overallotment option, resulting in net proceeds to it of approximately $300.8 million. The Trust contributed the net proceeds of this offering to the Operating Partnership in exchange for 17,250,000 OP Units, and the Operating Partnership used the net proceeds of the public offering to repay borrowings under its unsecured revolving credit facility and for general corporate purposes, including working capital and funding acquisitions.

In July 2017, the Trust completed a follow-on public offering of 21,500,000 common shares of beneficial interest, including 1,500,000 common shares issued upon partial exercise of the underwriters’ overallotment option, resulting in net proceeds to it of approximately $420.7 million. The Trust contributed the net proceeds of this offering to the Operating Partnership in exchange for 21,500,000 OP Units, and the Operating Partnership used the net proceeds of the public offering to repay borrowings under its unsecured revolving credit facility and for general corporate purposes, including working capital and funding acquisitions.

ATM Program

On August 5, 2016, the Trust and the Operating Partnership entered into separate At Market Issuance Sales Agreements (the “2016 Sales Agreements”) with each of KeyBanc Capital Markets Inc., Credit Agricole Securities (USA) Inc., JMP Securities LLC, Raymond James & Associates, Inc., and Stifel Nicolaus & Company, Incorporated (the “2016 Agents”), pursuant to which the Trust may issue and sell, from time to time, its common shares having an aggregate offering price of up to $300 million, through the Agents (the “2016 ATM Program”). The offering of the common shares from time to time were registered pursuant to the Trust’s Registration Statement on Form S-3ASR (File No. 333-205034), which became automatically effective upon filing with the Commission on June 17, 2015, as amended by Post-Effective Amendment No. 1 to the Registration Statement on Form S-3ASR, filed by the Trust with the Commission on January 19, 2016. In accordance with the 2016 Sales Agreements, the Trust may offer and sell its common shares through any of the 2016 Agents, from time to time, by any method deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended, which includes sales made directly on the NYSE or other existing market, or sales made to or through a market maker. With the Trust’s express written consent, sales also may be made in negotiated transactions or any other method permitted by law.

During 2017, the Trust’s issuance and sale of common shares pursuant to the 2016 ATM Program is as follows (in thousands, except common shares and price): 

	2017
	Common shares sold	Weighted average price		Net proceeds
Quarterly period ended March 31	—	$	—	$	—
Quarterly period ended June 30	4,150,000	20.07		82,440
Quarterly period ended September 30	—	—		—
Quarterly period ended December 31	2,197,914	18.39		40,011
Year ended December 31	6,347,914	$	19.48	$	122,451

As of February 23, 2018, we have $168.2 million remaining available under the 2016 ATM Program.

Dividend Reinvestment and Share Purchase Plan

On December 2, 2014, we adopted a Dividend Reinvestment and Share Purchase Plan (the “DRIP”). Under the DRIP:

• existing shareholders may purchase additional common shares by reinvesting all or a portion of the dividends paid on their common shares and by making optional cash payments of not less than $50 and up to a maximum of $10,000 per month;

• new investors may join the DRIP by making an initial investment of not less than $1,000 and up to a maximum of $10,000; and

• once enrolled in the DRIP, participants may authorize electronic deductions from their bank account for optional cash payments to purchase additional shares.

59

The DRIP is administered by our transfer agent, Computershare Trust Company, N.A. Our common shares sold under the DRIP will be newly issued or purchased in the open market, as further described in the DRIP. As of February 23, 2018, we have issued 47,633 common shares under the DRIP since its inception.

Critical Accounting Policies

Our consolidated financial statements are prepared in conformity with GAAP, which require us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Set forth below is a summary of our accounting policies that we believe are critical to the preparation of our consolidated financial statements.

Lease Accounting

We, as lessor, make a determination with respect to each of our leases whether they should be accounted for as operating leases or direct financing leases. The classification criteria is based on estimates regarding the fair value of the leased facilities, minimum lease payments, effective cost of funds, the economic life of the facilities, the existence of a bargain purchase option, and certain other terms in the lease agreements. We believe all of our leases should be accounted for as operating leases. Payments received under operating leases are accounted for in the consolidated statements of income as rental revenue for actual rent collected plus or minus a straight-line adjustment for estimated minimum lease escalators, adjustments relating to amortization of lease inducements and above/below-market leases, and rent abatements. Assets subject to operating leases are reported as real estate investments in the consolidated balance sheets.

Substantially all of our leases contain fixed or formula-based rent escalators. To the extent that escalator increases are tied to a fixed index or rate, lease payments are accounted for on a straight-line basis over the life of the lease.

Purchase of Investment Properties

A property acquired not subject to an existing lease is treated as an asset acquisition and recorded at its purchase price, inclusive of acquisition costs, allocated between the acquired assets and assumed liabilities, including identified intangible assets and liabilities, based upon their relative fair values at the date of acquisition. A property acquired with an existing lease is accounted for as a business combination pursuant to the acquisition method in accordance with ASC Topic 805, Business Combinations (“ASC 805”), and assets acquired and liabilities assumed, including identified intangible assets and liabilities, are recorded at fair value.

The determination of fair value involves the use of significant judgment and estimation. We make estimates of the fair value of the tangible and intangible acquired assets and assumed liabilities using information obtained from multiple sources as a result of pre-acquisition due diligence and may include the assistance of a third party appraiser. We estimate the fair value of buildings acquired on an as-if-vacant basis and depreciate the building value over its estimated remaining life. We determine the allocated value of other fixed assets, such as site improvements, based upon the replacement cost and depreciate such value over the assets’ estimated remaining useful lives as determined at the applicable acquisition date. The fair value of land is determined either by considering the sales prices of similar properties in recent transactions or based on internal analyses of recently acquired and existing comparable properties within our portfolio.

In recording identified intangible assets and liabilities in connection with a business combination, the value of above- or below-market leases is estimated based on the present value (using an interest rate which reflected the risks associated with the leases acquired) of the difference between contractual amounts to be received pursuant to the leases and management’s estimate of market lease rates measured over a period equal to the estimated remaining term of the lease. The capitalized above-market or below-market lease intangibles are amortized as a reduction or addition to rental income over the estimated remaining term of the respective leases.

In determining the value of in-place leases and tenant relationships, management considers current market conditions and costs to execute similar leases in arriving at an estimate of the carrying costs during the expected lease-up period from vacant to existing occupancy. In estimating carrying costs, management includes real estate taxes, insurance, other operating expenses, estimates of lost rental revenue during the expected lease-up periods, and costs to execute similar leases, including leasing commissions, tenant improvements, legal, and other related costs based on current market demand. The values assigned to in-place leases and tenant relationships are amortized over the estimated remaining term of the lease. If a lease terminates prior to its scheduled expiration, all unamortized costs related to that lease are written off.

60

The values assigned to all lease intangible assets and liabilities are amortized over the estimated remaining term of the lease. If a lease terminates prior to its scheduled expiration, all unamortized costs related to that lease are written off.

We calculate the fair value of any long-term debt assumed by discounting the remaining contractual cash flows on each instrument at the current market rate for those borrowings, which we approximate based on the rate at which it would be expected to incur a replacement instrument on the date of acquisition, and recognize any fair value adjustments related to long-term debt as effective yield adjustments over the remaining term of the instrument.

Based on these estimates, we recognize the acquired assets and assumed liabilities at their estimated fair values, which generally are determined using Level 3 inputs, such as market rental rates, capitalization rates, discount rates, or other available market data. Initial valuations are subject to change until the information is finalized, no later than 12 months from the acquisition date. We expense transaction costs associated with acquisitions accounted for as business combinations in the period incurred.

Real Estate Investment Properties and Identified Intangible Assets

We are required to make subjective assessments of the useful lives of our properties for purposes of determining the amount of depreciation to record on an annual basis with respect to our investments in real estate. These assessments have a direct impact on our net income because if we were to shorten the expected useful lives of our investments in real estate we would depreciate such investments over fewer years, resulting in more depreciation expense and lower net income on an annual basis. Real estate investment properties and identified intangible assets are carried at cost, net of accumulated depreciation and amortization. Medical office buildings are depreciated over their estimated useful lives, ranging up to 50 years, using the straight-line method. Tenant improvements and in-place leases are amortized over the lease life of the in-place leases or the tenant’s respective lease term. Cost of maintenance and repairs are charged to expense when incurred.

We periodically assess the carrying value of real estate investments and related intangible assets in accordance with ASC Topic 360, Property, Plant & Equipment (“ASC 360”), to determine if facts and circumstances exist that would suggest that the recorded amount of an asset might be impaired or that the estimated useful life should be modified. In the event impairment in value occurs and a portion of the carrying amount of the real estate investment will not be recovered in part or in whole, a provision will be recorded to reduce the carrying basis of the real estate investment and related intangibles to their estimated fair value. The estimated fair value of our real estate investments is determined by use of a number of customary industry standard methods that include discounted cash flow modeling using appropriate discount and capitalization rates and/or estimated cash proceeds received upon the anticipated disposition of the asset from market comparables. Estimates of future cash flows is based on a number of factors including the historical operating results, leases in place, known trends, and other market or economic factors affecting the real estate investment. The evaluation of anticipated cash flows is subjective and is based on assumptions regarding future occupancy, lease rates, and capital requirements that could differ materially from actual results. If our anticipated holding periods change or estimated cash flows decline based on market conditions or other unforeseen factors, impairment may be recorded. Long-lived assets to be disposed of are recorded at the lower of carrying value or fair value less estimated costs to sell.

Revenue

We recognize rental revenues in accordance with ASC 840, Leases (“ASC 840”). ASC 840 requires that rental revenue and adjustments relating to lease inducements and above- and below-market leases, be recognized on a straight-line basis over the term of the lease when collectability is reasonably assured. Recognizing rental revenue on a straight-line basis for leases may result in recognizing revenue for amounts more or less than amounts currently due from tenants. Amounts recognized in excess of amounts currently due are included in other assets on the consolidated balance sheets. If we determine the collectability of straight-line rents is not reasonably assured, we limit future recognition to amounts contractually owed and, where appropriate, establish an allowance for estimated losses.

Expense recoveries related to tenant reimbursement for real estate taxes, insurance, and other operating expenses are recognized as expense recoveries revenue in the period the applicable expenses are incurred. The reimbursements are recognized at gross, as we are generally the primary obligor with respect to real estate taxes and purchasing goods and services from third party suppliers, have discretion in selecting the supplier, and bear the credit risk.

We have certain tenants with absolute net leases. Under these lease agreements, the tenant is responsible for operating and building expenses. For absolute net leases, we do not recognize expense recoveries.

61

Use of Estimates

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates are made for the valuation of real estate and related intangibles, valuation of financial instruments, impairment assessments, and fair value assessments with respect to purchase price allocations. Actual results could differ from those estimates.

REIT Qualification Requirements

We are subject to a number of operational and organizational requirements necessary to qualify and maintain our qualification as a REIT. If we fail to qualify as a REIT or fail to remain qualified as a REIT in any taxable year, our income would be subject to federal income tax at regular corporate rates and potentially increased state and local taxes and we could incur substantial tax liabilities which could have an adverse impact upon our results of operations, liquidity, and distributions to our shareholders.

Off-Balance Sheet Arrangements

As of December 31, 2017, we had no off-balance sheet debt.

Contractual Obligations

The following table summarizes our material contractual payment obligations and commitments as of December 31, 2017:

			By Period (in thousands)
	Total		Less than 1 Year		2019-2020		2021-2022		2023 and Thereafter
Principal (1)	$	1,491,679	$	54,775	$	154,753	$	33,426	$	1,248,725
Interest – fixed rate debt (1)	460,308		47,500		103,813		100,607		208,388
Interest – variable rate debt (1)	21,441		7,967		13,474		—		—
Ground leases and other operating leases	132,203		2,678		5,153		5,148		119,224
Total	$	2,105,631	$	112,920	$	277,193	$	139,181	$	1,576,337

(1) Obligations shown represent 100% of debt service and do not reflect joint venture interests.

Inflation

Historically, inflation has not had a significant impact on the operating performance of our properties. Many of our lease agreements contain provisions designed to mitigate the adverse impact of inflation. These provisions include clauses that enable us to receive increased rent pursuant to escalation clauses which generally increase rental rates during the terms of the leases. These escalation clauses often provide for fixed rent increases or indexed escalations (based upon changes in the consumer price index or other measures). However, some of these contractual rent increases may be less than the actual rate of inflation. Most of our lease agreements also require the tenant to pay an allocable share of operating expenses, including common area maintenance costs, real estate taxes, and insurance. This requirement reduces our exposure to increases in these costs and operating expenses resulting from inflation.

Seasonality

Our business has not been and we do not expect it to become subject to material seasonal fluctuations.

62

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our future income, cash flows, and fair values relevant to financial instruments are dependent upon prevailing market interest rates. Market risk refers to the risk of loss from adverse changes in market prices and interest rates. We use certain derivative financial instruments to manage, or hedge, interest rate risks related to our borrowings. We do not use derivatives for trading or speculative purposes and only enter into contracts with major financial institutions based upon their credit rating and other factors. When the Company has derivative instruments embedded in other contracts, it records them either as an asset or a liability measured at their fair value unless they qualify for a normal purchase or normal sale exception. Our derivative instruments consist of five interest rate swaps. See Note 2 (Summary of Significant Accounting Policies) and Note 7 (Derivatives) to our consolidated financial statements included in Item 8 to this report for further detail on our interest rate swaps.

Interest risk amounts are our management’s estimates and were determined by considering the effect of hypothetical interest rates on our consolidated financial instruments. These analyses do not consider the effect of any change in overall economic activity that could occur in that environment. Further, in the event of a change of that magnitude, we may take actions to further mitigate our exposure to the change. However, due to the uncertainty of the specific actions that would be taken and their possible effects, these analyses assume no changes in our financial structure.

Fixed Interest Rate Debt

As of December 31, 2017, our consolidated fixed interest rate debt totaled $1.1 billion, which represented 76.0% of our total consolidated debt, excluding the impact of interest rate swaps. On July 7, 2016, we entered into a pay-fixed receive-variable rate swap for the full $250.0 million borrowing amount of our term loan borrowings, fixing the LIBOR component of the borrowing rate to 1.07%, for an all-in fixed rate of 2.87%. Both the borrowing and pay-fixed receive-variable swap have a maturity date of June 10, 2023.

Assuming the effects of the interest rate swap agreement we entered into on July 7, 2016 relating to our unsecured debt, our fixed interest rate debt would represent 92.7% of our total consolidated debt. Interest rate fluctuations on our fixed interest rate debt will generally not affect our future earnings or cash flows unless such instruments mature or are otherwise terminated. However, interest rate changes could affect the fair value of our fixed interest rate debt.

As of December 31, 2017, the fair value and the carrying value of our consolidated fixed interest rate debt were approximately $1.1 billion. The fair value estimate of our fixed interest rate debt was estimated using a discounted cash flow analysis utilizing rates we would expect to pay for debt of a similar type and remaining maturity if the loans were originated on December 31, 2017. As we expect to hold our fixed interest rate debt instruments to maturity, based on the underlying structure of the debt instrument, and the amounts due under such instruments are limited to the outstanding principal balance and any accrued and unpaid interest, we do not expect that market fluctuations in interest rates, and the resulting change in fair value of our fixed interest rate debt instruments, would have a significant impact on our operating cash flows.

Variable Interest Rate Debt

As of December 31, 2017, our consolidated variable interest rate debt totaled $358.5 million, which represented 24.0% of our total consolidated debt. Assuming the effects of the interest rate swap agreement we entered into on July 7, 2016 relating to our unsecured debt, our variable interest rate debt would represent 7.3% of our total consolidated debt. Interest rate changes on our variable rate debt could impact our future earnings and cash flows, but would not significantly affect the fair value of such debt. As of December 31, 2017, we were exposed to market risks related to fluctuations in interest rates on $108.5 million of consolidated borrowings. Assuming no increase in the amount of our variable rate debt, if LIBOR were to change by 100 basis points, interest expense on our variable rate debt as of December 31, 2017 would change by approximately $1.1 million annually.

Derivative Instruments

As of December 31, 2017, we had five outstanding interest rate swaps that were designated as cash flow hedges of interest rate risk, with a total notional amount of $250.0 million. See Note 7 (Derivatives) within our consolidated financial statements for further detail on our interest rate swaps. We are exposed to credit risk of the counterparty to our interest rate swap agreements in the event of non-performance under the terms of the agreements. If we were not able to replace these swaps in the event of non-performance by the counterparty, we would be subject to variability of the interest rate on the amount outstanding under our debt that is fixed through the use of the swaps.

63

Indebtedness

As of December 31, 2017, we had total consolidated indebtedness of approximately $1.5 billion. The weighted average interest rate on our consolidated indebtedness was 3.93% (based on the 30-day LIBOR rate as of December 31, 2017, of 1.49%). As of December 31, 2017, we had approximately $108.5 million, or approximately 7.3%, of our outstanding long-term debt exposed to fluctuations in short-term interest rates.

The following table sets forth certain information with respect to our consolidated indebtedness outstanding as of December 31, 2017 (in thousands):

	Principal			Fixed/Floating Rate	Rate		Maturity
Senior Unsecured Revolving Credit Facility	$	80,000		Floating	LIBOR + 1.20%		9/18/2020
Senior Unsecured Term Loan (1)	250,000			Fixed	2.87	%	6/10/2023
Senior Unsecured Notes
January 2016 - Series A	15,000			Fixed	4.03	%	1/7/2023
January 2016 - Series B	45,000			Fixed	4.43	%	1/7/2026
January 2016 - Series C	45,000			Fixed	4.57	%	1/7/2028
January 2016 - Series D	45,000			Fixed	4.74	%	1/7/2031
August 2016 - Series A	25,000			Fixed	4.09	%	8/11/2025
August 2016 - Series B	25,000			Fixed	4.18	%	8/11/2026
August 2016 - Series C	25,000			Fixed	4.24	%	8/11/2027
March 2017 Notes	400,000			Fixed	4.30	%	3/15/2027
December 2017 Notes	350,000			Fixed	3.95	%	1/15/2028
Peachtree Parking Deck	17,000			Fixed	3.00	%	1/5/2020
Mid Coast Hospital Medical Office Building (2)	7,009			Floating	LIBOR + 2.25%		5/16/2018
Valley West Hospital Medical Office Building	4,531			Fixed	4.83	%	12/1/2020
Oklahoma City, OK Medical Office Building	7,101			Fixed	4.71	%	1/10/2021
Crescent City Surgical Center	18,750			Fixed	5.00	%	1/23/2019
San Antonio, TX Hospital	7,691			Fixed	5.00	%	6/26/2022
Savage Medical Office Building	5,449			Fixed	5.50	%	2/1/2022
St. Luke's Cornwall MOB	9,500			Floating	LIBOR + 3.25%		2/26/2018
Columbia MOB	12,000			Floating	LIBOR + 3.25%		3/21/2018
Honor Health - Scottsdale Hospital	10,000			Fixed	5.41	%	7/2/2018
St. Vincent Fishers Medical Center	44,000			Fixed	4.00	%	1/10/2020
CareMount Medical- Lake Katrine	26,039			Fixed	4.63	%	11/6/2024
Gwinnett Physicians Center	17,610			Fixed	4.83	%	12/1/2022
Total principal	1,491,680
Unamortized deferred financing cost	(7,808		)
Unamortized discount	(6,663		)
Unamortized fair value adjustment	259
Total	$	1,477,468

(1) Our borrowings under the term loan feature of our Credit Agreement bear interest at a rate which is determined by our credit rating, currently equal to LIBOR + 1.80%. We have entered into a pay-fixed receive-variable interest rate swap, fixing the LIBOR component of this rate at 1.07%, resulting in an effective interest rate of 2.87%.

(2) We own a 66.3% interest in the joint venture that owns this property. Debt shown in this schedule is the full amount of the mortgage indebtedness on this property.

64

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

Index to Consolidated Financial Statements

	Page
Reports of Independent Registered Public Accounting Firm
Physicians Realty Trust	66
Physicians Realty L.P.	67
Report of Independent Registered Public Accounting Firm on Internal Control Over Financial Reporting
Physicians Realty Trust	68
Financial Statements of Physicians Realty Trust
Consolidated Balance Sheets at December 31, 2017 and 2016	69
Consolidated Statements of Income for the Years Ended December 31, 2017, 2016, and 2015	70
Consolidated Statements of Comprehensive Income for the Years Ended December 31, 2017, 2016, and 2015	71
Consolidated Statements of Equity for the Years Ended December 31, 2017, 2016, and 2015	72
Consolidated Statements of Cash Flows for the Years Ended December 31, 2017, 2016, and 2015	73
Financial Statements of Physicians Realty L.P.
Consolidated Balance Sheets at December 31, 2017 and 2016	74
Consolidated Statements of Income for the Years Ended December 31, 2017, 2016, and 2015	75
Consolidated Statements of Comprehensive Income for the Years Ended December 31, 2017, 2016, and 2015	76
Consolidated Statements of Changes in Capital for the Years Ended December 31, 2017, 2016, and 2015	77
Consolidated Statements of Cash Flows for the Years Ended December 31, 2017, 2016, and 2015	78
Notes for Physicians Realty Trust and Physicians Realty L.P.
Notes to Consolidated Financial Statements	79

65

Report of Independent Registered Public Accounting Firm

To the Shareholders and the Board of Trustees of Physicians Realty Trust

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Physicians Realty Trust (the “Company”) as of December 31, 2017 and 2016, the related consolidated statements of income, comprehensive income, shareholders’ equity and cash flows for each of the three years in the period ended December 31, 2017, and the related notes and financial statement schedule included in the Index at Item 15 (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2017 and 2016, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2017, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated March 1, 2018 expressed an unqualified opinion thereon.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ Ernst & Young LLP

We have served as the Company’s auditor since 2014.

Chicago, Illinois

March 1, 2018

66

Report of Independent Registered Public Accounting Firm

To the Partners of Physicians Realty L.P.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Physicians Realty L.P. (the “Company”) as of December 31, 2017 and 2016, the related consolidated statements of income, comprehensive income, changes in capital and cash flows for each of the three years in the period ended December 31, 2017, and the related notes and financial statement schedule included in the Index at Item 15 (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2017 and 2016, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2017, in conformity with U.S. generally accepted accounting principles.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ Ernst & Young LLP

We have served as the Company’s auditor since 2017.

Chicago, Illinois

March 1, 2018

67

Report of Independent Registered Public Accounting Firm

To the Shareholders and the Board of Trustees of Physicians Realty Trust

Opinion on Internal Control over Financial Reporting

We have audited Physicians Realty Trust’s internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Physicians Realty Trust (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2017, based on the COSO criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of Physicians Realty Trust at December 31, 2017 and 2016, the related consolidated statements of income, comprehensive income, shareholders’ equity and cash flows for each of the three years in the period ended December 31, 2017, and the related notes and financial statement schedule included in the Index at Item 15 and our report dated March 1, 2018 expressed an unqualified opinion thereon.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting include in the accompanying Management's Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.

Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control Over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of the financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ Ernst & Young LLP

Chicago, Illinois

March 1, 2018

68

Physicians Realty Trust

Consolidated Balance Sheets

(in thousands, except share and per share data)

	December 31, 2017			December 31, 2016
ASSETS
Investment properties:
Land and improvements	$	217,695		$	189,759
Building and improvements	3,568,858			2,402,643
Tenant improvements	23,056			14,133
Acquired lease intangibles	458,713			301,462
	4,268,322			2,907,997
Accumulated depreciation	(300,458		)	(181,785		)
Net real estate property	3,967,864			2,726,212
Real estate loans receivable	76,195			39,154
Investment in unconsolidated entities	1,329			2,258
Net real estate investments	4,045,388			2,767,624
Cash and cash equivalents	2,727			15,491
Tenant receivables, net	9,966			9,790
Other assets	106,302			95,187
Total assets	$	4,164,383		$	2,888,092
LIABILITIES AND EQUITY
Liabilities:
Credit facility	$	324,394		$	643,742
Notes payable	966,603			224,330
Mortgage debt	186,471			123,083
Accounts payable	11,023			4,423
Dividends and distributions payable	43,804			32,179
Accrued expenses and other liabilities	56,405			42,287
Acquired lease intangibles, net	15,702			9,253
Total liabilities	1,604,402			1,079,297
Redeemable noncontrolling interest - Series A Preferred Units (2016) and partially owned properties	12,347			26,477
Equity:
Common shares, $0.01 par value, 500,000,000 common shares authorized, 181,440,051 and 135,966,013 common shares issued and outstanding as of December 31, 2017 and December 31, 2016, respectively	1,814			1,360
Additional paid-in capital	2,772,823			1,920,644
Accumulated deficit	(315,417		)	(197,261		)
Accumulated other comprehensive income	13,952			13,708
Total shareholders’ equity	2,473,172			1,738,451
Noncontrolling interests:
Operating Partnership	73,844			43,142
Partially owned properties	618			725
Total noncontrolling interests	74,462			43,867
Total equity	2,547,634			1,782,318
Total liabilities and equity	$	4,164,383		$	2,888,092

The accompanying notes are an integral part of these consolidated financial statements.

69

Physicians Realty Trust

Consolidated Statements of Income

(in thousands, except share and per share data)

	December 31,
	2017			2016			2015
Revenues:
Rental revenues	$	259,673		$	186,301		$	103,974
Expense recoveries	75,425			45,875			21,587
Interest income on real estate loans and other	8,486			8,858			3,880
Total revenues	343,584			241,034			129,441
Expenses:
Interest expense	47,008			23,864			10,636
General and administrative	22,957			18,397			14,908
Operating expenses	97,035			65,999			31,026
Depreciation and amortization	125,159			86,589			45,471
Acquisition expenses	16,744			14,778			14,893
Impairment loss	965			—			—
Total expenses	309,868			209,627			116,934
Income before equity in income of unconsolidated entities and gain on sale of investment properties:	33,716			31,407			12,507
Equity in income of unconsolidated entities	183			115			104
Gain on sale of investment properties	5,874			—			130
Net income	39,773			31,522			12,741
Net income attributable to noncontrolling interests:
Operating Partnership	(1,136		)	(825		)	(576		)
Partially owned properties (1)	(491		)	(716		)	(377		)
Net income attributable to controlling interest	38,146			29,981			11,788
Preferred distributions	(731		)	(1,857		)	(1,189		)
Net income attributable to common shareholders	$	37,415		$	28,124		$	10,599
Net income per share:
Basic	$	0.23		$	0.22		$	0.15
Diluted	$	0.23		$	0.22		$	0.15
Weighted average common shares:
Basic	163,123,109			126,143,114			72,750,724
Diluted	168,231,299			130,466,893			76,792,073
Dividends and distributions declared per common share and OP unit	$	0.915		$	0.900		$	0.900

(1) An adjustment of $0.3 million and $0.1 million was required for net income attributable to redeemable noncontrolling interests for the year ended December 31, 2017 and December 31, 2016, respectively. No such adjustment was required for the year ended December 31, 2015.

The accompanying notes are an integral part of these consolidated financial statements.

70

Physicians Realty Trust

Consolidated Statements of Comprehensive Income

(in thousands)

	December 31,
	2017			2016			2015
Net income	$	39,773		$	31,522		$	12,741
Other comprehensive income:
Change in fair value of interest rate swap agreements, net	244			13,708			—
Total other comprehensive income	244			13,708			—
Comprehensive income	40,017			45,230			12,741
Comprehensive income attributable to noncontrolling interests - Operating Partnership	(1,143		)	(1,162		)	(576		)
Comprehensive income attributable to noncontrolling interests - partially owned properties	(491		)	(716		)	(377		)
Comprehensive income attributable to common shareholders	$	38,383		$	43,352		$	11,788

The accompanying notes are an integral part of these consolidated financial statements.

71

Physicians Realty Trust

Consolidated Statements of Equity

(in thousands)

	Par Value		Additional Paid in Capital			Accumulated Deficit			Accumulated Other Comprehensive Income		Total Shareholders’ Equity			Operating Partnership Noncontrolling interest			Partially Owned Properties Noncontrolling Interest			Total  Noncontrolling Interests			Total Equity
Balance at January 1, 2015	$	508	$	586,019		$	(51,797	)	$	—	$	534,730		$	33,727		$	752		$	34,479		$	569,209
Net proceeds from sale of common shares	361		544,756			—			—		545,117			—			—			—			545,117
Restricted share award grants, net	1		3,191			(284		)	—		2,908			—			—			—			2,908
Purchase of OP Units	—		—			—			—		—			(1,088		)	—			(1,088		)	(1,088		)
Conversion of OP Units	—		171			—			—		171			(171		)	—			(171		)	—
Dividends/distributions declared	—		—			(67,542		)	—		(67,542		)	(3,344		)	—			(3,344		)	(70,886		)
Preferred distributions	—		—			(1,189		)	—		(1,189		)	—			—			—			(1,189		)
Issuance of OP Units in connection with acquisition	—		—			—			—		—			10,973			—			10,973			10,973
Contributions	—		—			—			—		—			—			8,962			8,962			8,962
Distributions	—		—			—			—		—			—			(213		)	(213		)	(213		)
Change in market value of Redeemable Noncontrolling Interest in Operating Partnership	—		(73		)	—			—		(73		)	—			—			—			(73		)
Net income	—		—			11,788			—		11,788			576			377			953			12,741
Adjustment for Noncontrolling Interests ownership in Operating Partnership	—		(4,778		)	—			—		(4,778		)	4,778			—			4,778			—
Balance at December 31, 2015	870		1,129,286			(109,024		)	—		1,021,132			45,451			9,878			55,329			1,076,461
Net proceeds from sale of common shares	473		766,368			—			—		766,841			—			—			—			766,841
Restricted share award grants, net	1		4,893			(460		)	—		4,434			—			—			—			4,434
Purchase of OP Units	—		—			—			—		—			(3,671		)	—			(3,671		)	(3,671		)
Conversion of OP Units	6		11,613			—			—		11,619			(11,619		)	—			(11,619		)	—
Dividends/distributions declared	—		—			(115,901		)	—		(115,901		)	(3,106		)	—			(3,106		)	(119,007		)
Preferred distributions	—		—			(1,857		)	—		(1,857		)	—			—			—			(1,857		)
Issuance of common shares and OP Units in connection with acquisitions	10		17,069			—			—		17,079			6,869			(100		)	6,769			23,848
Contributions	—		—			—			—		—			—			50			50			50
Distributions	—		—			—			—		—			—			(543		)	(543		)	(543		)
Change in market value of Redeemable Noncontrolling Interest in Operating Partnership	—		(245		)	—			—		(245		)	—			—			—			(245		)
Reclassification of Noncontrolling Interest - partially owned properties	—		—			—			—		—			—			(8,514		)	(8,514		)	(8,514		)
Buyout of Noncontrolling Interests - partially owned property	—		53			—			—		53			—			(664		)	(664		)	(611		)
Change in fair value of interest rate swap agreements	—		—			—			13,708		13,708			—			—			—			13,708
Net income	—		—			29,981			—		29,981			825			618			1,443			31,424
Adjustment for Noncontrolling Interests ownership in Operating Partnership	—		(8,393		)	—			—		(8,393		)	8,393			—			8,393			—
Balance at December 31, 2016	1,360		1,920,644			(197,261		)	13,708		1,738,451			43,142			725			43,867			1,782,318
Net proceeds from sale of common shares	451		844,218			—			—		844,669			—			—			—			844,669
Restricted share award grants, net	2		4,103			(284		)	—		3,821			—			—			—			3,821
Purchase of OP Units	—		—			—			—		—			(3,886		)	—			(3,886		)	(3,886		)
Conversion of OP Units	1		929			—			—		930			(930		)	—			(930		)	—
Dividends/distributions declared	—		—			(153,970		)	—		(153,970		)	(4,867		)	—			(4,867		)	(158,837		)
Preferred distributions	—		—			(731		)	—		(731		)	—			—			—			(731		)
Issuance of OP Units in connection with acquisitions	—		—			—			—		—			44,259			—			44,259			44,259
Contributions	—		—			—			—		—			—			47			47			47
Distributions	—		—			—			—		—			—			(321		)	(321		)	(321		)
Buyout of Noncontrolling Interests - partially owned properties	—		(2,800		)	—			—		(2,800		)	719			(24		)	695			(2,105		)
Change in fair value of interest rate swap agreements and redeemable equity - property	—		—			(1,317		)	244		(1,073		)	—			—			—			(1,073		)
Net income	—		—			38,146			—		38,146			1,136			191			1,327			39,473
Adjustment for Noncontrolling Interests ownership in Operating Partnership	—		5,729			—			—		5,729			(5,729		)	—			(5,729		)	—
Balance at December 31, 2017	$	1,814	$	2,772,823		$	(315,417	)	$	13,952	$	2,473,172		$	73,844		$	618		$	74,462		$	2,547,634

 The accompanying notes are an integral part of these consolidated financial statements.

72

Physicians Realty Trust

Consolidated Statements of Cash Flows

(in thousands)

	Year Ended December 31,
	2017			2016			2015
Cash Flows from Operating Activities:
Net income	$	39,773		$	31,522		$	12,741
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation and amortization	125,159			86,589			45,471
Amortization of deferred financing costs	2,299			2,325			1,373
Amortization of lease inducements and above/below-market lease intangibles	5,083			3,906			2,577
Straight-line rental revenue/expense	(16,202		)	(16,226		)	(9,000		)
Amortization of unsecured bond discount	277			—			—
Amortization of above-market assumed debt	(178		)	(236		)	(173		)
Gain on sale of investment properties	(5,874		)	—			(130		)
Equity in income of unconsolidated entities	(183		)	(115		)	(104		)
Distribution from unconsolidated entities	210			82			106
Change in fair value of derivatives	150			(240		)	(166		)
Provision for bad debts	123			2,310			69
Non-cash share compensation	6,695			5,672			3,798
Net change in fair value of contingent consideration	(472		)	(840		)	—
Impairment on investment properties	965			—			—
Change in operating assets and liabilities:
Tenant receivables	(2,988		)	(10,058		)	(2,836		)
Other assets	(533		)	(19,230		)	(2,630		)
Accounts payable	6,600			3,779			(56		)
Accrued expenses and other liabilities	19,567			37,957			8,312
Net cash provided by operating activities	180,471			127,197			59,352
Cash Flows from Investing Activities:
Proceeds on sales of investment properties	20,397			—			3,039
Acquisition of investment properties, net	(1,268,442		)	(1,240,438		)	(752,807		)
Acquisition of non-controlling interests	(8,469		)	(4,690		)	—
Escrowed cash—acquisition deposits/earnest deposits	(1,280		)	(1,157		)	2,000
Capital expenditures on existing investment properties	(23,243		)	(11,304		)	(4,988		)
Pay down of contingent consideration	(156		)	(483		)	(999		)
Real estate loans receivable	(39,063		)	(10,207		)	(22,359		)
Note receivable	—			—			(20,545		)
Repayment of real estate loan receivable	4,711			11,336			—
Repayment of note receivable	16,423			4,118			—
Leasing commissions	(1,449		)	(1,034		)	(579		)
Lease inducements	(2,067		)	(8,957		)	(2,478		)
Net cash used in investing activities	(1,302,638		)	(1,262,816		)	(799,716		)
Cash Flows from Financing Activities:
Net proceeds from sale of common shares	844,669			766,841			545,117
Proceeds from credit facility borrowings	927,000			1,181,000			620,000
Payment on credit facility borrowings	(1,248,000		)	(925,000		)	(363,000		)
Proceeds from issuance of mortgage debt	61,000			39,500			—
Proceeds from issuance of senior unsecured notes	743,060			225,000			—
Principal payments on mortgage debt	(41,503		)	(10,232		)	(2,022		)
Debt issuance costs	(1,589		)	(4,816		)	(3,105		)
Dividends paid - shareholders	(143,108		)	(104,908		)	(63,720		)
Distributions to noncontrolling interest - Operating Partnership	(4,388		)	(3,162		)	(3,216		)
Preferred distributions paid - OP Unit holder	(600		)	(1,508		)	(563		)
Contributions to noncontrolling interest	47			—			—
Distributions to noncontrolling interest - partially owned properties	(748		)	(543		)	(213		)
Payments of employee taxes for withheld stock based compensation shares	(2,590		)	(778		)	(606		)
Purchase of Series A Preferred Units	(19,961		)	(9,756		)	—
Purchase of OP Units	(3,886		)	(3,671		)	(1,088		)
Net cash provided by financing activities	1,109,403			1,147,967			727,584
Net (decrease) increase in cash and cash equivalents	(12,764		)	12,348			(12,780		)
Cash and cash equivalents, beginning of year	15,491			3,143			15,923
Cash and cash equivalents, end of year	$	2,727		$	15,491		$	3,143
Supplemental disclosure of cash flow information - interest paid during the year	$	38,781		$	17,151		$	9,550
Supplemental disclosure of noncash activity - change in fair value of interest rate swap agreements and redeemable equity - property	$	244		$	13,708		$	—
Supplemental disclosure of noncash activity - assumed debt	$	43,989		$	—		$	18,690
Supplemental disclosure of noncash activity - issuance of OP Units and Series A Preferred Units in connection with acquisitions	$	44,978		$	6,769		$	40,376
Supplemental disclosure of noncash activity - contingent consideration	$	765		$	156		$	2,718

The accompanying notes are an integral part of these consolidated financial statements.

73

Physicians Realty L.P.

Consolidated Balance Sheets

(in thousands, except share and per share data)

	December 31, 2017			December 31, 2016
ASSETS
Investment properties:
Land and improvements	$	217,695		$	189,759
Building and improvements	3,568,858			2,402,643
Tenant improvements	23,056			14,133
Acquired lease intangibles	458,713			301,462
	4,268,322			2,907,997
Accumulated depreciation	(300,458		)	(181,785		)
Net real estate property	3,967,864			2,726,212
Real estate loans receivable	76,195			39,154
Investment in unconsolidated entities	1,329			2,258
Net real estate investments	4,045,388			2,767,624
Cash and cash equivalents	2,727			15,491
Tenant receivables, net	9,966			9,790
Other assets	106,302			95,187
Total assets	$	4,164,383		$	2,888,092
LIABILITIES AND CAPITAL
Liabilities:
Credit facility	$	324,394		$	643,742
Notes payable	966,603			224,330
Mortgage debt	186,471			123,083
Accounts payable	11,023			4,423
Dividends and distributions payable	43,804			32,179
Accrued expenses and other liabilities	56,405			42,287
Acquired lease intangibles, net	15,702			9,253
Total liabilities	1,604,402			1,079,297
Redeemable noncontrolling interest - Series A Preferred Units (2016) and partially owned properties	12,347			26,477
Capital:
Partners’ capital:
General partners’ capital, 181,440,051 and 135,966,013 units issued and outstanding as of December 31, 2017 and 2016, respectively	2,459,220			1,724,743
Limited partners’ capital, 5,364,632 and 3,436,207 units issued and outstanding as of December 31, 2017 and 2016, respectively	73,844			43,142
Accumulated other comprehensive income	13,952			13,708
Total partners’ capital	2,547,016			1,781,593
Noncontrolling interest - partially owned properties	618			725
Total capital	2,547,634			1,782,318
Total liabilities and capital	$	4,164,383		$	2,888,092

The accompanying notes are an integral part of these consolidated financial statements.

74

Physicians Realty L.P.

Consolidated Statements of Income

(in thousands, except unit and per unit data)

	December 31,
	2017			2016			2015
Revenues:
Rental revenues	$	259,673		$	186,301		$	103,974
Expense recoveries	75,425			45,875			21,587
Interest income on real estate loans and other	8,486			8,858			3,880
Total revenues	343,584			241,034			129,441
Expenses:
Interest expense	47,008			23,864			10,636
General and administrative	22,957			18,397			14,908
Operating expenses	97,035			65,999			31,026
Depreciation and amortization	125,159			86,589			45,471
Acquisition expenses	16,744			14,778			14,893
Impairment loss	965			—			—
Total expenses	309,868			209,627			116,934
Income before equity in income of unconsolidated entities and gain on sale of investment property	33,716			31,407			12,507
Equity in income of unconsolidated entities	183			115			104
Gain on sale of investment properties	5,874			—			130
Net income	39,773			31,522			12,741
Net income attributable to noncontrolling interests - partially owned properties (1)	(491		)	(716		)	(377		)
Net income attributable to controlling interest	39,282			30,806			12,364
Preferred distributions	(731		)	(1,857		)	(1,189		)
Net income attributable to common unitholders	$	38,551		$	28,949		$	11,175
Net income per common unit:
Basic	$	0.23		$	0.22		$	0.15
Diluted	$	0.23		$	0.22		$	0.15
Weighted average common units:
Basic	167,963,076			129,835,209			76,459,218
Diluted	168,231,299			130,466,893			76,792,073
Distributions declared per common unit	$	0.915		$	0.900		$	0.900

(1) An adjustment of $0.3 million and $0.1 million was required for net income attributable to redeemable noncontrolling interests for the year ended December 31, 2017 and December 31, 2016, respectively. No such adjustment was required for the year ended December 31, 2015.

The accompanying notes are an integral part of these consolidated financial statements.

75

Physicians Realty L.P.

Consolidated Statements of Comprehensive Income

(in thousands)

	December 31,
	2017			2016			2015
Net income	$	39,773		$	31,522		$	12,741
Other comprehensive income:
Change in fair value of interest rate swap agreements, net	244			13,708			—
Total other comprehensive income	244			13,708			—
Comprehensive income	40,017			45,230			12,741
Comprehensive income attributable to noncontrolling interests - partially owned properties	(491		)	(716		)	(377		)
Comprehensive income attributable to common unitholders	$	39,526		$	44,514		$	12,364

The accompanying notes are an integral part of these consolidated financial statements.

76

Physicians Realty L.P.

Consolidated Statements of Changes in Capital

(in thousands)

	General Partner			Limited Partner			Accumulated Other Comprehensive Income		Total Partners’ Capital			Partially Owned Properties Noncontrolling Interest			Total Partners’ Capital
Balance at January 1, 2015	$	534,730		$	33,727		$	—	$	568,457		$	752		$	569,209
Net proceeds from sale of Trust common shares and issuance of common units	545,117			—			—		545,117			—			545,117
Trust restricted share award grants, net	2,908			—			—		2,908			—			2,908
Purchase of OP Units	—			(1,088		)	—		(1,088		)	—			(1,088		)
Conversion of OP Units	171			(171		)	—		—			—			—
OP Units - distributions	(67,542		)	(3,344		)	—		(70,886		)	—			(70,886		)
Preferred distributions	(1,189		)	—			—		(1,189		)	—			(1,189		)
Issuance of OP Units in connection with acquisition	—			10,973			—		10,973			—			10,973
Contributions	—			—			—		—			8,962			8,962
Distributions	—			—			—		—			(213		)	(213		)
Change in market value of Redeemable Limited Partners	(73		)	—			—		(73		)	—			(73		)
Net income	11,788			576			—		12,364			377			12,741
Adjustments for Limited Partners ownership in Operating Partnership	(4,778		)	4,778			—		—			—			—
Balance at December 31, 2015	1,021,132			45,451			—		1,066,583			9,878			1,076,461
Net proceeds from sale of Trust common shares and issuance of common units	766,841			—			—		766,841			—			766,841
Trust restricted share award grants, net	4,434			—			—		4,434			—			4,434
Purchase of OP Units	—			(3,671		)	—		(3,671		)	—			(3,671		)
Conversion of OP Units	11,619			(11,619		)	—		—			—			—
OP Units - distributions	(115,901		)	(3,106		)	—		(119,007		)	—			(119,007		)
Preferred distributions	(1,857		)	—			—		(1,857		)	—			(1,857		)
Issuance of OP Units in connection with acquisition	17,079			6,869			—		23,948			(100		)	23,848
Contributions	—			—			—		—			50			50
Distributions	—			—			—		—			(543		)	(543		)
Change in market value of Redeemable Limited Partners	(245		)	—			—		(245		)	—			(245		)
Reclassification of Noncontrolling Interest - partially owned properties	—			—			—		—			(8,514		)	(8,514		)
Buyout of Noncontrolling Interest - partially owned properties	53			—			—		53			(664		)	(611		)
Change in fair value of interest rate swap agreements	—			—			13,708		13,708			—			13,708
Net income	29,981			825			—		30,806			618			31,424
Adjustments for Limited Partners ownership in Operating Partnership	(8,393		)	8,393			—		—			—			—
Balance at December 31, 2016	1,724,743			43,142			13,708		1,781,593			725			1,782,318
Net proceeds from sale of Trust common shares and issuance of common units	844,669			—			—		844,669			—			844,669
Trust Restricted share award grants, net	3,821			—			—		3,821			—			3,821
Purchase of OP Units	—			(3,886		)	—		(3,886		)	—			(3,886		)
Conversion of OP Units	930			(930		)	—		—			—			—
OP Units - distributions	(153,970		)	(4,867		)	—		(158,837		)	—			(158,837		)
Preferred distributions	(731		)	—			—		(731		)	—			(731		)
Issuance of OP Units in connection with acquisition	—			44,259			—		44,259			—			44,259
Contributions	—			—			—		—			47			47
Distributions	—			—			—		—			(321		)	(321		)
Buyout of Noncontrolling Interest - partially owned properties	(2,800		)	719			—		(2,081		)	(24		)	(2,105		)
Change in fair value of interest rate swap agreements and redeemable equity - property	(1,317		)	—			244		(1,073		)	—			(1,073		)
Net income	38,146			1,136			—		39,282			191			39,473
Adjustments for Limited Partners ownership in Operating Partnership	5,729			(5,729		)	—		—			—			—
Balance at December 31, 2017	$	2,459,220		$	73,844		$	13,952	$	2,547,016		$	618		$	2,547,634

The accompanying notes are an integral part of these consolidated financial statements.

77

Physicians Realty L.P.

Consolidated Statements of Cash Flows

(in thousands)

	Year Ended December 31,
	2017			2016			2015
Cash Flows from Operating Activities:
Net income	$	39,773		$	31,522		$	12,741
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation and amortization	125,159			86,589			45,471
Amortization of deferred financing costs	2,299			2,325			1,373
Amortization of lease inducements and above/below-market lease intangibles	5,083			3,906			2,577
Straight-line rental revenue/expense	(16,202		)	(16,226		)	(9,000		)
Amortization of unsecured bond discount	277			—			—
Amortization of above-market assumed debt	(178		)	(236		)	(173		)
Gain on sale of investment properties	(5,874		)	—			(130		)
Equity in income of unconsolidated entities	(183		)	(115		)	(104		)
Distribution from unconsolidated entities	210			82			106
Change in fair value of derivatives	150			(240		)	(166		)
Provision for bad debts	123			2,310			69
Non-cash share compensation	6,695			5,672			3,798
Net change in fair value of contingent consideration	(472		)	(840		)	—
Impairment on investment properties	965			—			—
Change in operating assets and liabilities:
Tenant receivables	(2,988		)	(10,058		)	(2,836		)
Other assets	(533		)	(19,230		)	(2,630		)
Accounts payable	6,600			3,779			(56		)
Accrued expenses and other liabilities	19,567			37,957			8,312
Net cash provided by operating activities	180,471			127,197			59,352
Cash Flows from Investing Activities:
Proceeds on sales of investment property	20,397			—			3,039
Acquisition of investment properties, net	(1,268,442		)	(1,240,438		)	(752,807		)
Acquisition of non-controlling interests	(8,469		)	(4,690		)	—
Escrowed cash—acquisition deposits/earnest deposits	(1,280		)	(1,157		)	2,000
Capital expenditures on existing investment properties	(23,243		)	(11,304		)	(4,988		)
Pay down of contingent consideration	(156		)	(483		)	(999		)
Real estate loans receivable	(39,063		)	(10,207		)	(22,359		)
Repayment of real estate loan receivable	4,711			11,336			—
Note receivable	—			—			(20,545		)
Repayment of note receivable	16,423			4,118			—
Leasing commissions	(1,449		)	(1,034		)	(579		)
Lease Inducements	(2,067		)	(8,957		)	(2,478		)
Net cash used in investing activities	(1,302,638		)	(1,262,816		)	(799,716		)
Cash Flows from Financing Activities:
Net proceeds from sale of Trust common shares and issuance of common units	844,669			766,841			545,117
Proceeds from credit facility borrowings	927,000			1,181,000			620,000
Payment on credit facility borrowings	(1,248,000		)	(925,000		)	(363,000		)
Proceeds from issuance of senior unsecured notes	743,060			225,000			—
Proceeds from issuance of mortgage debt	61,000			39,500			—
Principal payments on mortgage debt	(41,503		)	(10,232		)	(2,022		)
Debt issuance costs	(1,589		)	(4,816		)	(3,105		)
OP Units distributions - General Partner	(143,108		)	(104,908		)	(63,720		)
OP Units distributions - Limited Partner	(4,388		)	(3,162		)	(3,216		)
Preferred OP Units distributions - Limited Partner	(600		)	(1,508		)	—
Contributions to noncontrolling interest	47			—			—
Distributions to noncontrolling interest - partially owned properties	(748		)	(543		)	(213		)
Payments of employee taxes for withheld stock based compensation shares	(2,590		)	(778		)	(606		)
Purchase of Preferred Limited Partner Units	(19,961		)	(9,756		)	(563		)
Purchase of Limited Partner Units	(3,886		)	(3,671		)	(1,088		)
Net cash provided by financing activities	1,109,403			1,147,967			727,584
Net (decrease) increase in cash and cash equivalents	(12,764		)	12,348			(12,780		)
Cash and cash equivalents, beginning of year	15,491			3,143			15,923
Cash and cash equivalents, end of year	$	2,727		$	15,491		$	3,143
Supplemental disclosure of cash flow information - interest paid during the year	$	38,781		$	17,151		$	9,550
Supplemental disclosure of noncash activity - change in fair value of interest rate swap agreements and redeemable equity - property	$	244		$	13,708		$	—
Supplemental disclosure of noncash activity - assumed debt	$	43,989		$	—		$	18,690
Supplemental disclosure of noncash activity - issuance of OP Units and Series A Preferred Units in connection with acquisitions	$	44,978		$	6,769		$	40,376
Supplemental disclosure of noncash activity - contingent consideration	$	765		$	156		$	2,718

The accompanying notes are an integral part of these consolidated financial statements.

78

Physicians Realty Trust and Physicians Realty L.P.

Notes to Consolidated Financial Statements

Unless otherwise indicated or unless the context requires otherwise the use of the words “we,” “us” or “our” refers to Physicians Realty Trust and Physicians Realty L.P., collectively.

Note 1. Organization and Business

Physicians Realty Trust (the “Trust”) was organized in the state of Maryland on April 9, 2013. As of December 31, 2017, the Trust was authorized to issue up to 500,000,000 common shares of beneficial interest, par value $0.01 per share (“common shares”). The Trust filed a Registration Statement on Form S-11 with the Securities and Exchange Commission (the “Commission”) with respect to a proposed underwritten initial public offering (the “IPO”) and completed the IPO of its common shares and commenced operations on July 24, 2013.

The Trust contributed the net proceeds from the IPO to Physicians Realty L.P. (the “Operating Partnership” and together with the Trust and its consolidated subsidiaries, including the Operating Partnership, the “Company”), a Delaware limited partnership, and is the sole general partner of the Operating Partnership. The Trust and the Operating Partnership are managed and operated as one entity. The Trust has no significant assets other than its investment in the Operating Partnership. The Trust’s operations are conducted through the Operating Partnership and wholly-owned and majority-owned subsidiaries of the Operating Partnership. The Trust, as the general partner of the Operating Partnership, controls the Operating Partnership and consolidates the assets, liabilities, and results of operations of the Operating Partnership. Therefore, the assets and liabilities of the Trust and the Operating Partnership are the same.

The Trust is a self-managed real estate investment trust (“REIT”) formed primarily to acquire, selectively develop, own, and manage healthcare properties that are leased to physicians, hospitals, and healthcare delivery systems.

Equity Offerings

In March 2017, the Trust completed a follow-on public offering of 17,250,000 common shares of beneficial interest, including 2,250,000 common shares issued upon exercise of the underwriters’ overallotment option, resulting in net proceeds to it of approximately $300.8 million. The Trust contributed the net proceeds of this offering to the Operating Partnership in exchange for 17,250,000 OP Units, and the Operating Partnership used the net proceeds of the public offering to repay borrowings under its unsecured revolving credit facility and for general corporate purposes, including working capital and funding acquisitions.

In July 2017, the Trust completed a follow-on public offering of 21,500,000 common shares of beneficial interest, including 1,500,000 common shares issued upon partial exercise of the underwriters’ overallotment option, resulting in net proceeds to it of approximately $420.7 million. The Trust contributed the net proceeds of this offering to the Operating Partnership in exchange for 21,500,000 OP Units, and the Operating Partnership used the net proceeds of the public offering to repay borrowings under its unsecured revolving credit facility and for general corporate purposes, including working capital and funding acquisitions.

ATM Program

On August 5, 2016, the Trust and the Operating Partnership entered into separate At Market Issuance Sales Agreements (the “2016 Sales Agreements”) with each of KeyBanc Capital Markets Inc., Credit Agricole Securities (USA) Inc., JMP Securities LLC, Raymond James & Associates, Inc., and Stifel Nicolaus & Company, Incorporated (the “2016 Agents”), pursuant to which the Trust may issue and sell, from time to time, its common shares having an aggregate offering price of up to $300.0 million, through the Agents (the “2016 ATM Program”). In accordance with the 2016 Sales Agreements, the Trust may offer and sell its common shares through any of the 2016 Agents, from time to time, by any method deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended, which includes sales made directly on the NYSE or other existing market, or sales made to or through a market maker. With the Trust’s express written consent, sales may also be made in negotiated transactions or any other method permitted by law.

79

During 2016 and 2017, the Trust’s issuance and sale of common shares pursuant to the 2016 ATM Program is as follows (in thousands, except common shares and price): 

	2017					2016
	Common shares sold	Weighted average price		Net proceeds		Common shares sold	Weighted average price		Net proceeds
Quarterly period ended March 31	—	$	—	$	—	—	$	—	$	—
Quarterly period ended June 30	4,150,000	20.07		82,440		—	—		—
Quarterly period ended September 30	—	—		—		—	—		—
Quarterly period ended December 31	2,197,914	18.39		40,011		135,531	19.09		2,561
Year ended December 31	6,347,914	$	19.48	$	122,451	135,531	$	19.09	$	2,561

As of February 23, 2018, the Trust has $168.2 million remaining available under the 2016 ATM Program.

Note 2. Summary of Significant Accounting Policies

Principles of Consolidation

GAAP requires us to identify entities for which control is achieved through means other than voting rights and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). ASC 810 broadly defines a VIE as an entity in which either (i) the equity investors as a group, if any, lack the power through voting or similar rights to direct the activities of such entity that most significantly impact such entity’s economic performance or (ii) the equity investment at risk is insufficient to finance that entity’s activities without additional subordinated financial support. We identify the primary beneficiary of a VIE as the enterprise that has both of the following characteristics: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or receive benefits of the VIE that could potentially be significant to the entity. We consolidate our investment in a VIE when we determine that we are the VIE’s primary beneficiary. We may change our original assessment of a VIE upon subsequent events such as the modification of contractual arrangements that affect the characteristics or adequacy of the entity’s equity investments at risk and the disposition of all or a portion of an interest held by the primary beneficiary. We perform this analysis on an ongoing basis.

For property holding entities not determined to be VIEs, we consolidate such entities in which the Operating Partnership owns 100% of the equity or has a controlling financial interest evidenced by ownership of a majority voting interest. All intercompany balances and transactions are eliminated in consolidation. For entities in which the Operating Partnership owns less than 100% of the equity interest, the Operating Partnership consolidates the property if it has the direct or indirect ability to control the entities’ activities based upon the terms of the respective entities’ ownership agreements. For these entities, the Operating Partnership records a noncontrolling interest representing equity held by noncontrolling interests.

Noncontrolling Interests

The Company presents the portion of any equity it does not own in entities that it controls (and thus consolidates) as noncontrolling interests and classifies such interests as a component of consolidated equity, separate from the Company’s total shareholders’ equity, on the consolidated balance sheets.

Operating Partnership: Net income or loss is allocated to noncontrolling interests (limited partners) based on their respective ownership percentage of the Operating Partnership. The ownership percentage is calculated by dividing the number of OP Units held by the noncontrolling interests by the total OP Units held by the noncontrolling interests and the Trust. Issuance of additional common shares and OP Units changes the ownership interests of both the noncontrolling interests and the Trust. Such transactions and the related proceeds are treated as capital transactions.

During the year ended December 31, 2017, the Operating Partnership partially funded one property acquisition by issuing an aggregate of 2,247,817 OP Units valued at approximately $44.3 million on the date of issuance. The acquisition had a total purchase price of approximately $78.6 million. In addition, the Operating Partnership funded the acquisition of the remaining non-controlling interest on a property by issuing an aggregate of 38,641 OP Units valued at approximately $0.7 million.

During the year ended December 31, 2016, the Operating Partnership partially funded one property acquisition by issuing an aggregate of 174,085 OP Units valued at approximately $2.9 million on the date of issuance. The acquisition had a

80

total purchase price of approximately $8.5 million. In addition, the Operating Partnership funded the acquisition of the remaining non-controlling interest on a property by issuing an aggregate of 217,549 OP Units valued at approximately $4.0 million.

Noncontrolling interests in the Company include OP Units held by the Predecessor’s prior investors and other investors. As of December 31, 2017 and 2016, the Trust held a 97.1% and 97.5% interest in the Operating Partnership, respectively. As the sole general partner and the majority interest holder, the Trust consolidates the financial position and results of operations of the Operating Partnership.

Holders of OP Units may not transfer their units without the Trust’s prior written consent, as general partner of the Operating Partnership. Beginning on the first anniversary of the issuance of OP Units, OP Unit holders may tender their units for redemption by the Operating Partnership in exchange for cash equal to the market price of the Trust’s common shares at the time of redemption or for unregistered common shares on a one-for-one basis. Such selection to pay cash or issue common shares to satisfy an OP Unit holder’s redemption request is solely within the control of the Trust. Accordingly, the Trust presents the OP Units of the Operating Partnership held by investors other than the Trust as noncontrolling interests within equity in the consolidated balance sheet.

Partially Owned Properties: The Trust and OP reflect noncontrolling interests in partially owned properties on the balance sheet for the portion of consolidated properties that are not wholly owned by the Company. The earnings or losses from those properties attributable to the noncontrolling interests are reflected as noncontrolling interests in partially owned properties in the consolidated statements of income.

Redeemable Noncontrolling Interests-Series A Preferred Units and Partially Owned Properties 

On February 5, 2015, the Trust entered into a Second Amended and Restated Agreement of Limited Partnership (the “Partnership Agreement”) which provides for the designation and issuance of the newly designated Series A Participating Redeemable Preferred Units of the Operating Partnership (“Series A Preferred Units”). Series A Preferred Units have priority over all other partnership interests of the Operating Partnership with respect to distributions and liquidation. Holders of Series A Preferred Units are entitled to a 5% cumulative return and upon redemption, the receipt of one common share and $200. Series A Preferred Units are redeemable at the option of the holders; however, the holders of the Series A Preferred Units have agreed not to cause the Operating Partnership to redeem their Series A Preferred Units prior to one year from the issuance date. After such one year period, if the holders of Series A Preferred Units exercise their option to redeem Series A Preferred Units, the Trust may satisfy its redemption obligation, at the Trust’s option, in cash or registered common shares. Instruments that require settlement in registered common shares may not be classified in permanent equity as it is not always completely within an issuer’s control to deliver registered common shares. Due to the redemption rights associated with the Series A Preferred Units, the Trust classifies the Series A Preferred Units in the mezzanine section of its consolidated balance sheets. 

The Series A Preferred Units were evaluated for embedded features that should be bifurcated and separately accounted for as a freestanding derivative. The Company determined that the Series A Preferred Units contained features that require bifurcation. The Company records the carrying amount of the redeemable noncontrolling interests, less the value of the embedded derivative, at the greater of the carrying value or redemption value in the consolidated balance sheets.

On February 5, 2015, the acquisition of the Minnetonka MOB was partially funded with the issuance of 44,685 Series A Preferred Units which were valued at $9.7 million. On December 17, 2015, the acquisition of the Nashville MOB was partially funded with the issuance of 91,236 Series A Preferred Units which were valued at $19.7 million.

On April 1, 2016, the Series A Preferred Units issued in conjunction with the Minnetonka MOB acquisition were redeemed for a total value of $9.8 million. The fair value of the embedded derivative associated with the previously outstanding Series A Preferred Units was $2.7 million which was derecognized in the course of the redemption.

On January 12, 2017, the Series A Preferred Units issued in conjunction with the Nashville MOB acquisition were redeemed for a total value of $20.0 million. The fair value of the embedded derivative associated with the previously outstanding Series A Preferred Units was $5.6 million which was derecognized in the course of the redemption.

In connection with the acquisition of the Minnetonka MOB, the Trust received a $5 million equity investment from a third party, effective March 1, 2015. This investment earns a 15% cumulative preferred return. At any point subsequent to the third anniversary of the investment, the holder can require the Trust to redeem the instrument at a price for which the investor will realize a 15% internal rate of return. Due to the redemption provision, which is outside of the control of the Trust, the Trust

81

classifies the investment in the mezzanine section of its consolidated balance sheets. The Trust records the carrying amount of the redeemable noncontrolling interests at the greater of the carrying value or redemption value.

In connection with the acquisition on December 29, 2015 of a medical office building located on the campus of the Great Falls Clinic and Hospital in Great Falls, Montana (the “Great Falls Clinic”), physicians affiliated with the seller retained a non-controlling interest which may, at the holders’ option, be redeemed at any time. Due to the redemption provision, which is outside of the control of the Trust, the Trust classifies the investment in the mezzanine section of its consolidated balance sheet. The Trust records the carrying amount of the redeemable noncontrolling interests at the greater of the carrying value or redemption value. As of December 31, 2017, physicians affiliated with the seller redeemed a portion of their non-controlling interest for $1.1 million.

Dividends and Distributions

Dividends and distributions for the years ended December 31, 2017, 2016, and 2015 are as follows:

Declaration Date	Record Date	Payment Date	Cash Dividend per Share/Unit
December 21, 2017	January 3, 2018	January 18, 2018	$	0.230
September 21, 2017	October 3, 2017	October 18, 2017	$	0.230
June 12, 2017	July 3, 2017	July 18, 2017	$	0.230
March 17, 2017	April 5, 2017	April 18, 2017	$	0.225
December 22, 2016	January 5, 2017	January 18, 2017	$	0.225
September 26, 2016	October 6, 2016	October 18, 2016	$	0.225
June 23, 2016	July 5, 2016	July 18, 2016	$	0.225
March 18, 2016	April 1, 2016	April 18, 2016	$	0.225
December 31, 2015	January 15, 2016	January 29, 2016	$	0.225
September 28, 2015	October 16, 2015	October 30, 2015	$	0.225
July 1, 2015	July 17, 2015	July 31, 2015	$	0.225
April 6, 2015	April 17, 2015	May 1, 2015	$	0.225

Our shareholders are entitled to reinvest all or a portion of any cash distribution on their shares of our common stock by participating in our Dividend Reinvestment and Share Purchase Plan (“DRIP”), subject to the terms of the plan.

Tax Status of Dividends and Distributions

Our distributions of current and accumulated earnings and profits for U.S. federal income tax purposes generally are taxable to shareholders as ordinary income. Distributions in excess of these earnings and profits generally are treated as a non-taxable reduction of the shareholders’ basis in the shares to the extent thereof (non-dividend distributions) and thereafter as taxable gain.

Any cash distributions received by an OP Unit holder in respect of its OP Units generally will not be taxable to such OP Unit holder for U.S. federal income tax purposes, to the extent that such distribution does not exceed the OP Unit holder’s basis in its OP Units. Any such distribution will instead reduce the OP Unit holder’s basis in its OP Units (and OP Unit holders will be subject to tax on the taxable income allocated to them by the Operating Partnership in respect of their OP Units when such income is earned by the Operating Partnership, with such income allocation increasing the OP Unit holders’ basis in their OP Units).

82

The following table sets forth the federal income tax status of distributions per common share and OP Unit for the periods presented:

	Year Ended December 31,
	2017		2016		2015
Per common share and OP Unit:
Ordinary dividends	$	0.4529	$	0.5325	$	0.2693
Qualified dividends	—		—		—
Capital gain distributions	—		—		—
Non-dividend distributions	0.4571		0.3675		0.6307
Total	$	0.9100	$	0.9000	$	0.9000

Purchases of Investment Properties

A property acquired not subject to an existing lease is treated as an asset acquisition and recorded at its purchase price, inclusive of acquisition costs, allocated between the acquired assets and assumed liabilities, including identified intangible assets and liabilities, based upon their relative fair values at the date of acquisition. A property acquired with an existing lease is accounted for as a business combination pursuant to the acquisition method in accordance with ASC Topic 805, Business Combinations (“ASC 805”), and assets acquired and liabilities assumed, including identified intangible assets and liabilities, are recorded at fair value.

The determination of fair value involves the use of significant judgment and estimation. The Company makes estimates of the fair value of the tangible and intangible acquired assets and assumed liabilities using information obtained from multiple sources as a result of pre-acquisition due diligence and generally includes the assistance of a third party appraiser. The Company estimates the fair value of buildings acquired on an “as-if-vacant” basis and depreciates the building value over the estimated remaining life of the building. The Company determines the allocated value of other fixed assets, such as site improvements, based upon the replacement cost and depreciates such value over the assets’ estimated remaining useful lives as determined at the applicable acquisition date. The fair value of land is determined either by considering the sales prices of similar properties in recent transactions or based on internal analyses of recently acquired and existing comparable properties within the Company’s portfolio.

In recording identified intangible assets and liabilities in connection with a business combination, the value of above- or below-market leases is estimated based on the present value (using an interest rate which reflected the risks associated with the leases acquired) of the difference between contractual amounts to be received pursuant to the leases and management’s estimate of market lease rates measured over a period equal to the estimated remaining term of the lease. The capitalized above-market or below-market lease intangibles are amortized as a reduction or addition to rental income over the estimated remaining term of the respective leases plus the term of any renewal options that the lessee would be economically compelled to exercise.

In determining the value of in-place leases, management considers current market conditions and costs to execute similar leases in arriving at an estimate of the carrying costs during the expected lease-up period from vacant to existing occupancy. In estimating carrying costs, management includes real estate taxes, insurance, other operating expenses, estimates of lost rental revenue during the expected lease-up periods, and costs to execute similar leases, including leasing commissions, tenant improvements, legal, and other related costs based on current market demand. The values assigned to in-place leases are amortized to amortization expense over the estimated remaining term of the lease. If a lease terminates prior to its scheduled expiration, all unamortized costs related to that lease are written off, net of any required lease termination payments.

The Company calculates the fair value of any long-term debt assumed by discounting the remaining contractual cash flows on each instrument at the current market rate for those borrowings, which the Company approximates based on the rate it would expect to incur on a replacement instrument on the date of acquisition, and recognizes any fair value adjustments related to long-term debt as effective yield adjustments over the remaining term of the instrument.

Based on these estimates, the Company recognizes the acquired assets and assumed liabilities at their estimated fair values, which are generally determined using Level 3 inputs, such as market rental rates, capitalization rates, discount rates, or other available market data. Initial valuations are subject to change until the information is finalized, no later than 12 months from the acquisition date. The Company expenses transaction costs associated with acquisitions accounted for as business combinations in the period incurred.

83

 Impairment of Intangible and Long-Lived Assets

The Company periodically evaluates its long-lived assets, primarily consisting of investments in real estate, for impairment indicators or whenever events or changes in circumstances indicate that the recorded amount of an asset may not be fully recoverable. If indicators of impairment are present, the Company evaluates the carrying value of the related real estate properties in relation to the undiscounted expected future cash flows of the underlying operations. In performing this evaluation, management considers market conditions and current intentions with respect to holding or disposing of the real estate property. The Company adjusts the net book value of real estate properties to fair value if the sum of the expected future undiscounted cash flows, including sales proceeds, is less than book value. The Company records an impairment loss at the time it makes any such determination. If the Company determines that an asset is impaired, the impairment to be recorded is measured as the amount by which the book value of the asset exceeds its fair value. Fair value is typically determined using a discounted future cash flow analysis or other acceptable valuation techniques, which are based, in turn, upon Level 3 inputs, such as revenue and expense growth rates, capitalization rates, discount rates, or other available market data.

The Company recorded an impairment charge of $1.0 million on a vacant medical office building in Port Charlotte, Florida during the year ended December 31, 2017. There were no impairment charges in the years ended December 31, 2016, and 2015.

Assets Held for Sale and Discontinued Operations

The Company may sell properties from time to time for various reasons, including favorable market conditions. The Company classifies certain long-lived assets as held for sale once the criteria, as defined by GAAP, has been met. Long-lived assets to be disposed of are reported at the lower of their carrying amount or fair value minus cost to sell, and are no longer depreciated. No properties were classified as held for sale as of December 31, 2017, 2016, or 2015 and dispositions during the years ended December 31, 2017, 2016, and 2015 did not qualify as discontinued operations.

Investments in Unconsolidated Entities

The Company reports investments in unconsolidated entities over whose operating and financial policies it has the ability to exercise significant influence under the equity method of accounting. Under this method of accounting, the Company’s share of the investee’s earnings or losses is included in its consolidated statements of income. The initial carrying value of investments in unconsolidated entities is based on the amount paid to purchase the equity interest.

During 2014, the Company completed the acquisition of a 40% limited liability company membership interest in Jeff Orleans Medical Development Real Estate, L.L.C., the entity that owns and leases to the Company the land on which the Crescent City Surgical Centre is situated, for $1.3 million.

During 2016, the Company completed the acquisition of a 43% limited liability company membership interest in Desert Cove MOB, LLC. During 2017, the Company completed the acquisition of the remaining 57% interest in this facility for a purchase price of approximately $4.6 million and consolidated it effective December 2017. The Company has a total investment in the facility of $5.5 million.

Real Estate Loans Receivable

Real estate loans receivable consists of ten mezzanine loans and two term loans. Each mezzanine loan is collateralized by an ownership interest in the respective borrower, while the term loans are secured by equity interests in two medical office building developments. Interest income on the loans are recognized as earned based on the terms of the loans subject to evaluation of collectability risks and are included in the Company’s consolidated statements of income.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash on hand and short-term investments with maturities of three months or less from the date of purchase. The Company is subject to concentrations of credit risk as a result of its temporary cash investments. The Company places its temporary cash investments with high credit quality financial institutions in order to mitigate that risk.

84

Escrow Reserves

The Company is required to maintain various escrow reserves on certain notes payable to cover future property taxes and insurance and tenant improvements costs as defined in each loan agreement. The total reserves as of December 31, 2017 and 2016 are $2.0 million and $4.3 million, respectively, which are included in other assets in the consolidated balance sheets.

Deferred Costs

Deferred costs consist primarily of fees paid to obtain financing and costs associated with the origination of long-term leases on real estate properties. After the purchase of a property, lease commissions incurred to extend in-place leases or generate new leases are added to deferred lease costs. Deferred lease costs are included as a component of other assets and are amortized on a straight-line basis over the terms of their respective agreements. Deferred financing costs are shown as a direct reduction from the related debt liability. The Trust amortizes deferred financing costs as a component of interest expense over the terms of the related borrowings on a straight-line basis.

Derivative Instruments

When the Company has derivative instruments embedded in other contracts, it records them either as an asset or a liability measured at their fair value unless they qualify for a normal purchase or normal sales exception. When specific hedge accounting criteria are not met, changes in the Company’s derivative instruments’ fair value are recognized currently in earnings. If hedge accounting is applied to a derivative instrument, such changes are reported in accumulated other comprehensive income (“AOCI”) within the equity section of the consolidated balance sheets, exclusive of ineffectiveness amounts, which are recognized as adjustments to net income.

To manage interest rate risk for certain of its variable-rate debt, the Company uses interest rate swaps as part of its risk management strategy. These derivatives are designed to mitigate the risk of future interest rate increases by providing a fixed interest rate for a limited, pre-determined period of time. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. As of December 31, 2017, the Company had five outstanding interest rate swap contracts that are designated as cash flow hedges of interest rate risk. For presentational purposes, they are shown as one derivative due to the identical nature of their economic terms. Further detail is provided in Note 7 (Derivatives).

The effective portion of the change in the fair value of derivatives designated and that qualify as cash flow hedges is recorded in accumulated other comprehensive income (“AOCI”) on the consolidated balance sheets and is subsequently reclassified into earnings as interest expense for the period that the hedged forecasted transaction affects earnings. The ineffective portion of the change in fair value of the derivatives is recognized directly in earnings. For the twelve months ended months ended December 31, 2017, the Company recorded a $0.2 million loss as a result of hedge ineffectiveness. The Company expects hedge ineffectiveness to be insignificant in the next 12 months.

Tenant Receivables, Net

Tenant accounts receivable are stated net of the applicable allowance. Rental payments under these contracts are primarily due monthly. The Company assesses the collectability of tenant receivables, including straight-line rent receivables, and defers recognition of revenue if collectability is not reasonably assured. The Company bases its assessment of the collectability of rent receivables on several factors, including, among other things, payment history, the financial strength of the tenant, and current economic conditions. If management’s evaluation of these factors indicates it is probable that the Company will be unable to recover the full value of the receivable, the Company provides a reserve against the portion of the receivable that it estimates may not be recovered. At December 31, 2017 and 2016, the allowance for doubtful accounts was $1.6 million and $2.4 million, respectively.

Rental Revenue

Rental revenue is recognized on a straight-line basis over the terms of the related leases when collectability is reasonably assured. Recognizing rental revenue on a straight-line basis for leases may result in recognizing revenue for amounts more or less than amounts currently due from tenants. Accumulated amounts recognized in excess of amounts currently due from tenants, net of related allowances, are included in other assets and were approximately $47.6 million and $32.0 million as of December 31, 2017 and 2016, respectively. If the Company determines that collectability of straight-line rents is not reasonably assured, the Company limits future recognition to amounts contractually owed and, where appropriate, establishes an allowance for estimated losses. Allowances recognized against straight line rent were approximately $4.9 million

85

and $0.6 million as of December 31, 2017 and December 31, 2016, respectively. Rental revenue is adjusted by amortization of lease inducements and above- or below-market rents on certain leases. Lease inducements and above- or below-market rents are amortized on a straight line basis over the remaining life of the lease.

Expense Recoveries

Expense recoveries relate to tenant reimbursement of real estate taxes, insurance, and other operating expenses that are recognized as expense recovery revenue in the period the applicable expenses are incurred. The reimbursements are recorded at gross, as the Company is generally the primary obligor with respect to real estate taxes and purchasing goods and services from third-party suppliers, has discretion in selecting the supplier, and bears the credit risk of tenant reimbursement.

The Company has certain tenants with absolute net leases. Under these lease agreements, the tenant is responsible for operating and building expenses. For absolute net leases, the Company does not recognize expense recoveries.

Income Taxes

The Trust elected to be taxed as a REIT for federal tax purposes commencing with the filing of its tax return for the short taxable year ending December 31, 2013. The Trust had no taxable income prior to electing REIT status. To qualify as a REIT, the Trust must meet certain organizational and operational requirements, including a requirement to distribute at least 90% of its annual REIT taxable income to its shareholders (which is computed without regard to the dividends paid deduction or net capital gain and which does not necessarily equal net income as calculated in accordance with GAAP). As a REIT, the Trust generally will not be subject to federal income tax to the extent it distributes qualifying dividends to its shareholders. If the Trust fails to qualify as a REIT in any taxable year, it will be subject to federal income tax (including any applicable alternative minimum tax) on its taxable income at regular corporate income tax rates and generally will not be permitted to qualify for treatment as a REIT for federal income tax purposes for the four taxable years following the year during which qualification is lost unless the Internal Revenue Service grants the Trust relief under certain statutory provisions. Such an event could materially adversely affect the Trust’s net income and net cash available for distribution to shareholders. However, the Trust intends to continue to operate in such a manner as to continue qualifying for treatment as a REIT. Even if the Trust continues to qualify for taxation as a REIT, the Trust may be subject to state and local taxes on its income and property and federal income and excise taxes on its undistributed income.

As discussed in Note 1 (Organization and Business), the Trust conducts substantially all of its operations through the Operating Partnership. As a partnership, the Operating Partnership generally is not liable for federal income taxes. The income and loss from the operations of the Operating Partnership is included in the tax returns of its partners, including the Trust, who are responsible for reporting their allocable share of the partnership income and loss. Accordingly, no provision for income taxes has been made on the accompanying consolidated financial statements.

Management Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the amounts of revenue and expenses reported in the period. Significant estimates are made for the fair value assessments with respect to purchase price allocations, impairment assessments, and the valuation of financial instruments. Actual results could differ from these estimates.

Contingent Liabilities

The Company records liabilities for contingent consideration (included in accrued expenses and other liabilities on its consolidated balance sheets) at fair value as of the acquisition date and reassesses the fair value at the end of each reporting period, with any changes being recognized in earnings. Increases or decreases in the fair value of contingent consideration can result from changes in discount periods, discount rates, and probabilities that contingencies will be met.

Related Parties

In 2017, the Company recognized rental revenues totaling $0.6 million and $4.0 million from Aurora Health Care and Baylor Cancer Center, respectively. Both are healthcare facilities affiliated with certain members of the Trust’s Board of Trustees.

86

Reclassifications

Certain prior period amounts have been reclassified to conform to the current financial statement presentation, with no effect on the previously reported consolidated financial position or consolidated results of operations.

Segment Reporting

Under the provision of Codification Topic 280, Segment Reporting, the Company has determined that it has one reportable segment with activities related to leasing and managing healthcare properties.

New Accounting Pronouncements

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which creates a new Topic, Accounting Standards Codification Topic 606. The standard is principle-based and provides a five-step model to determine when and how revenue is recognized. The core principle is that a company should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This standard is effective for interim or annual periods beginning after December 15, 2017 and allows for either full retrospective or modified retrospective adoption. The Company will adopt ASU 2014-09 on January 1, 2018 via the modified retrospective approach. The modified retrospective approach applies the standard in the year of initial application and presents the cumulative effect of prior periods with an adjustment to beginning retained earnings, with no restatement of comparative periods. As leasing arrangements (which are excluded from ASU 2014-09) represent the primary source of revenue for the Company, the impact of adoption will be limited to the Company’s recognition and presentation of non-lease revenues, which are currently reflected as a component of other income. Adoption of ASU 2014-09 will not have a material impact on the amount and timing of the recognition of income subject to this standard and we do not intend to further break out income line items with no cumulative effect adjustment to be recognized upon adoption.

In February 2015, the FASB issued ASU 2015-02, Amendments to the Consolidation Analysis. ASU 2015-02 requires entities to evaluate whether they should consolidate certain legal entities. Principally, the new consolidation standard modified the evaluation of whether limited partnerships and similar legal entities are variable interest entities (“VIE”) or voting interest entities. The Company adopted ASU 2015-02 on January 1, 2016. Based on the Company’s review and subsequent analysis of the structure of the Company’s legal entities, the Company has concluded that the Operating Partnership is a VIE because the limited partners of the Operating Partnership do not have substantive kick-out or participating rights. The Trust is the general partner and controlling owner of approximately 97.1% of the Operating Partnership and will continue to consolidate the Operating Partnership under this new guidance. With respect to the Company’s investment in unconsolidated joint ventures, the new consolidation standard did not have an impact on previous consolidation conclusions.

In February 2016, the FASB issued ASU 2016-02, Leases. The update amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting. ASU 2016-02 will be effective for annual reporting periods beginning after December 15, 2018. Early adoption is permitted. As a result of adopting ASU 2016-02, the Company will recognize all of its operating leases for which it is the lessee, including ground leases, on its consolidated balance sheets. The Company is evaluating the impact of the adoption of ASU 2016-02 on January 1, 2019 to its consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting. This update simplifies several aspects of accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statements of cash flows. ASU 2016-09 is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2016. The Company adopted ASU 2016-09 on January 1, 2017, with no material effect on its consolidated financial statements with no adjustments made to prior periods.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses, which changes the impairment model for most financial instruments by requiring companies to recognize an allowance for expected losses, rather than incurred losses as required currently by the other-than-temporary impairment model. ASU 2016-13 will apply to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities, net investments in leases, and off-balance-sheet credit exposures (e.g., loan commitments). ASU 2016-13 is effective for reporting periods beginning after December 15, 2019, with early adoption permitted, and will be applied as a cumulative adjustment to retained earnings as of the effective date. We are currently assessing the potential effect the adoption of ASU 2016-13 will have on our consolidated financial statements.

87

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payment. ASU 2016-15 clarifies the guidance on the classification of certain cash receipts and payments in the statement of cash flows to reduce diversity in practice with respect to: (i) debt prepayment or debt extinguishment costs; (ii) settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; (iii) contingent consideration payments made after a business combination; (iv) proceeds from the settlement of insurance claims; (v) proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (vi) distributions received from equity method investees; (vii) beneficial interests in securitization transactions; and (viii) separately identifiable cash flows and application of the predominance principle. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. The Company adopted ASU 2016-15 on January 1, 2018, with no material effect on its consolidated financial statements and no adjustments made to prior periods.

In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows: Restricted Cash, which will require companies to include restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the statement of cash flows. ASU 2016-18 will require disclosure of a reconciliation between the balance sheet and the statement of cash flows when the balance sheet includes more than one line item for cash, cash equivalents, restricted cash, and restricted cash equivalents. An entity with material restricted cash and restricted cash equivalents balances will be required to disclose the nature of the restrictions. ASU 2016-18 is effective for reporting periods beginning after December 15, 2017, and is required to be applied retrospectively to all periods presented. The Company adopted ASU 2016-18 on January 1, 2018, with no material effect on its consolidated financial statements and no adjustments made to prior periods.

In January 2017, the FASB issued ASU 2017-01, Clarifying the Definition of a Business, that clarifies the framework for determining whether an integrated set of assets and activities meets the definition of a business. The revised framework establishes a screen for determining whether an integrated set of assets and activities is a business and narrows the definition of a business, which is expected to result in fewer transactions being accounted for as business combinations. Acquisitions of integrated sets of assets and activities that do not meet the definition of a business are accounted for as asset acquisitions. ASU 2017-01 will be effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017. Upon adoption of ASU 2017-01, the Company anticipates it will classify most prospective real estate acquisitions as asset acquisitions, rather than business combinations, and direct acquisition costs associated with these acquisitions will be capitalized. This is due to the fact that substantially all of the fair value of the gross assets the Company acquires are concentrated in a single asset or group of similar identifiable assets.

88

Note 3. Acquisitions and Dispositions

During 2017, the Company completed acquisitions of 40 operating healthcare properties, 2 condominium units, and 1 parking deck located in 15 states, for an aggregate purchase price of approximately $1.37 billion. In addition, the Company completed $39.1 million of loan investments, $1.1 million of redeemable noncontrolling interest buyouts, and $2.8 million of noncontrolling interest buyouts, resulting in total investment activity of approximately $1.41 billion.

Investment activity for the year ending December 31, 2017 is summarized below:

Property (1)			Location	Acquisition Date	Purchase Price (in thousands)
Orthopedic Associates	(2)		Flower Mound, TX	January 5, 2017	$	18,750
Medical Arts Center at Hartford	(2)		Plainville, CT	January 11, 2017	30,250
Noncontrolling Interest Buyout - New Albany	(3)		New Albany, OH	January 31, 2017	2,824
CareMount - Lake Katrine MOB	(2)	(4)	Lake Katrine, NY	February 14, 2017	41,791
CareMount - Rhinebeck MOB	(2)		Rhinebeck, NY	February 14, 2017	18,639
Syracuse Condos	(2)		Fayetteville & Liverpool, NY	February 27, 2017	2,659
Monterey Medical Center - MOB	(2)		Stuart, FL	March 7, 2017	18,979
Creighton University Medical Center	(5)		Omaha, NE	March 28, 2017	33,420
Strictly Pediatrics Specialty Center	(2)	(6)	Austin, TX	March 31, 2017	78,628
MedStar Stephen's Crossing	(2)		Brandywine, MD	June 16, 2017	20,900
2017 CHI Portfolio - Tranche 1 (8 MOBs)	(5)		AR, MN, ND, NE, TN, TX	June 29, 2017	124,181
St. Vincent Portfolio (2 MOBs)	(2)		Carmel & Fishers, IN	June 29, 2017	93,880
Baylor Charles A. Sammons Cancer Center	(2)		Dallas, TX	June 30, 2017	290,000
Orthopedic & Sports Institute of the Fox Valley	(7)		Appleton, WI	June 30, 2017	27,900
Peachtree Dunwoody Medical Center - Parking Deck	(7)		Atlanta, GA	June 30, 2017	25,000
Clearview Cancer Institute	(2)		Huntsville, AL	August 4, 2017	53,250
Northside Cherokee/Town Lake MOB	(2)		Atlanta, GA	August 15, 2017	37,127
HonorHealth Mesa MOB	(2)		Mesa, AZ	August 15, 2017	4,800
2017 CHI Portfolio - Tranche 2 (5 MOBs)	(5)		AR, MN, NE, TX	August 24, 2017 & August 31, 2017	33,694
Noncontrolling Interest Buyout - Great Falls Clinic	(8)		Great Falls, MT	September 21, 2017	1,061
Legends Park MOB & ASC	(2)		Midland, TX	September 27, 2017	30,000
Franklin MOB & ASC	(2)		Franklin, TN	October 12, 2017	9,950
Eagle Point MOB	(2)		Lake Elmo, MN	October 31, 2017	10,949
Edina East MOB	(2)		Edina, MN	October 31, 2017	7,800
Northside MOB - Center Pointe	(2)		Atlanta, GA	November 10, 2017	155,986
Gwinnett 500 Building	(2)		Lawrenceville, GA	November 17, 2017	25,297
Hudgens Professional Building	(2)		Duluth, GA	November 17, 2017	23,696
St. Vincent Building	(2)		Indianapolis, IN	November 17, 2017	60,124
Gwinnett Physicians Center	(2)	(9)	Lawrenceville, GA	December 1, 2017	51,721
Apple Valley Medical Center	(2)		Apple Valley, MN	December 18, 2017	21,500
Desert Cove MOB (57% Interest)	(2)	(10)	Scottsdale, AZ	December 18, 2017	4,560
Westgate MOB	(2)		Glendale, AZ	December 21, 2017	15,800

89

Property (1)		Location	Acquisition Date	Purchase Price (in thousands)
Loan Investments	(11)	Various	Various	39,063
				$	1,414,179

(1) “MOB” means medical office building. “ASC” means ambulatory surgery center.

(2) The Company accounted for these acquisitions as business combinations pursuant to the acquisition method and expensed total acquisition costs of $16.6 million.

(3) The Company acquired the previously outstanding interest in the New Albany MOB from the predecessor owner. As consideration, the Operating Partnership paid approximately $2.1 million in cash and issued 38,641 OP Units, representing approximately $2.8 million in aggregate.

(4) The Company partially funded this acquisition through the assumption of an existing mortgage valued at approximately $26.4 million.

(5) These acquisitions are part of the CHI Portfolio. The Company accounted for nine of these facilities, consisting of an aggregate purchase price of $143.0 million, as asset acquisitions and capitalized total acquisition costs of $0.4 million. The remaining six facilities, consisting of an aggregate purchase price of $48.3 million, were accounted for as business combinations pursuant to the acquisition method, with acquisition expense totaling $0.1 million.

(6) The Company partially funded the purchase price of this acquisition by issuing a total of 2,247,817 OP Units valued at approximately $44.3 million in the aggregate on the date of issuance.

(7) The Company accounted for these acquisitions as asset acquisitions and capitalized total acquisition costs of $0.5 million.

(8) The Company acquired an additional 3.2% interest in the Great Falls Clinic joint venture from the predecessor owner, increasing the Company’s total interest to 85.0%.

(9) As part of this acquisition, the Company assumed a $17.6 million mortgage on the facility.

(10) The Company acquired an additional 57.0% ownership interest in Desert Cove MOB, LLC increasing the Company’s total interest to 100%.

(11) The loan investments listed here include 8 separate transactions at a weighted average interest rate of 8.1%.

For 2017, the Company recorded revenues and net income of $49.6 million and $8.6 million, respectively, from its 2017 acquisitions.

During 2016, the Company completed acquisitions of 95 properties (including 5 condominium units and the CHI Portfolio) and 1 land parcel, located in 23 states, for an aggregate purchase price of approximately $1.27 billion. In addition, the Company completed $0.9 million of joint venture investments, $10.2 million of loan investments, $2.5 million of redeemable noncontrolling interest buyouts, and $0.6 million of equity buyouts, resulting in total investment activity of approximately $1.29 billion.

This aggregate purchase price does not include near-term capital expenditure commitments of $12.9 million and committed tenant improvement allowances of $8.9 million related to the Company’s acquisition of the CHI Portfolio.

Investment activity for the year ending December 31, 2016 is summarized below:

Property (1)			Location	Acquisition Date	Purchase Price  (in thousands)
Tinseltown - Loan Draws			Jacksonville, FL		$	2,192
Randall Road MOB - Suite 380	(3)		Elgin, IL	January 14, 2016	704
Great Falls Hospital	(2)		Great Falls, MT	January 25, 2016	29,043
Monterey Medical Center ASC	(2)		Stuart, FL	February 1, 2016	6,900
Physicians Medical Plaza MOB	(2)	(4)	Indianapolis, IN	February 1, 2016	8,500
Mezzanine Loan - Davis			Minnetonka, MN	February 4, 2016	500
Park Nicollet Clinic	(2)		Chanhassen, MN	February 8, 2016	18,600
HEB Cancer Center	(2)		Bedford, TX	February 12, 2016	13,980
Riverview Medical Center	(2)		Lancaster, OH	February 26, 2016	12,800
St. Luke's Cornwall MOB	(2)		Cornwall, NY	February 26, 2016	14,550
HonorHealth Glendale	(3)		Glendale, AZ	March 15, 2016	9,820
Columbia MOB	(2)		Hudson, NY	March 21, 2016	18,450

90

Property (1)			Location	Acquisition Date	Purchase Price  (in thousands)
St Vincent POB 1	(2)		Birmingham, AL	March 23, 2016	10,951
St Vincent POB 2	(2)		Birmingham, AL	March 23, 2016	7,945
St Vincent POB 3	(2)		Birmingham, AL	March 23, 2016	10,455
Emerson Medical Building	(2)		Creve Coeur, MO	March 24, 2016	14,250
Randall Road MOB - Suite 160	(3)		Elgin, IL	March 24, 2016	865
Patient Partners Surgery Center	(2)		Gallatin, TN	March 30, 2016	4,750
Eye Associates of NM - Santa Fe	(3)		Santa Fe, NM	March 31, 2016	8,739
Eye Associates of NM - Albuquerque	(3)		Albuquerque, NM	March 31, 2016	10,536
Gardendale Surgery Center	(2)		Gardendale, AL	April 11, 2016	7,450
HealthEast - Curve Crest	(2)		Stillwater, MN	April 14, 2016	4,144
HealthEast - Victor Gardens	(2)		Hugo, MN	April 14, 2016	6,025
NOMS - Clyde	(3)		Clyde, OH	May 10, 2016	6,342
Blandford MOB	(3)	(5)	Little Rock, AR	May 11, 2016	2,580
Cardwell MOB	(2)	(5)	Lufkin, TX	May 11, 2016	8,444
Dacono Neighborhood Health	(3)	(5)	Dacono, CO	May 11, 2016	5,152
Franciscan Health	(3)	(5)	Tacoma, WA	May 11, 2016	9,772
Grand Island Specialty Clinic	(3)	(5)	Grand Island, NE	May 11, 2016	2,891
Hot Springs MOB	(2)	(5)	Hot Springs Village, AR	May 11, 2016	3,626
Jewish Medical Center East	(3)	(5)	Louisville, KY	May 11, 2016	85,000
Jewish Medical Center South MOB - 1	(3)	(5)	Shepherdsville, KY	May 11, 2016	17,021
Jewish Medical Plaza I	(2)	(5)	Louisville, KY	May 11, 2016	9,650
Jewish Medical Plaza II	(2)	(5)	Louisville, KY	May 11, 2016	6,124
Jewish OCC	(3)	(5)	Louisville, KY	May 11, 2016	35,600
Lakeside Three Professional Center	(2)	(5)	Omaha, NE	May 11, 2016	1,581
Lexington Surgery Center	(2)	(5)	Lexington, KY	May 11, 2016	20,169
Medical Arts Pavilion	(2)	(5)	Lufkin, TX	May 11, 2016	6,304
Memorial Outpatient Center	(3)	(5)	Lufkin, TX	May 11, 2016	4,958
Midlands Two Professional Center	(2)	(5)	Papillion, NE	May 11, 2016	1,341
Parkview MOB	(2)	(5)	Little Rock, AR	May 11, 2016	5,060
Peak One ASC	(2)	(5)	Frisco, CO	May 11, 2016	6,587
Physicians Medical Center	(2)	(5)	Tacoma, WA	May 11, 2016	6,782
St. Alexius - Minot Medical Plaza	(3)	(5)	Minot, ND	May 11, 2016	26,570
St. Clare Medical Pavilion	(2)	(5)	Lakewood, WA	May 11, 2016	10,617
St. Joseph Medical Pavilion	(2)	(5)	Tacoma, WA	May 11, 2016	13,320
St. Joseph Office Park	(2)	(5)	Lexington, KY	May 11, 2016	17,228
St. Mary - Caritas Medical II	(2)	(5)	Louisville, KY	May 11, 2016	5,603
St. Mary - Caritas Medical III	(2)	(5)	Louisville, KY	May 11, 2016	842
Thornton Neighborhood Health	(3)	(5)	Thornton, CO	May 11, 2016	3,875
Medical Village at Kissimmee	(2)		Kissimmee, FL	May 26, 2016	4,923
Medical Village at Leesburg	(2)		Leesburg, FL	May 26, 2016	4,576
St. Francis MOB	(2)	(5)	Federal Way, WA	June 2, 2016	14,287
Children's Hospital MOB	(2)		Milwaukee, WI	June 3, 2016	5,850
Jewish Medical Center South MOB - 2	(2)		Shepherdsville, KY	June 8, 2016	4,343
Good Samaritan North Annex Building	(3)	(5)	Kearney, NE	June 28, 2016	2,874
NE Heart Institute Medical Building	(3)	(5)	Lincoln, NE	June 28, 2016	19,600

91

Property (1)			Location	Acquisition Date	Purchase Price  (in thousands)
St. Vincent West MOB	(3)	(5)	Little Rock, AR	June 29, 2016	14,120
Meridan MOB	(3)	(5)	Englewood, CO	June 29, 2016	17,329
St. Mary - Caritas Medical I	(2)	(5)	Louisville, KY	June 29, 2016	8,864
St. Alexius - Medical Arts Pavilion	(3)	(5)	Bismarck, ND	June 29, 2016	12,983
St. Alexius - Mandan Clinic	(3)	(5)	Mandan, ND	June 29, 2016	8,390
St. Alexius - Orthopaedic Center	(2)	(5)	Bismarck, ND	June 29, 2016	14,727
St. Alexius - Rehab Center	(3)	(5)	Bismarck, ND	June 29, 2016	6,215
St. Alexius - Tech & Ed	(3)	(5)	Bismarck, ND	June 29, 2016	16,680
Good Samaritan MOB	(2)	(5)	Kearney, NE	June 29, 2016	24,198
Lakeside Two Professional Building	(2)	(5)	Omaha, NE	June 29, 2016	13,691
Lakeside Wellness Center	(3)	(5)	Omaha, NE	June 29, 2016	10,138
McAuley Center	(3)	(5)	Omaha, NE	June 29, 2016	18,382
Memorial Health Center	(3)	(5)	Grand Island, NE	June 29, 2016	34,042
Missionary Ridge MOB	(2)	(5)	Chattanooga, TN	June 29, 2016	7,635
Pilot Medical Center	(3)		Birmingham, AL	June 29, 2016	17,351
St. Joseph Medical Clinic	(2)	(5)	Tacoma, WA	June 30, 2016	16,444
Woodlands Medical Arts Center	(2)	(5)	The Woodlands, TX	June 30, 2016	21,227
FESC MOB	(3)	(5)	Tacoma, WA	June 30, 2016	16,748
Mezzanine Loan - Catalyst			Pensacola, FL	June 30, 2016	1,340
Prairie Care MOB	(2)		Maplewood, MN	July 6, 2016	4,886
RE Loan - Chihuahua Development LLC			El Paso, TX	July 7, 2016	1,300
Springwoods MOB	(2)	(5)	Spring, TX	July 21, 2016	19,925
Equity Buyout - Foundation	(6)		TX / OK	July 26, 2016	611
Mezzanine Loan - Hazelwood			Minnetonka, MN	July 29, 2016	3,375
Jackson, Tennessee Land	(3)		Jackson, TN	August 2, 2016	1,000
Unity Portfolio (4 MOBs)	(2)		West Lafayette, IN	August 8, 2016	28,751
Medical Village at Maitland	(2)		Orlando, FL	August 23, 2016	23,211
Tri-State Orthopaedics MOB	(2)		Evansville, IN	August 30, 2016	22,000
Maury Regional Healthcare MOB	(2)	(8)	Spring Hill, TN	September 30, 2016	18,500
Spring Ridge Medical Center	(2)		Wyomissing, PA	September 30, 2016	6,100
Doctors Community Hospital POB	(2)		Lanham, MD	September 30, 2016	26,750
Gig Harbor Medical Pavilion	(3)	(5)	Gig Harbor, WA	September 30, 2016	4,766
Midlands One Professional Center	(2)	(5)	Papillion, NE	September 30, 2016	14,856
Noncontrolling Interest Buyout - Great Falls Clinic	(7)		Great Falls, MT	September 30, 2016	1,015
N.W. Michigan Surgery Center - Units #1 & #2	(3)	(9)	Traverse City, MI	October 28, 2016	29,448
United Surgical Partners Joint Venture	(10)		Scottsdale, AZ	October 31, 2016	903
N.W. Michigan Surgery Center - Unit #4	(3)	(11)	Traverse City, MI	November 4, 2016	2,715
Syracuse Portfolio (2 MOBs)	(2)		Syracuse, NY	November 23, 2016	54,239
Cincinnati Eye Institute	(3)		Cincinnati, OH	November 23, 2016	38,100
Curie Building Loan			El Paso, TX	December 2, 2016	1,500
HonorHealth - Scottsdale MOB	(3)		Scottsdale, AZ	December 2, 2016	6,900
Fox Valley Hematology & Oncology	(3)		Appleton, WI	December 8, 2016	28,200
Gastrointestinal Associates MOB	(2)		Powell, TN	December 9, 2016	6,287
Northern Vision Eye Center	(3)		Traverse City, MI	December 15, 2016	2,777

92

Property (1)		Location	Acquisition Date	Purchase Price  (in thousands)
Noncontrolling Interest Buyout - Great Falls Clinic	(12)	Great Falls, MT	December 15, 2016	1,497
Flower Mound Portfolio (3 MOBs)	(3)	Flower Mound, TX	December 16, 2016	27,800
HonorHealth IRF	(3)	Scottsdale, AZ	December 22, 2016	25,628
				$	1,285,185

(1) “MOB” means medical office building. “ASC” means ambulatory surgical center. “POB” means professional office building. “IRF” means inpatient rehabilitation facility.

(2) The Company accounted for these acquisitions as business combinations pursuant to the acquisition method and expensed total acquisition costs of $14.8 million.

(3) The Company accounted for these acquisitions as asset acquisitions and capitalized total acquisition costs of $3.0 million.

(4) The Company partially funded the purchase price of this acquisition by issuing a total of 174,085 OP Units valued at approximately $2.9 million in the aggregate on the date of issuance.

(5) These acquisitions are part of the CHI portfolio.

(6) The Company acquired the previously outstanding 1% noncontrolling interest retained by the predecessor owner on three properties, El Paso, Texas and Oklahoma City, Oklahoma.

(7) The Company acquired an additional 3% interest in the Great Falls Clinic joint venture from the predecessor owner, increasing the Company’s total interest to 77.3%.

(8) The Company acquired 99.7% of the ownership interest in this property, the remainder of which was retained by the seller.

(9) The Company partially funded the purchase price of the acquisition of two condominium units within the Northwest Michigan Surgery Center through unregistered issuance of 947,936 common shares of beneficial interest.

(10) The Company’s investment in the United Surgical Partners J.V. represents a 43% ownership interest.

(11) The Company partially funded the purchase price of the acquisition of one additional condominium unit within the Northwest Michigan Surgery Center through the unregistered issuance of 88,602 common shares of beneficial interest.

(12) The company acquired an additional 4.6% interest in the Great Falls Clinic joint venture from the predecessor owner, increasing the Company’s total interest to 81.8%.

For 2016, the Company recorded revenues and net income of $66.7 million and $14.9 million, respectively, from its 2016 acquisitions.

93

The following table summarizes the preliminary purchase price allocations of the assets acquired and the liabilities assumed, which the Company determined using Level 2 and Level 3 inputs (in thousands):

	December 31, 2017			December 31, 2016
Land	$	38,358		$	57,847
Building and improvements	1,168,741			1,112,746
In-place lease intangible	128,370			58,666
Above-market in-place lease intangible	18,967			9,359
Below-market in-place lease intangible	(4,270		)	(4,518		)
Above-market in-place ground lease	(4,620		)	(644		)
Below-market in-place ground lease	17,683			28,937
Contingent consideration	(765		)	(156		)
Receivable	434			104
Debt assumed	(43,989		)	—
Issuance of OP Units	(44,978		)	(2,869		)
Investment in unconsolidated entity	(2,871		)	903
Lease inducement	—			8,945
Prepaid expenses	—			2,659
Issuance of Common Shares	—			(20,980		)
Noncontrolling interest	—			(50		)
Net assets acquired	$	1,271,060		$	1,250,949

These preliminary allocations are subject to revision within the measurement period, not to exceed one year from the date of the acquisitions.

Dispositions

On April 7, 2017, the Company closed an agreement to sell a portfolio of four medical office buildings located in Georgia (the “Georgia Portfolio”), for approximately $18.2 million, which reflects a gain of approximately $5.2 million.

On August 15, 2017, the Company completed the disposition of land with a carrying value of $7.7 million in a sale-leaseback at the Peachtree Dunwoody Medical Center. The Company entered into a 90 year term ground lease at closing with all rent prepaid in consideration of the full present value of rent owed. There was no gain or loss recorded as a result of this transaction.

On December 18, 2017, the Company sold one 20,939 square foot medical office building located in Nebraska for approximately $2.5 million, recording a gain of approximately $0.7 million.

The following table summarizes revenues and net income related to the disposition properties for the periods presented (in thousands):

	Year Ended December 31,
	2017		2016		2015
Revenue	$	823	$	1,967	$	1,666
Income before gain on sale of investment properties	108		433		421
Gain on sale of investment properties	5,870		—		—
Net income	$	5,978	$	433	$	421

94

Unaudited Pro Forma Financial Information

Physicians Realty Trust

The following table illustrates the pro forma consolidated revenue, net income, and earnings per share as if the Company had acquired the 2017 acquisitions detailed above as of January 1, 2016 (in thousands, except share and per share amounts):

	Year Ended December 31,
	2017		2016
Revenue	$	405,320	$	352,432
Net income	42,149		39,233
Net income available to common shareholders	39,759		35,614
Earnings per share - basic	$	0.24	$	0.22
Earnings per share - diluted	$	0.24	$	0.22
Weighted average number of shares outstanding - basic	163,123,109		163,123,109
Weighted average number of shares outstanding - diluted	168,231,299		168,231,299

Physicians Realty L.P.

The following table illustrates the pro forma consolidated revenue, net income, and earnings per share as if the Company had acquired the 2017 acquisitions detailed above as of January 1, 2016 (in thousands, except unit and per unit amounts):

	Year Ended December 31,
	2017		2016
Revenue	$	405,320	$	352,432
Net income	42,149		39,233
Net income available to common unitholders	40,927		36,660
Earnings per unit - basic	$	0.24	$	0.22
Earnings per unit - diluted	$	0.24	$	0.22
Weighted average number of units outstanding - basic	167,963,076		167,963,076
Weighted average number of units outstanding - diluted	168,231,299		168,231,299

Note 4. Intangibles

The following is a summary of the carrying amount of intangible assets and liabilities as of December 31, 2017 and 2016 (in thousands):

	December 31, 2017							December 31, 2016
	Cost		Accumulated Amortization			Net		Cost		Accumulated Amortization			Net
Assets
In-place leases	$	343,429	$	(85,424	)	$	258,005	$	222,394	$	(55,605	)	$	166,789
Above-market leases	54,148		(11,968		)	42,180		35,478		(6,909		)	28,569
Leasehold interest	712		(183		)	529		712		(124		)	588
Below-market ground lease	60,424		(1,344		)	59,080		42,878		(539		)	42,339
Total	$	458,713	$	(98,919	)	$	359,794	$	301,462	$	(63,177	)	$	238,285
Liabilities
Below-market lease	$	14,344	$	(4,479	)	$	9,865	$	10,297	$	(2,345	)	$	7,952
Above-market ground lease	5,965		(128		)	5,837		1,345		(44		)	1,301
Total	$	20,309	$	(4,607	)	$	15,702	$	11,642	$	(2,389	)	$	9,253

95

The following is a summary of the acquired lease intangible amortization for the years ended December 31, 2017, 2016, and 2015 (in thousands):

	December 31,
	2017		2016		2015
Amortization expense related to in-place leases	$	37,073	$	28,902	$	15,300
Decrease of rental income related to above-market leases	5,357		4,403		2,596
Decrease of rental income related to leasehold interests	59		59		59
Increase of rental income related to below-market leases	2,309		1,835		643
Decrease of operating expense related to above-market ground leases	84		24		16
Increase in operating expense related to below-market ground leases	810		471		68

For the twelve months ended December 31, 2017, the Company wrote-off in-place lease intangible assets of approximately $3.5 million with accumulated amortization of approximately $2.1 million, resulting in the recognition of $1.4 million in additional amortization expense. The Company also wrote-off above-market lease intangible assets of approximately $0.3 million with accumulated amortization of approximately $0.1 million, resulting in the recognition of $0.2 million in additional amortization expense. In addition, the Company, wrote-off below-market lease intangible of approximately $0.1 million with accumulated amortization of approximately $36.0 thousand, resulting in the recognition of $0.1 million reduction in amortization expense, for a net recognition of approximately $1.5 million reduction in rental income from intangible amortization.

Future aggregate net amortization of the acquired lease intangibles as of December 31, 2017, is as follows (in thousands): 

	Net Decrease in Revenue			Net Increase in Expenses
2018	$	(3,355	)	$	41,455
2019	(3,376		)	36,429
2020	(3,392		)	33,009
2021	(3,333		)	30,582
2022	(2,872		)	26,225
Thereafter	(16,516		)	143,548
Total	$	(32,844	)	$	311,248

For the year ended December 31, 2017, the weighted average amortization period for asset lease intangibles and liability lease intangibles are 18 years and 20 years, respectively.

Note 5. Other Assets

Other assets consisted of the following as of December 31, 2017 and 2016 (in thousands):

	December 31,
	2017		2016
Straight line rent receivable	47,599		32,018
Prepaid expenses	18,103		8,928
Interest rate swap	14,693		13,881
Lease inducements, net	14,232		13,255
Leasing commissions, net	4,128		1,858
Earnest deposits	2,780		1,500
Escrows	1,996		4,334
Notes receivable	—		16,618
Other	2,771		2,795
Total	$	106,302	$	95,187

96

Note 6. Debt

The following is a summary of debt as of December 31, 2017 and 2016 (in thousands):

	December 31,
	2017				2016
Fixed interest mortgage notes	$	158,171		(1)	$	90,185		(2)
Variable interest mortgage notes	28,509			(3)	33,009			(4)
Total mortgage debt	186,680				123,194
$850 million unsecured revolving credit facility bearing variable interest of LIBOR plus 1.20%, due September 2020	80,000				401,000
$400 million senior unsecured notes bearing fixed interest of 4.30%, due March 2027	400,000				—
$350 million senior unsecured notes bearing fixed interest of 3.95%, due January 2028	350,000				—
$250 million unsecured term borrowing bearing fixed interest of 2.87%, due June 2023	250,000			(5)	250,000
$150 million senior unsecured notes bearing fixed interest of 4.03% to 4.74%, due January 2023 to 2031	150,000				150,000
$75 million senior unsecured notes bearing fixed interest of 4.09% to 4.24%, due August 2025 to 2027	75,000				75,000
Total principal	1,491,680				999,194
Unamortized deferred financing cost	(7,808		)		(8,477		)
Unamortized discount	(6,663		)		—
Unamortized fair value adjustment	259				438
Total debt	$	1,477,468			$	991,155

(1) Fixed interest mortgage notes, bearing interest from 3.00% to 5.50%, with a weighted average interest rate of 4.45%, and due in 2018, 2019, 2020, 2021, 2022, and 2024 collateralized by nine properties with a net book value of $267.7 million.

(2) Fixed interest mortgage notes, bearing interest from 4.71% to 6.58%, with a weighted average interest rate of 5.44%, and due in 2017, 2018, 2019, 2020, 2021, 2022, and 2032 collateralized by 11 properties with a net book value of $156.7 million.

(3) Variable interest mortgage notes, bearing variable interest of LIBOR plus 2.25% to 3.25%, with a weighted average interest rate of 4.50% and due in 2018, collateralized by three properties with a net book value of $39.2 million.

(4) Variable interest mortgage notes bearing variable interest of LIBOR plus 2.25% to 3.25%, with a weighted average interest rate of 3.68% and due in 2017 and 2018, collateralized by four properties with a net book value of $45.6 million.

(5) The Trust’s borrowings under the term loan feature of the Credit Agreement bear interest at a rate which is determined by the Trust’s credit rating, currently equal to LIBOR + 1.80%. The Trust has entered into a pay-fixed receive-variable interest rate swap, fixing the LIBOR component of this rate at 1.07%.

On June 10, 2016, the Operating Partnership, as borrower, and the Trust entered into an amended and restated Credit Agreement with KeyBank National Association, as administrative agent, KeyBanc Capital Markets Inc., BMO Capital Markets, and Citizens Bank N.A., as joint lead arrangers and co-book runners, BMO Capital Markets and Citizens Bank N.A., as co-syndication agents, and the lenders party thereto (the “Credit Agreement”) which increased the maximum principal amount available under an unsecured revolving credit facility from $750 million to $850 million. The Credit Agreement contains a 7-year term loan feature allowing the Operating Partnership to borrow in a single drawing up to $250 million, increasing the borrowing capacity to an aggregate $1.1 billion. The Credit Agreement also includes a swingline loan commitment for up to 10% of the maximum principal amount and provides an accordion feature allowing the Trust to increase borrowing capacity by up to an additional $500 million, subject to customary terms and conditions, resulting in a maximum borrowing capacity of $1.6 billion.

97

On July 7, 2016, the Operating Partnership borrowed $250.0 million under the 7-year term loan feature of the Credit Agreement. Borrowings under the term loan feature of the Credit Agreement bear interest on the outstanding principal amount at a rate which is determined by the Trust’s credit rating, currently equal to LIBOR + 1.80%. The Trust simultaneously entered into a pay-fixed receive-variable rate swap for the full borrowing amount, fixing the LIBOR component of the borrowing rate to 1.07%, for an all-in fixed rate of 2.87%. Both the borrowing and pay-fixed receive-variable swap have a maturity date of June 10, 2023.

The Credit Agreement has a maturity date of September 18, 2020 and includes a one year extension option. Borrowings under the Credit Agreement bear interest on the outstanding principal amount at an adjusted LIBOR rate, which is based on the Trust’s investment grade rating under the Credit Agreement. As of December 31, 2017, the Trust had an investment grade rating from Moody’s of Baa3 and from S&P of BBB-. As such, borrowings under the revolving credit facility of the Credit Agreement accrued interest on the outstanding principal at a rate of LIBOR plus 1.20%. The Credit Agreement includes a facility fee equal to 0.25% per annum, which is also determined by the Trust’s investment grade rating.

The Credit Agreement contains financial covenants that, among other things, require compliance with leverage and coverage ratios and maintenance of minimum tangible net worth, as well as covenants that may limit the Trust’s and the Operating Partnership’s ability to incur additional debt or make distributions. The Company may, at any time, voluntarily prepay any revolving or swingline loan under the Credit Agreement in whole or in part without premium or penalty. Prepayments of term borrowings require payment of premiums of up to 2.0% of the amount of prepayment, dependent on the date of such prepayment. As of December 31, 2017, the Company was in compliance with all financial covenants related to the Credit Agreement.

The Credit Agreement includes customary representations and warranties by the Trust and the Operating Partnership, and imposes customary covenants on the Operating Partnership and the Trust. The Credit Agreement also contains customary events of default, and if an event of default occurs and continues, the Operating Partnership is subject to certain actions by the administrative agent, including without limitation, the acceleration of repayment of all amounts outstanding under the Credit Agreement.

The Credit Agreement provides for revolving credit and term loans to the Trust and the Operating Partnership. Base Rate Loans, Adjusted LIBOR Rate Loans, and Letters of Credit (each, as defined in the Credit Agreement) will be subject to interest rates, based upon the Trust’s investment grade rating as follows:

Credit Rating	Margin for Revolving Loans: Adjusted LIBOR Rate Loans and Letter of Credit Fee	Margin for Revolving Loans: Base Rate Loans		Margin for Term Loans: Adjusted LIBOR Rate Loans and Letter of Credit Fee	Margin for Term Loans: Base Rate Loans
At Least A- or A3	LIBOR + 0.85%	—	%	LIBOR + 1.40%	0.40	%
At Least BBB+ or Baa1	LIBOR + 0.90%	—	%	LIBOR + 1.45%	0.45	%
At Least BBB or Baa2	LIBOR + 1.00%	0.10	%	LIBOR + 1.55%	0.55	%
At Least BBB- or Baa3	LIBOR + 1.20%	0.20	%	LIBOR + 1.80%	0.80	%
Below BBB- or Baa3	LIBOR + 1.55%	0.60	%	LIBOR + 2.25%	1.25	%

As of December 31, 2017, the Company had $80.0 million of borrowings outstanding under its unsecured revolving credit facility, and $250.0 million of borrowings outstanding under the term loan feature of the Credit Agreement. The Company also issued a letter of credit for $17.0 million with no outstanding balance as of December 31, 2017. As defined by the Credit Agreement, $753.0 million is available to borrow without adding additional properties to the unencumbered borrowing base of assets.

Notes Payable

On January 7, 2016, the Operating Partnership issued and sold $150.0 million aggregate principal amount of senior notes, comprised of (i) $15.0 million aggregate principal amount of 4.03% Senior Notes, Series A, due January 7, 2023, (ii) $45.0 million aggregate principal amount of 4.43% Senior Notes, Series B, due January 7, 2026, (iii) $45.0 million aggregate principal amount of 4.57% Senior Notes, Series C, due January 7, 2028, and (iv) $45.0 million aggregate principal amount of 4.74% Senior Notes, Series D, due January 7, 2031. On August 11, 2016, the note agreement for these notes was amended to make certain changes to its terms, including certain changes to affirmative covenants, negative covenants, and definitions contained therein. Interest on each respective series of the January 2016 Senior Notes is payable semi-annually.

On August 11, 2016, the Operating Partnership issued and sold $75.0 million aggregate principal amount of senior notes, comprised of (i) $25.0 million aggregate principal amount of 4.09% Senior Notes, Series A, due August 11, 2025, (ii)

98

$25.0 million aggregate principal amount of 4.18% Senior Notes, Series B, due August 11, 2026, and (iii) $25.0 million aggregate principal amount of 4.24% Senior Notes, Series C, due August 11, 2027. Interest on each respective series of the August 2016 Senior Notes is payable semi-annually.

On January 26, 2017, the Company entered into a $300.0 million notional amount forward starting swap to reduce the exposure to fluctuations in interest rates related to the forecasted issuance of the 4.30% senior notes due in 2027. Upon the issuance of the senior notes on March 7, 2017, the forward starting swap was terminated and the Company recorded a $0.8 million loss which will be recognized over the life of the notes utilizing the effective interest method.

On March 7, 2017, the Operating Partnership issued and sold $400.0 million aggregate principal amount of 4.30% Senior Notes which will mature on March 15, 2027. The Senior Notes began accruing interest on March 7, 2017 and began paying interest semi-annually beginning September 15, 2017. The Senior Notes were sold at an issue price of 99.68% of their face value, before the underwriters’ discount. Our net proceeds from the offering, after deducting underwriting discounts and expenses, were approximately $396.1 million.

On December 1, 2017, the Operating Partnership issued and sold $350.0 million aggregate principal amount of 3.95% Senior Notes which will mature on January 15, 2028. The Senior Notes began accruing interest on December 1, 2017 and will begin paying interest semi-annually beginning July 15, 2018. The Senior Notes were sold at an issue price of 99.78% of their face value, before the underwriters’ discount. Our net proceeds from the offering, after deducting underwriting discounts and expenses, were approximately $347.0 million.

Certain properties have mortgage debt that contains financial covenants. As of December 31, 2017, the Trust was in compliance with all mortgage debt financial covenants.

Scheduled principal payments due on debt as of December 31, 2017, are as follows (in thousands):

2018	$	54,775
2019	44,631
2020	110,122
2021	8,718
2022	24,708
Thereafter	1,248,726
Total Payments	$	1,491,680

As of December 31, 2017 and 2016, the Company had total consolidated indebtedness of approximately $1.5 billion and $1.0 billion, respectively. The weighted average interest rate on consolidated indebtedness was 3.93% as of December 31, 2017 (based on the 30-day LIBOR rate as of December 31, 2017 of 1.49%). The weighted average interest rate on consolidated indebtedness was 3.09% as of December 31, 2016 (based on the 30-day LIBOR rate as of December 31, 2016 of 0.72%).

For the years ended December 31, 2017 and 2016, the Company paid interest expense on its debt of $45.1 million and $21.5 million, respectively.

Note 7. Derivatives

In the normal course of business, a variety of financial instruments are used to manage or hedge interest rate risk. The Company has implemented ASC 815, Derivatives and Hedging (ASC 815), which establishes accounting and reporting standards requiring that all derivatives, including certain derivative instruments embedded in other contracts, be recorded as either an asset or a liability measured at their fair value unless they qualify for a normal purchase or normal sales exception.

When specific hedge accounting criteria are not met, ASC 815 requires that changes in a derivative’s fair value be recognized currently in earnings. Changes in the fair market values of the Company’s derivative instruments are recorded in the consolidated statements of income if such derivatives do not qualify for, or the Company does not elect to apply for, hedge accounting. If hedge accounting is applied to a derivative instrument, such changes are reported in accumulated other comprehensive income within the equity section of the consolidated balance sheets, exclusive of ineffectiveness amounts, which are recorded as adjustments to net income.

99

To manage interest rate risk for certain of its variable-rate debt, the Company uses interest rate swaps as part of its risk management strategy. These derivatives are designed to mitigate the risk of future interest rate increases by providing a fixed interest rate for a limited, pre-determined period of time. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. As of December 31, 2017, the Company had five outstanding interest rate swap contracts that are designated as cash flow hedges of interest rate risk. For presentational purposes, they are shown as one derivative due to the identical nature of their economic terms.

The effective portion of the change in the fair value of derivatives designated and that qualify as cash flow hedges is recorded in accumulated other comprehensive income on the consolidated balance sheets and is subsequently reclassified into earnings as interest expense for the period that the hedged forecasted transaction affects earnings. The ineffective portion of the change in fair value of the derivatives is recognized directly in earnings. For the twelve months ended December 31, 2017, the Company recorded a $0.2 million loss as a result of hedge ineffectiveness. The Company expects hedge ineffectiveness to be insignificant in the next 12 months.

The following table summarizes the location and aggregate fair value of the interest rate swaps on the Company’s consolidated balance sheets (in thousands):

Total notional amount		$	250,000
Effective fixed interest rate	(1)	2.87		%
Effective date		7/7/2016
Maturity date		6/10/2023
Asset balance at December 31, 2017 (included in Other assets)		$	14,693

(1) 1.07% effective swap rate plus 1.80% spread per Credit Agreement.

Note 8. Accrued Expenses and Other Liabilities

Accrued expenses and other liabilities consisted of the following as of December 31, 2017 and 2016 (in thousands):

	December 31,
	2017		2016
Real estate taxes payable	$	16,103	$	9,300
Accrued interest	11,107		4,905
Prepaid rent	10,496		5,834
Accrued expenses	8,751		3,453
Tenant improvement allowance	3,065		5,315
Security deposits	2,882		4,506
Accrued incentive compensation	1,625		1,405
Contingent consideration	1,454		1,392
Embedded derivative	—		5,571
Other	922		606
Total	$	56,405	$	42,287

Note 9. Stock-based Compensation

The Company follows ASC 718, Compensation – Stock Compensation (“ASC 718”), in accounting for its share-based payments. This guidance requires measurement of the cost of employee services received in exchange for stock compensation based on the grant-date fair value of the employee stock awards. This cost is recognized as compensation expense ratably over the employee’s requisite service period. Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized when incurred. Share-based payments classified as liability awards are marked to fair value at each reporting period. Any Common Shares issued pursuant to the Company’s incentive equity compensation and employee stock purchase plans will result in the Operating Partnership issuing OP Units to the Trust on a one-for-one basis, with the Operating Partnership receiving the net cash proceeds of such issuances.

100

Certain of the Company’s employee stock awards vest only upon the achievement of performance targets. ASC 718 requires recognition of compensation cost only when achievement of performance conditions is considered probable. Consequently, the Company’s determination of the amount of stock compensation expense requires a significant level of judgment in estimating the probability of achievement of these performance targets. Additionally, the Company must make estimates regarding employee forfeitures in determining compensation expense. Subsequent changes in actual experience are monitored and estimates are updated as information is available.

In connection with the IPO, the Trust adopted the 2013 Equity Incentive Plan (“2013 Plan”), which made available 600,000 common shares to be administered by the Compensation and Nominating Governance Committee of the Board of Trustees. On August 7, 2014, at the Annual Meeting of Shareholders of Physicians Realty Trust, the Trust’s shareholders approved an amendment to the 2013 Plan to increase the number of common shares authorized for issuance under the 2013 Plan by 1,850,000 common shares, for a total of 2,450,000 common shares authorized for issuance.

Restricted Common Shares:

Restricted common shares granted under the 2013 Plan are eligible for dividends as well as the right to vote. During 2015, a total of 162,522 restricted common shares with a total value of $2.6 million were granted to Trust employees and the Board of Trustees with vesting periods ranging from one to three years. During 2016, a total of 155,306 restricted common shares with a total value of $2.8 million were granted to Company employees with vesting periods ranging from one to three years. During 2017, the Trust granted a total of 143,593 restricted common shares with a total value of $2.8 million to the Company’s officers and certain of its employees, which have a one-year vesting period for senior management award-recipients and a three-year vesting period for employee award-recipients.

The following is summary of the status of the Trust’s non-vested restricted common shares during 2017, 2016, and 2015:

	Common Shares		Weighted Average Grant Date Fair Value
Non-vested at December 31, 2014	319,654		$	12.60
Granted	162,522		15.95
Vested	(170,337	)	12.93
Non-vested at December 31, 2015	311,839		14.17
Granted	155,306		17.96
Vested	(170,034	)	14.16
Forfeited	(326	)	15.36
Non-vested at December 31, 2016	296,785		16.16
Granted	143,593		19.74
Vested	(266,552	)	16.00
Forfeited	(550	)	18.78
Non-vested at December 31, 2017	173,276		$	19.36

For all service awards, the Company records compensation expense for the entire award on a straight-line basis over the requisite service period. For the years ended December 31, 2017, 2016, and 2015 the Company recognized non-cash share compensation of $3.1 million, $3.6 million, and $2.9 million, respectively. Unrecognized compensation expense at December 31, 2017, 2016, and 2015 was $1.0 million, $1.2 million, and $2.1 million, respectively. 

Restricted Share Units:

In March 2017, March 2016, and March 2015 under the Trust’s 2013 Plan, the Trust granted (i) restricted share units at a target level of 174,320, 104,553, and 75,250 respectively, to the Trust’s senior management, which are subject to certain performance and market conditions and a three-year service period and (ii) 32,831, 36,784, and 40,957 restricted share units, respectively, to the members of the Board of Trustees, which are subject to a two-year vesting period. Each restricted share unit contains one dividend equivalent. The recipient will accrue dividend equivalents on awarded share units equal to the cash dividend that would have been paid on the awarded share unit had the awarded share unit been an issued and outstanding common share on the record date for the dividend.

101

Approximately 70% of the restricted share units issued to officers in 2017, and 80% issued to officers in 2016 and 2015, vest based on certain market conditions. The market conditions were valued with the assistance of independent valuation specialists. The Company utilized a Monte Carlo simulation to calculate the weighted average grant date fair values in 2017, 2016, and 2015 of $33.43, $28.50, and $20.06 per unit, respectively, using the following assumptions:

	2017			2016			2015
Volatility	21.5		%	20.3		%	20.7		%
Dividend assumption	reinvested			reinvested			reinvested
Expected term in years	2.8 years			2.8 years			2.8 years
Risk-free rate	1.68		%	1.07		%	1.14		%
Stock price (per share)	$	19.80		$	17.67		$	15.87

 The remaining 30% of the restricted share units issued to officers in 2017, and 20% issued to officers in 2016 and 2015, vest based upon certain performance conditions. With respect to the performance conditions of the March 2017 grant, the grant date fair value of $19.80 per unit was based on the share price at the date of grant. The combined weighted average grant date fair value of the March 2017 restricted share units issued to officers is $29.34 per unit. With respect to the performance conditions of the March 2016 grant, the grant date fair value of $17.67 per unit was based on the share price at the date of grant. The combined weighted average grant date fair value of the March 2016 restricted share units issued to officers is $26.33 per unit. With respect to the performance conditions of the March 2015 grant, the grant date fair value of $15.87 per unit was based on the share price at the date of grant. The combined weighted average grant date fair value of the March 2015 restricted share units issued to officers is $19.22 per unit.

The following is a summary of the activity in the Trust’s restricted share units during 2017, 2016, and 2015: 

	Executive Awards				Trustee Awards
	Restricted Share Units		Weighted Average Grant Date Fair Value		Restricted Share Units		Weighted Average Grant Date Fair Value
Non-vested at December 31, 2014	55,680		$	16.94	—		$	—
Granted	75,250		19.22		40,957		15.87
Non-vested at December 31, 2015	130,930		18.48		40,957		15.87
Granted	104,553		26.33		36,784		17.67
Vested	—		—		(20,481	)	15.87
Non-vested at December 31, 2016	235,483		21.84		57,260		17.03
Granted	174,320		29.34		32,831		19.80
Vested	(55,680	)	16.94		(38,871	)	16.72
Non-vested at December 31, 2017	354,123		$	26.30	51,220		$	19.04

The Company recognized $3.6 million, $2.1 million, and $0.9 million of non-cash share unit compensation expense for the years ended December 31, 2017, 2016, and 2015, respectively. Unrecognized compensation expense at December 31, 2017, 2016, and 2015 was $5.0 million, $2.8 million, and $1.6 million, respectively.

Note 10. Fair Value Measurements

ASC Topic 820, Fair Value Measurement (“ASC 820”), requires certain assets and liabilities be reported and/or disclosed at fair value in the financial statements and provides a framework for establishing that fair value. The framework for determining fair value is based on a hierarchy that prioritizes the valuation techniques and inputs used to measure fair value.

In general, fair values determined by Level 1 inputs use quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Fair values determined by Level 2 inputs use other inputs that are observable, either directly or indirectly. These Level 2 inputs include quoted prices for similar assets and liabilities in active markets, and other inputs such as interest rates and yield curves that are observable at commonly quoted intervals.

Level 3 inputs are unobservable inputs, including inputs that are available in situations where there is little, if any, market activity for the related asset. These Level 3 fair value measurements are based primarily on management’s own estimates using pricing models, discounted cash flow methodologies, or similar techniques taking into account the

102

characteristics of the asset or liability. In instances where inputs used to measure fair value fall into different levels of the fair value hierarchy, fair value measurements in their entirety are categorized based on the lowest level input that is significant to the valuation. The assessment of the significance of particular inputs to these fair value measurements requires judgment and considers factors specific to each asset or liability.

The Company’s derivative instruments as of December 31, 2017, consist of five interest rate swaps. For presentational purposes, the Company’s interest rate swaps are shown as a single derivative due to the identical nature of their economic terms, as detailed in the Derivative Instruments section of Note 2 (Summary of Significant Accounting Policies) and Note 7 (Derivatives).

The Company’s interest rate swaps are not traded on an exchange. The Company’s derivative assets and liabilities are recorded at fair value based on a variety of observable inputs including contractual terms, interest rate curves, yield curves, measure of volatility, and correlations of such inputs. The Company measures its derivatives at fair value on a recurring basis. The fair values are based on Level 2 inputs described above. The Company considers its own credit risk, as well as the credit risk of its counterparties, when evaluating the fair value of its derivatives.

The Company also has assets that under certain conditions are subject to measurement at fair value on a non-recurring basis. This generally includes assets subject to impairment. There was one asset measured at fair value as of December 31, 2017.

The carrying amounts of cash and cash equivalents, tenant receivables, payables, and accrued interest are reasonable estimates of fair value because of the short term maturities of these instruments. Fair values for real estate loans receivable and mortgage debt are estimated based on rates currently prevailing for similar instruments of similar maturities and are based primarily on Level 2 inputs.

The following table presents the fair value of the Company’s financial instruments (in thousands):

	December 31,
	2017						2016
	Carrying Amount			Fair Value			Carrying Amount			Fair Value
Assets:
Real estate loans receivable	$	76,195		$	75,288		$	39,154		$	39,154
Notes receivable	$	—		$	—		$	16,618		$	16,618
Derivative assets	$	14,693		$	14,693		$	13,881		$	13,881
Liabilities:
Credit facility	$	(330,000	)	$	(330,000	)	$	(651,000	)	$	(651,000	)
Notes payable	$	(975,000	)	$	(970,975	)	$	(225,000	)	$	(214,584	)
Mortgage debt	$	(186,939	)	$	(185,743	)	$	(123,632	)	$	(125,420	)
Derivative liabilities	$	—		$	—		$	(5,571	)	$	(5,571	)

Note 11. Tenant Operating Leases

The Company is lessor of medical office buildings and other healthcare facilities. Leases have expirations from 2018 through 2045. As of December 31, 2017, the future minimum rental payments on non-cancelable leases, exclusive of expense recoveries, were as follows (in thousands):

2018	$	292,030
2019	291,338
2020	285,100
2021	278,095
2022	265,995
Thereafter	1,419,746
Total	$	2,832,304

103

Note 12. Rent Expense

The Company leases the rights to parking structures at 2 of its properties, the air space above 1 property, and the land upon which 78 of its properties are located from third party land owners pursuant to separate leases. In addition, the Company leases 4 individual office spaces. The leases require fixed rental payments and may also include escalation clauses and renewal options. These leases have terms of up to 98 years remaining, excluding extension options. As of December 31, 2017, the future minimum lease obligations under non-cancelable parking, air, ground, and office leases were as follows (in thousands):

2018	$	2,678
2019	2,604
2020	2,549
2021	2,563
2022	2,585
Thereafter	119,224
Total	$	132,203

Rent expense for the parking, air, and ground leases of $2.4 million, $1.9 million, and $1.3 million for the years ended December 31, 2017, 2016, and 2015, respectively, are reported in operating expenses in the consolidated statements of income. Rent expense for office leases for the year as of December 31, 2017 was $0.1 million and was insignificant for the years ended December 31, 2016, and 2015, and is reported within general and administrative expenses in the consolidated statements of income.

Note 13. Credit Concentration

The Company uses annualized base rent (“ABR”) as its credit concentration metric. Annualized base rent is calculated by multiplying contractual base rent for the month ended December 31, 2017 by 12, excluding the impact of concessions and straight-line rent. The following table summarizes certain information about the Company’s top five tenant credit concentrations as of December 31, 2017 (in thousands):

Tenant	Total ABR		Percent of ABR
CHI - Nebraska	$	15,906	5.6	%
CHI - KentuckyOne Health	13,120		4.6	%
Baylor Scott and White Health	7,402		2.6	%
US Oncology	6,706		2.4	%
CHI - St. Alexius (ND)	6,239		2.2	%
Remaining portfolio	236,297		82.6	%
Total	$	285,670	100.0	%

Annualized base rent collected from the Company’s top five tenant relationships comprises 17.4% of its total annualized base rent for the period ending December 31, 2017. Total annualized base rent from CHI affiliated tenants totals 18.7%, including the affiliates disclosed above. Although CHI is not a party to nor a guarantor of the related lease agreements, it controls each of the subsidiaries and the affiliates that are parties to the master lease agreements, which were entered into in connection with the closing of the transactions. Consolidated financial statements of CHI, the parent of the subsidiaries and affiliates of the entities party to master lease agreements, are publicly available on the Catholic Health Initiatives website (http://www.catholichealthinitiatives.org/). Information included on the CHI website is not incorporated by reference within this Annual Report on Form 10-K.

104

The following table summarizes certain information about the Company’s top five geographic concentrations as of December 31, 2017 (in thousands):

State	Total ABR		Percent of ABR
Texas	$	46,850	16.4	%
Georgia	27,457		9.6	%
Indiana	18,283		6.4	%
Nebraska	17,304		6.1	%
Kentucky	16,028		5.6	%
Other	159,748		55.9	%
Total	$	285,670	100.0	%

Note 14. Earnings Per Share and Earnings Per Unit

The following table shows the amounts used in computing the Trust’s basic and diluted earnings per share (in thousands, except share and per share data):

	Year Ended December 31,
	2017			2016			2015
Numerator for earnings per share - basic:
Net income	$	39,773		$	31,522		$	12,741
Net income attributable to noncontrolling interests:
Operating Partnership	(1,136		)	(825		)	(576		)
Partially owned properties	(491		)	(716		)	(377		)
Preferred distributions	(731		)	(1,857		)	(1,189		)
Numerator for earnings per share - basic:	$	37,415		$	28,124		$	10,599
Numerator for earnings per share - diluted:
Numerator for earnings per share - basic:	37,415			28,124			10,599
Operating Partnership net income	1,136			825			576
Numerator for earnings per share - diluted	$	38,551		$	28,949		$	11,175
Denominator for earnings per share - basic and diluted:
Weighted average number of shares outstanding - basic	163,123,109			126,143,114			72,750,724
Effect of dilutive securities:
Noncontrolling interest - Operating Partnership units	4,839,967			3,692,095			3,708,494
Restricted shares	89,497			205,036			190,619
Restricted share units	178,726			426,648			142,236
Denominator for earnings per share - diluted	168,231,299			130,466,893			76,792,073
Earnings per share - basic	$	0.23		$	0.22		$	0.15
Earnings per share - diluted	$	0.23		$	0.22		$	0.15

105

The following table shows the amounts used in computing the Operating Partnership’s basic and diluted earnings per unit (in thousands, except unit and per unit data):

	Year Ended December 31,
	2017			2016			2015
Numerator for earnings per unit - basic and diluted:
Net income	39,773			31,522			12,741
Net income attributable to noncontrolling interests - partially owned properties	(491		)	(716		)	(377		)
Preferred distributions	(731		)	(1,857		)	(1,189		)
Numerator for earnings per unit - basic and diluted	$	38,551		$	28,949		$	11,175
Denominator for earnings per unit - basic and diluted:
Weighted average number of units outstanding - basic	167,963,076			129,835,209			76,459,218
Effect of dilutive securities:
Restricted shares	89,497			205,036			190,619
Restricted share units	178,726			426,648			142,236
Denominator for earnings per unit - diluted	168,231,299			130,466,893			76,792,073
Earnings per unit - basic	$	0.23		$	0.22		$	0.15
Earnings per unit - diluted	$	0.23		$	0.22		$	0.15

Note 15. Subsequent Events

Since December 31, 2017, the Trust, through subsidiaries of its Operating Partnership, has completed acquisitions of 2 healthcare properties for an aggregate purchase price of $98.7 million containing an aggregate of 220,140 net leasable square feet and disposed of one property for $1.4 million which resulted in no gain or loss. In addition, the Operating Partnership funded a $2.0 million loan through a separate transaction, resulting in aggregate investment activity of $100.7 million. Property acquisitions are summarized below:

Property		Location	Acquisition Date	Investment (in thousands)
Hazelwood Medical Commons	(1)	Maplewood, MN	January 9, 2018	$	70,702
Lee's Hill Medical Plaza		Fredericksburg, VA	January 23, 2018	28,000
Loan Investment		Pensacola, FL	February 16, 2018	2,000
				$	100,702

(1) The Company partially funded the purchase price of this acquisition by issuing a total of 104,172 Preferred OP Units valued at approximately $22.7 million in the aggregate on the date of issuance.

106

Note 16. Quarterly Data

Physicians Realty Trust

The following unaudited quarterly data has been prepared on the basis of a December 31 year-end. Amounts are in thousands, except for common share and per share amounts.

As a result of the acquisition activity and equity offerings throughout 2017 and 2016, the quarterly periods are not comparable quarter over quarter.

	Quarter Ended
2017	March 31		June 30		September 30		December 31
Total revenues	$	76,666	$	76,599	$	92,999	$	97,320
Operating income	6,688		4,994		12,511		9,523
Net income	6,716		10,331		12,539		10,187
Net income attributable to common shareholders	6,191		9,670		12,018		9,536
Earnings per share – basic:
Net income available to common shareholders	$	0.04	$	0.06	$	0.07	$	0.05
Weighted average number of shares outstanding	138,986,629		155,366,080		177,847,424		179,683,948
Earnings per share – diluted:
Net income available to common shareholders	$	0.04	$	0.06	$	0.07	$	0.05
Weighted average number of shares outstanding	142,605,930		161,012,360		183,298,145		185,273,236

	Quarter Ended
2016	March 31		June 30		September 30		December 31
Total revenues	$	44,134	$	53,216	$	70,010	$	73,674
Operating income	5,392		7,158		10,267		8,590
Net income	5,424		7,184		10,294		8,620
Net income available to common shareholders	4,386		6,486		9,427		7,825
Earnings per share – basic:
Net income available to common shareholders	$	0.04	$	0.05	$	0.07	$	0.06
Weighted average number of shares outstanding	102,704,008		131,481,329		134,608,396		135,581,976
Earnings per share – diluted:
Net income available to common shareholders	$	0.04	$	0.05	$	0.07	$	0.06
Weighted average number of shares outstanding	107,148,380		135,944,722		138,880,787		139,602,349

107

Physicians Realty L.P.

The following unaudited quarterly data has been prepared on the basis of a December 31 year-end. Amounts are in thousands, except for common unit and per unit amounts.

As a result of the acquisition activity and equity offerings throughout 2017 and 2016, the quarterly periods are not comparable quarter over quarter.

	Quarter Ended
2017	March 31		June 30		September 30		December 31
Total revenues	$	76,666	$	76,599	$	92,999	$	97,320
Operating income	6,688		4,994		12,511		9,523
Net income	6,716		10,331		12,539		10,187
Net income attributable to common unitholders	6,338		9,984		12,380		9,849
Earnings per unit – basic:
Net income available to common unitholders	$	0.04	$	0.06	$	0.07	$	0.05
Weighted average number of units outstanding	142,172,746		160,765,345		183,227,405		185,048,580
Earnings per unit – diluted:
Net income available to common unitholders	$	0.04	$	0.06	$	0.07	$	0.05
Weighted average number of units outstanding	142,605,930		161,012,360		183,298,145		185,273,236

	Quarter Ended
2016	March 31		June 30		September 30		December 31
Total revenues	$	44,134	$	53,216	$	70,010	$	73,674
Operating income	5,392		7,158		10,267		8,590
Net income	5,424		7,184		10,294		8,620
Net income attributable to common unitholders	4,559		6,687		9,682		8,021
Earnings per unit – basic:
Net income available to common unitholders	$	0.04	$	0.05	$	0.07	$	0.06
Weighted average number of units outstanding	106,550,467		135,351,672		138,227,384		139,018,183
Earnings per unit – diluted:
Net income available to common unitholders	$	0.04	$	0.05	$	0.07	$	0.06
Weighted average number of units outstanding	107,148,380		135,944,722		138,880,787		139,602,349

108

Physicians Realty Trust and Physicians Realty L.P.

Schedule III – Real Estate and Accumulated Depreciation

December 31, 2017

(dollars in thousands)

109

Physicians Realty Trust and Physicians Realty L.P.

Schedule III – Real Estate and Accumulated Depreciation

December 31, 2017

(dollars in thousands)

110

Physicians Realty Trust and Physicians Realty L.P.

Schedule III – Real Estate and Accumulated Depreciation

December 31, 2017

(dollars in thousands)

111

Physicians Realty Trust and Physicians Realty L.P.

Schedule III – Real Estate and Accumulated Depreciation

December 31, 2017

(dollars in thousands)

				Initial Cost to Company							Gross Amount at Which Carried as of Close of Period
Description	Location	Encumbrances		Land		Buildings and Improvements		Cost Capitalized Subsequent to Acquisitions			Land		Buildings and Improvements		Total		Accumulated Depreciation			Year Built	Date  Acquired	Life on Which Building Depreciation in Income Statement is Computed
Arrowhead Commons	Phoenix, AZ	$	—	$	740	$	2,551	$	730		$	740	$	3,281	$	4,021	$	(563	)	2004	5/31/2008	46
Aurora Medical Office Building	Green Bay, WI	—		500		1,566		—			500		1,566		2,066		(243		)	2010	4/15/2010	50
El Paso Medical Office Building	El Paso, TX	—		860		2,866		406			860		3,272		4,132		(1,809		)	1987	8/24/2006	21
Farmington Professional Pavilion	Detroit, MI	—		580		1,793		132			580		1,925		2,505		(1,478		)	1972	1/5/2006	15
Firehouse Square	Milwaukee, WI	—		1,120		2,768		—			1,120		2,768		3,888		(961		)	2002	8/15/2007	30
Hackley Medical Center	Grand Rapids, MI	—		1,840		6,402		64			1,840		6,466		8,306		(2,381		)	1968	12/22/2006	30
MeadowView Professional Center	Kingsport, TN	—		2,270		11,344		—			2,270		11,344		13,614		(4,054		)	2005	5/10/2007	30
Mid Coast Hospital Medical Office Building	Portland, ME	7,009		—		11,247		81			—		11,328		11,328		(3,614		)	2008	5/1/2008	42
New Albany Professional Building	Columbus, OH	—		237		2,767		621			237		3,388		3,625		(799		)	2000	1/4/2008	42
Remington Medical Commons	Chicago, IL	—		895		6,499		319			895		6,818		7,713		(2,228		)	2008	6/1/2008	30
Summit Healthplex	Atlanta, GA	—		2,633		15,576		5,524			2,633		21,100		23,733		(5,518		)	2002	7/3/2008	44
Valley West Hospital Medical Office Building	Chicago, IL	4,531		—		6,275		620			—		6,895		6,895		(2,357		)	2007	11/1/2007	30
East El Paso Medical Office Building	El Paso, TX	—		710		4,500		—			710		4,500		5,210		(557		)	2004	8/30/2013	35
East El Paso Surgical Hospital	El Paso, TX	—		3,070		23,627		—			3,070		23,627		26,697		(2,844		)	2004	8/30/2013	36
LifeCare Plano LTACH	Plano, TX	—		3,370		11,689		455			3,370		12,144		15,514		(2,119		)	1987	9/18/2013	25
Crescent City Surgical Centre	New Orleans, LA	18,750		—		34,208		—			—		34,208		34,208		(3,029		)	2010	9/30/2013	48
Foundation Surgical Affiliates Medical Office Building	Oklahoma City, OK	7,101		1,300		12,724		—			1,300		12,724		14,024		(1,258		)	2004	9/30/2013	43
Pensacola Medical Office Building	Pensacola, FL	—		990		5,005		16			990		5,021		6,011		(437		)	2012	10/4/2013	49
Central Ohio Neurosurgical Surgeons Medical Office	Columbus, OH	—		981		7,620		—			981		7,620		8,601		(707		)	2007	11/27/2013	44
Great Falls Ambulatory Surgery Center	Great Falls, MT	—		203		3,224		67			203		3,291		3,494		(404		)	1999	12/11/2013	33
Eagles Landing Family Practice Medical Office Building	McDonough, GA	—		800		3,345		1,548			800		4,893		5,693		(532		)	2007	2/19/2014	36
Eagles Landing Family Practice Medical Office Building	Jackson, GA	—		800		3,345		1,255			800		4,600		5,400		(475		)	2006	2/19/2014	38
Eagles Landing Family Practice Medical Office Building	Conyers, GA	—		1,000		3,345		—			1,000		3,345		4,345		(360		)	2008	2/19/2014	37
Eagles Landing Family Practice Medical Office Building	McDonough, GA	—		400		3,345		1,741			400		5,086		5,486		(531		)	2010	2/19/2014	37
Foundation San Antonio Surgical Hospital	San Antonio, TX	7,691		2,230		23,346		43			2,230		23,389		25,619		(2,919		)	2007	2/19/2014	35
21st Century Radiation Oncology Centers — Sarasota	Sarasota, FL	—		633		6,557		—			633		6,557		7,190		(969		)	1975	2/26/2014	27
21st Century Radiation Oncology Centers - Venice	Venice, FL	—		814		2,952		—			814		2,952		3,766		(364		)	1987	2/26/2014	35
21st Century Radiation Oncology Centers - Englewood	Englewood, FL	—		350		1,878		—			350		1,878		2,228		(209		)	1992	2/26/2014	38
21st Century Radiation Oncology Centers — Port Charlotte	Port Charlotte, FL	—		269		2,326		(852		)	156		1,474		1,630		(262		)	1996	2/26/2014	36
Foundation San Antonio Healthplex	San Antonio, TX	—		911		4,189		—			911		4,189		5,100		(480		)	2007	2/28/2014	35
Peachtree Dunwoody Medical Center	Atlanta, GA	17,000		—		27,435		24,894			—		52,329		52,329		(5,076		)	1987	2/28/2014	25
LifeCare LTACH — Fort Worth	Fort Worth, TX	—		2,730		24,639		—			2,730		24,639		27,369		(3,162		)	1985	3/28/2014	30
LifeCare LTACH — Pittsburgh	Pittsburgh, PA	—		1,142		11,737		—			1,142		11,737		12,879		(1,575		)	1987	3/28/2014	30
PinnacleHealth Medical Office Building	Harrisburg, PA	—		795		4,601		—			795		4,601		5,396		(731		)	1990	4/22/2014	25
Pinnacle Health Medical Office Building	Carlisle, PA	—		424		2,232		—			424		2,232		2,656		(255		)	2002	4/22/2014	35
South Bend Orthopaedics Medical Office Building	Mishawaka, IN	—		2,418		11,355		—			2,418		11,355		13,773		(1,195		)	2007	4/30/2014	40
Grenada Medical Complex	Grenada, MS	—		185		5,820		116			185		5,936		6,121		(862		)	1975	4/30/2014	30
Mississippi Ortho Medical Office Building	Jackson, MS	—		1,272		14,177		626			1,272		14,803		16,075		(1,650		)	1987	5/23/2014	35
Carmel Medical Pavilion	Carmel, IN	—		—		3,917		99			—		4,016		4,016		(593		)	1993	5/28/2014	25
Renaissance Ambulatory Surgery Center	Oshkosh, WI	—		228		7,658		17			228		7,675		7,903		(696		)	2007	6/30/2014	40
Presbyterian Medical Plaza	Monroe, NC	—		1,195		5,681		27			1,195		5,708		6,903		(476		)	2008	6/30/2014	45
Summit Urology	Bloomington, IN	—		125		4,792		—			125		4,792		4,917		(573		)	1996	6/30/2014	30
500 Landmark	Bloomington, IN	—		627		3,549		—			627		3,549		4,176		(370		)	2000	7/1/2014	35
550 Landmark	Bloomington, IN	—		2,717		15,224		—			2,717		15,224		17,941		(1,586		)	2000	7/1/2014	35
574 Landmark	Bloomington, IN	—		418		1,493		—			418		1,493		1,911		(159		)	2004	7/1/2014	35
Carlisle II MOB	Carlisle, PA	—		412		3,962		—			412		3,962		4,374		(317		)	1996	7/25/2014	45
Surgical Institute of Monroe	Monroe, MI	—		410		5,743		—			410		5,743		6,153		(659		)	2010	7/28/2014	35
The Oaks @ Lady Lake	Lady Lake, FL	—		1,065		8,642		—			1,065		8,642		9,707		(710		)	2011	7/31/2014	42
Mansfield ASC	Mansfield, TX	—		1,491		6,471		—			1,491		6,471		7,962		(517		)	2010	9/2/2014	46
Eye Center of Southern Indiana	Bloomington, IN	—		910		11,477		—			910		11,477		12,387		(1,134		)	1995	9/5/2014	35
Wayne State	Troy, MI	—		3,560		43,052		—			3,560		43,052		46,612		(3,921		)	1986	9/10/2014	38
Zangmeister	Columbus, OH	—		1,610		31,120		4			1,610		31,124		32,734		(2,644		)	2007	9/30/2014	40
Ortho One - Columbus	Columbus, OH	—		—		16,234		7			—		16,241		16,241		(1,309		)	2009	9/30/2014	45
Ortho One - Westerville	Columbus, OH	—		362		3,944		—			362		3,944		4,306		(328		)	2007	9/30/2014	43
Berger Medical Center	Columbus, OH	—		—		5,950		—			—		5,950		5,950		(561		)	2007	9/30/2014	38
El Paso - Lee Trevino	El Paso, TX	—		2,294		11,316		412			2,294		11,728		14,022		(1,351		)	1983	9/30/2014	30
El Paso - Murchison	El Paso, TX	—		2,283		24,543		1,303			2,283		25,846		28,129		(2,895		)	1970	9/30/2014	30
El Paso - Kenworthy	El Paso, TX	—		728		2,178		25			728		2,203		2,931		(230		)	1983	9/30/2014	35
Pinnacle - 32 Northeast	Harrisburg, PA	—		408		3,232		91			408		3,323		3,731		(352		)	1994	10/29/2014	33
Pinnacle - 4518 Union Deposit	Harrisburg, PA	—		617		7,305		15			617		7,320		7,937		(803		)	2000	10/29/2014	31
Pinnacle - 4520 Union Deposit	Harrisburg, PA	—		169		2,055		—			169		2,055		2,224		(244		)	1997	10/29/2014	28

112

Physicians Realty Trust and Physicians Realty L.P.

Schedule III – Real Estate and Accumulated Depreciation

December 31, 2017

(dollars in thousands)

			Initial Cost to Company			Gross Amount at Which Carried as of Close of Period
Description	Location	Encumbrances	Land	Buildings and Improvements	Cost Capitalized Subsequent to Acquisitions	Land	Buildings and Improvements	Total	Accumulated Depreciation		Year Built	Date  Acquired	Life on Which Building Depreciation in Income Statement is Computed
Pinnacle - 240 Grandview	Harrisburg, PA	—	321	4,242	—	321	4,242	4,563	(411	)	1980	10/29/2014	35
Pinnacle - Market Place Way	Harrisburg, PA	—	808	2,383	6	808	2,389	3,197	(314	)	2004	10/29/2014	35
CRHS - 2000 10th Avenue	Columbus, GA	—	380	2,737	14	380	2,751	3,131	(415	)	1989	11/20/2014	22
CRHS - 1942 North Avenue	Columbus, GA	—	91	273	—	91	273	364	(73	)	1971	11/20/2014	12
CRHS - 920 18th Street	Columbus, GA	—	110	281	—	110	281	391	(113	)	1982	11/20/2014	8
CRHS - 1900 10th Avenue	Columbus, GA	—	474	5,580	131	474	5,711	6,185	(747	)	1976	11/20/2014	26
CRHS - 1800 10th Avenue	Columbus, GA	—	539	5,238	19	539	5,257	5,796	(615	)	1980	11/20/2014	28
CRHS - 705 17th Street	Columbus, GA	—	372	2,346	278	372	2,624	2,996	(582	)	1994	11/20/2014	15
CRHS - 615 19th Street	Columbus, GA	—	75	113	—	75	113	188	(107	)	1976	11/20/2014	3
CRHS - 1968 North Avenue	Columbus, GA	—	89	32	—	89	32	121	(26	)	1966	11/20/2014	4
CRHS - 633 19th Street	Columbus, GA	—	99	255	—	99	255	354	(92	)	1972	11/20/2014	9
CRHS - 500 18th Street	Columbus, GA	—	430	170	205	430	375	805	(111	)	1982	11/20/2014	8
CRHS - 2200 Hamilton Road	Columbus, GA	—	267	1,579	42	267	1,621	1,888	(248	)	1992	11/20/2014	22
CRHS - 1810 Stadium Drive	Phenix City, AL	—	202	149	26	202	175	377	(94	)	1999	11/20/2014	30
Carle Danville MOB	Danville, IL	—	607	7,136	—	607	7,136	7,743	(713	)	2007	11/26/2014	33
Middletown Medical - 111 Maltese	Middletown, NY	—	670	9,921	37	670	9,958	10,628	(909	)	1988	11/28/2014	35
Middletown Medical - 2 Edgewater	Middletown, NY	—	200	2,966	11	200	2,977	3,177	(272	)	1992	11/28/2014	35
Napoleon Medical Office Building	New Orleans, LA	—	1,202	7,412	763	1,202	8,175	9,377	(998	)	1974	12/19/2014	25
West TN Bone & Joint - Physicians Drive	Jackson, TN	—	1,661	2,960	—	1,661	2,960	4,621	(269	)	1991	12/30/2014	35
West TN Bone & Joint	Jackson, TN	—	1,250	5,210	—	1,250	5,210	6,460	(543	)	1996	12/30/2014	31
Edina MOB	Edina MN	—	504	10,006	959	504	10,965	11,469	(1,657	)	1979	1/22/2015	24
Crystal MOB	Crystal, MN	—	945	11,862	—	945	11,862	12,807	(879	)	2012	1/22/2015	47
Savage MOB	Savage, MN	5,449	1,281	10,021	—	1,281	10,021	11,302	(770	)	2011	1/22/2015	48
Dell Road MOB	Chanhassen, MN	—	800	4,520	29	800	4,549	5,349	(385	)	2008	1/22/2015	43
Columbus MOB	Columbus, GA	—	845	2,708	7	845	2,715	3,560	(432	)	1980	1/23/2015	22
Methodist Sports MOB	Greenwood, IN	—	1,050	8,556	—	1,050	8,556	9,606	(795	)	2008	1/28/2015	33
Vadnais Heights MOB	Vadnais Heights, MN	—	2,751	12,233	—	2,751	12,233	14,984	(1,069	)	2013	1/29/2015	43
Minnetonka MOB	Minnetonka, MN	—	1,770	19,797	—	1,770	19,797	21,567	(1,456	)	2014	2/5/2015	49
Jamestown MOB	Jamestown, ND	—	656	9,440	—	656	9,440	10,096	(855	)	2013	2/5/2015	43
Indiana American II	Greenwood, IN	—	862	6,901	600	862	7,501	8,363	(599	)	2008	2/13/2015	38
Indiana American III	Greenwood, IN	—	741	1,846	185	741	2,031	2,772	(313	)	2001	2/13/2015	31
Indiana American IV	Greenwood, IN	—	771	1,928	77	771	2,005	2,776	(205	)	2001	2/13/2015	31
Southpointe	Indianapolis, IN	—	563	1,741	259	563	2,000	2,563	(284	)	1993	2/13/2015	27
Minnesota Eye MOB	Minnetonka, MN	—	1,143	7,470	—	1,143	7,470	8,613	(592	)	2014	2/17/2015	44
Baylor Cancer Center	Dallas, TX	—	855	6,007	32	855	6,039	6,894	(427	)	2001	2/27/2015	43
Bridgeport Medical Center	Lakewood, WA	—	1,397	10,435	47	1,397	10,482	11,879	(899	)	2004	2/27/2015	35
Renaissance Office Building	Milwaukee, WI	—	1,379	4,182	2,834	1,379	7,016	8,395	(1,078	)	1896	3/27/2015	15
Calkins 125	Rochester, NY	—	534	10,164	326	534	10,490	11,024	(1,159	)	1997	3/31/2015	32
Calkins 200	Rochester, NY	—	210	3,317	32	210	3,349	3,559	(335	)	2000	3/31/2015	38
Calkins 300	Rochester, NY	—	372	6,645	24	372	6,669	7,041	(652	)	2002	3/31/2015	39
Calkins 400	Rochester, NY	—	353	8,226	34	353	8,260	8,613	(864	)	2007	3/31/2015	39
Calkins 500	Rochester, NY	—	282	7,074	28	282	7,102	7,384	(589	)	2008	3/31/2015	41
Avalon Park Florida Hospital MOB	Avalon Park, FL	—	1,041	10,685	—	1,041	10,685	11,726	(780	)	2009	3/31/2015	41
Premier Surgery Center of Louisville	Louisville, KY	—	1,106	5,437	—	1,106	5,437	6,543	(374	)	2013	4/10/2015	43
Baton Rouge MOB	Baton Rouge, LA	—	711	7,720	—	711	7,720	8,431	(636	)	2003	4/15/2015	35
Healthpark Medical Center	Grand Blanc, MI	—	—	17,624	—	—	17,624	17,624	(1,434	)	2006	4/30/2015	36
Plaza HCA MOB	Jacksonville, FL	—	1,112	12,553	—	1,112	12,553	13,665	(903	)	2007	4/30/2015	39
Northern Ohio Medical Center	Sheffield, OH	—	644	9,162	—	644	9,162	9,806	(1,225	)	1999	5/28/2015	20
University of Michigan - Northville MOB	Livonia, MI	—	2,200	8,627	166	2,200	8,793	10,993	(808	)	1988	5/29/2015	30
Coon Rapids Medical Center MOB	Coon Rapids, MN	—	607	5,857	—	607	5,857	6,464	(468	)	2007	6/1/2015	35
Premier Landmark MOB	Bloomington, IN	—	872	10,537	—	872	10,537	11,409	(730	)	2008	6/5/2015	39
Palm Beach ASC	Palm Beach, FL	—	2,576	7,675	—	2,576	7,675	10,251	(507	)	2003	6/26/2015	40
Brookstone Physician Center MOB	Jacksonville, AL	—	—	1,913	—	—	1,913	1,913	(166	)	2007	6/30/2015	31
Jackson Woman's Clinic MOB	Jackson, TN	—	555	3,800	19	555	3,819	4,374	(293	)	1998	6/30/2015	35
Hillside Medical Center MOB	Hanover, PA	—	812	13,217	63	812	13,280	14,092	(941	)	2003	6/30/2015	35
Randall Road MOB	Elgin, IL	—	1,124	15,404	486	1,124	15,890	17,014	(1,054	)	2006	6/30/2015	38
Medical Specialists of Palm Beach MOB	Atlantis, FL	—	—	7,560	6	—	7,566	7,566	(541	)	2002	7/24/2015	37
OhioHealth - SW Health Center MOB	Grove City, OH	—	1,363	8,516	—	1,363	8,516	9,879	(637	)	2001	7/31/2015	37
Trios Health MOB	Kennewick, WA	—	—	55,178	3,795	—	58,973	58,973	(3,169	)	2015	7/31/2015	45
IMS - Paradise Valley MOB	Phoenix, AZ	—	—	25,893	14	—	25,907	25,907	(1,638	)	2004	8/14/2015	43
IMS - Avondale MOB	Avondale, AZ	—	1,818	18,108	10	1,818	18,118	19,936	(1,020	)	2006	8/19/2015	45
IMS - Palm Valley MOB	Goodyear, AZ	—	2,666	28,655	—	2,666	28,655	31,321	(1,683	)	2006	8/19/2015	43
IMS - North Mountain MOB	Phoenix, AZ	—	—	42,877	495	—	43,372	43,372	(2,372	)	2008	8/31/2015	47
Memorial Hermann - Phase I	Katy, TX	—	822	6,797	19	822	6,816	7,638	(440	)	2005	9/1/2015	39
Memorial Hermann - Phase II	Katy, TX	—	1,560	25,601	6	1,560	25,607	27,167	(1,573	)	2006	9/1/2015	40
New Albany Medical Center MOB	New Albany, OH	—	1,600	8,505	216	1,600	8,721	10,321	(613	)	2005	9/9/2015	37
Fountain Hills Medical Campus MOB	Fountain Hills, AZ	—	2,593	7,635	618	2,593	8,253	10,846	(502	)	1995	9/30/2015	39
Fairhope MOB	Fairhope, AL	—	640	5,227	568	640	5,795	6,435	(349	)	2005	10/13/2015	38

			Initial Cost to Company			Gross Amount at Which Carried as of Close of Period
Description	Location	Encumbrances	Land	Buildings and Improvements	Cost Capitalized Subsequent to Acquisitions	Land	Buildings and Improvements	Total	Accumulated Depreciation		Year Built	Date  Acquired	Life on Which Building Depreciation in Income Statement is Computed
Foley MOB	Foley, AL	—	365	732	—	365	732	1,097	(48	)	1997	10/13/2015	40
Foley Venture	Foley, AL	—	420	1,118	—	420	1,118	1,538	(73	)	2002	10/13/2015	38
North Okaloosa MOB	Crestview, FL	—	190	1,010	—	190	1,010	1,200	(61	)	2005	10/13/2015	41
Commons on North Davis	Pensacola, FL	—	380	1,237	—	380	1,237	1,617	(75	)	2009	10/13/2015	41
Sorrento Road	Pensacola, FL	—	170	894	—	170	894	1,064	(55	)	2010	10/13/2015	41
Breakfast Point Medical Park	Panama City, FL	—	—	817	—	—	817	817	(47	)	2012	10/13/2015	42
Panama City Beach	Panama City, FL	—	—	739	—	—	739	739	(42	)	2012	10/13/2015	42
Perdido Medical Park	Pensacola, FL	—	100	1,147	—	100	1,147	1,247	(69	)	2010	10/13/2015	41
Ft. Walton Beach	Ft. Walton Beach, FL	—	230	914	—	230	914	1,144	(63	)	1979	10/13/2015	35
Panama City	Panama City, FL	—	—	661	—	—	661	661	(41	)	2003	10/13/2015	38
Pensacola - Catalyst	Pensacola, FL	—	220	1,685	—	220	1,685	1,905	(104	)	2001	10/13/2015	39
Arete Surgical Center	Johnstown, CO	—	399	6,667	—	399	6,667	7,066	(337	)	2013	10/19/2015	45
Cambridge Professional Center MOB	Waldorf, MD	—	590	8,520	130	590	8,650	9,240	(590	)	1999	10/30/2015	35
HonorHealth 44th Street MOB	Phoenix, AZ	—	515	3,884	1,320	515	5,204	5,719	(370	)	1988	11/13/2015	28
Mercy Medical Center MOB	Fenton, MO	—	1,201	6,778	—	1,201	6,778	7,979	(389	)	1999	12/1/2015	40
Nashville MOB	Nashville, TN	—	1,555	39,713	250	1,555	39,963	41,518	(1,771	)	2015	12/17/2015	46
KSF Orthopaedic MOB	Houston, TX	—	530	3,712	26	530	3,738	4,268	(430	)	1984	12/22/2015	19
Great Falls Clinic MOB	Great Falls, MT	—	—	27,402	441	—	27,843	27,843	(1,482	)	2004	12/29/2015	40
Great Falls Hospital	Great Falls, MT	—	—	25,262	—	—	25,262	25,262	(1,322	)	2015	1/25/2016	40
Monterey Medical Center ASC	Stuart, FL	—	380	5,064	—	380	5,064	5,444	(240	)	2013	2/1/2016	42
Physicians Medical Plaza MOB	Indianapolis, IN	—	—	6,703	17	—	6,720	6,720	(412	)	2004	2/1/2016	34
Park Nicollet Clinic	Chanhassen, MN	—	1,941	14,555	—	1,941	14,555	16,496	(758	)	2005	2/8/2016	40
HEB Cancer Center	Bedford, TX	—	—	11,839	—	—	11,839	11,839	(548	)	2014	2/12/2016	44
Riverview Medical Center	Lancaster, OH	—	1,313	10,243	63	1,313	10,306	11,619	(638	)	1997	2/26/2016	33
St. Luke's Cornwall MOB	Cornwall, NY	9,500	—	13,017	—	—	13,017	13,017	(761	)	2006	2/26/2016	35
HonorHealth Glendale	Glendale, AZ	—	1,770	8,089	—	1,770	8,089	9,859	(352	)	2015	3/15/2016	45
Columbia MOB	Hudson, NY	12,000	—	16,550	—	—	16,550	16,550	(867	)	2006	3/21/2016	35
St Vincent POB 1	Birmingham, AL	—	—	10,172	130	—	10,302	10,302	(1,246	)	1975	3/23/2016	15
St Vincent POB 2	Birmingham, AL	—	48	6,624	144	48	6,768	6,816	(853	)	1988	3/23/2016	15
St Vincent POB 3	Birmingham, AL	—	75	9,433	353	75	9,786	9,861	(726	)	1992	3/23/2016	25
Emerson Medical Building	Creve Coeur, MO	—	1,590	9,853	114	1,590	9,967	11,557	(522	)	1989	3/24/2016	35
Patient Partners Surgery Center	Gallatin, TN	—	203	3,376	—	203	3,376	3,579	(163	)	2007	3/30/2016	40
Eye Associates of NM - Santa Fe	Santa Fe, NM	—	900	6,604	—	900	6,604	7,504	(366	)	2002	3/31/2016	35
Eye Associates of NM - Albuquerque	Albuquerque, NM	—	1,020	7,832	—	1,020	7,832	8,852	(384	)	2007	3/31/2016	40
Gardendale Surgery Center	Gardendale, AL	—	200	5,732	—	200	5,732	5,932	(250	)	2011	4/11/2016	42
HealthEast - Curve Crest	Stillwater, MN	—	409	3,279	—	409	3,279	3,688	(148	)	2011	4/14/2016	43
HealthEast - Victor Gardens	Hugo, MN	—	572	4,400	51	572	4,451	5,023	(209	)	2008	4/14/2016	41
NOMS - Clyde	Clyde, OH	—	440	5,948	—	440	5,948	6,388	(240	)	2015	5/10/2016	44
Blandford MOB	Little Rock, AR	—	203	2,386	—	203	2,386	2,589	(107	)	1983	5/11/2016	40
Cardwell MOB	Lufkin, TX	—	—	8,348	138	—	8,486	8,486	(361	)	1999	5/11/2016	42
Dacono Neighborhood Health	Dacono, CO	—	2,258	2,911	20	2,258	2,931	5,189	(173	)	2014	5/11/2016	44
Franciscan Health	Tacoma, WA	—	711	9,096	65	711	9,161	9,872	(1,017	)	1951	5/11/2016	15
Grand Island Specialty Clinic	Grand Island, NE	—	102	2,802	150	102	2,952	3,054	(136	)	1978	5/11/2016	42
Hot Springs MOB	Hot Springs Village, AR	—	305	3,309	65	305	3,374	3,679	(209	)	1988	5/11/2016	30
Jewish Medical Center East	Louisville, KY	—	—	81,248	32	—	81,280	81,280	(3,138	)	2003	5/11/2016	45
Jewish Medical Center South MOB - 1	Shepherdsville, KY	—	—	15,861	225	—	16,086	16,086	(787	)	2005	5/11/2016	39
Jewish Medical Plaza I	Louisville, KY	—	—	8,808	172	—	8,980	8,980	(451	)	1970	5/11/2016	35
Jewish Medical Plaza II	Louisville, KY	—	—	5,216	1,070	—	6,286	6,286	(592	)	1964	5/11/2016	15
Jewish OCC	Louisville, KY	—	—	35,703	108	—	35,811	35,811	(1,767	)	1985	5/11/2016	34
Lexington Surgery Center	Lexington, KY	—	1,229	18,914	363	1,229	19,277	20,506	(1,074	)	2000	5/11/2016	30
Medical Arts Pavilion	Lufkin, TX	—	—	6,215	15	—	6,230	6,230	(337	)	2004	5/11/2016	33
Memorial Outpatient Center	Lufkin, TX	—	—	4,808	100	—	4,908	4,908	(206	)	1990	5/11/2016	45
Midlands Two Professional Center	Papillion, NE	—	—	587	57	—	644	644	(247	)	1976	5/11/2016	5
Parkview MOB	Little Rock, AR	—	705	4,343	44	705	4,387	5,092	(229	)	1988	5/11/2016	35
Peak One ASC	Frisco, CO	—	—	5,763	65	—	5,828	5,828	(238	)	2006	5/11/2016	44
Physicians Medical Center	Tacoma, WA	—	—	5,862	144	—	6,006	6,006	(376	)	1977	5/11/2016	27
St. Alexius - Minot Medical Plaza	Minot, ND	—	—	26,078	—	—	26,078	26,078	(1,023	)	2015	5/11/2016	49
St. Clare Medical Pavilion	Lakewood, WA	—	—	9,005	—	—	9,005	9,005	(535	)	1989	5/11/2016	33
St. Joseph Medical Pavilion	Tacoma, WA	—	—	11,497	31	—	11,528	11,528	(591	)	1989	5/11/2016	35
St. Joseph Office Park	Lexington, KY	—	3,722	12,675	3,228	3,722	15,903	19,625	(1,621	)	1992	5/11/2016	14
St. Mary - Caritas Medical II	Louisville, KY	—	—	5,587	23	—	5,610	5,610	(283	)	1979	5/11/2016	34
St. Mary - Caritas Medical III	Louisville, KY	—	—	383	194	—	577	577	(266	)	1974	5/11/2016	2
Thornton Neighborhood Health	Thornton, CO	—	1,609	2,287	—	1,609	2,287	3,896	(132	)	2014	5/11/2016	43
Medical Village at Kissimmee	Kissimmee, FL	—	634	3,365	—	634	3,365	3,999	(149	)	2006	5/26/2016	39
Medical Village at Leesburg	Leesburg, FL	—	802	3,047	—	802	3,047	3,849	(213	)	1979	5/26/2016	25
St. Francis MOB	Federal Way, WA	—	—	12,817	24	—	12,841	12,841	(615	)	1987	6/2/2016	38
Children's Hospital MOB	Milwaukee, WI	—	476	4,897	—	476	4,897	5,373	(197	)	2016	6/3/2016	45
Jewish Medical Center South MOB - 2	Shepherdsville, KY	—	27	3,827	—	27	3,827	3,854	(153	)	2006	6/8/2016	40
Good Samaritan North Annex Building	Kearney, NE	—	—	2,734	—	—	2,734	2,734	(132	)	1984	6/28/2016	37

			Initial Cost to Company			Gross Amount at Which Carried as of Close of Period
Description	Location	Encumbrances	Land	Buildings and Improvements	Cost Capitalized Subsequent to Acquisitions	Land	Buildings and Improvements	Total	Accumulated Depreciation		Year Built	Date  Acquired	Life on Which Building Depreciation in Income Statement is Computed
NE Heart Institute Medical Building	Lincoln, NE	—	—	19,738	—	—	19,738	19,738	(633	)	2004	6/28/2016	47
St. Vincent West MOB	Little Rock, AR	—	—	13,453	—	—	13,453	13,453	(447	)	2012	6/29/2016	49
Meridan MOB	Englewood, CO	—	1,608	15,774	141	1,608	15,915	17,523	(717	)	2002	6/29/2016	38
St. Mary - Caritas Medical I	Louisville, KY	—	—	8,774	283	—	9,057	9,057	(535	)	1991	6/29/2016	25
St. Alexius - Medical Arts Pavilion	Bismarck, ND	—	—	12,902	77	—	12,979	12,979	(624	)	1974	6/29/2016	32
St. Alexius - Mandan Clinic	Mandan, ND	—	708	7,700	74	708	7,774	8,482	(301	)	2014	6/29/2016	43
St. Alexius - Orthopaedic Center	Bismarck, ND	—	—	13,881	363	—	14,244	14,244	(563	)	1997	6/29/2016	39
St. Alexius - Rehab Center	Bismarck, ND	—	—	5,920	97	—	6,017	6,017	(380	)	1997	6/29/2016	25
St. Alexius - Tech & Ed	Bismarck, ND	—	—	16,688	2	—	16,690	16,690	(679	)	2011	6/29/2016	38
Good Samaritan MOB	Kearney, NE	—	—	24,154	72	—	24,226	24,226	(820	)	1999	6/29/2016	45
Lakeside Two Professional Building	Omaha, NE	—	—	13,358	144	—	13,502	13,502	(532	)	2000	6/29/2016	38
Lakeside Wellness Center	Omaha, NE	—	—	10,177	190	—	10,367	10,367	(397	)	2000	6/29/2016	39
McAuley Center	Omaha, NE	—	1,427	17,020	3	1,427	17,023	18,450	(927	)	1988	6/29/2016	30
Memorial Health Center	Grand Island, NE	—	—	33,967	146	—	34,113	34,113	(1,517	)	1955	6/29/2016	35
Missionary Ridge MOB	Chattanooga, TN	—	—	7,223	1,205	—	8,428	8,428	(1,089	)	1976	6/29/2016	10
Pilot Medical Center	Birmingham, AL	—	1,419	14,528	6	1,419	14,534	15,953	(666	)	2005	6/29/2016	35
St. Joseph Medical Clinic	Tacoma, WA	—	—	16,427	32	—	16,459	16,459	(828	)	1991	6/30/2016	30
Woodlands Medical Arts Center	The Woodlands, TX	—	—	19,168	198	—	19,366	19,366	(867	)	2001	6/30/2016	35
FESC MOB	Tacoma, WA	—	—	12,702	181	—	12,883	12,883	(961	)	1980	6/30/2016	22
Prairie Care MOB	Maplewood, MN	—	525	3,099	—	525	3,099	3,624	(113	)	2016	7/6/2016	45
Springwoods MOB	Spring, TX	—	3,821	14,830	3,492	3,821	18,322	22,143	(549	)	2015	7/21/2016	44
Unity - ASC, Imaging & MOB	West Lafayette, IN	—	960	9,991	—	960	9,991	10,951	(429	)	2001	8/8/2016	35
Unity - Medical Pavilion	West Lafayette, IN	—	1,070	12,454	—	1,070	12,454	13,524	(535	)	2001	8/8/2016	35
Unity - Faith, Hope & Love	West Lafayette, IN	—	280	1,862	—	280	1,862	2,142	(80	)	2001	8/8/2016	35
Unity - Immediate Care & OCC	West Lafayette, IN	—	300	1,833	—	300	1,833	2,133	(75	)	2004	8/8/2016	37
Medical Village at Maitland	Orlando, FL	—	2,393	18,543	—	2,393	18,543	20,936	(613	)	2006	8/23/2016	44
Tri-State Orthopaedics MOB	Evansville, IN	—	1,580	14,162	—	1,580	14,162	15,742	(553	)	2004	8/30/2016	37
Maury Regional Healthcare MOB	Spring Hill, TN	—	—	15,619	—	—	15,619	15,619	(503	)	2012	9/30/2016	41
Spring Ridge Medical Center	Wyomissing, PA	—	28	4,943	—	28	4,943	4,971	(177	)	2002	9/30/2016	37
Doctors Community Hospital POB	Lanham, MD	—	—	23,034	—	—	23,034	23,034	(602	)	2009	9/30/2016	48
Gig Harbor Medical Pavilion	Gig Harbor, WA	—	—	4,791	1,768	—	6,559	6,559	(271	)	1991	9/30/2016	30
Midlands One Professional Center	Papillion, NE	—	—	14,922	—	—	14,922	14,922	(507	)	2010	9/30/2016	37
N.W. Michigan Surgery Center      Units #1, #2, & #4	Traverse City, MI	—	2,748	30,005	—	2,748	30,005	32,753	(909	)	2004	10/28/2016	40
Northeast Medical Center	Fayetteville, NY	—	4,011	25,564	929	4,011	26,493	30,504	(1,045	)	1998	11/23/2016	33
North Medical Center	Liverpool, NY	—	1,337	18,680	844	1,337	19,524	20,861	(673	)	1989	11/23/2016	35
Cincinnati Eye Institute	Cincinnati, OH	—	2,050	32,546	—	2,050	32,546	34,596	(1,133	)	1985	11/23/2016	35
HonorHealth - Scottsdale MOB	Scottsdale, AZ	—	—	4,288	—	—	4,288	4,288	(135	)	2000	12/2/2016	45
Fox Valley Hematology & Oncology	Appleton, WI	—	1,590	26,666	—	1,590	26,666	28,256	(691	)	2015	12/8/2016	44
Gastrointestinal Associates MOB	Powell, TN	—	937	3,214	—	937	3,214	4,151	(129	)	1965	12/9/2016	30
Northern Vision Eye Center	Traverse City, MI	—	490	2,132	—	490	2,132	2,622	(71	)	2006	12/15/2016	35
Flower Mound MOB	Flower Mound, TX	—	1,945	8,312	—	1,945	8,312	10,257	(228	)	2011	12/16/2016	43
Carrollton MOB	Flower Mound, TX	—	2,183	10,461	—	2,183	10,461	12,644	(306	)	2002	12/16/2016	40
HonorHealth IRF	Scottsdale, AZ	10,000	—	19,331	—	—	19,331	19,331	(481	)	2000	12/22/2016	42
Orthopedic Associates	Flower Mound, TX	—	2,915	12,791	—	2,915	12,791	15,706	(319	)	2011	1/5/2017	43
Medical Arts Center at Hartford	Plainville, CT	—	1,499	24,627	—	1,499	24,627	26,126	(594	)	2015	1/11/2017	44
CareMount - Lake Katrine MOB	Lake Katrine, NY	26,039	1,941	27,434	—	1,941	27,434	29,375	(636	)	2013	2/14/2017	42
CareMount - Rhinebeck MOB	Rhinebeck, NY	—	869	12,220	—	869	12,220	13,089	(296	)	1965	2/14/2017	41
Monterey Medical Center - MOB	Stuart, FL	—	2,292	13,376	5	2,292	13,381	15,673	(323	)	2003	3/7/2017	37
Creighton University Medical Center	Omaha, NE	—	—	32,487	—	—	32,487	32,487	(575	)	2017	3/28/2017	49
Strictly Pediatrics Specialty Center	Austin, TX	—	4,457	62,527	39	4,457	62,566	67,023	(1,222	)	2006	3/31/2017	40
MedStar Stephen's Crossing	Brandywine, MD	—	1,975	14,810	—	1,975	14,810	16,785	(190	)	2015	6/16/2017	43
CHI Health Clinic Building	Omaha, NE	—	—	50,177	—	—	50,177	50,177	(501	)	2017	6/29/2017	49
St Gabriel's Centracare	Little Falls, MN	—	—	4,944	—	—	4,944	4,944	(110	)	1990	6/29/2017	25
Craven-Hagan Clinic	Williston, ND	—	—	8,739	—	—	8,739	8,739	(123	)	1984	6/29/2017	40
Chattanooga Heart Institute	Chattanooga, TN	—	—	18,639	—	—	18,639	18,639	(257	)	1993	6/29/2017	37
CHI St. Vincent Mercy Heart & Vascular Center	Hot Springs, AR	—	—	11,688	—	—	11,688	11,688	(145	)	1998	6/29/2017	45
South Campus MOB	Hot Springs, AR	—	—	13,369	—	—	13,369	13,369	(171	)	2009	6/29/2017	42
CHI St. Vincent Mercy Cancer Center	Hot Springs, AR	—	—	5,090	—	—	5,090	5,090	(72	)	2001	6/29/2017	39
St. Joseph Professional Office Building	Bryan, TX	—	—	11,169	—	—	11,169	11,169	(129	)	1996	6/29/2017	46
St. Vincent Carmel Women's Center	Carmel, IN	—	—	31,720	—	—	31,720	31,720	(339	)	2014	6/29/2017	48
St. Vincent Fishers Medical Center	Fishers, IN	44,000	—	62,870	—	—	62,870	62,870	(749	)	2008	6/29/2017	45
Baylor Charles A. Sammons Cancer Center	Dallas, TX	—	—	256,886	—	—	256,886	256,886	(2,994	)	2011	6/30/2017	43
Orthopedic & Sports Institute of the Fox Valley	Appleton, WI	—	2,003	26,394	100	2,003	26,494	28,497	(406	)	2005	6/30/2017	40
Clearview Cancer Institute	Huntsville, AL	—	2,736	43,220	—	2,736	43,220	45,956	(554	)	2006	8/4/2017	34
Northside Cherokee/Town Lake MOB	Atlanta, GA	—	—	30,627	—	—	30,627	30,627	(312	)	2013	8/15/2017	46
HonorHealth Mesa MOB	Mesa, AZ	—	362	3,059	—	362	3,059	3,421	(32	)	2013	8/15/2017	43
Little Falls Orthopedics	Little Falls, MN	—	246	1,977	—	246	1,977	2,223	(39	)	1999	8/24/2017	28

				Initial Cost to Company						Gross Amount at Which Carried as of Close of Period
Description	Location	Encumbrances		Land		Buildings and Improvements		Cost Capitalized Subsequent to Acquisitions		Land		Buildings and Improvements		Total		Accumulated Depreciation			Year Built	Date  Acquired	Life on Which Building Depreciation in Income Statement is Computed
Little Falls Dialysis Center	Little Falls, MN	—		—		2,885		—		—		2,885		2,885		(77		)	1959	8/24/2017	15
Immanuel One Professional Center	Omaha, NE	—		—		16,598		—		—		16,598		16,598		(210		)	1993	8/24/2017	35
SJRHC Cancer Center	Bryan, TX	—		—		5,065		—		—		5,065		5,065		(47		)	1997	8/24/2017	40
St. Vincent Women's Center	Hot Springs, AR	—		—		4,789		—		—		4,789		4,789		(41		)	2001	8/31/2017	40
Legends Park MOB & ASC	Midland, TX	—		1,658		24,178		—		1,658		24,178		25,836		(194		)	2003	9/27/2017	44
Franklin MOB & ASC	Franklin, TN	—		1,001		7,902		—		1,001		7,902		8,903		(49		)	2014	10/12/2017	42
Eagle Point MOB	Lake Elmo, MN	—		1,011		9,009		—		1,011		9,009		10,020		(36		)	2015	10/31/2017	48
Edina East MOB	Edina, MN	—		2,360		4,135		—		2,360		4,135		6,495		(26		)	1962	10/31/2017	30
Northside MOB - Center Pointe	Atlanta, GA	—		—		119,467		—		—		119,467		119,467		(323		)	2009	11/10/2017	31
Gwinnett 500 Building	Lawrenceville, GA	—		—		22,753		—		—		22,753		22,753		(90		)	1995	11/17/2017	45
Hudgens Professional Building	Duluth, GA	—		—		21,779		—		—		21,779		21,779		(98		)	1994	11/17/2017	40
St. Vincent Building	Indianapolis, IN	—		5,854		42,382		—		5,854		42,382		48,236		(182		)	2007	11/17/2017	45
Gwinnett Physicians Center	Lawrenceville, GA	17,609		—		48,304		—		—		48,304		48,304		(92		)	2010	12/1/2017	47
Apple Valley Medical Center	Apple Valley, MN	—		1,587		14,929		—		1,587		14,929		16,516		(40		)	1974	12/18/2017	33
Desert Cove MOB (57% Interest)	Scottsdale, AZ	—		1,689		5,207		—		1,689		5,207		6,896		(12		)	1991	12/18/2017	38
Westgate MOB	Glendale, AZ	—		—		13,379		—		—		13,379		13,379		(27		)	2016	12/21/2017	45
		$	186,679	$	217,808	$	3,518,259	$	73,655	$	217,695	$	3,591,914	$	3,809,609	$	(201,527	)

The aggregate cost for federal income tax purposes of the real estate as of December 31, 2017 is $3.83 billion, with accumulated tax depreciation of $175.8 million. The cost, net of accumulated depreciation, is approximately $3.65 billion (unaudited).

The cost capitalized subsequent to acquisitions is net of dispositions.

The changes in total real estate for the years ended December 31, 2017, 2016, and 2015 are as follows (in thousands): 

	Year Ended December 31,
	2017			2016		2015
Balance as of the beginning of the year	$	2,606,536		$	1,424,894	$	729,034
Acquisitions	1,207,098			1,170,593		695,693
Additions	12,243			11,049		4,440
Impairment	(965		)	—		—
Dispositions	(15,303		)	—		(4,273		)
Balance as of the end of the year	$	3,809,609		$	2,606,536	$	1,424,894

The changes in accumulated depreciation for the years ended December 31, 2017, 2016, and 2015 are as follows (in thousands):

	Year Ended December 31,
	2017			2016		2015
Balance as of the beginning of the year	$	118,609		$	61,242	$	32,772
Depreciation	87,531			57,367		29,958
Dispositions	(4,613		)	—		(1,488		)
Balance as of the end of the year	$	201,527		$	118,609	$	61,242

113

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A. CONTROLS AND PROCEDURES

Physicians Realty Trust

Evaluation of Disclosure Controls and Procedures.

The Trust’s management, with the participation of its Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Trust’s disclosure controls and procedures (as defined in Rules 13a- 15(e) and 15d- 15(e) under the Exchange Act), as of the end of the period covered by this report. Based on such evaluation, the Trust’s Chief Executive Officer and Chief Financial Officer concluded that as of December 31, 2017, the Trust’s disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information it is required to disclose in reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to the Trust’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting.

There have been no changes in the Trust’s system of internal control over financial reporting during the quarter ended December 31, 2017, that have materially affected, or are reasonably likely to materially affect, the Trust’s internal control over financial reporting.

Management’s Report on Internal Control over Financial Reporting.

The Trust’s management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Management conducted an assessment of the effectiveness of the Trust’s internal control over financial reporting based on the criteria set forth in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on the assessment, management has concluded that the Trust’s internal control over financial reporting was effective as of December 31, 2017 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP.

The effectiveness of the Trust’s internal control over financial reporting as of December 31, 2017 has been audited by Ernst & Young LLP (“EY”), an independent registered public accounting firm, as stated in their report included in Part II, Item 8 of this Annual Report on Form 10-K.

Limitations on Effectiveness of Controls and Procedures.

In designing and evaluating the disclosure controls and procedures and the Trust’s internal control over financial reporting, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures and the Trust’s internal control over financial reporting must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Physicians Realty L.P.

Evaluation of Disclosure Controls and Procedures.

The Operating Partnership’s management, with the participation of the Chief Executive Officer and Chief Financial Officer of the Operating Partnership’s general partner, has evaluated the effectiveness of the Operating Partnership’s disclosure controls and procedures (as defined in Rules 13a- 15(e) and 15d- 15(e) under the Exchange Act), as of the end of the period covered by this report. Based on such evaluation, the Chief Executive Officer and Chief Financial Officer of the Operating Partnership’s general partner concluded that as of December 31, 2017, the Operating Partnership’s disclosure controls and

114

procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information it is required to disclose in reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer of the Operating Partnership’s general partner, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting.

There have been no changes in the Operating Partnership’s system of internal control over financial reporting during the quarter ended December 31, 2017, that have materially affected, or are reasonably likely to materially affect, the Operating Partnership’s internal control over financial reporting.

Management’s Report on Internal Control over Financial Reporting.

The Operating Partnership’s management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Management conducted an assessment of the effectiveness of the Operating Partnership’s internal control over financial reporting based on the criteria set forth in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on the assessment, management has concluded that the Operating Partnership’s internal control over financial reporting was effective as of December 31, 2017 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP.

Limitations on Effectiveness of Controls and Procedures.

In designing and evaluating the disclosure controls and procedures and the Operating Partnership’s internal control over financial reporting, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures and the Operating Partnership’s internal control over financial reporting must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

ITEM 9B. OTHER INFORMATION

None.

115

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Incorporated herein by reference are “Proposal 1 - Election of Trustees”, “Section 16(a) Beneficial Ownership Reporting Compliance”, “Corporate Governance Matters”, “Executive Officers”, and “Report of the Audit Committee of the Board of Trustees” to be included in the Trust’s 2018 Proxy Statement, which will be filed with the SEC within 120 days after the end of its fiscal year ended December 31, 2017.

Code of Business Conduct and Ethics

Information regarding our Code of Business Conduct and Ethics is provided in “Part I., Item 1. Business - Available Information” and is incorporated herein by reference. 

ITEM 11. EXECUTIVE COMPENSATION

Incorporated herein by reference are “Executive Compensation”, “2017 Non-Employee Trustee Compensation”, “Compensation Committee Interlocks and Insider Participation”, and “Compensation Committee Report” to be included in the Trust’s 2018 Proxy Statement, which will be filed with the SEC within 120 days after the end of its fiscal year ended December 31, 2017.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

Incorporated herein by reference are “Security Ownership of Certain Beneficial Owners and Management” and “Equity Compensation Plan Information” to be included in the Trust’s 2018 Proxy Statement, which will be filed with the SEC within 120 days after the end of its fiscal year ended December 31, 2017.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE

Incorporated herein by reference are “Certain Relationships and Related Transactions” and “Trustee Independence” to be included in the Trust’s 2018 Proxy Statement, which will be filed with the SEC within 120 days after the end of its fiscal year ended December 31, 2017.

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

Incorporated herein by reference is “Proposal 2 - Ratification of Independent Registered Public Accounting Firm” to be included in the Trust’s 2018 Proxy Statement, which will be filed with the SEC within 120 days after the end of its fiscal year ended December 31, 2017.

116

PART IV

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

(a)The following documents are filed as part of this report:

(1)Financial Statements:

	Page
Reports of Independent Registered Public Accounting Firm
Physicians Realty Trust	66
Physicians Realty L.P.	67
Report of Independent Registered Public Accounting Firm on Internal Control Over Financial Reporting
Physicians Realty Trust	68
Financial Statements of Physicians Realty Trust
Consolidated Balance Sheets at December 31, 2017 and 2016	69
Consolidated Statements of Income for the Years Ended December 31, 2017, 2016, and 2015	70
Consolidated Statements of Comprehensive Income for the Years Ended December 31, 2017, 2016, and 2015	71
Consolidated Statements of Equity for the Years Ended December 31, 2017, 2016, and 2015	72
Consolidated Statements of Cash Flows for the Years Ended December 31, 2017, 2016, and 2015	73
Financial Statements of Physicians Realty L.P.
Consolidated Balance Sheets at December 31, 2017 and 2016	74
Consolidated Statements of Income for the Years Ended December 31, 2017, 2016, and 2015	75
Consolidated Statements of Comprehensive Income for the Years Ended December 31, 2017, 2016, and 2015	76
Consolidated Statements of Changes in Capital for the Years Ended December 31, 2017, 2016, and 2015	77
Consolidated Statements of Cash Flows for the Years Ended December 31, 2017, 2016, and 2015	78
Notes for Physicians Realty Trust and Physicians Realty L.P.
Notes to Consolidated Financial Statements	79

(2)Financial Statement Schedules:

Schedule III – Real Estate and Accumulated Depreciation 109

All other schedules for which provision is made in the applicable accounting regulations of the Securities and Exchange Commission are omitted because they are not required under the related instructions or are not applicable, or because the required information is shown in the consolidated financial statements or notes thereto.

(3)Exhibits:

See the Exhibit Index immediately following the signature page of this report on Form 10-K.

117

ITEM 16. FORM 10-K SUMMARY

None.

118

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		PHYSICIANS REALTY TRUST
Dated:	March 1, 2018	/s/ John T. Thomas
		John T. Thomas
		Chief Executive Officer and President
		(Principal Executive Officer)

Power of Attorney

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints John T. Thomas and Jeffrey N. Theiler and each of them severally, his or her true and lawful attorney-in-fact with power of substitution and resubstitution to sign in his or her name, place and stead, in any and all capacities, to do any and all things and execute any and all instruments that such attorney may deem necessary or advisable under the Securities Exchange Act of 1934 and any rules, regulations and requirements of the Securities and Exchange Commission in connection with this Annual Report on Form 10-K and any and all amendments hereto, as fully and for all intents and purposes as he or she might do or could do in person, and hereby ratifies and confirms all said attorneys-in-fact and agents, each acting alone, and his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

119

Signature	Title	Date
/s/ JOHN T. THOMAS	Chief Executive Officer and	March 1, 2018
John T. Thomas	President and Trustee (Principal Executive Officer)
/s/ JEFFREY N. THEILER	Executive Vice President and	March 1, 2018
Jeffrey N. Theiler	Chief Financial Officer (Principal Financial Officer)
/s/ JOHN W. LUCEY	Senior Vice President - Chief Accounting and	March 1, 2018
John W. Lucey	Administrative Officer (Principal Accounting Officer)
/s/ STANTON D. ANDERSON	Trustee	March 1, 2018
Stanton D. Anderson
/s/ MARK A. BAUMGARTNER	Trustee	March 1, 2018
Mark A. Baumgartner
/s/ ALBERT C. BLACK, JR.	Trustee	March 1, 2018
Albert C. Black, Jr.
/s/ WILLIAM A. EBINGER, M.D.	Trustee	March 1, 2018
William A. Ebinger, M.D.
/s/ TOMMY G. THOMPSON	Chairman	March 1, 2018
Tommy G. Thompson
/s/ RICHARD A. WEISS	Trustee	March 1, 2018
Richard A. Weiss
/s/ PAMELA J. KESSLER	Trustee	March 1, 2018
Pamela J. Kessler

120

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		PHYSICIANS REALTY L.P. by: Physicians Realty Trust, its general partner
Dated:	March 1, 2018	/s/ John T. Thomas
		John T. Thomas
		Chief Executive Officer and President
		(Principal Executive Officer)

Power of Attorney

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints John T. Thomas and Jeffrey N. Theiler and each of them severally, his or her true and lawful attorney-in-fact with power of substitution and resubstitution to sign in his or her name, place and stead, in any and all capacities, to do any and all things and execute any and all instruments that such attorney may deem necessary or advisable under the Securities Exchange Act of 1934 and any rules, regulations and requirements of the Securities and Exchange Commission in connection with this Annual Report on Form 10-K and any and all amendments hereto, as fully and for all intents and purposes as he or she might do or could do in person, and hereby ratifies and confirms all said attorneys-in-fact and agents, each acting alone, and his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

121

Signature	Title	Date
/s/ JOHN T. THOMAS	Chief Executive Officer and	March 1, 2018
John T. Thomas	President and Trustee (Principal Executive Officer) of Physicians Realty Trust, the general partner of Physicians Realty L.P.
/s/ JEFFREY N. THEILER	Executive Vice President and	March 1, 2018
Jeffrey N. Theiler	Chief Financial Officer (Principal Financial Officer) of Physicians Realty Trust, the general partner of Physicians Realty L.P.
/s/ JOHN W. LUCEY	Senior Vice President - Chief Accounting and	March 1, 2018
John W. Lucey	Administrative Officer (Principal Accounting Officer) of Physicians Realty Trust, the general partner of Physicians Realty L.P.
/s/ STANTON D. ANDERSON	Trustee of Physicians Realty Trust, the general partner of Physicians Realty L.P.	March 1, 2018
Stanton D. Anderson
/s/ MARK A. BAUMGARTNER	Trustee of Physicians Realty Trust, the general partner of Physicians Realty L.P.	March 1, 2018
Mark A. Baumgartner
/s/ ALBERT C. BLACK, JR.	Trustee of Physicians Realty Trust, the general partner of Physicians Realty L.P.	March 1, 2018
Albert C. Black, Jr.
/s/ WILLIAM A. EBINGER, M.D.	Trustee of Physicians Realty Trust, the general partner of Physicians Realty L.P.	March 1, 2018
William A. Ebinger, M.D.
/s/ TOMMY G. THOMPSON	Chairman of the Board of Trustees of Physicians Realty Trust, the general partner of Physicians Realty L.P.	March 1, 2018
Tommy G. Thompson
/s/ RICHARD A. WEISS	Trustee of Physicians Realty Trust, the general partner of Physicians Realty L.P.	March 1, 2018
Richard A. Weiss
/s/ PAMELA J. KESSLER	Trustee of Physicians Realty Trust, the general partner of Physicians Realty L.P.	March 1, 2018
Pamela J. Kessler

122

EXHIBIT INDEX

Exhibit No.		Title
3.1	(1)	Articles of Amendment and Restatement of Physicians Realty Trust
3.2	(2)	Bylaws of Physicians Realty Trust, as amended through February 22, 2017
3.3	(3)	Certificate of Limited Partnership of Physicians Realty L.P.
4.1	(1)	Form of Certificate of Common Shares of Physicians Realty Trust
4.2	(4)	Senior Indenture, dated as of March 7, 2017, among Physicians Realty L.P., Physicians Realty Trust and U.S. Bank National Association, as trustee
4.3	(4)	First Supplemental Indenture, dated as of March 7, 2017, among Physicians Realty L.P., Physicians Realty Trust and U.S. Bank National Association, as trustee
4.4	(4)	Form of 4.300% Senior Note due 2027 and guarantee thereof (included in Exhibit 4.3)
4.5	(5)	Second Supplemental Indenture, dated as of December 1, 2017, among Physicians Realty L.P., Physicians Realty Trust and U.S. Bank National Association, as trustee
4.6	(5)	Form of 3.950% Senior Notes due 2028 and guarantee thereof (included in Exhibit 4.5)
10.1	(6)	Second Amended and Restated Agreement of Limited Partnership of Physicians Realty L.P., dated February 5, 2015
10.2	(7)	Form of Restricted Shares Award Agreement (Time Vesting)**
10.3	(1)	Form of Indemnification Agreement between Physicians Realty Trust and its trustees and officers
10.3	(8)	Employment Agreement dated as of February 28, 2018, between the Trust and John T. Thomas**
10.4	(8)	Employment Agreement dated as of February 28, 2018 between the Trust and Jeffrey N. Theiler**
10.5	(8)	Employment Agreement dated as of February 28, 2018 between the Trust and John W. Lucey**
10.6	(8)	Employment Agreement dated as of February 28, 2018 between the Trust and Mark D. Theine**
10.7	(8)	Employment Agreement dated as of February 28, 2018 between the Trust and Del Mar Deeni Taylor**
10.8	(8)	Employment Agreement dated as of February 28, 2018, between the Trust and Bradley D. Page**
10.9	(8)	Employment Agreement dated as of February 28, 2018 between the Trust and Dan Klein* **
10.10	(9)	Physicians Realty Trust Incentive Bonus Plan**
10.12	(9)	Form of Restricted Share Award Agreement - Executive (Time Vesting)**
10.13	(9)	Form of Restricted Share Award Agreement - Trustees (Time Vesting)**
10.14	(9)	Form of Restricted Share Unit Award Agreement (Performance Units)**
10.15	(10)	Physicians Realty Trust 2013 Equity Incentive Plan, as amended effective August 7, 2014**
10.16	(11)	Form of Restricted Share Award Agreement - Executive (Time Vesting)**
10.17	(11)	Form of Restricted Share Unit Award Agreement - Executive (Performance Vesting)**
10.18	(11)	Form of Restricted Share Unit Award Agreement - Trustees (Time Vesting)**
10.19	(8)	Form of Restricted Share Unit Award Agreement (Performance Units)
10.20	(12)	Amended and Restated Credit Agreement, dated June 10, 2016, among Physicians Realty L.P., Physicians Realty Trust, KeyBank National Association, KeyBanc Capital Markets Inc., BMO Capital Markets, Citizens Bank, N.A., and the lenders party thereto.
10.21	(13)	Physicians Realty Trust 2015 Employee Stock Purchase Plan**
10.22	(14)	Note Purchase and Guarantee Agreement, dated as of January 7, 2016, among the Operating Partnership, the Trust and each of the purchasers identified therein
10.23	(14)	Form of 4.03% Senior Notes, Series A, due January 7, 2023 (included in Exhibit 10.22)
10.24	(14)	Form of 4.43% Senior Notes, Series B, due January 7, 2026 (included in Exhibit 10.22)
10.25	(14)	Form of 4.57% Senior Notes, Series C, due January 7, 2028 (included in Exhibit 10.22)
10.26	(14)	Form of 4.74% Senior Notes, Series D, due January 7, 2031 (included in Exhibit 10.22)
10.27	(15)	Note Purchase and Guarantee Agreement, dated as of August 11, 2016, among the Operating Partnership, the Trust and each of the purchasers identified therein
10.28	(15)	Form of 4.09% Senior Notes, Series A, due August 11, 2025 (included in Exhibit 10.27)
10.29	(15)	Form of 4.18% Senior Notes, Series B, due August 11, 2026 (included in Exhibit 10.27)
10.30	(15)	Form of 4.24% Senior Notes, Series C, due August 11, 2027 (included in Exhibit 10.27)
10.31	(15)	First Amendment to the Note Purchase and Guarantee Agreement, dated as of August 11, 2016, among the Operating Partnership, the Trust and the Required Noteholders
10.32	(16)	Contribution Agreement, dated as of February 5, 2015, by and among United Properties Investment, LLC, a Minnesota limited liability company, Minnetonka Medical Building, LLC, a Minnesota limited liability company and DOC-15450 State Highway 7 MOB, LLC, a Wisconsin limited liability company

123

Exhibit No.		Title
10.33	(17)	Purchase and Sale Agreement (Building Sale / Ground Lease Form), dated as of April 5, 2016, by and between the Seller Entities identified on Exhibit A thereto and Physicians Realty L.P.
10.34	(17)	Purchase and Sale Agreement (Fee Simple Form), dated as of April 5, 2016, by and between the Seller Entities identified on Exhibit A thereto and Physicians Realty L.P.
10.35	(18)	Real Estate Purchase and Sale Agreement, dated June 27, 2017, between BCC Cancer Center Venture, L.P. and DOC-3410 Worth St. MOB, LLC
12.1		Statement re Computation of Ratio of Earnings to Fixed Charges*
12.2		Statement re Computation of Ratio of Earnings to Fixed Charges and Preferred Unit Distributions*
21.1		List of Subsidiaries of the Registrant*
23.1		Consent of Ernst & Young LLP for Physicians Realty Trust*
23.2		Consent of Ernst & Young LLP for Physicians Realty L.P.*
24.1		Power of Attorney (included on signature pages)*
31.1		Certification of John T. Thomas, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Physicians Realty Trust*
31.2		Certification of Jeffrey N. Theiler, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Physicians Realty Trust*
31.3		Certification of John T. Thomas, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Physicians Realty L.P.*
31.4		Certification of Jeffrey N. Theiler, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Physicians Realty L.P.*
32.1		Certification of John T. Thomas and Jeffrey N. Theiler, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) for Physicians Realty Trust*
32.2		Certification of John T. Thomas and Jeffrey N. Theiler, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) for Physicians Realty L.P.*
101.INS		XBRL Instance Document(†)
101.SCH		XBRL Extension Schema Document(†)
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document(†)
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document(†)
101.LAB		XBRL Taxonomy Extension Label Linkbase Document(†)
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document(†)

*    Filed herewith

**     Indicates a management contract or compensatory plan or arrangement.

† Users of this data are advised pursuant to Rule 406T of Regulation S-T that this interactive data file is deemed not filed or part of a registration statement for purposes of Section 11 or 12 of the Securities Act, is deemed not filed for purposes of Section 18 of the Exchange Act, and otherwise is not subject to liability under these sections.

(1) Incorporated by reference to Amendment No. 2 to the Registrant’s Registration Statement on Form S-11 filed with the SEC on June 14, 2013 (File No. 333-188862).

(2) Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the SEC on February 24, 2017 (File No. 001-36007).

(3) Incorporated by reference to the Registrant’s Registration Statement on Form S-3 filed with the SEC on June 17, 2015 (File No. 333-205034).

(4) Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the SEC on March 7, 2017 (File No. 001-36007).

(5) Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the SEC on December 1, 2017 (File No. 001-36007).

(6) Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the SEC on February 6, 2015.

(7) Incorporated by reference to Amendment No. 3 to the Registrant’s Registration Statement on Form S-11 filed with the SEC on June 20, 2013 (File No. 333-188862).

124

(8) Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the SEC on February 28, 2018 (File No. 001-36007).

(9) Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the SEC on May 7, 2014 (File No. 001-36007).

(10) Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the SEC on August 7, 2014 (File No. 001-36007).

(11) Incorporated by reference to the Registrant’s Annual Report on Form 10-K filed with the SEC on March 12, 2015 (File No. 001-36007).

(12) Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the SEC on June 13, 2016 (File No. 001-36007).

(13) Incorporated by reference to the Registrant’s Quarterly Report on Form 10-Q filed with the SEC on August 10, 2015 (File No. 001-36007).

(14) Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the SEC on January 12, 2016 (File No. 001-36007).

(15) Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the SEC on August 11, 2016 (File No. 001-36007).

(16) Incorporated by reference to the Registrant’s Annual Report on Form 10-K filed with the SEC on March 12, 2015 (File No. 001-36007).

(17) Incorporated by reference to the Registrant’s Quarterly Report on Form 10-Q filed with the SEC on May 6, 2016 (File No. 001-36007).

(18) Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the SEC on July 7, 2017 (File No. 001-36007).

125

EX-12.1

Exhibit 12.1

Computation of Ratio of Earnings to Fixed Charges

Physicians Realty Trust

(amounts in thousands)

	Years Ended December 31,
	2017			2016			2015			2014			2013
Net income (loss)	$	39,773		$	31,522		$	12,741		$	(4,418	)	$	(2,636	)
Adjustment for equity investees	(183		)	(115		)	(104		)	(95		)	—
Net income (loss) before adjustment for equity investees	39,590			31,407			12,637			(4,513		)	(2,636		)
Plus fixed charges:
Interest expense	$	44,847		$	21,540		$	9,263		$	5,988		$	3,785
Amortization and write-off of debt issuance costs, amortization of bond discount, and capitalized interest	2,161			2,324			1,373			919			510
Estimated interest portion of rental expense	652			634			430			361			6
Fixed charges	47,660			24,498			11,066			7,268			4,301
Earnings	$	87,250		$	55,905		$	23,703		$	2,755		$	1,665
Ratio of Earnings to Fixed Charges (1)	1.83		x	2.28		x	2.14		x	—			—

(1) The computation of ratio of earnings to fixed charges indicates that earnings were inadequate to cover fixed charges on the basis of our historical financial statements by approximately $4.5 million and $2.6 million for the years ended December 31, 2014 and 2013, respectively.

EX-12.2

Exhibit 12.2

Computation of Ratio of Earnings to Combined Fixed Charges and Preferred Unit Distributions

Physicians Realty L.P.

(amounts in thousands)

				Years Ended December 31,
	2017			2016			2015			2014			2013
Net income (loss)	$	39,773		$	31,522		$	12,741		$	(4,418	)	$	(2,636	)
Adjustment for equity investees	(183		)	(115		)	(104		)	(95		)	—
Net income (loss) before adjustment for equity investees	39,590			31,407			12,637			(4,513		)	(2,636		)
Plus fixed charges:
Interest expense	$	44,847		$	21,540		$	9,263		$	5,988		$	3,785
Amortization and write-off of debt issuance costs, amortization of bond discount, and capitalized interest	2,161			2,324			1,373			919			510
Estimated interest portion of rental expense	652			634			430			361			6
Preferred distributions	731			1,857			1,189			—			—
Fixed charges and preferred unit distributions	48,391			26,355			12,255			7,268			4,301
Earnings	$	87,981		$	57,762		$	24,892		$	2,755		$	1,665
Ratio of Earnings to Fixed Charges and Preferred Unit Distributions (1)	1.82		x	2.19		x	2.03		x	—			—

(1) The computation of ratio of earnings to fixed charges and preferred unit distributions indicates that earnings were inadequate to cover fixed charges on the basis of our historical financial statements by approximately $4.5 million and $2.6 million for the years ended December 31, 2014 and 2013, respectively.

EX-21.1

Exhibit 21.1

LIST OF SUBSIDIARIES

(as of December 31, 2017)

ENTITY	STATE OF ORIGIN
Physicians Realty L.P.	Delaware
Ziegler-Florida 4, LLC	Wisconsin
Ziegler-Michigan 5, LLC	Wisconsin
Ziegler-Georgia 6, LLC	Wisconsin
Ziegler-Michigan 6, LLC	Wisconsin
Ziegler-Georgia 7, LLC	Wisconsin
Ziegler-Texas 8, LLC	Wisconsin
Ziegler-El Paso 8 Limited Partnership	Wisconsin
Ziegler-Ohio 9, LLC	Wisconsin
Ziegler-Illinois 12, LLC	Wisconsin
Ziegler-Michigan 12, LLC	Wisconsin
Ziegler-Tennessee 14, LLC	Wisconsin
Ziegler-Maine 15, LLC	Wisconsin
Ziegler-Wisconsin 16, LLC	Wisconsin
Ziegler-Georgia 17, LLC	Wisconsin
Ziegler-Illinois 18, LLC	Wisconsin
Ziegler-Ohio 19, LLC	Wisconsin
Ziegler-Georgia 20, LLC	Wisconsin
Ziegler-Georgia 21, LLC	Wisconsin
Ziegler-Arizona 23, LLC	Wisconsin
Ziegler-Wisconsin 24, LLC	Wisconsin
Sandwich Development Partners, LLC	Illinois
Remington Development Partners, LLC	Illinois
DOC-FSH El Paso Medical Center, LLC	Wisconsin
DOC-FSH El Paso Medical Center Partners, LLC	Wisconsin
DOC-LifeCare Plano LTACH	Wisconsin
DOC-ELFP Atlanta MOBs, LLC	Wisconsin
DOC-CCSC Crescent City Surgical Centre, LLC	Wisconsin
Crescent City Surgical Centre Facility, L.L.C.	Louisiana
DOC-MP TXAZ, LLC	Wisconsin
DOC-Greymark HQ OKC MOB, LLC	Wisconsin
DOC-SSH Slidell Surgical Center, LLC	Wisconsin
DOC-Cornerstone Pensacola MOB, LLC	Wisconsin
DOC-CONS Columbus MOB, LLC	Wisconsin
Eastwind MOB, LLC	Ohio
DOC-CCSC Crescent City Land, LLC	Wisconsin
DOC-Great Falls MT ASC, LLC	Wisconsin
DOC-FSH San Antonio Hospital, LLC	Wisconsin
DOC-FSH San Antonio MOB, LLC	Wisconsin
DOC-PDMC Atlanta, LLC	Wisconsin
DOC-21st Century Sarasota, LLC	Wisconsin
DOC-LifeCare Pittsburgh LTACH, LLC	Wisconsin
DOC-LifeCare Ft. Worth LTACH, LLC	Wisconsin
DOC-Pinnacle Harrisburg MOBs, LLC	Wisconsin
DOC-SBO MOB, LLC	Wisconsin
DOC-Grenada MOB, LLC	Wisconsin
DOC-Carmel MOB, LLC (Ground Lease)	Wisconsin

ENTITY	STATE OF ORIGIN
DOC-MSMOC Jackson MOB, LLC	Wisconsin
DOC-Premier Landmark MOBs, LLC	Wisconsin
DOC-PMP Monroe MOB, LLC	Wisconsin
DOC-Summit Bloomington MOB, LLC	Wisconsin
DOC-Renaissance Oshkosh MOB, LLC	Wisconsin
DOC-Baylor Mansfield ASC, LLC	Wisconsin
DOC-SIM Monroe ASC, LLC	Wisconsin
DOC-Oaks Lady Lake MOB, LLC	Wisconsin
DOC-CRMC Carlisle, MOB LLC	Wisconsin
DOC-WSUPG Troy MOB, LLC	Wisconsin
DOC-6138 Kennerly Road MOB, LLC	Delaware
DOC-Indiana 7 MOB, LLC	Wisconsin
DOC-2625 Market Place MOB, LLC	Wisconsin
DOC-4518 Union Deposit MOB, LLC	Wisconsin
DOC-4520 Union Deposit MOB, LLC	Wisconsin
DOC-240 Grandview Avenue MOB, LLC	Wisconsin
DOC-32 Northeast Drive MOB, LLC	Wisconsin
DOC-1755 Curie Drive MOB, LLC	Wisconsin
DOC-3100 Lee Trevino Drive MOB, LLC	Wisconsin
DOC-9999 Kenworthy Street MOB, LLC	Wisconsin
DOC-9085 Southern Street MOB, LLC	Wisconsin
Southern Point LLC	Delaware
DOC-3100 Plaza Properties Boulevard MOB, LLC	Wisconsin
Zangmeister Center LLC	Delaware
DOC-170 Taylor Station Road MOB, LLC	Wisconsin
COG Real Estate Partners II, LLC	Ohio
DOC-560 North Cleveland Avenue MOB, LLC	Wisconsin
Cardinal Westerville II LLC	Ohio
DOC-1810 Stadium Drive MOB, LLC	Wisconsin
DOC-500 18th Street MOB, LLC	Wisconsin
DOC-633 19th Street MOB, LLC	Wisconsin
DOC-920 18th Street MOB, LLC	Wisconsin
DOC-705 17th Street MOB, LLC	Wisconsin
DOC-615 19th Street MOB, LLC	Wisconsin
DOC-1800 10th Avenue MOB, LLC	Wisconsin
DOC-2000 10th Avenue MOB, LLC	Wisconsin
DOC-1942 North Avenue MOB, LLC	Wisconsin
DOC-1900 10th Avenue MOB, LLC	Wisconsin
DOC-1968 North Avenue MOB, LLC	Wisconsin
DOC-2200 Hamilton Road MOB, LLC	Wisconsin
DOC-610 19th Street MOB, LLC	Wisconsin
DOC-Middletown Medical MOBs, LLC	Wisconsin
DOC-311 West Fairchild Street MOB, LLC	Wisconsin
DOC-2633 Napoleon Avenue MOB, LLC	Wisconsin
DOC-8550 Naab Street MOB, LLC* (converted to DE LLC – DOC-8550 Naab Road MOB, LLC)	Wisconsin
DOC-24 Physicians Drive MOB, LLC	Wisconsin

ENTITY	STATE OF ORIGIN
DOC-207 Stonebridge Boulevard ASC, LLC	Wisconsin
DOC-DG Holding, LLC	Wisconsin
DOC-10709 Wayzata Boulevard MOB, LLC	Wisconsin
DOC-15450 State Highway 7 MOB, LLC	Wisconsin
DOC-1155 County Road E MOB, LLC	Wisconsin
DOC-2422 20th Street SW MOB, LLC	Wisconsin
DOC-5700 Bottineau Boulevard MOB, LLC	Wisconsin
DOC-7770 Dell Road MOB, LLC	Wisconsin
DOC-3400 West 66th Street MOB, LLC	Wisconsin
DOC-6350 143rd Street MOB, LLC	Wisconsin
MMB Medical Partners, LLC	Delaware
MTKA II MP LLC	Delaware
VH Medical Partners LLC	Delaware
Crystal Medical Building, LLC	Minnesota
Savage Medical Building, LLC	Minnesota
Dell Medical Building, LLC	Minnesota
DOC-MSM Greenwood MOBs, LLC	Wisconsin
CAN Real Estate, LLC	Indiana
DOC-Indiana American MOBs, LLC	Wisconsin
DOC-MP Holding, LLC	Wisconsin
DOC-4352 North Josey Lane MOB, LLC	Wisconsin
DOC-7308 Bridgeport Way W MOB, LLC	Wisconsin
DOC-309 Renaissance, LLC	Wisconsin
DOC-3701 Avalon Park W Boulevard MOB, LLC	Wisconsin
DOC-CCP MOBs, LLC	New York
DOC-2511 Terra Crossing Boulevard MOB, LLC	Wisconsin
DOC-9118 Bluebonnet Centre Boulevard MOB, LLC	Wisconsin
DOC-19900 Haggerty Road MOB, LLC	Wisconsin
DOC-679 East County Line Road MOB, LLC*	Wisconsin
DOC-600 Health Park Boulevard MOB, LLC	Wisconsin
DOC-5319 Hoag Drive MOB, LLC	Wisconsin
DOC-15255 Max Leggett Parkway MOB, LLC	Wisconsin
DOC-3833 Coon Rapids Boulevard NW MOB, LLC	Wisconsin
DOC-2605 East Creeks Edge Drive MOB, LLC	Wisconsin
DOC-1701B Pelham Road South MOB, LLC	Wisconsin
DOC-244 Coatsland Drive MOB, LLC	Wisconsin
DOC-1710 North Randall Road MOB, LLC	Wisconsin
DOC-250 Fame Avenue MOB, LLC	Wisconsin
DOC-3602 Kyoto Gardens Drive MOB, LLC	Wisconsin
DOC-5401 South Congress Avenue MOB, LLC	Wisconsin
DOC-3730 Plaza Way MOB, LLC	Wisconsin
DOC-2030 Stringtown Road MOB, LLC	Ohio
DOC-3815 East Bell Road MOB, LLC	Wisconsin
DOC-13555 West McDowell Road MOB, LLC	Wisconsin
DOC-10815 West McDowell Road MOB, LLC	Wisconsin

ENTITY	STATE OF ORIGIN
DOC-9250 North 3rd Street MOB, LLC	Wisconsin
DOC-MP Kyle, LLC	Wisconsin
DOC-Katy Medical MOBs, LLC	Wisconsin
DOC-7277 Smith’s Mill Road MOB, LLC	Wisconsin
DOC-16838 East Palisades Boulevard MOBs, LLC	Wisconsin
DOC-Great Falls Holding, LLC	Wisconsin
DOC-2000 Lewis Turner Boulevard MOB, LLC	Wisconsin
DOC-2101 Northside Drive MOB, LLC	Wisconsin
DOC-411 North Section Street MOB, LLC	Wisconsin
DOC-1624 North McKenzie Street MOB, LLC	Wisconsin
DOC-669 South McKenzie Street MOB, LLC	Wisconsin
DOC-12601 Sorrento Road MOB, LLC	Wisconsin
DOC-5150 North Davis Highway MOB, LLC	Wisconsin
DOC-1299 Industrial Drive MOB, LLC	Wisconsin
DOC-5101 North Davis Highway MOB, LLC	Wisconsin
DOC-10800 Panama City Beach Parkway MOB, LLC	Wisconsin
DOC-12600 Sorrento Road MOB, LLC	Wisconsin
DOC-4397 Ronald Reagan Boulevard ASC, LLC	Wisconsin
DOC-3510 Old Washington Road MOB, LLC	Wisconsin
DOC-LM Kansas City MOB, LLC	Wisconsin
DOC-3311 North 44th Street MOBs, LLC	Wisconsin
DOC-1203 Smizer Mill Road MOB, LLC	Wisconsin
DOC-Nashville MOB, LLC	Wisconsin
Cambridge Nashville Medical Center, L.P.	Tennessee
DOC-1709 Medical Park Drive MOB, LLC	Wisconsin
DOC-17270 Red Oak Drive MOB, LLC	Wisconsin
Great Falls Clinic-Frauenshuh, LLC	Minnesota
DOC-1155 SE Monterey Road ASC, LLC	Wisconsin
DOC-300 Lake Drive East MOB, LLC	Wisconsin
DOC-1609 Hospital Parkway MOB, LLC	Wisconsin
DOC-2405 North Columbus Street MOB, LLC	Wisconsin
DOC-21 Laurel Avenue MOB, LLC	Wisconsin
DOC-67 Prospect Avenue MOB, LLC	Wisconsin
DOC-6220 West Bell Road ASC, LLC	Wisconsin
DOC-833 St. Vincent’s Drive MOB, LLC	Wisconsin
DOC-2660 10th Avenue South MOB, LLC	Wisconsin
DOC-2700 10th Avenue South MOB, LLC	Wisconsin
DOC-633 Emerson Road MOB, LLC	Wisconsin
DOC-890 North Blue Jay Way MOB, LLC	Wisconsin
DOC-5757 Harper Drive NE MOB, LLC	Wisconsin
DOC-2947 Rodeo Park Drive East MOB, LLC	Wisconsin
DOC-2213 Decatur Highway ASC, LLC	Wisconsin
DOC-2900 Curve Crest MOB, LLC	Wisconsin
DOC-14688 Everton Avenue MOB, LLC	Wisconsin
DOC-FREH El Paso, LLC*	Wisconsin

ENTITY	STATE OF ORIGIN
DOC-1624 South I Street MOB, LLC	Wisconsin
DOC-1802 South Yakima Street MOB, LLC	Wisconsin
DOC-34509 9th Avenue South MOB, LLC	Wisconsin
DOC-100 East Liberty Street MOB, LLC	Wisconsin
DOC-250 East Liberty Street MOB, LLC	Wisconsin
DOC-3920 Dutchmans Lane MOB, LLC	Wisconsin
DOC-1903 West Hebron Lane MOB, LLC	Wisconsin
DOC-1111 West Frank Avenue MOB, LLC	Wisconsin
DOC-1105 West Frank Avenue MOB, LLC	Wisconsin
DOC-16929 Frances Street MOB, LLC	Wisconsin
DOC-1930 Port of Tacoma Road MOB, LLC	Wisconsin
DOC-225 Abraham Flexner Way MOB, LLC	Wisconsin
DOC-Harrodsburg Road MOBs, LLC	Wisconsin
DOC-1451 Harrodsburg Road MOB, LLC	Wisconsin
DOC-4419 North Highway 7 MOB, LLC	Wisconsin
DOC-1 St. Vincent Circle MOB, LLC	Wisconsin
DOC-5 St. Vincent Circle MOB, LLC	Wisconsin
DOC-908 North Howard MOB, LLC	Wisconsin
DOC-401 East Gold Coast Road MOB, LLC	Wisconsin
DOC-1118 NW 16th Street MOB, LLC	Wisconsin
DOC-4075 East 128th Avenue MOB, LLC	Wisconsin
DOC-350 Peak One Drive MOB, LLC	Wisconsin
DOC-3101 Summit View Drive MOB, LLC	Wisconsin
DOC-1301 West Frank Avenue MOB, LLC	Wisconsin
DOC-6401 Kimball Drive MOB, LLC	Wisconsin
DOC-11311 Bridgeport Way MOB, LLC	Wisconsin
DOC-1149 Market Street MOB, LLC	Wisconsin
DOC-1900 Bluegrass Avenue MOB, LLC	Wisconsin
DOC-4500 Churchman Avenue MOB, LLC	Wisconsin
DOC-2111 Landmark Circle MOB, LLC	Wisconsin
DOC-1351 East McPherson Highway MOB, LLC	Wisconsin
DOC-600 West N. Boulevard MOB, LLC	Wisconsin
DOC-1973 South John Young Parkway MOB, LLC	Wisconsin
DOC-12635 West Bluemound Road MOB, LLC	Wisconsin
DOC-1905 West Hebron Lane MOB, LLC	Wisconsin
DOC-3200 West 33rd Street MOB, LLC	Wisconsin
DOC-310 North 9th Street MOB, LLC	Wisconsin
DOC-725 Glenwood Drive MOB, LLC	Wisconsin
DOC-810 East Rosser Avenue MOB, LLC	Wisconsin
DOC-1212 East Main Street MOB, LLC	Wisconsin
DOC-1310 East Main Avenue MOB, LLC	Wisconsin
DOC-1708 South Yakima Street MOB, LLC	Wisconsin
DOC-2116 West Faidley Avenue MOB, LLC	Wisconsin
DOC-2255 East Mossy Oaks Drive MOB, LLC	Wisconsin
DOC-2420 South State Street MOB, LLC	Wisconsin

ENTITY	STATE OF ORIGIN
DOC-2500 Sunset Drive NW MOB, LLC	Wisconsin
DOC-3219 Central Avenue MOB, LLC	Wisconsin
DOC-4402 Churchman Avenue MOB, LLC	Wisconsin
DOC-7440 West 91st Street MOB, LLC	Wisconsin
DOC-11045 Lansing Circle MOB, LLC	Wisconsin
DOC-11109 South 84th Street MOB, LLC	Wisconsin
DOC-12809 West Dodge Road MOB, LLC	Wisconsin
DOC-16221 St. Vincent Way MOB, LLC	Wisconsin
DOC-16940 Lakeside Hills Plaza MOB, LLC	Wisconsin
DOC-17030 Lakeside Hills Plaza MOB, LLC	Wisconsin
DOC-17198 St. Luke’s Way MOB, LLC	Wisconsin
DOC-2001 Beam Avenue MOB, LLC	Wisconsin
DOC-Ocala Villages, LLC	Wisconsin
DOC-100 Pilot Medical Drive MOB, LLC	Wisconsin
DOC-DG Hazelwood MOB, LLC	Wisconsin
DOC-Unity Lafayette MOBS, LLC	Wisconsin
DOC-Medical Village at Maitland, LLC	Wisconsin
DOC-225 Crosslake Drive MOB, LLC	Wisconsin
DOC-1003 Reserve Boulevard MOB, LLC	Wisconsin
DOC-1320 Broadcasting Road MOB, LLC	Wisconsin
DOC-8116 Good Luck Road MOB, LLC	Wisconsin
DOC-Dutchmans Lane Property LLC	Wisconsin
DOC-4100 Park Forest MOB (Unit 4), LLC*	Michigan
DOC-4100 Park Forest MOB, LLC	Michigan
DOC-4000 Medical Center Drive MOB, LLC	Wisconsin
DOC-5100 West Taft Road MOB, LLC	Wisconsin
DOC-Desert Cove MOB, LLC*	Wisconsin
DOC-1561 Ulster Avenue MOB, LLC*	Delaware
CEI Drive MOB, LLC	Ohio
DOC-20745 North Scottsdale Road MOB, LLC	Wisconsin
DOC-629 Delozier Way MOB, LLC	Wisconsin
DOC-3925 North Gateway Drive MOB, LLC	Wisconsin
DOC-6734 Route 9 MOB, LLC	Wisconsin
DOC-Scottsdale IRF, LLC	Wisconsin
DOC-4033 Eastern Sky Drive MOB, LLC	Wisconsin
DOC-4921 Long Prairie Road MOB, LLC	Wisconsin
DOC-4951 Long Prairie Road MOB, LLC	Wisconsin
DOC-4780 North Josey Lane MOB, LLC	Wisconsin
DOC-5000 Long Prairie Road MOB, LLC	Wisconsin
DOC-201 North Mountain Road MOB, LLC	Wisconsin

EX-23.1

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statements (No. 333-190085, No. 333-198715 and 333-204032 on Forms S-8 and No. 333-197842 and No. 333-216214 on Forms S-3) of Physicians Realty Trust of our reports dated March 1, 2018 with respect to the consolidated financial statements and schedule of Physicians Realty Trust, and the effectiveness of internal control over financial reporting of Physicians Realty Trust, included in this Annual Report (Form 10-K) for the year ended December 31, 2017.

/s/ Ernst & Young LLP

Ernst & Young LLP

Chicago, Illinois

March 1, 2018

EX-23.2

Exhibit 23.2

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statement (No. 333-216214 on Form S-3) of Physicians Realty L.P of our report dated March 1, 2018 with respect to the consolidated financial statements and schedule of Physicians Realty L.P. included in this Annual Report (Form 10-K) for the year ended December 31, 2017

/s/ Ernst & Young LLP

Ernst & Young LLP

Chicago, Illinois

March 1, 2018

EX-31.1

Exhibit 31.1

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, John T. Thomas, certify that:

1. I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2017, of Physicians Realty Trust;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 1, 2018	/s/ John T. Thomas
	John T. Thomas
	Chief Executive Officer and President

EX-31.2

Exhibit 31.2

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Jeffrey N. Theiler, certify that:

1. I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2017, of Physicians Realty Trust;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 1, 2018	/s/ Jeffrey N. Theiler
	Jeffrey N. Theiler
	Executive Vice President and Chief Financial Officer

EX-31.3

Exhibit 31.3

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, John T. Thomas, certify that:

1. I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2017, of Physicians Realty L.P.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 1, 2018	/s/ John T. Thomas
	John T. Thomas
	Chief Executive Officer and President of Physicians Realty Trust, the general partner of the registrant

EX-31.4

Exhibit 31.4

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Jeffrey N. Theiler, certify that:

1. I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2017, of Physicians Realty L.P.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 1, 2018	/s/ Jeffrey N. Theiler
	Jeffrey N. Theiler
	Executive Vice President and Chief Financial Officer of Physicians Realty Trust, the general partner of the registrant

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

Each of the undersigned hereby certifies, for the purposes of 18 U.S.C. Section 1350, in his capacity as an officer of Physicians Realty Trust (the “Company”), that, to such person’s knowledge:

a. the Annual Report on Form 10-K of the Company for the fiscal year ended December 31, 2017, as filed with the Securities and Exchange Commission (the “Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

b. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 1, 2018

/s/ John T. Thomas

John T. Thomas

Chief Executive Officer and President

/s/ Jeffrey N. Theiler

Jeffrey N. Theiler

Executive Vice President and Chief Financial Officer

This certification is not deemed to be “filed” for purposes of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability under the Exchange Act. This certification is not deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

Each of the undersigned hereby certifies, for the purposes of 18 U.S.C. Section 1350, in his capacity as an officer of Physicians Realty Trust, the sole general partner of Physicians Realty L.P. (the “Operating Partnership”), that, to such person’s knowledge:

a. the Annual Report on Form 10-K of the Operating Partnership for the fiscal year ended December 31, 2017, as filed with the Securities and Exchange Commission (the “Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

b. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Operating Partnership.

Date: March 1, 2018

/s/ John T. Thomas

John T. Thomas

Chief Executive Officer and President of Physicians Realty Trust, the general partner of the registrant

/s/ Jeffrey N. Theiler

Jeffrey N. Theiler

Executive Vice President and Chief Financial Officer of Physicians Realty Trust, the general partner of the registrant

This certification is not deemed to be “filed” for purposes of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability under the Exchange Act. This certification is not deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, except to the extent that the Operating Partnership specifically incorporates it by reference.

XML

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Feb. 23, 2018	Jun. 30, 2017
Entity Information [Line Items]
Entity Registrant Name	Physicians Realty Trust
Entity Central Index Key	0001574540
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		181,758,250
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 3,154,991,308
Operating Partnership
Entity Information [Line Items]
Entity Registrant Name	Physicians Realty L.P.
Entity Central Index Key	0001583994
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 0

XML

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Investment properties:
Land and improvements	$ 217,695	$ 189,759
Building and improvements	3,568,858	2,402,643
Tenant improvements	23,056	14,133
Acquired lease intangibles	458,713	301,462
Gross real estate property	4,268,322	2,907,997
Accumulated depreciation	(300,458)	(181,785)
Net real estate property	3,967,864	2,726,212
Real estate loans receivable	76,195	39,154
Investment in unconsolidated entities	1,329	2,258
Net real estate investments	4,045,388	2,767,624
Cash and cash equivalents	2,727	15,491
Tenant receivables, net	9,966	9,790
Other assets	106,302	95,187
Total assets	4,164,383	2,888,092
Liabilities:
Credit facility	324,394	643,742
Notes payable	966,603	224,330
Mortgage debt	186,471	123,083
Accounts payable	11,023	4,423
Dividends and distributions payable	43,804	32,179
Accrued expenses and other liabilities	56,405	42,287
Acquired lease intangibles, net	15,702	9,253
Total liabilities	1,604,402	1,079,297
Redeemable noncontrolling interest - Series A Preferred Units (2016) and partially owned properties	12,347	26,477
Equity:
Common shares, $0.01 par value, 500,000,000 common shares authorized, 181,440,051 and 135,966,013 common shares issued and outstanding as of December 31, 2017 and December 31, 2016, respectively	1,814	1,360
Additional paid-in capital	2,772,823	1,920,644
Accumulated deficit	(315,417)	(197,261)
Accumulated other comprehensive income	13,952	13,708
Total shareholders’ equity	2,473,172	1,738,451
Noncontrolling interests:
Operating Partnership	73,844	43,142
Partially owned properties	618	725
Total noncontrolling interests	74,462	43,867
Total equity	2,547,634	1,782,318
Capital:
Total liabilities and equity	4,164,383	2,888,092
Operating Partnership
Investment properties:
Land and improvements	217,695	189,759
Building and improvements	3,568,858	2,402,643
Tenant improvements	23,056	14,133
Acquired lease intangibles	458,713	301,462
Gross real estate property	4,268,322	2,907,997
Accumulated depreciation	(300,458)	(181,785)
Net real estate property	3,967,864	2,726,212
Real estate loans receivable	76,195	39,154
Investment in unconsolidated entities	1,329	2,258
Net real estate investments	4,045,388	2,767,624
Cash and cash equivalents	2,727	15,491
Tenant receivables, net	9,966	9,790
Other assets	106,302	95,187
Total assets	4,164,383	2,888,092
Liabilities:
Credit facility	324,394	643,742
Notes payable	966,603	224,330
Mortgage debt	186,471	123,083
Accounts payable	11,023	4,423
Dividends and distributions payable	43,804	32,179
Accrued expenses and other liabilities	56,405	42,287
Acquired lease intangibles, net	15,702	9,253
Total liabilities	1,604,402	1,079,297
Redeemable noncontrolling interest - Series A Preferred Units (2016) and partially owned properties	12,347	26,477
Equity:
Accumulated other comprehensive income	13,952	13,708
Capital:
General partner’s capital, 134,620,300 and 86,864,063 units issued and outstanding as of September 31, 2016 and December 31, 2015, respectively	2,459,220	1,724,743
Limited partners’ capital, 3,618,988 and 3,879,115 units issued and outstanding as of September 31, 2016 and December 31, 2015, respectively	73,844	43,142
Total partners’ capital	2,547,016	1,781,593
Noncontrolling interests - partially owned properties	618	725
Total capital	2,547,634	1,782,318
Total liabilities and equity	$ 4,164,383	$ 2,888,092

XML

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Common stock, shares outstanding (in shares)	181,440,051	135,966,013
Common stock, shares authorized (in shares)	500,000,000	500,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares issued (in shares)	181,440,051	135,966,013
Partners' Capital, Number of Units, Par Value and Other Disclosures [Abstract]
General Partner units issued (in units)		135,966,013
General Partner units outstanding (in units)		135,966,013
Limited Partner units issued (in units)		3,436,207
Limited Partner units outstanding (in units)		3,436,207
Operating Partnership
Partners' Capital, Number of Units, Par Value and Other Disclosures [Abstract]
General Partner units issued (in units)	181,440,051
General Partner units outstanding (in units)	181,440,051
Limited Partner units issued (in units)	5,364,632
Limited Partner units outstanding (in units)	5,364,632

XML

Consolidated Statements of Income - USD ($)		3 Months Ended								12 Months Ended
		Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues:
Rental revenues										$ 259,673,000	$ 186,301,000	$ 103,974,000
Expense recoveries										75,425,000	45,875,000	21,587,000
Interest income on real estate loans and other										8,486,000	8,858,000	3,880,000
Total revenues		$ 97,320,000	$ 92,999,000	$ 76,599,000	$ 76,666,000	$ 73,674,000	$ 70,010,000	$ 53,216,000	$ 44,134,000	343,584,000	241,034,000	129,441,000
Expenses:
Interest expense										47,008,000	23,864,000	10,636,000
General and administrative										22,957,000	18,397,000	14,908,000
Operating expenses										97,035,000	65,999,000	31,026,000
Depreciation and amortization										125,159,000	86,589,000	45,471,000
Acquisition expenses										16,744,000	14,778,000	14,893,000
Impairment loss										965,000	0	0
Total expenses										309,868,000	209,627,000	116,934,000
Income before equity in income of unconsolidated entities and gain on sale of investment properties:		9,523,000	12,511,000	4,994,000	6,688,000	8,590,000	10,267,000	7,158,000	5,392,000	33,716,000	31,407,000	12,507,000
Equity in income of unconsolidated entities										183,000	115,000	104,000
Gain on sale of investment properties										5,874,000	0	130,000
Net income		10,187,000	12,539,000	10,331,000	6,716,000	8,620,000	10,294,000	7,184,000	5,424,000	39,773,000	31,522,000	12,741,000
Net income attributable to noncontrolling interests:
Operating Partnership										(1,136,000)	(825,000)	(576,000)
Partially owned properties	[1]									(491,000)	(716,000)	(377,000)
Net income attributable to controlling interest										38,146,000	29,981,000	11,788,000
Preferred distributions										(731,000)	(1,857,000)	(1,189,000)
Net income attributable to common shareholders		$ 9,536,000	$ 12,018,000	$ 9,670,000	$ 6,191,000	$ 7,825,000	$ 9,427,000	$ 6,486,000	$ 4,386,000	$ 37,415,000	$ 28,124,000	$ 10,599,000
Net income per share:
Earnings per share - basic (in dollars per share)		$ 0.05	$ 0.07	$ 0.06	$ 0.04	$ 0.06	$ 0.07	$ 0.05	$ 0.04	$ 0.23	$ 0.22	$ 0.15
Earnings per share - diluted (in dollars per share)		$ 0.05	$ 0.07	$ 0.06	$ 0.04	$ 0.06	$ 0.07	$ 0.05	$ 0.04	$ 0.23	$ 0.22	$ 0.15
Weighted average common shares:
Weighted average common shares - basic (in shares)		179,683,948	177,847,424	155,366,080	138,986,629	135,581,976	134,608,396	131,481,329	102,704,008	163,123,109	126,143,114	72,750,724
Weighted average common shares - diluted (in shares)		185,273,236	183,298,145	161,012,360	142,605,930	139,602,349	138,880,787	135,944,722	107,148,380	168,231,299	130,466,893	76,792,073
Dividends and distributions declared per common share and OP unit (in dollars per share)										$ 0.915	$ 0.900	$ 0.900
Earnings per unit:
Net income (loss) attributable to redeemable noncontrolling interest										$ 300,000	$ 100,000	$ 0
Operating Partnership
Revenues:
Rental revenues										259,673,000	186,301,000	103,974,000
Expense recoveries										75,425,000	45,875,000	21,587,000
Interest income on real estate loans and other										8,486,000	8,858,000	3,880,000
Total revenues		$ 97,320,000	$ 92,999,000	$ 76,599,000	$ 76,666,000	$ 73,674,000	$ 70,010,000	$ 53,216,000	$ 44,134,000	343,584,000	241,034,000	129,441,000
Expenses:
Interest expense										47,008,000	23,864,000	10,636,000
General and administrative										22,957,000	18,397,000	14,908,000
Operating expenses										97,035,000	65,999,000	31,026,000
Depreciation and amortization										125,159,000	86,589,000	45,471,000
Acquisition expenses										16,744,000	14,778,000	14,893,000
Impairment loss										965,000	0
Total expenses										309,868,000	209,627,000	116,934,000
Income before equity in income of unconsolidated entities and gain on sale of investment properties:		9,523,000	12,511,000	4,994,000	6,688,000	8,590,000	10,267,000	7,158,000	5,392,000	33,716,000	31,407,000	12,507,000
Equity in income of unconsolidated entities										183,000	115,000	104,000
Gain on sale of investment properties										5,874,000	0	130,000
Net income		10,187,000	12,539,000	10,331,000	6,716,000	8,620,000	10,294,000	7,184,000	5,424,000	39,773,000	31,522,000	12,741,000
Net income attributable to noncontrolling interests:
Partially owned properties										(491,000)	(716,000)	(377,000)	[1]
Net income attributable to controlling interest										39,282,000	30,806,000	12,364,000
Preferred distributions										(731,000)	(1,857,000)	(1,189,000)
Net income attributable to common shareholders		$ 9,849,000	$ 12,380,000	$ 9,984,000	$ 6,338,000	$ 8,021,000	$ 9,682,000	$ 6,687,000	$ 4,559,000	$ 38,551,000	$ 28,949,000	$ 11,175,000
Net income per share:
Earnings per share - basic (in dollars per share)		$ 0.05	$ 0.07	$ 0.06	$ 0.04	$ 0.06	$ 0.07	$ 0.05	$ 0.04
Earnings per share - diluted (in dollars per share)		$ 0.05	$ 0.07	$ 0.06	$ 0.04	$ 0.06	$ 0.07	$ 0.05	$ 0.04
Earnings per unit:
Earnings per unit - basic (in dollars per share)										$ 0.23	$ 0.22	$ 0.15
Earnings per unit - diluted (in dollars per share)										$ 0.23	$ 0.22	$ 0.15
Weighted average common units - basic (in shares)		185,048,580	183,227,405	160,765,345	142,172,746	139,018,183	138,227,384	135,351,672	106,550,467	167,963,076	129,835,209	76,459,218
Weighted average common units - diluted (in shares)		185,273,236	183,298,145		142,605,930		138,880,787	135,944,722	107,148,380	168,231,299	130,466,893	76,792,073
Distributions declared per common OP Unit (in dollars per share)										$ 0.915	$ 0.900	$ 0.900
Net income (loss) attributable to redeemable noncontrolling interest										$ 300,000	$ 100,000	$ 0

[1] adjustment of $0.3 million and $0.1 million was required for net income attributable to redeemable noncontrolling interests for the year ended December 31, 2017 and December 31, 2016, respectively. No such adjustment was required for the year ended December 31, 2015.

XML

Consolidated Statements of Comprehensive Income Statement - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Net income (loss)	$ 39,773	$ 31,522	$ 12,741
Other comprehensive income:
Change in fair value of interest rate swap agreements, net	244	13,708	0
Total other comprehensive income	244	13,708	0
Comprehensive income	40,017	45,230	12,741
Comprehensive income attributable to noncontrolling interests	(1,143)	(1,162)	(576)
Comprehensive income attributable to noncontrolling interests - partially owned properties	(491)	(716)	(377)
Comprehensive income (loss) attributable to common shareholders/unitholders	38,383	43,352	11,788
Operating Partnership
Net income (loss)	39,773	31,522	12,741
Other comprehensive income:
Change in fair value of interest rate swap agreements, net	244	13,708	0
Total other comprehensive income	244	13,708	0
Comprehensive income	40,017	45,230	12,741
Comprehensive income attributable to noncontrolling interests - partially owned properties	(491)	(716)	(377)
Comprehensive income (loss) attributable to common shareholders/unitholders	$ 39,526	$ 44,514	$ 12,364

XML

Consolidated and Combined Statement of Equity - USD ($) $ in Thousands	Total	Par Value	Additional Paid in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Total Shareholders’ Equity	Operating Partnership Noncontrolling interest	Partially Owned Properties Noncontrolling Interest	Total Noncontrolling Interests	Operating Partnership	Operating Partnership Partially Owned Properties Noncontrolling Interest	Operating Partnership General Partner	Operating Partnership Limited Partner	Operating Partnership Total Partners’ Capital
Shareholders' equity, beginning balance at Dec. 31, 2014	$ 569,209	$ 508	$ 586,019	$ (51,797)		$ 534,730	$ 33,727	$ 752	$ 34,479
Increase (Decrease) in Stockholders' Equity
Net proceeds from sale of common shares	545,117	361	544,756			545,117
Restricted share award grants, net	2,908	1	3,191	(284)		2,908
Purchase of OP Units	(1,088)						(1,088)		(1,088)
Conversion of OP Units		0	171			171	(171)		(171)
Dividends/distributions declared	(70,886)			(67,542)		(67,542)	(3,344)		(3,344)
Preferred distributions	(1,189)			(1,189)		(1,189)
Issuance of OP Units in connection with acquisitions	10,973						10,973		10,973
Contributions	8,962							8,962	8,962	$ 8,962	$ 8,962
Distributions	(213)		0			0	0	(213)	(213)	(213)	(213)
Change in market value of Redeemable Noncontrolling Interest in Operating Partnership	(73)		(73)			(73)		0	0
Net (loss) income	12,741			11,788		11,788	576	377	953	12,741	377	$ 11,788	$ 576	$ 12,364
Adjustments for Limited Partners ownership in Operating Partnership										0	0	(4,778)	4,778
Adjustment for Noncontrolling Interests ownership in Operating Partnership	0		(4,778)	0		(4,778)	4,778	0	4,778
Shareholders' equity, ending balance at Dec. 31, 2015	1,076,461	870	1,129,286	(109,024)		1,021,132	45,451	9,878	55,329
Increase (Decrease) in Stockholders' Equity
Net proceeds from sale of Trust common shares and issuance of common units										545,117		545,117		545,117
Change in market value of Redeemable Limited Partners										(73)		(73)	0	(73)
Trust Restricted share award grants, net										2,908		2,908		2,908
Purchase of OP Units										(1,088)		0	(1,088)	(1,088)
Conversion of OP Units										0		171	(171)
OP Units - distributions										(70,886)		(67,542)	(3,344)	(70,886)
Partners' Capital Account, Preferred Distributions										1,189		1,189	0	1,189
Issuance of OP Units in connection with acquisition										10,973		0	10,973	10,973
Net proceeds from sale of common shares	766,841	473	766,368			766,841
Restricted share award grants, net	4,434	1	4,893	(460)		4,434
Purchase of OP Units	(3,671)						(3,671)		(3,671)
Conversion of OP Units	0	6	11,613			11,619	(11,619)		(11,619)
Dividends/distributions declared	(119,007)		0	(115,901)		(115,901)	(3,106)		(3,106)
Preferred distributions	(1,857)			(1,857)		(1,857)	0		0
Issuance of OP Units in connection with acquisitions	23,848	10	17,069	0		17,079	6,869	(100)	6,769
Contributions	50						0	50	50	50	50
Distributions	(543)							(543)	(543)	(543)	(543)
Change in market value of Redeemable Noncontrolling Interest in Operating Partnership	(245)		(245)			(245)		0	0
Reclassification of Noncontrolling Interest - partially owned properties	8,514							8,514	8,514	8,514	8,514
Buyout of Noncontrolling Interests - partially owned properties	(611)		53			53	0	(664)	(664)	(611)	(664)	53	0	53
Change in fair value of interest rate swap agreements and redeemable equity - property	13,708		0		$ 13,708	13,708				13,708				13,708
Net (loss) income	31,424			29,981		29,981	825	618	1,443	31,424	618	29,981	825	30,806
Adjustments for Limited Partners ownership in Operating Partnership										0		(8,393)	8,393
Adjustment for Noncontrolling Interests ownership in Operating Partnership	0		(8,393)			(8,393)	8,393		8,393
Shareholders' equity, ending balance at Dec. 31, 2016	1,782,318	1,360	1,920,644	(197,261)	13,708	1,738,451	43,142	725	43,867
Increase (Decrease) in Stockholders' Equity
Net proceeds from sale of Trust common shares and issuance of common units										766,841		766,841		766,841
Change in market value of Redeemable Limited Partners										(245)		(245)		(245)
Trust Restricted share award grants, net										4,434		4,434		4,434
Purchase of OP Units										(3,671)			(3,671)	(3,671)
Conversion of OP Units										0		11,619	(11,619)
OP Units - distributions										(119,007)		(115,901)	(3,106)	(119,007)
Partners' Capital Account, Preferred Distributions										1,857		1,857		1,857
Issuance of OP Units in connection with acquisition										23,848	(100)	17,079	6,869	23,948
Net proceeds from sale of common shares	844,669	451	844,218			844,669
Restricted share award grants, net	3,821	2	4,103	(284)		3,821
Purchase of OP Units	(3,886)						(3,886)		(3,886)
Conversion of OP Units		1	929			930	(930)		(930)
Dividends/distributions declared	(158,837)			(153,970)		(153,970)	(4,867)		(4,867)
Preferred distributions	(731)			(731)		(731)
Issuance of OP Units in connection with acquisitions	44,259	0	0			0	44,259	0	44,259
Contributions	47							47	47	47	47
Distributions	(321)							(321)	(321)	(321)	(321)
Buyout of Noncontrolling Interests - partially owned properties	(2,105)		(2,800)			(2,800)	719	(24)	695	(2,105)	(24)	(2,800)	719	(2,081)
Change in fair value of interest rate swap agreements and redeemable equity - property	(1,073)			(1,317)	244	(1,073)				(1,073)		(1,317)		(1,073)
Net (loss) income	39,473			38,146		38,146	1,136	191	1,327	39,473	191	38,146	1,136	39,282
Adjustments for Limited Partners ownership in Operating Partnership										0		5,729	(5,729)
Adjustment for Noncontrolling Interests ownership in Operating Partnership	0		5,729			5,729	(5,729)		(5,729)
Shareholders' equity, ending balance at Dec. 31, 2017	$ 2,547,634	$ 1,814	$ 2,772,823	$ (315,417)	$ 13,952	$ 2,473,172	$ 73,844	$ 618	$ 74,462
Increase (Decrease) in Stockholders' Equity
Net proceeds from sale of Trust common shares and issuance of common units										844,669		844,669		844,669
Trust Restricted share award grants, net										3,821		3,821		3,821
Purchase of OP Units										(3,886)			(3,886)	(3,886)
Conversion of OP Units										0		930	(930)
OP Units - distributions										(158,837)		(153,970)	(4,867)	(158,837)
Partners' Capital Account, Preferred Distributions										731		731		731
Issuance of OP Units in connection with acquisition										$ 44,259	$ 0	$ 0	$ 44,259	$ 44,259

XML

Consolidated Statements of Changes in Capital - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Increase (Decrease) in Partners' Capital [Roll Forward]
Contributions	$ 47	$ 50	$ 8,962
Distributions	(321)	(543)	(213)
Reclassification of Noncontrolling Interest - partially owned properties		8,514
Buyout of Noncontrolling Interest - partially owned properties	(2,105)	(611)
Change in fair value of interest rate swap agreements and redeemable equity - property	(1,073)	13,708
Net (loss) income	39,473	31,424	12,741
Accumulated Other Comprehensive Income
Increase (Decrease) in Partners' Capital [Roll Forward]
Partners' capital, ending balance	13,952
Operating Partnership
Increase (Decrease) in Partners' Capital [Roll Forward]
Partners' capital, beginning balance	1,782,318	1,076,461	569,209
Net proceeds from sale of Trust common shares and issuance of common units	844,669	766,841	545,117
Trust Restricted share award grants, net	3,821	4,434	2,908
Purchase of OP Units	(3,886)	(3,671)	(1,088)
Conversion of OP Units	0	0	0
OP Units - distributions	(158,837)	(119,007)	(70,886)
Preferred distributions	(731)	(1,857)	(1,189)
Issuance of OP Units in connection with acquisition	44,259	23,848	10,973
Contributions	47	50	8,962
Distributions	(321)	(543)	(213)
Change in market value of Redeemable Limited Partners		(245)	(73)
Reclassification of Noncontrolling Interest - partially owned properties		8,514
Buyout of Noncontrolling Interest - partially owned properties	(2,105)	(611)
Change in fair value of interest rate swap agreements and redeemable equity - property	(1,073)	13,708
Net (loss) income	39,473	31,424	12,741
Adjustments for Limited Partners ownership in Operating Partnership	0	0	0
Partners' capital, ending balance	2,547,634	1,782,318	1,076,461
Operating Partnership | Accumulated Other Comprehensive Income
Increase (Decrease) in Partners' Capital [Roll Forward]
Partners' capital, beginning balance	13,708
Change in fair value of interest rate swap agreements and redeemable equity - property	244	13,708
Partners' capital, ending balance		13,708
Operating Partnership | General Partner
Increase (Decrease) in Partners' Capital [Roll Forward]
Partners' capital, beginning balance	1,724,743	1,021,132	534,730
Net proceeds from sale of Trust common shares and issuance of common units	844,669	766,841	545,117
Trust Restricted share award grants, net	3,821	4,434	2,908
Purchase of OP Units			0
Conversion of OP Units	930	11,619	171
OP Units - distributions	(153,970)	(115,901)	(67,542)
Preferred distributions	(731)	(1,857)	(1,189)
Issuance of OP Units in connection with acquisition	0	17,079	0
Change in market value of Redeemable Limited Partners		(245)	(73)
Buyout of Noncontrolling Interest - partially owned properties	(2,800)	53
Change in fair value of interest rate swap agreements and redeemable equity - property	(1,317)
Net (loss) income	38,146	29,981	11,788
Adjustments for Limited Partners ownership in Operating Partnership	5,729	(8,393)	(4,778)
Partners' capital, ending balance	2,459,220	1,724,743	1,021,132
Operating Partnership | Limited Partner
Increase (Decrease) in Partners' Capital [Roll Forward]
Partners' capital, beginning balance	43,142	45,451	33,727
Purchase of OP Units	(3,886)	(3,671)	(1,088)
Conversion of OP Units	(930)	(11,619)	(171)
OP Units - distributions	(4,867)	(3,106)	(3,344)
Preferred distributions			0
Issuance of OP Units in connection with acquisition	44,259	6,869	10,973
Change in market value of Redeemable Limited Partners			0
Buyout of Noncontrolling Interest - partially owned properties	719	0
Net (loss) income	1,136	825	576
Adjustments for Limited Partners ownership in Operating Partnership	(5,729)	8,393	4,778
Partners' capital, ending balance	73,844	43,142	45,451
Operating Partnership | Total Partners’ Capital
Increase (Decrease) in Partners' Capital [Roll Forward]
Partners' capital, beginning balance	1,781,593	1,066,583	568,457
Net proceeds from sale of Trust common shares and issuance of common units	844,669	766,841	545,117
Trust Restricted share award grants, net	3,821	4,434	2,908
Purchase of OP Units	(3,886)	(3,671)	(1,088)
OP Units - distributions	(158,837)	(119,007)	(70,886)
Preferred distributions	(731)	(1,857)	(1,189)
Issuance of OP Units in connection with acquisition	44,259	23,948	10,973
Change in market value of Redeemable Limited Partners		(245)	(73)
Buyout of Noncontrolling Interest - partially owned properties	(2,081)	53
Change in fair value of interest rate swap agreements and redeemable equity - property	(1,073)	13,708
Net (loss) income	39,282	30,806	12,364
Partners' capital, ending balance	2,547,016	1,781,593	1,066,583
Partially Owned Properties Noncontrolling Interest
Increase (Decrease) in Partners' Capital [Roll Forward]
Contributions	47	50	8,962
Distributions	(321)	(543)	(213)
Reclassification of Noncontrolling Interest - partially owned properties		8,514
Buyout of Noncontrolling Interest - partially owned properties	(24)	(664)
Net (loss) income	191	618	377
Partially Owned Properties Noncontrolling Interest | Operating Partnership
Increase (Decrease) in Partners' Capital [Roll Forward]
Partners' capital, beginning balance	725	9,878	752
Issuance of OP Units in connection with acquisition	0	(100)
Contributions	47	50	8,962
Distributions	(321)	(543)	(213)
Reclassification of Noncontrolling Interest - partially owned properties		8,514
Buyout of Noncontrolling Interest - partially owned properties	(24)	(664)
Net (loss) income	191	618	377
Adjustments for Limited Partners ownership in Operating Partnership			0
Partners' capital, ending balance	$ 618	$ 725	$ 9,878

XML

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Adjustments to reconcile net income to net cash provided by operating activities
Net income (loss)	$ 39,773,000	$ 31,522,000	$ 12,741,000
Depreciation and amortization	125,159,000	86,589,000	45,471,000
Amortization of deferred financing costs	2,299,000	2,325,000	1,373,000
Amortization of lease inducements and above/below-market lease intangibles	5,083,000	3,906,000	2,577,000
Straight-line rental revenue/expense	(16,202,000)	(16,226,000)	(9,000,000)
Amortization of unsecured bond discount	277,000	0	0
Amortization of above-market assumed debt	(178,000)	(236,000)	(173,000)
Gain on sale of investment properties	(5,874,000)	0	(130,000)
Equity in income of unconsolidated entities	(183,000)	(115,000)	(104,000)
Distribution from unconsolidated entities	210,000	82,000	106,000
Change in fair value of derivatives	150,000	(240,000)	(166,000)
Provision for bad debts	123,000	2,310,000	69,000
Non-cash share compensation	6,695,000	5,672,000	3,798,000
Net change in fair value of contingent consideration	(472,000)	(840,000)	0
Impairment on investment properties	965,000	0	0
Change in operating assets and liabilities:
Tenant receivables	(2,988,000)	(10,058,000)	(2,836,000)
Other assets	(533,000)	(19,230,000)	(2,630,000)
Accounts payable	6,600,000	3,779,000	(56,000)
Accrued expenses and other liabilities	19,567,000	37,957,000	8,312,000
Net cash provided by operating activities	180,471,000	127,197,000	59,352,000
Cash Flows from Investing Activities:
Proceeds on sales of investment properties	20,397,000	0	3,039,000
Acquisition of investment properties, net	(1,268,442,000)	(1,240,438,000)	(752,807,000)
Acquisition of non-controlling interest	(8,469,000)	(4,690,000)	0
Escrowed cash—acquisition deposits/earnest deposits	(1,280,000)	(1,157,000)	2,000,000
Capital expenditures on existing investment properties	(23,243,000)	(11,304,000)	(4,988,000)
Pay down of contingent consideration	(156,000)	(483,000)	(999,000)
Real estate loans receivable	(39,063,000)	(10,207,000)	(22,359,000)
Note receivable	0	0	(20,545,000)
Repayment of real estate loan receivable	4,711,000	11,336,000	0
Repayment of note receivable	16,423,000	4,118,000	0
Leasing commissions	(1,449,000)	(1,034,000)	(579,000)
Lease inducements	(2,067,000)	(8,957,000)	(2,478,000)
Net cash used in investing activities	(1,302,638,000)	(1,262,816,000)	(799,716,000)
Cash Flows from Financing Activities:
Net proceeds from sale of common shares	844,669,000	766,841,000	545,117,000
Proceeds from credit facility borrowings	927,000,000	1,181,000,000	620,000,000
Payment on credit facility borrowings	(1,248,000,000)	(925,000,000)	(363,000,000)
Proceeds from issuance of mortgage debt	61,000,000	39,500,000	0
Proceeds from issuance of senior unsecured notes	743,060,000	225,000,000	0
Principal payments on mortgage debt	(41,503,000)	(10,232,000)	(2,022,000)
Debt issuance costs	(1,589,000)	(4,816,000)	(3,105,000)
Dividends paid - shareholders	(143,108,000)	(104,908,000)	(63,720,000)
Distributions to noncontrolling interest - Operating Partnership	(4,388,000)	(3,162,000)	(3,216,000)
Preferred distributions paid - OP Unit holder	(600,000)	(1,508,000)	(563,000)
Contributions to noncontrolling interest	47,000	0	0
Distributions to noncontrolling interest - partially owned properties	(748,000)	(543,000)	(213,000)
Payments of employee taxes for withheld stock based compensation shares	(2,590,000)	(778,000)	(606,000)
Purchase of Series A Preferred Units	(19,961,000)	(9,756,000)	0
Purchase of OP Units	(3,886,000)	(3,671,000)	(1,088,000)
Net cash provided by financing activities	1,109,403,000	1,147,967,000	727,584,000
Net (decrease) increase in cash and cash equivalents	(12,764,000)	12,348,000	(12,780,000)
Cash and cash equivalents, beginning of period	15,491,000	3,143,000	15,923,000
Cash and cash equivalents, end of period	2,727,000	15,491,000	3,143,000
Supplemental cash flow information:
Supplemental disclosure of cash flow information - interest paid during the year	38,781,000	17,151,000	9,550,000
Other Comprehensive Income (Loss), Net of Tax	244,000	13,708,000	0
Noncash investing and financing activities:
Supplemental disclosure of noncash activity - assumed debt	43,989,000	0	18,690,000
Supplemental disclosure of noncash activity - issuance of OP Units and Series A Preferred Units in connection with acquisitions	44,978,000	6,769,000	40,376,000
Supplemental disclosure of noncash activity - contingent consideration	765,000	156,000	2,718,000
Operating Partnership
Adjustments to reconcile net income to net cash provided by operating activities
Net income (loss)	39,773,000	31,522,000	12,741,000
Depreciation and amortization	125,159,000	86,589,000	45,471,000
Amortization of deferred financing costs	2,299,000	2,325,000	1,373,000
Accelerated amortization of deferred financing costs	0	0	0
Amortization of lease inducements and above/below-market lease intangibles	5,083,000	3,906,000	2,577,000
Straight-line rental revenue/expense	(16,202,000)	(16,226,000)	(9,000,000)
Amortization of unsecured bond discount	277,000	0	0
Amortization of above-market assumed debt	(178,000)	(236,000)	(173,000)
Gain on sale of investment properties	(5,874,000)	0	(130,000)
Equity in income of unconsolidated entities	(183,000)	(115,000)	(104,000)
Distribution from unconsolidated entities	210,000	82,000	106,000
Change in fair value of derivatives	150,000	(240,000)	(166,000)
Provision for bad debts	123,000	2,310,000	69,000
Non-cash share compensation	6,695,000	5,672,000	3,798,000
Net change in fair value of contingent consideration	(472,000)	(840,000)	0
Impairment on investment properties	965,000	0
Change in operating assets and liabilities:
Tenant receivables	(2,988,000)	(10,058,000)	(2,836,000)
Other assets	(533,000)	(19,230,000)	(2,630,000)
Accounts payable	6,600,000	3,779,000	(56,000)
Accrued expenses and other liabilities	19,567,000	37,957,000	8,312,000
Net cash provided by operating activities	180,471,000	127,197,000	59,352,000
Cash Flows from Investing Activities:
Proceeds on sales of investment properties	20,397,000	0	3,039,000
Acquisition of investment properties, net	(1,268,442,000)	(1,240,438,000)	(752,807,000)
Acquisition of non-controlling interest	(8,469,000)	(4,690,000)	0
Escrowed cash—acquisition deposits/earnest deposits	(1,280,000)	(1,157,000)	2,000,000
Capital expenditures on existing investment properties	(23,243,000)	(11,304,000)	(4,988,000)
Pay down of contingent consideration	(156,000)	(483,000)	(999,000)
Real estate loans receivable	(39,063,000)	(10,207,000)	(22,359,000)
Note receivable	0	0	(20,545,000)
Repayment of real estate loan receivable	4,711,000	11,336,000	0
Repayment of note receivable	16,423,000	4,118,000	0
Leasing commissions	(1,449,000)	(1,034,000)	(579,000)
Lease inducements	(2,067,000)	(8,957,000)	(2,478,000)
Net cash used in investing activities	(1,302,638,000)	(1,262,816,000)	(799,716,000)
Cash Flows from Financing Activities:
Net proceeds from sale of common shares	844,669,000	766,841,000	545,117,000
Proceeds from credit facility borrowings	927,000,000	1,181,000,000	620,000,000
Payment on credit facility borrowings	(1,248,000,000)	(925,000,000)	(363,000,000)
Proceeds from issuance of mortgage debt	61,000,000	39,500,000	0
Proceeds from issuance of senior unsecured notes	743,060,000	225,000,000	0
Principal payments on mortgage debt	(41,503,000)	(10,232,000)	(2,022,000)
Debt issuance costs	(1,589,000)	(4,816,000)	(3,105,000)
Dividends paid - shareholders	(143,108,000)	(104,908,000)	(63,720,000)
Distributions to noncontrolling interest - Operating Partnership	(4,388,000)	(3,162,000)	(3,216,000)
Preferred distributions paid - OP Unit holder	(600,000)	(1,508,000)	0
Contributions to noncontrolling interest	47,000	0	0
Distributions to noncontrolling interest - partially owned properties	(748,000)	(543,000)	(213,000)
Payments of employee taxes for withheld stock based compensation shares	(2,590,000)	(778,000)	(606,000)
Purchase of Series A Preferred Units	(19,961,000)	(9,756,000)	(563,000)
Purchase of OP Units	(3,886,000)	(3,671,000)	(1,088,000)
Net cash provided by financing activities	1,109,403,000	1,147,967,000	727,584,000
Net (decrease) increase in cash and cash equivalents	(12,764,000)	12,348,000	(12,780,000)
Cash and cash equivalents, beginning of period	15,491,000	3,143,000	15,923,000
Cash and cash equivalents, end of period	2,727,000	15,491,000	3,143,000
Supplemental cash flow information:
Supplemental disclosure of cash flow information - interest paid during the year	38,781,000	17,151,000	9,550,000
Other Comprehensive Income (Loss), Net of Tax	244,000	13,708,000	0
Noncash investing and financing activities:
Supplemental disclosure of noncash activity - assumed debt	43,989,000	0	18,690,000
Supplemental disclosure of noncash activity - issuance of OP Units and Series A Preferred Units in connection with acquisitions	44,978,000	6,769,000	40,376,000
Supplemental disclosure of noncash activity - contingent consideration	$ 765,000	$ 156,000	$ 2,718,000

XML

Organization and Business

12 Months Ended

Dec. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Business

Organization and Business

Physicians Realty Trust (the “Trust”) was organized in the state of Maryland on April 9, 2013. As of December 31, 2017, the Trust was authorized to issue up to 500,000,000 common shares of beneficial interest, par value $0.01 per share (“common shares”). The Trust filed a Registration Statement on Form S-11 with the Securities and Exchange Commission (the “Commission”) with respect to a proposed underwritten initial public offering (the “IPO”) and completed the IPO of its common shares and commenced operations on July 24, 2013.

The Trust contributed the net proceeds from the IPO to Physicians Realty L.P. (the “Operating Partnership” and together with the Trust and its consolidated subsidiaries, including the Operating Partnership, the “Company”), a Delaware limited partnership, and is the sole general partner of the Operating Partnership. The Trust and the Operating Partnership are managed and operated as one entity. The Trust has no significant assets other than its investment in the Operating Partnership. The Trust’s operations are conducted through the Operating Partnership and wholly-owned and majority-owned subsidiaries of the Operating Partnership. The Trust, as the general partner of the Operating Partnership, controls the Operating Partnership and consolidates the assets, liabilities, and results of operations of the Operating Partnership. Therefore, the assets and liabilities of the Trust and the Operating Partnership are the same.

The Trust is a self-managed real estate investment trust (“REIT”) formed primarily to acquire, selectively develop, own, and manage healthcare properties that are leased to physicians, hospitals, and healthcare delivery systems.

Equity Offerings

In March 2017, the Trust completed a follow-on public offering of 17,250,000 common shares of beneficial interest, including 2,250,000 common shares issued upon exercise of the underwriters’ overallotment option, resulting in net proceeds to it of approximately $300.8 million. The Trust contributed the net proceeds of this offering to the Operating Partnership in exchange for 17,250,000 OP Units, and the Operating Partnership used the net proceeds of the public offering to repay borrowings under its unsecured revolving credit facility and for general corporate purposes, including working capital and funding acquisitions.

In July 2017, the Trust completed a follow-on public offering of 21,500,000 common shares of beneficial interest, including 1,500,000 common shares issued upon partial exercise of the underwriters’ overallotment option, resulting in net proceeds to it of approximately $420.7 million. The Trust contributed the net proceeds of this offering to the Operating Partnership in exchange for 21,500,000 OP Units, and the Operating Partnership used the net proceeds of the public offering to repay borrowings under its unsecured revolving credit facility and for general corporate purposes, including working capital and funding acquisitions.

ATM Program

On August 5, 2016, the Trust and the Operating Partnership entered into separate At Market Issuance Sales Agreements (the “2016 Sales Agreements”) with each of KeyBanc Capital Markets Inc., Credit Agricole Securities (USA) Inc., JMP Securities LLC, Raymond James & Associates, Inc., and Stifel Nicolaus & Company, Incorporated (the “2016 Agents”), pursuant to which the Trust may issue and sell, from time to time, its common shares having an aggregate offering price of up to $300.0 million, through the Agents (the “2016 ATM Program”). In accordance with the 2016 Sales Agreements, the Trust may offer and sell its common shares through any of the 2016 Agents, from time to time, by any method deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended, which includes sales made directly on the NYSE or other existing market, or sales made to or through a market maker. With the Trust’s express written consent, sales may also be made in negotiated transactions or any other method permitted by law.

During 2016 and 2017, the Trust’s issuance and sale of common shares pursuant to the 2016 ATM Program is as follows (in thousands, except common shares and price): 

	2017					2016
	Common shares sold	Weighted average price		Net proceeds		Common shares sold	Weighted average price		Net proceeds
Quarterly period ended March 31	—	$	—	$	—	—	$	—	$	—
Quarterly period ended June 30	4,150,000	20.07		82,440		—	—		—
Quarterly period ended September 30	—	—		—		—	—		—
Quarterly period ended December 31	2,197,914	18.39		40,011		135,531	19.09		2,561
Year ended December 31	6,347,914	$	19.48	$	122,451	135,531	$	19.09	$	2,561

As of February 23, 2018, the Trust has $168.2 million remaining available under the 2016 ATM Program.

XML

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

Principles of Consolidation

GAAP requires us to identify entities for which control is achieved through means other than voting rights and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). ASC 810 broadly defines a VIE as an entity in which either (i) the equity investors as a group, if any, lack the power through voting or similar rights to direct the activities of such entity that most significantly impact such entity’s economic performance or (ii) the equity investment at risk is insufficient to finance that entity’s activities without additional subordinated financial support. We identify the primary beneficiary of a VIE as the enterprise that has both of the following characteristics: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or receive benefits of the VIE that could potentially be significant to the entity. We consolidate our investment in a VIE when we determine that we are the VIE’s primary beneficiary. We may change our original assessment of a VIE upon subsequent events such as the modification of contractual arrangements that affect the characteristics or adequacy of the entity’s equity investments at risk and the disposition of all or a portion of an interest held by the primary beneficiary. We perform this analysis on an ongoing basis.

For property holding entities not determined to be VIEs, we consolidate such entities in which the Operating Partnership owns 100% of the equity or has a controlling financial interest evidenced by ownership of a majority voting interest. All intercompany balances and transactions are eliminated in consolidation. For entities in which the Operating Partnership owns less than 100% of the equity interest, the Operating Partnership consolidates the property if it has the direct or indirect ability to control the entities’ activities based upon the terms of the respective entities’ ownership agreements. For these entities, the Operating Partnership records a noncontrolling interest representing equity held by noncontrolling interests.

Noncontrolling Interests

The Company presents the portion of any equity it does not own in entities that it controls (and thus consolidates) as noncontrolling interests and classifies such interests as a component of consolidated equity, separate from the Company’s total shareholders’ equity, on the consolidated balance sheets.

Operating Partnership: Net income or loss is allocated to noncontrolling interests (limited partners) based on their respective ownership percentage of the Operating Partnership. The ownership percentage is calculated by dividing the number of OP Units held by the noncontrolling interests by the total OP Units held by the noncontrolling interests and the Trust. Issuance of additional common shares and OP Units changes the ownership interests of both the noncontrolling interests and the Trust. Such transactions and the related proceeds are treated as capital transactions.

During the year ended December 31, 2017, the Operating Partnership partially funded one property acquisition by issuing an aggregate of 2,247,817 OP Units valued at approximately $44.3 million on the date of issuance. The acquisition had a total purchase price of approximately $78.6 million. In addition, the Operating Partnership funded the acquisition of the remaining non-controlling interest on a property by issuing an aggregate of 38,641 OP Units valued at approximately $0.7 million.

During the year ended December 31, 2016, the Operating Partnership partially funded one property acquisition by issuing an aggregate of 174,085 OP Units valued at approximately $2.9 million on the date of issuance. The acquisition had a

total purchase price of approximately $8.5 million. In addition, the Operating Partnership funded the acquisition of the remaining non-controlling interest on a property by issuing an aggregate of 217,549 OP Units valued at approximately $4.0 million.

Noncontrolling interests in the Company include OP Units held by the Predecessor’s prior investors and other investors. As of December 31, 2017 and 2016, the Trust held a 97.1% and 97.5% interest in the Operating Partnership, respectively. As the sole general partner and the majority interest holder, the Trust consolidates the financial position and results of operations of the Operating Partnership.

Holders of OP Units may not transfer their units without the Trust’s prior written consent, as general partner of the Operating Partnership. Beginning on the first anniversary of the issuance of OP Units, OP Unit holders may tender their units for redemption by the Operating Partnership in exchange for cash equal to the market price of the Trust’s common shares at the time of redemption or for unregistered common shares on a one-for-one basis. Such selection to pay cash or issue common shares to satisfy an OP Unit holder’s redemption request is solely within the control of the Trust. Accordingly, the Trust presents the OP Units of the Operating Partnership held by investors other than the Trust as noncontrolling interests within equity in the consolidated balance sheet.

Partially Owned Properties: The Trust and OP reflect noncontrolling interests in partially owned properties on the balance sheet for the portion of consolidated properties that are not wholly owned by the Company. The earnings or losses from those properties attributable to the noncontrolling interests are reflected as noncontrolling interests in partially owned properties in the consolidated statements of income.

Redeemable Noncontrolling Interests-Series A Preferred Units and Partially Owned Properties 

On February 5, 2015, the Trust entered into a Second Amended and Restated Agreement of Limited Partnership (the “Partnership Agreement”) which provides for the designation and issuance of the newly designated Series A Participating Redeemable Preferred Units of the Operating Partnership (“Series A Preferred Units”). Series A Preferred Units have priority over all other partnership interests of the Operating Partnership with respect to distributions and liquidation. Holders of Series A Preferred Units are entitled to a 5% cumulative return and upon redemption, the receipt of one common share and $200. Series A Preferred Units are redeemable at the option of the holders; however, the holders of the Series A Preferred Units have agreed not to cause the Operating Partnership to redeem their Series A Preferred Units prior to one year from the issuance date. After such one year period, if the holders of Series A Preferred Units exercise their option to redeem Series A Preferred Units, the Trust may satisfy its redemption obligation, at the Trust’s option, in cash or registered common shares. Instruments that require settlement in registered common shares may not be classified in permanent equity as it is not always completely within an issuer’s control to deliver registered common shares. Due to the redemption rights associated with the Series A Preferred Units, the Trust classifies the Series A Preferred Units in the mezzanine section of its consolidated balance sheets. 

The Series A Preferred Units were evaluated for embedded features that should be bifurcated and separately accounted for as a freestanding derivative. The Company determined that the Series A Preferred Units contained features that require bifurcation. The Company records the carrying amount of the redeemable noncontrolling interests, less the value of the embedded derivative, at the greater of the carrying value or redemption value in the consolidated balance sheets.

On February 5, 2015, the acquisition of the Minnetonka MOB was partially funded with the issuance of 44,685 Series A Preferred Units which were valued at $9.7 million. On December 17, 2015, the acquisition of the Nashville MOB was partially funded with the issuance of 91,236 Series A Preferred Units which were valued at $19.7 million.

On April 1, 2016, the Series A Preferred Units issued in conjunction with the Minnetonka MOB acquisition were redeemed for a total value of $9.8 million. The fair value of the embedded derivative associated with the previously outstanding Series A Preferred Units was $2.7 million which was derecognized in the course of the redemption.

On January 12, 2017, the Series A Preferred Units issued in conjunction with the Nashville MOB acquisition were redeemed for a total value of $20.0 million. The fair value of the embedded derivative associated with the previously outstanding Series A Preferred Units was $5.6 million which was derecognized in the course of the redemption.

In connection with the acquisition of the Minnetonka MOB, the Trust received a $5 million equity investment from a third party, effective March 1, 2015. This investment earns a 15% cumulative preferred return. At any point subsequent to the third anniversary of the investment, the holder can require the Trust to redeem the instrument at a price for which the investor will realize a 15% internal rate of return. Due to the redemption provision, which is outside of the control of the Trust, the Trust

classifies the investment in the mezzanine section of its consolidated balance sheets. The Trust records the carrying amount of the redeemable noncontrolling interests at the greater of the carrying value or redemption value.

In connection with the acquisition on December 29, 2015 of a medical office building located on the campus of the Great Falls Clinic and Hospital in Great Falls, Montana (the “Great Falls Clinic”), physicians affiliated with the seller retained a non-controlling interest which may, at the holders’ option, be redeemed at any time. Due to the redemption provision, which is outside of the control of the Trust, the Trust classifies the investment in the mezzanine section of its consolidated balance sheet. The Trust records the carrying amount of the redeemable noncontrolling interests at the greater of the carrying value or redemption value. As of December 31, 2017, physicians affiliated with the seller redeemed a portion of their non-controlling interest for $1.1 million.

Dividends and Distributions

Dividends and distributions for the years ended December 31, 2017, 2016, and 2015 are as follows:

Declaration Date	Record Date	Payment Date	Cash Dividend per Share/Unit
December 21, 2017	January 3, 2018	January 18, 2018	$	0.230
September 21, 2017	October 3, 2017	October 18, 2017	$	0.230
June 12, 2017	July 3, 2017	July 18, 2017	$	0.230
March 17, 2017	April 5, 2017	April 18, 2017	$	0.225
December 22, 2016	January 5, 2017	January 18, 2017	$	0.225
September 26, 2016	October 6, 2016	October 18, 2016	$	0.225
June 23, 2016	July 5, 2016	July 18, 2016	$	0.225
March 18, 2016	April 1, 2016	April 18, 2016	$	0.225
December 31, 2015	January 15, 2016	January 29, 2016	$	0.225
September 28, 2015	October 16, 2015	October 30, 2015	$	0.225
July 1, 2015	July 17, 2015	July 31, 2015	$	0.225
April 6, 2015	April 17, 2015	May 1, 2015	$	0.225

Our shareholders are entitled to reinvest all or a portion of any cash distribution on their shares of our common stock by participating in our Dividend Reinvestment and Share Purchase Plan (“DRIP”), subject to the terms of the plan.

Tax Status of Dividends and Distributions

Our distributions of current and accumulated earnings and profits for U.S. federal income tax purposes generally are taxable to shareholders as ordinary income. Distributions in excess of these earnings and profits generally are treated as a non-taxable reduction of the shareholders’ basis in the shares to the extent thereof (non-dividend distributions) and thereafter as taxable gain.

Any cash distributions received by an OP Unit holder in respect of its OP Units generally will not be taxable to such OP Unit holder for U.S. federal income tax purposes, to the extent that such distribution does not exceed the OP Unit holder’s basis in its OP Units. Any such distribution will instead reduce the OP Unit holder’s basis in its OP Units (and OP Unit holders will be subject to tax on the taxable income allocated to them by the Operating Partnership in respect of their OP Units when such income is earned by the Operating Partnership, with such income allocation increasing the OP Unit holders’ basis in their OP Units).

The following table sets forth the federal income tax status of distributions per common share and OP Unit for the periods presented:

	Year Ended December 31,
	2017		2016		2015
Per common share and OP Unit:
Ordinary dividends	$	0.4529	$	0.5325	$	0.2693
Qualified dividends	—		—		—
Capital gain distributions	—		—		—
Non-dividend distributions	0.4571		0.3675		0.6307
Total	$	0.9100	$	0.9000	$	0.9000

Purchases of Investment Properties

A property acquired not subject to an existing lease is treated as an asset acquisition and recorded at its purchase price, inclusive of acquisition costs, allocated between the acquired assets and assumed liabilities, including identified intangible assets and liabilities, based upon their relative fair values at the date of acquisition. A property acquired with an existing lease is accounted for as a business combination pursuant to the acquisition method in accordance with ASC Topic 805, Business Combinations (“ASC 805”), and assets acquired and liabilities assumed, including identified intangible assets and liabilities, are recorded at fair value.

The determination of fair value involves the use of significant judgment and estimation. The Company makes estimates of the fair value of the tangible and intangible acquired assets and assumed liabilities using information obtained from multiple sources as a result of pre-acquisition due diligence and generally includes the assistance of a third party appraiser. The Company estimates the fair value of buildings acquired on an “as-if-vacant” basis and depreciates the building value over the estimated remaining life of the building. The Company determines the allocated value of other fixed assets, such as site improvements, based upon the replacement cost and depreciates such value over the assets’ estimated remaining useful lives as determined at the applicable acquisition date. The fair value of land is determined either by considering the sales prices of similar properties in recent transactions or based on internal analyses of recently acquired and existing comparable properties within the Company’s portfolio.

In recording identified intangible assets and liabilities in connection with a business combination, the value of above- or below-market leases is estimated based on the present value (using an interest rate which reflected the risks associated with the leases acquired) of the difference between contractual amounts to be received pursuant to the leases and management’s estimate of market lease rates measured over a period equal to the estimated remaining term of the lease. The capitalized above-market or below-market lease intangibles are amortized as a reduction or addition to rental income over the estimated remaining term of the respective leases plus the term of any renewal options that the lessee would be economically compelled to exercise.

In determining the value of in-place leases, management considers current market conditions and costs to execute similar leases in arriving at an estimate of the carrying costs during the expected lease-up period from vacant to existing occupancy. In estimating carrying costs, management includes real estate taxes, insurance, other operating expenses, estimates of lost rental revenue during the expected lease-up periods, and costs to execute similar leases, including leasing commissions, tenant improvements, legal, and other related costs based on current market demand. The values assigned to in-place leases are amortized to amortization expense over the estimated remaining term of the lease. If a lease terminates prior to its scheduled expiration, all unamortized costs related to that lease are written off, net of any required lease termination payments.

The Company calculates the fair value of any long-term debt assumed by discounting the remaining contractual cash flows on each instrument at the current market rate for those borrowings, which the Company approximates based on the rate it would expect to incur on a replacement instrument on the date of acquisition, and recognizes any fair value adjustments related to long-term debt as effective yield adjustments over the remaining term of the instrument.

Based on these estimates, the Company recognizes the acquired assets and assumed liabilities at their estimated fair values, which are generally determined using Level 3 inputs, such as market rental rates, capitalization rates, discount rates, or other available market data. Initial valuations are subject to change until the information is finalized, no later than 12 months from the acquisition date. The Company expenses transaction costs associated with acquisitions accounted for as business combinations in the period incurred.

 Impairment of Intangible and Long-Lived Assets

The Company periodically evaluates its long-lived assets, primarily consisting of investments in real estate, for impairment indicators or whenever events or changes in circumstances indicate that the recorded amount of an asset may not be fully recoverable. If indicators of impairment are present, the Company evaluates the carrying value of the related real estate properties in relation to the undiscounted expected future cash flows of the underlying operations. In performing this evaluation, management considers market conditions and current intentions with respect to holding or disposing of the real estate property. The Company adjusts the net book value of real estate properties to fair value if the sum of the expected future undiscounted cash flows, including sales proceeds, is less than book value. The Company records an impairment loss at the time it makes any such determination. If the Company determines that an asset is impaired, the impairment to be recorded is measured as the amount by which the book value of the asset exceeds its fair value. Fair value is typically determined using a discounted future cash flow analysis or other acceptable valuation techniques, which are based, in turn, upon Level 3 inputs, such as revenue and expense growth rates, capitalization rates, discount rates, or other available market data.

The Company recorded an impairment charge of $1.0 million on a vacant medical office building in Port Charlotte, Florida during the year ended December 31, 2017. There were no impairment charges in the years ended December 31, 2016, and 2015.

Assets Held for Sale and Discontinued Operations

The Company may sell properties from time to time for various reasons, including favorable market conditions. The Company classifies certain long-lived assets as held for sale once the criteria, as defined by GAAP, has been met. Long-lived assets to be disposed of are reported at the lower of their carrying amount or fair value minus cost to sell, and are no longer depreciated. No properties were classified as held for sale as of December 31, 2017, 2016, or 2015 and dispositions during the years ended December 31, 2017, 2016, and 2015 did not qualify as discontinued operations.

Investments in Unconsolidated Entities

The Company reports investments in unconsolidated entities over whose operating and financial policies it has the ability to exercise significant influence under the equity method of accounting. Under this method of accounting, the Company’s share of the investee’s earnings or losses is included in its consolidated statements of income. The initial carrying value of investments in unconsolidated entities is based on the amount paid to purchase the equity interest.

During 2014, the Company completed the acquisition of a 40% limited liability company membership interest in Jeff Orleans Medical Development Real Estate, L.L.C., the entity that owns and leases to the Company the land on which the Crescent City Surgical Centre is situated, for $1.3 million.

During 2016, the Company completed the acquisition of a 43% limited liability company membership interest in Desert Cove MOB, LLC. During 2017, the Company completed the acquisition of the remaining 57% interest in this facility for a purchase price of approximately $4.6 million and consolidated it effective December 2017. The Company has a total investment in the facility of $5.5 million.

Real Estate Loans Receivable

Real estate loans receivable consists of ten mezzanine loans and two term loans. Each mezzanine loan is collateralized by an ownership interest in the respective borrower, while the term loans are secured by equity interests in two medical office building developments. Interest income on the loans are recognized as earned based on the terms of the loans subject to evaluation of collectability risks and are included in the Company’s consolidated statements of income.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash on hand and short-term investments with maturities of three months or less from the date of purchase. The Company is subject to concentrations of credit risk as a result of its temporary cash investments. The Company places its temporary cash investments with high credit quality financial institutions in order to mitigate that risk.

Escrow Reserves

The Company is required to maintain various escrow reserves on certain notes payable to cover future property taxes and insurance and tenant improvements costs as defined in each loan agreement. The total reserves as of December 31, 2017 and 2016 are $2.0 million and $4.3 million, respectively, which are included in other assets in the consolidated balance sheets.

Deferred Costs

Deferred costs consist primarily of fees paid to obtain financing and costs associated with the origination of long-term leases on real estate properties. After the purchase of a property, lease commissions incurred to extend in-place leases or generate new leases are added to deferred lease costs. Deferred lease costs are included as a component of other assets and are amortized on a straight-line basis over the terms of their respective agreements. Deferred financing costs are shown as a direct reduction from the related debt liability. The Trust amortizes deferred financing costs as a component of interest expense over the terms of the related borrowings on a straight-line basis.

Derivative Instruments

When the Company has derivative instruments embedded in other contracts, it records them either as an asset or a liability measured at their fair value unless they qualify for a normal purchase or normal sales exception. When specific hedge accounting criteria are not met, changes in the Company’s derivative instruments’ fair value are recognized currently in earnings. If hedge accounting is applied to a derivative instrument, such changes are reported in accumulated other comprehensive income (“AOCI”) within the equity section of the consolidated balance sheets, exclusive of ineffectiveness amounts, which are recognized as adjustments to net income.

To manage interest rate risk for certain of its variable-rate debt, the Company uses interest rate swaps as part of its risk management strategy. These derivatives are designed to mitigate the risk of future interest rate increases by providing a fixed interest rate for a limited, pre-determined period of time. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. As of December 31, 2017, the Company had five outstanding interest rate swap contracts that are designated as cash flow hedges of interest rate risk. For presentational purposes, they are shown as one derivative due to the identical nature of their economic terms. Further detail is provided in Note 7 (Derivatives).

The effective portion of the change in the fair value of derivatives designated and that qualify as cash flow hedges is recorded in accumulated other comprehensive income (“AOCI”) on the consolidated balance sheets and is subsequently reclassified into earnings as interest expense for the period that the hedged forecasted transaction affects earnings. The ineffective portion of the change in fair value of the derivatives is recognized directly in earnings. For the twelve months ended months ended December 31, 2017, the Company recorded a $0.2 million loss as a result of hedge ineffectiveness. The Company expects hedge ineffectiveness to be insignificant in the next 12 months.

Tenant Receivables, Net

Tenant accounts receivable are stated net of the applicable allowance. Rental payments under these contracts are primarily due monthly. The Company assesses the collectability of tenant receivables, including straight-line rent receivables, and defers recognition of revenue if collectability is not reasonably assured. The Company bases its assessment of the collectability of rent receivables on several factors, including, among other things, payment history, the financial strength of the tenant, and current economic conditions. If management’s evaluation of these factors indicates it is probable that the Company will be unable to recover the full value of the receivable, the Company provides a reserve against the portion of the receivable that it estimates may not be recovered. At December 31, 2017 and 2016, the allowance for doubtful accounts was $1.6 million and $2.4 million, respectively.

Rental Revenue

Rental revenue is recognized on a straight-line basis over the terms of the related leases when collectability is reasonably assured. Recognizing rental revenue on a straight-line basis for leases may result in recognizing revenue for amounts more or less than amounts currently due from tenants. Accumulated amounts recognized in excess of amounts currently due from tenants, net of related allowances, are included in other assets and were approximately $47.6 million and $32.0 million as of December 31, 2017 and 2016, respectively. If the Company determines that collectability of straight-line rents is not reasonably assured, the Company limits future recognition to amounts contractually owed and, where appropriate, establishes an allowance for estimated losses. Allowances recognized against straight line rent were approximately $4.9 million

and $0.6 million as of December 31, 2017 and December 31, 2016, respectively. Rental revenue is adjusted by amortization of lease inducements and above- or below-market rents on certain leases. Lease inducements and above- or below-market rents are amortized on a straight line basis over the remaining life of the lease.

Expense Recoveries

Expense recoveries relate to tenant reimbursement of real estate taxes, insurance, and other operating expenses that are recognized as expense recovery revenue in the period the applicable expenses are incurred. The reimbursements are recorded at gross, as the Company is generally the primary obligor with respect to real estate taxes and purchasing goods and services from third-party suppliers, has discretion in selecting the supplier, and bears the credit risk of tenant reimbursement.

The Company has certain tenants with absolute net leases. Under these lease agreements, the tenant is responsible for operating and building expenses. For absolute net leases, the Company does not recognize expense recoveries.

Income Taxes

The Trust elected to be taxed as a REIT for federal tax purposes commencing with the filing of its tax return for the short taxable year ending December 31, 2013. The Trust had no taxable income prior to electing REIT status. To qualify as a REIT, the Trust must meet certain organizational and operational requirements, including a requirement to distribute at least 90% of its annual REIT taxable income to its shareholders (which is computed without regard to the dividends paid deduction or net capital gain and which does not necessarily equal net income as calculated in accordance with GAAP). As a REIT, the Trust generally will not be subject to federal income tax to the extent it distributes qualifying dividends to its shareholders. If the Trust fails to qualify as a REIT in any taxable year, it will be subject to federal income tax (including any applicable alternative minimum tax) on its taxable income at regular corporate income tax rates and generally will not be permitted to qualify for treatment as a REIT for federal income tax purposes for the four taxable years following the year during which qualification is lost unless the Internal Revenue Service grants the Trust relief under certain statutory provisions. Such an event could materially adversely affect the Trust’s net income and net cash available for distribution to shareholders. However, the Trust intends to continue to operate in such a manner as to continue qualifying for treatment as a REIT. Even if the Trust continues to qualify for taxation as a REIT, the Trust may be subject to state and local taxes on its income and property and federal income and excise taxes on its undistributed income.

As discussed in Note 1 (Organization and Business), the Trust conducts substantially all of its operations through the Operating Partnership. As a partnership, the Operating Partnership generally is not liable for federal income taxes. The income and loss from the operations of the Operating Partnership is included in the tax returns of its partners, including the Trust, who are responsible for reporting their allocable share of the partnership income and loss. Accordingly, no provision for income taxes has been made on the accompanying consolidated financial statements.

Management Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the amounts of revenue and expenses reported in the period. Significant estimates are made for the fair value assessments with respect to purchase price allocations, impairment assessments, and the valuation of financial instruments. Actual results could differ from these estimates.

Contingent Liabilities

The Company records liabilities for contingent consideration (included in accrued expenses and other liabilities on its consolidated balance sheets) at fair value as of the acquisition date and reassesses the fair value at the end of each reporting period, with any changes being recognized in earnings. Increases or decreases in the fair value of contingent consideration can result from changes in discount periods, discount rates, and probabilities that contingencies will be met.

Related Parties

In 2017, the Company recognized rental revenues totaling $0.6 million and $4.0 million from Aurora Health Care and Baylor Cancer Center, respectively. Both are healthcare facilities affiliated with certain members of the Trust’s Board of Trustees.

Reclassifications

Certain prior period amounts have been reclassified to conform to the current financial statement presentation, with no effect on the previously reported consolidated financial position or consolidated results of operations.

Segment Reporting

Under the provision of Codification Topic 280, Segment Reporting, the Company has determined that it has one reportable segment with activities related to leasing and managing healthcare properties.

New Accounting Pronouncements

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which creates a new Topic, Accounting Standards Codification Topic 606. The standard is principle-based and provides a five-step model to determine when and how revenue is recognized. The core principle is that a company should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This standard is effective for interim or annual periods beginning after December 15, 2017 and allows for either full retrospective or modified retrospective adoption. The Company will adopt ASU 2014-09 on January 1, 2018 via the modified retrospective approach. The modified retrospective approach applies the standard in the year of initial application and presents the cumulative effect of prior periods with an adjustment to beginning retained earnings, with no restatement of comparative periods. As leasing arrangements (which are excluded from ASU 2014-09) represent the primary source of revenue for the Company, the impact of adoption will be limited to the Company’s recognition and presentation of non-lease revenues, which are currently reflected as a component of other income. Adoption of ASU 2014-09 will not have a material impact on the amount and timing of the recognition of income subject to this standard and we do not intend to further break out income line items with no cumulative effect adjustment to be recognized upon adoption.

In February 2015, the FASB issued ASU 2015-02, Amendments to the Consolidation Analysis. ASU 2015-02 requires entities to evaluate whether they should consolidate certain legal entities. Principally, the new consolidation standard modified the evaluation of whether limited partnerships and similar legal entities are variable interest entities (“VIE”) or voting interest entities. The Company adopted ASU 2015-02 on January 1, 2016. Based on the Company’s review and subsequent analysis of the structure of the Company’s legal entities, the Company has concluded that the Operating Partnership is a VIE because the limited partners of the Operating Partnership do not have substantive kick-out or participating rights. The Trust is the general partner and controlling owner of approximately 97.1% of the Operating Partnership and will continue to consolidate the Operating Partnership under this new guidance. With respect to the Company’s investment in unconsolidated joint ventures, the new consolidation standard did not have an impact on previous consolidation conclusions.

In February 2016, the FASB issued ASU 2016-02, Leases. The update amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting. ASU 2016-02 will be effective for annual reporting periods beginning after December 15, 2018. Early adoption is permitted. As a result of adopting ASU 2016-02, the Company will recognize all of its operating leases for which it is the lessee, including ground leases, on its consolidated balance sheets. The Company is evaluating the impact of the adoption of ASU 2016-02 on January 1, 2019 to its consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting. This update simplifies several aspects of accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statements of cash flows. ASU 2016-09 is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2016. The Company adopted ASU 2016-09 on January 1, 2017, with no material effect on its consolidated financial statements with no adjustments made to prior periods.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses, which changes the impairment model for most financial instruments by requiring companies to recognize an allowance for expected losses, rather than incurred losses as required currently by the other-than-temporary impairment model. ASU 2016-13 will apply to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities, net investments in leases, and off-balance-sheet credit exposures (e.g., loan commitments). ASU 2016-13 is effective for reporting periods beginning after December 15, 2019, with early adoption permitted, and will be applied as a cumulative adjustment to retained earnings as of the effective date. We are currently assessing the potential effect the adoption of ASU 2016-13 will have on our consolidated financial statements.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payment. ASU 2016-15 clarifies the guidance on the classification of certain cash receipts and payments in the statement of cash flows to reduce diversity in practice with respect to: (i) debt prepayment or debt extinguishment costs; (ii) settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; (iii) contingent consideration payments made after a business combination; (iv) proceeds from the settlement of insurance claims; (v) proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (vi) distributions received from equity method investees; (vii) beneficial interests in securitization transactions; and (viii) separately identifiable cash flows and application of the predominance principle. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. The Company adopted ASU 2016-15 on January 1, 2018, with no material effect on its consolidated financial statements and no adjustments made to prior periods.

In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows: Restricted Cash, which will require companies to include restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the statement of cash flows. ASU 2016-18 will require disclosure of a reconciliation between the balance sheet and the statement of cash flows when the balance sheet includes more than one line item for cash, cash equivalents, restricted cash, and restricted cash equivalents. An entity with material restricted cash and restricted cash equivalents balances will be required to disclose the nature of the restrictions. ASU 2016-18 is effective for reporting periods beginning after December 15, 2017, and is required to be applied retrospectively to all periods presented. The Company adopted ASU 2016-18 on January 1, 2018, with no material effect on its consolidated financial statements and no adjustments made to prior periods.

In January 2017, the FASB issued ASU 2017-01, Clarifying the Definition of a Business, that clarifies the framework for determining whether an integrated set of assets and activities meets the definition of a business. The revised framework establishes a screen for determining whether an integrated set of assets and activities is a business and narrows the definition of a business, which is expected to result in fewer transactions being accounted for as business combinations. Acquisitions of integrated sets of assets and activities that do not meet the definition of a business are accounted for as asset acquisitions. ASU 2017-01 will be effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017. Upon adoption of ASU 2017-01, the Company anticipates it will classify most prospective real estate acquisitions as asset acquisitions, rather than business combinations, and direct acquisition costs associated with these acquisitions will be capitalized. This is due to the fact that substantially all of the fair value of the gross assets the Company acquires are concentrated in a single asset or group of similar identifiable assets.

XML

Acquisitions and Dispositions

12 Months Ended

Dec. 31, 2017

Business Combinations [Abstract]

Acquisitions and Dispositions

Acquisitions and Dispositions

During 2017, the Company completed acquisitions of 40 operating healthcare properties, 2 condominium units, and 1 parking deck located in 15 states, for an aggregate purchase price of approximately $1.37 billion. In addition, the Company completed $39.1 million of loan investments, $1.1 million of redeemable noncontrolling interest buyouts, and $2.8 million of noncontrolling interest buyouts, resulting in total investment activity of approximately $1.41 billion.

Investment activity for the year ending December 31, 2017 is summarized below:

Property (1)			Location	Acquisition Date	Purchase Price (in thousands)
Orthopedic Associates	(2)		Flower Mound, TX	January 5, 2017	$	18,750
Medical Arts Center at Hartford	(2)		Plainville, CT	January 11, 2017	30,250
Noncontrolling Interest Buyout - New Albany	(3)		New Albany, OH	January 31, 2017	2,824
CareMount - Lake Katrine MOB	(2)	(4)	Lake Katrine, NY	February 14, 2017	41,791
CareMount - Rhinebeck MOB	(2)		Rhinebeck, NY	February 14, 2017	18,639
Syracuse Condos	(2)		Fayetteville & Liverpool, NY	February 27, 2017	2,659
Monterey Medical Center - MOB	(2)		Stuart, FL	March 7, 2017	18,979
Creighton University Medical Center	(5)		Omaha, NE	March 28, 2017	33,420
Strictly Pediatrics Specialty Center	(2)	(6)	Austin, TX	March 31, 2017	78,628
MedStar Stephen's Crossing	(2)		Brandywine, MD	June 16, 2017	20,900
2017 CHI Portfolio - Tranche 1 (8 MOBs)	(5)		AR, MN, ND, NE, TN, TX	June 29, 2017	124,181
St. Vincent Portfolio (2 MOBs)	(2)		Carmel & Fishers, IN	June 29, 2017	93,880
Baylor Charles A. Sammons Cancer Center	(2)		Dallas, TX	June 30, 2017	290,000
Orthopedic & Sports Institute of the Fox Valley	(7)		Appleton, WI	June 30, 2017	27,900
Peachtree Dunwoody Medical Center - Parking Deck	(7)		Atlanta, GA	June 30, 2017	25,000
Clearview Cancer Institute	(2)		Huntsville, AL	August 4, 2017	53,250
Northside Cherokee/Town Lake MOB	(2)		Atlanta, GA	August 15, 2017	37,127
HonorHealth Mesa MOB	(2)		Mesa, AZ	August 15, 2017	4,800
2017 CHI Portfolio - Tranche 2 (5 MOBs)	(5)		AR, MN, NE, TX	August 24, 2017 & August 31, 2017	33,694
Noncontrolling Interest Buyout - Great Falls Clinic	(8)		Great Falls, MT	September 21, 2017	1,061
Legends Park MOB & ASC	(2)		Midland, TX	September 27, 2017	30,000
Franklin MOB & ASC	(2)		Franklin, TN	October 12, 2017	9,950
Eagle Point MOB	(2)		Lake Elmo, MN	October 31, 2017	10,949
Edina East MOB	(2)		Edina, MN	October 31, 2017	7,800
Northside MOB - Center Pointe	(2)		Atlanta, GA	November 10, 2017	155,986
Gwinnett 500 Building	(2)		Lawrenceville, GA	November 17, 2017	25,297
Hudgens Professional Building	(2)		Duluth, GA	November 17, 2017	23,696
St. Vincent Building	(2)		Indianapolis, IN	November 17, 2017	60,124
Gwinnett Physicians Center	(2)	(9)	Lawrenceville, GA	December 1, 2017	51,721
Apple Valley Medical Center	(2)		Apple Valley, MN	December 18, 2017	21,500
Desert Cove MOB (57% Interest)	(2)	(10)	Scottsdale, AZ	December 18, 2017	4,560
Westgate MOB	(2)		Glendale, AZ	December 21, 2017	15,800

Property (1)		Location	Acquisition Date	Purchase Price (in thousands)
Loan Investments	(11)	Various	Various	39,063
				$	1,414,179

(1) “MOB” means medical office building. “ASC” means ambulatory surgery center.

(2) The Company accounted for these acquisitions as business combinations pursuant to the acquisition method and expensed total acquisition costs of $16.6 million.

(3) The Company acquired the previously outstanding interest in the New Albany MOB from the predecessor owner. As consideration, the Operating Partnership paid approximately $2.1 million in cash and issued 38,641 OP Units, representing approximately $2.8 million in aggregate.

(4) The Company partially funded this acquisition through the assumption of an existing mortgage valued at approximately $26.4 million.

(5) These acquisitions are part of the CHI Portfolio. The Company accounted for nine of these facilities, consisting of an aggregate purchase price of $143.0 million, as asset acquisitions and capitalized total acquisition costs of $0.4 million. The remaining six facilities, consisting of an aggregate purchase price of $48.3 million, were accounted for as business combinations pursuant to the acquisition method, with acquisition expense totaling $0.1 million.

(6) The Company partially funded the purchase price of this acquisition by issuing a total of 2,247,817 OP Units valued at approximately $44.3 million in the aggregate on the date of issuance.

(7) The Company accounted for these acquisitions as asset acquisitions and capitalized total acquisition costs of $0.5 million.

(8) The Company acquired an additional 3.2% interest in the Great Falls Clinic joint venture from the predecessor owner, increasing the Company’s total interest to 85.0%.

(9) As part of this acquisition, the Company assumed a $17.6 million mortgage on the facility.

(10) The Company acquired an additional 57.0% ownership interest in Desert Cove MOB, LLC increasing the Company’s total interest to 100%.

(11) The loan investments listed here include 8 separate transactions at a weighted average interest rate of 8.1%.

For 2017, the Company recorded revenues and net income of $49.6 million and $8.6 million, respectively, from its 2017 acquisitions.

During 2016, the Company completed acquisitions of 95 properties (including 5 condominium units and the CHI Portfolio) and 1 land parcel, located in 23 states, for an aggregate purchase price of approximately $1.27 billion. In addition, the Company completed $0.9 million of joint venture investments, $10.2 million of loan investments, $2.5 million of redeemable noncontrolling interest buyouts, and $0.6 million of equity buyouts, resulting in total investment activity of approximately $1.29 billion.

This aggregate purchase price does not include near-term capital expenditure commitments of $12.9 million and committed tenant improvement allowances of $8.9 million related to the Company’s acquisition of the CHI Portfolio.

Investment activity for the year ending December 31, 2016 is summarized below:

Property (1)			Location	Acquisition Date	Purchase Price  (in thousands)
Tinseltown - Loan Draws			Jacksonville, FL		$	2,192
Randall Road MOB - Suite 380	(3)		Elgin, IL	January 14, 2016	704
Great Falls Hospital	(2)		Great Falls, MT	January 25, 2016	29,043
Monterey Medical Center ASC	(2)		Stuart, FL	February 1, 2016	6,900
Physicians Medical Plaza MOB	(2)	(4)	Indianapolis, IN	February 1, 2016	8,500
Mezzanine Loan - Davis			Minnetonka, MN	February 4, 2016	500
Park Nicollet Clinic	(2)		Chanhassen, MN	February 8, 2016	18,600
HEB Cancer Center	(2)		Bedford, TX	February 12, 2016	13,980
Riverview Medical Center	(2)		Lancaster, OH	February 26, 2016	12,800
St. Luke's Cornwall MOB	(2)		Cornwall, NY	February 26, 2016	14,550
HonorHealth Glendale	(3)		Glendale, AZ	March 15, 2016	9,820
Columbia MOB	(2)		Hudson, NY	March 21, 2016	18,450

Property (1)			Location	Acquisition Date	Purchase Price  (in thousands)
St Vincent POB 1	(2)		Birmingham, AL	March 23, 2016	10,951
St Vincent POB 2	(2)		Birmingham, AL	March 23, 2016	7,945
St Vincent POB 3	(2)		Birmingham, AL	March 23, 2016	10,455
Emerson Medical Building	(2)		Creve Coeur, MO	March 24, 2016	14,250
Randall Road MOB - Suite 160	(3)		Elgin, IL	March 24, 2016	865
Patient Partners Surgery Center	(2)		Gallatin, TN	March 30, 2016	4,750
Eye Associates of NM - Santa Fe	(3)		Santa Fe, NM	March 31, 2016	8,739
Eye Associates of NM - Albuquerque	(3)		Albuquerque, NM	March 31, 2016	10,536
Gardendale Surgery Center	(2)		Gardendale, AL	April 11, 2016	7,450
HealthEast - Curve Crest	(2)		Stillwater, MN	April 14, 2016	4,144
HealthEast - Victor Gardens	(2)		Hugo, MN	April 14, 2016	6,025
NOMS - Clyde	(3)		Clyde, OH	May 10, 2016	6,342
Blandford MOB	(3)	(5)	Little Rock, AR	May 11, 2016	2,580
Cardwell MOB	(2)	(5)	Lufkin, TX	May 11, 2016	8,444
Dacono Neighborhood Health	(3)	(5)	Dacono, CO	May 11, 2016	5,152
Franciscan Health	(3)	(5)	Tacoma, WA	May 11, 2016	9,772
Grand Island Specialty Clinic	(3)	(5)	Grand Island, NE	May 11, 2016	2,891
Hot Springs MOB	(2)	(5)	Hot Springs Village, AR	May 11, 2016	3,626
Jewish Medical Center East	(3)	(5)	Louisville, KY	May 11, 2016	85,000
Jewish Medical Center South MOB - 1	(3)	(5)	Shepherdsville, KY	May 11, 2016	17,021
Jewish Medical Plaza I	(2)	(5)	Louisville, KY	May 11, 2016	9,650
Jewish Medical Plaza II	(2)	(5)	Louisville, KY	May 11, 2016	6,124
Jewish OCC	(3)	(5)	Louisville, KY	May 11, 2016	35,600
Lakeside Three Professional Center	(2)	(5)	Omaha, NE	May 11, 2016	1,581
Lexington Surgery Center	(2)	(5)	Lexington, KY	May 11, 2016	20,169
Medical Arts Pavilion	(2)	(5)	Lufkin, TX	May 11, 2016	6,304
Memorial Outpatient Center	(3)	(5)	Lufkin, TX	May 11, 2016	4,958
Midlands Two Professional Center	(2)	(5)	Papillion, NE	May 11, 2016	1,341
Parkview MOB	(2)	(5)	Little Rock, AR	May 11, 2016	5,060
Peak One ASC	(2)	(5)	Frisco, CO	May 11, 2016	6,587
Physicians Medical Center	(2)	(5)	Tacoma, WA	May 11, 2016	6,782
St. Alexius - Minot Medical Plaza	(3)	(5)	Minot, ND	May 11, 2016	26,570
St. Clare Medical Pavilion	(2)	(5)	Lakewood, WA	May 11, 2016	10,617
St. Joseph Medical Pavilion	(2)	(5)	Tacoma, WA	May 11, 2016	13,320
St. Joseph Office Park	(2)	(5)	Lexington, KY	May 11, 2016	17,228
St. Mary - Caritas Medical II	(2)	(5)	Louisville, KY	May 11, 2016	5,603
St. Mary - Caritas Medical III	(2)	(5)	Louisville, KY	May 11, 2016	842
Thornton Neighborhood Health	(3)	(5)	Thornton, CO	May 11, 2016	3,875
Medical Village at Kissimmee	(2)		Kissimmee, FL	May 26, 2016	4,923
Medical Village at Leesburg	(2)		Leesburg, FL	May 26, 2016	4,576
St. Francis MOB	(2)	(5)	Federal Way, WA	June 2, 2016	14,287
Children's Hospital MOB	(2)		Milwaukee, WI	June 3, 2016	5,850
Jewish Medical Center South MOB - 2	(2)		Shepherdsville, KY	June 8, 2016	4,343
Good Samaritan North Annex Building	(3)	(5)	Kearney, NE	June 28, 2016	2,874
NE Heart Institute Medical Building	(3)	(5)	Lincoln, NE	June 28, 2016	19,600

Property (1)			Location	Acquisition Date	Purchase Price  (in thousands)
St. Vincent West MOB	(3)	(5)	Little Rock, AR	June 29, 2016	14,120
Meridan MOB	(3)	(5)	Englewood, CO	June 29, 2016	17,329
St. Mary - Caritas Medical I	(2)	(5)	Louisville, KY	June 29, 2016	8,864
St. Alexius - Medical Arts Pavilion	(3)	(5)	Bismarck, ND	June 29, 2016	12,983
St. Alexius - Mandan Clinic	(3)	(5)	Mandan, ND	June 29, 2016	8,390
St. Alexius - Orthopaedic Center	(2)	(5)	Bismarck, ND	June 29, 2016	14,727
St. Alexius - Rehab Center	(3)	(5)	Bismarck, ND	June 29, 2016	6,215
St. Alexius - Tech & Ed	(3)	(5)	Bismarck, ND	June 29, 2016	16,680
Good Samaritan MOB	(2)	(5)	Kearney, NE	June 29, 2016	24,198
Lakeside Two Professional Building	(2)	(5)	Omaha, NE	June 29, 2016	13,691
Lakeside Wellness Center	(3)	(5)	Omaha, NE	June 29, 2016	10,138
McAuley Center	(3)	(5)	Omaha, NE	June 29, 2016	18,382
Memorial Health Center	(3)	(5)	Grand Island, NE	June 29, 2016	34,042
Missionary Ridge MOB	(2)	(5)	Chattanooga, TN	June 29, 2016	7,635
Pilot Medical Center	(3)		Birmingham, AL	June 29, 2016	17,351
St. Joseph Medical Clinic	(2)	(5)	Tacoma, WA	June 30, 2016	16,444
Woodlands Medical Arts Center	(2)	(5)	The Woodlands, TX	June 30, 2016	21,227
FESC MOB	(3)	(5)	Tacoma, WA	June 30, 2016	16,748
Mezzanine Loan - Catalyst			Pensacola, FL	June 30, 2016	1,340
Prairie Care MOB	(2)		Maplewood, MN	July 6, 2016	4,886
RE Loan - Chihuahua Development LLC			El Paso, TX	July 7, 2016	1,300
Springwoods MOB	(2)	(5)	Spring, TX	July 21, 2016	19,925
Equity Buyout - Foundation	(6)		TX / OK	July 26, 2016	611
Mezzanine Loan - Hazelwood			Minnetonka, MN	July 29, 2016	3,375
Jackson, Tennessee Land	(3)		Jackson, TN	August 2, 2016	1,000
Unity Portfolio (4 MOBs)	(2)		West Lafayette, IN	August 8, 2016	28,751
Medical Village at Maitland	(2)		Orlando, FL	August 23, 2016	23,211
Tri-State Orthopaedics MOB	(2)		Evansville, IN	August 30, 2016	22,000
Maury Regional Healthcare MOB	(2)	(8)	Spring Hill, TN	September 30, 2016	18,500
Spring Ridge Medical Center	(2)		Wyomissing, PA	September 30, 2016	6,100
Doctors Community Hospital POB	(2)		Lanham, MD	September 30, 2016	26,750
Gig Harbor Medical Pavilion	(3)	(5)	Gig Harbor, WA	September 30, 2016	4,766
Midlands One Professional Center	(2)	(5)	Papillion, NE	September 30, 2016	14,856
Noncontrolling Interest Buyout - Great Falls Clinic	(7)		Great Falls, MT	September 30, 2016	1,015
N.W. Michigan Surgery Center - Units #1 & #2	(3)	(9)	Traverse City, MI	October 28, 2016	29,448
United Surgical Partners Joint Venture	(10)		Scottsdale, AZ	October 31, 2016	903
N.W. Michigan Surgery Center - Unit #4	(3)	(11)	Traverse City, MI	November 4, 2016	2,715
Syracuse Portfolio (2 MOBs)	(2)		Syracuse, NY	November 23, 2016	54,239
Cincinnati Eye Institute	(3)		Cincinnati, OH	November 23, 2016	38,100
Curie Building Loan			El Paso, TX	December 2, 2016	1,500
HonorHealth - Scottsdale MOB	(3)		Scottsdale, AZ	December 2, 2016	6,900
Fox Valley Hematology & Oncology	(3)		Appleton, WI	December 8, 2016	28,200
Gastrointestinal Associates MOB	(2)		Powell, TN	December 9, 2016	6,287
Northern Vision Eye Center	(3)		Traverse City, MI	December 15, 2016	2,777

Property (1)		Location	Acquisition Date	Purchase Price  (in thousands)
Noncontrolling Interest Buyout - Great Falls Clinic	(12)	Great Falls, MT	December 15, 2016	1,497
Flower Mound Portfolio (3 MOBs)	(3)	Flower Mound, TX	December 16, 2016	27,800
HonorHealth IRF	(3)	Scottsdale, AZ	December 22, 2016	25,628
				$	1,285,185

(1) “MOB” means medical office building. “ASC” means ambulatory surgical center. “POB” means professional office building. “IRF” means inpatient rehabilitation facility.

(2) The Company accounted for these acquisitions as business combinations pursuant to the acquisition method and expensed total acquisition costs of $14.8 million.

(3) The Company accounted for these acquisitions as asset acquisitions and capitalized total acquisition costs of $3.0 million.

(4) The Company partially funded the purchase price of this acquisition by issuing a total of 174,085 OP Units valued at approximately $2.9 million in the aggregate on the date of issuance.

(5) These acquisitions are part of the CHI portfolio.

(6) The Company acquired the previously outstanding 1% noncontrolling interest retained by the predecessor owner on three properties, El Paso, Texas and Oklahoma City, Oklahoma.

(7) The Company acquired an additional 3% interest in the Great Falls Clinic joint venture from the predecessor owner, increasing the Company’s total interest to 77.3%.

(8) The Company acquired 99.7% of the ownership interest in this property, the remainder of which was retained by the seller.

(9) The Company partially funded the purchase price of the acquisition of two condominium units within the Northwest Michigan Surgery Center through unregistered issuance of 947,936 common shares of beneficial interest.

(10) The Company’s investment in the United Surgical Partners J.V. represents a 43% ownership interest.

(11) The Company partially funded the purchase price of the acquisition of one additional condominium unit within the Northwest Michigan Surgery Center through the unregistered issuance of 88,602 common shares of beneficial interest.

(12) The company acquired an additional 4.6% interest in the Great Falls Clinic joint venture from the predecessor owner, increasing the Company’s total interest to 81.8%.

For 2016, the Company recorded revenues and net income of $66.7 million and $14.9 million, respectively, from its 2016 acquisitions.

The following table summarizes the preliminary purchase price allocations of the assets acquired and the liabilities assumed, which the Company determined using Level 2 and Level 3 inputs (in thousands):

	December 31, 2017			December 31, 2016
Land	$	38,358		$	57,847
Building and improvements	1,168,741			1,112,746
In-place lease intangible	128,370			58,666
Above-market in-place lease intangible	18,967			9,359
Below-market in-place lease intangible	(4,270		)	(4,518		)
Above-market in-place ground lease	(4,620		)	(644		)
Below-market in-place ground lease	17,683			28,937
Contingent consideration	(765		)	(156		)
Receivable	434			104
Debt assumed	(43,989		)	—
Issuance of OP Units	(44,978		)	(2,869		)
Investment in unconsolidated entity	(2,871		)	903
Lease inducement	—			8,945
Prepaid expenses	—			2,659
Issuance of Common Shares	—			(20,980		)
Noncontrolling interest	—			(50		)
Net assets acquired	$	1,271,060		$	1,250,949

These preliminary allocations are subject to revision within the measurement period, not to exceed one year from the date of the acquisitions.

Dispositions

On April 7, 2017, the Company closed an agreement to sell a portfolio of four medical office buildings located in Georgia (the “Georgia Portfolio”), for approximately $18.2 million, which reflects a gain of approximately $5.2 million.

On August 15, 2017, the Company completed the disposition of land with a carrying value of $7.7 million in a sale-leaseback at the Peachtree Dunwoody Medical Center. The Company entered into a 90 year term ground lease at closing with all rent prepaid in consideration of the full present value of rent owed. There was no gain or loss recorded as a result of this transaction.

On December 18, 2017, the Company sold one 20,939 square foot medical office building located in Nebraska for approximately $2.5 million, recording a gain of approximately $0.7 million.

The following table summarizes revenues and net income related to the disposition properties for the periods presented (in thousands):

	Year Ended December 31,
	2017		2016		2015
Revenue	$	823	$	1,967	$	1,666
Income before gain on sale of investment properties	108		433		421
Gain on sale of investment properties	5,870		—		—
Net income	$	5,978	$	433	$	421

Unaudited Pro Forma Financial Information

Physicians Realty Trust

The following table illustrates the pro forma consolidated revenue, net income, and earnings per share as if the Company had acquired the 2017 acquisitions detailed above as of January 1, 2016 (in thousands, except share and per share amounts):

	Year Ended December 31,
	2017		2016
Revenue	$	405,320	$	352,432
Net income	42,149		39,233
Net income available to common shareholders	39,759		35,614
Earnings per share - basic	$	0.24	$	0.22
Earnings per share - diluted	$	0.24	$	0.22
Weighted average number of shares outstanding - basic	163,123,109		163,123,109
Weighted average number of shares outstanding - diluted	168,231,299		168,231,299

Physicians Realty L.P.

The following table illustrates the pro forma consolidated revenue, net income, and earnings per share as if the Company had acquired the 2017 acquisitions detailed above as of January 1, 2016 (in thousands, except unit and per unit amounts):

	Year Ended December 31,
	2017		2016
Revenue	$	405,320	$	352,432
Net income	42,149		39,233
Net income available to common unitholders	40,927		36,660
Earnings per unit - basic	$	0.24	$	0.22
Earnings per unit - diluted	$	0.24	$	0.22
Weighted average number of units outstanding - basic	167,963,076		167,963,076
Weighted average number of units outstanding - diluted	168,231,299		168,231,299

XML

Intangibles

12 Months Ended

Dec. 31, 2017

Finite-Lived Intangible Assets, Net [Abstract]

Intangibles

Intangibles

The following is a summary of the carrying amount of intangible assets and liabilities as of December 31, 2017 and 2016 (in thousands):

	December 31, 2017							December 31, 2016
	Cost		Accumulated Amortization			Net		Cost		Accumulated Amortization			Net
Assets
In-place leases	$	343,429	$	(85,424	)	$	258,005	$	222,394	$	(55,605	)	$	166,789
Above-market leases	54,148		(11,968		)	42,180		35,478		(6,909		)	28,569
Leasehold interest	712		(183		)	529		712		(124		)	588
Below-market ground lease	60,424		(1,344		)	59,080		42,878		(539		)	42,339
Total	$	458,713	$	(98,919	)	$	359,794	$	301,462	$	(63,177	)	$	238,285
Liabilities
Below-market lease	$	14,344	$	(4,479	)	$	9,865	$	10,297	$	(2,345	)	$	7,952
Above-market ground lease	5,965		(128		)	5,837		1,345		(44		)	1,301
Total	$	20,309	$	(4,607	)	$	15,702	$	11,642	$	(2,389	)	$	9,253

The following is a summary of the acquired lease intangible amortization for the years ended December 31, 2017, 2016, and 2015 (in thousands):

	December 31,
	2017		2016		2015
Amortization expense related to in-place leases	$	37,073	$	28,902	$	15,300
Decrease of rental income related to above-market leases	5,357		4,403		2,596
Decrease of rental income related to leasehold interests	59		59		59
Increase of rental income related to below-market leases	2,309		1,835		643
Decrease of operating expense related to above-market ground leases	84		24		16
Increase in operating expense related to below-market ground leases	810		471		68

For the twelve months ended December 31, 2017, the Company wrote-off in-place lease intangible assets of approximately $3.5 million with accumulated amortization of approximately $2.1 million, resulting in the recognition of $1.4 million in additional amortization expense. The Company also wrote-off above-market lease intangible assets of approximately $0.3 million with accumulated amortization of approximately $0.1 million, resulting in the recognition of $0.2 million in additional amortization expense. In addition, the Company, wrote-off below-market lease intangible of approximately $0.1 million with accumulated amortization of approximately $36.0 thousand, resulting in the recognition of $0.1 million reduction in amortization expense, for a net recognition of approximately $1.5 million reduction in rental income from intangible amortization.

Future aggregate net amortization of the acquired lease intangibles as of December 31, 2017, is as follows (in thousands): 

	Net Decrease in Revenue			Net Increase in Expenses
2018	$	(3,355	)	$	41,455
2019	(3,376		)	36,429
2020	(3,392		)	33,009
2021	(3,333		)	30,582
2022	(2,872		)	26,225
Thereafter	(16,516		)	143,548
Total	$	(32,844	)	$	311,248

For the year ended December 31, 2017, the weighted average amortization period for asset lease intangibles and liability lease intangibles are 18 years and 20 years, respectively.

XML

Other Assets

12 Months Ended

Dec. 31, 2017

Other Assets, Unclassified [Abstract]

Other Assets

Other Assets

Other assets consisted of the following as of December 31, 2017 and 2016 (in thousands):

	December 31,
	2017		2016
Straight line rent receivable	47,599		32,018
Prepaid expenses	18,103		8,928
Interest rate swap	14,693		13,881
Lease inducements, net	14,232		13,255
Leasing commissions, net	4,128		1,858
Earnest deposits	2,780		1,500
Escrows	1,996		4,334
Notes receivable	—		16,618
Other	2,771		2,795
Total	$	106,302	$	95,187

XML

Debt

12 Months Ended

Dec. 31, 2017

Debt Disclosure [Abstract]

Debt

Debt

The following is a summary of debt as of December 31, 2017 and 2016 (in thousands):

	December 31,
	2017				2016
Fixed interest mortgage notes	$	158,171		(1)	$	90,185		(2)
Variable interest mortgage notes	28,509			(3)	33,009			(4)
Total mortgage debt	186,680				123,194
$850 million unsecured revolving credit facility bearing variable interest of LIBOR plus 1.20%, due September 2020	80,000				401,000
$400 million senior unsecured notes bearing fixed interest of 4.30%, due March 2027	400,000				—
$350 million senior unsecured notes bearing fixed interest of 3.95%, due January 2028	350,000				—
$250 million unsecured term borrowing bearing fixed interest of 2.87%, due June 2023	250,000			(5)	250,000
$150 million senior unsecured notes bearing fixed interest of 4.03% to 4.74%, due January 2023 to 2031	150,000				150,000
$75 million senior unsecured notes bearing fixed interest of 4.09% to 4.24%, due August 2025 to 2027	75,000				75,000
Total principal	1,491,680				999,194
Unamortized deferred financing cost	(7,808		)		(8,477		)
Unamortized discount	(6,663		)		—
Unamortized fair value adjustment	259				438
Total debt	$	1,477,468			$	991,155

(1) Fixed interest mortgage notes, bearing interest from 3.00% to 5.50%, with a weighted average interest rate of 4.45%, and due in 2018, 2019, 2020, 2021, 2022, and 2024 collateralized by nine properties with a net book value of $267.7 million.

(2) Fixed interest mortgage notes, bearing interest from 4.71% to 6.58%, with a weighted average interest rate of 5.44%, and due in 2017, 2018, 2019, 2020, 2021, 2022, and 2032 collateralized by 11 properties with a net book value of $156.7 million.

(3) Variable interest mortgage notes, bearing variable interest of LIBOR plus 2.25% to 3.25%, with a weighted average interest rate of 4.50% and due in 2018, collateralized by three properties with a net book value of $39.2 million.

(4) Variable interest mortgage notes bearing variable interest of LIBOR plus 2.25% to 3.25%, with a weighted average interest rate of 3.68% and due in 2017 and 2018, collateralized by four properties with a net book value of $45.6 million.

(5) The Trust’s borrowings under the term loan feature of the Credit Agreement bear interest at a rate which is determined by the Trust’s credit rating, currently equal to LIBOR + 1.80%. The Trust has entered into a pay-fixed receive-variable interest rate swap, fixing the LIBOR component of this rate at 1.07%.

On June 10, 2016, the Operating Partnership, as borrower, and the Trust entered into an amended and restated Credit Agreement with KeyBank National Association, as administrative agent, KeyBanc Capital Markets Inc., BMO Capital Markets, and Citizens Bank N.A., as joint lead arrangers and co-book runners, BMO Capital Markets and Citizens Bank N.A., as co-syndication agents, and the lenders party thereto (the “Credit Agreement”) which increased the maximum principal amount available under an unsecured revolving credit facility from $750 million to $850 million. The Credit Agreement contains a 7-year term loan feature allowing the Operating Partnership to borrow in a single drawing up to $250 million, increasing the borrowing capacity to an aggregate $1.1 billion. The Credit Agreement also includes a swingline loan commitment for up to 10% of the maximum principal amount and provides an accordion feature allowing the Trust to increase borrowing capacity by up to an additional $500 million, subject to customary terms and conditions, resulting in a maximum borrowing capacity of $1.6 billion.

On July 7, 2016, the Operating Partnership borrowed $250.0 million under the 7-year term loan feature of the Credit Agreement. Borrowings under the term loan feature of the Credit Agreement bear interest on the outstanding principal amount at a rate which is determined by the Trust’s credit rating, currently equal to LIBOR + 1.80%. The Trust simultaneously entered into a pay-fixed receive-variable rate swap for the full borrowing amount, fixing the LIBOR component of the borrowing rate to 1.07%, for an all-in fixed rate of 2.87%. Both the borrowing and pay-fixed receive-variable swap have a maturity date of June 10, 2023.

The Credit Agreement has a maturity date of September 18, 2020 and includes a one year extension option. Borrowings under the Credit Agreement bear interest on the outstanding principal amount at an adjusted LIBOR rate, which is based on the Trust’s investment grade rating under the Credit Agreement. As of December 31, 2017, the Trust had an investment grade rating from Moody’s of Baa3 and from S&P of BBB-. As such, borrowings under the revolving credit facility of the Credit Agreement accrued interest on the outstanding principal at a rate of LIBOR plus 1.20%. The Credit Agreement includes a facility fee equal to 0.25% per annum, which is also determined by the Trust’s investment grade rating.

The Credit Agreement contains financial covenants that, among other things, require compliance with leverage and coverage ratios and maintenance of minimum tangible net worth, as well as covenants that may limit the Trust’s and the Operating Partnership’s ability to incur additional debt or make distributions. The Company may, at any time, voluntarily prepay any revolving or swingline loan under the Credit Agreement in whole or in part without premium or penalty. Prepayments of term borrowings require payment of premiums of up to 2.0% of the amount of prepayment, dependent on the date of such prepayment. As of December 31, 2017, the Company was in compliance with all financial covenants related to the Credit Agreement.

The Credit Agreement includes customary representations and warranties by the Trust and the Operating Partnership, and imposes customary covenants on the Operating Partnership and the Trust. The Credit Agreement also contains customary events of default, and if an event of default occurs and continues, the Operating Partnership is subject to certain actions by the administrative agent, including without limitation, the acceleration of repayment of all amounts outstanding under the Credit Agreement.

The Credit Agreement provides for revolving credit and term loans to the Trust and the Operating Partnership. Base Rate Loans, Adjusted LIBOR Rate Loans, and Letters of Credit (each, as defined in the Credit Agreement) will be subject to interest rates, based upon the Trust’s investment grade rating as follows:

Credit Rating	Margin for Revolving Loans: Adjusted LIBOR Rate Loans and Letter of Credit Fee	Margin for Revolving Loans: Base Rate Loans		Margin for Term Loans: Adjusted LIBOR Rate Loans and Letter of Credit Fee	Margin for Term Loans: Base Rate Loans
At Least A- or A3	LIBOR + 0.85%	—	%	LIBOR + 1.40%	0.40	%
At Least BBB+ or Baa1	LIBOR + 0.90%	—	%	LIBOR + 1.45%	0.45	%
At Least BBB or Baa2	LIBOR + 1.00%	0.10	%	LIBOR + 1.55%	0.55	%
At Least BBB- or Baa3	LIBOR + 1.20%	0.20	%	LIBOR + 1.80%	0.80	%
Below BBB- or Baa3	LIBOR + 1.55%	0.60	%	LIBOR + 2.25%	1.25	%

As of December 31, 2017, the Company had $80.0 million of borrowings outstanding under its unsecured revolving credit facility, and $250.0 million of borrowings outstanding under the term loan feature of the Credit Agreement. The Company also issued a letter of credit for $17.0 million with no outstanding balance as of December 31, 2017. As defined by the Credit Agreement, $753.0 million is available to borrow without adding additional properties to the unencumbered borrowing base of assets.

Notes Payable

On January 7, 2016, the Operating Partnership issued and sold $150.0 million aggregate principal amount of senior notes, comprised of (i) $15.0 million aggregate principal amount of 4.03% Senior Notes, Series A, due January 7, 2023, (ii) $45.0 million aggregate principal amount of 4.43% Senior Notes, Series B, due January 7, 2026, (iii) $45.0 million aggregate principal amount of 4.57% Senior Notes, Series C, due January 7, 2028, and (iv) $45.0 million aggregate principal amount of 4.74% Senior Notes, Series D, due January 7, 2031. On August 11, 2016, the note agreement for these notes was amended to make certain changes to its terms, including certain changes to affirmative covenants, negative covenants, and definitions contained therein. Interest on each respective series of the January 2016 Senior Notes is payable semi-annually.

On August 11, 2016, the Operating Partnership issued and sold $75.0 million aggregate principal amount of senior notes, comprised of (i) $25.0 million aggregate principal amount of 4.09% Senior Notes, Series A, due August 11, 2025, (ii)

$25.0 million aggregate principal amount of 4.18% Senior Notes, Series B, due August 11, 2026, and (iii) $25.0 million aggregate principal amount of 4.24% Senior Notes, Series C, due August 11, 2027. Interest on each respective series of the August 2016 Senior Notes is payable semi-annually.

On January 26, 2017, the Company entered into a $300.0 million notional amount forward starting swap to reduce the exposure to fluctuations in interest rates related to the forecasted issuance of the 4.30% senior notes due in 2027. Upon the issuance of the senior notes on March 7, 2017, the forward starting swap was terminated and the Company recorded a $0.8 million loss which will be recognized over the life of the notes utilizing the effective interest method.

On March 7, 2017, the Operating Partnership issued and sold $400.0 million aggregate principal amount of 4.30% Senior Notes which will mature on March 15, 2027. The Senior Notes began accruing interest on March 7, 2017 and began paying interest semi-annually beginning September 15, 2017. The Senior Notes were sold at an issue price of 99.68% of their face value, before the underwriters’ discount. Our net proceeds from the offering, after deducting underwriting discounts and expenses, were approximately $396.1 million.

On December 1, 2017, the Operating Partnership issued and sold $350.0 million aggregate principal amount of 3.95% Senior Notes which will mature on January 15, 2028. The Senior Notes began accruing interest on December 1, 2017 and will begin paying interest semi-annually beginning July 15, 2018. The Senior Notes were sold at an issue price of 99.78% of their face value, before the underwriters’ discount. Our net proceeds from the offering, after deducting underwriting discounts and expenses, were approximately $347.0 million.

Certain properties have mortgage debt that contains financial covenants. As of December 31, 2017, the Trust was in compliance with all mortgage debt financial covenants.

Scheduled principal payments due on debt as of December 31, 2017, are as follows (in thousands):

2018	$	54,775
2019	44,631
2020	110,122
2021	8,718
2022	24,708
Thereafter	1,248,726
Total Payments	$	1,491,680

As of December 31, 2017 and 2016, the Company had total consolidated indebtedness of approximately $1.5 billion and $1.0 billion, respectively. The weighted average interest rate on consolidated indebtedness was 3.93% as of December 31, 2017 (based on the 30-day LIBOR rate as of December 31, 2017 of 1.49%). The weighted average interest rate on consolidated indebtedness was 3.09% as of December 31, 2016 (based on the 30-day LIBOR rate as of December 31, 2016 of 0.72%).

For the years ended December 31, 2017 and 2016, the Company paid interest expense on its debt of $45.1 million and $21.5 million, respectively.

XML

Derivatives

12 Months Ended

Dec. 31, 2017

Derivative Instrument Detail [Abstract]

Derivatives

Derivatives

In the normal course of business, a variety of financial instruments are used to manage or hedge interest rate risk. The Company has implemented ASC 815, Derivatives and Hedging (ASC 815), which establishes accounting and reporting standards requiring that all derivatives, including certain derivative instruments embedded in other contracts, be recorded as either an asset or a liability measured at their fair value unless they qualify for a normal purchase or normal sales exception.

When specific hedge accounting criteria are not met, ASC 815 requires that changes in a derivative’s fair value be recognized currently in earnings. Changes in the fair market values of the Company’s derivative instruments are recorded in the consolidated statements of income if such derivatives do not qualify for, or the Company does not elect to apply for, hedge accounting. If hedge accounting is applied to a derivative instrument, such changes are reported in accumulated other comprehensive income within the equity section of the consolidated balance sheets, exclusive of ineffectiveness amounts, which are recorded as adjustments to net income.

To manage interest rate risk for certain of its variable-rate debt, the Company uses interest rate swaps as part of its risk management strategy. These derivatives are designed to mitigate the risk of future interest rate increases by providing a fixed interest rate for a limited, pre-determined period of time. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. As of December 31, 2017, the Company had five outstanding interest rate swap contracts that are designated as cash flow hedges of interest rate risk. For presentational purposes, they are shown as one derivative due to the identical nature of their economic terms.

The effective portion of the change in the fair value of derivatives designated and that qualify as cash flow hedges is recorded in accumulated other comprehensive income on the consolidated balance sheets and is subsequently reclassified into earnings as interest expense for the period that the hedged forecasted transaction affects earnings. The ineffective portion of the change in fair value of the derivatives is recognized directly in earnings. For the twelve months ended December 31, 2017, the Company recorded a $0.2 million loss as a result of hedge ineffectiveness. The Company expects hedge ineffectiveness to be insignificant in the next 12 months.

The following table summarizes the location and aggregate fair value of the interest rate swaps on the Company’s consolidated balance sheets (in thousands):

Total notional amount		$	250,000
Effective fixed interest rate	(1)	2.87		%
Effective date		7/7/2016
Maturity date		6/10/2023
Asset balance at December 31, 2017 (included in Other assets)		$	14,693

(1)

1.07% effective swap rate plus 1.80% spread per Credit Agreement.

XML

Accrued Expenses and Other Liabilities

12 Months Ended

Dec. 31, 2017

Other Liabilities Disclosure [Abstract]

Accrued Expenses and Other Liabilities

Accrued Expenses and Other Liabilities

Accrued expenses and other liabilities consisted of the following as of December 31, 2017 and 2016 (in thousands):

	December 31,
	2017		2016
Real estate taxes payable	$	16,103	$	9,300
Accrued interest	11,107		4,905
Prepaid rent	10,496		5,834
Accrued expenses	8,751		3,453
Tenant improvement allowance	3,065		5,315
Security deposits	2,882		4,506
Accrued incentive compensation	1,625		1,405
Contingent consideration	1,454		1,392
Embedded derivative	—		5,571
Other	922		606
Total	$	56,405	$	42,287

XML

Stock-based Compensation

12 Months Ended

Dec. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-based Compensation

Stock-based Compensation

The Company follows ASC 718, Compensation – Stock Compensation (“ASC 718”), in accounting for its share-based payments. This guidance requires measurement of the cost of employee services received in exchange for stock compensation based on the grant-date fair value of the employee stock awards. This cost is recognized as compensation expense ratably over the employee’s requisite service period. Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized when incurred. Share-based payments classified as liability awards are marked to fair value at each reporting period. Any Common Shares issued pursuant to the Company’s incentive equity compensation and employee stock purchase plans will result in the Operating Partnership issuing OP Units to the Trust on a one-for-one basis, with the Operating Partnership receiving the net cash proceeds of such issuances.

Certain of the Company’s employee stock awards vest only upon the achievement of performance targets. ASC 718 requires recognition of compensation cost only when achievement of performance conditions is considered probable. Consequently, the Company’s determination of the amount of stock compensation expense requires a significant level of judgment in estimating the probability of achievement of these performance targets. Additionally, the Company must make estimates regarding employee forfeitures in determining compensation expense. Subsequent changes in actual experience are monitored and estimates are updated as information is available.

In connection with the IPO, the Trust adopted the 2013 Equity Incentive Plan (“2013 Plan”), which made available 600,000 common shares to be administered by the Compensation and Nominating Governance Committee of the Board of Trustees. On August 7, 2014, at the Annual Meeting of Shareholders of Physicians Realty Trust, the Trust’s shareholders approved an amendment to the 2013 Plan to increase the number of common shares authorized for issuance under the 2013 Plan by 1,850,000 common shares, for a total of 2,450,000 common shares authorized for issuance.

Restricted Common Shares:

Restricted common shares granted under the 2013 Plan are eligible for dividends as well as the right to vote. During 2015, a total of 162,522 restricted common shares with a total value of $2.6 million were granted to Trust employees and the Board of Trustees with vesting periods ranging from one to three years. During 2016, a total of 155,306 restricted common shares with a total value of $2.8 million were granted to Company employees with vesting periods ranging from one to three years. During 2017, the Trust granted a total of 143,593 restricted common shares with a total value of $2.8 million to the Company’s officers and certain of its employees, which have a one-year vesting period for senior management award-recipients and a three-year vesting period for employee award-recipients.

The following is summary of the status of the Trust’s non-vested restricted common shares during 2017, 2016, and 2015:

	Common Shares		Weighted Average Grant Date Fair Value
Non-vested at December 31, 2014	319,654		$	12.60
Granted	162,522		15.95
Vested	(170,337	)	12.93
Non-vested at December 31, 2015	311,839		14.17
Granted	155,306		17.96
Vested	(170,034	)	14.16
Forfeited	(326	)	15.36
Non-vested at December 31, 2016	296,785		16.16
Granted	143,593		19.74
Vested	(266,552	)	16.00
Forfeited	(550	)	18.78
Non-vested at December 31, 2017	173,276		$	19.36

For all service awards, the Company records compensation expense for the entire award on a straight-line basis over the requisite service period. For the years ended December 31, 2017, 2016, and 2015 the Company recognized non-cash share compensation of $3.1 million, $3.6 million, and $2.9 million, respectively. Unrecognized compensation expense at December 31, 2017, 2016, and 2015 was $1.0 million, $1.2 million, and $2.1 million, respectively. 

Restricted Share Units:

In March 2017, March 2016, and March 2015 under the Trust’s 2013 Plan, the Trust granted (i) restricted share units at a target level of 174,320, 104,553, and 75,250 respectively, to the Trust’s senior management, which are subject to certain performance and market conditions and a three-year service period and (ii) 32,831, 36,784, and 40,957 restricted share units, respectively, to the members of the Board of Trustees, which are subject to a two-year vesting period. Each restricted share unit contains one dividend equivalent. The recipient will accrue dividend equivalents on awarded share units equal to the cash dividend that would have been paid on the awarded share unit had the awarded share unit been an issued and outstanding common share on the record date for the dividend.

Approximately 70% of the restricted share units issued to officers in 2017, and 80% issued to officers in 2016 and 2015, vest based on certain market conditions. The market conditions were valued with the assistance of independent valuation specialists. The Company utilized a Monte Carlo simulation to calculate the weighted average grant date fair values in 2017, 2016, and 2015 of $33.43, $28.50, and $20.06 per unit, respectively, using the following assumptions:

	2017			2016			2015
Volatility	21.5		%	20.3		%	20.7		%
Dividend assumption	reinvested			reinvested			reinvested
Expected term in years	2.8 years			2.8 years			2.8 years
Risk-free rate	1.68		%	1.07		%	1.14		%
Stock price (per share)	$	19.80		$	17.67		$	15.87

 The remaining 30% of the restricted share units issued to officers in 2017, and 20% issued to officers in 2016 and 2015, vest based upon certain performance conditions. With respect to the performance conditions of the March 2017 grant, the grant date fair value of $19.80 per unit was based on the share price at the date of grant. The combined weighted average grant date fair value of the March 2017 restricted share units issued to officers is $29.34 per unit. With respect to the performance conditions of the March 2016 grant, the grant date fair value of $17.67 per unit was based on the share price at the date of grant. The combined weighted average grant date fair value of the March 2016 restricted share units issued to officers is $26.33 per unit. With respect to the performance conditions of the March 2015 grant, the grant date fair value of $15.87 per unit was based on the share price at the date of grant. The combined weighted average grant date fair value of the March 2015 restricted share units issued to officers is $19.22 per unit.

The following is a summary of the activity in the Trust’s restricted share units during 2017, 2016, and 2015: 

	Executive Awards				Trustee Awards
	Restricted Share Units		Weighted Average Grant Date Fair Value		Restricted Share Units		Weighted Average Grant Date Fair Value
Non-vested at December 31, 2014	55,680		$	16.94	—		$	—
Granted	75,250		19.22		40,957		15.87
Non-vested at December 31, 2015	130,930		18.48		40,957		15.87
Granted	104,553		26.33		36,784		17.67
Vested	—		—		(20,481	)	15.87
Non-vested at December 31, 2016	235,483		21.84		57,260		17.03
Granted	174,320		29.34		32,831		19.80
Vested	(55,680	)	16.94		(38,871	)	16.72
Non-vested at December 31, 2017	354,123		$	26.30	51,220		$	19.04

The Company recognized $3.6 million, $2.1 million, and $0.9 million of non-cash share unit compensation expense for the years ended December 31, 2017, 2016, and 2015, respectively. Unrecognized compensation expense at December 31, 2017, 2016, and 2015 was $5.0 million, $2.8 million, and $1.6 million, respectively.

XML

Fair Value Measurements

12 Months Ended

Dec. 31, 2017

Fair Value Disclosures [Abstract]

Fair Value Measurements

Fair Value Measurements

ASC Topic 820, Fair Value Measurement (“ASC 820”), requires certain assets and liabilities be reported and/or disclosed at fair value in the financial statements and provides a framework for establishing that fair value. The framework for determining fair value is based on a hierarchy that prioritizes the valuation techniques and inputs used to measure fair value.

In general, fair values determined by Level 1 inputs use quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Fair values determined by Level 2 inputs use other inputs that are observable, either directly or indirectly. These Level 2 inputs include quoted prices for similar assets and liabilities in active markets, and other inputs such as interest rates and yield curves that are observable at commonly quoted intervals.

Level 3 inputs are unobservable inputs, including inputs that are available in situations where there is little, if any, market activity for the related asset. These Level 3 fair value measurements are based primarily on management’s own estimates using pricing models, discounted cash flow methodologies, or similar techniques taking into account the

characteristics of the asset or liability. In instances where inputs used to measure fair value fall into different levels of the fair value hierarchy, fair value measurements in their entirety are categorized based on the lowest level input that is significant to the valuation. The assessment of the significance of particular inputs to these fair value measurements requires judgment and considers factors specific to each asset or liability.

The Company’s derivative instruments as of December 31, 2017, consist of five interest rate swaps. For presentational purposes, the Company’s interest rate swaps are shown as a single derivative due to the identical nature of their economic terms, as detailed in the Derivative Instruments section of Note 2 (Summary of Significant Accounting Policies) and Note 7 (Derivatives).

The Company’s interest rate swaps are not traded on an exchange. The Company’s derivative assets and liabilities are recorded at fair value based on a variety of observable inputs including contractual terms, interest rate curves, yield curves, measure of volatility, and correlations of such inputs. The Company measures its derivatives at fair value on a recurring basis. The fair values are based on Level 2 inputs described above. The Company considers its own credit risk, as well as the credit risk of its counterparties, when evaluating the fair value of its derivatives.

The Company also has assets that under certain conditions are subject to measurement at fair value on a non-recurring basis. This generally includes assets subject to impairment. There was one asset measured at fair value as of December 31, 2017.

The carrying amounts of cash and cash equivalents, tenant receivables, payables, and accrued interest are reasonable estimates of fair value because of the short term maturities of these instruments. Fair values for real estate loans receivable and mortgage debt are estimated based on rates currently prevailing for similar instruments of similar maturities and are based primarily on Level 2 inputs.

The following table presents the fair value of the Company’s financial instruments (in thousands):

	December 31,
	2017						2016
	Carrying Amount			Fair Value			Carrying Amount			Fair Value
Assets:
Real estate loans receivable	$	76,195		$	75,288		$	39,154		$	39,154
Notes receivable	$	—		$	—		$	16,618		$	16,618
Derivative assets	$	14,693		$	14,693		$	13,881		$	13,881
Liabilities:
Credit facility	$	(330,000	)	$	(330,000	)	$	(651,000	)	$	(651,000	)
Notes payable	$	(975,000	)	$	(970,975	)	$	(225,000	)	$	(214,584	)
Mortgage debt	$	(186,939	)	$	(185,743	)	$	(123,632	)	$	(125,420	)
Derivative liabilities	$	—		$	—		$	(5,571	)	$	(5,571	)

XML

Tenant Operating Leases

12 Months Ended

Dec. 31, 2017

Leases [Abstract]

Tenant Operating Leases

Tenant Operating Leases

The Company is lessor of medical office buildings and other healthcare facilities. Leases have expirations from 2018 through 2045. As of December 31, 2017, the future minimum rental payments on non-cancelable leases, exclusive of expense recoveries, were as follows (in thousands):

2018	$	292,030
2019	291,338
2020	285,100
2021	278,095
2022	265,995
Thereafter	1,419,746
Total	$	2,832,304

XML

Rent Expense

12 Months Ended

Dec. 31, 2017

Leases [Abstract]

Rent Expense

Rent Expense

The Company leases the rights to parking structures at 2 of its properties, the air space above 1 property, and the land upon which 78 of its properties are located from third party land owners pursuant to separate leases. In addition, the Company leases 4 individual office spaces. The leases require fixed rental payments and may also include escalation clauses and renewal options. These leases have terms of up to 98 years remaining, excluding extension options. As of December 31, 2017, the future minimum lease obligations under non-cancelable parking, air, ground, and office leases were as follows (in thousands):

2018	$	2,678
2019	2,604
2020	2,549
2021	2,563
2022	2,585
Thereafter	119,224
Total	$	132,203

Rent expense for the parking, air, and ground leases of $2.4 million, $1.9 million, and $1.3 million for the years ended December 31, 2017, 2016, and 2015, respectively, are reported in operating expenses in the consolidated statements of income. Rent expense for office leases for the year as of December 31, 2017 was $0.1 million and was insignificant for the years ended December 31, 2016, and 2015, and is reported within general and administrative expenses in the consolidated statements of income.

XML

Credit Concentration

12 Months Ended

Dec. 31, 2017

Risks and Uncertainties [Abstract]

Credit Concentration

Credit Concentration

The Company uses annualized base rent (“ABR”) as its credit concentration metric. Annualized base rent is calculated by multiplying contractual base rent for the month ended December 31, 2017 by 12, excluding the impact of concessions and straight-line rent. The following table summarizes certain information about the Company’s top five tenant credit concentrations as of December 31, 2017 (in thousands):

Tenant	Total ABR		Percent of ABR
CHI - Nebraska	$	15,906	5.6	%
CHI - KentuckyOne Health	13,120		4.6	%
Baylor Scott and White Health	7,402		2.6	%
US Oncology	6,706		2.4	%
CHI - St. Alexius (ND)	6,239		2.2	%
Remaining portfolio	236,297		82.6	%
Total	$	285,670	100.0	%

Annualized base rent collected from the Company’s top five tenant relationships comprises 17.4% of its total annualized base rent for the period ending December 31, 2017. Total annualized base rent from CHI affiliated tenants totals 18.7%, including the affiliates disclosed above. Although CHI is not a party to nor a guarantor of the related lease agreements, it controls each of the subsidiaries and the affiliates that are parties to the master lease agreements, which were entered into in connection with the closing of the transactions. Consolidated financial statements of CHI, the parent of the subsidiaries and affiliates of the entities party to master lease agreements, are publicly available on the Catholic Health Initiatives website (http://www.catholichealthinitiatives.org/). Information included on the CHI website is not incorporated by reference within this Annual Report on Form 10-K.

The following table summarizes certain information about the Company’s top five geographic concentrations as of December 31, 2017 (in thousands):

State	Total ABR		Percent of ABR
Texas	$	46,850	16.4	%
Georgia	27,457		9.6	%
Indiana	18,283		6.4	%
Nebraska	17,304		6.1	%
Kentucky	16,028		5.6	%
Other	159,748		55.9	%
Total	$	285,670	100.0	%

XML

Earnings Per Share and Earnings Per Unit

12 Months Ended

Dec. 31, 2017

Earnings Per Share [Abstract]

Earnings Per Share and Earnings Per Unit

Earnings Per Share and Earnings Per Unit

The following table shows the amounts used in computing the Trust’s basic and diluted earnings per share (in thousands, except share and per share data):

	Year Ended December 31,
	2017			2016			2015
Numerator for earnings per share - basic:
Net income	$	39,773		$	31,522		$	12,741
Net income attributable to noncontrolling interests:
Operating Partnership	(1,136		)	(825		)	(576		)
Partially owned properties	(491		)	(716		)	(377		)
Preferred distributions	(731		)	(1,857		)	(1,189		)
Numerator for earnings per share - basic:	$	37,415		$	28,124		$	10,599
Numerator for earnings per share - diluted:
Numerator for earnings per share - basic:	37,415			28,124			10,599
Operating Partnership net income	1,136			825			576
Numerator for earnings per share - diluted	$	38,551		$	28,949		$	11,175
Denominator for earnings per share - basic and diluted:
Weighted average number of shares outstanding - basic	163,123,109			126,143,114			72,750,724
Effect of dilutive securities:
Noncontrolling interest - Operating Partnership units	4,839,967			3,692,095			3,708,494
Restricted shares	89,497			205,036			190,619
Restricted share units	178,726			426,648			142,236
Denominator for earnings per share - diluted	168,231,299			130,466,893			76,792,073
Earnings per share - basic	$	0.23		$	0.22		$	0.15
Earnings per share - diluted	$	0.23		$	0.22		$	0.15

The following table shows the amounts used in computing the Operating Partnership’s basic and diluted earnings per unit (in thousands, except unit and per unit data):

	Year Ended December 31,
	2017			2016			2015
Numerator for earnings per unit - basic and diluted:
Net income	39,773			31,522			12,741
Net income attributable to noncontrolling interests - partially owned properties	(491		)	(716		)	(377		)
Preferred distributions	(731		)	(1,857		)	(1,189		)
Numerator for earnings per unit - basic and diluted	$	38,551		$	28,949		$	11,175
Denominator for earnings per unit - basic and diluted:
Weighted average number of units outstanding - basic	167,963,076			129,835,209			76,459,218
Effect of dilutive securities:
Restricted shares	89,497			205,036			190,619
Restricted share units	178,726			426,648			142,236
Denominator for earnings per unit - diluted	168,231,299			130,466,893			76,792,073
Earnings per unit - basic	$	0.23		$	0.22		$	0.15
Earnings per unit - diluted	$	0.23		$	0.22		$	0.15

XML

Subsequent Events

12 Months Ended

Dec. 31, 2017

Subsequent Events [Abstract]

Subsequent Events

Subsequent Events

Since December 31, 2017, the Trust, through subsidiaries of its Operating Partnership, has completed acquisitions of 2 healthcare properties for an aggregate purchase price of $98.7 million containing an aggregate of 220,140 net leasable square feet and disposed of one property for $1.4 million which resulted in no gain or loss. In addition, the Operating Partnership funded a $2.0 million loan through a separate transaction, resulting in aggregate investment activity of $100.7 million. Property acquisitions are summarized below:

Property		Location	Acquisition Date	Investment (in thousands)
Hazelwood Medical Commons	(1)	Maplewood, MN	January 9, 2018	$	70,702
Lee's Hill Medical Plaza		Fredericksburg, VA	January 23, 2018	28,000
Loan Investment		Pensacola, FL	February 16, 2018	2,000
				$	100,702

(1)

The Company partially funded the purchase price of this acquisition by issuing a total of 104,172 Preferred OP Units valued at approximately $22.7 million in the aggregate on the date of issuance.

XML

Quarterly Data

12 Months Ended

Dec. 31, 2017

Quarterly Financial Information Disclosure [Abstract]

Quarterly Data

Quarterly Data

Physicians Realty Trust

The following unaudited quarterly data has been prepared on the basis of a December 31 year-end. Amounts are in thousands, except for common share and per share amounts.

As a result of the acquisition activity and equity offerings throughout 2017 and 2016, the quarterly periods are not comparable quarter over quarter.

	Quarter Ended
2017	March 31		June 30		September 30		December 31
Total revenues	$	76,666	$	76,599	$	92,999	$	97,320
Operating income	6,688		4,994		12,511		9,523
Net income	6,716		10,331		12,539		10,187
Net income attributable to common shareholders	6,191		9,670		12,018		9,536
Earnings per share – basic:
Net income available to common shareholders	$	0.04	$	0.06	$	0.07	$	0.05
Weighted average number of shares outstanding	138,986,629		155,366,080		177,847,424		179,683,948
Earnings per share – diluted:
Net income available to common shareholders	$	0.04	$	0.06	$	0.07	$	0.05
Weighted average number of shares outstanding	142,605,930		161,012,360		183,298,145		185,273,236

	Quarter Ended
2016	March 31		June 30		September 30		December 31
Total revenues	$	44,134	$	53,216	$	70,010	$	73,674
Operating income	5,392		7,158		10,267		8,590
Net income	5,424		7,184		10,294		8,620
Net income available to common shareholders	4,386		6,486		9,427		7,825
Earnings per share – basic:
Net income available to common shareholders	$	0.04	$	0.05	$	0.07	$	0.06
Weighted average number of shares outstanding	102,704,008		131,481,329		134,608,396		135,581,976
Earnings per share – diluted:
Net income available to common shareholders	$	0.04	$	0.05	$	0.07	$	0.06
Weighted average number of shares outstanding	107,148,380		135,944,722		138,880,787		139,602,349

Physicians Realty L.P.

The following unaudited quarterly data has been prepared on the basis of a December 31 year-end. Amounts are in thousands, except for common unit and per unit amounts.

As a result of the acquisition activity and equity offerings throughout 2017 and 2016, the quarterly periods are not comparable quarter over quarter.

	Quarter Ended
2017	March 31		June 30		September 30		December 31
Total revenues	$	76,666	$	76,599	$	92,999	$	97,320
Operating income	6,688		4,994		12,511		9,523
Net income	6,716		10,331		12,539		10,187
Net income attributable to common unitholders	6,338		9,984		12,380		9,849
Earnings per unit – basic:
Net income available to common unitholders	$	0.04	$	0.06	$	0.07	$	0.05
Weighted average number of units outstanding	142,172,746		160,765,345		183,227,405		185,048,580
Earnings per unit – diluted:
Net income available to common unitholders	$	0.04	$	0.06	$	0.07	$	0.05
Weighted average number of units outstanding	142,605,930		161,012,360		183,298,145		185,273,236

	Quarter Ended
2016	March 31		June 30		September 30		December 31
Total revenues	$	44,134	$	53,216	$	70,010	$	73,674
Operating income	5,392		7,158		10,267		8,590
Net income	5,424		7,184		10,294		8,620
Net income attributable to common unitholders	4,559		6,687		9,682		8,021
Earnings per unit – basic:
Net income available to common unitholders	$	0.04	$	0.05	$	0.07	$	0.06
Weighted average number of units outstanding	106,550,467		135,351,672		138,227,384		139,018,183
Earnings per unit – diluted:
Net income available to common unitholders	$	0.04	$	0.05	$	0.07	$	0.06
Weighted average number of units outstanding	107,148,380		135,944,722		138,880,787		139,602,349

XML

SCHEDULE III - REAL ESTATE AND ACCUMULATED DEPRECIATION

12 Months Ended

Dec. 31, 2017

SEC Schedule III, Real Estate and Accumulated Depreciation Disclosure [Abstract]

SCHEDULE III - REAL ESTATE AND ACCUMULATED DEPRECIATION

				Initial Cost to Company							Gross Amount at Which Carried as of Close of Period
Description	Location	Encumbrances		Land		Buildings and Improvements		Cost Capitalized Subsequent to Acquisitions			Land		Buildings and Improvements		Total		Accumulated Depreciation			Year Built	Date  Acquired	Life on Which Building Depreciation in Income Statement is Computed
Arrowhead Commons	Phoenix, AZ	$	—	$	740	$	2,551	$	730		$	740	$	3,281	$	4,021	$	(563	)	2004	5/31/2008	46
Aurora Medical Office Building	Green Bay, WI	—		500		1,566		—			500		1,566		2,066		(243		)	2010	4/15/2010	50
El Paso Medical Office Building	El Paso, TX	—		860		2,866		406			860		3,272		4,132		(1,809		)	1987	8/24/2006	21
Farmington Professional Pavilion	Detroit, MI	—		580		1,793		132			580		1,925		2,505		(1,478		)	1972	1/5/2006	15
Firehouse Square	Milwaukee, WI	—		1,120		2,768		—			1,120		2,768		3,888		(961		)	2002	8/15/2007	30
Hackley Medical Center	Grand Rapids, MI	—		1,840		6,402		64			1,840		6,466		8,306		(2,381		)	1968	12/22/2006	30
MeadowView Professional Center	Kingsport, TN	—		2,270		11,344		—			2,270		11,344		13,614		(4,054		)	2005	5/10/2007	30
Mid Coast Hospital Medical Office Building	Portland, ME	7,009		—		11,247		81			—		11,328		11,328		(3,614		)	2008	5/1/2008	42
New Albany Professional Building	Columbus, OH	—		237		2,767		621			237		3,388		3,625		(799		)	2000	1/4/2008	42
Remington Medical Commons	Chicago, IL	—		895		6,499		319			895		6,818		7,713		(2,228		)	2008	6/1/2008	30
Summit Healthplex	Atlanta, GA	—		2,633		15,576		5,524			2,633		21,100		23,733		(5,518		)	2002	7/3/2008	44
Valley West Hospital Medical Office Building	Chicago, IL	4,531		—		6,275		620			—		6,895		6,895		(2,357		)	2007	11/1/2007	30
East El Paso Medical Office Building	El Paso, TX	—		710		4,500		—			710		4,500		5,210		(557		)	2004	8/30/2013	35
East El Paso Surgical Hospital	El Paso, TX	—		3,070		23,627		—			3,070		23,627		26,697		(2,844		)	2004	8/30/2013	36
LifeCare Plano LTACH	Plano, TX	—		3,370		11,689		455			3,370		12,144		15,514		(2,119		)	1987	9/18/2013	25
Crescent City Surgical Centre	New Orleans, LA	18,750		—		34,208		—			—		34,208		34,208		(3,029		)	2010	9/30/2013	48
Foundation Surgical Affiliates Medical Office Building	Oklahoma City, OK	7,101		1,300		12,724		—			1,300		12,724		14,024		(1,258		)	2004	9/30/2013	43
Pensacola Medical Office Building	Pensacola, FL	—		990		5,005		16			990		5,021		6,011		(437		)	2012	10/4/2013	49
Central Ohio Neurosurgical Surgeons Medical Office	Columbus, OH	—		981		7,620		—			981		7,620		8,601		(707		)	2007	11/27/2013	44
Great Falls Ambulatory Surgery Center	Great Falls, MT	—		203		3,224		67			203		3,291		3,494		(404		)	1999	12/11/2013	33
Eagles Landing Family Practice Medical Office Building	McDonough, GA	—		800		3,345		1,548			800		4,893		5,693		(532		)	2007	2/19/2014	36
Eagles Landing Family Practice Medical Office Building	Jackson, GA	—		800		3,345		1,255			800		4,600		5,400		(475		)	2006	2/19/2014	38
Eagles Landing Family Practice Medical Office Building	Conyers, GA	—		1,000		3,345		—			1,000		3,345		4,345		(360		)	2008	2/19/2014	37
Eagles Landing Family Practice Medical Office Building	McDonough, GA	—		400		3,345		1,741			400		5,086		5,486		(531		)	2010	2/19/2014	37
Foundation San Antonio Surgical Hospital	San Antonio, TX	7,691		2,230		23,346		43			2,230		23,389		25,619		(2,919		)	2007	2/19/2014	35
21st Century Radiation Oncology Centers — Sarasota	Sarasota, FL	—		633		6,557		—			633		6,557		7,190		(969		)	1975	2/26/2014	27
21st Century Radiation Oncology Centers - Venice	Venice, FL	—		814		2,952		—			814		2,952		3,766		(364		)	1987	2/26/2014	35
21st Century Radiation Oncology Centers - Englewood	Englewood, FL	—		350		1,878		—			350		1,878		2,228		(209		)	1992	2/26/2014	38
21st Century Radiation Oncology Centers — Port Charlotte	Port Charlotte, FL	—		269		2,326		(852		)	156		1,474		1,630		(262		)	1996	2/26/2014	36
Foundation San Antonio Healthplex	San Antonio, TX	—		911		4,189		—			911		4,189		5,100		(480		)	2007	2/28/2014	35
Peachtree Dunwoody Medical Center	Atlanta, GA	17,000		—		27,435		24,894			—		52,329		52,329		(5,076		)	1987	2/28/2014	25
LifeCare LTACH — Fort Worth	Fort Worth, TX	—		2,730		24,639		—			2,730		24,639		27,369		(3,162		)	1985	3/28/2014	30
LifeCare LTACH — Pittsburgh	Pittsburgh, PA	—		1,142		11,737		—			1,142		11,737		12,879		(1,575		)	1987	3/28/2014	30
PinnacleHealth Medical Office Building	Harrisburg, PA	—		795		4,601		—			795		4,601		5,396		(731		)	1990	4/22/2014	25
Pinnacle Health Medical Office Building	Carlisle, PA	—		424		2,232		—			424		2,232		2,656		(255		)	2002	4/22/2014	35
South Bend Orthopaedics Medical Office Building	Mishawaka, IN	—		2,418		11,355		—			2,418		11,355		13,773		(1,195		)	2007	4/30/2014	40
Grenada Medical Complex	Grenada, MS	—		185		5,820		116			185		5,936		6,121		(862		)	1975	4/30/2014	30
Mississippi Ortho Medical Office Building	Jackson, MS	—		1,272		14,177		626			1,272		14,803		16,075		(1,650		)	1987	5/23/2014	35
Carmel Medical Pavilion	Carmel, IN	—		—		3,917		99			—		4,016		4,016		(593		)	1993	5/28/2014	25
Renaissance Ambulatory Surgery Center	Oshkosh, WI	—		228		7,658		17			228		7,675		7,903		(696		)	2007	6/30/2014	40
Presbyterian Medical Plaza	Monroe, NC	—		1,195		5,681		27			1,195		5,708		6,903		(476		)	2008	6/30/2014	45
Summit Urology	Bloomington, IN	—		125		4,792		—			125		4,792		4,917		(573		)	1996	6/30/2014	30
500 Landmark	Bloomington, IN	—		627		3,549		—			627		3,549		4,176		(370		)	2000	7/1/2014	35
550 Landmark	Bloomington, IN	—		2,717		15,224		—			2,717		15,224		17,941		(1,586		)	2000	7/1/2014	35
574 Landmark	Bloomington, IN	—		418		1,493		—			418		1,493		1,911		(159		)	2004	7/1/2014	35
Carlisle II MOB	Carlisle, PA	—		412		3,962		—			412		3,962		4,374		(317		)	1996	7/25/2014	45
Surgical Institute of Monroe	Monroe, MI	—		410		5,743		—			410		5,743		6,153		(659		)	2010	7/28/2014	35
The Oaks @ Lady Lake	Lady Lake, FL	—		1,065		8,642		—			1,065		8,642		9,707		(710		)	2011	7/31/2014	42
Mansfield ASC	Mansfield, TX	—		1,491		6,471		—			1,491		6,471		7,962		(517		)	2010	9/2/2014	46
Eye Center of Southern Indiana	Bloomington, IN	—		910		11,477		—			910		11,477		12,387		(1,134		)	1995	9/5/2014	35
Wayne State	Troy, MI	—		3,560		43,052		—			3,560		43,052		46,612		(3,921		)	1986	9/10/2014	38
Zangmeister	Columbus, OH	—		1,610		31,120		4			1,610		31,124		32,734		(2,644		)	2007	9/30/2014	40
Ortho One - Columbus	Columbus, OH	—		—		16,234		7			—		16,241		16,241		(1,309		)	2009	9/30/2014	45
Ortho One - Westerville	Columbus, OH	—		362		3,944		—			362		3,944		4,306		(328		)	2007	9/30/2014	43
Berger Medical Center	Columbus, OH	—		—		5,950		—			—		5,950		5,950		(561		)	2007	9/30/2014	38
El Paso - Lee Trevino	El Paso, TX	—		2,294		11,316		412			2,294		11,728		14,022		(1,351		)	1983	9/30/2014	30
El Paso - Murchison	El Paso, TX	—		2,283		24,543		1,303			2,283		25,846		28,129		(2,895		)	1970	9/30/2014	30
El Paso - Kenworthy	El Paso, TX	—		728		2,178		25			728		2,203		2,931		(230		)	1983	9/30/2014	35
Pinnacle - 32 Northeast	Harrisburg, PA	—		408		3,232		91			408		3,323		3,731		(352		)	1994	10/29/2014	33
Pinnacle - 4518 Union Deposit	Harrisburg, PA	—		617		7,305		15			617		7,320		7,937		(803		)	2000	10/29/2014	31
Pinnacle - 4520 Union Deposit	Harrisburg, PA	—		169		2,055		—			169		2,055		2,224		(244		)	1997	10/29/2014	28

			Initial Cost to Company			Gross Amount at Which Carried as of Close of Period
Description	Location	Encumbrances	Land	Buildings and Improvements	Cost Capitalized Subsequent to Acquisitions	Land	Buildings and Improvements	Total	Accumulated Depreciation		Year Built	Date  Acquired	Life on Which Building Depreciation in Income Statement is Computed
Pinnacle - 240 Grandview	Harrisburg, PA	—	321	4,242	—	321	4,242	4,563	(411	)	1980	10/29/2014	35
Pinnacle - Market Place Way	Harrisburg, PA	—	808	2,383	6	808	2,389	3,197	(314	)	2004	10/29/2014	35
CRHS - 2000 10th Avenue	Columbus, GA	—	380	2,737	14	380	2,751	3,131	(415	)	1989	11/20/2014	22
CRHS - 1942 North Avenue	Columbus, GA	—	91	273	—	91	273	364	(73	)	1971	11/20/2014	12
CRHS - 920 18th Street	Columbus, GA	—	110	281	—	110	281	391	(113	)	1982	11/20/2014	8
CRHS - 1900 10th Avenue	Columbus, GA	—	474	5,580	131	474	5,711	6,185	(747	)	1976	11/20/2014	26
CRHS - 1800 10th Avenue	Columbus, GA	—	539	5,238	19	539	5,257	5,796	(615	)	1980	11/20/2014	28
CRHS - 705 17th Street	Columbus, GA	—	372	2,346	278	372	2,624	2,996	(582	)	1994	11/20/2014	15
CRHS - 615 19th Street	Columbus, GA	—	75	113	—	75	113	188	(107	)	1976	11/20/2014	3
CRHS - 1968 North Avenue	Columbus, GA	—	89	32	—	89	32	121	(26	)	1966	11/20/2014	4
CRHS - 633 19th Street	Columbus, GA	—	99	255	—	99	255	354	(92	)	1972	11/20/2014	9
CRHS - 500 18th Street	Columbus, GA	—	430	170	205	430	375	805	(111	)	1982	11/20/2014	8
CRHS - 2200 Hamilton Road	Columbus, GA	—	267	1,579	42	267	1,621	1,888	(248	)	1992	11/20/2014	22
CRHS - 1810 Stadium Drive	Phenix City, AL	—	202	149	26	202	175	377	(94	)	1999	11/20/2014	30
Carle Danville MOB	Danville, IL	—	607	7,136	—	607	7,136	7,743	(713	)	2007	11/26/2014	33
Middletown Medical - 111 Maltese	Middletown, NY	—	670	9,921	37	670	9,958	10,628	(909	)	1988	11/28/2014	35
Middletown Medical - 2 Edgewater	Middletown, NY	—	200	2,966	11	200	2,977	3,177	(272	)	1992	11/28/2014	35
Napoleon Medical Office Building	New Orleans, LA	—	1,202	7,412	763	1,202	8,175	9,377	(998	)	1974	12/19/2014	25
West TN Bone & Joint - Physicians Drive	Jackson, TN	—	1,661	2,960	—	1,661	2,960	4,621	(269	)	1991	12/30/2014	35
West TN Bone & Joint	Jackson, TN	—	1,250	5,210	—	1,250	5,210	6,460	(543	)	1996	12/30/2014	31
Edina MOB	Edina MN	—	504	10,006	959	504	10,965	11,469	(1,657	)	1979	1/22/2015	24
Crystal MOB	Crystal, MN	—	945	11,862	—	945	11,862	12,807	(879	)	2012	1/22/2015	47
Savage MOB	Savage, MN	5,449	1,281	10,021	—	1,281	10,021	11,302	(770	)	2011	1/22/2015	48
Dell Road MOB	Chanhassen, MN	—	800	4,520	29	800	4,549	5,349	(385	)	2008	1/22/2015	43
Columbus MOB	Columbus, GA	—	845	2,708	7	845	2,715	3,560	(432	)	1980	1/23/2015	22
Methodist Sports MOB	Greenwood, IN	—	1,050	8,556	—	1,050	8,556	9,606	(795	)	2008	1/28/2015	33
Vadnais Heights MOB	Vadnais Heights, MN	—	2,751	12,233	—	2,751	12,233	14,984	(1,069	)	2013	1/29/2015	43
Minnetonka MOB	Minnetonka, MN	—	1,770	19,797	—	1,770	19,797	21,567	(1,456	)	2014	2/5/2015	49
Jamestown MOB	Jamestown, ND	—	656	9,440	—	656	9,440	10,096	(855	)	2013	2/5/2015	43
Indiana American II	Greenwood, IN	—	862	6,901	600	862	7,501	8,363	(599	)	2008	2/13/2015	38
Indiana American III	Greenwood, IN	—	741	1,846	185	741	2,031	2,772	(313	)	2001	2/13/2015	31
Indiana American IV	Greenwood, IN	—	771	1,928	77	771	2,005	2,776	(205	)	2001	2/13/2015	31
Southpointe	Indianapolis, IN	—	563	1,741	259	563	2,000	2,563	(284	)	1993	2/13/2015	27
Minnesota Eye MOB	Minnetonka, MN	—	1,143	7,470	—	1,143	7,470	8,613	(592	)	2014	2/17/2015	44
Baylor Cancer Center	Dallas, TX	—	855	6,007	32	855	6,039	6,894	(427	)	2001	2/27/2015	43
Bridgeport Medical Center	Lakewood, WA	—	1,397	10,435	47	1,397	10,482	11,879	(899	)	2004	2/27/2015	35
Renaissance Office Building	Milwaukee, WI	—	1,379	4,182	2,834	1,379	7,016	8,395	(1,078	)	1896	3/27/2015	15
Calkins 125	Rochester, NY	—	534	10,164	326	534	10,490	11,024	(1,159	)	1997	3/31/2015	32
Calkins 200	Rochester, NY	—	210	3,317	32	210	3,349	3,559	(335	)	2000	3/31/2015	38
Calkins 300	Rochester, NY	—	372	6,645	24	372	6,669	7,041	(652	)	2002	3/31/2015	39
Calkins 400	Rochester, NY	—	353	8,226	34	353	8,260	8,613	(864	)	2007	3/31/2015	39
Calkins 500	Rochester, NY	—	282	7,074	28	282	7,102	7,384	(589	)	2008	3/31/2015	41
Avalon Park Florida Hospital MOB	Avalon Park, FL	—	1,041	10,685	—	1,041	10,685	11,726	(780	)	2009	3/31/2015	41
Premier Surgery Center of Louisville	Louisville, KY	—	1,106	5,437	—	1,106	5,437	6,543	(374	)	2013	4/10/2015	43
Baton Rouge MOB	Baton Rouge, LA	—	711	7,720	—	711	7,720	8,431	(636	)	2003	4/15/2015	35
Healthpark Medical Center	Grand Blanc, MI	—	—	17,624	—	—	17,624	17,624	(1,434	)	2006	4/30/2015	36
Plaza HCA MOB	Jacksonville, FL	—	1,112	12,553	—	1,112	12,553	13,665	(903	)	2007	4/30/2015	39
Northern Ohio Medical Center	Sheffield, OH	—	644	9,162	—	644	9,162	9,806	(1,225	)	1999	5/28/2015	20
University of Michigan - Northville MOB	Livonia, MI	—	2,200	8,627	166	2,200	8,793	10,993	(808	)	1988	5/29/2015	30
Coon Rapids Medical Center MOB	Coon Rapids, MN	—	607	5,857	—	607	5,857	6,464	(468	)	2007	6/1/2015	35
Premier Landmark MOB	Bloomington, IN	—	872	10,537	—	872	10,537	11,409	(730	)	2008	6/5/2015	39
Palm Beach ASC	Palm Beach, FL	—	2,576	7,675	—	2,576	7,675	10,251	(507	)	2003	6/26/2015	40
Brookstone Physician Center MOB	Jacksonville, AL	—	—	1,913	—	—	1,913	1,913	(166	)	2007	6/30/2015	31
Jackson Woman's Clinic MOB	Jackson, TN	—	555	3,800	19	555	3,819	4,374	(293	)	1998	6/30/2015	35
Hillside Medical Center MOB	Hanover, PA	—	812	13,217	63	812	13,280	14,092	(941	)	2003	6/30/2015	35
Randall Road MOB	Elgin, IL	—	1,124	15,404	486	1,124	15,890	17,014	(1,054	)	2006	6/30/2015	38
Medical Specialists of Palm Beach MOB	Atlantis, FL	—	—	7,560	6	—	7,566	7,566	(541	)	2002	7/24/2015	37
OhioHealth - SW Health Center MOB	Grove City, OH	—	1,363	8,516	—	1,363	8,516	9,879	(637	)	2001	7/31/2015	37
Trios Health MOB	Kennewick, WA	—	—	55,178	3,795	—	58,973	58,973	(3,169	)	2015	7/31/2015	45
IMS - Paradise Valley MOB	Phoenix, AZ	—	—	25,893	14	—	25,907	25,907	(1,638	)	2004	8/14/2015	43
IMS - Avondale MOB	Avondale, AZ	—	1,818	18,108	10	1,818	18,118	19,936	(1,020	)	2006	8/19/2015	45
IMS - Palm Valley MOB	Goodyear, AZ	—	2,666	28,655	—	2,666	28,655	31,321	(1,683	)	2006	8/19/2015	43
IMS - North Mountain MOB	Phoenix, AZ	—	—	42,877	495	—	43,372	43,372	(2,372	)	2008	8/31/2015	47
Memorial Hermann - Phase I	Katy, TX	—	822	6,797	19	822	6,816	7,638	(440	)	2005	9/1/2015	39
Memorial Hermann - Phase II	Katy, TX	—	1,560	25,601	6	1,560	25,607	27,167	(1,573	)	2006	9/1/2015	40
New Albany Medical Center MOB	New Albany, OH	—	1,600	8,505	216	1,600	8,721	10,321	(613	)	2005	9/9/2015	37
Fountain Hills Medical Campus MOB	Fountain Hills, AZ	—	2,593	7,635	618	2,593	8,253	10,846	(502	)	1995	9/30/2015	39
Fairhope MOB	Fairhope, AL	—	640	5,227	568	640	5,795	6,435	(349	)	2005	10/13/2015	38

			Initial Cost to Company			Gross Amount at Which Carried as of Close of Period
Description	Location	Encumbrances	Land	Buildings and Improvements	Cost Capitalized Subsequent to Acquisitions	Land	Buildings and Improvements	Total	Accumulated Depreciation		Year Built	Date  Acquired	Life on Which Building Depreciation in Income Statement is Computed
Foley MOB	Foley, AL	—	365	732	—	365	732	1,097	(48	)	1997	10/13/2015	40
Foley Venture	Foley, AL	—	420	1,118	—	420	1,118	1,538	(73	)	2002	10/13/2015	38
North Okaloosa MOB	Crestview, FL	—	190	1,010	—	190	1,010	1,200	(61	)	2005	10/13/2015	41
Commons on North Davis	Pensacola, FL	—	380	1,237	—	380	1,237	1,617	(75	)	2009	10/13/2015	41
Sorrento Road	Pensacola, FL	—	170	894	—	170	894	1,064	(55	)	2010	10/13/2015	41
Breakfast Point Medical Park	Panama City, FL	—	—	817	—	—	817	817	(47	)	2012	10/13/2015	42
Panama City Beach	Panama City, FL	—	—	739	—	—	739	739	(42	)	2012	10/13/2015	42
Perdido Medical Park	Pensacola, FL	—	100	1,147	—	100	1,147	1,247	(69	)	2010	10/13/2015	41
Ft. Walton Beach	Ft. Walton Beach, FL	—	230	914	—	230	914	1,144	(63	)	1979	10/13/2015	35
Panama City	Panama City, FL	—	—	661	—	—	661	661	(41	)	2003	10/13/2015	38
Pensacola - Catalyst	Pensacola, FL	—	220	1,685	—	220	1,685	1,905	(104	)	2001	10/13/2015	39
Arete Surgical Center	Johnstown, CO	—	399	6,667	—	399	6,667	7,066	(337	)	2013	10/19/2015	45
Cambridge Professional Center MOB	Waldorf, MD	—	590	8,520	130	590	8,650	9,240	(590	)	1999	10/30/2015	35
HonorHealth 44th Street MOB	Phoenix, AZ	—	515	3,884	1,320	515	5,204	5,719	(370	)	1988	11/13/2015	28
Mercy Medical Center MOB	Fenton, MO	—	1,201	6,778	—	1,201	6,778	7,979	(389	)	1999	12/1/2015	40
Nashville MOB	Nashville, TN	—	1,555	39,713	250	1,555	39,963	41,518	(1,771	)	2015	12/17/2015	46
KSF Orthopaedic MOB	Houston, TX	—	530	3,712	26	530	3,738	4,268	(430	)	1984	12/22/2015	19
Great Falls Clinic MOB	Great Falls, MT	—	—	27,402	441	—	27,843	27,843	(1,482	)	2004	12/29/2015	40
Great Falls Hospital	Great Falls, MT	—	—	25,262	—	—	25,262	25,262	(1,322	)	2015	1/25/2016	40
Monterey Medical Center ASC	Stuart, FL	—	380	5,064	—	380	5,064	5,444	(240	)	2013	2/1/2016	42
Physicians Medical Plaza MOB	Indianapolis, IN	—	—	6,703	17	—	6,720	6,720	(412	)	2004	2/1/2016	34
Park Nicollet Clinic	Chanhassen, MN	—	1,941	14,555	—	1,941	14,555	16,496	(758	)	2005	2/8/2016	40
HEB Cancer Center	Bedford, TX	—	—	11,839	—	—	11,839	11,839	(548	)	2014	2/12/2016	44
Riverview Medical Center	Lancaster, OH	—	1,313	10,243	63	1,313	10,306	11,619	(638	)	1997	2/26/2016	33
St. Luke's Cornwall MOB	Cornwall, NY	9,500	—	13,017	—	—	13,017	13,017	(761	)	2006	2/26/2016	35
HonorHealth Glendale	Glendale, AZ	—	1,770	8,089	—	1,770	8,089	9,859	(352	)	2015	3/15/2016	45
Columbia MOB	Hudson, NY	12,000	—	16,550	—	—	16,550	16,550	(867	)	2006	3/21/2016	35
St Vincent POB 1	Birmingham, AL	—	—	10,172	130	—	10,302	10,302	(1,246	)	1975	3/23/2016	15
St Vincent POB 2	Birmingham, AL	—	48	6,624	144	48	6,768	6,816	(853	)	1988	3/23/2016	15
St Vincent POB 3	Birmingham, AL	—	75	9,433	353	75	9,786	9,861	(726	)	1992	3/23/2016	25
Emerson Medical Building	Creve Coeur, MO	—	1,590	9,853	114	1,590	9,967	11,557	(522	)	1989	3/24/2016	35
Patient Partners Surgery Center	Gallatin, TN	—	203	3,376	—	203	3,376	3,579	(163	)	2007	3/30/2016	40
Eye Associates of NM - Santa Fe	Santa Fe, NM	—	900	6,604	—	900	6,604	7,504	(366	)	2002	3/31/2016	35
Eye Associates of NM - Albuquerque	Albuquerque, NM	—	1,020	7,832	—	1,020	7,832	8,852	(384	)	2007	3/31/2016	40
Gardendale Surgery Center	Gardendale, AL	—	200	5,732	—	200	5,732	5,932	(250	)	2011	4/11/2016	42
HealthEast - Curve Crest	Stillwater, MN	—	409	3,279	—	409	3,279	3,688	(148	)	2011	4/14/2016	43
HealthEast - Victor Gardens	Hugo, MN	—	572	4,400	51	572	4,451	5,023	(209	)	2008	4/14/2016	41
NOMS - Clyde	Clyde, OH	—	440	5,948	—	440	5,948	6,388	(240	)	2015	5/10/2016	44
Blandford MOB	Little Rock, AR	—	203	2,386	—	203	2,386	2,589	(107	)	1983	5/11/2016	40
Cardwell MOB	Lufkin, TX	—	—	8,348	138	—	8,486	8,486	(361	)	1999	5/11/2016	42
Dacono Neighborhood Health	Dacono, CO	—	2,258	2,911	20	2,258	2,931	5,189	(173	)	2014	5/11/2016	44
Franciscan Health	Tacoma, WA	—	711	9,096	65	711	9,161	9,872	(1,017	)	1951	5/11/2016	15
Grand Island Specialty Clinic	Grand Island, NE	—	102	2,802	150	102	2,952	3,054	(136	)	1978	5/11/2016	42
Hot Springs MOB	Hot Springs Village, AR	—	305	3,309	65	305	3,374	3,679	(209	)	1988	5/11/2016	30
Jewish Medical Center East	Louisville, KY	—	—	81,248	32	—	81,280	81,280	(3,138	)	2003	5/11/2016	45
Jewish Medical Center South MOB - 1	Shepherdsville, KY	—	—	15,861	225	—	16,086	16,086	(787	)	2005	5/11/2016	39
Jewish Medical Plaza I	Louisville, KY	—	—	8,808	172	—	8,980	8,980	(451	)	1970	5/11/2016	35
Jewish Medical Plaza II	Louisville, KY	—	—	5,216	1,070	—	6,286	6,286	(592	)	1964	5/11/2016	15
Jewish OCC	Louisville, KY	—	—	35,703	108	—	35,811	35,811	(1,767	)	1985	5/11/2016	34
Lexington Surgery Center	Lexington, KY	—	1,229	18,914	363	1,229	19,277	20,506	(1,074	)	2000	5/11/2016	30
Medical Arts Pavilion	Lufkin, TX	—	—	6,215	15	—	6,230	6,230	(337	)	2004	5/11/2016	33
Memorial Outpatient Center	Lufkin, TX	—	—	4,808	100	—	4,908	4,908	(206	)	1990	5/11/2016	45
Midlands Two Professional Center	Papillion, NE	—	—	587	57	—	644	644	(247	)	1976	5/11/2016	5
Parkview MOB	Little Rock, AR	—	705	4,343	44	705	4,387	5,092	(229	)	1988	5/11/2016	35
Peak One ASC	Frisco, CO	—	—	5,763	65	—	5,828	5,828	(238	)	2006	5/11/2016	44
Physicians Medical Center	Tacoma, WA	—	—	5,862	144	—	6,006	6,006	(376	)	1977	5/11/2016	27
St. Alexius - Minot Medical Plaza	Minot, ND	—	—	26,078	—	—	26,078	26,078	(1,023	)	2015	5/11/2016	49
St. Clare Medical Pavilion	Lakewood, WA	—	—	9,005	—	—	9,005	9,005	(535	)	1989	5/11/2016	33
St. Joseph Medical Pavilion	Tacoma, WA	—	—	11,497	31	—	11,528	11,528	(591	)	1989	5/11/2016	35
St. Joseph Office Park	Lexington, KY	—	3,722	12,675	3,228	3,722	15,903	19,625	(1,621	)	1992	5/11/2016	14
St. Mary - Caritas Medical II	Louisville, KY	—	—	5,587	23	—	5,610	5,610	(283	)	1979	5/11/2016	34
St. Mary - Caritas Medical III	Louisville, KY	—	—	383	194	—	577	577	(266	)	1974	5/11/2016	2
Thornton Neighborhood Health	Thornton, CO	—	1,609	2,287	—	1,609	2,287	3,896	(132	)	2014	5/11/2016	43
Medical Village at Kissimmee	Kissimmee, FL	—	634	3,365	—	634	3,365	3,999	(149	)	2006	5/26/2016	39
Medical Village at Leesburg	Leesburg, FL	—	802	3,047	—	802	3,047	3,849	(213	)	1979	5/26/2016	25
St. Francis MOB	Federal Way, WA	—	—	12,817	24	—	12,841	12,841	(615	)	1987	6/2/2016	38
Children's Hospital MOB	Milwaukee, WI	—	476	4,897	—	476	4,897	5,373	(197	)	2016	6/3/2016	45
Jewish Medical Center South MOB - 2	Shepherdsville, KY	—	27	3,827	—	27	3,827	3,854	(153	)	2006	6/8/2016	40
Good Samaritan North Annex Building	Kearney, NE	—	—	2,734	—	—	2,734	2,734	(132	)	1984	6/28/2016	37

			Initial Cost to Company			Gross Amount at Which Carried as of Close of Period
Description	Location	Encumbrances	Land	Buildings and Improvements	Cost Capitalized Subsequent to Acquisitions	Land	Buildings and Improvements	Total	Accumulated Depreciation		Year Built	Date  Acquired	Life on Which Building Depreciation in Income Statement is Computed
NE Heart Institute Medical Building	Lincoln, NE	—	—	19,738	—	—	19,738	19,738	(633	)	2004	6/28/2016	47
St. Vincent West MOB	Little Rock, AR	—	—	13,453	—	—	13,453	13,453	(447	)	2012	6/29/2016	49
Meridan MOB	Englewood, CO	—	1,608	15,774	141	1,608	15,915	17,523	(717	)	2002	6/29/2016	38
St. Mary - Caritas Medical I	Louisville, KY	—	—	8,774	283	—	9,057	9,057	(535	)	1991	6/29/2016	25
St. Alexius - Medical Arts Pavilion	Bismarck, ND	—	—	12,902	77	—	12,979	12,979	(624	)	1974	6/29/2016	32
St. Alexius - Mandan Clinic	Mandan, ND	—	708	7,700	74	708	7,774	8,482	(301	)	2014	6/29/2016	43
St. Alexius - Orthopaedic Center	Bismarck, ND	—	—	13,881	363	—	14,244	14,244	(563	)	1997	6/29/2016	39
St. Alexius - Rehab Center	Bismarck, ND	—	—	5,920	97	—	6,017	6,017	(380	)	1997	6/29/2016	25
St. Alexius - Tech & Ed	Bismarck, ND	—	—	16,688	2	—	16,690	16,690	(679	)	2011	6/29/2016	38
Good Samaritan MOB	Kearney, NE	—	—	24,154	72	—	24,226	24,226	(820	)	1999	6/29/2016	45
Lakeside Two Professional Building	Omaha, NE	—	—	13,358	144	—	13,502	13,502	(532	)	2000	6/29/2016	38
Lakeside Wellness Center	Omaha, NE	—	—	10,177	190	—	10,367	10,367	(397	)	2000	6/29/2016	39
McAuley Center	Omaha, NE	—	1,427	17,020	3	1,427	17,023	18,450	(927	)	1988	6/29/2016	30
Memorial Health Center	Grand Island, NE	—	—	33,967	146	—	34,113	34,113	(1,517	)	1955	6/29/2016	35
Missionary Ridge MOB	Chattanooga, TN	—	—	7,223	1,205	—	8,428	8,428	(1,089	)	1976	6/29/2016	10
Pilot Medical Center	Birmingham, AL	—	1,419	14,528	6	1,419	14,534	15,953	(666	)	2005	6/29/2016	35
St. Joseph Medical Clinic	Tacoma, WA	—	—	16,427	32	—	16,459	16,459	(828	)	1991	6/30/2016	30
Woodlands Medical Arts Center	The Woodlands, TX	—	—	19,168	198	—	19,366	19,366	(867	)	2001	6/30/2016	35
FESC MOB	Tacoma, WA	—	—	12,702	181	—	12,883	12,883	(961	)	1980	6/30/2016	22
Prairie Care MOB	Maplewood, MN	—	525	3,099	—	525	3,099	3,624	(113	)	2016	7/6/2016	45
Springwoods MOB	Spring, TX	—	3,821	14,830	3,492	3,821	18,322	22,143	(549	)	2015	7/21/2016	44
Unity - ASC, Imaging & MOB	West Lafayette, IN	—	960	9,991	—	960	9,991	10,951	(429	)	2001	8/8/2016	35
Unity - Medical Pavilion	West Lafayette, IN	—	1,070	12,454	—	1,070	12,454	13,524	(535	)	2001	8/8/2016	35
Unity - Faith, Hope & Love	West Lafayette, IN	—	280	1,862	—	280	1,862	2,142	(80	)	2001	8/8/2016	35
Unity - Immediate Care & OCC	West Lafayette, IN	—	300	1,833	—	300	1,833	2,133	(75	)	2004	8/8/2016	37
Medical Village at Maitland	Orlando, FL	—	2,393	18,543	—	2,393	18,543	20,936	(613	)	2006	8/23/2016	44
Tri-State Orthopaedics MOB	Evansville, IN	—	1,580	14,162	—	1,580	14,162	15,742	(553	)	2004	8/30/2016	37
Maury Regional Healthcare MOB	Spring Hill, TN	—	—	15,619	—	—	15,619	15,619	(503	)	2012	9/30/2016	41
Spring Ridge Medical Center	Wyomissing, PA	—	28	4,943	—	28	4,943	4,971	(177	)	2002	9/30/2016	37
Doctors Community Hospital POB	Lanham, MD	—	—	23,034	—	—	23,034	23,034	(602	)	2009	9/30/2016	48
Gig Harbor Medical Pavilion	Gig Harbor, WA	—	—	4,791	1,768	—	6,559	6,559	(271	)	1991	9/30/2016	30
Midlands One Professional Center	Papillion, NE	—	—	14,922	—	—	14,922	14,922	(507	)	2010	9/30/2016	37
N.W. Michigan Surgery Center      Units #1, #2, & #4	Traverse City, MI	—	2,748	30,005	—	2,748	30,005	32,753	(909	)	2004	10/28/2016	40
Northeast Medical Center	Fayetteville, NY	—	4,011	25,564	929	4,011	26,493	30,504	(1,045	)	1998	11/23/2016	33
North Medical Center	Liverpool, NY	—	1,337	18,680	844	1,337	19,524	20,861	(673	)	1989	11/23/2016	35
Cincinnati Eye Institute	Cincinnati, OH	—	2,050	32,546	—	2,050	32,546	34,596	(1,133	)	1985	11/23/2016	35
HonorHealth - Scottsdale MOB	Scottsdale, AZ	—	—	4,288	—	—	4,288	4,288	(135	)	2000	12/2/2016	45
Fox Valley Hematology & Oncology	Appleton, WI	—	1,590	26,666	—	1,590	26,666	28,256	(691	)	2015	12/8/2016	44
Gastrointestinal Associates MOB	Powell, TN	—	937	3,214	—	937	3,214	4,151	(129	)	1965	12/9/2016	30
Northern Vision Eye Center	Traverse City, MI	—	490	2,132	—	490	2,132	2,622	(71	)	2006	12/15/2016	35
Flower Mound MOB	Flower Mound, TX	—	1,945	8,312	—	1,945	8,312	10,257	(228	)	2011	12/16/2016	43
Carrollton MOB	Flower Mound, TX	—	2,183	10,461	—	2,183	10,461	12,644	(306	)	2002	12/16/2016	40
HonorHealth IRF	Scottsdale, AZ	10,000	—	19,331	—	—	19,331	19,331	(481	)	2000	12/22/2016	42
Orthopedic Associates	Flower Mound, TX	—	2,915	12,791	—	2,915	12,791	15,706	(319	)	2011	1/5/2017	43
Medical Arts Center at Hartford	Plainville, CT	—	1,499	24,627	—	1,499	24,627	26,126	(594	)	2015	1/11/2017	44
CareMount - Lake Katrine MOB	Lake Katrine, NY	26,039	1,941	27,434	—	1,941	27,434	29,375	(636	)	2013	2/14/2017	42
CareMount - Rhinebeck MOB	Rhinebeck, NY	—	869	12,220	—	869	12,220	13,089	(296	)	1965	2/14/2017	41
Monterey Medical Center - MOB	Stuart, FL	—	2,292	13,376	5	2,292	13,381	15,673	(323	)	2003	3/7/2017	37
Creighton University Medical Center	Omaha, NE	—	—	32,487	—	—	32,487	32,487	(575	)	2017	3/28/2017	49
Strictly Pediatrics Specialty Center	Austin, TX	—	4,457	62,527	39	4,457	62,566	67,023	(1,222	)	2006	3/31/2017	40
MedStar Stephen's Crossing	Brandywine, MD	—	1,975	14,810	—	1,975	14,810	16,785	(190	)	2015	6/16/2017	43
CHI Health Clinic Building	Omaha, NE	—	—	50,177	—	—	50,177	50,177	(501	)	2017	6/29/2017	49
St Gabriel's Centracare	Little Falls, MN	—	—	4,944	—	—	4,944	4,944	(110	)	1990	6/29/2017	25
Craven-Hagan Clinic	Williston, ND	—	—	8,739	—	—	8,739	8,739	(123	)	1984	6/29/2017	40
Chattanooga Heart Institute	Chattanooga, TN	—	—	18,639	—	—	18,639	18,639	(257	)	1993	6/29/2017	37
CHI St. Vincent Mercy Heart & Vascular Center	Hot Springs, AR	—	—	11,688	—	—	11,688	11,688	(145	)	1998	6/29/2017	45
South Campus MOB	Hot Springs, AR	—	—	13,369	—	—	13,369	13,369	(171	)	2009	6/29/2017	42
CHI St. Vincent Mercy Cancer Center	Hot Springs, AR	—	—	5,090	—	—	5,090	5,090	(72	)	2001	6/29/2017	39
St. Joseph Professional Office Building	Bryan, TX	—	—	11,169	—	—	11,169	11,169	(129	)	1996	6/29/2017	46
St. Vincent Carmel Women's Center	Carmel, IN	—	—	31,720	—	—	31,720	31,720	(339	)	2014	6/29/2017	48
St. Vincent Fishers Medical Center	Fishers, IN	44,000	—	62,870	—	—	62,870	62,870	(749	)	2008	6/29/2017	45
Baylor Charles A. Sammons Cancer Center	Dallas, TX	—	—	256,886	—	—	256,886	256,886	(2,994	)	2011	6/30/2017	43
Orthopedic & Sports Institute of the Fox Valley	Appleton, WI	—	2,003	26,394	100	2,003	26,494	28,497	(406	)	2005	6/30/2017	40
Clearview Cancer Institute	Huntsville, AL	—	2,736	43,220	—	2,736	43,220	45,956	(554	)	2006	8/4/2017	34
Northside Cherokee/Town Lake MOB	Atlanta, GA	—	—	30,627	—	—	30,627	30,627	(312	)	2013	8/15/2017	46
HonorHealth Mesa MOB	Mesa, AZ	—	362	3,059	—	362	3,059	3,421	(32	)	2013	8/15/2017	43
Little Falls Orthopedics	Little Falls, MN	—	246	1,977	—	246	1,977	2,223	(39	)	1999	8/24/2017	28

				Initial Cost to Company						Gross Amount at Which Carried as of Close of Period
Description	Location	Encumbrances		Land		Buildings and Improvements		Cost Capitalized Subsequent to Acquisitions		Land		Buildings and Improvements		Total		Accumulated Depreciation			Year Built	Date  Acquired	Life on Which Building Depreciation in Income Statement is Computed
Little Falls Dialysis Center	Little Falls, MN	—		—		2,885		—		—		2,885		2,885		(77		)	1959	8/24/2017	15
Immanuel One Professional Center	Omaha, NE	—		—		16,598		—		—		16,598		16,598		(210		)	1993	8/24/2017	35
SJRHC Cancer Center	Bryan, TX	—		—		5,065		—		—		5,065		5,065		(47		)	1997	8/24/2017	40
St. Vincent Women's Center	Hot Springs, AR	—		—		4,789		—		—		4,789		4,789		(41		)	2001	8/31/2017	40
Legends Park MOB & ASC	Midland, TX	—		1,658		24,178		—		1,658		24,178		25,836		(194		)	2003	9/27/2017	44
Franklin MOB & ASC	Franklin, TN	—		1,001		7,902		—		1,001		7,902		8,903		(49		)	2014	10/12/2017	42
Eagle Point MOB	Lake Elmo, MN	—		1,011		9,009		—		1,011		9,009		10,020		(36		)	2015	10/31/2017	48
Edina East MOB	Edina, MN	—		2,360		4,135		—		2,360		4,135		6,495		(26		)	1962	10/31/2017	30
Northside MOB - Center Pointe	Atlanta, GA	—		—		119,467		—		—		119,467		119,467		(323		)	2009	11/10/2017	31
Gwinnett 500 Building	Lawrenceville, GA	—		—		22,753		—		—		22,753		22,753		(90		)	1995	11/17/2017	45
Hudgens Professional Building	Duluth, GA	—		—		21,779		—		—		21,779		21,779		(98		)	1994	11/17/2017	40
St. Vincent Building	Indianapolis, IN	—		5,854		42,382		—		5,854		42,382		48,236		(182		)	2007	11/17/2017	45
Gwinnett Physicians Center	Lawrenceville, GA	17,609		—		48,304		—		—		48,304		48,304		(92		)	2010	12/1/2017	47
Apple Valley Medical Center	Apple Valley, MN	—		1,587		14,929		—		1,587		14,929		16,516		(40		)	1974	12/18/2017	33
Desert Cove MOB (57% Interest)	Scottsdale, AZ	—		1,689		5,207		—		1,689		5,207		6,896		(12		)	1991	12/18/2017	38
Westgate MOB	Glendale, AZ	—		—		13,379		—		—		13,379		13,379		(27		)	2016	12/21/2017	45
		$	186,679	$	217,808	$	3,518,259	$	73,655	$	217,695	$	3,591,914	$	3,809,609	$	(201,527	)

The aggregate cost for federal income tax purposes of the real estate as of December 31, 2017 is $3.83 billion, with accumulated tax depreciation of $175.8 million. The cost, net of accumulated depreciation, is approximately $3.65 billion (unaudited).

The cost capitalized subsequent to acquisitions is net of dispositions.

The changes in total real estate for the years ended December 31, 2017, 2016, and 2015 are as follows (in thousands): 

	Year Ended December 31,
	2017			2016		2015
Balance as of the beginning of the year	$	2,606,536		$	1,424,894	$	729,034
Acquisitions	1,207,098			1,170,593		695,693
Additions	12,243			11,049		4,440
Impairment	(965		)	—		—
Dispositions	(15,303		)	—		(4,273		)
Balance as of the end of the year	$	3,809,609		$	2,606,536	$	1,424,894

The changes in accumulated depreciation for the years ended December 31, 2017, 2016, and 2015 are as follows (in thousands):

	Year Ended December 31,
	2017			2016		2015
Balance as of the beginning of the year	$	118,609		$	61,242	$	32,772
Depreciation	87,531			57,367		29,958
Dispositions	(4,613		)	—		(1,488		)
Balance as of the end of the year	$	201,527		$	118,609	$	61,242

XML

Summary of Significant Accounting Policies - (Policies)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Principles of Consolidation

Principles of Consolidation

GAAP requires us to identify entities for which control is achieved through means other than voting rights and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). ASC 810 broadly defines a VIE as an entity in which either (i) the equity investors as a group, if any, lack the power through voting or similar rights to direct the activities of such entity that most significantly impact such entity’s economic performance or (ii) the equity investment at risk is insufficient to finance that entity’s activities without additional subordinated financial support. We identify the primary beneficiary of a VIE as the enterprise that has both of the following characteristics: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or receive benefits of the VIE that could potentially be significant to the entity. We consolidate our investment in a VIE when we determine that we are the VIE’s primary beneficiary. We may change our original assessment of a VIE upon subsequent events such as the modification of contractual arrangements that affect the characteristics or adequacy of the entity’s equity investments at risk and the disposition of all or a portion of an interest held by the primary beneficiary. We perform this analysis on an ongoing basis.

For property holding entities not determined to be VIEs, we consolidate such entities in which the Operating Partnership owns 100% of the equity or has a controlling financial interest evidenced by ownership of a majority voting interest. All intercompany balances and transactions are eliminated in consolidation. For entities in which the Operating Partnership owns less than 100% of the equity interest, the Operating Partnership consolidates the property if it has the direct or indirect ability to control the entities’ activities based upon the terms of the respective entities’ ownership agreements. For these entities, the Operating Partnership records a noncontrolling interest representing equity held by noncontrolling interests.

Noncontrolling Interests

Noncontrolling Interests

The Company presents the portion of any equity it does not own in entities that it controls (and thus consolidates) as noncontrolling interests and classifies such interests as a component of consolidated equity, separate from the Company’s total shareholders’ equity, on the consolidated balance sheets.

Operating Partnership: Net income or loss is allocated to noncontrolling interests (limited partners) based on their respective ownership percentage of the Operating Partnership. The ownership percentage is calculated by dividing the number of OP Units held by the noncontrolling interests by the total OP Units held by the noncontrolling interests and the Trust. Issuance of additional common shares and OP Units changes the ownership interests of both the noncontrolling interests and the Trust. Such transactions and the related proceeds are treated as capital transactions.

During the year ended December 31, 2017, the Operating Partnership partially funded one property acquisition by issuing an aggregate of 2,247,817 OP Units valued at approximately $44.3 million on the date of issuance. The acquisition had a total purchase price of approximately $78.6 million. In addition, the Operating Partnership funded the acquisition of the remaining non-controlling interest on a property by issuing an aggregate of 38,641 OP Units valued at approximately $0.7 million.

During the year ended December 31, 2016, the Operating Partnership partially funded one property acquisition by issuing an aggregate of 174,085 OP Units valued at approximately $2.9 million on the date of issuance. The acquisition had a

total purchase price of approximately $8.5 million. In addition, the Operating Partnership funded the acquisition of the remaining non-controlling interest on a property by issuing an aggregate of 217,549 OP Units valued at approximately $4.0 million.

Noncontrolling interests in the Company include OP Units held by the Predecessor’s prior investors and other investors. As of December 31, 2017 and 2016, the Trust held a 97.1% and 97.5% interest in the Operating Partnership, respectively. As the sole general partner and the majority interest holder, the Trust consolidates the financial position and results of operations of the Operating Partnership.

Holders of OP Units may not transfer their units without the Trust’s prior written consent, as general partner of the Operating Partnership. Beginning on the first anniversary of the issuance of OP Units, OP Unit holders may tender their units for redemption by the Operating Partnership in exchange for cash equal to the market price of the Trust’s common shares at the time of redemption or for unregistered common shares on a one-for-one basis. Such selection to pay cash or issue common shares to satisfy an OP Unit holder’s redemption request is solely within the control of the Trust. Accordingly, the Trust presents the OP Units of the Operating Partnership held by investors other than the Trust as noncontrolling interests within equity in the consolidated balance sheet.

Partially Owned Properties: The Trust and OP reflect noncontrolling interests in partially owned properties on the balance sheet for the portion of consolidated properties that are not wholly owned by the Company. The earnings or losses from those properties attributable to the noncontrolling interests are reflected as noncontrolling interests in partially owned properties in the consolidated statements of income.

Redeemable Noncontrolling Interests-Series A Preferred Units and Partially Owned Properties 

On February 5, 2015, the Trust entered into a Second Amended and Restated Agreement of Limited Partnership (the “Partnership Agreement”) which provides for the designation and issuance of the newly designated Series A Participating Redeemable Preferred Units of the Operating Partnership (“Series A Preferred Units”). Series A Preferred Units have priority over all other partnership interests of the Operating Partnership with respect to distributions and liquidation. Holders of Series A Preferred Units are entitled to a 5% cumulative return and upon redemption, the receipt of one common share and $200. Series A Preferred Units are redeemable at the option of the holders; however, the holders of the Series A Preferred Units have agreed not to cause the Operating Partnership to redeem their Series A Preferred Units prior to one year from the issuance date. After such one year period, if the holders of Series A Preferred Units exercise their option to redeem Series A Preferred Units, the Trust may satisfy its redemption obligation, at the Trust’s option, in cash or registered common shares. Instruments that require settlement in registered common shares may not be classified in permanent equity as it is not always completely within an issuer’s control to deliver registered common shares. Due to the redemption rights associated with the Series A Preferred Units, the Trust classifies the Series A Preferred Units in the mezzanine section of its consolidated balance sheets. 

The Series A Preferred Units were evaluated for embedded features that should be bifurcated and separately accounted for as a freestanding derivative. The Company determined that the Series A Preferred Units contained features that require bifurcation. The Company records the carrying amount of the redeemable noncontrolling interests, less the value of the embedded derivative, at the greater of the carrying value or redemption value in the consolidated balance sheets.

On February 5, 2015, the acquisition of the Minnetonka MOB was partially funded with the issuance of 44,685 Series A Preferred Units which were valued at $9.7 million. On December 17, 2015, the acquisition of the Nashville MOB was partially funded with the issuance of 91,236 Series A Preferred Units which were valued at $19.7 million.

On April 1, 2016, the Series A Preferred Units issued in conjunction with the Minnetonka MOB acquisition were redeemed for a total value of $9.8 million. The fair value of the embedded derivative associated with the previously outstanding Series A Preferred Units was $2.7 million which was derecognized in the course of the redemption.

On January 12, 2017, the Series A Preferred Units issued in conjunction with the Nashville MOB acquisition were redeemed for a total value of $20.0 million. The fair value of the embedded derivative associated with the previously outstanding Series A Preferred Units was $5.6 million which was derecognized in the course of the redemption.

In connection with the acquisition of the Minnetonka MOB, the Trust received a $5 million equity investment from a third party, effective March 1, 2015. This investment earns a 15% cumulative preferred return. At any point subsequent to the third anniversary of the investment, the holder can require the Trust to redeem the instrument at a price for which the investor will realize a 15% internal rate of return. Due to the redemption provision, which is outside of the control of the Trust, the Trust

classifies the investment in the mezzanine section of its consolidated balance sheets. The Trust records the carrying amount of the redeemable noncontrolling interests at the greater of the carrying value or redemption value.

Dividends and Distributions

Dividends and Distributions

Dividends and distributions for the years ended December 31, 2017, 2016, and 2015 are as follows:

Declaration Date	Record Date	Payment Date	Cash Dividend per Share/Unit
December 21, 2017	January 3, 2018	January 18, 2018	$	0.230
September 21, 2017	October 3, 2017	October 18, 2017	$	0.230
June 12, 2017	July 3, 2017	July 18, 2017	$	0.230
March 17, 2017	April 5, 2017	April 18, 2017	$	0.225
December 22, 2016	January 5, 2017	January 18, 2017	$	0.225
September 26, 2016	October 6, 2016	October 18, 2016	$	0.225
June 23, 2016	July 5, 2016	July 18, 2016	$	0.225
March 18, 2016	April 1, 2016	April 18, 2016	$	0.225
December 31, 2015	January 15, 2016	January 29, 2016	$	0.225
September 28, 2015	October 16, 2015	October 30, 2015	$	0.225
July 1, 2015	July 17, 2015	July 31, 2015	$	0.225
April 6, 2015	April 17, 2015	May 1, 2015	$	0.225

Our shareholders are entitled to reinvest all or a portion of any cash distribution on their shares of our common stock by participating in our Dividend Reinvestment and Share Purchase Plan (“DRIP”), subject to the terms of the plan.

Tax Status of Dividends and Distributions

Tax Status of Dividends and Distributions

Our distributions of current and accumulated earnings and profits for U.S. federal income tax purposes generally are taxable to shareholders as ordinary income. Distributions in excess of these earnings and profits generally are treated as a non-taxable reduction of the shareholders’ basis in the shares to the extent thereof (non-dividend distributions) and thereafter as taxable gain.

Any cash distributions received by an OP Unit holder in respect of its OP Units generally will not be taxable to such OP Unit holder for U.S. federal income tax purposes, to the extent that such distribution does not exceed the OP Unit holder’s basis in its OP Units. Any such distribution will instead reduce the OP Unit holder’s basis in its OP Units (and OP Unit holders will be subject to tax on the taxable income allocated to them by the Operating Partnership in respect of their OP Units when such income is earned by the Operating Partnership, with such income allocation increasing the OP Unit holders’ basis in their OP Units).

Purchase of Investment Properties

Purchases of Investment Properties

A property acquired not subject to an existing lease is treated as an asset acquisition and recorded at its purchase price, inclusive of acquisition costs, allocated between the acquired assets and assumed liabilities, including identified intangible assets and liabilities, based upon their relative fair values at the date of acquisition. A property acquired with an existing lease is accounted for as a business combination pursuant to the acquisition method in accordance with ASC Topic 805, Business Combinations (“ASC 805”), and assets acquired and liabilities assumed, including identified intangible assets and liabilities, are recorded at fair value.

The determination of fair value involves the use of significant judgment and estimation. The Company makes estimates of the fair value of the tangible and intangible acquired assets and assumed liabilities using information obtained from multiple sources as a result of pre-acquisition due diligence and generally includes the assistance of a third party appraiser. The Company estimates the fair value of buildings acquired on an “as-if-vacant” basis and depreciates the building value over the estimated remaining life of the building. The Company determines the allocated value of other fixed assets, such as site improvements, based upon the replacement cost and depreciates such value over the assets’ estimated remaining useful lives as determined at the applicable acquisition date. The fair value of land is determined either by considering the sales prices of similar properties in recent transactions or based on internal analyses of recently acquired and existing comparable properties within the Company’s portfolio.

In recording identified intangible assets and liabilities in connection with a business combination, the value of above- or below-market leases is estimated based on the present value (using an interest rate which reflected the risks associated with the leases acquired) of the difference between contractual amounts to be received pursuant to the leases and management’s estimate of market lease rates measured over a period equal to the estimated remaining term of the lease. The capitalized above-market or below-market lease intangibles are amortized as a reduction or addition to rental income over the estimated remaining term of the respective leases plus the term of any renewal options that the lessee would be economically compelled to exercise.

In determining the value of in-place leases, management considers current market conditions and costs to execute similar leases in arriving at an estimate of the carrying costs during the expected lease-up period from vacant to existing occupancy. In estimating carrying costs, management includes real estate taxes, insurance, other operating expenses, estimates of lost rental revenue during the expected lease-up periods, and costs to execute similar leases, including leasing commissions, tenant improvements, legal, and other related costs based on current market demand. The values assigned to in-place leases are amortized to amortization expense over the estimated remaining term of the lease. If a lease terminates prior to its scheduled expiration, all unamortized costs related to that lease are written off, net of any required lease termination payments.

The Company calculates the fair value of any long-term debt assumed by discounting the remaining contractual cash flows on each instrument at the current market rate for those borrowings, which the Company approximates based on the rate it would expect to incur on a replacement instrument on the date of acquisition, and recognizes any fair value adjustments related to long-term debt as effective yield adjustments over the remaining term of the instrument.

Based on these estimates, the Company recognizes the acquired assets and assumed liabilities at their estimated fair values, which are generally determined using Level 3 inputs, such as market rental rates, capitalization rates, discount rates, or other available market data. Initial valuations are subject to change until the information is finalized, no later than 12 months from the acquisition date. The Company expenses transaction costs associated with acquisitions accounted for as business combinations in the period incurred.

Impairment of Intangible and Long-Lived Assets

Impairment of Intangible and Long-Lived Assets

The Company periodically evaluates its long-lived assets, primarily consisting of investments in real estate, for impairment indicators or whenever events or changes in circumstances indicate that the recorded amount of an asset may not be fully recoverable. If indicators of impairment are present, the Company evaluates the carrying value of the related real estate properties in relation to the undiscounted expected future cash flows of the underlying operations. In performing this evaluation, management considers market conditions and current intentions with respect to holding or disposing of the real estate property. The Company adjusts the net book value of real estate properties to fair value if the sum of the expected future undiscounted cash flows, including sales proceeds, is less than book value. The Company records an impairment loss at the time it makes any such determination. If the Company determines that an asset is impaired, the impairment to be recorded is measured as the amount by which the book value of the asset exceeds its fair value. Fair value is typically determined using a discounted future cash flow analysis or other acceptable valuation techniques, which are based, in turn, upon Level 3 inputs, such as revenue and expense growth rates, capitalization rates, discount rates, or other available market data.

The Company recorded an impairment charge of $1.0 million on a vacant medical office building in Port Charlotte, Florida during the year ended December 31, 2017. There were no impairment charges in the years ended December 31, 2016, and 2015.

Assets Held for Sale and Discontinued Operations

Assets Held for Sale and Discontinued OperationsThe Company may sell properties from time to time for various reasons, including favorable market conditions. The Company classifies certain long-lived assets as held for sale once the criteria, as defined by GAAP, has been met. Long-lived assets to be disposed of are reported at the lower of their carrying amount or fair value minus cost to sell, and are no longer depreciated. No properties were classified as held for sale as of December 31, 2017, 2016, or 2015 and dispositions during the years ended December 31, 2017, 2016, and 2015 did not qualify as discontinued operations.

Investments in Unconsolidated Entities

Investments in Unconsolidated Entities

The Company reports investments in unconsolidated entities over whose operating and financial policies it has the ability to exercise significant influence under the equity method of accounting. Under this method of accounting, the Company’s share of the investee’s earnings or losses is included in its consolidated statements of income. The initial carrying value of investments in unconsolidated entities is based on the amount paid to purchase the equity interest.

During 2014, the Company completed the acquisition of a 40% limited liability company membership interest in Jeff Orleans Medical Development Real Estate, L.L.C., the entity that owns and leases to the Company the land on which the Crescent City Surgical Centre is situated, for $1.3 million.

During 2016, the Company completed the acquisition of a 43% limited liability company membership interest in Desert Cove MOB, LLC. During 2017, the Company completed the acquisition of the remaining 57% interest in this facility for a purchase price of approximately $4.6 million and consolidated it effective December 2017. The Company has a total investment in the facility of $5.5 million.

Real Estate Loans Receivable

Real Estate Loans Receivable

Real estate loans receivable consists of ten mezzanine loans and two term loans. Each mezzanine loan is collateralized by an ownership interest in the respective borrower, while the term loans are secured by equity interests in two medical office building developments. Interest income on the loans are recognized as earned based on the terms of the loans subject to evaluation of collectability risks and are included in the Company’s consolidated statements of income.

Cash and Cash Equivalents

Cash and Cash EquivalentsCash and cash equivalents consist of cash on hand and short-term investments with maturities of three months or less from the date of purchase. The Company is subject to concentrations of credit risk as a result of its temporary cash investments. The Company places its temporary cash investments with high credit quality financial institutions in order to mitigate that risk.

Escrow Reserves

Escrow ReservesThe Company is required to maintain various escrow reserves on certain notes payable to cover future property taxes and insurance and tenant improvements costs as defined in each loan agreement. The total reserves as of December 31, 2017 and 2016 are $2.0 million and $4.3 million, respectively, which are included in other assets in the consolidated balance sheets.

Deferred Costs

Deferred CostsDeferred costs consist primarily of fees paid to obtain financing and costs associated with the origination of long-term leases on real estate properties. After the purchase of a property, lease commissions incurred to extend in-place leases or generate new leases are added to deferred lease costs. Deferred lease costs are included as a component of other assets and are amortized on a straight-line basis over the terms of their respective agreements. Deferred financing costs are shown as a direct reduction from the related debt liability. The Trust amortizes deferred financing costs as a component of interest expense over the terms of the related borrowings on a straight-line basis.

Derivative Instruments

Derivative Instruments

When the Company has derivative instruments embedded in other contracts, it records them either as an asset or a liability measured at their fair value unless they qualify for a normal purchase or normal sales exception. When specific hedge accounting criteria are not met, changes in the Company’s derivative instruments’ fair value are recognized currently in earnings. If hedge accounting is applied to a derivative instrument, such changes are reported in accumulated other comprehensive income (“AOCI”) within the equity section of the consolidated balance sheets, exclusive of ineffectiveness amounts, which are recognized as adjustments to net income.

To manage interest rate risk for certain of its variable-rate debt, the Company uses interest rate swaps as part of its risk management strategy. These derivatives are designed to mitigate the risk of future interest rate increases by providing a fixed interest rate for a limited, pre-determined period of time. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. As of December 31, 2017, the Company had five outstanding interest rate swap contracts that are designated as cash flow hedges of interest rate risk. For presentational purposes, they are shown as one derivative due to the identical nature of their economic terms. Further detail is provided in Note 7 (Derivatives).

The effective portion of the change in the fair value of derivatives designated and that qualify as cash flow hedges is recorded in accumulated other comprehensive income (“AOCI”) on the consolidated balance sheets and is subsequently reclassified into earnings as interest expense for the period that the hedged forecasted transaction affects earnings. The ineffective portion of the change in fair value of the derivatives is recognized directly in earnings. For the twelve months ended months ended December 31, 2017, the Company recorded a $0.2 million loss as a result of hedge ineffectiveness. The Company expects hedge ineffectiveness to be insignificant in the next 12 months.

Tenant receivables, net

Tenant Receivables, NetTenant accounts receivable are stated net of the applicable allowance. Rental payments under these contracts are primarily due monthly. The Company assesses the collectability of tenant receivables, including straight-line rent receivables, and defers recognition of revenue if collectability is not reasonably assured. The Company bases its assessment of the collectability of rent receivables on several factors, including, among other things, payment history, the financial strength of the tenant, and current economic conditions. If management’s evaluation of these factors indicates it is probable that the Company will be unable to recover the full value of the receivable, the Company provides a reserve against the portion of the receivable that it estimates may not be recovered. At December 31, 2017 and 2016, the allowance for doubtful accounts was $1.6 million and $2.4 million, respectively.

Rental Revenue

Rental Revenue

Rental revenue is recognized on a straight-line basis over the terms of the related leases when collectability is reasonably assured. Recognizing rental revenue on a straight-line basis for leases may result in recognizing revenue for amounts more or less than amounts currently due from tenants. Accumulated amounts recognized in excess of amounts currently due from tenants, net of related allowances, are included in other assets and were approximately $47.6 million and $32.0 million as of December 31, 2017 and 2016, respectively. If the Company determines that collectability of straight-line rents is not reasonably assured, the Company limits future recognition to amounts contractually owed and, where appropriate, establishes an allowance for estimated losses. Allowances recognized against straight line rent were approximately $4.9 million

and $0.6 million as of December 31, 2017 and December 31, 2016, respectively. Rental revenue is adjusted by amortization of lease inducements and above- or below-market rents on certain leases. Lease inducements and above- or below-market rents are amortized on a straight line basis over the remaining life of the lease.

Expense Recoveries

Expense Recoveries

Expense recoveries relate to tenant reimbursement of real estate taxes, insurance, and other operating expenses that are recognized as expense recovery revenue in the period the applicable expenses are incurred. The reimbursements are recorded at gross, as the Company is generally the primary obligor with respect to real estate taxes and purchasing goods and services from third-party suppliers, has discretion in selecting the supplier, and bears the credit risk of tenant reimbursement.

The Company has certain tenants with absolute net leases. Under these lease agreements, the tenant is responsible for operating and building expenses. For absolute net leases, the Company does not recognize expense recoveries.

Income Taxes

Income Taxes

The Trust elected to be taxed as a REIT for federal tax purposes commencing with the filing of its tax return for the short taxable year ending December 31, 2013. The Trust had no taxable income prior to electing REIT status. To qualify as a REIT, the Trust must meet certain organizational and operational requirements, including a requirement to distribute at least 90% of its annual REIT taxable income to its shareholders (which is computed without regard to the dividends paid deduction or net capital gain and which does not necessarily equal net income as calculated in accordance with GAAP). As a REIT, the Trust generally will not be subject to federal income tax to the extent it distributes qualifying dividends to its shareholders. If the Trust fails to qualify as a REIT in any taxable year, it will be subject to federal income tax (including any applicable alternative minimum tax) on its taxable income at regular corporate income tax rates and generally will not be permitted to qualify for treatment as a REIT for federal income tax purposes for the four taxable years following the year during which qualification is lost unless the Internal Revenue Service grants the Trust relief under certain statutory provisions. Such an event could materially adversely affect the Trust’s net income and net cash available for distribution to shareholders. However, the Trust intends to continue to operate in such a manner as to continue qualifying for treatment as a REIT. Even if the Trust continues to qualify for taxation as a REIT, the Trust may be subject to state and local taxes on its income and property and federal income and excise taxes on its undistributed income.

As discussed in Note 1 (Organization and Business), the Trust conducts substantially all of its operations through the Operating Partnership. As a partnership, the Operating Partnership generally is not liable for federal income taxes. The income and loss from the operations of the Operating Partnership is included in the tax returns of its partners, including the Trust, who are responsible for reporting their allocable share of the partnership income and loss. Accordingly, no provision for income taxes has been made on the accompanying consolidated financial statements.

Management Estimates

Management EstimatesThe preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the amounts of revenue and expenses reported in the period. Significant estimates are made for the fair value assessments with respect to purchase price allocations, impairment assessments, and the valuation of financial instruments. Actual results could differ from these estimates.

Contingent Liabilities

Contingent LiabilitiesThe Company records liabilities for contingent consideration (included in accrued expenses and other liabilities on its consolidated balance sheets) at fair value as of the acquisition date and reassesses the fair value at the end of each reporting period, with any changes being recognized in earnings. Increases or decreases in the fair value of contingent consideration can result from changes in discount periods, discount rates, and probabilities that contingencies will be met.

Reclassifications

ReclassificationsCertain prior period amounts have been reclassified to conform to the current financial statement presentation, with no effect on the previously reported consolidated financial position or consolidated results of operations.

Segment Reporting

Segment ReportingUnder the provision of Codification Topic 280, Segment Reporting, the Company has determined that it has one reportable segment with activities related to leasing and managing healthcare properties.

New Accounting Pronouncements

New Accounting Pronouncements

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which creates a new Topic, Accounting Standards Codification Topic 606. The standard is principle-based and provides a five-step model to determine when and how revenue is recognized. The core principle is that a company should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This standard is effective for interim or annual periods beginning after December 15, 2017 and allows for either full retrospective or modified retrospective adoption. The Company will adopt ASU 2014-09 on January 1, 2018 via the modified retrospective approach. The modified retrospective approach applies the standard in the year of initial application and presents the cumulative effect of prior periods with an adjustment to beginning retained earnings, with no restatement of comparative periods. As leasing arrangements (which are excluded from ASU 2014-09) represent the primary source of revenue for the Company, the impact of adoption will be limited to the Company’s recognition and presentation of non-lease revenues, which are currently reflected as a component of other income. Adoption of ASU 2014-09 will not have a material impact on the amount and timing of the recognition of income subject to this standard and we do not intend to further break out income line items with no cumulative effect adjustment to be recognized upon adoption.

In February 2015, the FASB issued ASU 2015-02, Amendments to the Consolidation Analysis. ASU 2015-02 requires entities to evaluate whether they should consolidate certain legal entities. Principally, the new consolidation standard modified the evaluation of whether limited partnerships and similar legal entities are variable interest entities (“VIE”) or voting interest entities. The Company adopted ASU 2015-02 on January 1, 2016. Based on the Company’s review and subsequent analysis of the structure of the Company’s legal entities, the Company has concluded that the Operating Partnership is a VIE because the limited partners of the Operating Partnership do not have substantive kick-out or participating rights. The Trust is the general partner and controlling owner of approximately 97.1% of the Operating Partnership and will continue to consolidate the Operating Partnership under this new guidance. With respect to the Company’s investment in unconsolidated joint ventures, the new consolidation standard did not have an impact on previous consolidation conclusions.

In February 2016, the FASB issued ASU 2016-02, Leases. The update amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting. ASU 2016-02 will be effective for annual reporting periods beginning after December 15, 2018. Early adoption is permitted. As a result of adopting ASU 2016-02, the Company will recognize all of its operating leases for which it is the lessee, including ground leases, on its consolidated balance sheets. The Company is evaluating the impact of the adoption of ASU 2016-02 on January 1, 2019 to its consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting. This update simplifies several aspects of accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statements of cash flows. ASU 2016-09 is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2016. The Company adopted ASU 2016-09 on January 1, 2017, with no material effect on its consolidated financial statements with no adjustments made to prior periods.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses, which changes the impairment model for most financial instruments by requiring companies to recognize an allowance for expected losses, rather than incurred losses as required currently by the other-than-temporary impairment model. ASU 2016-13 will apply to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities, net investments in leases, and off-balance-sheet credit exposures (e.g., loan commitments). ASU 2016-13 is effective for reporting periods beginning after December 15, 2019, with early adoption permitted, and will be applied as a cumulative adjustment to retained earnings as of the effective date. We are currently assessing the potential effect the adoption of ASU 2016-13 will have on our consolidated financial statements.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payment. ASU 2016-15 clarifies the guidance on the classification of certain cash receipts and payments in the statement of cash flows to reduce diversity in practice with respect to: (i) debt prepayment or debt extinguishment costs; (ii) settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; (iii) contingent consideration payments made after a business combination; (iv) proceeds from the settlement of insurance claims; (v) proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (vi) distributions received from equity method investees; (vii) beneficial interests in securitization transactions; and (viii) separately identifiable cash flows and application of the predominance principle. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. The Company adopted ASU 2016-15 on January 1, 2018, with no material effect on its consolidated financial statements and no adjustments made to prior periods.

In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows: Restricted Cash, which will require companies to include restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the statement of cash flows. ASU 2016-18 will require disclosure of a reconciliation between the balance sheet and the statement of cash flows when the balance sheet includes more than one line item for cash, cash equivalents, restricted cash, and restricted cash equivalents. An entity with material restricted cash and restricted cash equivalents balances will be required to disclose the nature of the restrictions. ASU 2016-18 is effective for reporting periods beginning after December 15, 2017, and is required to be applied retrospectively to all periods presented. The Company adopted ASU 2016-18 on January 1, 2018, with no material effect on its consolidated financial statements and no adjustments made to prior periods.

In January 2017, the FASB issued ASU 2017-01, Clarifying the Definition of a Business, that clarifies the framework for determining whether an integrated set of assets and activities meets the definition of a business. The revised framework establishes a screen for determining whether an integrated set of assets and activities is a business and narrows the definition of a business, which is expected to result in fewer transactions being accounted for as business combinations. Acquisitions of integrated sets of assets and activities that do not meet the definition of a business are accounted for as asset acquisitions. ASU 2017-01 will be effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017. Upon adoption of ASU 2017-01, the Company anticipates it will classify most prospective real estate acquisitions as asset acquisitions, rather than business combinations, and direct acquisition costs associated with these acquisitions will be capitalized. This is due to the fact that substantially all of the fair value of the gross assets the Company acquires are concentrated in a single asset or group of similar identifiable assets.

XML

Organization and Business - (Tables)

12 Months Ended

Dec. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Trust's common shares issuance and sale

During 2016 and 2017, the Trust’s issuance and sale of common shares pursuant to the 2016 ATM Program is as follows (in thousands, except common shares and price): 

	2017					2016
	Common shares sold	Weighted average price		Net proceeds		Common shares sold	Weighted average price		Net proceeds
Quarterly period ended March 31	—	$	—	$	—	—	$	—	$	—
Quarterly period ended June 30	4,150,000	20.07		82,440		—	—		—
Quarterly period ended September 30	—	—		—		—	—		—
Quarterly period ended December 31	2,197,914	18.39		40,011		135,531	19.09		2,561
Year ended December 31	6,347,914	$	19.48	$	122,451	135,531	$	19.09	$	2,561

XML

Summary of Significant Accounting Policies - (Tables)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Schedule of dividends declared

Dividends and distributions for the years ended December 31, 2017, 2016, and 2015 are as follows:

Declaration Date	Record Date	Payment Date	Cash Dividend per Share/Unit
December 21, 2017	January 3, 2018	January 18, 2018	$	0.230
September 21, 2017	October 3, 2017	October 18, 2017	$	0.230
June 12, 2017	July 3, 2017	July 18, 2017	$	0.230
March 17, 2017	April 5, 2017	April 18, 2017	$	0.225
December 22, 2016	January 5, 2017	January 18, 2017	$	0.225
September 26, 2016	October 6, 2016	October 18, 2016	$	0.225
June 23, 2016	July 5, 2016	July 18, 2016	$	0.225
March 18, 2016	April 1, 2016	April 18, 2016	$	0.225
December 31, 2015	January 15, 2016	January 29, 2016	$	0.225
September 28, 2015	October 16, 2015	October 30, 2015	$	0.225
July 1, 2015	July 17, 2015	July 31, 2015	$	0.225
April 6, 2015	April 17, 2015	May 1, 2015	$	0.225

Dividends and distributions per share

The following table sets forth the federal income tax status of distributions per common share and OP Unit for the periods presented:

	Year Ended December 31,
	2017		2016		2015
Per common share and OP Unit:
Ordinary dividends	$	0.4529	$	0.5325	$	0.2693
Qualified dividends	—		—		—
Capital gain distributions	—		—		—
Non-dividend distributions	0.4571		0.3675		0.6307
Total	$	0.9100	$	0.9000	$	0.9000

XML

Acquisitions and Dispositions - (Tables)

12 Months Ended

Dec. 31, 2017

Business Combinations [Abstract]

Schedule of acquisitions and aggregate purchase price

This aggregate purchase price does not include near-term capital expenditure commitments of $12.9 million and committed tenant improvement allowances of $8.9 million related to the Company’s acquisition of the CHI Portfolio.

Investment activity for the year ending December 31, 2016 is summarized below:

Property (1)			Location	Acquisition Date	Purchase Price  (in thousands)
Tinseltown - Loan Draws			Jacksonville, FL		$	2,192
Randall Road MOB - Suite 380	(3)		Elgin, IL	January 14, 2016	704
Great Falls Hospital	(2)		Great Falls, MT	January 25, 2016	29,043
Monterey Medical Center ASC	(2)		Stuart, FL	February 1, 2016	6,900
Physicians Medical Plaza MOB	(2)	(4)	Indianapolis, IN	February 1, 2016	8,500
Mezzanine Loan - Davis			Minnetonka, MN	February 4, 2016	500
Park Nicollet Clinic	(2)		Chanhassen, MN	February 8, 2016	18,600
HEB Cancer Center	(2)		Bedford, TX	February 12, 2016	13,980
Riverview Medical Center	(2)		Lancaster, OH	February 26, 2016	12,800
St. Luke's Cornwall MOB	(2)		Cornwall, NY	February 26, 2016	14,550
HonorHealth Glendale	(3)		Glendale, AZ	March 15, 2016	9,820
Columbia MOB	(2)		Hudson, NY	March 21, 2016	18,450

Property (1)			Location	Acquisition Date	Purchase Price  (in thousands)
St Vincent POB 1	(2)		Birmingham, AL	March 23, 2016	10,951
St Vincent POB 2	(2)		Birmingham, AL	March 23, 2016	7,945
St Vincent POB 3	(2)		Birmingham, AL	March 23, 2016	10,455
Emerson Medical Building	(2)		Creve Coeur, MO	March 24, 2016	14,250
Randall Road MOB - Suite 160	(3)		Elgin, IL	March 24, 2016	865
Patient Partners Surgery Center	(2)		Gallatin, TN	March 30, 2016	4,750
Eye Associates of NM - Santa Fe	(3)		Santa Fe, NM	March 31, 2016	8,739
Eye Associates of NM - Albuquerque	(3)		Albuquerque, NM	March 31, 2016	10,536
Gardendale Surgery Center	(2)		Gardendale, AL	April 11, 2016	7,450
HealthEast - Curve Crest	(2)		Stillwater, MN	April 14, 2016	4,144
HealthEast - Victor Gardens	(2)		Hugo, MN	April 14, 2016	6,025
NOMS - Clyde	(3)		Clyde, OH	May 10, 2016	6,342
Blandford MOB	(3)	(5)	Little Rock, AR	May 11, 2016	2,580
Cardwell MOB	(2)	(5)	Lufkin, TX	May 11, 2016	8,444
Dacono Neighborhood Health	(3)	(5)	Dacono, CO	May 11, 2016	5,152
Franciscan Health	(3)	(5)	Tacoma, WA	May 11, 2016	9,772
Grand Island Specialty Clinic	(3)	(5)	Grand Island, NE	May 11, 2016	2,891
Hot Springs MOB	(2)	(5)	Hot Springs Village, AR	May 11, 2016	3,626
Jewish Medical Center East	(3)	(5)	Louisville, KY	May 11, 2016	85,000
Jewish Medical Center South MOB - 1	(3)	(5)	Shepherdsville, KY	May 11, 2016	17,021
Jewish Medical Plaza I	(2)	(5)	Louisville, KY	May 11, 2016	9,650
Jewish Medical Plaza II	(2)	(5)	Louisville, KY	May 11, 2016	6,124
Jewish OCC	(3)	(5)	Louisville, KY	May 11, 2016	35,600
Lakeside Three Professional Center	(2)	(5)	Omaha, NE	May 11, 2016	1,581
Lexington Surgery Center	(2)	(5)	Lexington, KY	May 11, 2016	20,169
Medical Arts Pavilion	(2)	(5)	Lufkin, TX	May 11, 2016	6,304
Memorial Outpatient Center	(3)	(5)	Lufkin, TX	May 11, 2016	4,958
Midlands Two Professional Center	(2)	(5)	Papillion, NE	May 11, 2016	1,341
Parkview MOB	(2)	(5)	Little Rock, AR	May 11, 2016	5,060
Peak One ASC	(2)	(5)	Frisco, CO	May 11, 2016	6,587
Physicians Medical Center	(2)	(5)	Tacoma, WA	May 11, 2016	6,782
St. Alexius - Minot Medical Plaza	(3)	(5)	Minot, ND	May 11, 2016	26,570
St. Clare Medical Pavilion	(2)	(5)	Lakewood, WA	May 11, 2016	10,617
St. Joseph Medical Pavilion	(2)	(5)	Tacoma, WA	May 11, 2016	13,320
St. Joseph Office Park	(2)	(5)	Lexington, KY	May 11, 2016	17,228
St. Mary - Caritas Medical II	(2)	(5)	Louisville, KY	May 11, 2016	5,603
St. Mary - Caritas Medical III	(2)	(5)	Louisville, KY	May 11, 2016	842
Thornton Neighborhood Health	(3)	(5)	Thornton, CO	May 11, 2016	3,875
Medical Village at Kissimmee	(2)		Kissimmee, FL	May 26, 2016	4,923
Medical Village at Leesburg	(2)		Leesburg, FL	May 26, 2016	4,576
St. Francis MOB	(2)	(5)	Federal Way, WA	June 2, 2016	14,287
Children's Hospital MOB	(2)		Milwaukee, WI	June 3, 2016	5,850
Jewish Medical Center South MOB - 2	(2)		Shepherdsville, KY	June 8, 2016	4,343
Good Samaritan North Annex Building	(3)	(5)	Kearney, NE	June 28, 2016	2,874
NE Heart Institute Medical Building	(3)	(5)	Lincoln, NE	June 28, 2016	19,600

Property (1)			Location	Acquisition Date	Purchase Price  (in thousands)
St. Vincent West MOB	(3)	(5)	Little Rock, AR	June 29, 2016	14,120
Meridan MOB	(3)	(5)	Englewood, CO	June 29, 2016	17,329
St. Mary - Caritas Medical I	(2)	(5)	Louisville, KY	June 29, 2016	8,864
St. Alexius - Medical Arts Pavilion	(3)	(5)	Bismarck, ND	June 29, 2016	12,983
St. Alexius - Mandan Clinic	(3)	(5)	Mandan, ND	June 29, 2016	8,390
St. Alexius - Orthopaedic Center	(2)	(5)	Bismarck, ND	June 29, 2016	14,727
St. Alexius - Rehab Center	(3)	(5)	Bismarck, ND	June 29, 2016	6,215
St. Alexius - Tech & Ed	(3)	(5)	Bismarck, ND	June 29, 2016	16,680
Good Samaritan MOB	(2)	(5)	Kearney, NE	June 29, 2016	24,198
Lakeside Two Professional Building	(2)	(5)	Omaha, NE	June 29, 2016	13,691
Lakeside Wellness Center	(3)	(5)	Omaha, NE	June 29, 2016	10,138
McAuley Center	(3)	(5)	Omaha, NE	June 29, 2016	18,382
Memorial Health Center	(3)	(5)	Grand Island, NE	June 29, 2016	34,042
Missionary Ridge MOB	(2)	(5)	Chattanooga, TN	June 29, 2016	7,635
Pilot Medical Center	(3)		Birmingham, AL	June 29, 2016	17,351
St. Joseph Medical Clinic	(2)	(5)	Tacoma, WA	June 30, 2016	16,444
Woodlands Medical Arts Center	(2)	(5)	The Woodlands, TX	June 30, 2016	21,227
FESC MOB	(3)	(5)	Tacoma, WA	June 30, 2016	16,748
Mezzanine Loan - Catalyst			Pensacola, FL	June 30, 2016	1,340
Prairie Care MOB	(2)		Maplewood, MN	July 6, 2016	4,886
RE Loan - Chihuahua Development LLC			El Paso, TX	July 7, 2016	1,300
Springwoods MOB	(2)	(5)	Spring, TX	July 21, 2016	19,925
Equity Buyout - Foundation	(6)		TX / OK	July 26, 2016	611
Mezzanine Loan - Hazelwood			Minnetonka, MN	July 29, 2016	3,375
Jackson, Tennessee Land	(3)		Jackson, TN	August 2, 2016	1,000
Unity Portfolio (4 MOBs)	(2)		West Lafayette, IN	August 8, 2016	28,751
Medical Village at Maitland	(2)		Orlando, FL	August 23, 2016	23,211
Tri-State Orthopaedics MOB	(2)		Evansville, IN	August 30, 2016	22,000
Maury Regional Healthcare MOB	(2)	(8)	Spring Hill, TN	September 30, 2016	18,500
Spring Ridge Medical Center	(2)		Wyomissing, PA	September 30, 2016	6,100
Doctors Community Hospital POB	(2)		Lanham, MD	September 30, 2016	26,750
Gig Harbor Medical Pavilion	(3)	(5)	Gig Harbor, WA	September 30, 2016	4,766
Midlands One Professional Center	(2)	(5)	Papillion, NE	September 30, 2016	14,856
Noncontrolling Interest Buyout - Great Falls Clinic	(7)		Great Falls, MT	September 30, 2016	1,015
N.W. Michigan Surgery Center - Units #1 & #2	(3)	(9)	Traverse City, MI	October 28, 2016	29,448
United Surgical Partners Joint Venture	(10)		Scottsdale, AZ	October 31, 2016	903
N.W. Michigan Surgery Center - Unit #4	(3)	(11)	Traverse City, MI	November 4, 2016	2,715
Syracuse Portfolio (2 MOBs)	(2)		Syracuse, NY	November 23, 2016	54,239
Cincinnati Eye Institute	(3)		Cincinnati, OH	November 23, 2016	38,100
Curie Building Loan			El Paso, TX	December 2, 2016	1,500
HonorHealth - Scottsdale MOB	(3)		Scottsdale, AZ	December 2, 2016	6,900
Fox Valley Hematology & Oncology	(3)		Appleton, WI	December 8, 2016	28,200
Gastrointestinal Associates MOB	(2)		Powell, TN	December 9, 2016	6,287
Northern Vision Eye Center	(3)		Traverse City, MI	December 15, 2016	2,777

Property (1)		Location	Acquisition Date	Purchase Price  (in thousands)
Noncontrolling Interest Buyout - Great Falls Clinic	(12)	Great Falls, MT	December 15, 2016	1,497
Flower Mound Portfolio (3 MOBs)	(3)	Flower Mound, TX	December 16, 2016	27,800
HonorHealth IRF	(3)	Scottsdale, AZ	December 22, 2016	25,628
				$	1,285,185

(1) “MOB” means medical office building. “ASC” means ambulatory surgical center. “POB” means professional office building. “IRF” means inpatient rehabilitation facility.

(2) The Company accounted for these acquisitions as business combinations pursuant to the acquisition method and expensed total acquisition costs of $14.8 million.

(3) The Company accounted for these acquisitions as asset acquisitions and capitalized total acquisition costs of $3.0 million.

(4) The Company partially funded the purchase price of this acquisition by issuing a total of 174,085 OP Units valued at approximately $2.9 million in the aggregate on the date of issuance.

(5) These acquisitions are part of the CHI portfolio.

(6) The Company acquired the previously outstanding 1% noncontrolling interest retained by the predecessor owner on three properties, El Paso, Texas and Oklahoma City, Oklahoma.

(7) The Company acquired an additional 3% interest in the Great Falls Clinic joint venture from the predecessor owner, increasing the Company’s total interest to 77.3%.

(8) The Company acquired 99.7% of the ownership interest in this property, the remainder of which was retained by the seller.

(9) The Company partially funded the purchase price of the acquisition of two condominium units within the Northwest Michigan Surgery Center through unregistered issuance of 947,936 common shares of beneficial interest.

(10) The Company’s investment in the United Surgical Partners J.V. represents a 43% ownership interest.

(11) The Company partially funded the purchase price of the acquisition of one additional condominium unit within the Northwest Michigan Surgery Center through the unregistered issuance of 88,602 common shares of beneficial interest.

(12)

The company acquired an additional 4.6% interest in the Great Falls Clinic joint venture from the predecessor owner, increasing the Company’s total interest to 81.8%. Investment activity for the year ending December 31, 2017 is summarized below:

Property (1)			Location	Acquisition Date	Purchase Price (in thousands)
Orthopedic Associates	(2)		Flower Mound, TX	January 5, 2017	$	18,750
Medical Arts Center at Hartford	(2)		Plainville, CT	January 11, 2017	30,250
Noncontrolling Interest Buyout - New Albany	(3)		New Albany, OH	January 31, 2017	2,824
CareMount - Lake Katrine MOB	(2)	(4)	Lake Katrine, NY	February 14, 2017	41,791
CareMount - Rhinebeck MOB	(2)		Rhinebeck, NY	February 14, 2017	18,639
Syracuse Condos	(2)		Fayetteville & Liverpool, NY	February 27, 2017	2,659
Monterey Medical Center - MOB	(2)		Stuart, FL	March 7, 2017	18,979
Creighton University Medical Center	(5)		Omaha, NE	March 28, 2017	33,420
Strictly Pediatrics Specialty Center	(2)	(6)	Austin, TX	March 31, 2017	78,628
MedStar Stephen's Crossing	(2)		Brandywine, MD	June 16, 2017	20,900
2017 CHI Portfolio - Tranche 1 (8 MOBs)	(5)		AR, MN, ND, NE, TN, TX	June 29, 2017	124,181
St. Vincent Portfolio (2 MOBs)	(2)		Carmel & Fishers, IN	June 29, 2017	93,880
Baylor Charles A. Sammons Cancer Center	(2)		Dallas, TX	June 30, 2017	290,000
Orthopedic & Sports Institute of the Fox Valley	(7)		Appleton, WI	June 30, 2017	27,900
Peachtree Dunwoody Medical Center - Parking Deck	(7)		Atlanta, GA	June 30, 2017	25,000
Clearview Cancer Institute	(2)		Huntsville, AL	August 4, 2017	53,250
Northside Cherokee/Town Lake MOB	(2)		Atlanta, GA	August 15, 2017	37,127
HonorHealth Mesa MOB	(2)		Mesa, AZ	August 15, 2017	4,800
2017 CHI Portfolio - Tranche 2 (5 MOBs)	(5)		AR, MN, NE, TX	August 24, 2017 & August 31, 2017	33,694
Noncontrolling Interest Buyout - Great Falls Clinic	(8)		Great Falls, MT	September 21, 2017	1,061
Legends Park MOB & ASC	(2)		Midland, TX	September 27, 2017	30,000
Franklin MOB & ASC	(2)		Franklin, TN	October 12, 2017	9,950
Eagle Point MOB	(2)		Lake Elmo, MN	October 31, 2017	10,949
Edina East MOB	(2)		Edina, MN	October 31, 2017	7,800
Northside MOB - Center Pointe	(2)		Atlanta, GA	November 10, 2017	155,986
Gwinnett 500 Building	(2)		Lawrenceville, GA	November 17, 2017	25,297
Hudgens Professional Building	(2)		Duluth, GA	November 17, 2017	23,696
St. Vincent Building	(2)		Indianapolis, IN	November 17, 2017	60,124
Gwinnett Physicians Center	(2)	(9)	Lawrenceville, GA	December 1, 2017	51,721
Apple Valley Medical Center	(2)		Apple Valley, MN	December 18, 2017	21,500
Desert Cove MOB (57% Interest)	(2)	(10)	Scottsdale, AZ	December 18, 2017	4,560
Westgate MOB	(2)		Glendale, AZ	December 21, 2017	15,800

Property (1)		Location	Acquisition Date	Purchase Price (in thousands)
Loan Investments	(11)	Various	Various	39,063
				$	1,414,179

(1) “MOB” means medical office building. “ASC” means ambulatory surgery center.

(2) The Company accounted for these acquisitions as business combinations pursuant to the acquisition method and expensed total acquisition costs of $16.6 million.

(3) The Company acquired the previously outstanding interest in the New Albany MOB from the predecessor owner. As consideration, the Operating Partnership paid approximately $2.1 million in cash and issued 38,641 OP Units, representing approximately $2.8 million in aggregate.

(4) The Company partially funded this acquisition through the assumption of an existing mortgage valued at approximately $26.4 million.

(5) These acquisitions are part of the CHI Portfolio. The Company accounted for nine of these facilities, consisting of an aggregate purchase price of $143.0 million, as asset acquisitions and capitalized total acquisition costs of $0.4 million. The remaining six facilities, consisting of an aggregate purchase price of $48.3 million, were accounted for as business combinations pursuant to the acquisition method, with acquisition expense totaling $0.1 million.

(6) The Company partially funded the purchase price of this acquisition by issuing a total of 2,247,817 OP Units valued at approximately $44.3 million in the aggregate on the date of issuance.

(7) The Company accounted for these acquisitions as asset acquisitions and capitalized total acquisition costs of $0.5 million.

(8) The Company acquired an additional 3.2% interest in the Great Falls Clinic joint venture from the predecessor owner, increasing the Company’s total interest to 85.0%.

(9) As part of this acquisition, the Company assumed a $17.6 million mortgage on the facility.

(10) The Company acquired an additional 57.0% ownership interest in Desert Cove MOB, LLC increasing the Company’s total interest to 100%.

(11)

The loan investments listed here include 8 separate transactions at a weighted average interest rate of 8.1%.

Schedule of preliminary purchase price allocations of assets acquired and liabilities assumed

The following table summarizes the preliminary purchase price allocations of the assets acquired and the liabilities assumed, which the Company determined using Level 2 and Level 3 inputs (in thousands):

	December 31, 2017			December 31, 2016
Land	$	38,358		$	57,847
Building and improvements	1,168,741			1,112,746
In-place lease intangible	128,370			58,666
Above-market in-place lease intangible	18,967			9,359
Below-market in-place lease intangible	(4,270		)	(4,518		)
Above-market in-place ground lease	(4,620		)	(644		)
Below-market in-place ground lease	17,683			28,937
Contingent consideration	(765		)	(156		)
Receivable	434			104
Debt assumed	(43,989		)	—
Issuance of OP Units	(44,978		)	(2,869		)
Investment in unconsolidated entity	(2,871		)	903
Lease inducement	—			8,945
Prepaid expenses	—			2,659
Issuance of Common Shares	—			(20,980		)
Noncontrolling interest	—			(50		)
Net assets acquired	$	1,271,060		$	1,250,949

Income related to disposition properties

The following table summarizes revenues and net income related to the disposition properties for the periods presented (in thousands):

	Year Ended December 31,
	2017		2016		2015
Revenue	$	823	$	1,967	$	1,666
Income before gain on sale of investment properties	108		433		421
Gain on sale of investment properties	5,870		—		—
Net income	$	5,978	$	433	$	421

Schedule of pro forma combined revenue, net income, and earnings per share-basic and diluted

The following table illustrates the pro forma consolidated revenue, net income, and earnings per share as if the Company had acquired the 2017 acquisitions detailed above as of January 1, 2016 (in thousands, except share and per share amounts):

	Year Ended December 31,
	2017		2016
Revenue	$	405,320	$	352,432
Net income	42,149		39,233
Net income available to common shareholders	39,759		35,614
Earnings per share - basic	$	0.24	$	0.22
Earnings per share - diluted	$	0.24	$	0.22
Weighted average number of shares outstanding - basic	163,123,109		163,123,109
Weighted average number of shares outstanding - diluted	168,231,299		168,231,299

Physicians Realty L.P.

The following table illustrates the pro forma consolidated revenue, net income, and earnings per share as if the Company had acquired the 2017 acquisitions detailed above as of January 1, 2016 (in thousands, except unit and per unit amounts):

	Year Ended December 31,
	2017		2016
Revenue	$	405,320	$	352,432
Net income	42,149		39,233
Net income available to common unitholders	40,927		36,660
Earnings per unit - basic	$	0.24	$	0.22
Earnings per unit - diluted	$	0.24	$	0.22
Weighted average number of units outstanding - basic	167,963,076		167,963,076
Weighted average number of units outstanding - diluted	168,231,299		168,231,299

XML

Intangibles - (Tables)

12 Months Ended

Dec. 31, 2017

Finite-Lived Intangible Assets, Net [Abstract]

Summary of the carrying amount of intangible assets and liabilities

The following is a summary of the carrying amount of intangible assets and liabilities as of December 31, 2017 and 2016 (in thousands):

	December 31, 2017							December 31, 2016
	Cost		Accumulated Amortization			Net		Cost		Accumulated Amortization			Net
Assets
In-place leases	$	343,429	$	(85,424	)	$	258,005	$	222,394	$	(55,605	)	$	166,789
Above-market leases	54,148		(11,968		)	42,180		35,478		(6,909		)	28,569
Leasehold interest	712		(183		)	529		712		(124		)	588
Below-market ground lease	60,424		(1,344		)	59,080		42,878		(539		)	42,339
Total	$	458,713	$	(98,919	)	$	359,794	$	301,462	$	(63,177	)	$	238,285
Liabilities
Below-market lease	$	14,344	$	(4,479	)	$	9,865	$	10,297	$	(2,345	)	$	7,952
Above-market ground lease	5,965		(128		)	5,837		1,345		(44		)	1,301
Total	$	20,309	$	(4,607	)	$	15,702	$	11,642	$	(2,389	)	$	9,253

Summary of the carrying amount of acquired lease intangibles

The following is a summary of the acquired lease intangible amortization for the years ended December 31, 2017, 2016, and 2015 (in thousands):

	December 31,
	2017		2016		2015
Amortization expense related to in-place leases	$	37,073	$	28,902	$	15,300
Decrease of rental income related to above-market leases	5,357		4,403		2,596
Decrease of rental income related to leasehold interests	59		59		59
Increase of rental income related to below-market leases	2,309		1,835		643
Decrease of operating expense related to above-market ground leases	84		24		16
Increase in operating expense related to below-market ground leases	810		471		68

Schedule of future amortization of the acquired lease intangibles

Future aggregate net amortization of the acquired lease intangibles as of December 31, 2017, is as follows (in thousands): 

	Net Decrease in Revenue			Net Increase in Expenses
2018	$	(3,355	)	$	41,455
2019	(3,376		)	36,429
2020	(3,392		)	33,009
2021	(3,333		)	30,582
2022	(2,872		)	26,225
Thereafter	(16,516		)	143,548
Total	$	(32,844	)	$	311,248

XML

Other Assets - (Tables)

12 Months Ended

Dec. 31, 2017

Other Assets, Unclassified [Abstract]

Schedule of other assets

Other assets consisted of the following as of December 31, 2017 and 2016 (in thousands):

	December 31,
	2017		2016
Straight line rent receivable	47,599		32,018
Prepaid expenses	18,103		8,928
Interest rate swap	14,693		13,881
Lease inducements, net	14,232		13,255
Leasing commissions, net	4,128		1,858
Earnest deposits	2,780		1,500
Escrows	1,996		4,334
Notes receivable	—		16,618
Other	2,771		2,795
Total	$	106,302	$	95,187

XML

Debt - (Tables)

12 Months Ended

Dec. 31, 2017

Debt Disclosure [Abstract]

Schedule of debt

The following is a summary of debt as of December 31, 2017 and 2016 (in thousands):

	December 31,
	2017				2016
Fixed interest mortgage notes	$	158,171		(1)	$	90,185		(2)
Variable interest mortgage notes	28,509			(3)	33,009			(4)
Total mortgage debt	186,680				123,194
$850 million unsecured revolving credit facility bearing variable interest of LIBOR plus 1.20%, due September 2020	80,000				401,000
$400 million senior unsecured notes bearing fixed interest of 4.30%, due March 2027	400,000				—
$350 million senior unsecured notes bearing fixed interest of 3.95%, due January 2028	350,000				—
$250 million unsecured term borrowing bearing fixed interest of 2.87%, due June 2023	250,000			(5)	250,000
$150 million senior unsecured notes bearing fixed interest of 4.03% to 4.74%, due January 2023 to 2031	150,000				150,000
$75 million senior unsecured notes bearing fixed interest of 4.09% to 4.24%, due August 2025 to 2027	75,000				75,000
Total principal	1,491,680				999,194
Unamortized deferred financing cost	(7,808		)		(8,477		)
Unamortized discount	(6,663		)		—
Unamortized fair value adjustment	259				438
Total debt	$	1,477,468			$	991,155

(1) Fixed interest mortgage notes, bearing interest from 3.00% to 5.50%, with a weighted average interest rate of 4.45%, and due in 2018, 2019, 2020, 2021, 2022, and 2024 collateralized by nine properties with a net book value of $267.7 million.

(2) Fixed interest mortgage notes, bearing interest from 4.71% to 6.58%, with a weighted average interest rate of 5.44%, and due in 2017, 2018, 2019, 2020, 2021, 2022, and 2032 collateralized by 11 properties with a net book value of $156.7 million.

(3) Variable interest mortgage notes, bearing variable interest of LIBOR plus 2.25% to 3.25%, with a weighted average interest rate of 4.50% and due in 2018, collateralized by three properties with a net book value of $39.2 million.

(4) Variable interest mortgage notes bearing variable interest of LIBOR plus 2.25% to 3.25%, with a weighted average interest rate of 3.68% and due in 2017 and 2018, collateralized by four properties with a net book value of $45.6 million.

(5)

The Trust’s borrowings under the term loan feature of the Credit Agreement bear interest at a rate which is determined by the Trust’s credit rating, currently equal to LIBOR + 1.80%. The Trust has entered into a pay-fixed receive-variable interest rate swap, fixing the LIBOR component of this rate at 1.07%.

Schedule of consolidated leverage ratios

The Credit Agreement provides for revolving credit and term loans to the Trust and the Operating Partnership. Base Rate Loans, Adjusted LIBOR Rate Loans, and Letters of Credit (each, as defined in the Credit Agreement) will be subject to interest rates, based upon the Trust’s investment grade rating as follows:

Credit Rating	Margin for Revolving Loans: Adjusted LIBOR Rate Loans and Letter of Credit Fee	Margin for Revolving Loans: Base Rate Loans		Margin for Term Loans: Adjusted LIBOR Rate Loans and Letter of Credit Fee	Margin for Term Loans: Base Rate Loans
At Least A- or A3	LIBOR + 0.85%	—	%	LIBOR + 1.40%	0.40	%
At Least BBB+ or Baa1	LIBOR + 0.90%	—	%	LIBOR + 1.45%	0.45	%
At Least BBB or Baa2	LIBOR + 1.00%	0.10	%	LIBOR + 1.55%	0.55	%
At Least BBB- or Baa3	LIBOR + 1.20%	0.20	%	LIBOR + 1.80%	0.80	%
Below BBB- or Baa3	LIBOR + 1.55%	0.60	%	LIBOR + 2.25%	1.25	%

Schedule of principal payments due on debt

Scheduled principal payments due on debt as of December 31, 2017, are as follows (in thousands):

2018	$	54,775
2019	44,631
2020	110,122
2021	8,718
2022	24,708
Thereafter	1,248,726
Total Payments	$	1,491,680

XML

Derivatives - (Tables)

12 Months Ended

Dec. 31, 2017

Derivative Instrument Detail [Abstract]

Schedule of Interest Rate Derivatives

The following table summarizes the location and aggregate fair value of the interest rate swaps on the Company’s consolidated balance sheets (in thousands):

Total notional amount		$	250,000
Effective fixed interest rate	(1)	2.87		%
Effective date		7/7/2016
Maturity date		6/10/2023
Asset balance at December 31, 2017 (included in Other assets)		$	14,693

(1)

1.07% effective swap rate plus 1.80% spread per Credit Agreement.

XML

Accrued Expenses and Other Liabilities - (Tables)

12 Months Ended

Dec. 31, 2017

Other Liabilities Disclosure [Abstract]

Schedule of accrued expenses and other liabilities

Accrued expenses and other liabilities consisted of the following as of December 31, 2017 and 2016 (in thousands):

	December 31,
	2017		2016
Real estate taxes payable	$	16,103	$	9,300
Accrued interest	11,107		4,905
Prepaid rent	10,496		5,834
Accrued expenses	8,751		3,453
Tenant improvement allowance	3,065		5,315
Security deposits	2,882		4,506
Accrued incentive compensation	1,625		1,405
Contingent consideration	1,454		1,392
Embedded derivative	—		5,571
Other	922		606
Total	$	56,405	$	42,287

XML

Stock-based Compensation - (Tables)

12 Months Ended

Dec. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of non-vested restricted common shares

The following is summary of the status of the Trust’s non-vested restricted common shares during 2017, 2016, and 2015:

	Common Shares		Weighted Average Grant Date Fair Value
Non-vested at December 31, 2014	319,654		$	12.60
Granted	162,522		15.95
Vested	(170,337	)	12.93
Non-vested at December 31, 2015	311,839		14.17
Granted	155,306		17.96
Vested	(170,034	)	14.16
Forfeited	(326	)	15.36
Non-vested at December 31, 2016	296,785		16.16
Granted	143,593		19.74
Vested	(266,552	)	16.00
Forfeited	(550	)	18.78
Non-vested at December 31, 2017	173,276		$	19.36

Schedule of weighted average grant date fair value assumptions

The Company utilized a Monte Carlo simulation to calculate the weighted average grant date fair values in 2017, 2016, and 2015 of $33.43, $28.50, and $20.06 per unit, respectively, using the following assumptions:

	2017			2016			2015
Volatility	21.5		%	20.3		%	20.7		%
Dividend assumption	reinvested			reinvested			reinvested
Expected term in years	2.8 years			2.8 years			2.8 years
Risk-free rate	1.68		%	1.07		%	1.14		%
Stock price (per share)	$	19.80		$	17.67		$	15.87

Summary of the activity in the restricted share units

The following is a summary of the activity in the Trust’s restricted share units during 2017, 2016, and 2015: 

	Executive Awards				Trustee Awards
	Restricted Share Units		Weighted Average Grant Date Fair Value		Restricted Share Units		Weighted Average Grant Date Fair Value
Non-vested at December 31, 2014	55,680		$	16.94	—		$	—
Granted	75,250		19.22		40,957		15.87
Non-vested at December 31, 2015	130,930		18.48		40,957		15.87
Granted	104,553		26.33		36,784		17.67
Vested	—		—		(20,481	)	15.87
Non-vested at December 31, 2016	235,483		21.84		57,260		17.03
Granted	174,320		29.34		32,831		19.80
Vested	(55,680	)	16.94		(38,871	)	16.72
Non-vested at December 31, 2017	354,123		$	26.30	51,220		$	19.04

XML

Fair Value Measurements - (Tables)

12 Months Ended

Dec. 31, 2017

Fair Value Disclosures [Abstract]

Schedule of fair value of other financial instruments

The following table presents the fair value of the Company’s financial instruments (in thousands):

	December 31,
	2017						2016
	Carrying Amount			Fair Value			Carrying Amount			Fair Value
Assets:
Real estate loans receivable	$	76,195		$	75,288		$	39,154		$	39,154
Notes receivable	$	—		$	—		$	16,618		$	16,618
Derivative assets	$	14,693		$	14,693		$	13,881		$	13,881
Liabilities:
Credit facility	$	(330,000	)	$	(330,000	)	$	(651,000	)	$	(651,000	)
Notes payable	$	(975,000	)	$	(970,975	)	$	(225,000	)	$	(214,584	)
Mortgage debt	$	(186,939	)	$	(185,743	)	$	(123,632	)	$	(125,420	)
Derivative liabilities	$	—		$	—		$	(5,571	)	$	(5,571	)

XML

Tenant Operating Leases - (Tables)

12 Months Ended

Dec. 31, 2017

Leases [Abstract]

Schedule of future minimum rental payments on non-cancelable leases, exclusive of expense recoveries

As of December 31, 2017, the future minimum rental payments on non-cancelable leases, exclusive of expense recoveries, were as follows (in thousands):

2018	$	292,030
2019	291,338
2020	285,100
2021	278,095
2022	265,995
Thereafter	1,419,746
Total	$	2,832,304

XML

Rent Expense - (Tables)

12 Months Ended

Dec. 31, 2017

Leases [Abstract]

Schedule of future minimum lease obligations under non-cancelable ground leases

As of December 31, 2017, the future minimum lease obligations under non-cancelable parking, air, ground, and office leases were as follows (in thousands):

2018	$	2,678
2019	2,604
2020	2,549
2021	2,563
2022	2,585
Thereafter	119,224
Total	$	132,203

XML

Credit Concentration - (Tables) - Sales Revenue, Services, Net

12 Months Ended

Dec. 31, 2017

Customer Concentration Risk

Concentration Risk [Line Items]

Schedules of Concentration of Risk, by Risk Factor

The following table summarizes certain information about the Company’s top five tenant credit concentrations as of December 31, 2017 (in thousands):

Tenant	Total ABR		Percent of ABR
CHI - Nebraska	$	15,906	5.6	%
CHI - KentuckyOne Health	13,120		4.6	%
Baylor Scott and White Health	7,402		2.6	%
US Oncology	6,706		2.4	%
CHI - St. Alexius (ND)	6,239		2.2	%
Remaining portfolio	236,297		82.6	%
Total	$	285,670	100.0	%

Geographic Concentration Risk

Concentration Risk [Line Items]

Schedules of Concentration of Risk, by Risk Factor

The following table summarizes certain information about the Company’s top five geographic concentrations as of December 31, 2017 (in thousands):

State	Total ABR		Percent of ABR
Texas	$	46,850	16.4	%
Georgia	27,457		9.6	%
Indiana	18,283		6.4	%
Nebraska	17,304		6.1	%
Kentucky	16,028		5.6	%
Other	159,748		55.9	%
Total	$	285,670	100.0	%

XML

Earnings Per Share and Earnings Per Unit - (Tables)

12 Months Ended

Dec. 31, 2017

Earnings Per Share [Abstract]

Schedule of amounts used in computing basic and diluted earnings per share

The following table shows the amounts used in computing the Trust’s basic and diluted earnings per share (in thousands, except share and per share data):

	Year Ended December 31,
	2017			2016			2015
Numerator for earnings per share - basic:
Net income	$	39,773		$	31,522		$	12,741
Net income attributable to noncontrolling interests:
Operating Partnership	(1,136		)	(825		)	(576		)
Partially owned properties	(491		)	(716		)	(377		)
Preferred distributions	(731		)	(1,857		)	(1,189		)
Numerator for earnings per share - basic:	$	37,415		$	28,124		$	10,599
Numerator for earnings per share - diluted:
Numerator for earnings per share - basic:	37,415			28,124			10,599
Operating Partnership net income	1,136			825			576
Numerator for earnings per share - diluted	$	38,551		$	28,949		$	11,175
Denominator for earnings per share - basic and diluted:
Weighted average number of shares outstanding - basic	163,123,109			126,143,114			72,750,724
Effect of dilutive securities:
Noncontrolling interest - Operating Partnership units	4,839,967			3,692,095			3,708,494
Restricted shares	89,497			205,036			190,619
Restricted share units	178,726			426,648			142,236
Denominator for earnings per share - diluted	168,231,299			130,466,893			76,792,073
Earnings per share - basic	$	0.23		$	0.22		$	0.15
Earnings per share - diluted	$	0.23		$	0.22		$	0.15

The following table shows the amounts used in computing the Operating Partnership’s basic and diluted earnings per unit (in thousands, except unit and per unit data):

	Year Ended December 31,
	2017			2016			2015
Numerator for earnings per unit - basic and diluted:
Net income	39,773			31,522			12,741
Net income attributable to noncontrolling interests - partially owned properties	(491		)	(716		)	(377		)
Preferred distributions	(731		)	(1,857		)	(1,189		)
Numerator for earnings per unit - basic and diluted	$	38,551		$	28,949		$	11,175
Denominator for earnings per unit - basic and diluted:
Weighted average number of units outstanding - basic	167,963,076			129,835,209			76,459,218
Effect of dilutive securities:
Restricted shares	89,497			205,036			190,619
Restricted share units	178,726			426,648			142,236
Denominator for earnings per unit - diluted	168,231,299			130,466,893			76,792,073
Earnings per unit - basic	$	0.23		$	0.22		$	0.15
Earnings per unit - diluted	$	0.23		$	0.22		$	0.15

XML

Subsequent Events - (Tables)

12 Months Ended

Dec. 31, 2017

Subsequent Events [Abstract]

Schedule of acquisitions through subsidiaries of operating partnership

In addition, the Operating Partnership funded a $2.0 million loan through a separate transaction, resulting in aggregate investment activity of $100.7 million. Property acquisitions are summarized below:

Property		Location	Acquisition Date	Investment (in thousands)
Hazelwood Medical Commons	(1)	Maplewood, MN	January 9, 2018	$	70,702
Lee's Hill Medical Plaza		Fredericksburg, VA	January 23, 2018	28,000
Loan Investment		Pensacola, FL	February 16, 2018	2,000
				$	100,702

(1)

The Company partially funded the purchase price of this acquisition by issuing a total of 104,172 Preferred OP Units valued at approximately $22.7 million in the aggregate on the date of issuance.

XML

Quarterly Data - (Tables)

12 Months Ended

Dec. 31, 2017

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Data

The following unaudited quarterly data has been prepared on the basis of a December 31 year-end. Amounts are in thousands, except for common unit and per unit amounts.

As a result of the acquisition activity and equity offerings throughout 2017 and 2016, the quarterly periods are not comparable quarter over quarter.

	Quarter Ended
2017	March 31		June 30		September 30		December 31
Total revenues	$	76,666	$	76,599	$	92,999	$	97,320
Operating income	6,688		4,994		12,511		9,523
Net income	6,716		10,331		12,539		10,187
Net income attributable to common unitholders	6,338		9,984		12,380		9,849
Earnings per unit – basic:
Net income available to common unitholders	$	0.04	$	0.06	$	0.07	$	0.05
Weighted average number of units outstanding	142,172,746		160,765,345		183,227,405		185,048,580
Earnings per unit – diluted:
Net income available to common unitholders	$	0.04	$	0.06	$	0.07	$	0.05
Weighted average number of units outstanding	142,605,930		161,012,360		183,298,145		185,273,236

	Quarter Ended
2016	March 31		June 30		September 30		December 31
Total revenues	$	44,134	$	53,216	$	70,010	$	73,674
Operating income	5,392		7,158		10,267		8,590
Net income	5,424		7,184		10,294		8,620
Net income attributable to common unitholders	4,559		6,687		9,682		8,021
Earnings per unit – basic:
Net income available to common unitholders	$	0.04	$	0.05	$	0.07	$	0.06
Weighted average number of units outstanding	106,550,467		135,351,672		138,227,384		139,018,183
Earnings per unit – diluted:
Net income available to common unitholders	$	0.04	$	0.05	$	0.07	$	0.06
Weighted average number of units outstanding	107,148,380		135,944,722		138,880,787		139,602,349

As a result of the acquisition activity and equity offerings throughout 2017 and 2016, the quarterly periods are not comparable quarter over quarter.

	Quarter Ended
2017	March 31		June 30		September 30		December 31
Total revenues	$	76,666	$	76,599	$	92,999	$	97,320
Operating income	6,688		4,994		12,511		9,523
Net income	6,716		10,331		12,539		10,187
Net income attributable to common shareholders	6,191		9,670		12,018		9,536
Earnings per share – basic:
Net income available to common shareholders	$	0.04	$	0.06	$	0.07	$	0.05
Weighted average number of shares outstanding	138,986,629		155,366,080		177,847,424		179,683,948
Earnings per share – diluted:
Net income available to common shareholders	$	0.04	$	0.06	$	0.07	$	0.05
Weighted average number of shares outstanding	142,605,930		161,012,360		183,298,145		185,273,236

	Quarter Ended
2016	March 31		June 30		September 30		December 31
Total revenues	$	44,134	$	53,216	$	70,010	$	73,674
Operating income	5,392		7,158		10,267		8,590
Net income	5,424		7,184		10,294		8,620
Net income available to common shareholders	4,386		6,486		9,427		7,825
Earnings per share – basic:
Net income available to common shareholders	$	0.04	$	0.05	$	0.07	$	0.06
Weighted average number of shares outstanding	102,704,008		131,481,329		134,608,396		135,581,976
Earnings per share – diluted:
Net income available to common shareholders	$	0.04	$	0.05	$	0.07	$	0.06
Weighted average number of shares outstanding	107,148,380		135,944,722		138,880,787		139,602,349

XML

Organization and Business - (Details) - USD ($)		1 Months Ended		3 Months Ended								12 Months Ended
	Aug. 05, 2016	Jul. 31, 2017	Mar. 31, 2017	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Feb. 23, 2018
Organization and Business
Common stock, shares authorized (in shares)				500,000,000				500,000,000				500,000,000	500,000,000
Common stock, par value (in dollars per share)				$ 0.01				$ 0.01				$ 0.01	$ 0.01
Common shares sold (in shares)		21,500,000	17,250,000
Stock issued during period shares upon exercise of underwriters overallotment option (in shares)		1,500,000	2,250,000
Net proceeds from issuance of common stock (approximately)		$ 420,700,000	$ 300,800,000
Other ownership interests, units issued		21,500,000	17,250,000				17,250,000
Subsequent Events
Organization and Business
Amount remaining available														$ 168,200,000
2016 ATM Program | ATM Program | Operating Partnership
Organization and Business
Common shares sold (in shares)				2,197,914	0	4,150,000	0	135,531	0	0	0	6,347,914	135,531
Net proceeds from issuance of common stock (approximately)				$ 40,011,000	$ 0	$ 82,440,000	$ 0	$ 2,561,000	$ 0	$ 0	$ 0	$ 122,451,000	$ 2,561,000
2016 ATM Program | ATM Program | Maximum
Organization and Business
Aggregate offering price of common stock	$ 300,000,000.0

XML

Organization and Business - Schedule of Issuance and Sale of Common Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended								12 Months Ended
	Jul. 31, 2017	Mar. 31, 2017	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Class of Stock [Line Items]
Common shares sold (in shares)	21,500,000	17,250,000
Net proceeds from issuance of common stock (approximately)	$ 420,700	$ 300,800
2016 ATM Program | ATM Program | Operating Partnership
Class of Stock [Line Items]
Common shares sold (in shares)			2,197,914	0	4,150,000	0	135,531	0	0	0	6,347,914	135,531
Weighted average price (in dollars per share)			$ 18.39	$ 0	$ 20.07	$ 0	$ 19.09	$ 0	$ 0	$ 0	$ 19.48	$ 19.09
Net proceeds from issuance of common stock (approximately)			$ 40,011	$ 0	$ 82,440	$ 0	$ 2,561	$ 0	$ 0	$ 0	$ 122,451	$ 2,561

XML

Summary of Significant Accounting Policies - Principals of Consolidation (Details)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Ownership interest in consolidated subsidiaries (as a percent)	100.00%

XML

Summary of Significant Accounting Policies - Noncontrolling Interests (Details) $ / shares in Units, $ in Thousands					12 Months Ended
	Jan. 12, 2017 USD ($)	Dec. 17, 2015 USD ($) shares	Mar. 01, 2015 USD ($)	Feb. 05, 2015 USD ($) $ / shares shares	Dec. 31, 2017 USD ($) properties shares	Dec. 31, 2016 USD ($) properties shares	Apr. 01, 2016 USD ($)
Business Acquisition [Line Items]
Value of units issued for funding purchase price					$ 0	$ 20,980
Acquisition price					$ 1,414,179	$ 1,285,185
Percentage of interest held					97.10%	97.50%
Conversion ratio					1
Embedded derivative	$ 5,600				$ 0	$ 5,571
Aggregate purchase price					1,370,000	1,270,000
Equity investment			$ 5,000
Internal rate of return			15.00%
Redeemable noncontrolling interest, equity, redemption value					1,100
Operating Partnership
Business Acquisition [Line Items]
Acquisition price					$ 78,600	$ 8,500
Units | Operating Partnership
Business Acquisition [Line Items]
Number of real estate properties acquired | properties					1	1
Number of units issued for funding purchase price (in shares) | shares					2,247,817	174,085
Value of units issued for funding purchase price					$ 44,300	$ 2,900
Noncontrolling interest, decrease from redemptions or purchase of interests					$ 700	$ 4,000
Series A Preferred units
Business Acquisition [Line Items]
Cumulative preferred return				5.00%
Shares issued upon conversion				1
Redemption value per share | $ / shares				$ 200
Period of time before redeemable				1 year
Joint venture, Operating Partnership and Medical Center of New Albany I, LLC [Member] | Units | Operating Partnership
Business Acquisition [Line Items]
Number of shares (in shares) | shares					38,641	217,549
Park Nicollet Clinic
Business Acquisition [Line Items]
Number of units issued for funding purchase price (in shares) | shares				44,685
Value of preferred units				$ 9,700
Internal rate of return			15.00%
Park Nicollet Clinic | Units
Business Acquisition [Line Items]
Business acquisition, equity interest redeemed, value assigned							$ 9,800
Embedded derivative							$ 2,700
HonorHealth - Scottsdale MOB
Business Acquisition [Line Items]
Number of units issued for funding purchase price (in shares) | shares		91,236
Value of preferred units		$ 19,700
Aggregate purchase price	$ 20,000

XML

Summary of Significant Accounting Policies - Dividends and Distributions (Details) - $ / shares													12 Months Ended
	Dec. 21, 2017	Sep. 21, 2017	Jun. 12, 2017	Mar. 17, 2017	Dec. 22, 2016	Sep. 26, 2016	Jun. 23, 2016	Apr. 18, 2016	Dec. 31, 2015	Sep. 28, 2015	Jul. 01, 2015	Apr. 06, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Dividends and distributions declared per common share and unit (in dollars per share)	$ 0.230	$ 0.230	$ 0.230	$ 0.225	$ 0.225	$ 0.225	$ 0.225	$ 0.225	$ 0.225	$ 0.225	$ 0.225	$ 0.225	$ 0.915	$ 0.900	$ 0.900

XML

Summary of Significant Accounting Policies - Tax Status of Dividends and Distributions (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Ordinary dividends (dollars per share)	$ 0.4529	$ 0.5325	$ 0.2693
Qualified dividends (dollars per share)	0	0	0
Capital gain distribution (dollars per share)	0	0	0
Non-dividend distributions (dollars per share)	0.4571	0.3675	0.6307
Total (dollars per share)	$ 0.9100	$ 0.9000	$ 0.9000

XML

Summary of Significant Accounting Policies - Impairment of Intangible and Long-Lived Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Impairment loss	$ 965,000	$ 0	$ 0

XML

Summary of Significant Accounting Policies - Investments in Unconsolidated Entities (Details) - USD ($) $ in Thousands		12 Months Ended
	Dec. 18, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2014
Business Acquisition [Line Items]
Percentage of interest held		97.10%	97.50%
Acquisition price		$ 1,414,179	$ 1,285,185
Investment in unconsolidated entity		$ (2,871)	$ 903
Jeff Orleans Medical Development Real Estate L L C
Business Acquisition [Line Items]
Percentage of interest held				40.00%
Acquisition price				$ 1,300
Desert Cove MOB, LLC [Member]
Business Acquisition [Line Items]
Percentage of interest held			43.00%
Noncontrolling interest, increase from business combination, percent		57.00%
Acquisition price	$ 4,560	$ 4,600
Investment in unconsolidated entity		$ 5,500

XML

Summary of Significant Accounting Policies - Real Estate Loans Receivable (Details)	12 Months Ended
	Dec. 31, 2017 buildings mezzanine_loan
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of medical office building developments, as collateral for real estate loans receivable | buildings	2
Mezzanine Loan Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of loans	10
Term Loan Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of loans	2

XML

Summary of Significant Accounting Policies - Escrow Revenue (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Escrows	$ 1,996	$ 4,334

XML

Summary of Significant Accounting Policies - Derivative Instruments (Details) - Cash Flow Hedging - Interest Rate Swaps $ in Millions	12 Months Ended
	Dec. 31, 2017 USD ($) instruments
Derivative [Line Items]
Number of derivative instruments | instruments	5,000
Gain, hedge ineffectiveness | $	$ 0.2

XML

Summary of Significant Accounting Policies - Tenant Receivables, Net (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Receivables [Abstract]
Allowance for doubtful accounts	$ 1.6	$ 2.4

XML

Summary of Significant Accounting Policies - Rental Revenue (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Straight line rent receivable	$ 47,599	$ 32,018
Allowance recognized against straight line rent	$ 4,900	$ 600

XML

Summary of Significant Accounting Policies - Related Parties (Details) $ in Millions	12 Months Ended
	Dec. 31, 2017 USD ($)
Aurora Health Care
Related Party Transaction [Line Items]
Rental revenue	$ 0.6
Baylor Cancer Center
Related Party Transaction [Line Items]
Rental revenue	$ 4.0

XML

Summary of Significant Accounting Policies - Segment Reporting (Details)	12 Months Ended
	Dec. 31, 2017 segments
Accounting Policies [Abstract]
Number of reportable segments	1

XML

Summary of Significant Accounting Policies - New Accounting Pronouncements (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of interest held	97.10%	97.50%
Debt issuance costs	$ 7,808	$ 8,477
Liabilities, Tota | Accounting Standards Update 2015-03
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt issuance costs			$ 6,000

XML

Acquisitions and Dispositions - (Details) $ in Thousands				3 Months Ended								12 Months Ended
	May 11, 2016 USD ($)	Jan. 23, 2015 USD ($)	Jan. 22, 2015 USD ($)	Dec. 31, 2017 USD ($)	Sep. 30, 2017 USD ($)	Jun. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2017 USD ($) states healthcareproperty condominium_units parking_deck	Dec. 31, 2016 USD ($) properties states condominium_units land	Dec. 31, 2015 USD ($)
Business Acquisition [Line Items]
Number of states in which operating healthcare properties and land parcel located | states												15
Aggregate purchase price												$ 1,370,000	$ 1,270,000
Acquisition price												1,414,179	1,285,185
Total revenues				$ 97,320	$ 92,999	$ 76,599	$ 76,666	$ 73,674	$ 70,010	$ 53,216	$ 44,134	343,584	241,034	$ 129,441
Net income (loss)				$ 10,187	$ 12,539	$ 10,331	$ 6,716	8,620	$ 10,294	$ 7,184	$ 5,424	$ 39,773	31,522	$ 12,741
Capital committed to fund future improvements								12,900					12,900
Revenue of acquiree since acquisition date													66,700
Earnings or loss of acquiree since acquisition date													$ 14,900
Series of Individually Immaterial Business Acquisitions
Business Acquisition [Line Items]
Number of operating healthcare properties												40	95
Number of condominium units | condominium_units												2	5
Number of parking decks | parking_deck												1
Number of states in which operating healthcare properties and land parcel located | states													23
Aggregate purchase price												$ 1,410,000
Total revenues												49,600
Net income (loss)												8,600
Number of land parcels | land													1
Loan Investment
Business Acquisition [Line Items]
Acquisition price												39,063
Redeemable Noncontrolling Interest Buyouts
Business Acquisition [Line Items]
Acquisition price												1,100
CHI Portfolio
Business Acquisition [Line Items]
Capital committed to fund future improvements								$ 8,900					$ 8,900
Crystal MOB
Business Acquisition [Line Items]
Acquisition price			$ 900
Edina MOB
Business Acquisition [Line Items]
Acquisition price			10,200
Savage MOB
Business Acquisition [Line Items]
Acquisition price			2,500									2,800
Dell Road MOB
Business Acquisition [Line Items]
Acquisition price			$ 600
Columbus MOB
Business Acquisition [Line Items]
Acquisition price		$ 1,290,000
CHI Portfolio
Business Acquisition [Line Items]
Acquisition price												$ 143,000
CHI Portfolio | Medical Arts Pavilion
Business Acquisition [Line Items]
Acquisition price	$ 6,304

XML

Acquisitions and Dispositions - 2017 Acquisitions (Details)																													2 Months Ended	12 Months Ended
	Feb. 16, 2018 USD ($)	Dec. 21, 2017 USD ($)	Dec. 18, 2017 USD ($)	Dec. 01, 2017 USD ($)	Nov. 17, 2017 USD ($)	Nov. 10, 2017 USD ($)	Oct. 31, 2017 USD ($)	Oct. 12, 2017 USD ($)	Sep. 27, 2017 USD ($)	Sep. 21, 2017 USD ($)	Aug. 31, 2017 USD ($) buildings	Aug. 15, 2017 USD ($)	Aug. 04, 2017 USD ($)	Jun. 30, 2017 USD ($)	Jun. 29, 2017 USD ($) buildings	Jun. 16, 2017 USD ($)	Mar. 31, 2017 USD ($)	Mar. 28, 2017 USD ($)	Mar. 07, 2017 USD ($)	Feb. 27, 2017 USD ($)	Feb. 14, 2017 USD ($)	Jan. 31, 2017 USD ($)	Jan. 11, 2017 USD ($)	Jan. 05, 2017 USD ($)	Dec. 16, 2016 USD ($) buildings	Nov. 23, 2016 USD ($) buildings	Sep. 30, 2016 USD ($)	Aug. 08, 2016 USD ($) buildings	Mar. 01, 2018 USD ($)	Dec. 31, 2017 USD ($) facilities transactions shares	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Business Acquisition [Line Items]
Acquisition price																														$ 1,414,179,000	$ 1,285,185,000
Acquisition expenses																														16,744,000	14,778,000	$ 14,893,000
Acquisition costs capitalized																														500,000	3,000,000.0
Aggregate purchase price																														1,370,000,000	1,270,000,000
Value of units issued for funding purchase price																														0	20,980,000
Mortgage assumed																														43,989,000	$ 0
Orthopedic Associates
Business Acquisition [Line Items]
Acquisition price																								$ 18,750,000
Lee's Hill Medical Plaza
Business Acquisition [Line Items]
Acquisition price																							$ 30,250,000
Noncontrolling Interest Buyout - New Albany
Business Acquisition [Line Items]
Acquisition price																						$ 2,824,000
Aggregate purchase price																														2,100,000
Value of units issued for funding purchase price																														$ 2,800,000
Number of units issued for funding purchase price (in shares) | shares																														38,641
CareMount - Lake Katrine MOB
Business Acquisition [Line Items]
Business combination, recognized identifiable assets acquired and liabilities assumed, liabilities																														$ 26,400,000
CareMount - Rhinebeck MOB
Business Acquisition [Line Items]
Acquisition price																					$ 18,639,000
Syracuse Condos
Business Acquisition [Line Items]
Acquisition price																				$ 2,659,000
Monterey Medical Center - MOB
Business Acquisition [Line Items]
Acquisition price																			$ 18,979,000
Strictly Pediatrics Specialty Center
Business Acquisition [Line Items]
Acquisition price																	$ 78,628,000
Value of units issued for funding purchase price																														$ 44,300,000
Number of units issued for funding purchase price (in shares) | shares																														2,247,817
MedStar Stephen's Crossing
Business Acquisition [Line Items]
Acquisition price																$ 20,900,000
St. Vincent Portfolio (2 MOBs)
Business Acquisition [Line Items]
Acquisition price															$ 93,880,000
Baylor Charles A. Sammons Cancer Center
Business Acquisition [Line Items]
Acquisition price														$ 290,000,000
Orthopedic & Sports Institute of the Fox Valley
Business Acquisition [Line Items]
Acquisition price														27,900,000
Peachtree Dunwoody Medical Center - Parking Deck
Business Acquisition [Line Items]
Acquisition price														$ 25,000,000
Clearview Cancer Institute
Business Acquisition [Line Items]
Acquisition price													$ 53,250,000
Northside Cherokee/Town Lake MOB
Business Acquisition [Line Items]
Acquisition price												$ 37,127,000
HonorHealth Mesa MOB
Business Acquisition [Line Items]
Acquisition price												$ 4,800,000
Noncontrolling Interest Buyout - Great Falls Clinic
Business Acquisition [Line Items]
Acquisition price										$ 1,061,000																	$ 1,015,000
Noncontrolling interest, increase from business combination, percent																														3.20%	4.60%
Noncontrolling interest, ownership percentage by parent																														85.00%	81.80%
Legends Park MOB & ASC
Business Acquisition [Line Items]
Acquisition price									$ 30,000,000
Franklin MOB & ASC
Business Acquisition [Line Items]
Acquisition price								$ 9,950,000
Eagle Point MOB
Business Acquisition [Line Items]
Acquisition price							$ 10,949,000
Edina East MOB
Business Acquisition [Line Items]
Acquisition price							$ 7,800,000
Northside MOB - Center Pointe
Business Acquisition [Line Items]
Acquisition price						$ 155,986,000
Gwinnett 500 Building
Business Acquisition [Line Items]
Acquisition price					$ 25,297,000
Hudgens Professional Building
Business Acquisition [Line Items]
Acquisition price					23,696,000
St. Vincent Building
Business Acquisition [Line Items]
Acquisition price					$ 60,124,000
Gwinnett Physicians Center
Business Acquisition [Line Items]
Acquisition price				$ 51,721,000
Mortgage assumed																														$ 17,600,000
Desert Cove MOB, LLC [Member]
Business Acquisition [Line Items]
Acquisition price			$ 4,560,000																											$ 4,600,000
Noncontrolling interest, increase from business combination, percent																														57.00%
Apple Valley Medical Center
Business Acquisition [Line Items]
Acquisition price			$ 21,500,000
Desert Cove MOB (57% Interest)
Business Acquisition [Line Items]
Noncontrolling interest, ownership percentage by parent																														100.00%
Westgate MOB
Business Acquisition [Line Items]
Acquisition price		$ 15,800,000
Loan Investment
Business Acquisition [Line Items]
Acquisition price																														$ 39,063,000
Number of Transactions | transactions																														8
Weighted average interest rate																														8.10%
Unity Portfolio (4 MOBs)
Business Acquisition [Line Items]
Number of medical office buildings | buildings																												4
Acquisition price																												$ 28,751,000
Syracuse Portfolio (2 MOBs)
Business Acquisition [Line Items]
Number of medical office buildings | buildings																										2
Acquisition price																										$ 54,239,000
Flower Mound Portfolio (3 MOBs)
Business Acquisition [Line Items]
Number of medical office buildings | buildings																									3
Acquisition price																									$ 27,800,000
CHI Portfolio
Business Acquisition [Line Items]
Acquisition price																														$ 143,000,000.0
Acquisition expenses																														16,600,000
Acquisition costs capitalized																														$ 400,000
Facilities accounted for as business combinations | facilities																														6
Business combination, consideration transferred, accounted for as business combinations																														$ 48,300,000
Business combination, acquisition related costs, accounted for as business combinations																														$ 100,000
Facilities accounted for as asset acquisitions | facilities																														9
CHI Portfolio | CareMount - Lake Katrine MOB
Business Acquisition [Line Items]
Acquisition price																					$ 41,791,000
CHI Portfolio | Creighton University Medical Center
Business Acquisition [Line Items]
Acquisition price																		$ 33,420,000
CHI Portfolio | 2017 CHI Portfolio - Tranche 1 (8 MOBs)
Business Acquisition [Line Items]
Number of medical office buildings | buildings															8,000
Acquisition price															$ 124,181,000
CHI Portfolio | 2017 CHI Portfolio - Tranche 2 (5 MOBs)
Business Acquisition [Line Items]
Number of medical office buildings | buildings											5,000
Acquisition price											$ 33,694,000
Subsequent Events
Business Acquisition [Line Items]
Acquisition price																													$ 100,700,000
Aggregate purchase price																													$ 98,700,000
Subsequent Events | Loan Investment
Business Acquisition [Line Items]
Acquisition price	$ 2,000,000
Operating Partnership
Business Acquisition [Line Items]
Acquisition price																														$ 78,600,000	$ 8,500,000
Acquisition expenses																														$ 16,744,000	$ 14,778,000	$ 14,893,000

XML

Acquisitions and Dispositions - 2016 Acquisitions (Details) - USD ($)																																																																				12 Months Ended
	Dec. 21, 2017	Dec. 18, 2017	Dec. 01, 2017	Nov. 17, 2017	Nov. 10, 2017	Oct. 31, 2017	Oct. 12, 2017	Sep. 27, 2017	Sep. 21, 2017	Aug. 31, 2017	Aug. 15, 2017	Aug. 04, 2017	Jun. 30, 2017	Jun. 29, 2017	Jun. 16, 2017	Mar. 31, 2017	Mar. 28, 2017	Mar. 07, 2017	Feb. 27, 2017	Feb. 14, 2017	Jan. 31, 2017	Jan. 11, 2017	Jan. 05, 2017	Dec. 22, 2016	Dec. 16, 2016	Dec. 15, 2016	Dec. 09, 2016	Dec. 08, 2016	Dec. 02, 2016	Nov. 23, 2016	Nov. 04, 2016	Oct. 31, 2016	Oct. 28, 2016	Sep. 30, 2016	Aug. 30, 2016	Aug. 23, 2016	Aug. 08, 2016	Aug. 02, 2016	Jul. 29, 2016	Jul. 26, 2016	Jul. 21, 2016	Jul. 07, 2016	Jul. 06, 2016	Jun. 30, 2016	Jun. 29, 2016	Jun. 28, 2016	Jun. 08, 2016	Jun. 03, 2016	Jun. 02, 2016	May 26, 2016	May 11, 2016	May 10, 2016	Apr. 14, 2016	Apr. 11, 2016	Mar. 31, 2016	Mar. 30, 2016	Mar. 24, 2016	Mar. 23, 2016	Mar. 21, 2016	Mar. 15, 2016	Feb. 26, 2016	Feb. 12, 2016	Feb. 08, 2016	Feb. 04, 2016	Feb. 01, 2016	Jan. 25, 2016	Jan. 14, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Acquisition price																																																																				$ 1,414,179,000	$ 1,285,185,000
Buyout of noncontrolling interests - partially owned properties																																																																				2,105,000	611,000
Acquisition expenses																																																																				16,744,000	14,778,000	$ 14,893,000
Acquisition costs capitalized																																																																				500,000	3,000,000.0
Value of units issued for funding purchase price																																																																				$ 0	$ 20,980,000
Percentage of interest held																																																																				97.10%	97.50%
HonorHealth Mesa MOB
Business Acquisition [Line Items]
Acquisition price											$ 4,800,000
Orthopedic Associates
Business Acquisition [Line Items]
Acquisition price																							$ 18,750,000
Lee's Hill Medical Plaza
Business Acquisition [Line Items]
Acquisition price																						$ 30,250,000
Noncontrolling Interest Buyout - New Albany
Business Acquisition [Line Items]
Acquisition price																					$ 2,824,000
Number of units issued for funding purchase price (in shares)																																																																				38,641
Value of units issued for funding purchase price																																																																				$ 2,800,000
CareMount - Rhinebeck MOB
Business Acquisition [Line Items]
Acquisition price																				$ 18,639,000
Syracuse Condos
Business Acquisition [Line Items]
Acquisition price																			$ 2,659,000
Monterey Medical Center - MOB
Business Acquisition [Line Items]
Acquisition price																		$ 18,979,000
Strictly Pediatrics Specialty Center
Business Acquisition [Line Items]
Acquisition price																$ 78,628,000
Number of units issued for funding purchase price (in shares)																																																																				2,247,817
Value of units issued for funding purchase price																																																																				$ 44,300,000
MedStar Stephen's Crossing
Business Acquisition [Line Items]
Acquisition price															$ 20,900,000
St. Vincent Portfolio (2 MOBs)
Business Acquisition [Line Items]
Acquisition price														$ 93,880,000
Baylor Charles A. Sammons Cancer Center
Business Acquisition [Line Items]
Acquisition price													$ 290,000,000
Orthopedic & Sports Institute of the Fox Valley
Business Acquisition [Line Items]
Acquisition price													27,900,000
Peachtree Dunwoody Medical Center - Parking Deck
Business Acquisition [Line Items]
Acquisition price													$ 25,000,000
Tinseltown - Loan Draws
Business Acquisition [Line Items]
Acquisition price																																																																					$ 2,192,000
Randall Road MOB - Suite 320
Business Acquisition [Line Items]
Acquisition price																																																																			$ 704,000
Great Falls Hospital
Business Acquisition [Line Items]
Acquisition price																																																																		$ 29,043,000
Monterey Medical Center ASC
Business Acquisition [Line Items]
Acquisition price																																																																	$ 6,900,000
Physicians Medical Plaza MOB
Business Acquisition [Line Items]
Acquisition price																																																																	$ 8,500,000
Number of units issued for funding purchase price (in shares)																																																																					174,085
Value of units issued for funding purchase price																																																																					$ 2,900,000
Great Falls Clinic MOB
Business Acquisition [Line Items]
Noncontrolling interest, increase from business combination, percent																																																																					3.00%
Noncontrolling interest, ownership percentage by parent																																																																					77.30%
Mezzanine Loan - Davis
Business Acquisition [Line Items]
Acquisition price																																																																$ 500,000
Park Nicollet Clinic
Business Acquisition [Line Items]
Acquisition price																																																															$ 18,600,000
HEB Cancer Center
Business Acquisition [Line Items]
Acquisition price																																																														$ 13,980,000
Riverview Medical Center
Business Acquisition [Line Items]
Acquisition price																																																													$ 12,800,000
St. Luke's Cornwall MOB
Business Acquisition [Line Items]
Acquisition price																																																													$ 14,550,000
HonorHealth Glendale
Business Acquisition [Line Items]
Acquisition price																																																												$ 9,820,000
Columbia MOB
Business Acquisition [Line Items]
Acquisition price																																																											$ 18,450,000
St Vincent POB 1
Business Acquisition [Line Items]
Acquisition price																																																										$ 10,951,000
St Vincent POB 2
Business Acquisition [Line Items]
Acquisition price																																																										7,945,000
St Vincent POB 3
Business Acquisition [Line Items]
Acquisition price																																																										$ 10,455,000
Emerson Medical Building
Business Acquisition [Line Items]
Acquisition price																																																									$ 14,250,000
Randall Road MOB - Suite 160
Business Acquisition [Line Items]
Acquisition price																																																									$ 865,000
Patient Partners Surgery Center
Business Acquisition [Line Items]
Acquisition price																																																								$ 4,750,000
Eye Associates of NM - Santa Fe
Business Acquisition [Line Items]
Acquisition price																																																							$ 8,739,000
Eye Associates of NM - Albuquerque
Business Acquisition [Line Items]
Acquisition price																																																							$ 10,536,000
Gardendale Surgery Center
Business Acquisition [Line Items]
Acquisition price																																																						$ 7,450,000
HealthEast - Curve Crest
Business Acquisition [Line Items]
Acquisition price																																																					$ 4,144,000
HealthEast - Victor Gardens
Business Acquisition [Line Items]
Acquisition price																																																					$ 6,025,000
NOMS - Clyde
Business Acquisition [Line Items]
Acquisition price																																																				$ 6,342,000
Franklin MOB & ASC
Business Acquisition [Line Items]
Acquisition price							$ 9,950,000
Eagle Point MOB
Business Acquisition [Line Items]
Acquisition price						$ 10,949,000
Edina East MOB
Business Acquisition [Line Items]
Acquisition price						$ 7,800,000
Northside MOB - Center Pointe
Business Acquisition [Line Items]
Acquisition price					$ 155,986,000
Gwinnett 500 Building
Business Acquisition [Line Items]
Acquisition price				$ 25,297,000
Hudgens Professional Building
Business Acquisition [Line Items]
Acquisition price				23,696,000
St. Vincent Building
Business Acquisition [Line Items]
Acquisition price				$ 60,124,000
Gwinnett Physicians Center
Business Acquisition [Line Items]
Acquisition price			$ 51,721,000
Medical Village at Kissimmee
Business Acquisition [Line Items]
Acquisition price																																																		$ 4,923,000
Medical Village at Leesburg
Business Acquisition [Line Items]
Acquisition price																																																		$ 4,576,000
Children's Hospital MOB
Business Acquisition [Line Items]
Acquisition price																																																$ 5,850,000
Jewish Medical Center South MOB - 2
Business Acquisition [Line Items]
Acquisition price																																															$ 4,343,000
Pilot Medical Center
Business Acquisition [Line Items]
Acquisition price																																													$ 17,351,000
Mezzanine Loan - Catalyst
Business Acquisition [Line Items]
Secured loans on real estate, loan amount																																												$ 1,340,000
Prairie Care MOB
Business Acquisition [Line Items]
Acquisition price																																											$ 4,886,000
RE Loan - Chihuahua Development LLC
Business Acquisition [Line Items]
Secured loans on real estate, loan amount																																										$ 1,300,000
Equity Buyout - Foundation
Business Acquisition [Line Items]
Buyout of noncontrolling interests - partially owned properties																																								$ 611,000
Noncontrolling interest, increase from business combination, percent																																																																					1.00%
Mezzanine Loan - Hazelwood
Business Acquisition [Line Items]
Secured loans on real estate, loan amount																																							$ 3,375,000
Jackson, Tennessee Land
Business Acquisition [Line Items]
Acquisition price																																						$ 1,000,000
Unity Portfolio (4 MOBs)
Business Acquisition [Line Items]
Acquisition price																																					$ 28,751,000
Medical Village at Maitland
Business Acquisition [Line Items]
Acquisition price																																				$ 23,211,000
Tri-State Orthopaedics MOB
Business Acquisition [Line Items]
Acquisition price																																			$ 22,000,000
Maury Regional Healthcare MOB
Business Acquisition [Line Items]
Acquisition price																																		$ 18,500,000
Percentage of interest acquired																																																																					99.70%
Spring Ridge Medical Center
Business Acquisition [Line Items]
Acquisition price																																		6,100,000
Doctors Community Hospital POB
Business Acquisition [Line Items]
Acquisition price																																		26,750,000
N.W. Michigan Surgery Center - Units 1 & 2
Business Acquisition [Line Items]
Acquisition price																																	$ 29,448,000
Number of units issued for funding purchase price (in shares)																																																																					947,936
United Surgical Partners Joint Venture
Business Acquisition [Line Items]
Acquisition price																																$ 903,000
N.W. Michigan Surgery Center - Unit 4
Business Acquisition [Line Items]
Acquisition price																															$ 2,715,000
Number of units issued for funding purchase price (in shares)																																																																					88,602
Syracuse Portfolio (2 MOBs)
Business Acquisition [Line Items]
Acquisition price																														$ 54,239,000
Cincinnati Eye Institute
Business Acquisition [Line Items]
Acquisition price																														$ 38,100,000
Curie Building Loan
Business Acquisition [Line Items]
Secured loans on real estate, loan amount																													$ 1,500,000
HonorHealth - Scottsdale MOB
Business Acquisition [Line Items]
Acquisition price																													$ 6,900,000
Fox Valley Hematology & Oncology
Business Acquisition [Line Items]
Acquisition price																												$ 28,200,000
Gastrointestinal Associates MOB
Business Acquisition [Line Items]
Acquisition price																											$ 6,287,000
Northern Vision Eye Center
Business Acquisition [Line Items]
Acquisition price																										$ 2,777,000
Noncontrolling Interest Buyout - Great Falls Clinic
Business Acquisition [Line Items]
Acquisition price									$ 1,061,000																									1,015,000
Buyout of redeemable noncontrolling interest																										$ 1,497,000
Noncontrolling interest, increase from business combination, percent																																																																				3.20%	4.60%
Noncontrolling interest, ownership percentage by parent																																																																				85.00%	81.80%
Legends Park MOB & ASC
Business Acquisition [Line Items]
Acquisition price								$ 30,000,000
Flower Mound Portfolio (3 MOBs)
Business Acquisition [Line Items]
Acquisition price																									$ 27,800,000
HonorHealth IRF
Business Acquisition [Line Items]
Acquisition price																								$ 25,628,000
Clearview Cancer Institute
Business Acquisition [Line Items]
Acquisition price												$ 53,250,000
Apple Valley Medical Center
Business Acquisition [Line Items]
Acquisition price		$ 21,500,000
Desert Cove MOB (57% Interest)
Business Acquisition [Line Items]
Noncontrolling interest, ownership percentage by parent																																																																				100.00%
Westgate MOB
Business Acquisition [Line Items]
Acquisition price	$ 15,800,000
Loan Investment
Business Acquisition [Line Items]
Acquisition price																																																																				$ 39,063,000
CHI Portfolio
Business Acquisition [Line Items]
Acquisition price																																																																				143,000,000.0
Acquisition expenses																																																																				16,600,000
Acquisition costs capitalized																																																																				$ 400,000
CHI Portfolio | 2017 CHI Portfolio - Tranche 2 (5 MOBs)
Business Acquisition [Line Items]
Acquisition price										$ 33,694,000
CHI Portfolio | CareMount - Lake Katrine MOB
Business Acquisition [Line Items]
Acquisition price																				$ 41,791,000
CHI Portfolio | Creighton University Medical Center
Business Acquisition [Line Items]
Acquisition price																	$ 33,420,000
CHI Portfolio | 2017 CHI Portfolio - Tranche 1 (8 MOBs)
Business Acquisition [Line Items]
Acquisition price														$ 124,181,000
CHI Portfolio | Blandford MOB
Business Acquisition [Line Items]
Acquisition price																																																			$ 2,580,000
CHI Portfolio | Cardwell MOB
Business Acquisition [Line Items]
Acquisition price																																																			8,444,000
CHI Portfolio | Dacono Neighborhood Health
Business Acquisition [Line Items]
Acquisition price																																																			5,152,000
CHI Portfolio | Franciscan Health
Business Acquisition [Line Items]
Acquisition price																																																			9,772,000
CHI Portfolio | Grand Island Specialty Clinic
Business Acquisition [Line Items]
Acquisition price																																																			2,891,000
CHI Portfolio | Hot Springs MOB
Business Acquisition [Line Items]
Acquisition price																																																			3,626,000
CHI Portfolio | Jewish Medical Center East
Business Acquisition [Line Items]
Acquisition price																																																			85,000,000
CHI Portfolio | Jewish Medical Center South MOB - 1
Business Acquisition [Line Items]
Acquisition price																																																			17,021,000
CHI Portfolio | Jewish Medical Plaza I
Business Acquisition [Line Items]
Acquisition price																																																			9,650,000
CHI Portfolio | Jewish Medical Plaza II
Business Acquisition [Line Items]
Acquisition price																																																			6,124,000
CHI Portfolio | Jewish OCC
Business Acquisition [Line Items]
Acquisition price																																																			35,600,000
CHI Portfolio | Lakeside Three Professional Center
Business Acquisition [Line Items]
Acquisition price																																																			1,581,000
CHI Portfolio | Lexington Surgery Center
Business Acquisition [Line Items]
Acquisition price																																																			20,169,000
CHI Portfolio | Medical Arts Pavilion
Business Acquisition [Line Items]
Acquisition price																																																			6,304,000
CHI Portfolio | Memorial Outpatient Center
Business Acquisition [Line Items]
Acquisition price																																																			4,958,000
CHI Portfolio | Midlands Two Professional Center
Business Acquisition [Line Items]
Acquisition price																																																			1,341,000
CHI Portfolio | Parkview MOB
Business Acquisition [Line Items]
Acquisition price																																																			5,060,000
CHI Portfolio | Peak One ASC
Business Acquisition [Line Items]
Acquisition price																																																			6,587,000
CHI Portfolio | Physicians Medical Center
Business Acquisition [Line Items]
Acquisition price																																																			6,782,000
CHI Portfolio | St. Alexius - Minot Medical Plaza
Business Acquisition [Line Items]
Acquisition price																																																			26,570,000
CHI Portfolio | St. Clare Medical Pavilion
Business Acquisition [Line Items]
Acquisition price																																																			10,617,000
CHI Portfolio | St. Joseph Medical Pavilion
Business Acquisition [Line Items]
Acquisition price																																																			13,320,000
CHI Portfolio | St. Joseph Office Park
Business Acquisition [Line Items]
Acquisition price																																																			17,228,000
CHI Portfolio | St. Mary - Caritas Medical II
Business Acquisition [Line Items]
Acquisition price																																																			5,603,000
CHI Portfolio | St. Mary - Caritas Medical III
Business Acquisition [Line Items]
Acquisition price																																																			842,000
CHI Portfolio | Thornton Neighborhood Health
Business Acquisition [Line Items]
Acquisition price																																																			$ 3,875,000
CHI Portfolio | St. Francis MOB
Business Acquisition [Line Items]
Acquisition price																																																	$ 14,287,000
CHI Portfolio | Good Samaritan North Annex Building
Business Acquisition [Line Items]
Acquisition price																																														$ 2,874,000
CHI Portfolio | NE Heart Institute Medical Building
Business Acquisition [Line Items]
Acquisition price																																														$ 19,600,000
CHI Portfolio | St. Vincent West MOB
Business Acquisition [Line Items]
Acquisition price																																													14,120,000
CHI Portfolio | Meridan MOB
Business Acquisition [Line Items]
Acquisition price																																													17,329,000
CHI Portfolio | St. Mary - Caritas Medical I
Business Acquisition [Line Items]
Acquisition price																																													8,864,000
CHI Portfolio | St. Alexius - Medical Arts Pavilion
Business Acquisition [Line Items]
Acquisition price																																													12,983,000
CHI Portfolio | St. Alexius - Mandan Clinic
Business Acquisition [Line Items]
Acquisition price																																													8,390,000
CHI Portfolio | St. Alexius - Orthopaedic Center
Business Acquisition [Line Items]
Acquisition price																																													14,727,000
CHI Portfolio | St. Alexius - Rehab Center
Business Acquisition [Line Items]
Acquisition price																																													6,215,000
CHI Portfolio | St. Alexius - Tech & Ed
Business Acquisition [Line Items]
Acquisition price																																													16,680,000
CHI Portfolio | Good Samaritan MOB
Business Acquisition [Line Items]
Acquisition price																																													24,198,000
CHI Portfolio | Lakeside Two Professional Building
Business Acquisition [Line Items]
Acquisition price																																													13,691,000
CHI Portfolio | Lakeside Wellness Center
Business Acquisition [Line Items]
Acquisition price																																													10,138,000
CHI Portfolio | McAuley Center
Business Acquisition [Line Items]
Acquisition price																																													18,382,000
CHI Portfolio | Memorial Health Center
Business Acquisition [Line Items]
Acquisition price																																													34,042,000
CHI Portfolio | Missionary Ridge MOB
Business Acquisition [Line Items]
Acquisition price																																													$ 7,635,000
CHI Portfolio | St. Joseph Medical Clinic
Business Acquisition [Line Items]
Acquisition price																																												16,444,000
CHI Portfolio | Woodlands Medical Arts Center
Business Acquisition [Line Items]
Acquisition price																																												21,227,000
CHI Portfolio | FESC MOB
Business Acquisition [Line Items]
Acquisition price																																												$ 16,748,000
CHI Portfolio | Springwoods MOB
Business Acquisition [Line Items]
Acquisition price																																									$ 19,925,000
CHI Portfolio | Gig Harbor Medical Pavilion
Business Acquisition [Line Items]
Acquisition price																																		4,766,000
CHI Portfolio | Midlands One Professional Center
Business Acquisition [Line Items]
Acquisition price																																		$ 14,856,000

XML

Acquisitions and Dispositions - Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Fair values of the assets acquired and the liabilities assumed
Land	$ 38,358	$ 57,847
Building and improvements	1,168,741	1,112,746
Contingent consideration	(765)	(156)
Receivable	434	104
Debt assumed	(43,989)	0
Issuance of OP Units	(44,978)	(2,869)
Investment in unconsolidated entity	(2,871)	903
Lease inducement	0	8,945
Prepaid expenses	0	2,659
Issuance of Common Shares	0	(20,980)
Noncontrolling interest	0	(50)
Net assets acquired	1,271,060	1,250,949
In-place lease intangible
Fair values of the assets acquired and the liabilities assumed
Intangible assets	128,370	58,666
Above-market in-place lease intangible
Fair values of the assets acquired and the liabilities assumed
Intangible assets	18,967	9,359
Below-market in-place lease intangible
Fair values of the assets acquired and the liabilities assumed
Intangible liabilities	(4,270)	(4,518)
Above market in-place ground lease [Member]
Fair values of the assets acquired and the liabilities assumed
Intangible liabilities	(4,620)	(644)
Below-market in-place ground lease
Fair values of the assets acquired and the liabilities assumed
Intangible liabilities	$ 17,683	$ 28,937

XML

Acquisitions and Dispositions - Dispositions (Details) - Disposal Group, Disposed of by Sale, Not Discontinued Operations $ in Thousands				12 Months Ended
	Dec. 18, 2017 USD ($) ft² buildings	Aug. 15, 2017 USD ($)	Apr. 07, 2017 USD ($) buildings	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Georgia Portfolio
Business Acquisition [Line Items]
Number of medical office buildings | buildings			4
Proceeds from divestiture of businesses			$ 18,200
Revenue				$ 823	$ 1,967	$ 1,666
Income before gain on sale of investment properties				108	433	421
Gain on sale of investment properties			$ 5,200	5,870	0	0
Net income				$ 5,978	$ 433	$ 421
Peachtree Dunwoody Medical Center
Business Acquisition [Line Items]
Land		$ 7,700
Term of contract		90 years
Nebraska
Business Acquisition [Line Items]
Number of medical office buildings | buildings	1
Square feet of building being disposed | ft²	20,939
Proceeds from divestiture of businesses	$ 2,500
Gain on sale of investment properties	$ 700

XML

Acquisitions and Dispositions - Pro Forma Information (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Revenue	$ 405,320	$ 352,432
Net income	42,149	39,233
Net income available to common shareholders	$ 39,759	$ 35,614
Earnings per share basic (in dollars per share)	$ 0.24	$ 0.22
Earnings per share diluted (in dollars per share)	$ 0.24	$ 0.22
Weighted average number of shares outstanding - basic (in shares)	163,123,109	163,123,109
Weight average number of shares outstanding - diluted (in shares)	168,231,299	168,231,299
Operating Partnership
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Revenue	$ 405,320	$ 352,432
Net income	42,149	39,233
Net income available to common shareholders	$ 40,927	$ 36,660
Earnings per unit basic (in dollars per share)	$ 0.24	$ 0.22
Earnings per unit diluted (in dollars per share)	$ 0.24	$ 0.22
Weighted average limited partnership units outstanding, basic (in shares)	167,963,076	167,963,076
Weighted average number of units outstanding - diluted (in shares)	168,231,299	168,231,299

XML

Intangibles - (Details)	12 Months Ended
	Dec. 31, 2017 USD ($)
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible items, net income impact	$ (1,500,000)
Weighted average amortization period for lease intangibles	18 years
Weighted average amortization period for lease intangible liability	20 years
In-place leases
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, disposals	$ 3,500,000
Impairment of intangible assets, accumulated amortization	2,100,000
Impairment of intangible assets	(1,400,000)
Above-market leases
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, disposals	300,000
Impairment of intangible assets, accumulated amortization	100,000
Impairment of intangible assets	(200,000)
Below-market lease
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets	100,000
Impairment of intangible liabilities, finite-lived	100,000
Impairment of intangible liabilities, finite-lived, accumulated accretion	$ 36,000.0

XML

Intangibles - Carrying Amount of Intangible Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Cost	$ 458,713	$ 301,462
Accumulated Amortization	(98,919)	(63,177)
Net	359,794	238,285
Liability
Cost	20,309	11,642
Accumulated Amortization	(4,607)	(2,389)
Net	15,702	9,253
In-place leases
Finite-Lived Intangible Assets [Line Items]
Cost	343,429	222,394
Accumulated Amortization	(85,424)	(55,605)
Net	258,005	166,789
Above-market leases
Finite-Lived Intangible Assets [Line Items]
Cost	54,148	35,478
Accumulated Amortization	(11,968)	(6,909)
Net	42,180	28,569
Leasehold interest
Finite-Lived Intangible Assets [Line Items]
Cost	712	712
Accumulated Amortization	(183)	(124)
Net	529	588
Below-market ground lease
Finite-Lived Intangible Assets [Line Items]
Cost	60,424	42,878
Accumulated Amortization	(1,344)	(539)
Net	59,080	42,339
Below-market lease
Liability
Below market lease, cost	14,344	10,297
Below market lease, accumulated amortization	(4,479)	(2,345)
Below Market Lease, Net	9,865	7,952
Above-market ground lease
Liability
Cost	5,965	1,345
Accumulated Amortization	(128)	(44)
Net	$ 5,837	$ 1,301

XML

Intangibles - Acquired Lease Intangible Amortization (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
In-place leases
Finite-Lived Intangible Assets [Line Items]
Amortization expense related to in-place leases	$ 37,073	$ 28,902	$ 15,300
Above-market leases
Finite-Lived Intangible Assets [Line Items]
Decrease of rental income	5,357	4,403	2,596
Leasehold interest
Finite-Lived Intangible Assets [Line Items]
Decrease of rental income	59	59	59
Below-market lease
Finite-Lived Intangible Assets [Line Items]
Increase of rental income related to below-market leases	2,309	1,835	643
Below-market in-place ground lease
Finite-Lived Intangible Assets [Line Items]
Decrease (increase) of operating expense	84	24	16
Below-market ground lease
Finite-Lived Intangible Assets [Line Items]
Decrease (increase) of operating expense	$ 810	$ 471	$ 68

XML

Intangibles - Amortization of Acquired Lease Intangibles (Details) $ in Thousands	Dec. 31, 2017 USD ($)
Future aggregate net amortization of acquired lease intangibles (Net decrease in Revenue)
2018	$ (3,355)
2019	(3,376)
2020	(3,392)
2021	(3,333)
2022	(2,872)
Thereafter	(16,516)
Total	(32,844)
Future aggregate net amortization of acquired lease intangibles (Net Increase in Expenses)
2018	41,455
2019	36,429
2020	33,009
2021	30,582
2022	26,225
Thereafter	143,548
Total	$ 311,248

XML

Other Assets - Additional Information (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Other Assets, Unclassified [Abstract]
Straight line rent receivable	$ 47,599	$ 32,018
Prepaid expenses	18,103	8,928
Interest rate swap	14,693	13,881
Lease inducements, net	14,232	13,255
Leasing commissions, net	4,128	1,858
Earnest deposits	2,780	1,500
Escrows	1,996	4,334
Notes receivable	0	16,618
Other	2,771	2,795
Total other assets	$ 106,302	$ 95,187

XML

Debt - (Details) - USD ($)				12 Months Ended
	Dec. 01, 2017	Mar. 07, 2017	Jun. 10, 2016	Dec. 31, 2017	Dec. 31, 2016	Jan. 26, 2017	Aug. 11, 2016	Jul. 07, 2016	Jun. 09, 2016	Jan. 07, 2016
Debt
Debt, gross				$ 1,491,680,000	$ 999,194,000
Interest expense, debt				45,100,000	$ 21,500,000
Credit Agreement Amendment
Debt
Current borrowing capacity			$ 1,100,000,000
Maximum borrowing capacity as a percentage of maximum principal amount			10.00%
Increase in maximum borrowing capacity			$ 500,000,000
Maximum borrowing capacity			$ 1,600,000,000
Unused fee (as a percent)			0.25%
Prepayment of premium percentage, maximum			2.00%
Series A
Debt
Effective fixed interest rate							4.09%			4.03%
Series B
Debt
Effective fixed interest rate							4.18%			4.43%
Series C
Debt
Effective fixed interest rate										4.57%
Series D
Debt
Effective fixed interest rate										4.74%
LIBOR | Credit Agreement Amendment
Debt
Reference rate (as a percent)			1.20%
Senior Notes
Debt
Fixed interest rate	3.95%					4.30%
Gain (Loss) on Repurchase of Debt Instrument		$ 800,000
Total mortgage debt	$ 350,000,000.0	400,000,000.0				$ 300,000,000.0	$ 75,000,000.0			$ 150,000,000.0
Proceeds from issuance of debt	$ 347,000,000.0	$ 396,100,000
Debt instrument, redemption price, percentage	99.78%	99.68%
Senior Notes | Series A
Debt
Total mortgage debt							25,000,000.0			15,000,000.0
Senior Notes | Series B
Debt
Total mortgage debt							$ 25,000,000.0			45,000,000.0
Senior Notes | Series C
Debt
Effective fixed interest rate							4.24%
Total mortgage debt							$ 25,000,000.0			45,000,000.0
Senior Notes | Series D
Debt
Total mortgage debt										$ 45,000,000.0
Term Loan
Debt
Amount outstanding				250,000,000.0				$ 250,000,000.0
Term Loan | Credit Agreement Amendment
Debt
Current borrowing capacity			$ 250,000,000
Debt instrument, term			7 years
Letter of Credit
Debt
Amount outstanding				17,000,000.0
Credit Agreement
Debt
Current borrowing capacity				753,000,000.0
Amount outstanding				$ 80,000,000.0
Term of extension option			1 year
Minimum | Credit Agreement | Credit Agreement Amendment
Debt
Current borrowing capacity									$ 750,000,000
Maximum | Credit Agreement | Credit Agreement Amendment
Debt
Current borrowing capacity			$ 850,000,000
Interest Rate Swaps | Unsecured Debt | LIBOR
Debt
Fixed interest rate				1.07%
Effective fixed interest rate				2.87%
Operating Partnership | Credit Agreement
Debt
Debt instrument, interest rate, effective percentage				3.93%	3.09%
Operating Partnership | Credit Agreement | LIBOR
Debt
Reference rate (as a percent)				1.49%	0.72%

XML

Debt - Summary of Debt (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017 USD ($) healthcareproperty	Dec. 31, 2016 USD ($) properties	Dec. 01, 2017	Jan. 26, 2017
Debt
Debt, gross	$ 1,491,680	$ 999,194
Unamortized deferred financing cost	(7,808)	(8,477)
Unamortized discount	(6,663)	0
Unamortized fair value adjustment	259	438
Total debt	1,477,468	991,155
Mortgages
Debt
Debt, gross	$ 186,680	123,194
Senior Notes
Debt
Fixed interest rate			3.95%	4.30%
Interest Rate Swaps | Unsecured Debt | LIBOR
Debt
Effective fixed interest rate	2.87%
Fixed interest rate	1.07%
Mortgage Notes Bearing Fixed Interest Rate | Mortgages
Debt
Debt, gross	$ 158,171	$ 90,185
Weighted average interest rate (as a percent)	4.45%	5.44%
Number of properties included in collateralized	9	11
Net book value of properties included in the collateralized	$ 267,700	$ 156,700
Mortgage Notes Bearing Fixed Interest Rate | Mortgages | Minimum
Debt
Effective fixed interest rate	3.00%	4.71%
Mortgage Notes Bearing Fixed Interest Rate | Mortgages | Maximum
Debt
Effective fixed interest rate	5.50%	6.58%
Mortgage Notes Bearing Variable Interest | Mortgages
Debt
Debt, gross	$ 28,509	$ 33,009
Mortgage Notes Bearing Variable Interest Due in 2017 and 2018 | Mortgages
Debt
Weighted average interest rate (as a percent)	4.50%	3.68%
Number of properties included in collateralized	3	4
Net book value of properties included in the collateralized	$ 39,200	$ 45,600
Mortgage Notes Bearing Variable Interest Due in 2017 and 2018 | Mortgages | Minimum | LIBOR
Debt
Reference rate (as a percent)	2.25%	2.25%
Mortgage Notes Bearing Variable Interest Due in 2017 and 2018 | Mortgages | Maximum | LIBOR
Debt
Reference rate (as a percent)	3.25%	3.25%
Revolving Credit Facility Due September 2020 | Credit Agreement
Debt
Debt, gross	$ 80,000	$ 401,000
Reference rate (as a percent)	1.20%
Unsecured Notes Bearing Fixed Interest Due March 2027 [Member] | Senior Notes
Debt
Debt, gross	$ 400,000	0
Effective fixed interest rate	4.30%
Unsecured Notes Bearing Fixed Interest Due January 2028 | Senior Notes
Debt
Debt, gross	$ 350,000	0
Effective fixed interest rate	3.95%
Unsecured Term Loan Due June 2023 | Unsecured Debt
Debt
Debt, gross	$ 250,000	250,000
Effective fixed interest rate	2.87%
Unsecured Term Loan Due June 2023 | Unsecured Debt | LIBOR
Debt
Reference rate (as a percent)	1.80%
Unsecured Notes Bearing Fixed Interest Due January 2023 to 2031 | Senior Notes
Debt
Debt, gross	$ 150,000	150,000
Unsecured Notes Bearing Fixed Interest Due January 2023 to 2031 | Senior Notes | Minimum
Debt
Effective fixed interest rate	4.03%
Unsecured Notes Bearing Fixed Interest Due January 2023 to 2031 | Senior Notes | Maximum
Debt
Effective fixed interest rate	4.74%
Senior Unsecured Notes Due August 2025 to 2027 | Senior Notes
Debt
Debt, gross	$ 75,000	$ 75,000
Senior Unsecured Notes Due August 2025 to 2027 | Senior Notes | Minimum
Debt
Effective fixed interest rate	4.09%
Senior Unsecured Notes Due August 2025 to 2027 | Senior Notes | Maximum
Debt
Effective fixed interest rate	4.24%

XML

Debt - Investment Grade Rating Schedule (Details)		12 Months Ended
	Sep. 30, 2016	Dec. 31, 2017
Credit rating at least A- or A3 | Adjusted LIBOR Rate Loans and Letter of Credit | LIBOR
Debt
Reference rate (as a percent)	0.85%
Credit rating at least A- or A3 | Adjusted LIBOR Rate Term Loans and Letter Of Credit | LIBOR
Debt
Reference rate (as a percent)	1.40%
Credit rating at least BBBplus or BAA1 | Adjusted LIBOR Rate Loans and Letter of Credit | LIBOR
Debt
Reference rate (as a percent)	0.90%
Credit rating at least BBBplus or BAA1 | Adjusted LIBOR Rate Term Loans and Letter Of Credit | LIBOR
Debt
Reference rate (as a percent)	1.45%
Credit rating at least BBB or BAA2 | Adjusted LIBOR Rate Loans and Letter of Credit | LIBOR
Debt
Reference rate (as a percent)	1.00%
Credit rating at least BBB or BAA2 | Adjusted LIBOR Rate Term Loans and Letter Of Credit | LIBOR
Debt
Reference rate (as a percent)	1.55%
Credit rating at least BBB- or BAA3 | Adjusted LIBOR Rate Loans and Letter of Credit | LIBOR
Debt
Reference rate (as a percent)	1.20%
Credit rating at least BBB- or BAA3 | Adjusted LIBOR Rate Term Loans and Letter Of Credit | LIBOR
Debt
Reference rate (as a percent)	1.80%
Credit rating below BBB- or BAA3 | Adjusted LIBOR Rate Loans and Letter of Credit | LIBOR
Debt
Reference rate (as a percent)	1.55%
Credit rating below BBB- or BAA3 | Adjusted LIBOR Rate Term Loans and Letter Of Credit | LIBOR
Debt
Reference rate (as a percent)	2.25%
Credit Agreement | Credit rating at least A- or A3 | Base Rate Loans | Base Rate
Debt
Reference rate (as a percent)		0.00%
Credit Agreement | Credit rating at least BBBplus or BAA1 | Base Rate Loans | Base Rate
Debt
Reference rate (as a percent)		0.00%
Credit Agreement | Credit rating at least BBB or BAA2 | Base Rate Loans | Base Rate
Debt
Reference rate (as a percent)		0.10%
Credit Agreement | Credit rating at least BBB- or BAA3 | Base Rate Loans | Base Rate
Debt
Reference rate (as a percent)		0.20%
Credit Agreement | Credit rating below BBB- or BAA3 | Base Rate Loans | Base Rate
Debt
Reference rate (as a percent)		0.60%
Term Loan | Credit rating at least A- or A3 | Base Rate Loans | Base Rate
Debt
Reference rate (as a percent)		0.40%
Term Loan | Credit rating at least BBBplus or BAA1 | Base Rate Loans | Base Rate
Debt
Reference rate (as a percent)		0.45%
Term Loan | Credit rating at least BBB or BAA2 | Base Rate Loans | Base Rate
Debt
Reference rate (as a percent)		0.55%
Term Loan | Credit rating at least BBB- or BAA3 | Base Rate Loans | Base Rate
Debt
Reference rate (as a percent)		0.80%
Term Loan | Credit rating below BBB- or BAA3 | Base Rate Loans | Base Rate
Debt
Reference rate (as a percent)		1.25%

XML

Debt - Principal Payments Due on Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Scheduled principal payments
2018	$ 54,775
2019	44,631
2020	110,122
2021	8,718
2022	24,708
Thereafter	1,248,726
Total Payments	$ 1,491,680	$ 999,194

XML

Derivatives - (Details) - Cash Flow Hedging - Interest Rate Swaps $ in Millions	12 Months Ended
	Dec. 31, 2017 USD ($) instruments
Derivative [Line Items]
Number of derivative instruments | instruments	5,000
Gain, hedge ineffectiveness | $	$ (0.2)

XML

Derivatives - Fair Value Interest Rate Swaps (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Derivative [Line Items]
Total notional amount	$ 250,000
Effective date	Jul. 07, 2016
Maturity date	Jun. 10, 2023
Reported Value Measurement | Recurring | Interest Rate Swaps
Derivative [Line Items]
Asset balance at December 31, 2017 (included in Other assets)	$ 14,693	$ 13,881
Unsecured Debt | LIBOR | Interest Rate Swaps
Derivative [Line Items]
Effective fixed interest rate	2.87%
Effective fixed interest rate	1.07%
Unsecured Debt | Unsecured Term Loan Due June 2023
Derivative [Line Items]
Effective fixed interest rate	2.87%
Unsecured Debt | Unsecured Term Loan Due June 2023 | LIBOR
Derivative [Line Items]
Derivative, basis spread on variable rate	1.80%

XML

Accrued Expenses and Other Liabilities - (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Jan. 12, 2017	Dec. 31, 2016
Other Liabilities Disclosure [Abstract]
Real estate taxes payable	$ 16,103		$ 9,300
Accrued interest	11,107		4,905
Prepaid rent	10,496		5,834
Accrued expenses	8,751		3,453
Tenant improvement allowance	3,065		5,315
Security deposits	2,882		4,506
Accrued incentive compensation	1,625		1,405
Contingent consideration	1,454		1,392
Embedded derivative	0	$ 5,600	5,571
Other	922		606
Total	$ 56,405		$ 42,287

XML

Stock-based Compensation - (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended			3 Months Ended		12 Months Ended
	Aug. 07, 2014	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2017	Mar. 31, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Jul. 24, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-cash share compensation							$ 6,695	$ 5,672	$ 3,798
2013 Plan | Restricted common shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized	2,450,000										600,000
Number of additional shares authorized	1,850,000
Granted (in shares)							143,593	155,306	162,522
Share-based compensation, gross							$ 2,800	$ 2,800	$ 2,600
Non-cash share compensation						$ 2,900	3,100	3,600
Unrecognized compensation expense					$ 1,000		$ 1,000	$ 1,200		$ 2,100
Grant date value (in dollars per share)							$ 19.74	$ 17.96	$ 15.95
2013 Plan | Restricted common shares | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period							1 year	1 year	1 year
2013 Plan | Restricted common shares | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period							3 years	3 years	3 years
2013 Plan | Restricted Share Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)				75,250
Non-cash share compensation						$ 900	$ 3,600	$ 2,100
Unrecognized compensation expense					$ 5,000		$ 5,000	$ 2,800		$ 1,600
2013 Plan | Trustee Awards, Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)							32,831	36,784	40,957
Grant date value (in dollars per share)							$ 19.80	$ 17.67	$ 15.87
2013 Plan | Performance based restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares awarded					30.00%			20.00%	20.00%
Grant date value (in dollars per share)					$ 29.34			$ 26.33	$ 19.22
Grant date fair value (in dollars per share)					$ 19.80			$ 17.67	$ 15.87
Officer | 2013 Plan | Restricted Share Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)		174,320	104,553
Vesting period							3 years
Officer | 2013 Plan | Market Based RSU
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares awarded							70.00%	80.00%	80.00%
Grant date value (in dollars per share)							$ 33.43	$ 28.50	$ 20.06
Trustees | 2013 Plan | Restricted Share Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period							2 years
Number of dividend equivalent included in award		1
Trustees | 2013 Plan | Trustee Awards, Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)		32,831	36,784	40,957

XML

Stock-based Compensation - Summary of Non-Vested Restricted Common Shares (Details) - 2013 Plan - Restricted common shares - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Shares
Non-vested at the beginning of the period (in shares)	296,785	311,839	319,654
Granted (in shares)	143,593	155,306	162,522
Vested (in shares)	(266,552)	(170,034)	(170,337)
Forfeited (in shares)	(550)	(326)
Non-vested at the beginning of the period (in shares)	173,276	296,785	311,839
Weighted Average Grant Date Fair Value
Non-vested at beginning of period (in dollars per share)	$ 16.16	$ 14.17	$ 12.60
Grant date value (in dollars per share)	19.74	17.96	15.95
Vested (in dollars per share)	16.00	14.16	12.93
Forfeited (in dollars per share)	18.78	15.36
Non-vested at beginning of period (in dollars per share)	$ 19.36	$ 16.16	$ 14.17

XML

Stock-based Compensation - Weighted Average Grant Date Fair Value Assumptions (Details) - 2013 Plan - Restricted Share Units - $ / shares	3 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	21.50%	20.30%	20.70%
Expected term in years	2 years 9 months 18 days	2 years 9 months 18 days	2 years 9 months 18 days
Risk-free rate	1.68%	1.07%	1.14%
Stock price (per share)	$ 19.80	$ 17.67	$ 15.87

XML

Stock-based Compensation - Trust Restricted Share Activity (Details) - 2013 Plan - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Executive Awards, Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-vested at the beginning of the period (in shares)	354,123	235,483	130,930	55,680
Non-vested at beginning of period (in dollars per share)	$ 26.30	$ 21.84	$ 18.48	$ 16.94
Granted (in shares)	174,320	104,553	75,250
Grant date value (in dollars per share)	$ 29.34	$ 26.33	$ 19.22
Vested (in shares)	(55,680)	0
Vested (in dollars per share)	$ 16.94	$ 0
Trustee Awards, Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-vested at the beginning of the period (in shares)	51,220	57,260	40,957	0
Non-vested at beginning of period (in dollars per share)	$ 19.04	$ 17.03	$ 15.87	$ 0
Granted (in shares)	32,831	36,784	40,957
Grant date value (in dollars per share)	$ 19.80	$ 17.67	$ 15.87
Vested (in shares)	(38,871)	(20,481)
Vested (in dollars per share)	$ 16.72	$ 15.87

XML

Fair Value Measurements - (Details)	Dec. 31, 2017 USD ($) instruments
Cash Flow Hedging | Interest Rate Swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Number of derivative instruments | instruments	5,000
Fair Value, Measurements, Nonrecurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets subject to impairment measured at fair value | $	$ 1,000

XML

Fair Value Measurements - Fair Value Financial Instruments (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Assets:
Notes receivable	$ 0	$ 16,618
Liabilities:
Credit facility	(324,394)	(643,742)
Notes payable	(966,603)	(224,330)
Recurring | Reported Value Measurement
Assets:
Real estate loans receivable	76,195	39,154
Notes receivable	0	16,618
Liabilities:
Credit facility	(330,000)	(651,000)
Notes payable	(975,000)	(225,000)
Mortgage debt	(186,939)	(123,632)
Recurring | Reported Value Measurement | Interest Rate Swaps
Assets:
Derivative assets	14,693	13,881
Recurring | Reported Value Measurement | Embedded Derivative Financial Instruments
Liabilities:
Derivative liabilities	0	(5,571)
Recurring | Estimate of Fair Value Measurement
Assets:
Real estate loans receivable	75,288	39,154
Notes receivable	0	16,618
Liabilities:
Credit facility	(330,000)	(651,000)
Notes payable	(970,975)	(214,584)
Mortgage debt	(185,743)	(125,420)
Recurring | Estimate of Fair Value Measurement | Interest Rate Swaps
Assets:
Derivative assets	14,693	13,881
Recurring | Estimate of Fair Value Measurement | Embedded Derivative Financial Instruments
Liabilities:
Derivative liabilities	$ 0	$ (5,571)

XML

Tenant Operating Leases - (Details) $ in Thousands	Dec. 31, 2017 USD ($)
Future minimum rental payments on non-cancelable leases
2018	$ 292,030
2019	291,338
2020	285,100
2021	278,095
2022	265,995
Thereafter	1,419,746
Total	$ 2,832,304

XML

Rent Expense - (Details) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2015 USD ($)	Dec. 31, 2017 USD ($) properties healthcareproperty	Dec. 31, 2016 USD ($)
Operating Leased Assets [Line Items]
Number of properties pursuant to parking lease		2
Number Of properties subject to air space lease | healthcareproperty		1
Number of properties pursuant to ground leases		78
Number of office space leases		4
Maximum lease terms		98 years
Parking, Air And Ground Leases | Operating Expense
Operating Leased Assets [Line Items]
Rent expenses for parking and ground leases | $	$ 1.3	$ 2.4	$ 1.9
Office Leases | Operating Expense
Operating Leased Assets [Line Items]
Rent expenses for parking and ground leases | $		$ 0.1

XML

Rent Expense - Schedule of Minimum Lease Obligations (Details) $ in Thousands	Dec. 31, 2017 USD ($)
Future minimum lease obligations under non-cancelable ground leases
2018	$ 2,678
2019	2,604
2020	2,549
2021	2,563
2022	2,585
Thereafter	119,224
Total	$ 132,203

XML

Credit Concentration - (Details) - Sales Revenue, Services, Net	12 Months Ended
	Dec. 31, 2017
Concentration Risk [Line Items]
Concentration risk, percentage	100.00%
Top five tenant relationships | Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	17.40%
CHI Portfolio | Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	18.70%

XML

Credit Concentration - Top Five Tenant Credit Concentrations (Details) - Sales Revenue, Services, Net $ in Thousands	12 Months Ended
	Dec. 31, 2017 USD ($)
Concentration Risk [Line Items]
Total ABR	$ 285,670
Percent of ABR	100.00%
CHI - Nebraska | Customer Concentration Risk
Concentration Risk [Line Items]
Total ABR	$ 15,906
Percent of ABR	5.60%
CHI - KentuckyOne Health | Customer Concentration Risk
Concentration Risk [Line Items]
Total ABR	$ 13,120
Percent of ABR	4.60%
Baylor Scott and White Health | Customer Concentration Risk
Concentration Risk [Line Items]
Total ABR	$ 7,402
Percent of ABR	2.60%
US Oncology | Customer Concentration Risk
Concentration Risk [Line Items]
Total ABR	$ 6,706
Percent of ABR	2.40%
US Oncology | Customer Concentration Risk
Concentration Risk [Line Items]
Total ABR	$ 6,239
Percent of ABR	2.20%
Remaining portfolio | Customer Concentration Risk
Concentration Risk [Line Items]
Total ABR	$ 236,297
Percent of ABR	82.60%

XML

Credit Concentration - Top Five Geographic Concentrations (Details) - Sales Revenue, Services, Net $ in Thousands	12 Months Ended
	Dec. 31, 2017 USD ($)
Concentration Risk [Line Items]
Total ABR	$ 285,670
Percent of ABR	100.00%
Texas | Geographic Concentration Risk
Concentration Risk [Line Items]
Total ABR	$ 46,850
Percent of ABR	16.40%
Georgia | Geographic Concentration Risk
Concentration Risk [Line Items]
Total ABR	$ 27,457
Percent of ABR	9.60%
Nebraska | Geographic Concentration Risk
Concentration Risk [Line Items]
Total ABR	$ 18,283
Percent of ABR	6.40%
Nebraska | Geographic Concentration Risk
Concentration Risk [Line Items]
Total ABR	$ 17,304
Percent of ABR	6.10%
Georgia | Geographic Concentration Risk
Concentration Risk [Line Items]
Total ABR	$ 16,028
Percent of ABR	5.60%
Other | Geographic Concentration Risk
Concentration Risk [Line Items]
Total ABR	$ 159,748
Percent of ABR	55.90%

XML

Earnings Per Share and Earnings Per Unit - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended									12 Months Ended
		Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Numerator for earnings per share - basic:
Net income (loss)		$ 10,187	$ 12,539	$ 10,331	$ 6,716	$ 8,620	$ 10,294	$ 7,184	$ 5,424		$ 39,773	$ 31,522	$ 12,741
Net Income (Loss) Attributable to Noncontrolling Interest [Abstract]
Operating Partnership											(1,136)	(825)	(576)
Partially owned properties	[1]										(491)	(716)	(377)
Preferred distributions											(731)	(1,857)	(1,189)
Net income attributable to common shareholders		9,536	12,018	9,670	6,191	7,825	9,427	6,486	4,386		37,415	28,124	10,599
Numerator for earnings per share - diluted:
Net income attributable to common shareholders		$ 9,536	$ 12,018	$ 9,670	$ 6,191	$ 7,825	$ 9,427	$ 6,486	$ 4,386		37,415	28,124	10,599
Operating Partnership net income											1,136	825	576
Numerator for earnings per share - diluted											$ 38,551	$ 28,949	$ 11,175
Weighted average number of shares outstanding - basic (in shares)											163,123,109	163,123,109
Denominator for earnings per share - basic and diluted:
Weighted average number of shares outstanding - basic (in shares)		179,683,948	177,847,424	155,366,080	138,986,629	135,581,976	134,608,396	131,481,329	102,704,008		163,123,109	126,143,114	72,750,724
Effect of dilutive securities:
Noncontrolling interest - Operating Partnership units											4,839,967	3,692,095	3,708,494
Weighted average number of shares outstanding - diluted (in shares)		185,273,236	183,298,145	161,012,360	142,605,930	139,602,349	138,880,787	135,944,722	107,148,380		168,231,299	130,466,893	76,792,073
Earnings per share/unit, basic and diluted:
Earnings per share - basic (in dollars per share)		$ 0.05	$ 0.07	$ 0.06	$ 0.04	$ 0.06	$ 0.07	$ 0.05	$ 0.04		$ 0.23	$ 0.22	$ 0.15
Earnings per share - diluted (in dollars per share)		$ 0.05	$ 0.07	$ 0.06	$ 0.04	$ 0.06	$ 0.07	$ 0.05	$ 0.04		$ 0.23	$ 0.22	$ 0.15
Restricted shares
Effect of dilutive securities:
Effect of dilutive securities, restricted shares and RSUs											89,497	205,036	190,619
Restricted share units
Effect of dilutive securities:
Effect of dilutive securities, restricted shares and RSUs											178,726	426,648	142,236
Operating Partnership
Numerator for earnings per share - basic:
Net income (loss)		$ 10,187	$ 12,539	$ 10,331	$ 6,716	$ 8,620	$ 10,294	$ 7,184	$ 5,424		$ 39,773	$ 31,522	$ 12,741
Net Income (Loss) Attributable to Noncontrolling Interest [Abstract]
Partially owned properties											(491)	(716)	(377)	[1]
Preferred distributions											(731)	(1,857)	(1,189)
Net income attributable to common shareholders		9,849	12,380	9,984	6,338	8,021	9,682	6,687	4,559		38,551	28,949	11,175
Numerator for earnings per unit - basic and diluted											38,551	28,949	11,175
Numerator for earnings per share - diluted:
Net income attributable to common shareholders		$ 9,849	$ 12,380	$ 9,984	$ 6,338	$ 8,021	$ 9,682	$ 6,687	$ 4,559		$ 38,551	$ 28,949	$ 11,175
Denominator for earnings per share - basic and diluted:
Weighted average number of units outstanding - basic (in shares)		185,048,580	183,227,405	160,765,345	142,172,746	139,018,183	138,227,384	135,351,672	106,550,467	76,459,218	167,963,076	129,835,209	76,459,218
Effect of dilutive securities:
Weighted average number of units outstanding - diluted (in shares)		185,273,236	183,298,145		142,605,930		138,880,787	135,944,722	107,148,380	76,792,073	168,231,299	130,466,893	76,792,073
Earnings per share/unit, basic and diluted:
Earnings per share - basic (in dollars per share)		$ 0.05	$ 0.07	$ 0.06	$ 0.04	$ 0.06	$ 0.07	$ 0.05	$ 0.04
Earnings per share - diluted (in dollars per share)		$ 0.05	$ 0.07	$ 0.06	$ 0.04	$ 0.06	$ 0.07	$ 0.05	$ 0.04
Earnings per unit - basic (in dollars per share)										$ 0.15	$ 0.23	$ 0.22	$ 0.15
Earnings per unit - diluted (in dollars per share)										$ 0.15	$ 0.23	$ 0.22	$ 0.15
Operating Partnership | Restricted shares
Effect of dilutive securities:
Effect of dilutive securities, restricted shares and RSUs										190,619	89,497	205,036
Operating Partnership | Restricted share units
Effect of dilutive securities:
Effect of dilutive securities, restricted shares and RSUs										142,236	178,726	426,648

[1] adjustment of $0.3 million and $0.1 million was required for net income attributable to redeemable noncontrolling interests for the year ended December 31, 2017 and December 31, 2016, respectively. No such adjustment was required for the year ended December 31, 2015.

XML

Subsequent Events - Additional Information (Details) $ in Thousands				2 Months Ended	12 Months Ended
	Feb. 16, 2018 USD ($)	Jan. 23, 2018 USD ($)	Jan. 09, 2018 USD ($) shares	Mar. 01, 2018 USD ($) ft² healthcareproperty	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Subsequent events
Purchase price					$ 1,414,179	$ 1,285,185
Aggregate purchase price					1,370,000	1,270,000
Value of units issued for funding purchase price					0	$ 20,980
Loan Investment
Subsequent events
Purchase price					$ 39,063
Subsequent Events
Subsequent events
Purchase price				$ 100,700
Mezzanine term loan				2,000
Aggregate purchase price				$ 98,700
Subsequent Events | Two Healthcare Properties Acquired in early 2018
Subsequent events
Number of operating healthcare properties | healthcareproperty				2
Area of property (in square feet) | ft²				220,140
Subsequent Events | One Health Care Property Disposed of Early 2018
Subsequent events
Number of operating healthcare properties | healthcareproperty				1
Aggregate purchase price				$ 1,400
Subsequent Events | Hazelwood Medical Commons
Subsequent events
Purchase price			$ 70,702
Number of units issued for funding purchase price (in shares) | shares			104,172
Value of units issued for funding purchase price			$ 22,700
Subsequent Events | Lee's Hill Medical Plaza
Subsequent events
Purchase price		$ 28,000
Subsequent Events | Loan Investment
Subsequent events
Purchase price	$ 2,000
Subsequent Events | Three Healthcare Properties Acquired in Early 2018
Subsequent events
Purchase price				$ 100,702

XML

Quarterly Data - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Total revenues	$ 97,320	$ 92,999	$ 76,599	$ 76,666	$ 73,674	$ 70,010	$ 53,216	$ 44,134	$ 343,584	$ 241,034	$ 129,441
Operating income	9,523	12,511	4,994	6,688	8,590	10,267	7,158	5,392	33,716	31,407	12,507
Net income	10,187	12,539	10,331	6,716	8,620	10,294	7,184	5,424	39,773	31,522	12,741
Net income attributable to common shareholders	$ 9,536	$ 12,018	$ 9,670	$ 6,191	$ 7,825	$ 9,427	$ 6,486	$ 4,386	$ 37,415	$ 28,124	$ 10,599
Earnings per share – basic:
Earnings per share - basic (in dollars per share)	$ 0.05	$ 0.07	$ 0.06	$ 0.04	$ 0.06	$ 0.07	$ 0.05	$ 0.04	$ 0.23	$ 0.22	$ 0.15
Weighted average number of shares outstanding - basic (in shares)	179,683,948	177,847,424	155,366,080	138,986,629	135,581,976	134,608,396	131,481,329	102,704,008	163,123,109	126,143,114	72,750,724
Earnings per share – diluted:
Earnings per share - diluted (in dollars per share)	$ 0.05	$ 0.07	$ 0.06	$ 0.04	$ 0.06	$ 0.07	$ 0.05	$ 0.04	$ 0.23	$ 0.22	$ 0.15
Weighted Average Number of Shares Outstanding, Diluted	185,273,236	183,298,145	161,012,360	142,605,930	139,602,349	138,880,787	135,944,722	107,148,380	168,231,299	130,466,893	76,792,073

XML

SCHEDULE III - REAL ESTATE AND ACCUMULATED DEPRECIATION - Real Estate and Accumulated Depreciation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 186,679
Initial Cost to Company, Land	217,808
Initial Cost to Company, Buildings and Improvements	3,518,259
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	73,655
Gross Amount at Which Carried as of Close of Period, Land	217,695
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	3,591,914
Gross Amount at Which Carried as of Close of Period, Total	3,809,609	$ 2,606,536	$ 1,424,894	$ 729,034
Accumulated Depreciation	(201,527)	$ (118,609)	$ (61,242)	$ (32,772)
Arrowhead Commons
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost to Company, Land	740
Initial Cost to Company, Buildings and Improvements	2,551
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	730
Gross Amount at Which Carried as of Close of Period, Land	740
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	3,281
Gross Amount at Which Carried as of Close of Period, Total	4,021
Accumulated Depreciation	$ (563)
Life on Which Building Depreciation in Income Statement is Computed	46 years
Aurora Medical Office Building
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	500
Initial Cost to Company, Buildings and Improvements	1,566
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	500
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	1,566
Gross Amount at Which Carried as of Close of Period, Total	2,066
Accumulated Depreciation	$ (243)
Life on Which Building Depreciation in Income Statement is Computed	50 years
El Paso Medical Office Building
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	860
Initial Cost to Company, Buildings and Improvements	2,866
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	406
Gross Amount at Which Carried as of Close of Period, Land	860
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	3,272
Gross Amount at Which Carried as of Close of Period, Total	4,132
Accumulated Depreciation	$ (1,809)
Life on Which Building Depreciation in Income Statement is Computed	21 years
Farmington Professional Pavilion
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	580
Initial Cost to Company, Buildings and Improvements	1,793
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	132
Gross Amount at Which Carried as of Close of Period, Land	580
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	1,925
Gross Amount at Which Carried as of Close of Period, Total	2,505
Accumulated Depreciation	$ (1,478)
Life on Which Building Depreciation in Income Statement is Computed	15 years
Firehouse Square
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,120
Initial Cost to Company, Buildings and Improvements	2,768
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,120
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	2,768
Gross Amount at Which Carried as of Close of Period, Total	3,888
Accumulated Depreciation	$ (961)
Life on Which Building Depreciation in Income Statement is Computed	30 years
Hackley Medical Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,840
Initial Cost to Company, Buildings and Improvements	6,402
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	64
Gross Amount at Which Carried as of Close of Period, Land	1,840
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	6,466
Gross Amount at Which Carried as of Close of Period, Total	8,306
Accumulated Depreciation	$ (2,381)
Life on Which Building Depreciation in Income Statement is Computed	30 years
MeadowView Professional Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	2,270
Initial Cost to Company, Buildings and Improvements	11,344
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	2,270
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	11,344
Gross Amount at Which Carried as of Close of Period, Total	13,614
Accumulated Depreciation	$ (4,054)
Life on Which Building Depreciation in Income Statement is Computed	30 years
Mid Coast Hospital Medical Office Building
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 7,009
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	11,247
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	81
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	11,328
Gross Amount at Which Carried as of Close of Period, Total	11,328
Accumulated Depreciation	$ (3,614)
Life on Which Building Depreciation in Income Statement is Computed	42 years
New Albany Professional Building
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	237
Initial Cost to Company, Buildings and Improvements	2,767
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	621
Gross Amount at Which Carried as of Close of Period, Land	237
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	3,388
Gross Amount at Which Carried as of Close of Period, Total	3,625
Accumulated Depreciation	$ (799)
Life on Which Building Depreciation in Income Statement is Computed	42 years
Remington Medical Commons
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	895
Initial Cost to Company, Buildings and Improvements	6,499
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	319
Gross Amount at Which Carried as of Close of Period, Land	895
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	6,818
Gross Amount at Which Carried as of Close of Period, Total	7,713
Accumulated Depreciation	$ (2,228)
Life on Which Building Depreciation in Income Statement is Computed	30 years
Summit Healthplex
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	2,633
Initial Cost to Company, Buildings and Improvements	15,576
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	5,524
Gross Amount at Which Carried as of Close of Period, Land	2,633
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	21,100
Gross Amount at Which Carried as of Close of Period, Total	23,733
Accumulated Depreciation	$ (5,518)
Life on Which Building Depreciation in Income Statement is Computed	44 years
Valley West Hospital Medical Office Building
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 4,531
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	6,275
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	620
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	6,895
Gross Amount at Which Carried as of Close of Period, Total	6,895
Accumulated Depreciation	$ (2,357)
Life on Which Building Depreciation in Income Statement is Computed	30 years
East El Paso Medical Office Building
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	710
Initial Cost to Company, Buildings and Improvements	4,500
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	710
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	4,500
Gross Amount at Which Carried as of Close of Period, Total	5,210
Accumulated Depreciation	$ (557)
Life on Which Building Depreciation in Income Statement is Computed	35 years
East El Paso Surgical Hospital
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	3,070
Initial Cost to Company, Buildings and Improvements	23,627
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	3,070
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	23,627
Gross Amount at Which Carried as of Close of Period, Total	26,697
Accumulated Depreciation	$ (2,844)
Life on Which Building Depreciation in Income Statement is Computed	36 years
LifeCare Plano LTACH
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	3,370
Initial Cost to Company, Buildings and Improvements	11,689
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	455
Gross Amount at Which Carried as of Close of Period, Land	3,370
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	12,144
Gross Amount at Which Carried as of Close of Period, Total	15,514
Accumulated Depreciation	$ (2,119)
Life on Which Building Depreciation in Income Statement is Computed	25 years
Crescent City Surgical Centre
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 18,750
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	34,208
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	34,208
Gross Amount at Which Carried as of Close of Period, Total	34,208
Accumulated Depreciation	$ (3,029)
Life on Which Building Depreciation in Income Statement is Computed	48 years
Foundation Surgical Affiliates Medical Office Building
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 7,101
Initial Cost to Company, Land	1,300
Initial Cost to Company, Buildings and Improvements	12,724
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,300
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	12,724
Gross Amount at Which Carried as of Close of Period, Total	14,024
Accumulated Depreciation	$ (1,258)
Life on Which Building Depreciation in Income Statement is Computed	43 years
Pensacola Medical Office Building
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	990
Initial Cost to Company, Buildings and Improvements	5,005
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	16
Gross Amount at Which Carried as of Close of Period, Land	990
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	5,021
Gross Amount at Which Carried as of Close of Period, Total	6,011
Accumulated Depreciation	$ (437)
Life on Which Building Depreciation in Income Statement is Computed	49 years
Central Ohio Neurosurgical Surgeons Medical Office
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	981
Initial Cost to Company, Buildings and Improvements	7,620
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	981
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	7,620
Gross Amount at Which Carried as of Close of Period, Total	8,601
Accumulated Depreciation	$ (707)
Life on Which Building Depreciation in Income Statement is Computed	44 years
Great Falls Ambulatory Surgery Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	203
Initial Cost to Company, Buildings and Improvements	3,224
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	67
Gross Amount at Which Carried as of Close of Period, Land	203
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	3,291
Gross Amount at Which Carried as of Close of Period, Total	3,494
Accumulated Depreciation	$ (404)
Life on Which Building Depreciation in Income Statement is Computed	33 years
Eagles Landing Family Practice Medical Office Building — McDonough 2007
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	800
Initial Cost to Company, Buildings and Improvements	3,345
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	1,548
Gross Amount at Which Carried as of Close of Period, Land	800
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	4,893
Gross Amount at Which Carried as of Close of Period, Total	5,693
Accumulated Depreciation	$ (532)
Life on Which Building Depreciation in Income Statement is Computed	36 years
Eagles Landing Family Practice Medical Office Building — Jackson
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	800
Initial Cost to Company, Buildings and Improvements	3,345
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	1,255
Gross Amount at Which Carried as of Close of Period, Land	800
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	4,600
Gross Amount at Which Carried as of Close of Period, Total	5,400
Accumulated Depreciation	$ (475)
Life on Which Building Depreciation in Income Statement is Computed	38 years
Eagles Landing Family Practice Medical Office Building — Conyers
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,000
Initial Cost to Company, Buildings and Improvements	3,345
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,000
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	3,345
Gross Amount at Which Carried as of Close of Period, Total	4,345
Accumulated Depreciation	$ (360)
Life on Which Building Depreciation in Income Statement is Computed	37 years
Eagles Landing Family Practice Medical Office Building — McDonough 2010
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	400
Initial Cost to Company, Buildings and Improvements	3,345
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	1,741
Gross Amount at Which Carried as of Close of Period, Land	400
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	5,086
Gross Amount at Which Carried as of Close of Period, Total	5,486
Accumulated Depreciation	$ (531)
Life on Which Building Depreciation in Income Statement is Computed	37 years
Foundation San Antonio Surgical Hospital
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 7,691
Initial Cost to Company, Land	2,230
Initial Cost to Company, Buildings and Improvements	23,346
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	43
Gross Amount at Which Carried as of Close of Period, Land	2,230
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	23,389
Gross Amount at Which Carried as of Close of Period, Total	25,619
Accumulated Depreciation	$ (2,919)
Life on Which Building Depreciation in Income Statement is Computed	35 years
21st Century Radiation Oncology Centers — Sarasota
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	633
Initial Cost to Company, Buildings and Improvements	6,557
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	633
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	6,557
Gross Amount at Which Carried as of Close of Period, Total	7,190
Accumulated Depreciation	$ (969)
Life on Which Building Depreciation in Income Statement is Computed	27 years
21st Century Radiation Oncology Centers — Venice
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	814
Initial Cost to Company, Buildings and Improvements	2,952
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	814
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	2,952
Gross Amount at Which Carried as of Close of Period, Total	3,766
Accumulated Depreciation	$ (364)
Life on Which Building Depreciation in Income Statement is Computed	35 years
21st Century Radiation Oncology Centers — Engelwood
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	350
Initial Cost to Company, Buildings and Improvements	1,878
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	350
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	1,878
Gross Amount at Which Carried as of Close of Period, Total	2,228
Accumulated Depreciation	$ (209)
Life on Which Building Depreciation in Income Statement is Computed	38 years
21st Century Radiation Oncology Centers — Port Charlotte
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	269
Initial Cost to Company, Buildings and Improvements	2,326
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	(852)
Gross Amount at Which Carried as of Close of Period, Land	156
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	1,474
Gross Amount at Which Carried as of Close of Period, Total	1,630
Accumulated Depreciation	$ (262)
Life on Which Building Depreciation in Income Statement is Computed	36 years
Foundation San Antonio Healthplex
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	911
Initial Cost to Company, Buildings and Improvements	4,189
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	911
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	4,189
Gross Amount at Which Carried as of Close of Period, Total	5,100
Accumulated Depreciation	$ (480)
Life on Which Building Depreciation in Income Statement is Computed	35 years
Peachtree Dunwoody Medical Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 17,000
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	27,435
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	24,894
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	52,329
Gross Amount at Which Carried as of Close of Period, Total	52,329
Accumulated Depreciation	$ (5,076)
Life on Which Building Depreciation in Income Statement is Computed	25 years
LifeCare LTACH — Fort Worth
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	2,730
Initial Cost to Company, Buildings and Improvements	24,639
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	2,730
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	24,639
Gross Amount at Which Carried as of Close of Period, Total	27,369
Accumulated Depreciation	$ (3,162)
Life on Which Building Depreciation in Income Statement is Computed	30 years
LifeCare LTACH — Pittsburgh
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,142
Initial Cost to Company, Buildings and Improvements	11,737
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,142
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	11,737
Gross Amount at Which Carried as of Close of Period, Total	12,879
Accumulated Depreciation	$ (1,575)
Life on Which Building Depreciation in Income Statement is Computed	30 years
PinnacleHealth Medical Office Building
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	795
Initial Cost to Company, Buildings and Improvements	4,601
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	795
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	4,601
Gross Amount at Which Carried as of Close of Period, Total	5,396
Accumulated Depreciation	$ (731)
Life on Which Building Depreciation in Income Statement is Computed	25 years
Pinnacle Health Medical Office Building
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	424
Initial Cost to Company, Buildings and Improvements	2,232
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	424
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	2,232
Gross Amount at Which Carried as of Close of Period, Total	2,656
Accumulated Depreciation	$ (255)
Life on Which Building Depreciation in Income Statement is Computed	35 years
South Bend Orthopaedics Medical Office Building
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	2,418
Initial Cost to Company, Buildings and Improvements	11,355
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	2,418
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	11,355
Gross Amount at Which Carried as of Close of Period, Total	13,773
Accumulated Depreciation	$ (1,195)
Life on Which Building Depreciation in Income Statement is Computed	40 years
Grenada Medical Complex
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	185
Initial Cost to Company, Buildings and Improvements	5,820
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	116
Gross Amount at Which Carried as of Close of Period, Land	185
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	5,936
Gross Amount at Which Carried as of Close of Period, Total	6,121
Accumulated Depreciation	$ (862)
Life on Which Building Depreciation in Income Statement is Computed	30 years
Mississippi Ortho Medical Office Building
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,272
Initial Cost to Company, Buildings and Improvements	14,177
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	626
Gross Amount at Which Carried as of Close of Period, Land	1,272
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	14,803
Gross Amount at Which Carried as of Close of Period, Total	16,075
Accumulated Depreciation	$ (1,650)
Life on Which Building Depreciation in Income Statement is Computed	35 years
Carmel Medical Pavilion
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	3,917
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	99
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	4,016
Gross Amount at Which Carried as of Close of Period, Total	4,016
Accumulated Depreciation	$ (593)
Life on Which Building Depreciation in Income Statement is Computed	25 years
Renaissance Ambulatory Surgery Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	228
Initial Cost to Company, Buildings and Improvements	7,658
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	17
Gross Amount at Which Carried as of Close of Period, Land	228
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	7,675
Gross Amount at Which Carried as of Close of Period, Total	7,903
Accumulated Depreciation	$ (696)
Life on Which Building Depreciation in Income Statement is Computed	40 years
Presbyterian Medical Plaza
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,195
Initial Cost to Company, Buildings and Improvements	5,681
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	27
Gross Amount at Which Carried as of Close of Period, Land	1,195
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	5,708
Gross Amount at Which Carried as of Close of Period, Total	6,903
Accumulated Depreciation	$ (476)
Life on Which Building Depreciation in Income Statement is Computed	45 years
Summit Urology
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	125
Initial Cost to Company, Buildings and Improvements	4,792
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	125
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	4,792
Gross Amount at Which Carried as of Close of Period, Total	4,917
Accumulated Depreciation	$ (573)
Life on Which Building Depreciation in Income Statement is Computed	30 years
500 Landmark
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	627
Initial Cost to Company, Buildings and Improvements	3,549
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	627
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	3,549
Gross Amount at Which Carried as of Close of Period, Total	4,176
Accumulated Depreciation	$ (370)
Life on Which Building Depreciation in Income Statement is Computed	35 years
550 Landmark
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	2,717
Initial Cost to Company, Buildings and Improvements	15,224
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	2,717
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	15,224
Gross Amount at Which Carried as of Close of Period, Total	17,941
Accumulated Depreciation	$ (1,586)
Life on Which Building Depreciation in Income Statement is Computed	35 years
574 Landmark
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	418
Initial Cost to Company, Buildings and Improvements	1,493
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	418
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	1,493
Gross Amount at Which Carried as of Close of Period, Total	1,911
Accumulated Depreciation	$ (159)
Life on Which Building Depreciation in Income Statement is Computed	35 years
Carlisle II MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	412
Initial Cost to Company, Buildings and Improvements	3,962
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	412
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	3,962
Gross Amount at Which Carried as of Close of Period, Total	4,374
Accumulated Depreciation	$ (317)
Life on Which Building Depreciation in Income Statement is Computed	45 years
Surgical Institute of Monroe
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	410
Initial Cost to Company, Buildings and Improvements	5,743
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	410
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	5,743
Gross Amount at Which Carried as of Close of Period, Total	6,153
Accumulated Depreciation	$ (659)
Life on Which Building Depreciation in Income Statement is Computed	35 years
The Oaks @ Lady Lake
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,065
Initial Cost to Company, Buildings and Improvements	8,642
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,065
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	8,642
Gross Amount at Which Carried as of Close of Period, Total	9,707
Accumulated Depreciation	$ (710)
Life on Which Building Depreciation in Income Statement is Computed	42 years
Mansfield ASC
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,491
Initial Cost to Company, Buildings and Improvements	6,471
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,491
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	6,471
Gross Amount at Which Carried as of Close of Period, Total	7,962
Accumulated Depreciation	$ (517)
Life on Which Building Depreciation in Income Statement is Computed	46 years
Eye Center of Southern Indiana
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	910
Initial Cost to Company, Buildings and Improvements	11,477
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	910
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	11,477
Gross Amount at Which Carried as of Close of Period, Total	12,387
Accumulated Depreciation	$ (1,134)
Life on Which Building Depreciation in Income Statement is Computed	35 years
Wayne State
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	3,560
Initial Cost to Company, Buildings and Improvements	43,052
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	3,560
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	43,052
Gross Amount at Which Carried as of Close of Period, Total	46,612
Accumulated Depreciation	$ (3,921)
Life on Which Building Depreciation in Income Statement is Computed	38 years
Zangmeister
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,610
Initial Cost to Company, Buildings and Improvements	31,120
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	4
Gross Amount at Which Carried as of Close of Period, Land	1,610
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	31,124
Gross Amount at Which Carried as of Close of Period, Total	32,734
Accumulated Depreciation	$ (2,644)
Life on Which Building Depreciation in Income Statement is Computed	40 years
Ortho One - Columbus
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	16,234
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	7
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	16,241
Gross Amount at Which Carried as of Close of Period, Total	16,241
Accumulated Depreciation	$ (1,309)
Life on Which Building Depreciation in Income Statement is Computed	45 years
Ortho One - Westerville
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	362
Initial Cost to Company, Buildings and Improvements	3,944
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	362
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	3,944
Gross Amount at Which Carried as of Close of Period, Total	4,306
Accumulated Depreciation	$ (328)
Life on Which Building Depreciation in Income Statement is Computed	43 years
Berger Medical Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	5,950
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	5,950
Gross Amount at Which Carried as of Close of Period, Total	5,950
Accumulated Depreciation	$ (561)
Life on Which Building Depreciation in Income Statement is Computed	38 years
El Paso - Lee Trevino
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	2,294
Initial Cost to Company, Buildings and Improvements	11,316
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	412
Gross Amount at Which Carried as of Close of Period, Land	2,294
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	11,728
Gross Amount at Which Carried as of Close of Period, Total	14,022
Accumulated Depreciation	$ (1,351)
Life on Which Building Depreciation in Income Statement is Computed	30 years
El Paso - Murchison
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	2,283
Initial Cost to Company, Buildings and Improvements	24,543
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	1,303
Gross Amount at Which Carried as of Close of Period, Land	2,283
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	25,846
Gross Amount at Which Carried as of Close of Period, Total	28,129
Accumulated Depreciation	$ (2,895)
Life on Which Building Depreciation in Income Statement is Computed	30 years
El Paso - Kenworthy
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	728
Initial Cost to Company, Buildings and Improvements	2,178
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	25
Gross Amount at Which Carried as of Close of Period, Land	728
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	2,203
Gross Amount at Which Carried as of Close of Period, Total	2,931
Accumulated Depreciation	$ (230)
Life on Which Building Depreciation in Income Statement is Computed	35 years
Pinnacle - 32 Northeast
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	408
Initial Cost to Company, Buildings and Improvements	3,232
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	91
Gross Amount at Which Carried as of Close of Period, Land	408
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	3,323
Gross Amount at Which Carried as of Close of Period, Total	3,731
Accumulated Depreciation	$ (352)
Life on Which Building Depreciation in Income Statement is Computed	33 years
Pinnacle - 4518 Union Deposit
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	617
Initial Cost to Company, Buildings and Improvements	7,305
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	15
Gross Amount at Which Carried as of Close of Period, Land	617
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	7,320
Gross Amount at Which Carried as of Close of Period, Total	7,937
Accumulated Depreciation	$ (803)
Life on Which Building Depreciation in Income Statement is Computed	31 years
Pinnacle - 4520 Union Deposit
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	169
Initial Cost to Company, Buildings and Improvements	2,055
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	169
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	2,055
Gross Amount at Which Carried as of Close of Period, Total	2,224
Accumulated Depreciation	$ (244)
Life on Which Building Depreciation in Income Statement is Computed	28 years
Pinnacle - 240 Grandview
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	321
Initial Cost to Company, Buildings and Improvements	4,242
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	321
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	4,242
Gross Amount at Which Carried as of Close of Period, Total	4,563
Accumulated Depreciation	$ (411)
Life on Which Building Depreciation in Income Statement is Computed	35 years
Pinnacle - Market Place Way
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	808
Initial Cost to Company, Buildings and Improvements	2,383
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	6
Gross Amount at Which Carried as of Close of Period, Land	808
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	2,389
Gross Amount at Which Carried as of Close of Period, Total	3,197
Accumulated Depreciation	$ (314)
Life on Which Building Depreciation in Income Statement is Computed	35 years
CRHS - 2000 10th Avenue
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	380
Initial Cost to Company, Buildings and Improvements	2,737
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	14
Gross Amount at Which Carried as of Close of Period, Land	380
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	2,751
Gross Amount at Which Carried as of Close of Period, Total	3,131
Accumulated Depreciation	$ (415)
Life on Which Building Depreciation in Income Statement is Computed	22 years
CRHS - 1942 North Avenue
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	91
Initial Cost to Company, Buildings and Improvements	273
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	91
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	273
Gross Amount at Which Carried as of Close of Period, Total	364
Accumulated Depreciation	$ (73)
Life on Which Building Depreciation in Income Statement is Computed	12 years
CRHS - 920 18th Street
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	110
Initial Cost to Company, Buildings and Improvements	281
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	110
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	281
Gross Amount at Which Carried as of Close of Period, Total	391
Accumulated Depreciation	$ (113)
Life on Which Building Depreciation in Income Statement is Computed	8 years
CRHS - 1900 10th Avenue
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	474
Initial Cost to Company, Buildings and Improvements	5,580
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	131
Gross Amount at Which Carried as of Close of Period, Land	474
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	5,711
Gross Amount at Which Carried as of Close of Period, Total	6,185
Accumulated Depreciation	$ (747)
Life on Which Building Depreciation in Income Statement is Computed	26 years
CRHS - 1800 10th Avenue
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	539
Initial Cost to Company, Buildings and Improvements	5,238
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	19
Gross Amount at Which Carried as of Close of Period, Land	539
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	5,257
Gross Amount at Which Carried as of Close of Period, Total	5,796
Accumulated Depreciation	$ (615)
Life on Which Building Depreciation in Income Statement is Computed	28 years
CRHS - 705 17th Street
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	372
Initial Cost to Company, Buildings and Improvements	2,346
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	278
Gross Amount at Which Carried as of Close of Period, Land	372
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	2,624
Gross Amount at Which Carried as of Close of Period, Total	2,996
Accumulated Depreciation	$ (582)
Life on Which Building Depreciation in Income Statement is Computed	15 years
CRHS - 615 19th Street
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	75
Initial Cost to Company, Buildings and Improvements	113
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	75
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	113
Gross Amount at Which Carried as of Close of Period, Total	188
Accumulated Depreciation	$ (107)
Life on Which Building Depreciation in Income Statement is Computed	3 years
CRHS - 1968 North Avenue
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	89
Initial Cost to Company, Buildings and Improvements	32
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	89
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	32
Gross Amount at Which Carried as of Close of Period, Total	121
Accumulated Depreciation	$ (26)
Life on Which Building Depreciation in Income Statement is Computed	4 years
CRHS - 633 19th Street
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	99
Initial Cost to Company, Buildings and Improvements	255
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	99
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	255
Gross Amount at Which Carried as of Close of Period, Total	354
Accumulated Depreciation	$ (92)
Life on Which Building Depreciation in Income Statement is Computed	9 years
CRHS - 500 18th Street
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	430
Initial Cost to Company, Buildings and Improvements	170
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	205
Gross Amount at Which Carried as of Close of Period, Land	430
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	375
Gross Amount at Which Carried as of Close of Period, Total	805
Accumulated Depreciation	$ (111)
Life on Which Building Depreciation in Income Statement is Computed	8 years
CRHS - 2200 Hamilton Road
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	267
Initial Cost to Company, Buildings and Improvements	1,579
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	42
Gross Amount at Which Carried as of Close of Period, Land	267
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	1,621
Gross Amount at Which Carried as of Close of Period, Total	1,888
Accumulated Depreciation	$ (248)
Life on Which Building Depreciation in Income Statement is Computed	22 years
CRHS - 1810 Stadium Drive
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	202
Initial Cost to Company, Buildings and Improvements	149
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	26
Gross Amount at Which Carried as of Close of Period, Land	202
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	175
Gross Amount at Which Carried as of Close of Period, Total	377
Accumulated Depreciation	$ (94)
Life on Which Building Depreciation in Income Statement is Computed	30 years
Carle Danville MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	607
Initial Cost to Company, Buildings and Improvements	7,136
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	607
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	7,136
Gross Amount at Which Carried as of Close of Period, Total	7,743
Accumulated Depreciation	$ (713)
Life on Which Building Depreciation in Income Statement is Computed	33 years
Middletown Medical - 111 Maltese
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	670
Initial Cost to Company, Buildings and Improvements	9,921
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	37
Gross Amount at Which Carried as of Close of Period, Land	670
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	9,958
Gross Amount at Which Carried as of Close of Period, Total	10,628
Accumulated Depreciation	$ (909)
Life on Which Building Depreciation in Income Statement is Computed	35 years
Middletown Medical - 2 Edgewater
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	200
Initial Cost to Company, Buildings and Improvements	2,966
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	11
Gross Amount at Which Carried as of Close of Period, Land	200
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	2,977
Gross Amount at Which Carried as of Close of Period, Total	3,177
Accumulated Depreciation	$ (272)
Life on Which Building Depreciation in Income Statement is Computed	35 years
Napoleon Medical Office Building
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,202
Initial Cost to Company, Buildings and Improvements	7,412
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	763
Gross Amount at Which Carried as of Close of Period, Land	1,202
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	8,175
Gross Amount at Which Carried as of Close of Period, Total	9,377
Accumulated Depreciation	$ (998)
Life on Which Building Depreciation in Income Statement is Computed	25 years
West TN Bone & Joint - Physicians Drive
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,661
Initial Cost to Company, Buildings and Improvements	2,960
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,661
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	2,960
Gross Amount at Which Carried as of Close of Period, Total	4,621
Accumulated Depreciation	$ (269)
Life on Which Building Depreciation in Income Statement is Computed	35 years
West TN Bone & Joint
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,250
Initial Cost to Company, Buildings and Improvements	5,210
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,250
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	5,210
Gross Amount at Which Carried as of Close of Period, Total	6,460
Accumulated Depreciation	$ (543)
Life on Which Building Depreciation in Income Statement is Computed	31 years
Edina MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	504
Initial Cost to Company, Buildings and Improvements	10,006
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	959
Gross Amount at Which Carried as of Close of Period, Land	504
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	10,965
Gross Amount at Which Carried as of Close of Period, Total	11,469
Accumulated Depreciation	$ (1,657)
Life on Which Building Depreciation in Income Statement is Computed	24 years
Crystal MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	945
Initial Cost to Company, Buildings and Improvements	11,862
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	945
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	11,862
Gross Amount at Which Carried as of Close of Period, Total	12,807
Accumulated Depreciation	$ (879)
Life on Which Building Depreciation in Income Statement is Computed	47 years
Savage MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 5,449
Initial Cost to Company, Land	1,281
Initial Cost to Company, Buildings and Improvements	10,021
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,281
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	10,021
Gross Amount at Which Carried as of Close of Period, Total	11,302
Accumulated Depreciation	$ (770)
Life on Which Building Depreciation in Income Statement is Computed	48 years
Dell Road MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	800
Initial Cost to Company, Buildings and Improvements	4,520
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	29
Gross Amount at Which Carried as of Close of Period, Land	800
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	4,549
Gross Amount at Which Carried as of Close of Period, Total	5,349
Accumulated Depreciation	$ (385)
Life on Which Building Depreciation in Income Statement is Computed	43 years
Columbus MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	845
Initial Cost to Company, Buildings and Improvements	2,708
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	7
Gross Amount at Which Carried as of Close of Period, Land	845
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	2,715
Gross Amount at Which Carried as of Close of Period, Total	3,560
Accumulated Depreciation	$ (432)
Life on Which Building Depreciation in Income Statement is Computed	22 years
Methodist Sports MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,050
Initial Cost to Company, Buildings and Improvements	8,556
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,050
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	8,556
Gross Amount at Which Carried as of Close of Period, Total	9,606
Accumulated Depreciation	$ (795)
Life on Which Building Depreciation in Income Statement is Computed	33 years
Vadnais Heights MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	2,751
Initial Cost to Company, Buildings and Improvements	12,233
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	2,751
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	12,233
Gross Amount at Which Carried as of Close of Period, Total	14,984
Accumulated Depreciation	$ (1,069)
Life on Which Building Depreciation in Income Statement is Computed	43 years
Minnetonka MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,770
Initial Cost to Company, Buildings and Improvements	19,797
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,770
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	19,797
Gross Amount at Which Carried as of Close of Period, Total	21,567
Accumulated Depreciation	$ (1,456)
Life on Which Building Depreciation in Income Statement is Computed	49 years
Jamestown MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	656
Initial Cost to Company, Buildings and Improvements	9,440
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	656
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	9,440
Gross Amount at Which Carried as of Close of Period, Total	10,096
Accumulated Depreciation	$ (855)
Life on Which Building Depreciation in Income Statement is Computed	43 years
Indiana American II
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	862
Initial Cost to Company, Buildings and Improvements	6,901
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	600
Gross Amount at Which Carried as of Close of Period, Land	862
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	7,501
Gross Amount at Which Carried as of Close of Period, Total	8,363
Accumulated Depreciation	$ (599)
Life on Which Building Depreciation in Income Statement is Computed	38 years
Indiana American III
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	741
Initial Cost to Company, Buildings and Improvements	1,846
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	185
Gross Amount at Which Carried as of Close of Period, Land	741
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	2,031
Gross Amount at Which Carried as of Close of Period, Total	2,772
Accumulated Depreciation	$ (313)
Life on Which Building Depreciation in Income Statement is Computed	31 years
Indiana American IV
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	771
Initial Cost to Company, Buildings and Improvements	1,928
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	77
Gross Amount at Which Carried as of Close of Period, Land	771
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	2,005
Gross Amount at Which Carried as of Close of Period, Total	2,776
Accumulated Depreciation	$ (205)
Life on Which Building Depreciation in Income Statement is Computed	31 years
Southpointe
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	563
Initial Cost to Company, Buildings and Improvements	1,741
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	259
Gross Amount at Which Carried as of Close of Period, Land	563
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	2,000
Gross Amount at Which Carried as of Close of Period, Total	2,563
Accumulated Depreciation	$ (284)
Life on Which Building Depreciation in Income Statement is Computed	27 years
Minnesota Eye MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,143
Initial Cost to Company, Buildings and Improvements	7,470
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,143
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	7,470
Gross Amount at Which Carried as of Close of Period, Total	8,613
Accumulated Depreciation	$ (592)
Life on Which Building Depreciation in Income Statement is Computed	44 years
Baylor Cancer Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	855
Initial Cost to Company, Buildings and Improvements	6,007
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	32
Gross Amount at Which Carried as of Close of Period, Land	855
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	6,039
Gross Amount at Which Carried as of Close of Period, Total	6,894
Accumulated Depreciation	$ (427)
Life on Which Building Depreciation in Income Statement is Computed	43 years
Bridgeport Medical Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,397
Initial Cost to Company, Buildings and Improvements	10,435
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	47
Gross Amount at Which Carried as of Close of Period, Land	1,397
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	10,482
Gross Amount at Which Carried as of Close of Period, Total	11,879
Accumulated Depreciation	$ (899)
Life on Which Building Depreciation in Income Statement is Computed	35 years
Renaissance Office Building
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,379
Initial Cost to Company, Buildings and Improvements	4,182
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	2,834
Gross Amount at Which Carried as of Close of Period, Land	1,379
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	7,016
Gross Amount at Which Carried as of Close of Period, Total	8,395
Accumulated Depreciation	$ (1,078)
Life on Which Building Depreciation in Income Statement is Computed	15 years
Calkins 125
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	534
Initial Cost to Company, Buildings and Improvements	10,164
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	326
Gross Amount at Which Carried as of Close of Period, Land	534
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	10,490
Gross Amount at Which Carried as of Close of Period, Total	11,024
Accumulated Depreciation	$ (1,159)
Life on Which Building Depreciation in Income Statement is Computed	32 years
Calkins 200
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	210
Initial Cost to Company, Buildings and Improvements	3,317
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	32
Gross Amount at Which Carried as of Close of Period, Land	210
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	3,349
Gross Amount at Which Carried as of Close of Period, Total	3,559
Accumulated Depreciation	$ (335)
Life on Which Building Depreciation in Income Statement is Computed	38 years
Calkins 300
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	372
Initial Cost to Company, Buildings and Improvements	6,645
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	24
Gross Amount at Which Carried as of Close of Period, Land	372
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	6,669
Gross Amount at Which Carried as of Close of Period, Total	7,041
Accumulated Depreciation	$ (652)
Life on Which Building Depreciation in Income Statement is Computed	39 years
Calkins 400
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	353
Initial Cost to Company, Buildings and Improvements	8,226
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	34
Gross Amount at Which Carried as of Close of Period, Land	353
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	8,260
Gross Amount at Which Carried as of Close of Period, Total	8,613
Accumulated Depreciation	$ (864)
Life on Which Building Depreciation in Income Statement is Computed	39 years
Calkins 500
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	282
Initial Cost to Company, Buildings and Improvements	7,074
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	28
Gross Amount at Which Carried as of Close of Period, Land	282
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	7,102
Gross Amount at Which Carried as of Close of Period, Total	7,384
Accumulated Depreciation	$ (589)
Life on Which Building Depreciation in Income Statement is Computed	41 years
Avalon Park Florida Hospital MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,041
Initial Cost to Company, Buildings and Improvements	10,685
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,041
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	10,685
Gross Amount at Which Carried as of Close of Period, Total	11,726
Accumulated Depreciation	$ (780)
Life on Which Building Depreciation in Income Statement is Computed	41 years
Premier Surgery Center of Louisville
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,106
Initial Cost to Company, Buildings and Improvements	5,437
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,106
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	5,437
Gross Amount at Which Carried as of Close of Period, Total	6,543
Accumulated Depreciation	$ (374)
Life on Which Building Depreciation in Income Statement is Computed	43 years
Baton Rouge MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	711
Initial Cost to Company, Buildings and Improvements	7,720
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	711
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	7,720
Gross Amount at Which Carried as of Close of Period, Total	8,431
Accumulated Depreciation	$ (636)
Life on Which Building Depreciation in Income Statement is Computed	35 years
Healthpark Medical Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	17,624
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	17,624
Gross Amount at Which Carried as of Close of Period, Total	17,624
Accumulated Depreciation	$ (1,434)
Life on Which Building Depreciation in Income Statement is Computed	36 years
Plaza HCA MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,112
Initial Cost to Company, Buildings and Improvements	12,553
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,112
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	12,553
Gross Amount at Which Carried as of Close of Period, Total	13,665
Accumulated Depreciation	$ (903)
Life on Which Building Depreciation in Income Statement is Computed	39 years
Northern Ohio Medical Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	644
Initial Cost to Company, Buildings and Improvements	9,162
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	644
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	9,162
Gross Amount at Which Carried as of Close of Period, Total	9,806
Accumulated Depreciation	$ (1,225)
Life on Which Building Depreciation in Income Statement is Computed	20 years
University of Michigan - Northville MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	2,200
Initial Cost to Company, Buildings and Improvements	8,627
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	166
Gross Amount at Which Carried as of Close of Period, Land	2,200
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	8,793
Gross Amount at Which Carried as of Close of Period, Total	10,993
Accumulated Depreciation	$ (808)
Life on Which Building Depreciation in Income Statement is Computed	30 years
Coon Rapids Medical Center MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	607
Initial Cost to Company, Buildings and Improvements	5,857
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	607
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	5,857
Gross Amount at Which Carried as of Close of Period, Total	6,464
Accumulated Depreciation	$ (468)
Life on Which Building Depreciation in Income Statement is Computed	35 years
Premier Landmark MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	872
Initial Cost to Company, Buildings and Improvements	10,537
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	872
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	10,537
Gross Amount at Which Carried as of Close of Period, Total	11,409
Accumulated Depreciation	$ (730)
Life on Which Building Depreciation in Income Statement is Computed	39 years
Palm Beach ASC
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	2,576
Initial Cost to Company, Buildings and Improvements	7,675
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	2,576
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	7,675
Gross Amount at Which Carried as of Close of Period, Total	10,251
Accumulated Depreciation	$ (507)
Life on Which Building Depreciation in Income Statement is Computed	40 years
Brookstone Physician Center MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	1,913
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	1,913
Gross Amount at Which Carried as of Close of Period, Total	1,913
Accumulated Depreciation	$ (166)
Life on Which Building Depreciation in Income Statement is Computed	31 years
Jackson Woman's Clinic MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	555
Initial Cost to Company, Buildings and Improvements	3,800
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	19
Gross Amount at Which Carried as of Close of Period, Land	555
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	3,819
Gross Amount at Which Carried as of Close of Period, Total	4,374
Accumulated Depreciation	$ (293)
Life on Which Building Depreciation in Income Statement is Computed	35 years
Hillside Medical Center MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	812
Initial Cost to Company, Buildings and Improvements	13,217
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	63
Gross Amount at Which Carried as of Close of Period, Land	812
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	13,280
Gross Amount at Which Carried as of Close of Period, Total	14,092
Accumulated Depreciation	$ (941)
Life on Which Building Depreciation in Income Statement is Computed	35 years
Randall Road MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,124
Initial Cost to Company, Buildings and Improvements	15,404
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	486
Gross Amount at Which Carried as of Close of Period, Land	1,124
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	15,890
Gross Amount at Which Carried as of Close of Period, Total	17,014
Accumulated Depreciation	$ (1,054)
Life on Which Building Depreciation in Income Statement is Computed	38 years
Medical Specialists of Palm Beach MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	7,560
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	6
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	7,566
Gross Amount at Which Carried as of Close of Period, Total	7,566
Accumulated Depreciation	$ (541)
Life on Which Building Depreciation in Income Statement is Computed	37 years
OhioHealth - SW Health Center MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,363
Initial Cost to Company, Buildings and Improvements	8,516
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,363
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	8,516
Gross Amount at Which Carried as of Close of Period, Total	9,879
Accumulated Depreciation	$ (637)
Life on Which Building Depreciation in Income Statement is Computed	37 years
Trios Health MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	55,178
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	3,795
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	58,973
Gross Amount at Which Carried as of Close of Period, Total	58,973
Accumulated Depreciation	$ (3,169)
Life on Which Building Depreciation in Income Statement is Computed	45 years
IMS - Paradise Valley MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	25,893
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	14
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	25,907
Gross Amount at Which Carried as of Close of Period, Total	25,907
Accumulated Depreciation	$ (1,638)
Life on Which Building Depreciation in Income Statement is Computed	43 years
IMS - Avondale MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,818
Initial Cost to Company, Buildings and Improvements	18,108
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	10
Gross Amount at Which Carried as of Close of Period, Land	1,818
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	18,118
Gross Amount at Which Carried as of Close of Period, Total	19,936
Accumulated Depreciation	$ (1,020)
Life on Which Building Depreciation in Income Statement is Computed	45 years
IMS - Palm Valley MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	2,666
Initial Cost to Company, Buildings and Improvements	28,655
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	2,666
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	28,655
Gross Amount at Which Carried as of Close of Period, Total	31,321
Accumulated Depreciation	$ (1,683)
Life on Which Building Depreciation in Income Statement is Computed	43 years
IMS - North Mountain MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	42,877
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	495
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	43,372
Gross Amount at Which Carried as of Close of Period, Total	43,372
Accumulated Depreciation	$ (2,372)
Life on Which Building Depreciation in Income Statement is Computed	47 years
Memorial Hermann - Phase I
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	822
Initial Cost to Company, Buildings and Improvements	6,797
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	19
Gross Amount at Which Carried as of Close of Period, Land	822
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	6,816
Gross Amount at Which Carried as of Close of Period, Total	7,638
Accumulated Depreciation	$ (440)
Life on Which Building Depreciation in Income Statement is Computed	39 years
Memorial Hermann - Phase II
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,560
Initial Cost to Company, Buildings and Improvements	25,601
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	6
Gross Amount at Which Carried as of Close of Period, Land	1,560
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	25,607
Gross Amount at Which Carried as of Close of Period, Total	27,167
Accumulated Depreciation	$ (1,573)
Life on Which Building Depreciation in Income Statement is Computed	40 years
New Albany Medical Center MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,600
Initial Cost to Company, Buildings and Improvements	8,505
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	216
Gross Amount at Which Carried as of Close of Period, Land	1,600
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	8,721
Gross Amount at Which Carried as of Close of Period, Total	10,321
Accumulated Depreciation	$ (613)
Life on Which Building Depreciation in Income Statement is Computed	37 years
Fountain Hills Medical Campus MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	2,593
Initial Cost to Company, Buildings and Improvements	7,635
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	618
Gross Amount at Which Carried as of Close of Period, Land	2,593
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	8,253
Gross Amount at Which Carried as of Close of Period, Total	10,846
Accumulated Depreciation	$ (502)
Life on Which Building Depreciation in Income Statement is Computed	39 years
Fairhope MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	640
Initial Cost to Company, Buildings and Improvements	5,227
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	568
Gross Amount at Which Carried as of Close of Period, Land	640
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	5,795
Gross Amount at Which Carried as of Close of Period, Total	6,435
Accumulated Depreciation	$ (349)
Life on Which Building Depreciation in Income Statement is Computed	38 years
Foley MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	365
Initial Cost to Company, Buildings and Improvements	732
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	365
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	732
Gross Amount at Which Carried as of Close of Period, Total	1,097
Accumulated Depreciation	$ (48)
Life on Which Building Depreciation in Income Statement is Computed	40 years
Foley Venture
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	420
Initial Cost to Company, Buildings and Improvements	1,118
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	420
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	1,118
Gross Amount at Which Carried as of Close of Period, Total	1,538
Accumulated Depreciation	$ (73)
Life on Which Building Depreciation in Income Statement is Computed	38 years
North Okaloosa MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	190
Initial Cost to Company, Buildings and Improvements	1,010
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	190
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	1,010
Gross Amount at Which Carried as of Close of Period, Total	1,200
Accumulated Depreciation	$ (61)
Life on Which Building Depreciation in Income Statement is Computed	41 years
Commons on North Davis
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	380
Initial Cost to Company, Buildings and Improvements	1,237
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	380
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	1,237
Gross Amount at Which Carried as of Close of Period, Total	1,617
Accumulated Depreciation	$ (75)
Life on Which Building Depreciation in Income Statement is Computed	41 years
Sorrento Road
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	170
Initial Cost to Company, Buildings and Improvements	894
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	170
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	894
Gross Amount at Which Carried as of Close of Period, Total	1,064
Accumulated Depreciation	$ (55)
Life on Which Building Depreciation in Income Statement is Computed	41 years
Breakfast Point Medical Park
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	817
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	817
Gross Amount at Which Carried as of Close of Period, Total	817
Accumulated Depreciation	$ (47)
Life on Which Building Depreciation in Income Statement is Computed	42 years
Panama City Beach
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	739
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	739
Gross Amount at Which Carried as of Close of Period, Total	739
Accumulated Depreciation	$ (42)
Life on Which Building Depreciation in Income Statement is Computed	42 years
Perdido Medical Park
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	100
Initial Cost to Company, Buildings and Improvements	1,147
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	100
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	1,147
Gross Amount at Which Carried as of Close of Period, Total	1,247
Accumulated Depreciation	$ (69)
Life on Which Building Depreciation in Income Statement is Computed	41 years
Ft. Walton Beach
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	230
Initial Cost to Company, Buildings and Improvements	914
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	230
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	914
Gross Amount at Which Carried as of Close of Period, Total	1,144
Accumulated Depreciation	$ (63)
Life on Which Building Depreciation in Income Statement is Computed	35 years
Panama City
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	661
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	661
Gross Amount at Which Carried as of Close of Period, Total	661
Accumulated Depreciation	$ (41)
Life on Which Building Depreciation in Income Statement is Computed	38 years
Pensacola - Catalyst
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	220
Initial Cost to Company, Buildings and Improvements	1,685
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	220
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	1,685
Gross Amount at Which Carried as of Close of Period, Total	1,905
Accumulated Depreciation	$ (104)
Life on Which Building Depreciation in Income Statement is Computed	39 years
Arete Surgical Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	399
Initial Cost to Company, Buildings and Improvements	6,667
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	399
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	6,667
Gross Amount at Which Carried as of Close of Period, Total	7,066
Accumulated Depreciation	$ (337)
Life on Which Building Depreciation in Income Statement is Computed	45 years
Cambridge Professional Center MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	590
Initial Cost to Company, Buildings and Improvements	8,520
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	130
Gross Amount at Which Carried as of Close of Period, Land	590
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	8,650
Gross Amount at Which Carried as of Close of Period, Total	9,240
Accumulated Depreciation	$ (590)
Life on Which Building Depreciation in Income Statement is Computed	35 years
HonorHealth 44th Street MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	515
Initial Cost to Company, Buildings and Improvements	3,884
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	1,320
Gross Amount at Which Carried as of Close of Period, Land	515
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	5,204
Gross Amount at Which Carried as of Close of Period, Total	5,719
Accumulated Depreciation	$ (370)
Life on Which Building Depreciation in Income Statement is Computed	28 years
Mercy Medical Center MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,201
Initial Cost to Company, Buildings and Improvements	6,778
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,201
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	6,778
Gross Amount at Which Carried as of Close of Period, Total	7,979
Accumulated Depreciation	$ (389)
Life on Which Building Depreciation in Income Statement is Computed	40 years
Nashville MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,555
Initial Cost to Company, Buildings and Improvements	39,713
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	250
Gross Amount at Which Carried as of Close of Period, Land	1,555
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	39,963
Gross Amount at Which Carried as of Close of Period, Total	41,518
Accumulated Depreciation	$ (1,771)
Life on Which Building Depreciation in Income Statement is Computed	46 years
KSF Orthopaedic MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	530
Initial Cost to Company, Buildings and Improvements	3,712
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	26
Gross Amount at Which Carried as of Close of Period, Land	530
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	3,738
Gross Amount at Which Carried as of Close of Period, Total	4,268
Accumulated Depreciation	$ (430)
Life on Which Building Depreciation in Income Statement is Computed	19 years
Great Falls Clinic MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	27,402
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	441
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	27,843
Gross Amount at Which Carried as of Close of Period, Total	27,843
Accumulated Depreciation	$ (1,482)
Life on Which Building Depreciation in Income Statement is Computed	40 years
Great Falls Hospital
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	25,262
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	25,262
Gross Amount at Which Carried as of Close of Period, Total	25,262
Accumulated Depreciation	$ (1,322)
Life on Which Building Depreciation in Income Statement is Computed	40 years
Monterey Medical Center ASC
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	380
Initial Cost to Company, Buildings and Improvements	5,064
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	380
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	5,064
Gross Amount at Which Carried as of Close of Period, Total	5,444
Accumulated Depreciation	$ (240)
Life on Which Building Depreciation in Income Statement is Computed	42 years
Physicians Medical Plaza MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	6,703
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	17
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	6,720
Gross Amount at Which Carried as of Close of Period, Total	6,720
Accumulated Depreciation	$ (412)
Life on Which Building Depreciation in Income Statement is Computed	34 years
Park Nicollet Clinic
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,941
Initial Cost to Company, Buildings and Improvements	14,555
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,941
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	14,555
Gross Amount at Which Carried as of Close of Period, Total	16,496
Accumulated Depreciation	$ (758)
Life on Which Building Depreciation in Income Statement is Computed	40 years
HEB Cancer Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	11,839
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	11,839
Gross Amount at Which Carried as of Close of Period, Total	11,839
Accumulated Depreciation	$ (548)
Life on Which Building Depreciation in Income Statement is Computed	44 years
Riverview Medical Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,313
Initial Cost to Company, Buildings and Improvements	10,243
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	63
Gross Amount at Which Carried as of Close of Period, Land	1,313
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	10,306
Gross Amount at Which Carried as of Close of Period, Total	11,619
Accumulated Depreciation	$ (638)
Life on Which Building Depreciation in Income Statement is Computed	33 years
St. Luke's Cornwall MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 9,500
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	13,017
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	13,017
Gross Amount at Which Carried as of Close of Period, Total	13,017
Accumulated Depreciation	$ (761)
Life on Which Building Depreciation in Income Statement is Computed	35 years
HonorHealth Glendale
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,770
Initial Cost to Company, Buildings and Improvements	8,089
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,770
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	8,089
Gross Amount at Which Carried as of Close of Period, Total	9,859
Accumulated Depreciation	$ (352)
Life on Which Building Depreciation in Income Statement is Computed	45 years
Columbia MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 12,000
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	16,550
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	16,550
Gross Amount at Which Carried as of Close of Period, Total	16,550
Accumulated Depreciation	$ (867)
Life on Which Building Depreciation in Income Statement is Computed	35 years
St Vincent POB 1
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	10,172
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	130
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	10,302
Gross Amount at Which Carried as of Close of Period, Total	10,302
Accumulated Depreciation	$ (1,246)
Life on Which Building Depreciation in Income Statement is Computed	15 years
St Vincent POB 2
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	48
Initial Cost to Company, Buildings and Improvements	6,624
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	144
Gross Amount at Which Carried as of Close of Period, Land	48
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	6,768
Gross Amount at Which Carried as of Close of Period, Total	6,816
Accumulated Depreciation	$ (853)
Life on Which Building Depreciation in Income Statement is Computed	15 years
St Vincent POB 3
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	75
Initial Cost to Company, Buildings and Improvements	9,433
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	353
Gross Amount at Which Carried as of Close of Period, Land	75
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	9,786
Gross Amount at Which Carried as of Close of Period, Total	9,861
Accumulated Depreciation	$ (726)
Life on Which Building Depreciation in Income Statement is Computed	25 years
Emerson Medical Building
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,590
Initial Cost to Company, Buildings and Improvements	9,853
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	114
Gross Amount at Which Carried as of Close of Period, Land	1,590
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	9,967
Gross Amount at Which Carried as of Close of Period, Total	11,557
Accumulated Depreciation	$ (522)
Life on Which Building Depreciation in Income Statement is Computed	35 years
Patient Partners Surgery Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	203
Initial Cost to Company, Buildings and Improvements	3,376
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	203
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	3,376
Gross Amount at Which Carried as of Close of Period, Total	3,579
Accumulated Depreciation	$ (163)
Life on Which Building Depreciation in Income Statement is Computed	40 years
Eye Associates of NM - Santa Fe
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	900
Initial Cost to Company, Buildings and Improvements	6,604
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	900
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	6,604
Gross Amount at Which Carried as of Close of Period, Total	7,504
Accumulated Depreciation	$ (366)
Life on Which Building Depreciation in Income Statement is Computed	35 years
Eye Associates of NM - Albuquerque
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,020
Initial Cost to Company, Buildings and Improvements	7,832
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,020
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	7,832
Gross Amount at Which Carried as of Close of Period, Total	8,852
Accumulated Depreciation	$ (384)
Life on Which Building Depreciation in Income Statement is Computed	40 years
Gardendale Surgery Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	200
Initial Cost to Company, Buildings and Improvements	5,732
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	200
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	5,732
Gross Amount at Which Carried as of Close of Period, Total	5,932
Accumulated Depreciation	$ (250)
Life on Which Building Depreciation in Income Statement is Computed	42 years
HealthEast - Curve Crest
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	409
Initial Cost to Company, Buildings and Improvements	3,279
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	409
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	3,279
Gross Amount at Which Carried as of Close of Period, Total	3,688
Accumulated Depreciation	$ (148)
Life on Which Building Depreciation in Income Statement is Computed	43 years
HealthEast - Victor Gardens
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	572
Initial Cost to Company, Buildings and Improvements	4,400
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	51
Gross Amount at Which Carried as of Close of Period, Land	572
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	4,451
Gross Amount at Which Carried as of Close of Period, Total	5,023
Accumulated Depreciation	$ (209)
Life on Which Building Depreciation in Income Statement is Computed	41 years
NOMS - Clyde
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	440
Initial Cost to Company, Buildings and Improvements	5,948
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	440
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	5,948
Gross Amount at Which Carried as of Close of Period, Total	6,388
Accumulated Depreciation	$ (240)
Life on Which Building Depreciation in Income Statement is Computed	44 years
Blandford MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	203
Initial Cost to Company, Buildings and Improvements	2,386
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	203
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	2,386
Gross Amount at Which Carried as of Close of Period, Total	2,589
Accumulated Depreciation	$ (107)
Life on Which Building Depreciation in Income Statement is Computed	40 years
Cardwell MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	8,348
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	138
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	8,486
Gross Amount at Which Carried as of Close of Period, Total	8,486
Accumulated Depreciation	$ (361)
Life on Which Building Depreciation in Income Statement is Computed	42 years
Dacono Neighborhood Health
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	2,258
Initial Cost to Company, Buildings and Improvements	2,911
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	20
Gross Amount at Which Carried as of Close of Period, Land	2,258
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	2,931
Gross Amount at Which Carried as of Close of Period, Total	5,189
Accumulated Depreciation	$ (173)
Life on Which Building Depreciation in Income Statement is Computed	44 years
Franciscan Health
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	711
Initial Cost to Company, Buildings and Improvements	9,096
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	65
Gross Amount at Which Carried as of Close of Period, Land	711
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	9,161
Gross Amount at Which Carried as of Close of Period, Total	9,872
Accumulated Depreciation	$ (1,017)
Life on Which Building Depreciation in Income Statement is Computed	15 years
Grand Island Specialty Clinic
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	102
Initial Cost to Company, Buildings and Improvements	2,802
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	150
Gross Amount at Which Carried as of Close of Period, Land	102
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	2,952
Gross Amount at Which Carried as of Close of Period, Total	3,054
Accumulated Depreciation	$ (136)
Life on Which Building Depreciation in Income Statement is Computed	42 years
Hot Springs MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	305
Initial Cost to Company, Buildings and Improvements	3,309
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	65
Gross Amount at Which Carried as of Close of Period, Land	305
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	3,374
Gross Amount at Which Carried as of Close of Period, Total	3,679
Accumulated Depreciation	$ (209)
Life on Which Building Depreciation in Income Statement is Computed	30 years
Jewish Medical Center East
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	81,248
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	32
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	81,280
Gross Amount at Which Carried as of Close of Period, Total	81,280
Accumulated Depreciation	$ (3,138)
Life on Which Building Depreciation in Income Statement is Computed	45 years
Jewish Medical Center South MOB - 1
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	15,861
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	225
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	16,086
Gross Amount at Which Carried as of Close of Period, Total	16,086
Accumulated Depreciation	$ (787)
Life on Which Building Depreciation in Income Statement is Computed	39 years
Jewish Medical Plaza I
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	8,808
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	172
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	8,980
Gross Amount at Which Carried as of Close of Period, Total	8,980
Accumulated Depreciation	$ (451)
Life on Which Building Depreciation in Income Statement is Computed	35 years
Jewish Medical Plaza II
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	5,216
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	1,070
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	6,286
Gross Amount at Which Carried as of Close of Period, Total	6,286
Accumulated Depreciation	$ (592)
Life on Which Building Depreciation in Income Statement is Computed	15 years
Jewish OCC
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	35,703
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	108
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	35,811
Gross Amount at Which Carried as of Close of Period, Total	35,811
Accumulated Depreciation	$ (1,767)
Life on Which Building Depreciation in Income Statement is Computed	34 years
Lexington Surgery Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,229
Initial Cost to Company, Buildings and Improvements	18,914
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	363
Gross Amount at Which Carried as of Close of Period, Land	1,229
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	19,277
Gross Amount at Which Carried as of Close of Period, Total	20,506
Accumulated Depreciation	$ (1,074)
Life on Which Building Depreciation in Income Statement is Computed	30 years
Medical Arts Pavilion
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	6,215
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	15
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	6,230
Gross Amount at Which Carried as of Close of Period, Total	6,230
Accumulated Depreciation	$ (337)
Life on Which Building Depreciation in Income Statement is Computed	33 years
Memorial Outpatient Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	4,808
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	100
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	4,908
Gross Amount at Which Carried as of Close of Period, Total	4,908
Accumulated Depreciation	$ (206)
Life on Which Building Depreciation in Income Statement is Computed	45 years
Midlands Two Professional Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	587
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	57
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	644
Gross Amount at Which Carried as of Close of Period, Total	644
Accumulated Depreciation	$ (247)
Life on Which Building Depreciation in Income Statement is Computed	5 years
Parkview MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	705
Initial Cost to Company, Buildings and Improvements	4,343
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	44
Gross Amount at Which Carried as of Close of Period, Land	705
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	4,387
Gross Amount at Which Carried as of Close of Period, Total	5,092
Accumulated Depreciation	$ (229)
Life on Which Building Depreciation in Income Statement is Computed	35 years
Peak One ASC
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	5,763
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	65
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	5,828
Gross Amount at Which Carried as of Close of Period, Total	5,828
Accumulated Depreciation	$ (238)
Life on Which Building Depreciation in Income Statement is Computed	44 years
Physicians Medical Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	5,862
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	144
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	6,006
Gross Amount at Which Carried as of Close of Period, Total	6,006
Accumulated Depreciation	$ (376)
Life on Which Building Depreciation in Income Statement is Computed	27 years
St. Alexius - Minot Medical Plaza
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	26,078
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	26,078
Gross Amount at Which Carried as of Close of Period, Total	26,078
Accumulated Depreciation	$ (1,023)
Life on Which Building Depreciation in Income Statement is Computed	49 years
St. Clare Medical Pavilion
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	9,005
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	9,005
Gross Amount at Which Carried as of Close of Period, Total	9,005
Accumulated Depreciation	$ (535)
Life on Which Building Depreciation in Income Statement is Computed	33 years
St. Joseph Medical Pavilion
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	11,497
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	31
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	11,528
Gross Amount at Which Carried as of Close of Period, Total	11,528
Accumulated Depreciation	$ (591)
Life on Which Building Depreciation in Income Statement is Computed	35 years
St. Joseph Office Park
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	3,722
Initial Cost to Company, Buildings and Improvements	12,675
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	3,228
Gross Amount at Which Carried as of Close of Period, Land	3,722
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	15,903
Gross Amount at Which Carried as of Close of Period, Total	19,625
Accumulated Depreciation	$ (1,621)
Life on Which Building Depreciation in Income Statement is Computed	14 years
St. Mary - Caritas Medical II
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	5,587
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	23
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	5,610
Gross Amount at Which Carried as of Close of Period, Total	5,610
Accumulated Depreciation	$ (283)
Life on Which Building Depreciation in Income Statement is Computed	34 years
St. Mary - Caritas Medical III
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	383
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	194
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	577
Gross Amount at Which Carried as of Close of Period, Total	577
Accumulated Depreciation	$ (266)
Life on Which Building Depreciation in Income Statement is Computed	2 years
Thornton Neighborhood Health
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,609
Initial Cost to Company, Buildings and Improvements	2,287
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,609
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	2,287
Gross Amount at Which Carried as of Close of Period, Total	3,896
Accumulated Depreciation	$ (132)
Life on Which Building Depreciation in Income Statement is Computed	43 years
Medical Village at Kissimmee
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	634
Initial Cost to Company, Buildings and Improvements	3,365
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	634
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	3,365
Gross Amount at Which Carried as of Close of Period, Total	3,999
Accumulated Depreciation	$ (149)
Life on Which Building Depreciation in Income Statement is Computed	39 years
Medical Village at Leesburg
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	802
Initial Cost to Company, Buildings and Improvements	3,047
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	802
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	3,047
Gross Amount at Which Carried as of Close of Period, Total	3,849
Accumulated Depreciation	$ (213)
Life on Which Building Depreciation in Income Statement is Computed	25 years
St. Francis MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	12,817
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	24
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	12,841
Gross Amount at Which Carried as of Close of Period, Total	12,841
Accumulated Depreciation	$ (615)
Life on Which Building Depreciation in Income Statement is Computed	38 years
Children's Hospital MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	476
Initial Cost to Company, Buildings and Improvements	4,897
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	476
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	4,897
Gross Amount at Which Carried as of Close of Period, Total	5,373
Accumulated Depreciation	$ (197)
Life on Which Building Depreciation in Income Statement is Computed	45 years
Jewish Medical Center South MOB - 2
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	27
Initial Cost to Company, Buildings and Improvements	3,827
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	27
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	3,827
Gross Amount at Which Carried as of Close of Period, Total	3,854
Accumulated Depreciation	$ (153)
Life on Which Building Depreciation in Income Statement is Computed	40 years
Good Samaritan North Annex Building
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	2,734
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	2,734
Gross Amount at Which Carried as of Close of Period, Total	2,734
Accumulated Depreciation	$ (132)
Life on Which Building Depreciation in Income Statement is Computed	37 years
NE Heart Institute Medical Building
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	19,738
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	19,738
Gross Amount at Which Carried as of Close of Period, Total	19,738
Accumulated Depreciation	$ (633)
Life on Which Building Depreciation in Income Statement is Computed	47 years
St. Vincent West MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	13,453
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	13,453
Gross Amount at Which Carried as of Close of Period, Total	13,453
Accumulated Depreciation	$ (447)
Life on Which Building Depreciation in Income Statement is Computed	49 years
Meridan MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,608
Initial Cost to Company, Buildings and Improvements	15,774
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	141
Gross Amount at Which Carried as of Close of Period, Land	1,608
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	15,915
Gross Amount at Which Carried as of Close of Period, Total	17,523
Accumulated Depreciation	$ (717)
Life on Which Building Depreciation in Income Statement is Computed	38 years
St. Mary - Caritas Medical I
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	8,774
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	283
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	9,057
Gross Amount at Which Carried as of Close of Period, Total	9,057
Accumulated Depreciation	$ (535)
Life on Which Building Depreciation in Income Statement is Computed	25 years
St. Alexius - Medical Arts Pavilion
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	12,902
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	77
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	12,979
Gross Amount at Which Carried as of Close of Period, Total	12,979
Accumulated Depreciation	$ (624)
Life on Which Building Depreciation in Income Statement is Computed	32 years
St. Alexius - Mandan Clinic
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	708
Initial Cost to Company, Buildings and Improvements	7,700
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	74
Gross Amount at Which Carried as of Close of Period, Land	708
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	7,774
Gross Amount at Which Carried as of Close of Period, Total	8,482
Accumulated Depreciation	$ (301)
Life on Which Building Depreciation in Income Statement is Computed	43 years
St. Alexius - Orthopaedic Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	13,881
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	363
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	14,244
Gross Amount at Which Carried as of Close of Period, Total	14,244
Accumulated Depreciation	$ (563)
Life on Which Building Depreciation in Income Statement is Computed	39 years
St. Alexius - Rehab Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	5,920
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	97
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	6,017
Gross Amount at Which Carried as of Close of Period, Total	6,017
Accumulated Depreciation	$ (380)
Life on Which Building Depreciation in Income Statement is Computed	25 years
St. Alexius - Tech & Ed
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	16,688
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	2
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	16,690
Gross Amount at Which Carried as of Close of Period, Total	16,690
Accumulated Depreciation	$ (679)
Life on Which Building Depreciation in Income Statement is Computed	38 years
Good Samaritan MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	24,154
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	72
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	24,226
Gross Amount at Which Carried as of Close of Period, Total	24,226
Accumulated Depreciation	$ (820)
Life on Which Building Depreciation in Income Statement is Computed	45 years
Lakeside Two Professional Building
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	13,358
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	144
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	13,502
Gross Amount at Which Carried as of Close of Period, Total	13,502
Accumulated Depreciation	$ (532)
Life on Which Building Depreciation in Income Statement is Computed	38 years
Lakeside Wellness Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	10,177
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	190
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	10,367
Gross Amount at Which Carried as of Close of Period, Total	10,367
Accumulated Depreciation	$ (397)
Life on Which Building Depreciation in Income Statement is Computed	39 years
McAuley Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,427
Initial Cost to Company, Buildings and Improvements	17,020
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	3
Gross Amount at Which Carried as of Close of Period, Land	1,427
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	17,023
Gross Amount at Which Carried as of Close of Period, Total	18,450
Accumulated Depreciation	$ (927)
Life on Which Building Depreciation in Income Statement is Computed	30 years
Memorial Health Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	33,967
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	146
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	34,113
Gross Amount at Which Carried as of Close of Period, Total	34,113
Accumulated Depreciation	$ (1,517)
Life on Which Building Depreciation in Income Statement is Computed	35 years
Missionary Ridge MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	7,223
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	1,205
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	8,428
Gross Amount at Which Carried as of Close of Period, Total	8,428
Accumulated Depreciation	$ (1,089)
Life on Which Building Depreciation in Income Statement is Computed	10 years
Pilot Medical Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,419
Initial Cost to Company, Buildings and Improvements	14,528
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	6
Gross Amount at Which Carried as of Close of Period, Land	1,419
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	14,534
Gross Amount at Which Carried as of Close of Period, Total	15,953
Accumulated Depreciation	$ (666)
Life on Which Building Depreciation in Income Statement is Computed	35 years
St. Joseph Medical Clinic
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	16,427
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	32
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	16,459
Gross Amount at Which Carried as of Close of Period, Total	16,459
Accumulated Depreciation	$ (828)
Life on Which Building Depreciation in Income Statement is Computed	30 years
Woodlands Medical Arts Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	19,168
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	198
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	19,366
Gross Amount at Which Carried as of Close of Period, Total	19,366
Accumulated Depreciation	$ (867)
Life on Which Building Depreciation in Income Statement is Computed	35 years
FESC MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	12,702
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	181
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	12,883
Gross Amount at Which Carried as of Close of Period, Total	12,883
Accumulated Depreciation	$ (961)
Life on Which Building Depreciation in Income Statement is Computed	22 years
Prairie Care MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	525
Initial Cost to Company, Buildings and Improvements	3,099
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	525
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	3,099
Gross Amount at Which Carried as of Close of Period, Total	3,624
Accumulated Depreciation	$ (113)
Life on Which Building Depreciation in Income Statement is Computed	45 years
Springwoods MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	3,821
Initial Cost to Company, Buildings and Improvements	14,830
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	3,492
Gross Amount at Which Carried as of Close of Period, Land	3,821
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	18,322
Gross Amount at Which Carried as of Close of Period, Total	22,143
Accumulated Depreciation	$ (549)
Life on Which Building Depreciation in Income Statement is Computed	44 years
Unity - ASC, Imaging & MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	960
Initial Cost to Company, Buildings and Improvements	9,991
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	960
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	9,991
Gross Amount at Which Carried as of Close of Period, Total	10,951
Accumulated Depreciation	$ (429)
Life on Which Building Depreciation in Income Statement is Computed	35 years
Unity - Medical Pavilion
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,070
Initial Cost to Company, Buildings and Improvements	12,454
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,070
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	12,454
Gross Amount at Which Carried as of Close of Period, Total	13,524
Accumulated Depreciation	$ (535)
Life on Which Building Depreciation in Income Statement is Computed	35 years
Unity - Faith, Hope & Love
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	280
Initial Cost to Company, Buildings and Improvements	1,862
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	280
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	1,862
Gross Amount at Which Carried as of Close of Period, Total	2,142
Accumulated Depreciation	$ (80)
Life on Which Building Depreciation in Income Statement is Computed	35 years
Unity - Immediate Care & OCC
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	300
Initial Cost to Company, Buildings and Improvements	1,833
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	300
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	1,833
Gross Amount at Which Carried as of Close of Period, Total	2,133
Accumulated Depreciation	$ (75)
Life on Which Building Depreciation in Income Statement is Computed	37 years
Medical Village at Maitland
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	2,393
Initial Cost to Company, Buildings and Improvements	18,543
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	2,393
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	18,543
Gross Amount at Which Carried as of Close of Period, Total	20,936
Accumulated Depreciation	$ (613)
Life on Which Building Depreciation in Income Statement is Computed	44 years
Tri-State Orthopaedics MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,580
Initial Cost to Company, Buildings and Improvements	14,162
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,580
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	14,162
Gross Amount at Which Carried as of Close of Period, Total	15,742
Accumulated Depreciation	$ (553)
Life on Which Building Depreciation in Income Statement is Computed	37 years
Maury Regional Healthcare MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	15,619
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	15,619
Gross Amount at Which Carried as of Close of Period, Total	15,619
Accumulated Depreciation	$ (503)
Life on Which Building Depreciation in Income Statement is Computed	41 years
Spring Ridge Medical Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	28
Initial Cost to Company, Buildings and Improvements	4,943
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	28
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	4,943
Gross Amount at Which Carried as of Close of Period, Total	4,971
Accumulated Depreciation	$ (177)
Life on Which Building Depreciation in Income Statement is Computed	37 years
Doctors Community Hospital POB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	23,034
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	23,034
Gross Amount at Which Carried as of Close of Period, Total	23,034
Accumulated Depreciation	$ (602)
Life on Which Building Depreciation in Income Statement is Computed	48 years
Gig Harbor Medical Pavilion
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	4,791
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	1,768
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	6,559
Gross Amount at Which Carried as of Close of Period, Total	6,559
Accumulated Depreciation	$ (271)
Life on Which Building Depreciation in Income Statement is Computed	30 years
Midlands One Professional Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	14,922
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	14,922
Gross Amount at Which Carried as of Close of Period, Total	14,922
Accumulated Depreciation	$ (507)
Life on Which Building Depreciation in Income Statement is Computed	37 years
N.W. Michigan Surgery Center Units 1, 2, & 4
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	2,748
Initial Cost to Company, Buildings and Improvements	30,005
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	2,748
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	30,005
Gross Amount at Which Carried as of Close of Period, Total	32,753
Accumulated Depreciation	$ (909)
Life on Which Building Depreciation in Income Statement is Computed	40 years
Northeast Medical Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	4,011
Initial Cost to Company, Buildings and Improvements	25,564
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	929
Gross Amount at Which Carried as of Close of Period, Land	4,011
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	26,493
Gross Amount at Which Carried as of Close of Period, Total	30,504
Accumulated Depreciation	$ (1,045)
Life on Which Building Depreciation in Income Statement is Computed	33 years
North Medical Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,337
Initial Cost to Company, Buildings and Improvements	18,680
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	844
Gross Amount at Which Carried as of Close of Period, Land	1,337
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	19,524
Gross Amount at Which Carried as of Close of Period, Total	20,861
Accumulated Depreciation	$ (673)
Life on Which Building Depreciation in Income Statement is Computed	35 years
Cincinnati Eye Institute
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	2,050
Initial Cost to Company, Buildings and Improvements	32,546
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	2,050
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	32,546
Gross Amount at Which Carried as of Close of Period, Total	34,596
Accumulated Depreciation	$ (1,133)
Life on Which Building Depreciation in Income Statement is Computed	35 years
HonorHealth - Scottsdale MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	4,288
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	4,288
Gross Amount at Which Carried as of Close of Period, Total	4,288
Accumulated Depreciation	$ (135)
Life on Which Building Depreciation in Income Statement is Computed	45 years
Fox Valley Hematology & Oncology
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,590
Initial Cost to Company, Buildings and Improvements	26,666
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,590
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	26,666
Gross Amount at Which Carried as of Close of Period, Total	28,256
Accumulated Depreciation	$ (691)
Life on Which Building Depreciation in Income Statement is Computed	44 years
Gastrointestinal Associates MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	937
Initial Cost to Company, Buildings and Improvements	3,214
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	937
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	3,214
Gross Amount at Which Carried as of Close of Period, Total	4,151
Accumulated Depreciation	$ (129)
Life on Which Building Depreciation in Income Statement is Computed	30 years
Northern Vision Eye Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	490
Initial Cost to Company, Buildings and Improvements	2,132
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	490
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	2,132
Gross Amount at Which Carried as of Close of Period, Total	2,622
Accumulated Depreciation	$ (71)
Life on Which Building Depreciation in Income Statement is Computed	35 years
Flower Mound MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,945
Initial Cost to Company, Buildings and Improvements	8,312
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,945
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	8,312
Gross Amount at Which Carried as of Close of Period, Total	10,257
Accumulated Depreciation	$ (228)
Life on Which Building Depreciation in Income Statement is Computed	43 years
Carrollton MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	2,183
Initial Cost to Company, Buildings and Improvements	10,461
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	2,183
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	10,461
Gross Amount at Which Carried as of Close of Period, Total	12,644
Accumulated Depreciation	$ (306)
Life on Which Building Depreciation in Income Statement is Computed	40 years
HonorHealth IRF
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 10,000
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	19,331
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	19,331
Gross Amount at Which Carried as of Close of Period, Total	19,331
Accumulated Depreciation	$ (481)
Life on Which Building Depreciation in Income Statement is Computed	42 years
Orthopedic Associates
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	2,915
Initial Cost to Company, Buildings and Improvements	12,791
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	2,915
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	12,791
Gross Amount at Which Carried as of Close of Period, Total	15,706
Accumulated Depreciation	$ (319)
Life on Which Building Depreciation in Income Statement is Computed	43 years
Lee's Hill Medical Plaza
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,499
Initial Cost to Company, Buildings and Improvements	24,627
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,499
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	24,627
Gross Amount at Which Carried as of Close of Period, Total	26,126
Accumulated Depreciation	$ (594)
Life on Which Building Depreciation in Income Statement is Computed	44 years
CareMount - Lake Katrine MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 26,039
Initial Cost to Company, Land	1,941
Initial Cost to Company, Buildings and Improvements	27,434
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,941
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	27,434
Gross Amount at Which Carried as of Close of Period, Total	29,375
Accumulated Depreciation	$ (636)
Life on Which Building Depreciation in Income Statement is Computed	42 years
CareMount - Rhinebeck MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	869
Initial Cost to Company, Buildings and Improvements	12,220
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	869
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	12,220
Gross Amount at Which Carried as of Close of Period, Total	13,089
Accumulated Depreciation	$ (296)
Life on Which Building Depreciation in Income Statement is Computed	41 years
Monterey Medical Center - MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	2,292
Initial Cost to Company, Buildings and Improvements	13,376
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	5
Gross Amount at Which Carried as of Close of Period, Land	2,292
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	13,381
Gross Amount at Which Carried as of Close of Period, Total	15,673
Accumulated Depreciation	$ (323)
Life on Which Building Depreciation in Income Statement is Computed	37 years
Creighton University Medical Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	32,487
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	32,487
Gross Amount at Which Carried as of Close of Period, Total	32,487
Accumulated Depreciation	$ (575)
Life on Which Building Depreciation in Income Statement is Computed	49 years
Strictly Pediatrics Specialty Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	4,457
Initial Cost to Company, Buildings and Improvements	62,527
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	39
Gross Amount at Which Carried as of Close of Period, Land	4,457
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	62,566
Gross Amount at Which Carried as of Close of Period, Total	67,023
Accumulated Depreciation	$ (1,222)
Life on Which Building Depreciation in Income Statement is Computed	40 years
MedStar Stephen's Crossing
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,975
Initial Cost to Company, Buildings and Improvements	14,810
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,975
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	14,810
Gross Amount at Which Carried as of Close of Period, Total	16,785
Accumulated Depreciation	$ (190)
Life on Which Building Depreciation in Income Statement is Computed	43 years
CHI Health Clinic Building
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	50,177
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	50,177
Gross Amount at Which Carried as of Close of Period, Total	50,177
Accumulated Depreciation	$ (501)
Life on Which Building Depreciation in Income Statement is Computed	49 years
St Gabriel's Centracare
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	4,944
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	4,944
Gross Amount at Which Carried as of Close of Period, Total	4,944
Accumulated Depreciation	$ (110)
Life on Which Building Depreciation in Income Statement is Computed	25 years
Craven-Hagan Clinic
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	8,739
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	8,739
Gross Amount at Which Carried as of Close of Period, Total	8,739
Accumulated Depreciation	$ (123)
Life on Which Building Depreciation in Income Statement is Computed	40 years
Chattanooga Heart Institute
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	18,639
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	18,639
Gross Amount at Which Carried as of Close of Period, Total	18,639
Accumulated Depreciation	$ (257)
Life on Which Building Depreciation in Income Statement is Computed	37 years
CHI St. Vincent Mercy Heart & Vascular Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	11,688
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	11,688
Gross Amount at Which Carried as of Close of Period, Total	11,688
Accumulated Depreciation	$ (145)
Life on Which Building Depreciation in Income Statement is Computed	45 years
South Campus MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	13,369
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	13,369
Gross Amount at Which Carried as of Close of Period, Total	13,369
Accumulated Depreciation	$ (171)
Life on Which Building Depreciation in Income Statement is Computed	42 years
CHI St. Vincent Mercy Cancer Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	5,090
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	5,090
Gross Amount at Which Carried as of Close of Period, Total	5,090
Accumulated Depreciation	$ (72)
Life on Which Building Depreciation in Income Statement is Computed	39 years
St. Joseph Professional Office Building
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	11,169
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	11,169
Gross Amount at Which Carried as of Close of Period, Total	11,169
Accumulated Depreciation	$ (129)
Life on Which Building Depreciation in Income Statement is Computed	46 years
St. Vincent Carmel Women's Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	31,720
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	31,720
Gross Amount at Which Carried as of Close of Period, Total	31,720
Accumulated Depreciation	$ (339)
Life on Which Building Depreciation in Income Statement is Computed	48 years
St. Vincent Fishers Medical Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 44,000
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	62,870
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	62,870
Gross Amount at Which Carried as of Close of Period, Total	62,870
Accumulated Depreciation	$ (749)
Life on Which Building Depreciation in Income Statement is Computed	45 years
Baylor Charles A. Sammons Cancer Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	256,886
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	256,886
Gross Amount at Which Carried as of Close of Period, Total	256,886
Accumulated Depreciation	$ (2,994)
Life on Which Building Depreciation in Income Statement is Computed	43 years
Orthopedic & Sports Institute of the Fox Valley
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	2,003
Initial Cost to Company, Buildings and Improvements	26,394
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	100
Gross Amount at Which Carried as of Close of Period, Land	2,003
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	26,494
Gross Amount at Which Carried as of Close of Period, Total	28,497
Accumulated Depreciation	$ (406)
Life on Which Building Depreciation in Income Statement is Computed	40 years
Clearview Cancer Institute
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	2,736
Initial Cost to Company, Buildings and Improvements	43,220
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	2,736
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	43,220
Gross Amount at Which Carried as of Close of Period, Total	45,956
Accumulated Depreciation	$ (554)
Life on Which Building Depreciation in Income Statement is Computed	34 years
Northside Cherokee/Town Lake MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	30,627
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	30,627
Gross Amount at Which Carried as of Close of Period, Total	30,627
Accumulated Depreciation	$ (312)
Life on Which Building Depreciation in Income Statement is Computed	46 years
HonorHealth Mesa MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	362
Initial Cost to Company, Buildings and Improvements	3,059
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	362
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	3,059
Gross Amount at Which Carried as of Close of Period, Total	3,421
Accumulated Depreciation	$ (32)
Life on Which Building Depreciation in Income Statement is Computed	43 years
Little Falls Orthopedics
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	246
Initial Cost to Company, Buildings and Improvements	1,977
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	246
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	1,977
Gross Amount at Which Carried as of Close of Period, Total	2,223
Accumulated Depreciation	$ (39)
Life on Which Building Depreciation in Income Statement is Computed	28 years
Little Falls Dialysis Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	2,885
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	2,885
Gross Amount at Which Carried as of Close of Period, Total	2,885
Accumulated Depreciation	$ (77)
Life on Which Building Depreciation in Income Statement is Computed	15 years
Immanuel One Professional Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	16,598
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	16,598
Gross Amount at Which Carried as of Close of Period, Total	16,598
Accumulated Depreciation	$ (210)
Life on Which Building Depreciation in Income Statement is Computed	35 years
SJRHC Cancer Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	5,065
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	5,065
Gross Amount at Which Carried as of Close of Period, Total	5,065
Accumulated Depreciation	$ (47)
Life on Which Building Depreciation in Income Statement is Computed	40 years
St. Vincent Women's Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	4,789
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	4,789
Gross Amount at Which Carried as of Close of Period, Total	4,789
Accumulated Depreciation	$ (41)
Life on Which Building Depreciation in Income Statement is Computed	40 years
Legends Park MOB & ASC
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,658
Initial Cost to Company, Buildings and Improvements	24,178
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,658
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	24,178
Gross Amount at Which Carried as of Close of Period, Total	25,836
Accumulated Depreciation	$ (194)
Life on Which Building Depreciation in Income Statement is Computed	44 years
Franklin MOB & ASC
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,001
Initial Cost to Company, Buildings and Improvements	7,902
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,001
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	7,902
Gross Amount at Which Carried as of Close of Period, Total	8,903
Accumulated Depreciation	$ (49)
Life on Which Building Depreciation in Income Statement is Computed	42 years
Eagle Point MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,011
Initial Cost to Company, Buildings and Improvements	9,009
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,011
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	9,009
Gross Amount at Which Carried as of Close of Period, Total	10,020
Accumulated Depreciation	$ (36)
Life on Which Building Depreciation in Income Statement is Computed	48 years
Edina East MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	2,360
Initial Cost to Company, Buildings and Improvements	4,135
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	2,360
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	4,135
Gross Amount at Which Carried as of Close of Period, Total	6,495
Accumulated Depreciation	$ (26)
Life on Which Building Depreciation in Income Statement is Computed	30 years
Northside MOB - Center Pointe
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	119,467
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	119,467
Gross Amount at Which Carried as of Close of Period, Total	119,467
Accumulated Depreciation	$ (323)
Life on Which Building Depreciation in Income Statement is Computed	31 years
Gwinnett 500 Building
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	22,753
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	22,753
Gross Amount at Which Carried as of Close of Period, Total	22,753
Accumulated Depreciation	$ (90)
Life on Which Building Depreciation in Income Statement is Computed	45 years
Hudgens Professional Building
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	21,779
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	21,779
Gross Amount at Which Carried as of Close of Period, Total	21,779
Accumulated Depreciation	$ (98)
Life on Which Building Depreciation in Income Statement is Computed	40 years
St. Vincent Building
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	5,854
Initial Cost to Company, Buildings and Improvements	42,382
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	5,854
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	42,382
Gross Amount at Which Carried as of Close of Period, Total	48,236
Accumulated Depreciation	$ (182)
Life on Which Building Depreciation in Income Statement is Computed	45 years
Gwinnett Physicians Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 17,609
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	48,304
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	48,304
Gross Amount at Which Carried as of Close of Period, Total	48,304
Accumulated Depreciation	$ (92)
Life on Which Building Depreciation in Income Statement is Computed	47 years
Apple Valley Medical Center
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,587
Initial Cost to Company, Buildings and Improvements	14,929
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,587
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	14,929
Gross Amount at Which Carried as of Close of Period, Total	16,516
Accumulated Depreciation	$ (40)
Life on Which Building Depreciation in Income Statement is Computed	33 years
Desert Cove MOB (57% Interest)
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	1,689
Initial Cost to Company, Buildings and Improvements	5,207
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	1,689
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	5,207
Gross Amount at Which Carried as of Close of Period, Total	6,896
Accumulated Depreciation	$ (12)
Life on Which Building Depreciation in Income Statement is Computed	38 years
Westgate MOB
SEC Schedule III, Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost to Company, Land	0
Initial Cost to Company, Buildings and Improvements	13,379
Initial Cost to Company, Cost Capitalized Subsequent to Acquisitions	0
Gross Amount at Which Carried as of Close of Period, Land	0
Gross Amount at Which Carried as of Close of Period, Buildings and Improvements	13,379
Gross Amount at Which Carried as of Close of Period, Total	13,379
Accumulated Depreciation	$ (27)
Life on Which Building Depreciation in Income Statement is Computed	45 years

XML

SCHEDULE III - REAL ESTATE AND ACCUMULATED DEPRECIATION - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
SEC Schedule III, Real Estate and Accumulated Depreciation Disclosure [Abstract]
Aggregate cost for federal Income tax purposes	$ 3,830,000
Accumulated tax depreciation	175,800
Aggregate cost for federal income tax purposes, net of accumulated tax depreciation	3,650,000
SEC Schedule III, Reconciliation of Carrying Amount of Real Estate Investments [Roll Forward]
Balance as of the beginning of the year	2,606,536	$ 1,424,894	$ 729,034
Acquisitions	1,207,098	1,170,593	695,693
Additions	12,243	11,049	4,440
Impairment	(965)	0	0
Dispositions	(15,303)	0	(4,273)
Balance as of the end of the year	3,809,609	2,606,536	1,424,894
SEC Schedule III, Reconciliation of Real Estate Accumulated Depreciation [Roll Forward]
Balance as of the beginning of the year	118,609	61,242	32,772
Depreciation	87,531	57,367	29,958
Dispositions	(4,613)	0	(1,488)
Balance as of the end of the year	$ 201,527	$ 118,609	$ 61,242